<html lang="en"><head><!-- Shady DOM styles for custom-style --><!-- Shady DOM styles for dom-template --><!-- Shady DOM styles for dom-repeat --><!-- Shady DOM styles for array-selector --><!-- Shady DOM styles for dom-if --><!-- Shady DOM styles for state-modifier --><style scope="state-modifier">a[inherit].state-modifier {
  color: inherit;
}</style><!-- Shady DOM styles for browser-ui --><!-- Shady DOM styles for outlined-text-field --><style scope="outlined-text-field">outlined-text-field {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: column;
}

outlined-text-field span.outlined-text-field {
  display: flex;
  flex-direction: row;
  align-items: center;
}

outlined-text-field input.outlined-text-field {
  height: 40px;
  padding: 0 33px 0 16px;
  
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  flex-grow: 1;
}

outlined-text-field[orig] input.outlined-text-field {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-text-field[dense] input.outlined-text-field {
  height: 32px;
}

outlined-text-field[uppercase] input.outlined-text-field {
  text-transform: uppercase;
}

outlined-text-field:not([wizard-focused]):hover input.outlined-text-field {
  border-color: #737375;
  color: #414447;
}

outlined-text-field:not([wizard-focused]):focus-within input.outlined-text-field,outlined-text-field[wizard-focused] input.outlined-text-field {
  border-color: #3574e0;
  caret-color: #80a5f1;
}

outlined-text-field[wizard-focused] input.outlined-text-field {
  border-width: 2px;
}

outlined-text-field input.outlined-text-field::placeholder {
  color: #65686c;
}

outlined-text-field[uppercase] input.outlined-text-field::placeholder {
  text-transform: none;
}</style><!-- Shady DOM styles for mat-keyword-editor --><!-- Shady DOM styles for mat-chips-input --><!-- Shady DOM styles for mat-input-chip --><!-- Shady DOM styles for pat-dialog --><style scope="pat-dialog">pat-dialog {
  background: white;
  position: absolute;
  border-radius: 8px;
  
  box-shadow: 0 24px 38px 3px rgb(0 0 0 / 14%),
              0 9px 46px 8px rgb(0 0 0 / 12%),
              0 11px 15px -7px rgb(0 0 0 / 20%);
  z-index: 1;
  display: flex;
  flex-direction: column;
}

pat-dialog:not([open]) {
  display: none;
}</style><!-- Shady DOM styles for mat-tabs --><!-- Shady DOM styles for filter-chip --><style scope="filter-chip">filter-chip {
  align-items: center;
  background-color: #fff;
  border-color: #dadce0;
  border-radius: 8px;
  border-style: solid;
  border-width: 1px;
  color: #606368;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 32px;
  letter-spacing: 0.2px;
  padding: 0 16px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

filter-chip[disabled] {
  background-color: #e8e8e8;
  border-color: #e8e8e8;
  color: #a9abad;
  cursor: auto;
}

filter-chip svg.filter-chip {
  visibility: collapse;
  font-size: 18px;
  width: 0;
  height: 18px;
}

filter-chip[selected] svg.filter-chip {
  visibility: visible;
  margin: 0 8px;
  width: 18px;
}

filter-chip[selected] svg.filter-chip path.filter-chip {
  fill: #4577d1;
}

filter-chip:not([disabled]):hover {
  background-color: #f7f8f8;
  border-color: #d7d9dc;
  color: #454649;
}

filter-chip:not([disabled]):hover:active {
  background-color: #eff0f0;
  border-color: #d2d5d8;
  color: #222326;
}

filter-chip:not([disabled]):focus {
  background-color: #e7e8e8;
  border-color: #232528;
  color: #202124;
}

filter-chip:not([disabled])[selected] {
  background-color: #e9f0fd;
  border-color: #e9f0fd;
  color: #4577d1;
  padding-left: 0;
}

filter-chip:not([disabled]):focus[selected] {
  background-color: #d5e1fb;
  border-color: #d5e1fb;
  color: #2550a0;
}

filter-chip:not([disabled]):hover[selected] {
  box-shadow: rgba(0, 0, 0, 0.2) 0px 3px 1px -2px,
    rgba(0, 0, 0, 0.14) 0px 2px 2px 0px, rgba(0, 0, 0, 0.12) 0px 1px 5px 0px;
}

filter-chip:not([disabled]):hover:active[selected] {
  background-color: #abc8f2;
  border-color: #abc8f2;
  color: #2a54a3;
}</style><!-- Shady DOM styles for figure-callout --><!-- Shady DOM styles for mat-button --><style scope="mat-button-0">.mat-button-0 {
  ;
  align-items: center;
  border-radius: 4px;
  color: hsl(217 4% 39%); 
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: 0.2px;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

.mat-button-0[filled] {
  background-color: hsl(217 73% 54%); 
  color: white;
}

.mat-button-0[filled]:hover {
  background-color: hsl(217 60% 47%);
}

.mat-button-0[filled]:focus {
  background-color: hsl(217 59% 44%);
}

.mat-button-0[filled]:active {
  background-color: hsl(217 59% 45%);
}

.mat-button-0[filled][disabled] {
  background-color: hsl(217 2% 90%); 
  color: hsl(217 1% 65%);
}</style><!-- Shady DOM styles for search-term-wizard --><style scope="search-term-wizard">search-term-wizard:not([open]) {
  display: none;
}

search-term-wizard .header.search-term-wizard {
  border-bottom: 1px solid #e5e5e5;
  padding: 24px;
  padding-bottom: 0;
}

search-term-wizard .title.search-term-wizard {
  color: #3c4043;
  font-family: Google Sans,Roboto,Arial,sans-serif;
  font-size: 22px;
  user-select: none;
  margin: 0 48px;
}

search-term-wizard #panels.search-term-wizard > *.search-term-wizard:not([selected]) {
  display: none;
}</style><!-- Shady DOM styles for outlined-textarea --><style scope="outlined-textarea">outlined-textarea {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: row;
  
  position: relative;
}

outlined-textarea span.outlined-textarea {
  display: flex;
  flex-direction: column;
  flex-grow: 1;
  justify-content: center;
}

outlined-textarea span.right-button-container.outlined-textarea {
  position: absolute;
  right: 0;
  height: 100%;
}

outlined-textarea textarea.outlined-textarea {
  padding: 16px 16px 0 16px;
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  resize: none;
}

outlined-textarea[dense] textarea.outlined-textarea {
  padding: 8px;
}

outlined-textarea[has-icon] textarea.outlined-textarea {
  padding-right: 38px;
}

outlined-textarea[orig] textarea.outlined-textarea {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-textarea:not([rows]) textarea.outlined-textarea {
  height: 40px;
}

outlined-textarea textarea.resizable.outlined-textarea {
  resize: vertical;
}

outlined-textarea textarea.outlined-textarea:focus,outlined-textarea[wizard-focused] textarea.outlined-textarea,outlined-textarea textarea.outlined-textarea:focus:hover {
  border-color: #3574e0 !important;
  
  outline: none !important;
}

outlined-textarea textarea.outlined-textarea:hover {
  border-color: #202124;
  color: #414447;
}

outlined-textarea.hasValue textarea.outlined-textarea {
  border-color: #888d91;
  color: #45474a;
}

outlined-textarea #helperText.outlined-textarea {
  color: #6a6c71;
  font-size: 12px;
  letter-spacing: 0.3px;
  margin-left: 17px;
  margin-top: 6px;
  user-select: none;
}

outlined-textarea:not([helper-text]) #helperText.outlined-textarea {
  display: none;
}

outlined-textarea[error] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
  color: #3d4043;
}

outlined-textarea textarea.outlined-textarea::placeholder {
  font-size: 14px;
  font-weight: 400;
}

outlined-textarea:not([error]):not([disabled]) textarea.outlined-textarea::placeholder {
  color: #6a6c71;
}

outlined-textarea[error] textarea.outlined-textarea::placeholder {
  color: #c84132;
}

outlined-textarea[error] #helperText.outlined-textarea {
  color: #cd5648;
}

outlined-textarea[error] textarea.outlined-textarea:focus {
  border-color: #c84031;
  border-width: 2px;
  outline: none !important;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover {
  border-color: #97231b;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover::placeholder,outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover + #helperText.outlined-textarea {
  color: #a94945;
}

outlined-textarea[disabled] textarea.outlined-textarea {
  border-color: #e9e9e9;
  color: #b5b6b8;
}

outlined-textarea[disabled] #helperText.outlined-textarea {
  color: #c4c6c7;
}

outlined-textarea[error][disabled] {
  opacity: 50%;
}

outlined-textarea[error][disabled] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
}

outlined-textarea[error][disabled] #helperText.outlined-textarea,outlined-textarea[error][disabled] textarea.outlined-textarea {
  color: #a94945;
}

outlined-textarea[error][disabled] textarea.outlined-textarea::placeholder {
  color: #c84132;
}</style><!-- Shady DOM styles for chemistry-search-term-wizard --><style scope="chemistry-search-term-wizard">chemistry-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

chemistry-search-term-wizard .suggestions.chemistry-search-term-wizard {
  margin-top: 4px;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard svg.chemistry-search-term-wizard {
  margin-right: 24px;
}

chemistry-search-term-wizard path.chemistry-search-term-wizard {
  fill: #5f6368;
}

chemistry-search-term-wizard .help.chemistry-search-term-wizard {
  margin-left: 12px;
  margin-right: 0;
  cursor: pointer;
}

chemistry-search-term-wizard outlined-text-field.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard mat-button.chemistry-search-term-wizard {
  margin-left: 48px;
}

chemistry-search-term-wizard filter-chip.chemistry-search-term-wizard {
  margin-right: 4px;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard outlined-text-field[batchMode].chemistry-search-term-wizard {
  display: none;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard:not([batchMode]) {
  display: none;
}</style><!-- Shady DOM styles for text-search-term-wizard --><style scope="text-search-term-wizard">text-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

text-search-term-wizard > span.text-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

text-search-term-wizard > span.text-search-term-wizard svg.text-search-term-wizard {
  margin-right: 24px;
}

text-search-term-wizard path.text-search-term-wizard {
  fill: #5f6368;
}

text-search-term-wizard outlined-text-field.text-search-term-wizard {
  flex-grow: 1;
}

text-search-term-wizard mat-button.text-search-term-wizard {
  margin-left: 48px;
}

text-search-term-wizard filter-chip.text-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for classification-wizard --><style scope="classification-wizard">classification-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

classification-wizard > span.classification-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

classification-wizard .suggestions.classification-wizard {
  margin-top: 4px;
}

classification-wizard > span.classification-wizard svg.classification-wizard {
  margin-right: 24px;
}

classification-wizard path.classification-wizard {
  fill: #5f6368;
}

classification-wizard outlined-text-field.classification-wizard {
  flex-grow: 1;
}

classification-wizard mat-button.classification-wizard {
  margin-left: 48px;
}

classification-wizard filter-chip.classification-wizard {
  margin-right: 4px;
}

classification-wizard .no-matches.classification-wizard {
  margin-left: 64px;
}

classification-wizard .table-container.classification-wizard {
  max-height: 300px;
  overflow: scroll;
  margin-top: 8px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar {
  -webkit-appearance: none;
  width: 10px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar-thumb {
  border-radius: 5px;
  background-color: #5f636880;
  -webkit-box-shadow: 0 0 1px rgba(255,255,255,.5);
}

classification-wizard table.classification-wizard {
  margin-left: 51px;
  max-width: 575px;
}

classification-wizard tr.classification-wizard {
  margin-top: 4px;
}

classification-wizard tr.classification-wizard suggestive-chip.classification-wizard {
  margin-right: 8px;
}

classification-wizard #spinner.classification-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}</style><!-- Shady DOM styles for suggestive-chip --><!-- Shady DOM styles for mat-checkbox --><!-- Shady DOM styles for measure-search-term-wizard --><style scope="measure-search-term-wizard">measure-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

measure-search-term-wizard > span.measure-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

measure-search-term-wizard .suggestions.measure-search-term-wizard {
  margin-top: 4px;
}

measure-search-term-wizard > span.measure-search-term-wizard svg.measure-search-term-wizard {
  margin-right: 24px;
}

measure-search-term-wizard path.measure-search-term-wizard {
  fill: #5f6368;
}

measure-search-term-wizard outlined-text-field.measure-search-term-wizard {
  flex-grow: 1;
}

measure-search-term-wizard mat-button.measure-search-term-wizard {
  margin-left: 48px;
}

measure-search-term-wizard filter-chip.measure-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for numerical-search-term-wizard --><style scope="numerical-search-term-wizard">numerical-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

numerical-search-term-wizard .suggestions.numerical-search-term-wizard {
  margin-top: 4px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard svg.numerical-search-term-wizard {
  margin-right: 24px;
}

numerical-search-term-wizard path.numerical-search-term-wizard {
  fill: #5f6368;
}

numerical-search-term-wizard outlined-text-field.numerical-search-term-wizard,numerical-search-term-wizard outlined-textarea.numerical-search-term-wizard {
  flex-grow: 1;
}

numerical-search-term-wizard mat-button.numerical-search-term-wizard {
  margin-left: 48px;
}

numerical-search-term-wizard filter-chip.numerical-search-term-wizard {
  margin-right: 4px;
}

numerical-search-term-wizard #spinner.numerical-search-term-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}

numerical-search-term-wizard #suggestions.numerical-search-term-wizard {
  margin-left: 58px;
  display: flex;
  flex-direction: column;
  align-items: flex-start;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard mat-checkbox.numerical-search-term-wizard {
  margin-right: 8px;
}</style><!-- Shady DOM styles for text-button --><style scope="text-button">text-button {
  align-items: center;
  border-radius: 4px;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: .25px;
  margin: 6px 0;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
  line-height: 36px;
  text-decoration: none;
  text-transform: none;
  color: #5f6368;
}

text-button:hover {
  background-color: #f8f9fa;
}

text-button:active {
  background-color: #d5e2fa;
}

text-button[selected] {
  background-color: #e8f0fe;
  color: #1967d2;
}

text-button[selected]:active {
  background-color: #d2e3fc;
}</style><!-- Shady DOM styles for mat-spinner --><!-- Shady DOM styles for requery-tile --><style scope="requery-tile">requery-tile {
  display: flex;
  justify-content: space-between;
  align-items: center;
  box-sizing: border-box;
  min-height: 40px;
  padding: 8px 12px 8px 8px;
  gap: 8px;

  border-radius: 16px;
  background: #f7f8f9;
  color: #1f1f1f;
}

requery-tile:hover {
  background: #d7d8d9;
}

requery-tile > [slot="image"] {
  flex-shrink: 0;

  border-radius: 8px;

  background: #fff;
}

.label.requery-tile {
  flex-grow: 999;

  font: 16px/20px "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
}

.search-icon.requery-tile {
  flex-shrink: 0;

  width: 24px;
  height: 24px;
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/search/default/24px.svg');
}</style><!-- Shady DOM styles for s-more-inline --><style scope="s-more-inline">s-more-inline {
  display: block;
  margin-top: 24px;
  padding: 16px;
  padding-top: 0;
  position: relative;

  line-height: 18px;
  text-overflow: ellipsis;
  white-space: nowrap;
  cursor: pointer;
}

hr.s-more-inline {
  background-color: #dadce0;
  margin-top: 18px;
  position: absolute;
  border: 0;
  height: 1px;
  left: 0;
  width: 100%;
}

.button.s-more-inline {
  display: flex;
  align-items: center;
  justify-content: center;

  position: relative; 
  margin: 0 auto;

  font: 400 14px Roboto, arial, sans-serif;
  height: 36px;
  width: 300px;
  border-radius: 18px;
  background-color: #f1f3f4;
}

.button.s-more-inline:hover {
  background-color: #d8d7dc;
}

.button.s-more-inline > [slot] {
  padding-right: 8px;
}

.expand.s-more-inline {
  display: inline-block;
  width: 20px;
  height: 20px;
}

.expand.less.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_less/default/20px.svg');
}

.expand.more.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_more/default/20px.svg');
}</style><!-- Shady DOM styles for workspace-ui-search --><!-- Shady DOM styles for keyword-wizard --><style scope="keyword-wizard">keyword-wizard {
  display: inline-block;
}

iron-icon.keyword-wizard {
  height: 20px;
    width: 20px;
    color: #999;
    cursor: pointer;
}

iron-icon[active].keyword-wizard {
  color: #4285f4 !important;
}

iron-icon.keyword-wizard:hover {
  color: #ccc;
}

#wizardIcon.keyword-wizard {
  padding-left: 1px;
    height: 16px;
    width: 16px;
    margin: 4px 1px 1px 1px;
}

#wizard.keyword-wizard {
  padding: 0;
    left: 0;
    top: 37px;
    position: absolute;
    background-color: white;
    z-index: 2;
    overflow: hidden;
}

.wizard-header.keyword-wizard {
  display: block;
    width: 100%;
    color: #737373;
    text-transform: uppercase;
    font-size: 13px;
    margin: 16px 0 6px 12px;
}

.filter-chips.keyword-wizard {
  margin-left: 20px;
}

.chip.keyword-wizard {
  background-color: #ebebeb;
    color: #6a6a6a;
    display: inline-block;
    font-size: 13px;
    font-family: inherit;
    border-radius: 12px;
    padding: 6px 12px;
}

.chip.keyword-wizard:hover {
  cursor: pointer;
}

.chip[selected].keyword-wizard {
  background-color: #4285f4;
    color: white;
}

.input-label.keyword-wizard {
  display: inline-block;
    font-size: 13px;
    font-family: inherit;
}

.keyword-input.keyword-wizard {
  display: inline-block;
    border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    padding: 3px;
}

.keyword-input.keyword-wizard::placeholder {
  font-style: italic;
}

.keyword-input.keyword-wizard:hover,.keyword-input.keyword-wizard:focus {
  border-color: #4284f4;
    border-width: 1px;
    outline: none;
}

.cpc-field.keyword-wizard {
  display: inline-block;
    margin: 6px 0 0 24px;
}

#checkboxCPC.keyword-wizard:hover {
  cursor: pointer;
}

.checkbox-label.keyword-wizard {
  font-size: 13px;
    font-style: italic;
    color: #737373;
}

.chemistry-field.keyword-wizard {
  display: block;
}

#inputChem.input-batch.keyword-wizard {
  height: 150px;
    border: 1px solid #dfe1e5;
    padding: 6px;
}

#inputChem.keyword-wizard {
  resize: none;
    height: 15px;
    vertical-align: text-top;
    font-size: 13px;
    font-family: inherit;
    padding: 2px;
}

.chem-type-label.keyword-wizard {
  display: inline;
    font-size: 13px;
    margin-left: 12px;
    margin-right: 4px;
}

#chemType.keyword-wizard {
  border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    margin: 6px;
    padding: 2px;
    outline: none;
    font-family: inherit;
    font-size: 13px;
}

.import.keyword-wizard {
  font-size: 13px;
    font-family: inherit;
}

.import-text.keyword-wizard {
  vertical-align: middle;
    display: inline-block;
}

.import-button.keyword-wizard {
  margin: 6px 0 0 24px;
}

.import-button.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.import-button.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard {
  float: right;
    padding: 12px;
}

.wizard-buttons.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    margin: 2px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
}

@media screen and (max-width: 700px) {
#wizard.keyword-wizard {
  width: 275px;
}

.chip.keyword-wizard {
  margin: 4px 2px;
}

.keyword-input.keyword-wizard {
  width: 82%;
      margin: 4px 12px 12px 24px;
}

.search-within.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 225px;
      margin: 12px 0 6px 0;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  margin-top: 6px;
}

#inputChem.keyword-wizard {
  width: 82%;
      padding: 2px;
      margin: 8px 12px 12px 24px;
}

#inputChem.input-batch.keyword-wizard {
  width: 220px;
      padding: 4px;
}

#chemType.keyword-wizard {
  width: 150px;
}

.import-text.keyword-wizard {
  margin: 6px 12px 6px 24px;
      width: 220px;
}

iron-icon.help-header.keyword-wizard {
  display: none;
}

}

@media screen and (min-width: 700px) {
#wizard.keyword-wizard {
  width: 540px;
}

.chip.keyword-wizard {
  margin: 0 2px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 240px;
      margin: 12px 16px 6px 6px;
}

.cpc-inputs.keyword-wizard {
  display: inline;
}

.find-patents.keyword-wizard .keyword-input.keyword-wizard {
  width: 53%;
      margin: 4px 10px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard::placeholder,#inputAnd.keyword-wizard::placeholder,#inputExact.keyword-wizard::placeholder,#inputOr.keyword-wizard::placeholder,#inputMinus.keyword-wizard::placeholder {
  color: white;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  width: 35%;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  width: 42%;
      margin: 6px 4px;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

#inputChem.keyword-wizard {
  width: 290px;
      margin: 2px 12px 2px 6px;
}

#inputChem.input-batch.keyword-wizard {
  width: 280px;
      padding: 6px;
}

.import-text.keyword-wizard {
  margin: 6px 12px;
      width: 415px;
}

#chemType.keyword-wizard {
  width: 105px;
}

iron-icon.keyword-wizard:hover.help-header {
  cursor: default;
}

iron-icon.help-header.keyword-wizard {
  height: 16px;
      padding: 0 2px 2px 2px;
      color: #a3a3a3;
}

.help.keyword-wizard p.keyword-wizard {
  margin: 0 0 8px 0
}

.help.keyword-wizard .q.keyword-wizard {
  font-family: monospace;
      color: #0b8043;
      white-space: nowrap;
}

.help.keyword-wizard {
  z-index: 4;
      position: absolute;
      right: 10px;
      padding: 12px;
      border-radius: 2px;
      border: 1px solid #e0e0e0;
      box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.2), 0 6px 10px 0 rgba(0, 0, 0, 0.3);
      background: white;
      font-size: 13px;
      line-height: 20px;
      width: 450px;
      max-height: 400px;
      overflow: auto;
}

#withinHelp.keyword-wizard {
  top: 75px;
}

#chemHelp.keyword-wizard {
  top: 0;
}

#searchBooleanHelp.keyword-wizard {
  top: 140px;
}

}</style><!-- Shady DOM styles for bottom-bar --><style scope="bottom-bar">.fixed.bottom-bar {
  display: block;
  position: fixed;
  height: 46px;
  bottom: 0;
}

.fixed[medium].bottom-bar {
  height: 280px;
}

.fixed[large].bottom-bar {
  height: 480px;
}

.shadow.bottom-bar {
  background: white;
  padding: 16px;
  border-radius: 8px 8px 0px 0px;
  box-shadow: 0px 8px 10px 1px rgba(0,0,0,.14), 0px 3px 14px 2px rgba(0,0,0,.12), 0px 5px 5px -3px rgba(0,0,0,.2);
}

.oneline.bottom-bar {
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  cursor: pointer;
}

.button.bottom-bar {
  cursor: pointer;
}

.buttonAlign.bottom-bar {
  margin-top: -4px;
}

.header.bottom-bar {
  height: 30px;
  font-family: 'Google Sans';
  font-size: 18px;
  padding-bottom: 8px;
}

.list.bottom-bar {
  overflow-y: auto;
  line-height: 20px;
}

.definition.bottom-bar {
  padding: 0px 0px 4px 0px;
  cursor: pointer;
}

[medium].bottom-bar .content.bottom-bar {
  height: 230px;
}

[large].bottom-bar .content.bottom-bar {
  height: 430px;
}

[medium].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 200px;
}

[large].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 400px;
}

[hidden].bottom-bar {
  display: none;
}

.label.bottom-bar {
  font-family: 'Google Sans';
  font-size: 12px;
  line-height: 16px;
  font-weight: 400;
  padding: 6px 0px 4px 0px;
  color: #1f1f1f;
}

[pad].bottom-bar {
  margin-left: 16px;
}

.layout.vertical.bottom-bar {
  display: flex;
  flex-direction: column;
}

.layout.horizontal.bottom-bar {
  display: flex;
  flex-direction: row;
}

.flex.bottom-bar {
  flex: 1;
  flex-basis: 0.000000001px;
}

.layout.start.bottom-bar {
  align-items: flex-start;
}

.layout.center.bottom-bar {
  align-items: center;
}

.layout.end.bottom-bar {
  align-items: flex-end;
}

.flex-2.bottom-bar {
  flex: 2;
}

.flex-3.bottom-bar {
  flex: 3;
}

.flex-4.bottom-bar {
  flex: 4;
}

.flex-5.bottom-bar {
  flex: 5;
}

.flex-6.bottom-bar {
  flex: 6;
}

.flex-7.bottom-bar {
  flex: 7;
}

.flex-8.bottom-bar {
  flex: 8;
}

.flex-9.bottom-bar {
  flex: 9;
}

.flex-10.bottom-bar {
  flex: 10;
}

.flex-11.bottom-bar {
  flex: 11;
}

.flex-12.bottom-bar {
  flex: 12;
}</style><!-- Shady DOM styles for landscape-link --><!-- Shady DOM styles for landscape-summary-box --><!-- Shady DOM styles for search-state --><!-- Shady DOM styles for iron-overlay-backdrop --><!-- Shady DOM styles for opaque-animation --><!-- Shady DOM styles for iron-dropdown --><style scope="iron-dropdown">iron-dropdown {
  position: fixed;
}

#contentWrapper.iron-dropdown  > * {
  overflow: auto;
}

#contentWrapper.animating.iron-dropdown  > * {
  overflow: hidden;
}</style><!-- Shady DOM styles for iron-meta --><!-- Shady DOM styles for iron-icon --><style scope="iron-icon-0">.iron-icon-0 {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;-ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;-ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
        position: relative;

        vertical-align: middle;

        fill: currentcolor;
        stroke: none;

        width: 24px;
        height: 24px;;
}

.iron-icon-0[hidden] {
  display: none;
}</style><!-- Shady DOM styles for iron-iconset-svg --><!-- Shady DOM styles for iron-list --><!-- Shady DOM styles for paper-icon-item --><!-- Shady DOM styles for paper-item-body --><!-- Shady DOM styles for paper-item --><!-- Shady DOM styles for dropdown-menu --><style scope="dropdown-menu">dropdown-menu {
  display: inline-block;
        line-height: 24px;
}

.label.dropdown-menu {
  cursor: pointer;
        color: #666;
        align-items: center;
        margin-right: 8px;
        display: inline-block;
        padding: 2px 0;
}

#selected.dropdown-menu {
  color: #212121;
}

.label[open].dropdown-menu {
  border-color: #e0e0e0;
}

iron-dropdown.dropdown-menu {
  margin-top: 26px;
}

iron-icon.dropdown-menu {
  height: 15px;
        width: 15px;
}

#menu.dropdown-menu {
  max-height: 300px;
        padding: 8px 0;
        background: white;
        display: block;
        border-radius: 2px;
        box-shadow: 0 0 2px rgba(0,0,0,0.12), 0 2px 2px rgba(0,0,0,0.24);
}

.item.dropdown-menu {
  cursor: pointer;
        color: rgba(0,0,0,.87);
        font-size: 13px;
        line-height: 18px;
        padding: 6px 18px;
}

.item.dropdown-menu:hover {
  background-color: #e0e0e0;
}

.item[selected].dropdown-menu {
  background-color: #e0e0e0;
}

[multi].dropdown-menu .item.dropdown-menu {
  padding: 6px 18px 6px 34px;
}

[multi].dropdown-menu .item[selected].dropdown-menu {
  background-image: url('https://www.gstatic.com/images/icons/material/system/2x/done_grey600_24dp.png');
        background-position: 8px center;
        background-size: 16px;
        background-repeat: no-repeat;
}</style><!-- Shady DOM styles for chips-input --><!-- Shady DOM styles for input-chip --><!-- Shady DOM styles for keyword-editor --><!-- Shady DOM styles for paper-ripple --><!-- Shady DOM styles for paper-button --><!-- Shady DOM styles for date-editor --><!-- Shady DOM styles for metadata-editor --><!-- Shady DOM styles for restrict-editor --><!-- Shady DOM styles for overlay-tooltip --><style scope="overlay-tooltip">overlay-tooltip {
  display: none;
        color: #fff;
        background-color: #000;
        padding: 10px 12px;
        border-radius: 3px;
        font-size: 13px;
        font-weight: normal;
        line-height: normal;
        position: fixed;
        z-index: 100;
}

#arrow.overlay-tooltip {
  width: 0;
        height: 0;
        border-style: solid;
        border-width: 0 6px 8px 6px;
        border-color: transparent transparent #000 transparent;
        position: absolute;
        top: -8px;
        left: calc(50% - 6px);
}</style><!-- Shady DOM styles for query-renderer --><!-- Shady DOM styles for result-nav --><style scope="result-nav">result-nav {
  display: block;
        white-space: nowrap;
        padding: 0 30px;
        line-height: 30px;
        height: 30px;
        margin-top: 17px;
        font-weight: 500;
        font-size: 15px;
}

state-modifier.result-nav {
  color: #333;
}

state-modifier[disabled].result-nav {
  pointer-events: none;
        color: #ccc;
}</style><!-- Shady DOM styles for raw-html --><!-- Shady DOM styles for paper-material --><style scope="paper-material-0">.paper-material-0 {
  display: block;
        position: relative;
}

.paper-material-0[elevation="1"] {
  box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.14),
                    0 1px 5px 0 rgba(0, 0, 0, 0.12),
                    0 3px 1px -2px rgba(0, 0, 0, 0.2);
}

.paper-material-0[elevation="2"] {
  box-shadow: 0 4px 5px 0 rgba(0, 0, 0, 0.14),
                    0 1px 10px 0 rgba(0, 0, 0, 0.12),
                    0 2px 4px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="3"] {
  box-shadow: 0 6px 10px 0 rgba(0, 0, 0, 0.14),
                    0 1px 18px 0 rgba(0, 0, 0, 0.12),
                    0 3px 5px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="4"] {
  box-shadow: 0 8px 10px 1px rgba(0, 0, 0, 0.14),
                    0 3px 14px 2px rgba(0, 0, 0, 0.12),
                    0 5px 5px -3px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="5"] {
  box-shadow: 0 16px 24px 2px rgba(0, 0, 0, 0.14),
                    0  6px 30px 5px rgba(0, 0, 0, 0.12),
                    0  8px 10px -5px rgba(0, 0, 0, 0.4);
}

.paper-material-0[animated] {
  transition: box-shadow 0.28s cubic-bezier(0.4, 0, 0.2, 1);
}

.paper-material-0 {
  ;
}</style><!-- Shady DOM styles for search-box --><style scope="search-box">.layout.horizontal.search-box,.layout.vertical.search-box {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-box {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-box {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-box {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-box {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-box {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-box,.layout.center-center.search-box {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-box,.layout.center-center.search-box {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-box {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-box {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-box {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.inputbox.search-box {
  border: 1px solid #ccc;
        padding: 0 12px;
        background: white;
}

.inputbox[focused].search-box {
  border: 1px solid #4285f4 !important;
}

.inputbox.search-box:hover {
  border: 1px solid #999;
}

#searchInput.search-box {
  font-family: inherit;
        font-size: 16px;
        padding: 8px 0;
        outline: none;
        border-right: none;
        width: 100%;
        margin-right: 0;
        border: 0;
}

#searchButton.search-box {
  cursor: pointer;
        background-color: #4285f4;
        border: none;
        color: #fff;
        vertical-align: top;
        width: 70px;
        height: 37px;
        outline: none;
}

.suggest-bg.search-box {
  display: inline-block;
        min-width: 0;
        white-space: nowrap;
}

#suggestMenu.search-box {
  position: absolute;
        margin-top: 38px;
        width: 100%;
        background: white;
        z-index: 1;
}

#suggestMenu.search-box .row.search-box {
  font-size: 13px;
        line-height: 28px;
        white-space: nowrap;
        overflow: hidden;
        text-overflow: ellipsis;
        padding: 4px 2px;
        cursor: pointer;
}

.row[selected].search-box {
  background: rgba(0, 0, 0, 0.05);
}

.suggest-icon.search-box {
  height: 20px;
        width: 20px;
        padding: 0 12px 0 6px;
        transition: transform .15s linear;
        transform: scale(1);
}

.suggest-icon[hide].search-box {
  transform: scale(0);
}

#corpora.search-box {
  padding: 6px 0;
        user-select: none;
}

#corpora.search-box iron-icon.search-box {
  height: 20px;
        width: 20px;
        color: #ccc;
        cursor: pointer;
}

#corpora.search-box iron-icon[active].search-box {
  color: #4285f4 !important;
}

#corpora.search-box iron-icon.search-box:hover {
  color: #999;
}</style><!-- Shady DOM styles for iron-media-query --><!-- Shady DOM styles for paper-header-panel --><!-- Shady DOM styles for iron-a11y-announcer --><style scope="iron-a11y-announcer">iron-a11y-announcer {
  display: inline-block;
        position: fixed;
        clip: rect(0px,0px,0px,0px);
}</style><!-- Shady DOM styles for iron-autogrow-textarea --><!-- Shady DOM styles for iron-input --><!-- Shady DOM styles for paper-input-char-counter --><!-- Shady DOM styles for paper-input-container --><!-- Shady DOM styles for paper-input-error --><!-- Shady DOM styles for paper-input --><!-- Shady DOM styles for paper-textarea --><!-- Shady DOM styles for paper-toast --><style scope="paper-toast-0">.paper-toast-0 {
  display: block;
        position: fixed;
        background-color: #323232;
        color: #f1f1f1;
        min-height: 48px;
        min-width: 288px;
        padding: 16px 24px;
        box-sizing: border-box;
        box-shadow: 0 2px 5px 0 rgba(0, 0, 0, 0.26);
        border-radius: 2px;
        margin: 12px;
        font-size: 14px;
        cursor: default;
        -webkit-transition: -webkit-transform 0.3s, opacity 0.3s;
        transition: transform 0.3s, opacity 0.3s;
        opacity: 0;
        -webkit-transform: translateY(100px);
        transform: translateY(100px);font-family: 'Roboto', 'Noto', sans-serif;
        -webkit-font-smoothing: antialiased;
}

.paper-toast-0.capsule {
  border-radius: 24px;
}

.paper-toast-0.fit-bottom {
  width: 100%;
        min-width: 0;
        border-radius: 0;
        margin: 0;
}

.paper-toast-0.paper-toast-open {
  opacity: 1;
        -webkit-transform: translateY(0px);
        transform: translateY(0px);
}</style><!-- Shady DOM styles for paper-toolbar --><!-- Shady DOM styles for search-footer --><style scope="search-footer">#footer.search-footer {
  font-size: 13px;
        margin-top: 10px;
        background: #fafafa;
        padding: 20px 10px;
        align-items: center;
        border-top: 1px solid #ebebeb;
}

#footer.search-footer .links.search-footer > *.search-footer {
  display: inline-block;
        margin: 0 12px;
}

.layout.horizontal.search-footer,.layout.vertical.search-footer {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-footer {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-footer {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-footer {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-footer {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-footer {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-footer {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-footer {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-footer {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-footer {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-footer {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-footer {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-footer {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-footer {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-footer {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-footer {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-footer {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-footer {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-footer {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-footer {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-footer {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-footer {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-footer {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-footer {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-footer {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-footer {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-header --><style scope="search-header">search-header {
  display: block;
}

.lockup-logo.search-header,.lockup-text.search-header {
  display: inline-block;
}

.lockup-logo.search-header {
  width: 74px;
        height: 24px;
        background-image: url('https://www.gstatic.com/images/branding/googlelogo/1x/googlelogo_color_74x24dp.png');
        background-size: 74px 24px;
}

.lockup-text.search-header {
  font-family: "Product Sans", Arial, Helvetica, sans-serif;

        
        font-size: 22.1px;

        
        text-rendering: optimizeLegibility;

        
        position: relative;
        top: -6px;
        left: -5px;

        
        -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
}

.lockup-brand.search-header {
  opacity: 0.54;
}

@media (-webkit-min-device-pixel-ratio: 1.5), (min-resolution: 144dpi) {
.lockup-logo.search-header {
  background-image: url('https://www.gstatic.com/images/branding/googlelogo/2x/googlelogo_color_74x24dp.png');
}

.lockup-text.search-header {
  font-size: 21.3px;
          left: -7px;
}

}

header.search-header {
  background-color: #fafafa;
        border-bottom: 1px solid #ebebeb;
        color: #333;
        height: 60px;
        width: 100%;
        z-index: 1;
        display: block;
}

[latestStyle].search-header header.search-header {
  background-color: transparent;
}

.headerpad.search-header {
  margin-left: 16px;
}

[wide].search-header .headerpad.search-header {
  margin-left: 32px;
}

.leftheader.search-header {
  width: 322px;
}

header.search-header h1.search-header {
  display: none;
}

header.search-header h1.search-header state-modifier.search-header {
  color: #777;
        text-decoration: none;
        display: inline-block;
}

[wide].search-header header.search-header h1.search-header {
  box-sizing: border-box;
        margin: 0;
        padding: 20px 0 10px;
        font-size: 20px;
        font-weight: 400;
        white-space: nowrap;
        display: block;
}

search-box.search-header {
  height: 37px;
        padding: 0 16px;
        width: 900px;
        align-self: center;
}

.layout.horizontal.search-header,.layout.vertical.search-header {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-header {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-header {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-header {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-header {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-header {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-header {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-header {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-header {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-header {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-header {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-header {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-header {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-header {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-header {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-header {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-header {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-header {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-header {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-header {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-header {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-header {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-header {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-header {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-header {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-header {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-ui --><style scope="search-ui-0">.search-ui-0 paper-button.search-ui {
  display: inline-block;
        text-align: center;
        font-family: inherit;
}

.search-ui-0 .layout.horizontal.search-ui,.search-ui-0 .layout.vertical.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.search-ui-0 .layout.inline.search-ui {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.search-ui-0 .layout.horizontal.search-ui {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.search-ui-0 .layout.vertical.search-ui {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.search-ui-0 .layout.wrap.search-ui {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.search-ui-0 .layout.no-wrap.search-ui {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .flex.search-ui {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.search-ui-0 .flex-auto.search-ui {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.search-ui-0 .flex-none.search-ui {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.search-ui-0 .layout.start.search-ui {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.end.search-ui {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.search-ui-0 .layout.baseline.search-ui {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.search-ui-0 .layout.start-justified.search-ui {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .layout.end-justified.search-ui {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.search-ui-0 .layout.around-justified.search-ui {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.search-ui-0 .layout.justified.search-ui {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.search-ui-0 .self-start.search-ui {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.search-ui-0 .self-center.search-ui {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.search-ui-0 .self-end.search-ui {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.search-ui-0 .self-stretch.search-ui {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.search-ui-0 .self-baseline.search-ui {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.search-ui-0 .layout.start-aligned.search-ui {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.search-ui-0 .layout.end-aligned.search-ui {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.search-ui-0 .layout.center-aligned.search-ui {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.search-ui-0 .layout.between-aligned.search-ui {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.search-ui-0 .layout.around-aligned.search-ui {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.search-ui-0 {
  display: block;
        min-width: 350px;
        height: 100%;
}

.search-ui-0 #content.search-ui {
  height: 100%;
}

.search-ui-0 #leftBarOverflow.search-ui {
  padding-right: 16px;
}

.search-ui-0 [wide].search-ui #leftBarOverflow.search-ui {
  overflow: auto;
}

.search-ui-0 #leftBar.search-ui {
  box-sizing: border-box;
        color: #666;
        font-size: 13px;
        padding: 16px 0 16px 16px;
        border-bottom: 1px solid #e5e5e5;
}

.search-ui-0 [wide].search-ui #leftBar.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;

        -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
        position: relative;
        width: 350px;
        margin-bottom: 0;
        padding-bottom: 0;
        border-bottom: none;
}

@media print {
.search-ui-0 #leftBar.search-ui {
  display: none !important;
}

}

.search-ui-0 #leftBar.search-ui h3.search-ui {
  text-transform: uppercase;
        font-size: 13px;
        font-weight: normal;
        margin-top: 6px;
        margin-bottom: 6px;
        cursor: default;
        display: inline-block;
        color: #a3a3a3;
}

.search-ui-0 #closeButton.search-ui {
  position: absolute;
        right: 0;
}

.search-ui-0 #searchTermsHeader.search-ui {
  position: relative;
}

.search-ui-0 #searchTermsQ.search-ui iron-icon.search-ui {
  height: 16px;
        padding: 0 2px 2px 2px;
        color: #a3a3a3;
}

.search-ui-0 #searchTermsHeader.search-ui:hover iron-icon.search-ui {
  color: #4285f4;
}

.search-ui-0 #closeLeftBar.search-ui {
  height: 16px;
        width: 16px;
        padding: 0 0 8px 0;
        cursor: pointer;
}

.search-ui-0 #compactQuery.search-ui iron-icon.search-ui {
  height: 20px;
}

.search-ui-0 #backToResultsButton.search-ui {
  color: #fff;
        background: #4285f4;
        margin-top: 20px;
        text-align: center;
}

.search-ui-0 #main.search-ui {
  display: block;
        min-height: calc(100vh - 127px);
}

@media print {
.search-ui-0 [wide].search-ui main.search-ui {
  margin-left: 0;
}

}</style><!-- Shady DOM styles for import-list --><!-- Shady DOM styles for iron-request --><!-- Shady DOM styles for iron-ajax --><!-- Shady DOM styles for paper-dialog --><!-- Shady DOM styles for coverage-stats --><!-- Shady DOM styles for iron-image --><!-- Shady DOM styles for iron-selector --><!-- Shady DOM styles for paper-card --><!-- Shady DOM styles for paper-checkbox --><!-- Shady DOM styles for landing-page --><!-- Shady DOM styles for remote-fetch --><!-- Shady DOM styles for paper-spinner --><style scope="paper-spinner-0">.paper-spinner-0 {
  display: inline-block;
        position: relative;
        width: 28px;
        height: 28px;
}

.paper-spinner-0 #spinnerContainer.paper-spinner {
  width: 100%;
        height: 100%;

        
        direction: ltr;
}

.paper-spinner-0 #spinnerContainer.active.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite;
        animation: container-rotate-paper-spinner-0 1568ms linear infinite;
}

@-webkit-keyframes container-rotate-paper-spinner-0 {
to {
  -webkit-transform: rotate(360deg)
}

}

@keyframes container-rotate-paper-spinner-0 {
to {
  transform: rotate(360deg)
}

}

.paper-spinner-0 .spinner-layer.paper-spinner {
  position: absolute;
        width: 100%;
        height: 100%;
        opacity: 0;
        white-space: nowrap;
        color: #4285f4;
}

.paper-spinner-0 .layer-1.paper-spinner {
  color: #4285f4;
}

.paper-spinner-0 .layer-2.paper-spinner {
  color: #db4437;
}

.paper-spinner-0 .layer-3.paper-spinner {
  color: #f4b400;
}

.paper-spinner-0 .layer-4.paper-spinner {
  color: #0f9d58;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0;
        -webkit-animation-duration: 5332ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-name: fill-unfill-rotate-paper-spinner-0;
        animation-duration: 5332ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
        opacity: 1;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-1.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-2.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-3.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-4.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
}

@-webkit-keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  -webkit-transform: rotate(135deg)
}

25% {
  -webkit-transform: rotate(270deg)
}

37.5% {
  -webkit-transform: rotate(405deg)
}

50% {
  -webkit-transform: rotate(540deg)
}

62.5% {
  -webkit-transform: rotate(675deg)
}

75% {
  -webkit-transform: rotate(810deg)
}

87.5% {
  -webkit-transform: rotate(945deg)
}

to {
  -webkit-transform: rotate(1080deg)
}

}

@keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  transform: rotate(135deg)
}

25% {
  transform: rotate(270deg)
}

37.5% {
  transform: rotate(405deg)
}

50% {
  transform: rotate(540deg)
}

62.5% {
  transform: rotate(675deg)
}

75% {
  transform: rotate(810deg)
}

87.5% {
  transform: rotate(945deg)
}

to {
  transform: rotate(1080deg)
}

}

@-webkit-keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@-webkit-keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

.paper-spinner-0 .circle-clipper.paper-spinner {
  display: inline-block;
        position: relative;
        width: 50%;
        height: 100%;
        overflow: hidden;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after {
  left: 45%;
        width: 10%;
        border-top-style: solid;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after,.paper-spinner-0 .circle-clipper.paper-spinner::after {
  content: '';
        box-sizing: border-box;
        position: absolute;
        top: 0;
        border-width: 3px;
        border-radius: 50%;
}

.paper-spinner-0 .circle-clipper.paper-spinner::after {
  bottom: 0;
        width: 200%;
        border-style: solid;
        border-bottom-color: transparent !important;
}

.paper-spinner-0 .circle-clipper.left.paper-spinner::after {
  left: 0;
        border-right-color: transparent !important;
        -webkit-transform: rotate(129deg);
        transform: rotate(129deg);
}

.paper-spinner-0 .circle-clipper.right.paper-spinner::after {
  left: -100%;
        border-left-color: transparent !important;
        -webkit-transform: rotate(-129deg);
        transform: rotate(-129deg);
}

.paper-spinner-0 .active.paper-spinner .gap-patch.paper-spinner::after,.paper-spinner-0 .active.paper-spinner .circle-clipper.paper-spinner::after {
  -webkit-animation-duration: 1333ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-duration: 1333ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.left.paper-spinner::after {
  -webkit-animation-name: left-spin-paper-spinner-0;
        animation-name: left-spin-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.right.paper-spinner::after {
  -webkit-animation-name: right-spin-paper-spinner-0;
        animation-name: right-spin-paper-spinner-0;
}

@-webkit-keyframes left-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(130deg)
}

50% {
  -webkit-transform: rotate(-5deg)
}

to {
  -webkit-transform: rotate(130deg)
}

}

@keyframes left-spin-paper-spinner-0 {
0% {
  transform: rotate(130deg)
}

50% {
  transform: rotate(-5deg)
}

to {
  transform: rotate(130deg)
}

}

@-webkit-keyframes right-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(-130deg)
}

50% {
  -webkit-transform: rotate(5deg)
}

to {
  -webkit-transform: rotate(-130deg)
}

}

@keyframes right-spin-paper-spinner-0 {
0% {
  transform: rotate(-130deg)
}

50% {
  transform: rotate(5deg)
}

to {
  transform: rotate(-130deg)
}

}

.paper-spinner-0 #spinnerContainer.cooldown.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
        animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
}

@-webkit-keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}</style><!-- Shady DOM styles for paper-spinner-lite --><!-- Shady DOM styles for concept-card --><!-- Shady DOM styles for concept-mention --><style scope="concept-mention">.block.concept-mention {
  display: block;
}

[hidden].concept-mention {
  display: none !important;
}

.invisible.concept-mention {
  visibility: hidden !important;
}

.relative.concept-mention {
  position: relative;
}

.fit.concept-mention {
  position: absolute;
        top: 0;
        right: 0;
        bottom: 0;
        left: 0;
}

body.fullbleed.concept-mention {
  margin: 0;
        height: 100vh;
}

.scroll.concept-mention {
  -webkit-overflow-scrolling: touch;
        overflow: auto;
}

.fixed-bottom.concept-mention,.fixed-left.concept-mention,.fixed-right.concept-mention,.fixed-top.concept-mention {
  position: fixed;
}

.fixed-top.concept-mention {
  top: 0;
        left: 0;
        right: 0;
}

.fixed-right.concept-mention {
  top: 0;
        right: 0;
        bottom: 0;
}

.fixed-bottom.concept-mention {
  right: 0;
        bottom: 0;
        left: 0;
}

.fixed-left.concept-mention {
  top: 0;
        bottom: 0;
        left: 0;
}

#target.concept-mention:hover {
  background-color: #e8f0fe;
}

#target[noicon].concept-mention {
  padding: 1px;
}

#target.concept-mention:hover[noicon] {
  border: 1px solid #e8f0fe;
        padding: 0;
}

#target.concept-mention {
  display: inline-block;
}

.inline-icon.concept-mention {
  cursor: pointer;
        height: 12px;
        width: 12px;
        padding-left: 4px;
        color: #5e6368;
}

concept-card.concept-mention {
  z-index: 1;
        position: absolute;
}</style><!-- Shady DOM styles for fterm-concept-card --><!-- Shady DOM styles for fterm-concept-mention --><!-- Shady DOM styles for paper-fab --><!-- Shady DOM styles for paper-icon-button --><!-- Shady DOM styles for paper-icon-button-light --><!-- Shady DOM styles for classification-tree --><style scope="classification-tree">.layout.horizontal.classification-tree,.layout.vertical.classification-tree {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.classification-tree {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.classification-tree {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.classification-tree {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.classification-tree {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.classification-tree {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.classification-tree {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.classification-tree {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.classification-tree {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

classification-tree {
  display: block;
        line-height: 20px;
}

.wrap.classification-tree {
  padding: 6px 12px;
}

.wrap.classification-tree:hover {
  background: #fafafa;
}

.description.classification-tree {
  padding-left: 4px;
}

iron-icon.classification-tree {
  color: #eaeaea;
}

.code[first].classification-tree {
  font-weight: 500;
}

.code[additional].classification-tree {
  font-style: italic;
}</style><!-- Shady DOM styles for classification-viewer --><style scope="classification-viewer">.table.classification-viewer {
  border: 1px solid #eaeaea;
        display: block;
}

.more.classification-viewer {
  padding: 6px 12px;
        cursor: pointer;
        font-style: italic;
        color: #aaa;
}

.more.classification-viewer:hover {
  background: #fafafa;
}

.chip.classification-viewer {
  display: inline-block;
        padding: 4px 6px;
        border-radius: 2px;
}

.chip[additional].classification-viewer {
  font-style: italic;
}</style><!-- Shady DOM styles for image-carousel --><!-- Shady DOM styles for image-viewer --><!-- Shady DOM styles for patent-result --><style scope="patent-result">#wrapper.patent-result {
  padding: 20px;
        max-width: 1050px;
        outline: 0;
}

.scroll-target.patent-result:before {
  display: block;
        content: '';
        visibility: hidden;
}

h1.patent-result {
  font-weight: 500;
        font-size: 20px;
        margin: 0 0 20px 0;
}

h3.patent-result {
  font-size: 15px;
        font-weight: 500;
        margin: 28px 0 18px 0;
}

dl.patent-result {
  line-height: 1.5;
        font-size: 0;
}

dt.patent-result,dd.patent-result {
  display: inline;
        font-size: 13px;
        margin: 0;
}

dt.patent-result {
  font-weight: 500;
        color: #000;
}

dt.patent-result::after {
  content: ': ';
}

dd.patent-result {
  color: #aaa;
}

dd.patent-result ~ dd.patent-result::before {
  content: ', ';
}

dt.patent-result + dd.patent-result::before {
  content: '';
}

dd.patent-result ~ dt.patent-result::before {
  display: block;
        content: '';
        margin-top: 8px;
}

dd.patent-result core-icon.patent-result {
  width: 14px;
        height: 14px;
        vertical-align: top;
        color: inherit;
}

.table.patent-result {
  display: table;
        border-collapse: collapse;
        border-spacing: 0;
        border: 1px solid #eaeaea;
        width: 100%;
        box-sizing: border-box;
}

.tr.patent-result {
  display: table-row;
        border-bottom: 1px solid #eaeaea;
}

.th.patent-result,.td.patent-result {
  display: table-cell;
        padding: 10px 12px;
}

.thead.patent-result {
  display: table-header-group;
}

.tbody.patent-result {
  display: table-row-group;
}

.th.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.td.patent-result {
  vertical-align: top;
}

.td.patent-result > p.patent-result {
  margin-top: 0;
}

.nowrap.patent-result {
  white-space: nowrap;
}

.knowledge-card.patent-result {
  border: 1px solid #e5e5e5;
        border-radius: 2px;
}

.knowledge-card.patent-result > header.patent-result {
  -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
        background: #4285f4;
        color: #fff;
        padding: 20px 12px;
}

.knowledge-card.patent-result > header.patent-result state-modifier.patent-result,.knowledge-card.patent-result > header.patent-result a.patent-result {
  color: inherit;
        margin: 0 12px 0 0;
        display: inline-block;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result,.knowledge-card.patent-result > header.patent-result .tagline.patent-result {
  margin: 0;
        font-weight: normal;
        padding-top: 4px;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result {
  font-size: 20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result {
  background: #3367d6;
        padding: 10px 12px;
        margin: 20px -12px -20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result core-icon.patent-result {
  margin-right: 12px;
        width: 24px;
        height: 24px;
}

.knowledge-card.patent-result dl.patent-result {
  padding: 16px 12px;
}

.knowledge-card.patent-result hr.patent-result {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 0;
}

.main-link.patent-result {
  margin: 14px;
        font-weight: 500;
}

.footer.patent-result h3.patent-result state-modifier.patent-result,.footer.patent-result h3.patent-result a.patent-result {
  float: right;
        font-weight: 400;
        font-size: 13px;
        line-height: 24px;
}

.footer.patent-result dl.patent-result {
  margin-left: 30px;
}

.footer.patent-result > ul.patent-result > li.patent-result {
  margin-bottom: 8px;
}

h3.patent-result .righthead.patent-result {
  color: #aaa;
        font-weight: 400;
        font-size: 13px;
        cursor: help;
}

.tooltip-hint.patent-result {
  border-bottom: 1px dotted #ccc;
}

[marginRight].patent-result {
  margin-right: 60px;
}

.flex-width.patent-result {
  min-width: 0;
        word-break: break-word;
}

.responsive-table.patent-result {
  width: 100%;
        overflow-x: auto;
        overflow-y: hidden;
}

.layout.horizontal.patent-result,.layout.vertical.patent-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.flex.patent-result,.flex-1.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-2.patent-result {
  -ms-flex: 2;
        -webkit-flex: 2;
        flex: 2;
}

.flex-3.patent-result {
  -ms-flex: 3;
        -webkit-flex: 3;
        flex: 3;
}

.flex-4.patent-result {
  -ms-flex: 4;
        -webkit-flex: 4;
        flex: 4;
}

.flex-5.patent-result {
  -ms-flex: 5;
        -webkit-flex: 5;
        flex: 5;
}

.flex-6.patent-result {
  -ms-flex: 6;
        -webkit-flex: 6;
        flex: 6;
}

.flex-7.patent-result {
  -ms-flex: 7;
        -webkit-flex: 7;
        flex: 7;
}

.flex-8.patent-result {
  -ms-flex: 8;
        -webkit-flex: 8;
        flex: 8;
}

.flex-9.patent-result {
  -ms-flex: 9;
        -webkit-flex: 9;
        flex: 9;
}

.flex-10.patent-result {
  -ms-flex: 10;
        -webkit-flex: 10;
        flex: 10;
}

.flex-11.patent-result {
  -ms-flex: 11;
        -webkit-flex: 11;
        flex: 11;
}

.flex-12.patent-result {
  -ms-flex: 12;
        -webkit-flex: 12;
        flex: 12;
}

@media print {
#text.patent-result {
  flex-direction: column-reverse !important;
}

}

patent-result-ref-list.patent-result {
  width: 100%;
}

patent-result-ref-list.patent-result + patent-result-ref-list.patent-result {
  margin-left: 10px;
}

[narrow].patent-result {
  flex-direction: column-reverse !important;
}

.famheader.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.collapse.patent-result {
  color: #616161;
        font-size: 13px;
        cursor: pointer;
}

#imageDrag.patent-result {
  position: fixed;
        cursor: col-resize;
}

#imageDrag.patent-result div.patent-result {
  width: 4px;
        height: 100%;
        margin: 0 4px;
        background: #eee;
}

#imageDrag.patent-result:hover {
  background: #eee;
}

#imageDrag.patent-result:hover div.patent-result {
  background: #ccc;
}

.imageWrapper.patent-result {
  position: fixed;
        top: 60px;
        background: white;
        margin-left: 12px;
}

#notices.patent-result {
  padding: 20px;
}

#figures.patent-result {
  background: #efefef;
}

.headerButton.patent-result {
  color: #3c80f6;
        cursor: pointer;
        display: inline-block;
        padding: 0 14px;
        line-height: 27px;
}

.headerButton.patent-result iron-icon.patent-result {
  width: 16px;
        height: 16px;
}

.tr.conceptDomain.patent-result {
  display: table-row;
}

.responsive-grid.patent-result {
  display: grid;
        gap: 8px;
        grid-template-columns: none;
}</style><!-- Shady DOM styles for family-viewer --><!-- Shady DOM styles for app-row --><!-- Shady DOM styles for application-timeline --><style scope="application-timeline">.layout.horizontal.application-timeline,.layout.vertical.application-timeline {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.application-timeline {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.application-timeline {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.application-timeline {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.application-timeline {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.application-timeline {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.application-timeline {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.application-timeline {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.application-timeline {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.wrap.application-timeline {
  padding: 16px 12px;
}

.event.application-timeline {
  padding: 3px 0;
}

[date].application-timeline {
  color: #5f6368;
        font-size: 13px;
        padding: 3px 0;
        width: 70px;
        line-height: 16px;
}

[critical].application-timeline [date].application-timeline {
  color: #202124;
        font-weight: 500;
        line-height: 18px;
}

.line.application-timeline {
  margin: 9px 6px;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
}

.dot.application-timeline {
  margin: 3px 0;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
        display: inline-block;
}

[critical].application-timeline .line.application-timeline {
  background: #4285f4;
}

[current].application-timeline .line.application-timeline {
  background: #81c995;
}

[current][critical].application-timeline .line.application-timeline {
  background: #81c995;
}

.title.application-timeline {
  font-size: 13px;
        padding: 3px 0;
        line-height: 16px;
}

.title-text.application-timeline {
  color: #5f6368;
}

.description-item.application-timeline {
  font-size: 12px;
        padding: 6px 0;
        max-width: 300px;
}

#legal.application-timeline {
  height: 14px;
        width: 14px;
        padding: 0 3px 1px 3px;
        vertical-align: text-bottom;
}

#icon.application-timeline {
  height: 12px;
        width: 12px;
        padding: 0 3px 3px 3px;
        vertical-align: text-bottom;
}

.unknown.application-timeline {
  font-style: italic;
}

.not_active.application-timeline {
  text-decoration: line-through;
}

.active.application-timeline {
  font-weight: 500;
}

#cc[this].application-timeline {
  color: #202124 !important;
        text-decoration: underline;
}

#cc[this].not_active.application-timeline {
  text-decoration: line-through underline;
}

hr.application-timeline {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 10px 0 16px 0;
}

.header.application-timeline {
  font-size: 13px;
        line-height: 20px;
        font-weight: 500;
        color: #202124;
        padding-bottom: 8px;
}

.block.application-timeline {
  padding: 0 6px 0 0;
}

.year.application-timeline {
  color: #5f6368;
        font-size: 13px;
        font-weight: 500;
        padding: 3px 1px;
        width: 70px;
}

.expand.application-timeline {
  cursor: pointer;
        padding: 6px 0 3px 0;
}</style><!-- Shady DOM styles for patent-text --><style scope="patent-text">.layout.horizontal.patent-text,.layout.vertical.patent-text {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-text {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-text {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-text {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-text {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-text {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-text {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-text {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-text {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-text {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-text {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-text {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-text {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-text {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-text {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-text {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-text {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-text {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-text {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-text {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-text {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-text {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-text {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-text {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-text {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-text {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

patent-text {
  display: block;
}

#text.patent-text {
  line-height: 20px;
        min-width: 0;
}

#margin.patent-text {
  width: 16px;
}

#createHighlight.patent-text {
  position: relative;
        width: 16px;
        height: 16px;
        cursor: pointer;
}

.notranslate.patent-text > .google-src-text.patent-text {
  display: none;
}

.notranslate.patent-text:hover,mark.patent-text {
  background-color: #fbfcae;
}

.description-paragraph.patent-text {
  margin-block-start: 1em;
        margin-block-end: 1em;
}

.claim-text.patent-text {
  margin: 14px 0 0 20px;
}

.claim-dependent.patent-text {
  margin-left: 40px;
        color: #888;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim-text.patent-text {
  height: 0;
        width: 0;
        visibility: hidden;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim.patent-text:after {
  content: "…"
}

.patent-full-image.patent-text {
  max-width: 100%;
        height: auto;
}

.small-patent-image.patent-text {
  display: inline;
}

ul.patent-text {
  padding: 0 0 0 50px;
}

li.patent-text {
  list-style-type: none;
        position: relative;
}

ol.claims.patent-text li.patent-text {
  list-style-type: decimal;
        font-weight: bold;
}

ol.claims.patent-text li.patent-text > *.patent-text {
  font-weight: normal;
}

li.patent-text > para-num.patent-text {
  position: absolute;
        left: -45px;
        color: #888;
}

mark.patent-text {
  background: #fff59d;
}

mark.searchText.patent-text {
  background: #80deea;
}

.searchTextHeader.patent-text {
  font-weight: 500;
}

pre.patent-text {
  white-space: pre-wrap;
}

heading.patent-text {
  display: block;
        font-weight: 500;
        font-size: 13px;
}

#comment.patent-text {
  width: 16px;
        height: 16px;
}

[has-search][no-results].patent-text {
  display: none;
}

.highlight.patent-text {
  background-color: #fef7e0;
}</style><!-- Shady DOM styles for para-num --><!-- Shady DOM styles for result-container --><style scope="result-container">paper-spinner.result-container {
  position: absolute;
        
        top: calc(50%  + 56px - 16px);
        left: calc(50% + 175px - 16px);
}</style><!-- Shady DOM styles for scholar-result --><!-- Shady DOM styles for search-result --><style scope="search-result">.layout.horizontal.search-result,.layout.vertical.search-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

search-result {
  display: block;
        font-size: 13px;
}

#mainContainer.search-result {
  min-height: calc(100vh - 127px);
        color: #333;
}

#compactQuery.search-result {
  padding: 18px 20px 10px 20px;
        cursor: pointer;
}

#compactQuery.search-result > span.search-result {
  padding: 0 14px 0 0;
}

#compactQuery.search-result iron-icon.search-result {
  padding-right: 6px;
        height: 16px;
        width: 16px;
}</style><!-- Shady DOM styles for webdoc-result --><!-- Shady DOM styles for iron-pages --><!-- Shady DOM styles for paper-tab --><!-- Shady DOM styles for paper-tabs --><!-- Shady DOM styles for debug-info --><!-- Shady DOM styles for search-paging --><!-- Shady DOM styles for search-result-item --><!-- Shady DOM styles for search-result-image --><!-- Shady DOM styles for search-result-entities --><!-- Shady DOM styles for search-result-measures --><!-- Shady DOM styles for search-results --><!-- Shady DOM styles for summary-box --><!-- Shady DOM styles for timeline-page --><!-- Shady DOM styles for iron-localstorage --><!-- Shady DOM styles for search-app --><style scope="search-app">search-app {
  display: block;
        height: 100%;
}

#toast.search-app {
  min-height: 64px;
        min-width: 742px;
}</style><style>body {transition: opacity ease-in 0.2s; } 
body[unresolved] {opacity: 0; display: block; overflow: hidden; position: relative; } 
</style>
    <title>US11370801B2 - Pyrrolobenzodiazepine conjugates 
        - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/US11370801B2/en">
    <meta name="description" content="
     A compound of formula I and salts and solvates thereof, wherein: R 6  and R 9  are independently selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, nitro, Me 3 Sn and halo; where R and R′ are independently selected from optionally substituted C 1-12  alkyl, C 3-20  heterocyclyl and C 5-20  aryl groups; R 7  is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, nitro, Me 3 Sn and halo; R″ is a C 3-12  alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, NR N2  (where R N2  is H or C 1-4  alkyl), and/or aromatic rings, e.g. benzene or pyridine; Y and Y′ are selected from O, S, or NH; R 6 , R 7 , R 9  are selected from the same groups as R 6 , R 7  and R 9  respectively; R 11b  is selected from OH, OR A , where R A  is C 1-4  alkyl; and R L  is a linker for connection to a cell binding agent. 
     
       
         
         
             
             
         
       
     
   
   ">
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="Pyrrolobenzodiazepine conjugates 
       ">
    <meta name="DC.date" content="2018-04-18" scheme="dateSubmitted">
    <meta name="DC.description" content="
     A compound of formula I and salts and solvates thereof, wherein: R 6  and R 9  are independently selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, nitro, Me 3 Sn and halo; where R and R′ are independently selected from optionally substituted C 1-12  alkyl, C 3-20  heterocyclyl and C 5-20  aryl groups; R 7  is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, nitro, Me 3 Sn and halo; R″ is a C 3-12  alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, NR N2  (where R N2  is H or C 1-4  alkyl), and/or aromatic rings, e.g. benzene or pyridine; Y and Y′ are selected from O, S, or NH; R 6 , R 7 , R 9  are selected from the same groups as R 6 , R 7  and R 9  respectively; R 11b  is selected from OH, OR A , where R A  is C 1-4  alkyl; and R L  is a linker for connection to a cell binding agent. 
     
       
         
         
             
             
         
       
     
   
   ">
    <meta name="citation_patent_application_number" content="US:16/605,962">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/9d/49/2d/c9313e48b71124/US11370801.pdf">
    <meta name="citation_patent_number" content="US:11370801">
    <meta name="DC.date" content="2022-06-28" scheme="issue">
    <meta name="DC.contributor" content="Philip Wilson Howard" scheme="inventor">
    <meta name="DC.contributor" content="Stephen John Gregson" scheme="inventor">
    <meta name="DC.contributor" content="MedImmune Ltd" scheme="assignee">
    <meta name="DC.relation" content="US:3361742" scheme="references">
    <meta name="DC.relation" content="US:3523941" scheme="references">
    <meta name="DC.relation" content="US:3524849" scheme="references">
    <meta name="DC.relation" content="FR:2027356:A1" scheme="references">
    <meta name="DC.relation" content="GB:1299198:A" scheme="references">
    <meta name="DC.relation" content="US:3794644" scheme="references">
    <meta name="DC.relation" content="US:4185016" scheme="references">
    <meta name="DC.relation" content="US:4239683" scheme="references">
    <meta name="DC.relation" content="GB:2053894:A" scheme="references">
    <meta name="DC.relation" content="US:4309437" scheme="references">
    <meta name="DC.relation" content="JP:S57131791:A" scheme="references">
    <meta name="DC.relation" content="US:4353827" scheme="references">
    <meta name="DC.relation" content="US:4382032" scheme="references">
    <meta name="DC.relation" content="US:4386028" scheme="references">
    <meta name="DC.relation" content="US:4405516" scheme="references">
    <meta name="DC.relation" content="US:4405517" scheme="references">
    <meta name="DC.relation" content="US:4407752" scheme="references">
    <meta name="DC.relation" content="JP:S58180487:A" scheme="references">
    <meta name="DC.relation" content="US:4427588" scheme="references">
    <meta name="DC.relation" content="US:4427587" scheme="references">
    <meta name="DC.relation" content="US:4701325" scheme="references">
    <meta name="DC.relation" content="US:4816567" scheme="references">
    <meta name="DC.relation" content="FR:2586683:A1" scheme="references">
    <meta name="DC.relation" content="US:5583024" scheme="references">
    <meta name="DC.relation" content="US:5674713" scheme="references">
    <meta name="DC.relation" content="US:4923984" scheme="references">
    <meta name="DC.relation" content="WO:1991002536:A1" scheme="references">
    <meta name="DC.relation" content="JP:H053790:A" scheme="references">
    <meta name="DC.relation" content="US:5792616" scheme="references">
    <meta name="DC.relation" content="WO:1992007574:A1" scheme="references">
    <meta name="DC.relation" content="WO:1992017497:A1" scheme="references">
    <meta name="DC.relation" content="US:5440021" scheme="references">
    <meta name="DC.relation" content="US:5561119" scheme="references">
    <meta name="DC.relation" content="WO:1992019620:A1" scheme="references">
    <meta name="DC.relation" content="EP:0522868:A1" scheme="references">
    <meta name="DC.relation" content="US:5854399" scheme="references">
    <meta name="DC.relation" content="US:5362852" scheme="references">
    <meta name="DC.relation" content="US:5976551" scheme="references">
    <meta name="DC.relation" content="US:6011146" scheme="references">
    <meta name="DC.relation" content="US:6153408" scheme="references">
    <meta name="DC.relation" content="WO:1993018045:A1" scheme="references">
    <meta name="DC.relation" content="US:5418241" scheme="references">
    <meta name="DC.relation" content="WO:1994010312:A1" scheme="references">
    <meta name="DC.relation" content="US:5644033" scheme="references">
    <meta name="DC.relation" content="US:5869445" scheme="references">
    <meta name="DC.relation" content="US:6214345" scheme="references">
    <meta name="DC.relation" content="WO:1994028931:A1" scheme="references">
    <meta name="DC.relation" content="WO:1995004718:A1" scheme="references">
    <meta name="DC.relation" content="US:5773223" scheme="references">
    <meta name="DC.relation" content="US:5621002" scheme="references">
    <meta name="DC.relation" content="US:6518404" scheme="references">
    <meta name="DC.relation" content="US:20030109676:A1" scheme="references">
    <meta name="DC.relation" content="WO:1996030514:A1" scheme="references">
    <meta name="DC.relation" content="US:5700670" scheme="references">
    <meta name="DC.relation" content="US:20020193567:A1" scheme="references">
    <meta name="DC.relation" content="WO:1997007198:A2" scheme="references">
    <meta name="DC.relation" content="EP:1295944:A2" scheme="references">
    <meta name="DC.relation" content="US:6218519" scheme="references">
    <meta name="DC.relation" content="WO:1997044452:A1" scheme="references">
    <meta name="DC.relation" content="WO:1998013059:A1" scheme="references">
    <meta name="DC.relation" content="US:6759509" scheme="references">
    <meta name="DC.relation" content="WO:1998037193:A1" scheme="references">
    <meta name="DC.relation" content="US:20030185830:A1" scheme="references">
    <meta name="DC.relation" content="US:20030157089:A1" scheme="references">
    <meta name="DC.relation" content="WO:1998040403:A1" scheme="references">
    <meta name="DC.relation" content="US:20010055751:A1" scheme="references">
    <meta name="DC.relation" content="US:20030105292:A1" scheme="references">
    <meta name="DC.relation" content="US:6555339" scheme="references">
    <meta name="DC.relation" content="EP:0875569:A1" scheme="references">
    <meta name="DC.relation" content="WO:1998051824:A1" scheme="references">
    <meta name="DC.relation" content="WO:1998051805:A1" scheme="references">
    <meta name="DC.relation" content="US:20040018553:A1" scheme="references">
    <meta name="DC.relation" content="US:6602677" scheme="references">
    <meta name="DC.relation" content="US:20030060612:A1" scheme="references">
    <meta name="DC.relation" content="US:20020034749:A1" scheme="references">
    <meta name="DC.relation" content="WO:1999028468:A1" scheme="references">
    <meta name="DC.relation" content="WO:1999046284:A2" scheme="references">
    <meta name="DC.relation" content="WO:1999058658:A2" scheme="references">
    <meta name="DC.relation" content="US:6534482" scheme="references">
    <meta name="DC.relation" content="US:20030064397:A1" scheme="references">
    <meta name="DC.relation" content="US:6835807" scheme="references">
    <meta name="DC.relation" content="WO:2000003291:A1" scheme="references">
    <meta name="DC.relation" content="WO:2000012509:A2" scheme="references">
    <meta name="DC.relation" content="WO:2000012508:A2" scheme="references">
    <meta name="DC.relation" content="WO:2000012507:A2" scheme="references">
    <meta name="DC.relation" content="US:20030195196:A1" scheme="references">
    <meta name="DC.relation" content="US:7704924" scheme="references">
    <meta name="DC.relation" content="US:6747144" scheme="references">
    <meta name="DC.relation" content="WO:2000012130:A1" scheme="references">
    <meta name="DC.relation" content="US:6562806" scheme="references">
    <meta name="DC.relation" content="US:20040198722:A1" scheme="references">
    <meta name="DC.relation" content="US:6608192" scheme="references">
    <meta name="DC.relation" content="WO:2000012506:A2" scheme="references">
    <meta name="DC.relation" content="US:7049311" scheme="references">
    <meta name="DC.relation" content="US:7067511" scheme="references">
    <meta name="DC.relation" content="US:7265105" scheme="references">
    <meta name="DC.relation" content="WO:2000014228:A1" scheme="references">
    <meta name="DC.relation" content="WO:2000020579:A1" scheme="references">
    <meta name="DC.relation" content="WO:2000022129:A1" scheme="references">
    <meta name="DC.relation" content="WO:2000032752:A1" scheme="references">
    <meta name="DC.relation" content="US:20030124140:A1" scheme="references">
    <meta name="DC.relation" content="WO:2000036107:A2" scheme="references">
    <meta name="DC.relation" content="US:20030065143:A1" scheme="references">
    <meta name="DC.relation" content="WO:2000040614:A2" scheme="references">
    <meta name="DC.relation" content="WO:2000044899:A1" scheme="references">
    <meta name="DC.relation" content="WO:2000053216:A2" scheme="references">
    <meta name="DC.relation" content="WO:2000055351:A1" scheme="references">
    <meta name="DC.relation" content="US:20030119122:A1" scheme="references">
    <meta name="DC.relation" content="US:6268488" scheme="references">
    <meta name="DC.relation" content="US:6677435" scheme="references">
    <meta name="DC.relation" content="WO:2000075655:A1" scheme="references">
    <meta name="DC.relation" content="WO:2001000244:A2" scheme="references">
    <meta name="DC.relation" content="US:20030062401:A1" scheme="references">
    <meta name="DC.relation" content="US:20030119128:A1" scheme="references">
    <meta name="DC.relation" content="US:20030119129:A1" scheme="references">
    <meta name="DC.relation" content="US:20030119130:A1" scheme="references">
    <meta name="DC.relation" content="WO:2001016104:A1" scheme="references">
    <meta name="DC.relation" content="US:6909006" scheme="references">
    <meta name="DC.relation" content="WO:2001016318:A2" scheme="references">
    <meta name="DC.relation" content="US:20030129192:A1" scheme="references">
    <meta name="DC.relation" content="US:20030232056:A1" scheme="references">
    <meta name="DC.relation" content="US:20030206918:A1" scheme="references">
    <meta name="DC.relation" content="US:20030165504:A1" scheme="references">
    <meta name="DC.relation" content="WO:2001040309:A2" scheme="references">
    <meta name="DC.relation" content="WO:2001038490:A2" scheme="references">
    <meta name="DC.relation" content="WO:2001040269:A2" scheme="references">
    <meta name="DC.relation" content="US:20040101899:A1" scheme="references">
    <meta name="DC.relation" content="WO:2001041787:A1" scheme="references">
    <meta name="DC.relation" content="WO:2001046232:A2" scheme="references">
    <meta name="DC.relation" content="WO:2001046261:A1" scheme="references">
    <meta name="DC.relation" content="US:20040005320:A1" scheme="references">
    <meta name="DC.relation" content="WO:2001048204:A1" scheme="references">
    <meta name="DC.relation" content="US:20020042366:A1" scheme="references">
    <meta name="DC.relation" content="WO:2001045746:A2" scheme="references">
    <meta name="DC.relation" content="US:20030119131:A1" scheme="references">
    <meta name="DC.relation" content="WO:2001053463:A2" scheme="references">
    <meta name="DC.relation" content="WO:2001057188:A2" scheme="references">
    <meta name="DC.relation" content="US:20030186372:A1" scheme="references">
    <meta name="DC.relation" content="US:20030219806:A1" scheme="references">
    <meta name="DC.relation" content="WO:2001062794:A2" scheme="references">
    <meta name="DC.relation" content="WO:2001066689:A2" scheme="references">
    <meta name="DC.relation" content="WO:2001072962:A2" scheme="references">
    <meta name="DC.relation" content="WO:2001072830:A2" scheme="references">
    <meta name="DC.relation" content="WO:2001075177:A2" scheme="references">
    <meta name="DC.relation" content="WO:2001077172:A2" scheme="references">
    <meta name="DC.relation" content="WO:2001088133:A2" scheme="references">
    <meta name="DC.relation" content="WO:2001090304:A2" scheme="references">
    <meta name="DC.relation" content="WO:2001094641:A2" scheme="references">
    <meta name="DC.relation" content="WO:2001098351:A2" scheme="references">
    <meta name="DC.relation" content="WO:2002002624:A2" scheme="references">
    <meta name="DC.relation" content="WO:2002002587:A1" scheme="references">
    <meta name="DC.relation" content="WO:2002002634:A2" scheme="references">
    <meta name="DC.relation" content="WO:2002006339:A2" scheme="references">
    <meta name="DC.relation" content="WO:2002006317:A2" scheme="references">
    <meta name="DC.relation" content="US:20040044179:A1" scheme="references">
    <meta name="DC.relation" content="WO:2002010187:A1" scheme="references">
    <meta name="DC.relation" content="WO:2002010382:A2" scheme="references">
    <meta name="DC.relation" content="WO:2002012341:A2" scheme="references">
    <meta name="DC.relation" content="WO:2002013847:A2" scheme="references">
    <meta name="DC.relation" content="WO:2002014503:A2" scheme="references">
    <meta name="DC.relation" content="WO:2002016413:A2" scheme="references">
    <meta name="DC.relation" content="WO:2002016429:A2" scheme="references">
    <meta name="DC.relation" content="WO:2002022660:A2" scheme="references">
    <meta name="DC.relation" content="US:20030186373:A1" scheme="references">
    <meta name="DC.relation" content="WO:2002022153:A2" scheme="references">
    <meta name="DC.relation" content="WO:2002022636:A1" scheme="references">
    <meta name="DC.relation" content="US:20030119121:A1" scheme="references">
    <meta name="DC.relation" content="WO:2002022808:A2" scheme="references">
    <meta name="DC.relation" content="WO:2002024909:A2" scheme="references">
    <meta name="DC.relation" content="US:6660742" scheme="references">
    <meta name="DC.relation" content="US:20040005598:A1" scheme="references">
    <meta name="DC.relation" content="WO:2002026822:A2" scheme="references">
    <meta name="DC.relation" content="WO:2002030268:A2" scheme="references">
    <meta name="DC.relation" content="WO:2002038766:A2" scheme="references">
    <meta name="DC.relation" content="US:20020150573:A1" scheme="references">
    <meta name="DC.relation" content="US:20040018194:A1" scheme="references">
    <meta name="DC.relation" content="WO:2002061087:A2" scheme="references">
    <meta name="DC.relation" content="WO:2002054940:A2" scheme="references">
    <meta name="DC.relation" content="US:20030119125:A1" scheme="references">
    <meta name="DC.relation" content="US:20030119126:A1" scheme="references">
    <meta name="DC.relation" content="US:20030118592:A1" scheme="references">
    <meta name="DC.relation" content="WO:2002059377:A2" scheme="references">
    <meta name="DC.relation" content="WO:2002060317:A2" scheme="references">
    <meta name="DC.relation" content="WO:2002064798:A1" scheme="references">
    <meta name="DC.relation" content="US:20040052793:A1" scheme="references">
    <meta name="DC.relation" content="WO:2002072596:A1" scheme="references">
    <meta name="DC.relation" content="WO:2002071928:A2" scheme="references">
    <meta name="DC.relation" content="US:20040121940:A1" scheme="references">
    <meta name="DC.relation" content="US:7223837" scheme="references">
    <meta name="DC.relation" content="WO:2002078524:A2" scheme="references">
    <meta name="DC.relation" content="US:6362331" scheme="references">
    <meta name="DC.relation" content="WO:2002081646:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003008537:A2" scheme="references">
    <meta name="DC.relation" content="US:20040005538:A1" scheme="references">
    <meta name="DC.relation" content="WO:2002083866:A2" scheme="references">
    <meta name="DC.relation" content="WO:2002086443:A2" scheme="references">
    <meta name="DC.relation" content="WO:2002088170:A2" scheme="references">
    <meta name="DC.relation" content="WO:2002088172:A2" scheme="references">
    <meta name="DC.relation" content="WO:2002089747:A2" scheme="references">
    <meta name="DC.relation" content="WO:2002092836:A2" scheme="references">
    <meta name="DC.relation" content="WO:2002094852:A2" scheme="references">
    <meta name="DC.relation" content="US:20040044180:A1" scheme="references">
    <meta name="DC.relation" content="US:20030096961:A1" scheme="references">
    <meta name="DC.relation" content="WO:2003000842:A2" scheme="references">
    <meta name="DC.relation" content="WO:2002098358:A2" scheme="references">
    <meta name="DC.relation" content="WO:2002099074:A2" scheme="references">
    <meta name="DC.relation" content="WO:2002099122:A1" scheme="references">
    <meta name="DC.relation" content="WO:2002101075:A2" scheme="references">
    <meta name="DC.relation" content="US:20040005563:A1" scheme="references">
    <meta name="DC.relation" content="WO:2002102235:A2" scheme="references">
    <meta name="DC.relation" content="US:20030091580:A1" scheme="references">
    <meta name="DC.relation" content="WO:2003004989:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003002717:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003004529:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003003906:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003003984:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003055439:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003009814:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003014294:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003016475:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003016494:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003018621:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003029262:A2" scheme="references">
    <meta name="DC.relation" content="US:20030124579:A1" scheme="references">
    <meta name="DC.relation" content="WO:2003022995:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003023013:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003025138:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003024392:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003025228:A1" scheme="references">
    <meta name="DC.relation" content="WO:2003025148:A2" scheme="references">
    <meta name="DC.relation" content="US:20030096743:A1" scheme="references">
    <meta name="DC.relation" content="US:20030130189:A1" scheme="references">
    <meta name="DC.relation" content="WO:2003026577:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003026493:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003029277:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003029421:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003034984:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003035846:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003055443:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003077836:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003042661:A2" scheme="references">
    <meta name="DC.relation" content="US:20030232350:A1" scheme="references">
    <meta name="DC.relation" content="WO:2003043583:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003045422:A1" scheme="references">
    <meta name="DC.relation" content="EP:2298817:A1" scheme="references">
    <meta name="DC.relation" content="WO:2003048202:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003054152:A2" scheme="references">
    <meta name="DC.relation" content="US:20030175775:A1" scheme="references">
    <meta name="DC.relation" content="US:20030134790:A1" scheme="references">
    <meta name="DC.relation" content="WO:2003060612:A1" scheme="references">
    <meta name="DC.relation" content="WO:2003062401:A2" scheme="references">
    <meta name="DC.relation" content="US:20030143557:A1" scheme="references">
    <meta name="DC.relation" content="WO:2003072036:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003072035:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003083047:A2" scheme="references">
    <meta name="DC.relation" content="US:6660856" scheme="references">
    <meta name="DC.relation" content="WO:2004000997:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003081210:A2" scheme="references">
    <meta name="DC.relation" content="EP:1347046:A1" scheme="references">
    <meta name="DC.relation" content="WO:2003083041:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003089624:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003083074:A2" scheme="references">
    <meta name="DC.relation" content="US:20030194704:A1" scheme="references">
    <meta name="DC.relation" content="WO:2003087306:A2" scheme="references">
    <meta name="DC.relation" content="US:20040101874:A1" scheme="references">
    <meta name="DC.relation" content="WO:2003087768:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003088808:A2" scheme="references">
    <meta name="DC.relation" content="US:20030228319:A1" scheme="references">
    <meta name="DC.relation" content="WO:2003089904:A2" scheme="references">
    <meta name="DC.relation" content="WO:2004042346:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003093444:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003097803:A2" scheme="references">
    <meta name="DC.relation" content="US:20030224454:A1" scheme="references">
    <meta name="DC.relation" content="WO:2003101400:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003101283:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003104275:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003104270:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003104399:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003105758:A2" scheme="references">
    <meta name="DC.relation" content="US:20040249130:A1" scheme="references">
    <meta name="DC.relation" content="US:20040022727:A1" scheme="references">
    <meta name="DC.relation" content="WO:2004000221:A2" scheme="references">
    <meta name="DC.relation" content="WO:2004001004:A2" scheme="references">
    <meta name="DC.relation" content="US:20040001827:A1" scheme="references">
    <meta name="DC.relation" content="WO:2004005598:A1" scheme="references">
    <meta name="DC.relation" content="WO:2004009622:A2" scheme="references">
    <meta name="DC.relation" content="WO:2004011611:A2" scheme="references">
    <meta name="DC.relation" content="WO:2004032828:A2" scheme="references">
    <meta name="DC.relation" content="US:20080213289:A1" scheme="references">
    <meta name="DC.relation" content="EP:1394274:A2" scheme="references">
    <meta name="DC.relation" content="WO:2004015426:A1" scheme="references">
    <meta name="DC.relation" content="WO:2004016225:A2" scheme="references">
    <meta name="DC.relation" content="WO:2004020583:A2" scheme="references">
    <meta name="DC.relation" content="WO:2004020595:A2" scheme="references">
    <meta name="DC.relation" content="US:20050271615:A1" scheme="references">
    <meta name="DC.relation" content="WO:2004022778:A1" scheme="references">
    <meta name="DC.relation" content="WO:2004022709:A2" scheme="references">
    <meta name="DC.relation" content="WO:2004040000:A2" scheme="references">
    <meta name="DC.relation" content="WO:2004027049:A2" scheme="references">
    <meta name="DC.relation" content="JP:2004113151:A" scheme="references">
    <meta name="DC.relation" content="WO:2004031238:A2" scheme="references">
    <meta name="DC.relation" content="WO:2004032842:A2" scheme="references">
    <meta name="DC.relation" content="US:20040138269:A1" scheme="references">
    <meta name="DC.relation" content="WO:2004043361:A2" scheme="references">
    <meta name="DC.relation" content="WO:2004044178:A2" scheme="references">
    <meta name="DC.relation" content="US:7407951" scheme="references">
    <meta name="DC.relation" content="US:20060116422:A1" scheme="references">
    <meta name="DC.relation" content="WO:2004043963:A1" scheme="references">
    <meta name="DC.relation" content="WO:2004045553:A2" scheme="references">
    <meta name="DC.relation" content="WO:2004045520:A2" scheme="references">
    <meta name="DC.relation" content="WO:2004045516:A2" scheme="references">
    <meta name="DC.relation" content="WO:2004046342:A2" scheme="references">
    <meta name="DC.relation" content="WO:2004047749:A2" scheme="references">
    <meta name="DC.relation" content="WO:2004048938:A2" scheme="references">
    <meta name="DC.relation" content="WO:2004053079:A2" scheme="references">
    <meta name="DC.relation" content="EP:1439393:A2" scheme="references">
    <meta name="DC.relation" content="US:20040197325:A1" scheme="references">
    <meta name="DC.relation" content="WO:2004058309:A1" scheme="references">
    <meta name="DC.relation" content="WO:2004063709:A2" scheme="references">
    <meta name="DC.relation" content="WO:2004063355:A2" scheme="references">
    <meta name="DC.relation" content="WO:2004063362:A2" scheme="references">
    <meta name="DC.relation" content="WO:2004065577:A2" scheme="references">
    <meta name="DC.relation" content="WO:2004065576:A2" scheme="references">
    <meta name="DC.relation" content="WO:2004074320:A2" scheme="references">
    <meta name="DC.relation" content="US:20030224411:A1" scheme="references">
    <meta name="DC.relation" content="US:6884799" scheme="references">
    <meta name="DC.relation" content="US:7429658" scheme="references">
    <meta name="DC.relation" content="WO:2005023814:A1" scheme="references">
    <meta name="DC.relation" content="US:20060264622:A1" scheme="references">
    <meta name="DC.relation" content="US:7511032" scheme="references">
    <meta name="DC.relation" content="US:20090149449:A1" scheme="references">
    <meta name="DC.relation" content="WO:2005042535:A1" scheme="references">
    <meta name="DC.relation" content="WO:2005040170:A2" scheme="references">
    <meta name="DC.relation" content="US:7244724" scheme="references">
    <meta name="DC.relation" content="US:20070072846:A1" scheme="references">
    <meta name="DC.relation" content="US:7498298" scheme="references">
    <meta name="DC.relation" content="WO:2005079479:A2" scheme="references">
    <meta name="DC.relation" content="WO:2005082023:A2" scheme="references">
    <meta name="DC.relation" content="US:7375078" scheme="references">
    <meta name="DC.relation" content="WO:2005085177:A2" scheme="references">
    <meta name="DC.relation" content="WO:2005085250:A1" scheme="references">
    <meta name="DC.relation" content="US:20110160192:A1" scheme="references">
    <meta name="DC.relation" content="WO:2005085251:A1" scheme="references">
    <meta name="DC.relation" content="WO:2005085259:A2" scheme="references">
    <meta name="DC.relation" content="US:20070191349:A1" scheme="references">
    <meta name="DC.relation" content="US:20070191309:A1" scheme="references">
    <meta name="DC.relation" content="US:7557099" scheme="references">
    <meta name="DC.relation" content="US:7741319" scheme="references">
    <meta name="DC.relation" content="US:20070249591:A1" scheme="references">
    <meta name="DC.relation" content="US:20070185336:A1" scheme="references">
    <meta name="DC.relation" content="WO:2005085260:A1" scheme="references">
    <meta name="DC.relation" content="US:7528126" scheme="references">
    <meta name="DC.relation" content="US:20070232592:A1" scheme="references">
    <meta name="DC.relation" content="WO:2005105113:A2" scheme="references">
    <meta name="DC.relation" content="US:8034808" scheme="references">
    <meta name="DC.relation" content="US:20110039969:A1" scheme="references">
    <meta name="DC.relation" content="US:20080090812:A1" scheme="references">
    <meta name="DC.relation" content="WO:2005110423:A2" scheme="references">
    <meta name="DC.relation" content="US:7521541" scheme="references">
    <meta name="DC.relation" content="WO:2006065533:A2" scheme="references">
    <meta name="DC.relation" content="US:20080092940:A1" scheme="references">
    <meta name="DC.relation" content="US:20080206239:A1" scheme="references">
    <meta name="DC.relation" content="US:20090148942:A1" scheme="references">
    <meta name="DC.relation" content="US:8633185" scheme="references">
    <meta name="DC.relation" content="CN:101171257:A" scheme="references">
    <meta name="DC.relation" content="US:20100113425:A1" scheme="references">
    <meta name="DC.relation" content="US:7612062" scheme="references">
    <meta name="DC.relation" content="WO:2006111759:A1" scheme="references">
    <meta name="DC.relation" content="US:8637664" scheme="references">
    <meta name="DC.relation" content="US:20080214525:A1" scheme="references">
    <meta name="DC.relation" content="US:20070154906:A1" scheme="references">
    <meta name="DC.relation" content="WO:2007039752:A1" scheme="references">
    <meta name="DC.relation" content="WO:2007044515:A1" scheme="references">
    <meta name="DC.relation" content="EP:1813614:A1" scheme="references">
    <meta name="DC.relation" content="US:20090036431:A1" scheme="references">
    <meta name="DC.relation" content="WO:2007085930:A1" scheme="references">
    <meta name="DC.relation" content="US:8163736" scheme="references">
    <meta name="DC.relation" content="WO:2008010101:A2" scheme="references">
    <meta name="DC.relation" content="US:20100047257:A1" scheme="references">
    <meta name="DC.relation" content="WO:2008022152:A2" scheme="references">
    <meta name="DC.relation" content="US:20080112961:A1" scheme="references">
    <meta name="DC.relation" content="WO:2008047242:A2" scheme="references">
    <meta name="DC.relation" content="US:20090304710:A1" scheme="references">
    <meta name="DC.relation" content="WO:2008050140:A2" scheme="references">
    <meta name="DC.relation" content="WO:2008070593:A2" scheme="references">
    <meta name="DC.relation" content="US:7723485" scheme="references">
    <meta name="DC.relation" content="WO:2009016516:A2" scheme="references">
    <meta name="DC.relation" content="US:20100316656:A1" scheme="references">
    <meta name="DC.relation" content="EP:2019104:A1" scheme="references">
    <meta name="DC.relation" content="WO:2009016647:A1" scheme="references">
    <meta name="DC.relation" content="WO:2009052249:A1" scheme="references">
    <meta name="DC.relation" content="WO:2009060215:A1" scheme="references">
    <meta name="DC.relation" content="WO:2009060208:A1" scheme="references">
    <meta name="DC.relation" content="WO:2009117531:A1" scheme="references">
    <meta name="DC.relation" content="US:8321774" scheme="references">
    <meta name="DC.relation" content="US:20090274713:A1" scheme="references">
    <meta name="DC.relation" content="US:20100028346:A1" scheme="references">
    <meta name="DC.relation" content="US:8501934" scheme="references">
    <meta name="DC.relation" content="WO:2010010347:A1" scheme="references">
    <meta name="DC.relation" content="US:8940733" scheme="references">
    <meta name="DC.relation" content="US:8487092" scheme="references">
    <meta name="DC.relation" content="US:20150111880:A1" scheme="references">
    <meta name="DC.relation" content="US:9624227" scheme="references">
    <meta name="DC.relation" content="US:20110196148:A1" scheme="references">
    <meta name="DC.relation" content="US:8592576" scheme="references">
    <meta name="DC.relation" content="US:20110201803:A1" scheme="references">
    <meta name="DC.relation" content="WO:2010043877:A1" scheme="references">
    <meta name="DC.relation" content="WO:2010043880:A1" scheme="references">
    <meta name="DC.relation" content="US:20100203007:A1" scheme="references">
    <meta name="DC.relation" content="WO:2010091150:A1" scheme="references">
    <meta name="DC.relation" content="US:20130266596:A1" scheme="references">
    <meta name="DC.relation" content="WO:2010095031:A2" scheme="references">
    <meta name="DC.relation" content="JP:5382792:B2" scheme="references">
    <meta name="DC.relation" content="US:20140155590:A1" scheme="references">
    <meta name="DC.relation" content="WO:2011023883:A1" scheme="references">
    <meta name="DC.relation" content="US:20110091372:A1" scheme="references">
    <meta name="DC.relation" content="US:20110070227:A1" scheme="references">
    <meta name="DC.relation" content="WO:2011038159:A2" scheme="references">
    <meta name="DC.relation" content="WO:2011100227:A1" scheme="references">
    <meta name="DC.relation" content="US:20110195021:A1" scheme="references">
    <meta name="DC.relation" content="US:20110195022:A1" scheme="references">
    <meta name="DC.relation" content="US:20180134717:A1" scheme="references">
    <meta name="DC.relation" content="WO:2011130615:A2" scheme="references">
    <meta name="DC.relation" content="US:20110256157:A1" scheme="references">
    <meta name="DC.relation" content="EP:2528625:A1" scheme="references">
    <meta name="DC.relation" content="US:20130028917:A1" scheme="references">
    <meta name="DC.relation" content="US:20130028919:A1" scheme="references">
    <meta name="DC.relation" content="US:20140066435:A1" scheme="references">
    <meta name="DC.relation" content="WO:2011128650:A1" scheme="references">
    <meta name="DC.relation" content="WO:2011130613:A1" scheme="references">
    <meta name="DC.relation" content="US:9732084" scheme="references">
    <meta name="DC.relation" content="US:8697688" scheme="references">
    <meta name="DC.relation" content="US:9592240" scheme="references">
    <meta name="DC.relation" content="WO:2011130616:A1" scheme="references">
    <meta name="DC.relation" content="US:8829184" scheme="references">
    <meta name="DC.relation" content="WO:2011130598:A1" scheme="references">
    <meta name="DC.relation" content="US:9242013" scheme="references">
    <meta name="DC.relation" content="WO:2011133039:A2" scheme="references">
    <meta name="DC.relation" content="US:20130137659:A1" scheme="references">
    <meta name="DC.relation" content="WO:2012014147:A1" scheme="references">
    <meta name="DC.relation" content="WO:2012064733:A2" scheme="references">
    <meta name="DC.relation" content="WO:2012128868:A1" scheme="references">
    <meta name="DC.relation" content="WO:2012112687:A1" scheme="references">
    <meta name="DC.relation" content="US:20130302359:A1" scheme="references">
    <meta name="DC.relation" content="WO:2012112708:A1" scheme="references">
    <meta name="DC.relation" content="US:20140088089:A1" scheme="references">
    <meta name="DC.relation" content="US:20120238731:A1" scheme="references">
    <meta name="DC.relation" content="US:20120233172:A1" scheme="references">
    <meta name="DC.relation" content="US:20150158869:A1" scheme="references">
    <meta name="DC.relation" content="US:9399641" scheme="references">
    <meta name="DC.relation" content="WO:2013041606:A1" scheme="references">
    <meta name="DC.relation" content="WO:2013053873:A1" scheme="references">
    <meta name="DC.relation" content="US:9399073" scheme="references">
    <meta name="DC.relation" content="US:20140302066:A1" scheme="references">
    <meta name="DC.relation" content="US:20130266595:A1" scheme="references">
    <meta name="DC.relation" content="US:20140286970:A1" scheme="references">
    <meta name="DC.relation" content="US:20140274907:A1" scheme="references">
    <meta name="DC.relation" content="US:9102704" scheme="references">
    <meta name="DC.relation" content="US:20140275522:A1" scheme="references">
    <meta name="DC.relation" content="WO:2013055987:A1" scheme="references">
    <meta name="DC.relation" content="US:20170298137:A1" scheme="references">
    <meta name="DC.relation" content="US:20170290924:A1" scheme="references">
    <meta name="DC.relation" content="WO:2013055990:A1" scheme="references">
    <meta name="DC.relation" content="US:9713647" scheme="references">
    <meta name="DC.relation" content="US:9707301" scheme="references">
    <meta name="DC.relation" content="WO:2013053871:A1" scheme="references">
    <meta name="DC.relation" content="WO:2013055993:A1" scheme="references">
    <meta name="DC.relation" content="US:9526798" scheme="references">
    <meta name="DC.relation" content="US:20140234346:A1" scheme="references">
    <meta name="DC.relation" content="WO:2013053872:A1" scheme="references">
    <meta name="DC.relation" content="US:9388187" scheme="references">
    <meta name="DC.relation" content="US:9387259" scheme="references">
    <meta name="DC.relation" content="US:20130244171:A1" scheme="references">
    <meta name="DC.relation" content="US:20150126495:A1" scheme="references">
    <meta name="DC.relation" content="US:20150133435:A1" scheme="references">
    <meta name="DC.relation" content="US:9376440" scheme="references">
    <meta name="DC.relation" content="US:9321774" scheme="references">
    <meta name="DC.relation" content="WO:2013164593:A1" scheme="references">
    <meta name="DC.relation" content="WO:2013164592:A1" scheme="references">
    <meta name="DC.relation" content="WO:2013165940:A1" scheme="references">
    <meta name="DC.relation" content="US:20130304357:A1" scheme="references">
    <meta name="DC.relation" content="WO:2013177481:A1" scheme="references">
    <meta name="DC.relation" content="WO:2014011518:A1" scheme="references">
    <meta name="DC.relation" content="WO:2014011519:A1" scheme="references">
    <meta name="DC.relation" content="US:20140030279:A1" scheme="references">
    <meta name="DC.relation" content="US:20140030280:A1" scheme="references">
    <meta name="DC.relation" content="US:9464141" scheme="references">
    <meta name="DC.relation" content="WO:2014022679:A2" scheme="references">
    <meta name="DC.relation" content="US:20150183883:A1" scheme="references">
    <meta name="DC.relation" content="WO:2014031566:A1" scheme="references">
    <meta name="DC.relation" content="US:20150273077:A1" scheme="references">
    <meta name="DC.relation" content="WO:2014057114:A1" scheme="references">
    <meta name="DC.relation" content="WO:2014057117:A1" scheme="references">
    <meta name="DC.relation" content="US:9889207" scheme="references">
    <meta name="DC.relation" content="WO:2014057074:A1" scheme="references">
    <meta name="DC.relation" content="WO:2014057120:A1" scheme="references">
    <meta name="DC.relation" content="US:9745303" scheme="references">
    <meta name="DC.relation" content="WO:2014057113:A1" scheme="references">
    <meta name="DC.relation" content="WO:2014057072:A1" scheme="references">
    <meta name="DC.relation" content="WO:2014057119:A1" scheme="references">
    <meta name="DC.relation" content="WO:2014057122:A1" scheme="references">
    <meta name="DC.relation" content="WO:2014057115:A1" scheme="references">
    <meta name="DC.relation" content="WO:2014057118:A1" scheme="references">
    <meta name="DC.relation" content="US:20150297746:A1" scheme="references">
    <meta name="DC.relation" content="US:9415117" scheme="references">
    <meta name="DC.relation" content="WO:2014057073:A1" scheme="references">
    <meta name="DC.relation" content="US:20140120118:A1" scheme="references">
    <meta name="DC.relation" content="US:20140127239:A1" scheme="references">
    <meta name="DC.relation" content="US:20150265722:A1" scheme="references">
    <meta name="DC.relation" content="US:20150273078:A1" scheme="references">
    <meta name="DC.relation" content="US:20150283258:A1" scheme="references">
    <meta name="DC.relation" content="US:20150274737:A1" scheme="references">
    <meta name="DC.relation" content="US:20150283263:A1" scheme="references">
    <meta name="DC.relation" content="US:20150283262:A1" scheme="references">
    <meta name="DC.relation" content="WO:2014080251:A1" scheme="references">
    <meta name="DC.relation" content="WO:2014096365:A1" scheme="references">
    <meta name="DC.relation" content="US:9562049" scheme="references">
    <meta name="DC.relation" content="US:20150315196:A1" scheme="references">
    <meta name="DC.relation" content="US:20150344482:A1" scheme="references">
    <meta name="DC.relation" content="WO:2014096368:A1" scheme="references">
    <meta name="DC.relation" content="WO:2014130879:A2" scheme="references">
    <meta name="DC.relation" content="US:20160015828:A1" scheme="references">
    <meta name="DC.relation" content="US:20160031887:A1" scheme="references">
    <meta name="DC.relation" content="US:20180125997:A1" scheme="references">
    <meta name="DC.relation" content="US:9649390" scheme="references">
    <meta name="DC.relation" content="WO:2014159981:A2" scheme="references">
    <meta name="DC.relation" content="US:20160144052:A1" scheme="references">
    <meta name="DC.relation" content="US:20140294868:A1" scheme="references">
    <meta name="DC.relation" content="WO:2014140174:A1" scheme="references">
    <meta name="DC.relation" content="WO:2014140862:A2" scheme="references">
    <meta name="DC.relation" content="WO:2014174111:A1" scheme="references">
    <meta name="DC.relation" content="WO:2015031693:A1" scheme="references">
    <meta name="DC.relation" content="WO:2015052333:A1" scheme="references">
    <meta name="DC.relation" content="WO:2015052535:A1" scheme="references">
    <meta name="DC.relation" content="WO:2015052334:A1" scheme="references">
    <meta name="DC.relation" content="WO:2015052321:A1" scheme="references">
    <meta name="DC.relation" content="US:20160250346:A1" scheme="references">
    <meta name="DC.relation" content="US:20160250344:A1" scheme="references">
    <meta name="DC.relation" content="US:20160250345:A1" scheme="references">
    <meta name="DC.relation" content="US:20160256561:A1" scheme="references">
    <meta name="DC.relation" content="US:20160263242:A1" scheme="references">
    <meta name="DC.relation" content="WO:2015052532:A1" scheme="references">
    <meta name="DC.relation" content="WO:2015052534:A1" scheme="references">
    <meta name="DC.relation" content="US:9956298" scheme="references">
    <meta name="DC.relation" content="WO:2015052335:A1" scheme="references">
    <meta name="DC.relation" content="WO:2015052533:A1" scheme="references">
    <meta name="DC.relation" content="WO:2015052322:A1" scheme="references">
    <meta name="DC.relation" content="WO:2015052332:A1" scheme="references">
    <meta name="DC.relation" content="US:20160310611:A1" scheme="references">
    <meta name="DC.relation" content="WO:2015095124:A1" scheme="references">
    <meta name="DC.relation" content="WO:2015112822:A1" scheme="references">
    <meta name="DC.relation" content="WO:2015159076:A1" scheme="references">
    <meta name="DC.relation" content="WO:2016037644:A1" scheme="references">
    <meta name="DC.relation" content="US:20170340752:A1" scheme="references">
    <meta name="DC.relation" content="US:20160075787:A1" scheme="references">
    <meta name="DC.relation" content="WO:2016040868:A1" scheme="references">
    <meta name="DC.relation" content="US:20170239365:A1" scheme="references">
    <meta name="DC.relation" content="WO:2016044560:A1" scheme="references">
    <meta name="DC.relation" content="US:20160074527:A1" scheme="references">
    <meta name="DC.relation" content="WO:2016053107:A1" scheme="references">
    <meta name="DC.relation" content="WO:2016166297:A1" scheme="references">
    <meta name="DC.relation" content="WO:2016166298:A1" scheme="references">
    <meta name="DC.relation" content="WO:2016166302:A1" scheme="references">
    <meta name="DC.relation" content="WO:2016166307:A1" scheme="references">
    <meta name="DC.relation" content="WO:2016166305:A1" scheme="references">
    <meta name="DC.relation" content="WO:2016166299:A1" scheme="references">
    <meta name="DC.relation" content="WO:2018069490:A1" scheme="references">
    <meta name="DC.relation" content="US:10799595" scheme="references">
    <meta name="citation_reference" content="Adair et al., “Antibody-drug conjugates—a perfect synergy,” Exp. Opin. Biol. Ther. (2012), pp. 1-16." scheme="references">
    <meta name="citation_reference" content="Adams et al., “Molecular modelling of a sequence-specific DNA-binding agent based on the pyrrolo[2,1-c][1,4]benzodiazepines,” Pharm. Pharmacol. Commun. (1999) 5:555-560." scheme="references">
    <meta name="citation_reference" content="Aird et al., “ABCB1 genetic polymorphism influences the pharmacology of the new pyrrolobenzodiazepine derivative SJG-136,” Pharmacogenomics Journal (2008) 8(4):289-296." scheme="references">
    <meta name="citation_reference" content="Alley et al., “SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross- linking agent with potent and broad spectrum antitumor activity. Part 2: Efficacy evaluations,” Cancer Res. (2004) 64:6700-6706." scheme="references">
    <meta name="citation_reference" content="Alley, M.C., “Efficacy evaluations of SJG-136 (NSC 694501), a novel pyrrolobenzodiazepine dimer with broad spectrum antitumor activity,” Proceedings of the American Association for Cancer Research Annual Meeting (Mar. 2002) 43:63." scheme="references">
    <meta name="citation_reference" content="Alley, S. C., “Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates” Bioconjugate Chem 2008, 19, 759-765." scheme="references">
    <meta name="citation_reference" content="Althius, T. H. and Hess, H. J., “Synthesis and Identification of the Major Metabolites of Prazosin Formed in Dog and Rat,” J. Medicinal Chem. (1977) 20(1):146-148." scheme="references">
    <meta name="citation_reference" content="Altuvia et al., “Ranking potential binding peptides to MHC molecules by a computational threading approach.” J. Mol. Biol., 249, 244-250 (1995)." scheme="references">
    <meta name="citation_reference" content="Amiel J., et al., “Heterozygous endothelin receptor B {EDNRB) mutations in isolated Hirschsprung disease,” Hum. Mol. Genet. 5, 355-357, 1996." scheme="references">
    <meta name="citation_reference" content="Amir et al., “Self-lmmolative Dendrimers,” (2003) Angew. Chem. Int. Ed. 42:4494-4499." scheme="references">
    <meta name="citation_reference" content="Amsberry, et al., “The Lactonization of 2'-Hydroxyhydrocinnamic Acid Amides: A Potential Prodrug for Amines,” (1990) J. Org. Chem. 55:5867-5877." scheme="references">
    <meta name="citation_reference" content="Antonow, D. et al., “Structure-activity relationships of monomeric C2-aryl pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumor agents.”J Med Chem. Apr. 8, 2010;53(7):2927-41." scheme="references">
    <meta name="citation_reference" content="Antonow, D. et al., “Synthesis of DNA-lnteractive Pyrrolo [2,1-c][1,4] benzodiazepines (PBDs)” Chemical Reviews, 2011, 111(4):2815-2864." scheme="references">
    <meta name="citation_reference" content="Antonow, D. et al.,“Parallel synthesis of a novel C2-aryl pyrrolo[2,1-c][1,4]benzodiazepine (PBD) library,” J. Comb. Chem. (2007) 9:437-445." scheme="references">
    <meta name="citation_reference" content="Arai H., et al., “Molecular cloning of human endothelin receptors and their expressiOn in vascular endothelial cells and smooth muscle cells,” Jpn. Circ. J. 56, 1303-1307, 1992." scheme="references">
    <meta name="citation_reference" content="Arai H., et al., “The Human Endotbelin-B Receptor Gene. Structural Organization and Chromosomal Assignment,” J. Biol. Chem. 268, 3463-3470, 1993." scheme="references">
    <meta name="citation_reference" content="Arima et al., “Studies on Tomaymycin, a New Antibiotic. I. Isolation and Properties of Tomaymycin,” J. Antibiotics (1972) 25:437-444." scheme="references">
    <meta name="citation_reference" content="Arnould, S., “Impact on the cell cycle and involvement of ATM, ATR, chk1 and chk2 kinases in the cytotoxicity of SJG-136, a new pyrrolobenzodiazepine dimer,” Proceedings of the American Association for Cancer Research Annual Meeting (Mar. 2004) 45:1298, Abstract No. 5618." scheme="references">
    <meta name="citation_reference" content="Arnould, S., “Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling,” Mol. Canc. Therap. 5(6):1602-1609 (2006)." scheme="references">
    <meta name="citation_reference" content="Attoe T., et al., “Mutation of the endothelin-receptor B gene in Waardenburg-Hirschsprung disease,” Hum. Mol. Genet. 4, 2407-2409, 1995." scheme="references">
    <meta name="citation_reference" content="Auricchio A., et al., “Endothelin-B receptor mutations in patients with isolated Hirschsprung disease from a non-inbred population,” Hum. Mol. Genet. 5:351-354, 1996." scheme="references">
    <meta name="citation_reference" content="Axup et al., “Synthesis of site-specific antibody-drug conjugates using unnatural amino acids.” Proc Natl Acad Sci U S A. Oct. 2, 2012; 109(40):16101-6." scheme="references">
    <meta name="citation_reference" content="Bahrenberg et al., “Reduced Expression of PSCA, a Member of the LY-6 Family of Cell Surface Antigens, in Bladder, Esophagus, and Stomach Tumors,” Biochem. Biophys. Res. Commun. (2000) 275(3):783-788." scheme="references">
    <meta name="citation_reference" content="Banker, G.S. et al., “Modern Pharmaceutics”, Third edition, Marcel Dekker, New York (1996) 451 and 596." scheme="references">
    <meta name="citation_reference" content="Barel M., et al., “Evidence for a new transcript of the Epstein-Barr virus/C3d receptor (CR2, CD21) which is due to alternative exon usage,” Mol. Immunol. 35, 1025-1031, 1998." scheme="references">
    <meta name="citation_reference" content="Barella et al., “Sequence variation of a novel heptahelical leucocyte receptor through alternative transcript formation,” (1995) Biochem. J. 309:773-779." scheme="references">
    <meta name="citation_reference" content="Barnett T., et al., “Carcinoembryonic Antigen Family: Characterization of cDNAs Coding for NCA and CEA and Suggestion of Nonrandom Sequence Variation in Their Conserved Loop-Domains,” Genomics 3, 59-66, 1988." scheme="references">
    <meta name="citation_reference" content="Batisse, et al., “A new delivery system for Auristatin in STxB-drug conjugate therapy.” European J. Medicinal Chemistry, 2015, 95: 483-491." scheme="references">
    <meta name="citation_reference" content="Beck et al., “DNA Sequence Analysis of 66 kb of the Human MHC Class II Region Encoding a Cluster of Genes for Antigen Processing,” (1992) J. Mol. Biol. 228:433-441." scheme="references">
    <meta name="citation_reference" content="Beck et al., “Evolutionary Dynamics of Non-coding Sequences Within the Class II Region of the Human MHC,” (1996) J. Mol. Biol. 25 255:1-13." scheme="references">
    <meta name="citation_reference" content="Berge et al., “Pharmaceutical Salts,” J. Pharm. Sci. (1977) 66:1-19." scheme="references">
    <meta name="citation_reference" content="Berry, J. M. et al., “Solid-phase synthesis of DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepines,” Tetrahedron Letters (2000) 41:6171-6174." scheme="references">
    <meta name="citation_reference" content="Berry, J.M. et al., “Synthesis and biological evaluation of an N10-Psec substituted pyrrolo[2,1-c][1,4]benzodiazepine prodrug,” Bioorg. Med. Chem. Lett. (2002) 12:1413-1416." scheme="references">
    <meta name="citation_reference" content="Bien &amp; Balcerska, “Serum Soluble Interleukin 2 receptor in human cancer of adults and children: a review,” Biomarkers, 2008, 13(1): 1-26." scheme="references">
    <meta name="citation_reference" content="Blanc et al., “SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies,” Clin Cancer Res., 2011, 17(20):6448-58." scheme="references">
    <meta name="citation_reference" content="Blumberg H., et al., “Interleukin 20: Discovery, Receptor Identification, and Role in Epidermal Function,” Cell 104, 9-19, 2001." scheme="references">
    <meta name="citation_reference" content="Bose et al., “New Approaches to Pyrrolo[2,1-c][1,4]benzodiazepines: Synthesis, DNA-binding and cytotoxicity of DC-81,” Tetrahedron, 48, 751-758 (1992)." scheme="references">
    <meta name="citation_reference" content="Bose, D.S. et al., “Effect of linker length on DNA-binding affinity, cross-linking efficiency and cytotoxicity of C8 linked pyrrolobenzodiazepine dimers,” J. Chem. Soc. Chem. Commun. (1992) 20:1518-1520." scheme="references">
    <meta name="citation_reference" content="Bose, D.S. et al., “Rational Design of a Highly Efficient Irreversible DNA Interstrand Cross-Linking Agent Based on the Pyrrolobenzodiazepine Ring System,” J. Am. Chem. Soc., 114, 4939-4941 (1992)." scheme="references">
    <meta name="citation_reference" content="Bourgeois C., et al., “Endothelin-1 and ETA Receptor Expression in Vascular Smooth Muscle Cells from Human Placenta: A New ETA Receptor Messenger Ribonucleic Acid Is Generated by Alternative Splicing of Exon 3,” J. Clin. Endocrinol. Metab. 82, 3116-3123, 1997." scheme="references">
    <meta name="citation_reference" content="Brand et al., Prospect for anti-HER2 receptor therapy in breast cancer. Anticancer Res. Jan.-Feb. 2006;26(1B):463-70." scheme="references">
    <meta name="citation_reference" content="Brinster et al., “Introits increase transcriptional efficiency in transgenic mice,” (1988) Proc. Natl. Acad. Sci. USA 85:836-840." scheme="references">
    <meta name="citation_reference" content="Buchman et al., “Comparison of Intron-Dependent and Intron-Independent Gene Expression,” (1988) Mol. Cell. Biol. 8:4395-4405." scheme="references">
    <meta name="citation_reference" content="Buhrow, S.A., “LC-MS/MS assay and dog pharmacokinetics of the dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501),” J. Chromat. B: Anal. Tech. Biomed. Life Sci. (2006) 840(1):56-62." scheme="references">
    <meta name="citation_reference" content="Burke, P.J. et al., “Anti-CD70 antibody-drug conjugates containing pyrrolobenzodiazepine dimers demonstrate robust antitumor activity,” AACR National Meeting, Apr. 2012, Chicago, Illinois, Abstract No. 4631." scheme="references">
    <meta name="citation_reference" content="Burke, P.J. et al., “Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system,” Bioorg. Med. Chem. Lett., Apr. 2009, 19(10):2650-2653." scheme="references">
    <meta name="citation_reference" content="Calcutt, M.W., “Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study,” J. Mass Spectrom. (2008) 43(1):42-52." scheme="references">
    <meta name="citation_reference" content="Cancer, 2012, http://wiki.answers.eom/Q/How-many-different-types of cancer are there." scheme="references">
    <meta name="citation_reference" content="Cancer2, 2012, http://en.wikipedia.org/wiki/Management of cancer." scheme="references">
    <meta name="citation_reference" content="Carl et al., “A Novel Connector Linkage Applicable in Prodrug Design,” (1981) J. Med. Chem. 24:479-480." scheme="references">
    <meta name="citation_reference" content="Carlsson et al., “Protein Thiolation and Reversible Protein-Protein Conjugation,” (1978) Biochem. J. 173:723-737." scheme="references">
    <meta name="citation_reference" content="Carter, P., “Potent antibody therapeutics by design,” (2006) Nature Reviews Immunology 6:343-357." scheme="references">
    <meta name="citation_reference" content="Casset et al., “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design.” Biochem Biophys Res Commun. Jul. 18, 2003; 307(1):198-205." scheme="references">
    <meta name="citation_reference" content="CellTiter-Glo Luminescent Cell Viability Assay, Promega Corp. Technical Bulletin TB288, dated Jan. 13, 2012 (14 pages)." scheme="references">
    <meta name="citation_reference" content="Chakravarty et al., “Plasmin-Activated Prodrugs for Cancer Chemotherapy. 2. Synthesis and Biological Activity of Peptidyl Derivatives of Doxorubicin,” (1983) J. Med. Chem. 26:638-644." scheme="references">
    <meta name="citation_reference" content="Chan, J. and Watt, V.M., “eek and erk, new members of the eph subclass of receptor protein-tyrosine kinases,” Oncogene 6 (6), 1057-1061 (1991)." scheme="references">
    <meta name="citation_reference" content="Chang et al., “Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers,” Proc. Natl. Acad. Sci. U.S.A. 93 (1):136-140 (1996)." scheme="references">
    <meta name="citation_reference" content="Chen, Z. et al., “A novel approach to the synthesis of cytotoxic C2-C3 unsaturated pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) with conjugated acrylyl C2-substituents,” Biorg. Med. Chem. Lett. (2004) 14:1547-1549." scheme="references">
    <meta name="citation_reference" content="Cheung, A., “Direct liquid chromatography determination of the reactive imine SJG-136 (NSC 694501),” J. Chromat. B: Anal. Techn. Biomed. Life Sci. (2005) 822(1-2):10-20." scheme="references">
    <meta name="citation_reference" content="Child et al., “Translational Control by an Upstream Open Reading Frame in the HER-2/neu Transcript,” (1999) J. Bioi. Chern. 274: 24335-24341." scheme="references">
    <meta name="citation_reference" content="Cho et al., “Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab,” Nature 421, 756-760, 2003." scheme="references">
    <meta name="citation_reference" content="Ciccodicola, A, et al., “Molecular characterization of a gene of the ‘EGF family’ expressed in undifferentiated human NTERA2 teratocarcinoma cells,” EMBO J. 8 (7):1987-1991 (1989)." scheme="references">
    <meta name="citation_reference" content="Cipolla, L., “Pyrrolo[2,1-c][1,4]benzodiazepine as a scaffold for the design and synthesis of anti-tumour drugs,” Anti-Cancer Agents in Medicinal Chemistry (Jan. 2009) 9(1):1-31." scheme="references">
    <meta name="citation_reference" content="Clackson et al., “Making antibody fragments using phage display libraries,” (1991) Nature, 352:624-628." scheme="references">
    <meta name="citation_reference" content="Clark H.F., et al., “The Secreted Protein Discovery Initiative (SPDI) , a Large-Scale Effort to Identify Novel Human Secreted and Transmembrane Proteins: A Bioinformatics Assessment,” Genome Res. 13, 2265-2270, 2003." scheme="references">
    <meta name="citation_reference" content="Clingen, P.H., “The role of nucleotide excision repair and homologous recomination in the sensitivity of mammalian cells to the minor groove crosslinking pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136 (NSC694501),” Proceedings of the American Association for Cancer Research Annual Meeting (Jul. 2003) 44:524." scheme="references">
    <meta name="citation_reference" content="Clingen, P.H., “the XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136,” Nucl. Acids Res. (2005) 33(10):3283-3291." scheme="references">
    <meta name="citation_reference" content="Clinical Trial, “Translational research: 4 ways to fix the clinical trial.” 2011, http://www.nature.com/news/2011/110928/full/477526a.html." scheme="references">
    <meta name="citation_reference" content="Collins, “Generation and initial analysis of more than 15,000 full-length human and mouse eDNA sequences,” Proc. Natl. Acad. Sci. U.S.A. 99 (26):16899-16903 (2002)." scheme="references">
    <meta name="citation_reference" content="Cooper, N. et al., “Synthesis of novel PBDs as anti-tumour agents,” Chem. Commun. (2002) 16:1764-1765." scheme="references">
    <meta name="citation_reference" content="Cooper, N., “Design, Synthesis and Evaluation of Novel C2-Aryl Pyrrolobenzodiazepines as Potential Anticancer Agents,” Thesis submitted to School of Pharmacy, University of London, Dated Oct. 5, 2006." scheme="references">
    <meta name="citation_reference" content="Corey et al., “LuCap35: a new model of prostate cancer progression to androgen independence.” The Prostate 2003;55:239-46." scheme="references">
    <meta name="citation_reference" content="Courtney, S. M. et al., “A new convenient procedure for the synthesis of pyrrolo[2,1-c][1,4]benzodiazepines”, Tetrahedron Letters, vol. 34, No. 33, 5327-28 (1993)." scheme="references">
    <meta name="citation_reference" content="Coussens L., et al., “Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location With neu Oncogene,” Science (1985) 230(4730):1132-1139." scheme="references">
    <meta name="citation_reference" content="Cragg et al., “The alternative transcript of CD79b is overexpressed in B-CLL and inhibits signaling for apoptosis,” Blood (2002) 100 (9):3068-3076." scheme="references">
    <meta name="citation_reference" content="Cree et al., “Methotrexate chemosensitivity by ATP luminescence in human leukemia cell lines and in breast cancer primary cultures: comparison of the TCA-100 assay with a clonogenic assay,” (1995) AntiCancer Drugs 6:398-404." scheme="references">
    <meta name="citation_reference" content="Crouch et al., “The use- of ATP bioluminescence as a measure of cell proliferation and cytotoxicity,” (1993) J. Immunol. Meth. 160:81-88." scheme="references">
    <meta name="citation_reference" content="Dall'acqua, W. F. et al., “Antibody humanization by framework shuffling” Methods, 36, 43-60 (2005)." scheme="references">
    <meta name="citation_reference" content="Dattolo, G. et al., “Polycondensed nitrogen heterocycles. IX. 5,6-dihydro-7H-pyrrolo[1,2-d][1,4]benzodiazepin-6-one,” J. Heterocyclic. Chem. (1980) 17:701-703." scheme="references">
    <meta name="citation_reference" content="Davis et al., “Identification of a family of Fe receptor homo logs with preferential B cell expression,” (2001) Proc. Natl. Acad. Sci. USA 98(17):9772-9777." scheme="references">
    <meta name="citation_reference" content="De Groot et al., “Cascade-Release Dendrimers” Liberate All End Groups upon a Single Triggering Event in the Dendritic Core, (2003) Angew. Chern. Int. Ed. 42:4490-4494." scheme="references">
    <meta name="citation_reference" content="De Groot et al., “Elongated Multiple Electronic Cascade and Cyclization Spacer Systems in Activatible Anticancer Prodrug for Enhanced Drug Release,” (2001) J. Org. Chern. 66:8815-8830." scheme="references">
    <meta name="citation_reference" content="De Pascalis et al., “Grafting of “abbreviated” complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody.” J Immunol. Sep. 15, 2002;169(6):3076-84." scheme="references">
    <meta name="citation_reference" content="Dennis et al., (2002) “Albumin Binding As A General Strategy For Improving The Pharmacokinetics Of Proteins” J Biol Chem. 277:35035-35043." scheme="references">
    <meta name="citation_reference" content="Dobner et al., “Differentiation-specific expression of a novel G protein-coupled receptor from Burkitt's lymphoma,” (1992) Eur. J. Immunol. 22:2795-2799." scheme="references">
    <meta name="citation_reference" content="Dong, Q. et al., “Reductive cleavage of TROC groups under neutral conditions with cadmium-lead couple,” Tetrahedron Lett. (1995) 36(32):5681-5682." scheme="references">
    <meta name="citation_reference" content="Dono et al., “Isolation and Characterization of the CRI PTO Autosomal Gene and Its X-linked Related Sequence,” Am. J. Hum. Genet. 49:555-565, 1991." scheme="references">
    <meta name="citation_reference" content="Dornan et al., “Therapeutic potential of an anti -CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma,” (2009) Blood 114(13):2721-2729." scheme="references">
    <meta name="citation_reference" content="Doronina et al., “Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity,” (2006) Bioconj. Chem. 17:114-124." scheme="references">
    <meta name="citation_reference" content="Doronina, S.O. et al., “Development of potent monoclonal antibody auristatin conjugates for cancer therapy,” Nature Biotech. (2003) 21:778-784." scheme="references">
    <meta name="citation_reference" content="Dorwald, F.Z., Side Reactions in Organic Synthesis: a Guide to Successful Synthesis Design, Weinheim: Wiley-VCH Verlag GmbH &amp; Co., KGaA (2005) Preface." scheme="references">
    <meta name="citation_reference" content="Doyle, M., “Response of staphylococcus aureus to subinhibitory concentrations of a sequence-selective, DNA minor groove cross-linking pyrrolobenzodiazepine dimer,” J. Antimicrob. Chemo., Aug. 2009, 64(5):949-959." scheme="references">
    <meta name="citation_reference" content="Dubowchik et al., “Cathepsin B-Labile Dipeptide Linkers for Lysosomal Release of Doxorubicin from Internalizing Immunoconjugates: Model Studies of Enzymatic Drug Release and Antigen-Specific In Vitro Anticancer Activity,” Bioconjugate Chem. (2002) 13, 855-869." scheme="references">
    <meta name="citation_reference" content="Dubowchik et al., “Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin.” Bioorg Med Chem Lett. Dec. 1, 1998; 8(23):3341-6." scheme="references">
    <meta name="citation_reference" content="Dubowchik et al., “Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin.” Bioorganic &amp; Medicinal Chemistry Letters, 8:3347-3352, (1998)." scheme="references">
    <meta name="citation_reference" content="Dubowchik et al., “Monomethoxytrityl (MMT) as a Versatile Amino Protecting Group for Complex Prodrugs of Anticancer Compounds Sensitive to Strong Acids, Bases and Nucleophiles,” (1997) Tetrahedron Letters. 38:5257-5260." scheme="references">
    <meta name="citation_reference" content="Duke, P., et al., “Characterization of Type I Receptors for Transforming Growth Factor-beta and Activin,” Science 264 (5155):101-104 (1994)." scheme="references">
    <meta name="citation_reference" content="Dumoutier L., et al., “Cutting Edge: STAT Activation By IL-19, IL-20 and mda-7 Through IL-20 Receptor Complexes of Two Types,” J. Immunol. 167, 3545-3549, 2001." scheme="references">
    <meta name="citation_reference" content="Dupont, C. et al., “Synthesis of rhazinilam analogue acting as an inhibitor of tubulin assembly,” Tetrahedron Lett. (2000) 41:5853-5856." scheme="references">
    <meta name="citation_reference" content="Ehsani A., et al., “Characterization of a New Allele of the Human ERBB2 Gene by Allele-Specific Competition Hybridization,” (1993) Genomics 15, 426-429." scheme="references">
    <meta name="citation_reference" content="Eliel et al., Stereochemistry of Organic Compounds, John Wiley &amp; Sons, Inc., New York (1994)." scheme="references">
    <meta name="citation_reference" content="Elshourbagy N.A., et al., “Molecular Characterization and Regulation of the Human Endothelin Receptors,” J. Biol. Chem. 268, 3873-3879, 1993." scheme="references">
    <meta name="citation_reference" content="Erickson et al., “Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing,” (2006) Cancer Res. 66(8): 4426-4433." scheme="references">
    <meta name="citation_reference" content="Farmer, J.D. et al., “DNA binding properties of a new class of linked anthramycin analogs,”, Chemical Abstracts, Abstract No. 239940r, vol. 114, No. 25, 25 899-903 (1991)." scheme="references">
    <meta name="citation_reference" content="Farmer, J.D. et al., “Synthesis and DNA crosslinking ability of a dimeric anthramycin analog,” Tetrahedron Letters (1988) 29(40):5105-5108, Abstract only." scheme="references">
    <meta name="citation_reference" content="Fey, T. et al., “Silica-supported TEMPO catalyst: synthesis and application in the anelli oxidation of alcohols,” J. Org. Chem. (2001) 66:8154-8159." scheme="references">
    <meta name="citation_reference" content="Field, J.A., et al., “Cloning and Functional Characterization of a Sodium-Dependent Phosphate Transporter Expressed in Human Lung and Small Intestine,” (1999) Biochem. Biophys. Res. Commun. 258 (3):578-582." scheme="references">
    <meta name="citation_reference" content="Fields, G. and Noble, R. (1990) “Solid phase peptide synthesis utilizing 9-fluoroenylmethoxycarbonyl amino acids”, Int. J. Peptide Protein Res. 35:161-214." scheme="references">
    <meta name="citation_reference" content="Firsching, A. et al., “Antiproliferative and angiostatic activity of suramin analogues,” Cancer Res. (1995) 55:4957-4961." scheme="references">
    <meta name="citation_reference" content="Flanagan et al., “The ephrins and Eph receptors in neural development,” Annu. Rev. Neurosci. 21:309-345 (1998)." scheme="references">
    <meta name="citation_reference" content="Flygare, “Antibody-drug conjugates for the treatment of cancer,” Chern. Biol. &amp; Drug Design (2013) 81(1):113-121." scheme="references">
    <meta name="citation_reference" content="Flynn et al., “Pre-Clinical Activity of Adct-301, a Novel Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies,” https://www.researchgate.net/publication/275520174." scheme="references">
    <meta name="citation_reference" content="Foloppe, M.P. et al., “DNA-binding properties of pyrrolo[2,1-c][1,4]benzodiazephine N10-C11 amidines,” Eur. J. Med. Chem., 31, 407-410 (1996)." scheme="references">
    <meta name="citation_reference" content="Fox et al., “cDNA cloning and tissue distribution of five human EPH-like receptor protein-tyrosine kinases,” Oncogene 10 (5):897-905 (1995)." scheme="references">
    <meta name="citation_reference" content="Fuchs S., et al., “Functional Characterization of Three Mutations of the Endothelin B Receptor Gene in Patients With Hirschsprung's Disease: Evidence for Selective Loss of Gi Coupling,” Mol. Med. 7, 115-124, 2001." scheme="references">
    <meta name="citation_reference" content="Fujisaku et al., “Genomic Organization and Polymorphisms of the Human C3d/Epstein-Barr Virus Receptor,” (1989) J. Biol. Chem. 264 (4):2118-2125." scheme="references">
    <meta name="citation_reference" content="Fujisawa Pharmaceutical Co. Ltd., “Benzodiazepine derivatives,” SciFinder Scholar, 2-3 (2002)." scheme="references">
    <meta name="citation_reference" content="Fujisawa Pharmaceutical Co., Ltd., Abstract No. 139983k, “Benzodiazepine derivatives”, Chemical Abstracts, vol. 99, No. 17, 603 (1983)." scheme="references">
    <meta name="citation_reference" content="Fujisawa Pharmaceutical Co., Ltd., Abstract No. 72145x, “Benzodiazepine derivatives”, Chemical Abstracts, vol. 98, No. 9, 638 (1983)." scheme="references">
    <meta name="citation_reference" content="Fukuyama, T. et al., “Total Synthesis of (+)-Porothramycin B,” Tetrahedron Letters, vol. 34, 16, 2577-2580 (1993)." scheme="references">
    <meta name="citation_reference" content="Gallmeier, E., “Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options,” Gastroenterology (2006) 130(7):2145-2154." scheme="references">
    <meta name="citation_reference" content="Gary S.C., et al., “cDNA cloning chromosomal localization, and expression analysis of human BEHAB/brevican, a brain specific proteoglycan regulated during cortical development and in glioma,” Gene 256, 139-147, 2000." scheme="references">
    <meta name="citation_reference" content="Gaugitsch, H.W., et al., “A novel transiently expressed, integral membrane protein linked to cell activation. Molecular cloning via the rapid degradation signal AUUUA.,” (1992) J. Biol. Chem. 267 (16):11267-11273." scheme="references">
    <meta name="citation_reference" content="Gavezzotti, A., “Are crystal structures predictable?” Acc. Chem. Res. (1994) 27:309-314." scheme="references">
    <meta name="citation_reference" content="Geiser et al. “Automation of solid-phase peptide synthesis” in Macromolecular Sequencing and Synthesis, Alan R. Liss, Inc., 1988, pp. 199-218." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. 11038674 (2013)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. 20 NM_006424 (2013)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. AB040878 (2001)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. AF116456 (1999)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. AF179274 (2001)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. AF229053 (2000)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. AF343662 (2001)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. AF343663 (2001)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. AF343664 (2001)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. AF343665 (2001)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. AF361486 (2003)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. AF369794 (2001)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. AF397453 (2001)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. AF455138 (2003)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. AJ297436 (2008)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. AK026467 (2006)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. AK089756 (2010)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. AK090423 (2006)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. AK090475 (2006)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. AL834187 (2008)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. AX092328 (2001)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. AY158090 (2003)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. AY260763 (2003)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. AY275463 (2003)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. AY358085 (2003)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. AY358628 (2003)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. AY358907 (2003)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. AY506558 (2004)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. BC017023 (2006)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. CAA76847.1 (2001)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. CAF85723 (2004)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. CQ782436 (2004)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. M11730 (1995)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. M18728 (1995)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. M26004 (1993)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. NM_000626 (2013)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. NM_001178098.1 (2012)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. NM_001203 (2013)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. NM_003212 (2013)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. NM_003486 (2013)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. NM_004442 (2013)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. NM_005823 (2013)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. NM_012449 (2013)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. NM_017636 (2013)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. NM_030764 (2013)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. NP 002111.1 (2013)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. NP_001171569.1 (1992)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. NP_001194 (2013)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. NP_001707.1 (2013)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. NP_001773.1 (2013)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. NP_001774.10 (2013)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. NP_002552.2 (2013)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. NP_003203 (2013)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. NP_005573.1 (2007)." scheme="references">
    <meta name="citation_reference" content="Genbank accession No. NP_112571.1 (2007)." scheme="references">
    <meta name="citation_reference" content="Geoghegan &amp; Stroh, “Site-Directed Conjugation of Nonpeptide Groups to Peptides and Proteins via Periodate Oxidation of a 2-Amino Alcohol. Application to Modification at N-Terminal Serine,” (1992) Bioconjugate Chem. 3:138-146." scheme="references">
    <meta name="citation_reference" content="Getz et al., “A Comparison between the Sulfhydryl Reductants Tris(2-carboxyethyl)phosphine and Dithiothreitol for Use in Protein Biochemistry,” (1999) Anal. Biochem. vol. 273:73-80." scheme="references">
    <meta name="citation_reference" content="Glynne-Jones et al., “TENB2, a proteogl yean identified in prostate cancer that is associated with disease progression and androgen independence,” (2001) Int J Cancer. Oct. 15; 94(2): 178-184." scheme="references">
    <meta name="citation_reference" content="Gordon et al., “Somatic hypermutation of the B cell receptor genes B29 (Igβ, CD79b) and mb1 (Igα, CD79a),” PNAS, Apr. 11, 2003, vol. 100, No. 7, 4126-4131." scheme="references">
    <meta name="citation_reference" content="Greene, T.W et al., Protective Groups in Organic Synthesis, John Wiley &amp; Sons (1999) 3rd Edition, 23-200." scheme="references">
    <meta name="citation_reference" content="Greene, T.W et al., Protective Groups in Organic Synthesis, John Wiley &amp; Sons (1999) 3rd Edition, 503-549." scheme="references">
    <meta name="citation_reference" content="Greene, T.W et al., Protective Groups in Organic Synthesis, John Wiley &amp; Sons (1999) 3rd Edition, 633-647." scheme="references">
    <meta name="citation_reference" content="Greene, T.W. and Wuts, P.G.M., Protective Groups in Organic Synthesis, John Wiley &amp; Sons, 2nd ed., Ch 7, 315-345 (1991)." scheme="references">
    <meta name="citation_reference" content="Gregson, S. et al., “Synthesis of a novel C2/C2'-exo unsaturated pyrrolobenzodiazepine cross-linking agent with remarkable DNA binding affinity and cytotoxicity,” Chemical Communications, 797-798 (1999)." scheme="references">
    <meta name="citation_reference" content="Gregson, S.J. et al., “Design, Synthesis and Evaluation of a Novel Pyrrolobenzodiazepine DNA-lnteractive Agent with Highly Efficient Cross-Linking Ability and Potent Cytotoxicity”, J. Med. Chem., 44: 737-748 (2001)." scheme="references">
    <meta name="citation_reference" content="Gregson, S.J. et al., “Effect of C2/C3-endo unsaturation on the cytotoxicity and DNA-binding reactivity of pyrrolo-[2,1-c][1,4]-benzodiazepines,” Bioorg. Med. Chem. Lett. (2000) 10(16):1849-1851." scheme="references">
    <meta name="citation_reference" content="Gregson, S.J. et al., “Effect of C2-exo Unsaturation on the Cytotoxicity and DNA-Binding Reactivity of Pyrrolo[2,1-c]1,4]benzodiazepines”, Bioorganic &amp; Medicinal Chemistry Letters, 10: 1845-1847 (2000)." scheme="references">
    <meta name="citation_reference" content="Gregson, S.J. et al., “Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8'ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers,” J. Med. Chem. (2004) 1161-1174." scheme="references">
    <meta name="citation_reference" content="Gregson, S.J. et al., “Synthesis of the first example of a C2-C3/C2'-C3'-endo unsaturated pyrrolo[2,1-c][1,4]benzodiazepine dimer,” Biorg. Med. Chem. Lett. (2001) 11:2859-2862." scheme="references">
    <meta name="citation_reference" content="Gregson, S.J. et al., “Synthesis of the first examples of A-C8/C-C2 amide-linked pyrrolo[2,1-c][1,4]benzodiazepine dimers,” Biorg. Med. Chem. Lett. (2003) 13:2277-2280." scheme="references">
    <meta name="citation_reference" content="Gu Z., et al., “Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer,” Oncogene 19, 1288-1296, 2000." scheme="references">
    <meta name="citation_reference" content="Guichard, S.M., “Influence of P-glycoprotein expression on in vitro cytotoxicity and in vivo antitumour activity of the novel pyrrolobenzodiazepine dimer SJG-136,” Eur. J. Cancer (2005) 41(12):1811-1818." scheme="references">
    <meta name="citation_reference" content="Guiotto, A. et al., “Synthesis of novel C7-aryl substituted pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) via Pro- N10-troc protection and Suzuki coupling,” Bioorganic &amp; Medicinal Chemistry Letters, 8, No. 21, 3017-3018 (1998)." scheme="references">
    <meta name="citation_reference" content="Guselnikov et al., “A family of highly diverse human and mouse genes structurally links leukocyte FcR, gp42 and PECAM-1,” Immunogenetics 54 (2):87-95 (2002)." scheme="references">
    <meta name="citation_reference" content="Ha et al., “molecular cloning and expression pattern of a human gene homologous to the murine mb-1 gene,” (1992) J. Immunol. 148(5):1526-1531." scheme="references">
    <meta name="citation_reference" content="Hadjivassileva, T., “Antibacterial activity of pyrrolobenzodiazepine dimers, a novel group of DNA-binding compounds,” Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy (Oct.-Nov. 2004) 44:202." scheme="references">
    <meta name="citation_reference" content="Hadjivassileva, T., “Interactions of pyrrolobenzodiazepine dimers and duplex DNA from methicillin-resistant staphylococcus aureus,” Int. J. Antimicrob. Agents (2007) 29(6):672-678." scheme="references">
    <meta name="citation_reference" content="Hadjivassileva, T., “Pyrrolobenzodiazepine dimers: novel sequence-selective, DNA-interactive, cross-linking agents with activity against Gram-positive bacteria,” J. Antimicrob. Chemo. (2005) 56(3):513-518." scheme="references">
    <meta name="citation_reference" content="Haendler B., et al., “Molecular Cloning of Human Endothelin (ET) Receptors ETA and Etb,” J. Cardiovasc. Pharmacal. 20, s1-S4, 1992." scheme="references">
    <meta name="citation_reference" content="Haisma et al., “Comparison of two antracycline-based prodrugs for activation by a monoclonal antibody-β-glucuronidase conjugate in the specific treatment of cancer.” Cell biophysics, Humana Press Inc. 1994, 24/25: 185-192." scheme="references">
    <meta name="citation_reference" content="Hamaguchi, A., “DNA cross-linking and in vivo antitumour activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057 (DRG-16),” EJC Supplements (Nov. 2006) 4(12):96." scheme="references">
    <meta name="citation_reference" content="Hamann P. “Monoclonal antibody-drug conjugates,” (2005) Expert Opin. Ther. Patents 15(9):1087-1103." scheme="references">
    <meta name="citation_reference" content="Hamblett et al., “Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate,” (2004) Clin. Cancer Res. 10:7063-7070." scheme="references">
    <meta name="citation_reference" content="Handbook of Food Additives, 2nd Ed. (eds. M. Ash and I. Ash), Synapse Information Resources, Inc., Endicott, New York, USA (2001)." scheme="references">
    <meta name="citation_reference" content="Handbook of Pharmaceutical Excipients, 2nd edition, 1994, Edited by Ainley Wade and Paul J. Weller." scheme="references">
    <meta name="citation_reference" content="Hara et al., “DC 102, a new glycosidic pyrrolo(1,4)benzodiazepine antibiotic produced by streptomyces sp.”, J. Antibiotics, 41, 702-704 (1988)." scheme="references">
    <meta name="citation_reference" content="Hartley J A: “The development of pyrrolobenzodiazepines as antitumour agents”, Expert Opinion on Investigational Drugs, Ashley Publications Ltd., vol. 28, No. 6, Jan. 1, 2011, pp. 733-744." scheme="references">
    <meta name="citation_reference" content="Hartley, J.A. et al., “Abstract 2856: pyrrolobenzodiazepine (PBD) dimers—potent next generation warheads in antibody drug conjugates (ADCs) targeted at both solid and haematological tumors,” Cancer Res. (2013) 78(8)Supp 1:2856." scheme="references">
    <meta name="citation_reference" content="Hartley, J.A. et al., “SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity,” Cancer Res., Sep. 2010, 70(17):6849-6858." scheme="references">
    <meta name="citation_reference" content="Hartley, J.A. et al., “SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 1: Cellular pharmacology, in vitro and initial in vivo antitumor activity,” Cancer Res. (2004) 64:6693-6699." scheme="references">
    <meta name="citation_reference" content="Hartley, J.A., “In vitro antitumor activity and in vivo DNA interstrand crosslinking by the novel pyrrolobenzodiazepine dimer SJG-136 (NSC 694501),” Proceedings of the American Association for Cancer Research Annual Meeting (Mar. 2002) 43:489." scheme="references">
    <meta name="citation_reference" content="Hartley, J.A., “SJG-136 (NSC-D694501)—a novel DNA sequence specific minor groove crosslinking agent with significant antitumor activity,” Proceedings of the American Association for Cancer Research Annual Meeting (Mar. 2000) 41:425." scheme="references">
    <meta name="citation_reference" content="Hashimoto et al., “Chromosomal localization, genomic structure, and allelic polymorphism of the human CD79a (lg-alpha/mb-1) gene,” (1994) Immunogenetics 40(4 ):287-295." scheme="references">
    <meta name="citation_reference" content="Hay et al., “A 2-nitroimidazole carbamate prodrug of 5-amin0-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-1,2-dihydr0-3h-benz[e]indole (amino-seco-cbi-tmi) for use with adept and gdept,” (1999) Bioorg. Med. Chem. Lett. 9:2237-2242." scheme="references">
    <meta name="citation_reference" content="Herdwijn et al., “Synthesis of trans(+ )6-phenoxyacetamido-1-methylene-3,3-dicarboxymethyl-1-carbapenam,” Canadian Journal of Chemistry. 1982, 60, 2903-2907." scheme="references">
    <meta name="citation_reference" content="Hermanson, G.T., “Heterobifunctional Cross-linkers,” (1996) Bioconjugate Techniques; Academic Press: New York, p. 228-286." scheme="references">
    <meta name="citation_reference" content="Hochhauser, D., “Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors,” Clin. Cancer Res., Mar. 2009, 15(6):2140-2147." scheme="references">
    <meta name="citation_reference" content="Hochlowski, J. et al., “Abbeymycin, a new anthramycin-type antibiotic produced by a streptomycete,” J. Antibiotics, 40, 145-148 (1987)." scheme="references">
    <meta name="citation_reference" content="Hofstra R.M.W., et al., “A homozygous mUtation in the endothelin-3 gene associated with a combined Waardenburg type 2 and Hirschsprung phenotype (Shah-Waardenburg syndrome)” Nat. Genet. 12, 445-447, 1996." scheme="references">
    <meta name="citation_reference" content="Hofstra R.M.W., et al., “Mutations in Hirschsprung Disease: When Does a Mutation Contribute to the Phenotype,” Eur. J. Hum. Genet. 5, 180-185, 1997." scheme="references">
    <meta name="citation_reference" content="Horie et al., “Identification and Characterization of TMEFF2, a Novel Surviv Factor for Hippocampal and Mesencephalic Neurons,” (2000) Genomics 67: 146-152." scheme="references">
    <meta name="citation_reference" content="Howard, P.W et al., “Design, synthesis and biological evaluation of ZC-423, a novel C2-aryl substituted pyrrolobenzodiazepine (PBD) dimer,” Clinical Cancer Research (2005) 11(23):9015S-9016S (A205)." scheme="references">
    <meta name="citation_reference" content="Howard, P.W. et al., “Synthesis of a novel C2/C2'-aryl-substituted pyrrolo[2,1-c][1,4]benzodiazepine dimer prodrug with improved water solubility and reduced DNA reaction rate,” Bioorg. Med. Chem., Sep. 2009, In Press, 4 pages now: Sep. 2009, 19:6463-6466." scheme="references">
    <meta name="citation_reference" content="Howard, P.W. et al., “The design, synthesis and biological evaluation of a set of C2-aryl substituted pyrrolo[2,1-c][1,4]benzodiazepine dimers,” EJC Supplements (2006) 4(12):95—Poster Abstract 301." scheme="references">
    <meta name="citation_reference" content="Howard, P.W., “Design, synthesis and biological evaluation of novel C2-aryl-substituted pyrrolo[2,1-c][1,4]benzodiazepine monomers,” Proceedings of the American Association for Cancer Research Annual Meeting (Apr. 2006) 47:132." scheme="references">
    <meta name="citation_reference" content="Hubert, R.S., et al., “STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors,” (1999) Proc. Natl. Acad. Sci. U.S.A. 96 (25):14523-14528." scheme="references">
    <meta name="citation_reference" content="Hurley, L. and Needham-Vandevanter, D., “Covalent Binding of Antitumor Antibiotics in the Minor Groove of DNA. Mechanism of Action of CC-1065 and the yrrolo(1,4)benzodiazepines,” Acc. Chem. Res., 19, 230-237 (1986)." scheme="references">
    <meta name="citation_reference" content="Ide et al., “Cloning of human bone morphogenetic protein type IB receptor (BMPRIB) and its expression in prostate cancer in comparison with other BMPRs,” Oncogene (1997) 14, 1377-1382." scheme="references">
    <meta name="citation_reference" content="Iida, H. et al. “Design and synthesis of pyrrolo[2,1-c][1,4]benzodiazepine (PBD)-polyaminoalkyl conjugates by the use of SNA4 reaction 2-nitro-5-fluorobenzoate precursor as key reaction,” Heterocycles (2004) 62:693-711." scheme="references">
    <meta name="citation_reference" content="International Search Report and Written Opinion for Application No. PCT/EP2012/070233 dated Jan. 28, 2013 (8 pages)." scheme="references">
    <meta name="citation_reference" content="International Search Report and Written Opinion for Application No. PCT/EP2013/071346 dated Feb. 5, 2014 (11 pages)." scheme="references">
    <meta name="citation_reference" content="International Search Report and Written Opinion for Application No. PCT/EP2013/071352 dated Feb. 5, 2014 (14 pages)." scheme="references">
    <meta name="citation_reference" content="International Search Report and Written Opinion for Application No. PCT/EP2014/054958 dated Jul. 2, 2014 (13 pages)." scheme="references">
    <meta name="citation_reference" content="International Search Report and Written Opinion for Application No. PCT/EP2018/053162 dated Apr. 24, 2018 (9 pages)." scheme="references">
    <meta name="citation_reference" content="International Search Report and Written Opinion for Application No. PCT/GB2015/052629 dated Nov. 2, 2015 (12 pages)." scheme="references">
    <meta name="citation_reference" content="International Search Report and Written Opinion for Application No. PCT/US2011/032664 dated Aug. 19, 2011 (13 pages)." scheme="references">
    <meta name="citation_reference" content="International Search Report and Written Opinion for Application No. PCT/US2011/032668 dated May 26, 2011 (12 pages)." scheme="references">
    <meta name="citation_reference" content="International Search Report and Written Opinion for Application No. PCT/US2015/050634 dated Jan. 29, 2016 (14 pages)." scheme="references">
    <meta name="citation_reference" content="Itoh et al., “Sibanomicin, a new pyrrolo(1,4)benzodiazepine antitumor antibiotic produced by a micromonospora sp.” J. Antibiotics, 41, 1281-1284 (1988)." scheme="references">
    <meta name="citation_reference" content="Janjigian, Y.Y., “A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors,” Cancer Chemotherapy and Pharmacology, Aug. 2009, 65(5):833-838." scheme="references">
    <meta name="citation_reference" content="Jeffrey et al., “A Potent Anti-CD70 Antibody-Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology.” Bioconj. Chem. 2013, 24, 1256-1263." scheme="references">
    <meta name="citation_reference" content="Jeffrey et al., “Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates.” Bioconjugate Chemistry, 5, 2006, 17, 831-840. (Abstract)." scheme="references">
    <meta name="citation_reference" content="Jeffrey, S.C. et al., “Development of Pyrrolobenzodiazepine-Based Antibody-Drug Conjugates for Cancer,” AACR Annual Meeting 2013, Abstract No. 4321." scheme="references">
    <meta name="citation_reference" content="Jeffrey, S.C., “Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates,” J. Med. Chem. (2005) 48(5):1344-1358." scheme="references">
    <meta name="citation_reference" content="Jespers, L. S., “Guiding the Selection of Human Antibodies from Phage Display Repertoires to a Single Epitope of an Antigen” Nature Biotech., 12, 899-903 (1994)." scheme="references">
    <meta name="citation_reference" content="Jia, L., “Interspecies differences in pharmacokinetics and time-dissociated toxicokinetics of SJG-136,” Proceedings of the American Association for Cancer Research Annual Meeting (Mar. 2004) 45:487." scheme="references">
    <meta name="citation_reference" content="Jia, L., “Use of the comet assay as a surrogate biomarker for the in vivo measurement of DNA damage to lymphocytes,” Proceedings of the American Association for Cancer Research Annual Meeting (Mar. 2004) 45:452-453." scheme="references">
    <meta name="citation_reference" content="Johnson &amp; Goldin, “The clinical impact of screening and other experimental tumor studies.” Cancer Treat Rev. Mar. 1975; 2(1):1-31." scheme="references">
    <meta name="citation_reference" content="Jones et al., “Releasable Luciferin—Transporter Conjugates: Tools for the Real-Time Analysis of Cellular Uptake and Release,” J. Am. Chem. Soc., 2006, 128, 6526-6527." scheme="references">
    <meta name="citation_reference" content="Jonsson et al., “Human class II DNA and DOB genes display low sequence variability,” (1989) Immunogenetics 29(6):411-413." scheme="references">
    <meta name="citation_reference" content="Jordan, V.C., “Tamoxifen: a most unlikely pioneering medicine,” Nature Reviews: Drug Discovery (2003) 2:205-213." scheme="references">
    <meta name="citation_reference" content="Junutula et al., “Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs,” (2008) Jour of Immun. Methods 332:41-52." scheme="references">
    <meta name="citation_reference" content="Junutula, et al., “Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index,” 2008b Nature Biotech., 26(8):925-932, 2008." scheme="references">
    <meta name="citation_reference" content="Kamal et a., “Pyrrolo[2,1-c][1,4]benzodiazepine-β-glucuronide prodrugs with a potential for selective therapy of solid tumors by PMT and ADEPT strategies” Bioorganic &amp; Medicinal Chemistry Letters 2008, 18:3769-3773." scheme="references">
    <meta name="citation_reference" content="Kamal et al., “Synthesis and DNA-binding affinity of A-C8/C-C2 alkoxyamido-linked pyrrolo[2,1-c][1,4]benzodiazepine dimers” Biorg. Med. Chem. Lett. (2003) 13(22): 3955-3958." scheme="references">
    <meta name="citation_reference" content="Kamal, A. et al., “Design, synthesis and evaluation of new noncross-linking pyrrolobenzodiazepine dimers with efficient DNA binding ability and potent antitumor activity,” J. Med. Chem. (2002) 45:4679-4688." scheme="references">
    <meta name="citation_reference" content="Kamal, A., “Development of pyrrolo[2,1-c][1,4]benzodiazepine beta-galactoside prodrugs for selective therapy of cancer by ADEPT and PMT,” Chemmedchem (2008) 3:794-802." scheme="references">
    <meta name="citation_reference" content="Kamal, A., “Remarkable DNA binding affinity and potential anticancer activity of pyrrolo[2,1- c][1,4]benzodiazepine-naphthalamide conjugates linked through piperazine side-armed alkane spacers,” Bioorg. Med. Chem. (2008) 16(15):7218-7224." scheme="references">
    <meta name="citation_reference" content="Kamal, A., “Remarkable enhancement in the DNA-binding ability of C2-fluoro substituted pyrrolo[2,1- c][1,4]benzodiazepines and their anticancer potential,” Bioorg. Med. Chem., Jan. 2009, 17(4):1557-1572." scheme="references">
    <meta name="citation_reference" content="Kamal, A., “Synthesis of fluorinated analogues of SJG-136 and their DNA-binding potential,” Bioorg. Med. Chem. Lett (2004) 14(22):5699-5702." scheme="references">
    <meta name="citation_reference" content="Kamal, A., et al., “An Efficient Synthesis of Pyrrolo[2,1-c][1,4] Benzodiazepine Antibiotics via Reductive Cyclization,” Bioorg. Med. Chem. Ltrs, 7, No. 14, 1825-1828 (1997)." scheme="references">
    <meta name="citation_reference" content="Kamal, A., et al., “Synthesis of Pyrrolo [2,1-c][1,4]-Benzodiazepene Antibiotics: Oxidation of Cyclic Secondary Amine with TPAP”, Tetrahedron, v. 53, No. 9, 3223-3230 (1997)." scheme="references">
    <meta name="citation_reference" content="Kamal, et al., “Synthesis of pyrrolo[2,1-c][1,4]benzodiazepines via reductive cyclization of w-azido carbonyl compounds by TMSI: an efficient preparation of antibiotic DC-81 and its dimers,” Biorg. Med. Chem. Lett. (2000) 10:2311-2313." scheme="references">
    <meta name="citation_reference" content="Kaneko, T. et al., “Bicyclic and tricyclic analogues of anthramycin,” J. Med. Chem. (1985) 28:388-392." scheme="references">
    <meta name="citation_reference" content="Kang, G.-D et al., “Synthesis of a novel C2-aryl substituted 1,2-unsaturated pyrrolobenzodiazepine,” Chern. Commun. (2003) 1680-1689." scheme="references">
    <meta name="citation_reference" content="Kasahara et al., “Nucleotide sequence of a chimpanzee DOB eDNA clone,” (1989) Immunogenetics 30(1):66-68." scheme="references">
    <meta name="citation_reference" content="King et al., “Facile synthesis of maleimide bifunctional Jinkers,” (2002) Tetrahedron Letters 43:1987-1990." scheme="references">
    <meta name="citation_reference" content="Kingsbury et al., “A Novel Peptide Delivery System Involving Peptidase Activated Prodrugs as Antimicrobial Agents. Synthesis and Biological Activity of Peptidyl Derivatives of 5 Fluorouracil,” (1984) J. Med. Chem. 27:1447-1451." scheme="references">
    <meta name="citation_reference" content="Kohler et al., “Continuous cultures of fused cells secreting antibody of predefined specificity,” (1975) Nature 256:495-497." scheme="references">
    <meta name="citation_reference" content="Kohn, K., “Anthramycin,” Antibiotics III, Springer-Verlag, NY, 3-11 (1975)." scheme="references">
    <meta name="citation_reference" content="Kojima et al., “Molecular Cloning and Expression of Megakaryocyte Potentiating Factor eDNA,” The Journal of Biological Chemistry, vol. 270, No. 37, Issue of Sep. 15, pp. 21984-21990, 1995." scheme="references">
    <meta name="citation_reference" content="Konishi, M. et al., “Chicamycin, a new antitumor antibiotic II. Structure determination of chicamycins A and B,” J. Antibiotics, 37, 200-206 (1984)." scheme="references">
    <meta name="citation_reference" content="Kovtun et al., “Antibody-Drug Conjugates Designed to Eradicate Tumors with Homogeneous and Heterogeneous Expression of the Target Antigen,” (2006) Cancer Res. 66(6):3214-3121." scheme="references">
    <meta name="citation_reference" content="Kreitman et al., “Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients with Hematologic Malignancies,” J. Clin. Oncol., 2000, 18:1622-1636." scheme="references">
    <meta name="citation_reference" content="Kuhns J.J., et al., “Poor Binding of a HER-2/neu Epitope (GP2) to HLA-A2.1 Is due to a Lack of Interactions with the Center of the Peptide,” J. Biol. Chem. 274, 36422-36427, 1999." scheme="references">
    <meta name="citation_reference" content="Kunimoto et al., “Mazethramycin, a new member of anthramycin group antibiotics,” J. Antibiotics, 33, 665-667 (1980)." scheme="references">
    <meta name="citation_reference" content="Kurebayashi et al., “Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6,” (1999) Brit. Jour. Cancer 79(5-6):707-717." scheme="references">
    <meta name="citation_reference" content="Lambert, “Drug-conjugated monoclonal antibodies for the treatment of cancer,” (2005) Current Opin. In Pharmacal. 5:543-549." scheme="references">
    <meta name="citation_reference" content="Langley, D.R. and Thurston, D.E., “A versatile and efficient synthesis of carbinolamine-containing pyrrolo[1,4]benzodiazepines via the cyclization of N-92-aminobenzoyl)pyrrolidine-2-carboxaldehyde diethyl thioacetals: total synthesis of prothracarcin,” J. Org. Chem., 52, 91-97 (1987)." scheme="references">
    <meta name="citation_reference" content="Langlois, N. et al., “Synthesis and cytotoxicity on sensitive and doxorubicin-resistant cell lines of new pyrrolo[2,1-c][1,4]benzodiazepines related to anthramycin,” J. Med. Chem. (2001) 44:3754-3757." scheme="references">
    <meta name="citation_reference" content="Larhammar et al., “Sequence of Gene and eDNA Encoding Murine Major Histocompatibility Complex Class II Gene AP2*,” (1985) J. Biol. Chem. 260(26):14111-14119." scheme="references">
    <meta name="citation_reference" content="Launay et al., “TRPM4 Is a Ca2+ -Activated Nonselective Cation Channel Mediating Cell Membrane Depolarization,” Cell 109 (3):397-407 (2002)." scheme="references">
    <meta name="citation_reference" content="Law et al., “Lymphocyte Activation Antigen CD70 Expressed by Renal Cell Carcinoma Is a Potential Therapeutic Target for Anti-CD70 Antibody-Drug Conjugates,” (2006) Cancer Res. 66(4):2328-2337." scheme="references">
    <meta name="citation_reference" content="Lazar et al., “A molecular immunology approach to antibody humanization and functional optimization” Molecular Immunology, 2007, 44(8), 1986-1998." scheme="references">
    <meta name="citation_reference" content="Le et al., “Primary structure and expression of a naturally truncated human P2X ATP receptor subunit from brain and immune system,” (1997) FEBS Lett. 418(1-2):195-199." scheme="references">
    <meta name="citation_reference" content="Leabman; et al., “Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys.” MAbs. Nov.-Dec. 2013; 5(6):896-903." scheme="references">
    <meta name="citation_reference" content="Leber, J.D. et al., “A revised structure for sibiromycin,” J. Am. Chem. Soc., 110, 2992-2993 (1988)." scheme="references">
    <meta name="citation_reference" content="Leimgruber, W. et al., “Isolation and characterization of anthramycin, a new antitumor antibiotic,” J. Am. Chem. Soc., 87, 5791-5793 (1965)." scheme="references">
    <meta name="citation_reference" content="Leimgruber, W. et al., “The structure of anthramycin,” J. Am. Chem. Soc., 87, 5793-5795 (1965)." scheme="references">
    <meta name="citation_reference" content="Leimgruber, W. et al., “Total synthesis of anthramycin,” J. Am. Chem. Soc., 90, 5641-5643 (1968)." scheme="references">
    <meta name="citation_reference" content="Leonard et al., “Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma,” J. Clin. Oncology (2003) 21(16):3051-3059." scheme="references">
    <meta name="citation_reference" content="Leonard et al., “Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies,” Oncogene (2007) 26:3704-3713." scheme="references">
    <meta name="citation_reference" content="Leung et al., “Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2,” Mol. Immunol. (1995) 32(17-18):1413-1427." scheme="references">
    <meta name="citation_reference" content="Levenson et al., “MCF-7: The First Hormone-responsive Breast Cancer Cell Line,” (1997) Cancer Res. 57(15):3071-3078." scheme="references">
    <meta name="citation_reference" content="Lewis Phillips et al., “Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate,” Cancer Res, 2008, 68: (22)." scheme="references">
    <meta name="citation_reference" content="Liang et al., “The Gene for a Novel Transmembrane Protein Containing Epidermal Growth Factor and Follistatin Domains Is Frequently Hypermethylated in Human Tumor Cells,” (2000) Cancer Res. 60:4907-4912." scheme="references">
    <meta name="citation_reference" content="Linden et al., “Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab,” J. Clin. Cancer Res. (2005) 11:5215-5222." scheme="references">
    <meta name="citation_reference" content="Lonberg, “Fully Human antibodies from transgenic mouse and phage display platforms” Curr. Opinion, 20(4), 450-459 (2008)." scheme="references">
    <meta name="citation_reference" content="Lown et al., “Molecular Mechanism of Binding of Pyrrolo(1,4)benzodiazepine antitumour agents to deoxyribonucleic acid—anthramycin and tomaymycin,” Biochem. Pharmacol. (1979), 28 (13), 2017-2026." scheme="references">
    <meta name="citation_reference" content="Manfre et al., “Syntheses of Proline Analogues as Potential Mechanism-Based Inhibitors of Proline Dehydrogenase: 4-Methylene-L-, (E)- and (Z)-4 (Fluoromethylene)-L-, cis- and trans-5-Ethynyl-(±)-, and cis- and trans -5-Vinyl-L-proline,” J. Org. Chem. 1992, 57, 2060-2065." scheme="references">
    <meta name="citation_reference" content="Marin, D., “Voltammetric studies of the interaction of pyrrolo[2,1-c][1,4]benzodiazepine (PBD) monomers and dimers with DNA,” J. Electroanal. Chem. (2006) 593(1-2):241-246." scheme="references">
    <meta name="citation_reference" content="Marks et al., “By-passing Immunization, Human Antibodies from V-gene Libraries Displayed on Phage,” (1991) J. Mol. Biol., 222:581-597." scheme="references">
    <meta name="citation_reference" content="Martin, C. et al., “Sequence-selective interaction of the minor-groove interstrand cross-linking agent SJG-136 with naked and cellular DNA: footprinting and enzyme inhibition studies,” Biochem. (2005) 44(11):4135-4147." scheme="references">
    <meta name="citation_reference" content="Mastroberardino et al., “Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family,” Nature 395 (6699):288-291 (1998)." scheme="references">
    <meta name="citation_reference" content="Matsumoto, K. et al., “Synthesis of polyaminoalkyl substituted conjugates of pyrrolo[2,1-c][1,4]benzodiazepine (PBD)-polyaminoalkyl involving SNA4 reaction of 2-nitro-5-fluorobenzoate precursors,” Heterocycles (2000) 52(3):1015-1020." scheme="references">
    <meta name="citation_reference" content="McDonagh, “Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment,” (2006) Protein Eng. Design &amp; Sel. 19(7): 299-307." scheme="references">
    <meta name="citation_reference" content="Mendoza et al., “Inhibition of Ligand-mediated HER2 Activation in Androgen-independent Prostate Cancer,” (2002) Cancer Res. 62:5485-5488." scheme="references">
    <meta name="citation_reference" content="Miller et al., “Design, Construction, and In Vitro Analyses of Multivalent Antibodies,” (2003) Jour, of Immunology 170:4854-4861." scheme="references">
    <meta name="citation_reference" content="Miller et al., “IRTAs: a new family of immunoglobulinlike receptors differentially expressed in B cells,” Blood 99 (8):2662-2669 (2002)." scheme="references">
    <meta name="citation_reference" content="Miura et al., “Molecular cloning of a human RP105 homologue and chromosomal localization of the mouse and human RP105 genes (Ly64 and LY64).” Genomics. Dec. 15, 1996; 38(3):299-304." scheme="references">
    <meta name="citation_reference" content="Miura et al., “RPIOS Is Associated With MD-1 and Transmits an Activation Signal in Human B Cells,” (1998) Blood 92:2815-2822." scheme="references">
    <meta name="citation_reference" content="Moore M., et al., “Molecular cloning of the eDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes,” Proc. Natl. Acad. Sci. U.S.A. 84, 9194-9198, 1987." scheme="references">
    <meta name="citation_reference" content="Mori, M. et al., “Total syntheses of prothracarcin and tomaymycin by use of palladium catalyzed carbonylation,” Tetrahedron (1986) 42(14):3793-3806." scheme="references">
    <meta name="citation_reference" content="Morrison et al., “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains,” (1984) Proc. Natl. Acad. Sci. USA, 81:6851-6855." scheme="references">
    <meta name="citation_reference" content="Mountzouris, J.A. et al., “Comparison of a DSB-120 DNA interstrand cross-linked adduct with the corresponding bis-Tomamycin adduct,” J. Med. Chem. (1994) 37:3132-3140." scheme="references">
    <meta name="citation_reference" content="Muller et al., “Cloning and sequencing of the eDNA encoding the human homologue of the murine immunoglobulin-associated protein B29,” (1992) Eur. J. Immunol. 22 (6): 1621-1625." scheme="references">
    <meta name="citation_reference" content="Mungall A.J., et al., “The DNA sequence and analysis of human chromosome 6,” Nature 425, 805-811, 2003." scheme="references">
    <meta name="citation_reference" content="Nadler et al., “B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes,” Journal of Immunology, 1983, 131(1):244-250." scheme="references">
    <meta name="citation_reference" content="Nagasaka, T. and Koseki, Y, “Stereoselective Synthesis of Tilivalline,” Journal of Organic Chemistry, vol. 63, No. 20, 6797-6801 (1998)." scheme="references">
    <meta name="citation_reference" content="Nagasaka, T. et al., “Stereoselective Synthesis of Tilivalline,” Tetrahedron Letters, 30:14, 1871-1872(1989)." scheme="references">
    <meta name="citation_reference" content="Nagase T., et al., “Prediction of the Coding Sequences of Unidentified Human Genes. XVII. The Complete Sequences of 100 New eDNA Clones from Brain Which Code for Large Proteins in vitro,” (2000) DNA Res. 7 (2):143-150." scheme="references">
    <meta name="citation_reference" content="Nakamuta M., et al., “Cloning and sequence analysis of a cDNA encoding human non—selective type of endothelin receptor,” Biochem. Biophys. Res. Commun. 177, 34-39, 1991." scheme="references">
    <meta name="citation_reference" content="Nakayama et al., “Altered Gene Expression upon BCR Cross-Linking in Burkitt's Lymphoma B Cell Line,” (2000) Biochem. Biophys. Res. Commun. 277(1):124-127." scheme="references">
    <meta name="citation_reference" content="Narayanaswamy, M., “A novel HPLC/MS assay to measure DNA interstrand cross-linking efficacy in oligonucleotides of varying sequence,” EJC Supplements (Nov. 2006) 4(12):92-93." scheme="references">
    <meta name="citation_reference" content="Narayanaswamy, M., “An assay combinding high-performance liquid chromatography and mass spectrometry to measure DNA interstrand cross-linking efficiency in oligonucleotides of varying sequences,” Anal. Biochem. (2008) 374(1):173-181." scheme="references">
    <meta name="citation_reference" content="Narayanaswamy, M., “Use of HPLC-MS to characterize novel mono and intrastrand cross-linked DNA adducts formed by the sequence-selective DNA-interactive agent SJG-136,” Proceedings of the American Association for Cancer Research Annual Meeting (Apr. 2007) 48:760-761." scheme="references">
    <meta name="citation_reference" content="Narukawa, Y., “General and efficient synthesis of 2-alkylcarbapenems synthesis of dethia carba analogs of clinically useful carbapenems via palladium-catalyzed cross-coupling reaction,” Tetrahedron (1997) 53:539-556." scheme="references">
    <meta name="citation_reference" content="Naruse et al., “The HLA-DOB gene displays limited polymorphism with only one amino acid substitution,” (2002) Tissue Antigens 59:512-519." scheme="references">
    <meta name="citation_reference" content="Neuberger and Williams, “The intron requirement for immunoglobulin gene expression is dependent upon the promoter,” (1988) Nucleic Acids Res. 16:6713-6724." scheme="references">
    <meta name="citation_reference" content="Nicolaou et al., “Calicheamicin θ: A Rationally Designed Molecule with Extremely Potent and Selective DNA Cleaving Properties and Apoptosis Inducing Activity,” Angew Chem. Intl. Ed. Engl. (1994) 33:183-186." scheme="references">
    <meta name="citation_reference" content="Nilius et al., “Voltage Dependence of the Ca2+ -activated Cation Channel TRPM4,” The Journal of Biological Chemistry, vol. 278, No. 33, Issue of Aug. 15, p. 30813-30820, 2003." scheme="references">
    <meta name="citation_reference" content="Ogawa Y., et al., “Molecular Cloning of a Non-Isopeptide-Selective Human Endothelin Receptor,” Biochem. Biophys. Res. Commun. 178, 248-255, 1991." scheme="references">
    <meta name="citation_reference" content="Okamoto Y., et al. “Palmitoylation of Human Endothelin B,” Biol. Chem. 272, 21589-21596, 1997." scheme="references">
    <meta name="citation_reference" content="O'Neil, Chemical Abstract No. 171573p, “The synthesis of Functionalized Pyrrolo-[2,1-c][1,4]-Benzodiazepines”, Chemical Abstracts, vol. 126, No. 13, 618 (1997)." scheme="references">
    <meta name="citation_reference" content="O'Neil, I.A. et al., “DPPE: A Convenient Replacement for Triphenylphosphine in the Staudinger and Mitsunobu Reactions”, Tetrahedron Letters, vol. 39, No. 42, 7787-7790 (1998)." scheme="references">
    <meta name="citation_reference" content="O'Neil, I.A., et al., “The Synthesis of Functionalized Pyrrolo-[2,1-c][1,4]-Benzodiazepines,” Synlett, 75-78 (1997)." scheme="references">
    <meta name="citation_reference" content="Parrish-Novak J., et al., “Interleukins 19, 20, and 24 Signal through Two Distinct Receptor Complexes,” J. Biol. Chem. 277, 47517-47523, 2002." scheme="references">
    <meta name="citation_reference" content="Paul, Fundamental Immunology, 3rd Edition, pp. 292-295, 1993." scheme="references">
    <meta name="citation_reference" content="Payne, G. “Progress in immunoconjugate cancer therapeutics,” (2003) Cancer Cell 3:207-212." scheme="references">
    <meta name="citation_reference" content="PCT/US2012/059864 International Search Report and Written Opinion dated Dec. 21, 2012 (7 pages)." scheme="references">
    <meta name="citation_reference" content="Pepper, C., “Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells,” Br. J. Cancer (2007) 97(2):253-259." scheme="references">
    <meta name="citation_reference" content="Pepper, C.J. et al., “The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53- independent mechanism of cell kill,” Cancer Res. (2004) 64:6750-6755." scheme="references">
    <meta name="citation_reference" content="Phillips et al., “Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate,” (2008) Cancer Res. 68(22):9280-9290." scheme="references">
    <meta name="citation_reference" content="Pingault V., et al., “SOX10 mutations in chronic intestinal pseudo-obstruction suggest a complex physiopathological mechanism,” (2002) Hum. Genet. 111, 198-206." scheme="references">
    <meta name="citation_reference" content="Pletnev S., et al., “Characterization of the Recombinant Extracellular Domains of Human Interleukin-20 Receptors and Their Complexe with Interleukin-19 and Interleukin-20,” (2003) Biochemistry 42:12617-12624." scheme="references">
    <meta name="citation_reference" content="Porkaa et al., “Cloning and Characterization of a Novel Six-Transmembrane Protein STEAP2, Expressed in Normal and Malignant Prostate,” Lab. Invest. 82 (11):1573-1582 (2002)." scheme="references">
    <meta name="citation_reference" content="Prasad et al., “Human LAT1, a Subunit of System L Amino Acid Transporter: Molecular Cloning and Transport Function,” Biochem. Biophys. Res. Commun. 255 (2), 283-288 (1999)." scheme="references">
    <meta name="citation_reference" content="Preud'homme et al., “Structure and expression of the mb-1 transcript in human lymphoid cells,” (1992) Clin. Exp. Immunol. 90(1):141-146." scheme="references">
    <meta name="citation_reference" content="Puffenberger E.G., et al., “A Missense Mutation of the Endothelin-B Receptor Gene in Multigenic Hirschsprung's Disease,” Cell 79, 1257-1266, 1994." scheme="references">
    <meta name="citation_reference" content="Purser, et al., “Fluorine in Medicinal Chemistry.” Chem. Soc. Rev., 2008, 37, 320-330." scheme="references">
    <meta name="citation_reference" content="Puzanov, I., “Phase I and pharmacokinetic trial of SJG-136 administered on a daily x5 schedule,” EJC Supplements (Nov. 2006) 4(12):93." scheme="references">
    <meta name="citation_reference" content="Quintas-Cardama, A., “Sequencing of subcloned PCR products facilitates earlier detetction of BCR-ABL1 and other mutants compared to direct sequencing of the ABL1 kinase domain,” Leukemia (2008) 22(4):877-878." scheme="references">
    <meta name="citation_reference" content="Rahman et al. “Antistaphylococcal activity of DNA-interactive pyrrolobenzodiazepine (PBD) dimers and PBD-biaryl conjugates.” J Antimicrob Chemother. Jul. 2012; 67(7):1683-96." scheme="references">
    <meta name="citation_reference" content="Rahman, K.M., “Effect of microwave irradiation on covalent ligand-DNA interactions,” Chem. Commun. (Cambridge, UK), Apr. 2009, 20:2875-2877." scheme="references">
    <meta name="citation_reference" content="Rahman, K.M., “Rules of DNA adduct formation for pyrrolobenzodiazepine (PBD) dimers,” Proceedings of the American Association for Cancer Research Annual Meeting (Apr. 2010) 51:851." scheme="references">
    <meta name="citation_reference" content="Rahman, K.M., “The pyrrolobenzodiazepine dimer SJG-136 forms sequencedependent intrastrand DNA cross- lins and monoalkylated adducts in addition to interstrand cross-links,” J. Am. Chem. Soc., Sep. 2009, 131(38):13756-13766." scheme="references">
    <meta name="citation_reference" content="Rao et al., “Influence of diet on mammary cancer in transgenic mice bearing an oncogene expressed in mammary tissue,” (1997) Breast Cancer Res. and Treatment 45:149-158." scheme="references">
    <meta name="citation_reference" content="Reid, J.M., “LC-MS/MS assay and rat pharmacokinetics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136,” Proceedings of the American Association for Cancer Research Annual Meeting (Mar. 2004) 45:1248." scheme="references">
    <meta name="citation_reference" content="Reiter R.E., et al., “Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer,” Proc. Natl. Acad. Sci. U.S.A. 95, 1735-1740, 1998." scheme="references">
    <meta name="citation_reference" content="Remmers et al., “Conformations of complexes between pyrrolo[1,4]benzodiazepines and DNA segments,” J Med Chem. Dec. 1986;29(12):2492-2503." scheme="references">
    <meta name="citation_reference" content="Rich, I.N., “Validation and development of a predictive paradigm for hemotoxicology using a multifunctional bioluminescence colony-forming proliferation assay,” Toxicological Sci. (2005) 87(2):427-441." scheme="references">
    <meta name="citation_reference" content="Rodrigues et al., “Synthesis and beta-lactamase-mediated activation of a cephalosporin-taxol prodrug,” (1995) Chemistry Biology 2:223-227." scheme="references">
    <meta name="citation_reference" content="Roguska et al., “A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing,” Protein Eng, 1996, 9(10):895-904." scheme="references">
    <meta name="citation_reference" content="Roguska et al., “Humanization of murine monoclonal antibodies through variable domain resurfacing,” PNAS, 1994, 91(3):969-973." scheme="references">
    <meta name="citation_reference" content="Ross et al., “Prostate Stem Cell Antigen as Therapy Target: Tissue Expression and in Vivo Efficacy of an Immunoconjugate,” (2002) Cancer Res. 62:2546-2553." scheme="references">
    <meta name="citation_reference" content="Rudikoff et al., Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A. Mar. 1982; 79(6):1979-83." scheme="references">
    <meta name="citation_reference" content="Sagnou, M.J. et al., “Design and Synthesis of Novel Pyrrolobenzodiazepine (PDB) Prodrugs for ADEPT and GDEPT,” Bioorganic &amp; Medicinal Chemistry Letters, 10, 2083-2086 (2000)." scheme="references">
    <meta name="citation_reference" content="Sakaguchi et al., “8 lymphocyte lineage-restricted expression of mb-1, a gene with CD3-like structural properties,” (1988) EMBO J. 7(11):3457-3464." scheme="references">
    <meta name="citation_reference" content="Sakamoto A, Yanagisawa M., et al., “Cloning and Functional Expression of Human cDNA For the ETB Endothelin Receptor,” Biochem. Biophys. Res. Commun. 178, 656-663, 1991." scheme="references">
    <meta name="citation_reference" content="Sanderson et al., “In vivo Drug-Linker Stability of an Anti-CD30 Dipeptide-Linked Auristatin Immunoconjugate,” (2005) Clin. Cancer Res. 11:843-852." scheme="references">
    <meta name="citation_reference" content="Scholler et al., “Soluble member(s) of the mesothelin/ megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma,” Proc. Natl. Acad. Sci. USA vol. 96, p. 11531-11536, Sep. 1999." scheme="references">
    <meta name="citation_reference" content="SCHRODER and Lubke, The Peptides, vol. 1. pp. 76-136 (1965) Academic Press." scheme="references">
    <meta name="citation_reference" content="Schweikart, K., “In vitro myelosuppression of SJG-136, a pyrrolobenzodiazepine dimer: comparison to bizelesin,” Proceedings of the American Association for Cancer Research Annual Meeting (Mar. 2004) 45:486." scheme="references">
    <meta name="citation_reference" content="Segawa et al., “Growth-related Renal Type II Na/Pi Cotransporter,” The Journal of Biological Chemistry, vol. 277. No. 22, Issue of May 31, p. 19665-19672, 2002." scheme="references">
    <meta name="citation_reference" content="Semba K., et al., “A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1 /epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma,” 15 Proc. Natl. Acad. Sci. U.S.A 82, 6497-6501, 1985." scheme="references">
    <meta name="citation_reference" content="Servenius et al., “Class II Genes of the Human Major Histocompatibility Complex, The DOBeta Gene is a Divergent Member of the Class II P Gene Family,” (1987) J. Biol. Chem. 262:8759-8766." scheme="references">
    <meta name="citation_reference" content="Shamis et al., “Bioactivation of Self-lmmolative Dendritic Prodrugs by Catalytic Antibody 38C2,” (2004) J . Am. Chem. Soc. 126:1726-1731." scheme="references">
    <meta name="citation_reference" content="Sharkey et al., “Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies,” Mol. Cancer Ther. (2012) 11(1):224-234." scheme="references">
    <meta name="citation_reference" content="Sheikh F., et al., “Cutting Edge: IL-26 Signals through a Novel Receptor Complex Composed of IL-20 Receptor 1 and IL-10 Receptor 21,” (2004) J.Immunol, 172, 2006-2010." scheme="references">
    <meta name="citation_reference" content="Shen et al., “Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates,” (2012) Nature Biotech., 30(2):184-191." scheme="references">
    <meta name="citation_reference" content="Shimizu, K et al., “Prothracarcin, a Novel Antitumor Antibiotic,” J. Antibiotics, 35, 972-978 (1982)." scheme="references">
    <meta name="citation_reference" content="Sinha S.K., et al., “Characterization of the EBV /C3d Receptor on the Human Jurkat T Cell Line: Evidence for a Novel Transcript,” (1993) J. Immunol. 150, 5311-5320." scheme="references">
    <meta name="citation_reference" content="Smellie, M. et al., “Cellular pharmacology of novel C8-linked anthramycin-based sequence-selective DNA minor groove cross-linking agents,” Br. J. Cancer (1994) 70:48-53." scheme="references">
    <meta name="citation_reference" content="Smellie, M. et al., “Sequence selective recognition of duplex DNA through covalent interstrand cross-linking,” Biochem. (2003) 42:8232-8239." scheme="references">
    <meta name="citation_reference" content="Smith, P. K et al., “Measurement of protein using bicinchoninic acid.” Anal Biochem. Oct. 1985; 150(1):76-85." scheme="references">
    <meta name="citation_reference" content="Souillac, P. et al., “Characterization of delivery systems, differential scanning calorimetry,” Encyclopedia of Controlled Drug Delivery (1999) 212-227 (pp. 217-218)." scheme="references">
    <meta name="citation_reference" content="Storm et al., “Effect of Small Changes in Orientation on Reaction Rate,” (1972) J. Amer. Chem. Soc. 94:5815-5825." scheme="references">
    <meta name="citation_reference" content="Strausberg et al., “Generation and initial analysis of more than 15,000 full-length human and mouse eDNA sequences,” (2002) Proc. Natl. Acad. Sci USA 99:16899-16903." scheme="references">
    <meta name="citation_reference" content="Suggitt, M., “The hollow fibre model—facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare,” Int. J. Oncol. (2006) 29(6):1493-1499." scheme="references">
    <meta name="citation_reference" content="Suggs, J.W. et al., “Synthesis and structure of anthramycin analogs via hydride reduction of dilactams,” Tetrahedron Letters, 26, No. 40, 4871-4874 (1985)." scheme="references">
    <meta name="citation_reference" content="Sun et al., “Enabling ScFvs as Multi-Drug Carriers: A Dendritic Approach,” (2003) Bioorganic &amp; Medicinal Chemistry 11:1761-1768." scheme="references">
    <meta name="citation_reference" content="Sun et al., “Syntheses of Dendritic Linkers Containing Chlorambucil Residues for the Preparation of Antibody- Multidrug Immunoconjugates,” (2002) Bioorganic &amp; Medicinal Chemistry Letters 12:2213-2215." scheme="references">
    <meta name="citation_reference" content="Sutherland, M.S.K. et al., “SGN-CD33A: a novel CD33-directed antibody-drug conjugate, utilizing pyrrolobenzodiazepine dimers, demonstrates preclinical anti-tumor activity against multi-drug resistant human AML,” American Society of Hematology (Dec. 8-12, 2012) Atlanta, Georgia, Abstract No. 3589." scheme="references">
    <meta name="citation_reference" content="Svensson P.J., et al., “Phenotypic variation in a family with mutations in two Hirschsprung-related genes (RET and endothelin receptor B),” Hum. Genet. 103, 145-148, 1998." scheme="references">
    <meta name="citation_reference" content="Swiercz J.M., et al., “Plexin-81 /RhoGEF-mediated Rho A activation involves the receptor tyrosine kinase ErbB-2,” J. Cell Biol. 165, 869-880, 2004." scheme="references">
    <meta name="citation_reference" content="Syrigos and Epenetos, “Antibody Directed Enzyme Prodrug Therapy (ADEPT): A Review of the Experimental and Clinical Considerations,” (1999) Anticancer Research 19:605-614." scheme="references">
    <meta name="citation_reference" content="Takeuchi, T et al., “Neothramycins A and B, New Antitumor Antibiotics,” J. Antibiotics, 29, 93-96 (1976)." scheme="references">
    <meta name="citation_reference" content="Talpur et al., “CD25 Expression is Correlated with Histological Grade and Response to Denileukin Diftitox in Cutaneous T-Cell Lymphoma,” J. Investigative Dermatology, 2006, 126: 575-583." scheme="references">
    <meta name="citation_reference" content="Tawaragi Y., et al., “Primary Structure of Nonspecific Crossreacting Antigen (NCA), a Member of Carcinoembryonic Antigen (CEA) Gene Family, Deduced From cDNA Sequence,” Biochem. Biophys. Res. Commun. 150, 89-96, 1988." scheme="references">
    <meta name="citation_reference" content="Tercel, M. et al., “Unsymmetrical DNA cross-linking agents: combination of the CBI and PBD pharmacophores,” J. Med. Chem. (2003) 46:2132-2151." scheme="references">
    <meta name="citation_reference" content="Thompson J.S., et al., “BAFF-R, a Newly Identified TNF Receptor That Specifically Interacts with BAFF,” Science 293 (5537), 2108-2111 (2001)." scheme="references">
    <meta name="citation_reference" content="Thurston, D. E., “Advances in the study of Pyrrolo[2,1-c][1,4] benzodiazepine (PBD) Antitumour Antibiotics”, Molecular Aspects of Anticancer Drug-DNA Interaction, Neidle, S. and Waring, M.J., Eds.; Macmillan Press Ltd, 1:54-88 (1993)." scheme="references">
    <meta name="citation_reference" content="Thurston, D.E. and Bose, D.S., “Synthesis of DNA-lnteractive Pyrrolo[2,1-c][1,4]benzodiazepines,” Chem. Rev., 94:433-465 (1994)." scheme="references">
    <meta name="citation_reference" content="Thurston, D.E. and Thompson, A.S., “The molecular recognition of DNA,” Chem. Brit., 26, 767-772 (1990)." scheme="references">
    <meta name="citation_reference" content="Thurston, D.E. et al., “Effect of A-ring modifications on the DNA-binding behavior and cytotoxicity of pyrrolo[2,1-c][1,4]benzodiazepines”, Journal of Medicinal Chemistry, 42:1951-1964 (1999)." scheme="references">
    <meta name="citation_reference" content="Thurston, D.E. et al., “Synthesis of a novel GC-specific covalent-binding DNA affinity-cleavage agent based on pyrrolobenzodiazepines (PBDs),” Chemical Communications, 563-565 (1996)." scheme="references">
    <meta name="citation_reference" content="Thurston, D.E. et al., “Synthesis of Sequence-selective C8-linked Pyrrolo [2,1-c][1,4] Benzodiazepine DNA Interstrand Cross-linking Agent,” J. Org. Chem., 61:8141-8147 (1996)." scheme="references">
    <meta name="citation_reference" content="Thurston, D.E., “Nucleic acid targeting: therapeutic strategies for the 21st century,” Brit. J. Cancer (1999) 80(1):65-85." scheme="references">
    <meta name="citation_reference" content="Tiberghien, A.C. et al., “Application of the stille coupling reaction to the synthesis of C2-substituted endo-exo unsaturated pyrrolo[2,1-c][1,4]benzodiazepines (PBDs),” Biorg. Med. Chem. Lett. (2004) 14:5041-5044." scheme="references">
    <meta name="citation_reference" content="Tiberghien, A.C., “Application of the stille coupling reaction to the synthesis of C2-substituted endo-exo unsaturated pyrrolo[2,1-c][1,4]benzodiazepines (PBDs),” Bioorg. Med. Chem. Lett. (2008) 18(6):2073-2077." scheme="references">
    <meta name="citation_reference" content="Toki et al., “Protease-Mediated Fragmentation of p-Amidobenzyl Ethers: A New Strategy for the Activation of Anticancer Prodrugs,” (2002) J. Org. Chem. 67:1866-1872." scheme="references">
    <meta name="citation_reference" content="Tonnelle et al., “DO Beta a new chain gene in HLA-D with a distinct regulation of expression,” (1985) EMBO J. 4(11):2839-2847." scheme="references">
    <meta name="citation_reference" content="Touchman et al., “The Genomic Region Encompassing the Nephropathic Cystinosis Gene (CTNS): Complete Sequencing of a 200-kb Segment and Discovery of a Novel Gene within the Common Cystinosis-Causing Deletion,” (2000) Genome Res. 10:165-173." scheme="references">
    <meta name="citation_reference" content="Tozuka et al., “Studies on tomaymycin. II. Total synthesis of the antitumor antibiotics, E-and Z-tomaymycins,” J. Antibiotics (Tokyo) (1983) 36:276-282." scheme="references">
    <meta name="citation_reference" content="Trail et al., “Monoclonal antibody drug immunoconjugates for targeted treatment of cancer,” (2003) Cancer Immunol. Immunother. 52:328-337." scheme="references">
    <meta name="citation_reference" content="Tsunakawa, M. et al., “Porothramycin, a new antibiotic of the anthramycin group: Production, isolation, structure and biological activity,” J. Antibiotics, 41:1366-1373 (1988)." scheme="references">
    <meta name="citation_reference" content="Tsutsumi M., et al., “Novel endothelin B receptor transcripts with the potential of generating a new receptor,” Gene 228, 43-49, 1999." scheme="references">
    <meta name="citation_reference" content="Uchida et al., “A Novel Epidermal Growth Factor-like Molecule Containing Two Follistatin Modules Stimulates Tyrosine Phosphorylation of erbB-4 in MKN28 Gastric Cancer Cells,” (1999) Biochem. Biophys. Res. Commun. 266:593-602." scheme="references">
    <meta name="citation_reference" content="Umezawa, H. et al., “Mazethramycins,” SciFinder Scholar, 2-3 (2002)." scheme="references">
    <meta name="citation_reference" content="Umezawa, H. et al., Chemical Abstract No. 4427a, “Mazethramycins” Chemical Abstracts, vol. 90, No. 1, 428 (1979)." scheme="references">
    <meta name="citation_reference" content="Van Geel et al., “Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates,” (2015) Bioconjugate Chem. 26: 2233-2242." scheme="references">
    <meta name="citation_reference" content="Verheij J.B., et al., “ABCD Syndrome Is Caused by a Homozygous Mutation in the EDNRB Gene,” Am. J. Med. 15 Genet. 108, 223-225, 2002." scheme="references">
    <meta name="citation_reference" content="Vippagunta, S.R. et al., “Crystalline solids,” Adv. Drug Delivery Rev. (2001) 48:3-26." scheme="references">
    <meta name="citation_reference" content="Von Hoegen et al., “Identifigation of a human protein homologous to the mouse Lyb-2 B cell differentiation antigen and sequence of the corresponding cDNA,” (1990) J. Immunol. 144(12):4870-4877." scheme="references">
    <meta name="citation_reference" content="Wang, J.H., “Determination of antitumor agent AJG-136 in human serum by HPLC with tandem mass spectrometric detection (HPLC-MS/MS),” Abstracts of Papers American Chemical Society (Mar. 13, 2005) 229(1):U119." scheme="references">
    <meta name="citation_reference" content="Webster et al., “Mammary tumorigenesis and metastasis in transgenic mice,” (1994) Semin. Cancer Biol. 5:69-76." scheme="references">
    <meta name="citation_reference" content="Weidner-Wells, M.A. et al., “Photochemical approach to the synthesis of the pyrrolo[1,4]benzodiazepine antibiotics,” J. Org. Chem. (1989) 54:5746-5758." scheme="references">
    <meta name="citation_reference" content="Weis J.J., et al., “Identification of a partial eDNA clone for the C3d/Epstein-Barr virus receptor of human B lymphocytes: Homology with the receptor for fragments C3b and C4b of the third and fourth components of complement,” Proc. Natl. Acad. Sci. U.S.A. 83, 5639-5643, 1986." scheme="references">
    <meta name="citation_reference" content="Weis J.J., et al., “Structure of the human b lymphocyte receptor for c3d and the epstein-barr virus and relatedness to other members of the family of C3/C4 binding proteins,” J. Exp. Med. 167, 1047-1066, 1988." scheme="references">
    <meta name="citation_reference" content="Wells, G. et al., “Design, synthesis and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugates,” J. Med. Chem. (2006) 49:5442-5461." scheme="references">
    <meta name="citation_reference" content="Wilkinson “Eph Receptors and Ephrins: Regulators of Guidance and Assembly,” Int. Rev. Cytol. 196:177-244 (2000)." scheme="references">
    <meta name="citation_reference" content="Wilkinson, G.P., “Pharmacokinetics and intracellular pharmacological characteristics of the novel pyrrolobenzodiazepine (PBD) dimer SJG-136,” Proceedings of the American Association for Cancer Research Annual Meeting (Jul. 2003) 44:320." scheme="references">
    <meta name="citation_reference" content="Wilkinson, G.P., “Pharmacokinetics, metabolism and glutathione reactivity of SJG-136,” Br. J. Cancer (2003) 88(Supp. 1):S29." scheme="references">
    <meta name="citation_reference" content="Wilkinson, G.P., “Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent,” Investigational New Drugs (2004) 22(3):231-240." scheme="references">
    <meta name="citation_reference" content="Wilson et al., “eDNA Cloning of the B Cell Membrane Protein CD22: A Mediator of B-B Cell Interactions,” (1991) J. Exp. Med. 173:137-146." scheme="references">
    <meta name="citation_reference" content="Wilson, S.C et al., “Design and Synthesis of a Novel Epoxide-Containing Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) via a New Cyclization Procedure,” Tetrahedron Letters, 36, No. 35, 6333-6336 (1995)." scheme="references">
    <meta name="citation_reference" content="Wilson, S.C. et al., “Design, Synthesis, and Evaluation of a Novel Sequence-Selective Epoxide-Containing DNA Cross-Linking Agent Based on the Pyrrolo[2,1-c][1,4]benzodiazepine System”, J. Med. Chem. 42: 4028-4041 (1999)." scheme="references">
    <meta name="citation_reference" content="Wolff, M.E., Burger's Medicinal Chemistry, 4th Edition, Part 1, Wiley: New York (1979) 336-337." scheme="references">
    <meta name="citation_reference" content="Wolff, M.E., Burger's Medicinal Chemistry, 5th Edition, Part I, John Wiley &amp; Sons (1995) 975-977." scheme="references">
    <meta name="citation_reference" content="Workman, P. et al., “United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition),” Br. J. Cancer (1998) 77(1):1-10." scheme="references">
    <meta name="citation_reference" content="Wu et al., “Arming antibodies: prospects and challenges for immunoconjugates,” (2005) Nature Biotech. 23(9):1137-1145." scheme="references">
    <meta name="citation_reference" content="Xie et al., “In vivo behaviour of antibody- drug conjugates for the targeted treatment of cancer,” (2006) Expert. Opin Biol. Ther. 6(3):281-291." scheme="references">
    <meta name="citation_reference" content="Xie, G. et al., “Bisindolylmaleimides linked to DNA minor groove binding lexitropsins: synthesis, inhibitory activity against topoisomerasel, and biological evaluation,” J. Med. Chem. (1996) 39:1049-1055." scheme="references">
    <meta name="citation_reference" content="Xu et al., “Molecular Cloning, Functional Characterization, Tissue Distribution, and Chromosomal Localization of a Human, Small Intestinal Sodium-Phosphate (Na + -Pi) Transporter (SLC34A2),” Genomics 62 (2):281-284 (1999)." scheme="references">
    <meta name="citation_reference" content="Xu, M.J., et al., “Molecular Cloning and Characterization of SPAP1, an Inhibitory Receptor,” (2001) Biochem. Biophys. Res. Commun. 280 (3):768-775." scheme="references">
    <meta name="citation_reference" content="Xu, X.Z., et al., “Regulation of melastatin, a TRP-related protein, through interaction with a cytoplasmic isoform,” Proc. Natl. Acad. Sci. U.S.A. 98 (19):10692-10697 (2001)." scheme="references">
    <meta name="citation_reference" content="Yamaguchi, N., et al., “A Novel Cytokine Exhibiting Megakaryocyte Potentiating Activity From a Human Pancreatic Tumor Cell Line HPC-Y5,” Biol. Chem. 269 (2), 805-808 (1994)." scheme="references">
    <meta name="citation_reference" content="Yamamoto T., et al., “Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor,” Nature 319, 230-234, 1986." scheme="references">
    <meta name="citation_reference" content="Yang et al., “Murine Six-Transmembrane Epithelial Antigen of the Prostate, Prostate Stem Cell Antigen, and Prostate-specific Membrane Antigen: Prostate-specific Cell-Surface Antigens Highly Expressed in Prostate Cancer of Transgenic Adenocarcinoma Mouse Prostate Mice,” Cancer Research, 61, 5857-5860. Aug. 1, 2001." scheme="references">
    <meta name="citation_reference" content="Yin &amp; Lloyd, “Molecular Cloning of the CA125 Ovarian Cancer Antigen,” J. Biol. Chem. 276 (29):27371-27375 (2001)." scheme="references">
    <meta name="citation_reference" content="Younes et al., “Phase 1 multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma,” J Clin Oncol., 2012, 30(22):2776-82." scheme="references">
    <meta name="citation_reference" content="Yu et al., “Human mb-1 gene: complete edna sequence and its expression in b cells bearing membrane Ig of various isotypes,” (1992) J. Immunol. 148(2) 633-637." scheme="references">
    <meta name="citation_reference" content="Zammarchi et al., “Pre-Clinical Development of Adct-4O2, a Novel Pyrrolobenzodiazepine (PBD)—Based Antibody Drug Conjugate (ADC) Targeting CD19-Expressing B-Cell Malignancies,” Blood, 2015, 126:1564, Abstract." scheme="references">
    <meta name="citation_reference" content="Zhao et al., “Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors,” (2016) Clin. Cancer Drugs 3: 76-86." scheme="references">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      body { transition: none; }
    </style>

    <script src="https://apis.google.com/_/scs/abc-static/_/js/k=gapi.lb.en.IKZeRvoAYNY.O/m=client/rt=j/sv=1/d=1/ed=1/am=AAAQ/rs=AHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw/cb=gapi.loaded_0?le=scs" async=""></script><script>
      window.version = 'patent-search.search_20240531_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <style>[hidden]:not([style-scope]):not(.style-scope) {
  display: none !important;
}

</style><style></style><style></style><style></style><style></style><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,300,300italic,400italic,500,500italic,700,700italic"><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto+Mono:400,700"><style></style><style></style><style>
  html, body {
    min-width: 100%;
    width: 100%;
    min-height: 100%;
    height: 100%;
  }

  body {
    background-color: #fff;
    font-family: 'Roboto', sans-serif;
    color: #333;
    margin: 0;
    padding: 0;
    /*
     * Turn off https://github.com/WICG/ScrollAnchoring/blob/master/explainer.md
     * https://memegen.googleplex.com/5230756293246976
     */
    overflow-anchor: none;
  }

  body h1, body h2, body h3 {
    -webkit-font-smoothing: antialiased;
    -moz-osx-font-smoothing: grayscale;
  }

  body a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  body a:visited {
    color: #3c80f6;
  }

  body a[open-result]:visited {
    color: #7e57c2;
  }

  /* For Firefox */
  a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  a:visited {
    color: #3c80f6;
  }

  a[open-result]:visited {
    color: #7e57c2;
  }

  ::selection , body ::selection {
    background-color: #c6dafc;
    color: #333;
  }
</style><link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.html">
  <style>[hidden] { display: none !important; }</style><script type="text/javascript" charset="UTF-8" src="https://apis.google.com/js/client.js" gapi_processed="true"></script></head>
  <body>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.js"></script><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span>
    <search-app>
    
    <remote-fetch class="style-scope search-app"></remote-fetch>
    <search-state class="style-scope search-app"></search-state>
    <browser-ui class="style-scope search-app"></browser-ui>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    
      <search-result id="result" class="style-scope search-app">
    
    
    <search-ui mode="result" class="style-scope search-result x-scope search-ui-0">
    
    
    
    <div id="content" class="style-scope search-ui" wide="">
      <search-header show-search="" class="style-scope search-ui">
    
    
    <div class="style-scope search-header" wide="">
      <header class="style-scope search-header">
        <div class="layout horizontal headerpad style-scope search-header">
          <div class="layout horizontal leftheader style-scope search-header">
            <h1 class="style-scope search-header">
              <state-modifier inherit="" act="{&quot;type&quot;: &quot;HOME&quot;}" class="style-scope search-header"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                <div class="lockup style-scope search-header">
                  <span class="lockup-logo style-scope search-header"></span>
                  <span class="lockup-text style-scope search-header">
                    <span class="lockup-brand style-scope search-header">&nbsp;Patents</span>
                  </span>
                </div>
              </a></state-modifier>
            </h1>
          </div>
          
            <search-box class="style-scope search-header">
    
    <div class="layout horizontal style-scope search-box" style="position: relative;">
      <div class="inputbox flex layout horizontal style-scope search-box">
        <div class="suggest-bg flex style-scope search-box">
          <input name="q" id="searchInput" data-proto="SEARCH_INPUT" autocomplete="off" class="style-scope search-box">
        </div>
        <div id="corpora" class="style-scope search-box">
          <iron-icon icon="icons:lightbulb-outline" id="patentIcon" class="style-scope search-box x-scope iron-icon-0" active=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M9 21c0 .55.45 1 1 1h4c.55 0 1-.45 1-1v-1H9v1zm3-19C8.14 2 5 5.14 5 9c0 2.38 1.19 4.47 3 5.74V17c0 .55.45 1 1 1h6c.55 0 1-.45 1-1v-2.26c1.81-1.27 3-3.36 3-5.74 0-3.86-3.14-7-7-7zm2.85 11.1l-.85.6V16h-4v-2.3l-.85-.6C7.8 12.16 7 10.63 7 9c0-2.76 2.24-5 5-5s5 2.24 5 5c0 1.63-.8 3.16-2.15 4.1z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#patentIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include patents
    </div>
  </overlay-tooltip>
          <iron-icon icon="social:school" id="nplIcon" class="style-scope search-box x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M5 13.18v4L12 21l7-3.82v-4L12 17l-7-3.82zM12 3L1 9l11 6 9-4.91V17h2V9L12 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#nplIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include non-patent literature
    </div>
  </overlay-tooltip>
          <keyword-wizard id="wizardIcon" class="style-scope search-box">


<div id="wizardContainer" class="style-scope keyword-wizard">
  <iron-icon icon="image:tune" id="wizardIcon" class="style-scope keyword-wizard x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M3 17v2h6v-2H3zM3 5v2h10V5H3zm10 16v-2h8v-2h-8v-2h-2v6h2zM7 9v2H3v2h4v2h2V9H7zm14 4v-2H11v2h10zm-6-4h2V7h4V5h-4V3h-2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
  <paper-material elevation="2" id="wizard" class="style-scope keyword-wizard x-scope paper-material-0" hidden="">
    
    

    
    
    <div class="search-within style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Search within
        <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="within"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="withinHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search within the title, abstract, claims, or full patent document</b>: You can
          restrict your search to a specific field using field names.</p>
        <p class="style-scope keyword-wizard">Use <span class="q style-scope keyword-wizard">TI=</span> to search in the title, <span class="q style-scope keyword-wizard">AB=</span> for the
          abstract, <span class="q style-scope keyword-wizard">CL=</span> for the claims, or <span class="q style-scope keyword-wizard">TAC=</span> for
          all three. For example, <span class="q style-scope keyword-wizard">TI=(safety belt)</span>.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search by Cooperative Patent Classifications (CPCs)</b>: These are commonly used to
          represent ideas in place of keywords, and can also be entered in a search term box. If
          you're searching for<span class="q style-scope keyword-wizard">seat belts</span>, you could also search for
          <span class="q style-scope keyword-wizard">B60R22/00</span> to retrieve documents that mention safety belts or body
          harnesses. <span class="q style-scope keyword-wizard">CPC=B60R22</span> will match documents with exactly this CPC,
          <span class="q style-scope keyword-wizard">CPC=B60R22/low</span> matches documents with this CPC or a child
          classification of this CPC.
        </p>
          <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="filter-chips style-scope keyword-wizard">
        <span class="chip style-scope keyword-wizard" id="title" selected="">Title</span>
        <span class="chip style-scope keyword-wizard" id="abstract" selected="">Abstract</span>
        <span class="chip style-scope keyword-wizard" id="claims" selected="">Claims</span>
        <span class="chip style-scope keyword-wizard" id="fullDoc" selected="">Full Document</span>
      </div>
      
      <div class="cpc-field style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputCPC" class="style-scope keyword-wizard">or CPC</label></span>
        <div class="cpc-inputs style-scope keyword-wizard">
          <input class="keyword-input style-scope keyword-wizard" id="inputCPC" placeholder="Or search with CPC">
          <input type="checkbox" id="childCPC" checked="" class="style-scope keyword-wizard">
          <label class="checkbox-label style-scope keyword-wizard" for="childCPC">
            Include child classifications
          </label>
        </div>
      </div>
    </div>
    
    <div class="find-patents style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Find patents
        <iron-icon class="help-header style-scope keyword-wizard x-scope iron-icon-0" icon="icons:help-outline" id="searchBoolean"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="searchBooleanHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Keywords and boolean syntax (USPTO or EPO format)</b>:
          <span class="q style-scope keyword-wizard">seat belt</span> searches these two words, or their plurals and close
          synonyms. <span class="q style-scope keyword-wizard">"seat belt"</span> searches this exact phrase, in order.
          <span class="q style-scope keyword-wizard">-seat -belt</span> searches for documents not containing either word.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">For searches using boolean logic</b>, the default operator is
          <span class="q style-scope keyword-wizard">AND</span> with left associativity. <i class="style-scope keyword-wizard">Note:</i> this means
          <span class="q style-scope keyword-wizard">safety OR seat belt</span> is searched as <span class="q style-scope keyword-wizard">(safety OR seat)
          AND belt</span>. Each word automatically includes plurals and close synonyms. Adjacent
          words that are implicitly ANDed together, such as <span class="q style-scope keyword-wizard">(safety belt)</span>,
          are treated as a phrase when generating synonyms.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputAnd" class="style-scope keyword-wizard">with ALL of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputAnd" placeholder="with ALL of the words">
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputExact" class="style-scope keyword-wizard">with the EXACT PHRASE</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputExact" placeholder="with the EXACT PHRASE"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputOr" class="style-scope keyword-wizard">with AT LEAST ONE of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputOr" placeholder="with AT LEAST ONE of the words"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputMinus" class="style-scope keyword-wizard">WITHOUT the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputMinus" placeholder="WITHOUT the words"></div>
    </div>
    <div class="search-by style-scope keyword-wizard">
      <div class="wizard-header style-scope keyword-wizard">
          Search by
          <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="chem"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </div>
      
      <div class="help style-scope keyword-wizard" id="chemHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Chemistry searches</b> match terms (trade names, IUPAC names, etc.
          extracted from the entire document, and processed from .MOL files.)
        </p>
        <p class="style-scope keyword-wizard">Substructure (use <span class="q style-scope keyword-wizard">SSS=</span>) and similarity (use
          <span class="q style-scope keyword-wizard">~</span>) searches are limited to one per search at the top-level
          <span class="q style-scope keyword-wizard">AND</span> condition. Exact searches can be used multiple times throughout
          the search query.
        </p>
        <p class="style-scope keyword-wizard">Searching by SMILES or InChi key requires no special syntax. To search by SMARTS, use
          <span class="q style-scope keyword-wizard">SMARTS=</span>.
        </p>
        <p class="style-scope keyword-wizard">To search for multiple molecules, select "Batch" in the "Type" menu. Enter multiple
          molecules separated by whitespace or by comma.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      
      <div class="chemistry-field style-scope keyword-wizard">
          <span class="input-label style-scope keyword-wizard"><label for="inputChem" class="style-scope keyword-wizard">Chemistry</label></span>
          <span class="chem-type-label style-scope keyword-wizard"><label for="chemType" hidden="" class="style-scope keyword-wizard">Type</label></span>
          <select id="chemType" class="style-scope keyword-wizard">
            <option value="identical" class="style-scope keyword-wizard">Identical</option>
            <option value="substructure" class="style-scope keyword-wizard">Substructure</option>
            <option value="smarts" class="style-scope keyword-wizard">SMARTS</option>
            <option value="similarity" class="style-scope keyword-wizard">Similarity</option>
            <option value="batch" class="style-scope keyword-wizard">Batch</option>
          </select>
          <textarea class="keyword-input style-scope keyword-wizard" id="inputChem" placeholder="Trade name, SMILES, InChiKey"></textarea>
      </div>
      <div class="import style-scope keyword-wizard">
        <div class="wizard-header style-scope keyword-wizard">
          Patent numbers
        </div>
        <span class="import-button style-scope keyword-wizard">
          <a href="https://patents.google.com/import" class="style-scope keyword-wizard"><button class="style-scope keyword-wizard">Import</button></a>
        </span>
        <p class="import-text style-scope keyword-wizard">
          Search specific patents by importing a CSV or list of patent publication or application numbers.
        </p>
      </div>
    </div>
    
    <div class="wizard-buttons style-scope keyword-wizard">
      <button type="reset" class="style-scope keyword-wizard">Close</button>
      <button type="button" autofocus="" class="style-scope keyword-wizard">Add</button>
    </div>
  
  </paper-material>
</div>
</keyword-wizard>
          <overlay-tooltip positioning-target="#wizardIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Display advanced search options
    </div>
  </overlay-tooltip>
        </div>
      </div>
      <paper-material id="suggestMenu" class="style-scope search-box x-scope paper-material-0" elevation="1" hidden="">
    
    

    
        <template is="dom-repeat" class="style-scope search-box"></template>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Sorry, we couldn't find this patent number.
        </div>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> 
        </div>
      
  </paper-material>
      <button id="searchButton" class="style-scope search-box"><iron-icon class="style-scope search-box x-scope iron-icon-0" icon="search"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></button>
    </div>
  </search-box>
          <template is="dom-if" class="style-scope search-header"></template>
          <div class="flex style-scope search-header"></div>
          
            <div id="header-container" class="style-scope search-header">
              <result-nav class="style-scope search-header">
    
    <div class="style-scope result-nav" hidden="">
      <state-modifier id="current" act="{&quot;type&quot;: &quot;BACK_TO_RESULTS&quot;}" inherit="" class="style-scope result-nav"><a id="link" href="#" class="style-scope state-modifier" inherit=""><span class="style-scope result-nav"></span> of
      <template is="dom-if" class="style-scope result-nav"></template>
      0<template is="dom-if" class="style-scope result-nav"></template></a></state-modifier>
      <state-modifier id="prevResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-left" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.41 7.41L14 6l-6 6 6 6 1.41-1.41L10.83 12z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier><state-modifier id="nextResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-right" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M10 6L8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier>
      <overlay-tooltip positioning-target="#prevResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Previous result
    </div>
  </overlay-tooltip>
      <overlay-tooltip positioning-target="#nextResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Next result
    </div>
  </overlay-tooltip>
    </div>
  </result-nav>
            </div>
          <template is="dom-if" class="style-scope search-header"></template>
        </div>
      </header>
    </div>
  </search-header>

      <div class="layout horizontal style-scope search-ui">
        <template is="dom-if" class="style-scope search-ui"></template>

        <div id="main" class="style-scope search-ui">
          <search-term-wizard class="style-scope search-ui"><pat-dialog open="" class="style-scope search-term-wizard">
  <span class="header style-scope search-term-wizard">
    <span class="title style-scope search-term-wizard">Search tools</span>
    <span id="language" class="style-scope search-term-wizard">
      <text-button id="textButton" selected="" class="style-scope search-term-wizard">Text
</text-button>
      <text-button id="classificationButton" class="style-scope search-term-wizard">Classification
</text-button>
      <text-button id="chemistryButton" class="style-scope search-term-wizard">Chemistry
</text-button>
      <text-button id="measureButton" class="style-scope search-term-wizard">Measure
</text-button>
      <text-button id="numbersButton" class="style-scope search-term-wizard">Numbers
</text-button>
    </span>
  </span>
  <span id="panels" class="style-scope search-term-wizard">
    <text-search-term-wizard id="textPanel" class="style-scope search-term-wizard" selected=""><span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Type a concept you want to search for here" class="style-scope text-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Type a concept you want to search for here">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="title" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Title</filter-chip>
  <filter-chip id="abstract" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Abstract</filter-chip>
  <filter-chip id="claims" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="all" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
All</filter-chip>
  <filter-chip id="any" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Any</filter-chip>
  <filter-chip id="exact" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="not" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Not</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope text-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope text-search-term-wizard">Add AND condition</span></mat-button></span></text-search-term-wizard>
    <classification-wizard id="classificationPanel" class="style-scope search-term-wizard"><span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope classification-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Enter a CPC here" uppercase="" class="style-scope classification-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Enter a CPC here">
  
</span>
</outlined-text-field>
</span>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope classification-wizard"></path>
  </svg>
  <filter-chip id="notExact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These CPCs and their children
  </filter-chip>
  <filter-chip selected="" id="exact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These exact CPCs
  </filter-chip>
</span>
<span class="style-scope classification-wizard">
  <mat-button id="button" filled="" class="style-scope classification-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope classification-wizard">Add AND condition</span></mat-button>
</span></classification-wizard>
    <chemistry-search-term-wizard id="chemistryPanel" class="style-scope search-term-wizard"><span class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Trade name, SMILES, InChI Key" class="style-scope chemistry-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Trade name, SMILES, InChI Key">
  
</span>
</outlined-text-field>
  <outlined-textarea id="textArea" placeholder="Enter multiple SMILES or InChI Keys, one per line" rows="4" class="style-scope chemistry-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple SMILES or InChI Keys, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
  <a href="https://support.google.com/faqs/answer/7049475#zippy=%2Csearching-by-chemistry" target="_blank" class="style-scope chemistry-search-term-wizard">
    <svg class="help style-scope chemistry-search-term-wizard" xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49">
      <path d="M11.95 18q.525 0 .888-.363.362-.362.362-.887t-.362-.887q-.363-.363-.888-.363t-.888.363q-.362.362-.362.887t.362.887q.363.363.888.363Zm-.9-3.85h1.85q0-.825.188-1.3.187-.475 1.062-1.3.65-.65 1.025-1.238.375-.587.375-1.412 0-1.4-1.025-2.15T12.1 6q-1.425 0-2.312.75-.888.75-1.238 1.8l1.65.65q.125-.45.563-.975Q11.2 7.7 12.1 7.7q.8 0 1.2.437.4.438.4.963 0 .5-.3.937-.3.438-.75.813-1.1.975-1.35 1.475-.25.5-.25 1.825ZM12 22q-2.075 0-3.9-.788-1.825-.787-3.175-2.137-1.35-1.35-2.137-3.175Q2 14.075 2 12t.788-3.9q.787-1.825 2.137-3.175 1.35-1.35 3.175-2.138Q9.925 2 12 2t3.9.787q1.825.788 3.175 2.138 1.35 1.35 2.137 3.175Q22 9.925 22 12t-.788 3.9q-.787 1.825-2.137 3.175-1.35 1.35-3.175 2.137Q14.075 22 12 22Zm0-2q3.35 0 5.675-2.325Q20 15.35 20 12q0-3.35-2.325-5.675Q15.35 4 12 4 8.65 4 6.325 6.325 4 8.65 4 12q0 3.35 2.325 5.675Q8.65 20 12 20Zm0-8Z" class="style-scope chemistry-search-term-wizard"></path>
    </svg>
  </a>
</span>
<span id="chemQuantifiers" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M5 21.2q-1.4 0-2-1.25-.6-1.25.3-2.325l5.5-6.7V5.15h-.825q-.475 0-.8-.338Q6.85 4.475 6.85 4q0-.475.325-.813.325-.337.8-.337h8.05q.475 0 .8.337.325.338.325.813 0 .475-.325.812-.325.338-.8.338H15.2v5.775l5.5 6.7q.9 1.075.3 2.325-.6 1.25-2 1.25Zm2.15-3.275h9.7l-3.275-3.85h-3.15Zm-2 1h13.7l-5.925-7.2V5.15h-1.85v6.575Zm6.85-6.9Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="exact" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="exactBatch" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact Batch</filter-chip>
  <filter-chip id="similar" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Similar</filter-chip>
  <filter-chip id="substructure" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure</filter-chip>
  <filter-chip id="smarts" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure (SMARTS)</filter-chip>
</span>
<span id="location" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="claims" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims only</filter-chip>
</span>
<span class="style-scope chemistry-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope chemistry-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope chemistry-search-term-wizard">Add AND condition</span></mat-button>
</span>
</chemistry-search-term-wizard>
    <measure-search-term-wizard id="measurePanel" class="style-scope search-term-wizard"><span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M4.1 18.15q-.95 0-1.612-.663-.663-.662-.663-1.612v-7.75q0-.95.663-1.613Q3.15 5.85 4.1 5.85h15.8q.95 0 1.613.662.662.663.662 1.613v7.75q0 .95-.662 1.612-.663.663-1.613.663Zm0-2.275h15.8v-7.75H17V12h-2V8.125h-2V12h-2V8.125H9V12H7V8.125H4.1v7.75ZM7 12h2Zm4 0h2Zm4 0h2Zm-3 0Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="measureExpression" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M3.875 20.15V8.85h4.25v11.3Zm6 0V3.85h4.25v16.3Zm6 0v-7.3h4.25v7.3Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="context" placeholder="activity, wavelength, embossing depth, absorption" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="activity, wavelength, embossing depth, absorption">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope measure-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope measure-search-term-wizard">Add AND condition</span></mat-button>
</span>
</measure-search-term-wizard>
    <numerical-search-term-wizard id="numericalPanel" class="style-scope search-term-wizard"><span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-textarea id="batch" placeholder="Enter multiple Patent Application and Publication Numbers, one per line" rows="4" class="style-scope numerical-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple Patent Application and Publication Numbers, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
</span>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="m10.825 23.45-1.6-1.625L10.9 20.15H8q-.35.9-1.162 1.488-.813.587-1.838.587-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.025.588-1.837Q2.95 16.35 3.85 16V8q-.9-.35-1.487-1.163Q1.775 6.025 1.775 5q0-1.35.938-2.288Q3.65 1.775 5 1.775q1.025 0 1.838.587Q7.65 2.95 8 3.85h2.9L9.225 2.175l1.6-1.625L15.275 5l-4.45 4.45-1.6-1.625L10.9 6.15H8q-.25.65-.725 1.125T6.15 8v8q.65.25 1.125.725T8 17.85h2.9l-1.675-1.675 1.6-1.625 4.45 4.45ZM19 22.225q-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.05.588-1.863.587-.812 1.487-1.137V8q-.9-.325-1.487-1.137-.588-.813-.588-1.863 0-1.35.938-2.288.937-.937 2.287-.937 1.35 0 2.288.937.937.938.937 2.288 0 1.05-.587 1.863Q21.05 7.675 20.15 8v8q.9.35 1.488 1.163.587.812.587 1.837 0 1.35-.937 2.288-.938.937-2.288.937ZM5 19.95q.4 0 .675-.275T5.95 19q0-.4-.275-.675T5 18.05q-.4 0-.675.275T4.05 19q0 .4.275.675T5 19.95Zm14 0q.4 0 .675-.275T19.95 19q0-.4-.275-.675T19 18.05q-.4 0-.675.275T18.05 19q0 .4.275.675t.675.275Zm-14-14q.4 0 .675-.275T5.95 5q0-.4-.275-.675T5 4.05q-.4 0-.675.275T4.05 5q0 .4.275.675T5 5.95Zm14 0q.4 0 .675-.275T19.95 5q0-.4-.275-.675T19 4.05q-.4 0-.675.275T18.05 5q0 .4.275.675T19 5.95ZM5 19Zm14 0ZM5 5Zm14 0Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <filter-chip id="applicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Application Numbers</filter-chip>
  <filter-chip id="publicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Publication Numbers</filter-chip>
  <filter-chip id="either" selected="" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Either</filter-chip>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M12 22.2q-2.1 0-3.962-.8-1.863-.8-3.25-2.175Q3.4 17.85 2.6 15.988 1.8 14.125 1.8 12t.8-3.988q.8-1.862 2.188-3.237Q6.175 3.4 8.038 2.6 9.9 1.8 12 1.8q2.125 0 3.988.8 1.862.8 3.237 2.175Q20.6 6.15 21.4 8.012q.8 1.863.8 3.988t-.8 3.988q-.8 1.862-2.175 3.237Q17.85 20.6 15.988 21.4q-1.863.8-3.988.8Zm-1-2.325v-1.95q-.8 0-1.387-.575-.588-.575-.588-1.4v-.975L4.275 10.2q-.075.45-.137.9-.063.45-.063.9 0 3 1.975 5.25T11 19.875Zm6.85-2.525q.5-.55.888-1.175.387-.625.65-1.313.262-.687.4-1.412.137-.725.137-1.45 0-2.425-1.338-4.438-1.337-2.012-3.612-2.887v.375q0 .825-.587 1.4-.588.575-1.388.575h-2v2q0 .4-.287.687-.288.288-.688.288h-2v2h5.95q.425 0 .713.287.287.288.287.688v2.975h1q.65 0 1.163.387.512.388.712 1.013Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryFilter" placeholder="Restrict search to these countries" class="style-scope numerical-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Restrict search to these countries">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M2.85 18.225V15.95h6.3v2.275Zm0-5.075v-2.3h12.3v2.3Zm0-5.1V5.775h18.3V8.05Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryOrder" placeholder="Prefer results from these countries in this order" class="style-scope numerical-search-term-wizard" value="US, EP, WO, JP, CN"><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Prefer results from these countries in this order">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope numerical-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope numerical-search-term-wizard">Add AND condition</span></mat-button>
</span>
</numerical-search-term-wizard>
  </span>

</pat-dialog>
</search-term-wizard>
          
      <div content="" class="style-scope search-result">
        <div id="mainContainer" class="vertical layout style-scope search-result">
          <template is="dom-if" class="style-scope search-result"></template>
          <result-container class="style-scope search-result">
    

    <paper-spinner class="style-scope result-container x-scope paper-spinner-0" aria-hidden="true" hidden=""><div id="spinnerContainer" class="  style-scope paper-spinner"><div class="spinner-layer layer-1 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-2 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-3 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-4 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div></div></paper-spinner>
    
      <patent-result class="style-scope result-container">
    
    
    <div class="layout horizontal style-scope patent-result">
      <div style="width: 1200px; height: auto; overflow: auto;" class="style-scope patent-result">
        <div id="wrapper" tabindex="0" class="style-scope patent-result">
          <result-tags class="style-scope patent-result"></result-tags>
          <h1 id="title" class="scroll-target style-scope patent-result">
            Pyrrolobenzodiazepine conjugates 
       </h1>
          <div class="horizontal layout style-scope patent-result">
            
            <div class="flex-3 style-scope patent-result" style="margin-top:-20px;overflow:hidden;" marginright="">
              <section id="abstract" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Abstract</div>
                  <div class="righthead style-scope patent-result" hidden="">translated from </div>
                </h3>
                <patent-text name="abstract" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><abstract mxw-id="PA505123589" lang="EN" load-source="patent-office" class="style-scope patent-text">
    <div id="p-0001" num="0000" class="abstract style-scope patent-text">A compound of formula I and salts and solvates thereof, wherein: R<sup class="style-scope patent-text">6 </sup>and R<sup class="style-scope patent-text">9 </sup>are independently selected from H, R, OH, OR, SH, SR, NH<sub class="style-scope patent-text">2</sub>, NHR, NRR′, nitro, Me<sub class="style-scope patent-text">3</sub>Sn and halo; where R and R′ are independently selected from optionally substituted C<sub class="style-scope patent-text">1-12 </sub>alkyl, C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl and C<sub class="style-scope patent-text">5-20 </sub>aryl groups; R<sup class="style-scope patent-text">7 </sup>is selected from H, R, OH, OR, SH, SR, NH<sub class="style-scope patent-text">2</sub>, NHR, NRR′, nitro, Me<sub class="style-scope patent-text">3</sub>Sn and halo; R″ is a C<sub class="style-scope patent-text">3-12 </sub>alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, NR<sup class="style-scope patent-text">N2 </sup>(where R<sup class="style-scope patent-text">N2 </sup>is H or C<sub class="style-scope patent-text">1-4 </sub>alkyl), and/or aromatic rings, e.g. benzene or pyridine; Y and Y′ are selected from O, S, or NH; R<sup class="style-scope patent-text">6</sup>, R<sup class="style-scope patent-text">7</sup>, R<sup class="style-scope patent-text">9 </sup>are selected from the same groups as R<sup class="style-scope patent-text">6</sup>, R<sup class="style-scope patent-text">7 </sup>and R<sup class="style-scope patent-text">9 </sup>respectively; R<sup class="style-scope patent-text">11b </sup>is selected from OH, OR<sup class="style-scope patent-text">A</sup>, where R<sup class="style-scope patent-text">A </sup>is C<sub class="style-scope patent-text">1-4 </sub>alkyl; and R<sup class="style-scope patent-text">L </sup>is a linker for connection to a cell binding agent.</div>
    <div id="p-0002" num="0000" class="abstract style-scope patent-text">
      <chemistry id="CHEM-US-00001" num="00001" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/ce/d6/93/36662faacacbca/US11370801-20220628-C00001.png" class="style-scope patent-text"><img id="EMI-C00001" he="38.35mm" wi="74.85mm" file="US11370801-20220628-C00001.TIF" alt="Figure US11370801-20220628-C00001" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="299" height="153" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/ce/d6/93/36662faacacbca/US11370801-20220628-C00001.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00001" attachment-type="cdx" file="US11370801-20220628-C00001.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00001" attachment-type="mol" file="US11370801-20220628-C00001.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
    </div>
  </abstract>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <section id="classifications" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Classifications</div>
                  <div id="machineClassifiedWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">machine-classified</div>
                  <div id="machineClassifiedCPCWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">cpc-machine-classified</div>
                  <div id="machineClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-machine-classified</div>
                  <div class="style-scope patent-result" hidden="">&nbsp;</div>
                  <div id="familyClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-family-classified</div>
                </h3>
                <overlay-tooltip positioning-target="#machineClassifiedWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedCPCWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The CPC classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#familyClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned based on a patent family member containing these classification codes.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <classification-viewer class="style-scope patent-result">
    
    <div class="table style-scope classification-viewer">
      
        <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07D"><a id="link" href="#" class="style-scope state-modifier">C07D</a></state-modifier>
                  <span class="description style-scope classification-tree">HETEROCYCLIC COMPOUNDS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" first="true" data-cpc="C07D519/00"><a id="link" href="#" class="style-scope state-modifier">C07D519/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
      <template is="dom-repeat" class="style-scope classification-viewer"></template>
      
      <div class="style-scope classification-viewer">
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/50"><a id="link" href="#" class="style-scope state-modifier">A61K47/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/51"><a id="link" href="#" class="style-scope state-modifier">A61K47/51</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/68"><a id="link" href="#" class="style-scope state-modifier">A61K47/68</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/50"><a id="link" href="#" class="style-scope state-modifier">A61K47/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/51"><a id="link" href="#" class="style-scope state-modifier">A61K47/51</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/68"><a id="link" href="#" class="style-scope state-modifier">A61K47/68</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6801"><a id="link" href="#" class="style-scope state-modifier">A61K47/6801</a></state-modifier>
                  <span class="description style-scope classification-tree">Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6803"><a id="link" href="#" class="style-scope state-modifier">A61K47/6803</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/50"><a id="link" href="#" class="style-scope state-modifier">A61K47/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/51"><a id="link" href="#" class="style-scope state-modifier">A61K47/51</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/68"><a id="link" href="#" class="style-scope state-modifier">A61K47/68</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6835"><a id="link" href="#" class="style-scope state-modifier">A61K47/6835</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6851"><a id="link" href="#" class="style-scope state-modifier">A61K47/6851</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/50"><a id="link" href="#" class="style-scope state-modifier">A61K47/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/51"><a id="link" href="#" class="style-scope state-modifier">A61K47/51</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/68"><a id="link" href="#" class="style-scope state-modifier">A61K47/68</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6835"><a id="link" href="#" class="style-scope state-modifier">A61K47/6835</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6851"><a id="link" href="#" class="style-scope state-modifier">A61K47/6851</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6855"><a id="link" href="#" class="style-scope state-modifier">A61K47/6855</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P35/00"><a id="link" href="#" class="style-scope state-modifier">A61P35/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Antineoplastic agents</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K5/00"><a id="link" href="#" class="style-scope state-modifier">C07K5/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K5/04"><a id="link" href="#" class="style-scope state-modifier">C07K5/04</a></state-modifier>
                  <span class="description style-scope classification-tree">Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K5/06"><a id="link" href="#" class="style-scope state-modifier">C07K5/06</a></state-modifier>
                  <span class="description style-scope classification-tree">Dipeptides</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        <template is="dom-repeat" class="style-scope classification-viewer"></template>
        <div class="more style-scope classification-viewer" style="" hidden="">View 6 more classifications</div>
        <div class="more style-scope classification-viewer">Hide more classifications</div>
      </div>
      <template is="dom-if" class="style-scope classification-viewer"></template>
    </div>
  </classification-viewer>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              
                <section class="style-scope patent-result">
                  <h3 class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Landscapes</div>
                  </h3>
                  <div class="responsive-grid style-scope patent-result">
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Health &amp; Medical Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Health &amp; Medical Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Chemical &amp; Material Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Chemical &amp; Material Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    <template is="dom-repeat" class="style-scope patent-result"></template>
                  </div>
                  <s-more-inline class="style-scope patent-result"><hr aria-hidden="true" class="style-scope s-more-inline">

<div class="button style-scope s-more-inline">
  <span slot="expand_text" class="style-scope patent-result">Show more</span>
  <span class="expand more style-scope s-more-inline"></span>
</div>
<div class="button style-scope s-more-inline" hidden="">
  <span slot="collapse_text" class="style-scope patent-result">Show less</span>
  <span class="expand less style-scope s-more-inline"></span>
</div>
</s-more-inline>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
            <div class="flex-2 style-scope patent-result">
              <section class="knowledge-card style-scope patent-result">
                <header class="style-scope patent-result">
                  <h2 id="pubnum" class="style-scope patent-result">US11370801B2</h2>
                  <p class="tagline style-scope patent-result">United States</p>
                  <overlay-tooltip positioning-target="#pubnum" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                    <div style="max-width: 300px;" class="style-scope patent-result">Patent ( having previously published pre-grant publication)</div>
                  
    </div>
  </overlay-tooltip>

                  <div class="knowledge-card-action-bar style-scope patent-result">
                    <a target="_blank" class="style-scope patent-result" href="https://patentimages.storage.googleapis.com/9d/49/2d/c9313e48b71124/US11370801.pdf"><iron-icon icon="description" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download PDF</a>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_FIND_PRIOR_ART&quot;, &quot;keywords&quot;: $keywords, &quot;before&quot;: &quot;$before&quot;}" class="style-scope patent-result" data-keywords="[&quot;genbank&quot;,&quot;seq&quot;,&quot;antibody&quot;,&quot;update date&quot;,&quot;record update&quot;]" data-before="20170418"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="find-in-page" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 19.59V8l-6-6H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c.45 0 .85-.15 1.19-.4l-4.43-4.43c-.8.52-1.74.83-2.76.83-2.76 0-5-2.24-5-5s2.24-5 5-5 5 2.24 5 5c0 1.02-.31 1.96-.83 2.75L20 19.59zM9 13c0 1.66 1.34 3 3 3s3-1.34 3-3-1.34-3-3-3-3 1.34-3 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Find Prior Art
                    </a></state-modifier>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_SIMILAR_DOCUMENTS&quot;, &quot;id&quot;: &quot;$id&quot;}" class="style-scope patent-result" data-id="patent/US11370801B2"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="editor:functions" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M18 4H6v2l6.5 6L6 18v2h12v-3h-7l5-5-5-5h7z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Similar
                    </a></state-modifier>
                  </div>
                </header>

                <dl class="important-people style-scope patent-result">
                  <template is="dom-if" class="style-scope patent-result"></template>
                  
                  <dt class="style-scope patent-result">Inventor</dt>
                  <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Philip Wilson Howard"><a id="link" href="#" class="style-scope state-modifier">Philip Wilson Howard</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Stephen John Gregson"><a id="link" href="#" class="style-scope state-modifier">Stephen John Gregson</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>

                  
                  <dt class="style-scope patent-result">
                    <span class="tooltip-hint style-scope patent-result" id="assigneeWarning">Current Assignee</span>
                    <overlay-tooltip positioning-target="#assigneeWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                      The listed assignees may be inaccurate.<br class="style-scope patent-result">
                      Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.
                    
    </div>
  </overlay-tooltip>
                  </dt>
                  <dd class="style-scope patent-result">
                    
    MedImmune Ltd
  
                  </dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                </dl>

                <hr class="style-scope patent-result">

                <application-timeline class="style-scope patent-result">
    
    
    <div class="wrap style-scope application-timeline">
      <div class="header style-scope application-timeline">Worldwide applications</div>
      <div class="event style-scope application-timeline">
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2018</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/PT3612537T/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">PT</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PT187184528T</div>
                <div class="style-scope application-timeline">Filing date: 2018-04-18</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/HUE059828T2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">HU</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: HUE18718452A</div>
                <div class="style-scope application-timeline">Filing date: 2018-04-18</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ES2926144T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">ES</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: ES18718452T</div>
                <div class="style-scope application-timeline">Filing date: 2018-04-18</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CN110582505B/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CN</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CN201880025726.7A</div>
                <div class="style-scope application-timeline">Filing date: 2018-04-18</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/PL3612537T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">PL</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PL18718452.8T</div>
                <div class="style-scope application-timeline">Filing date: 2018-04-18</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/LT3612537T/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">LT</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: LTEPPCT/EP2018/059846T</div>
                <div class="style-scope application-timeline">Filing date: 2018-04-18</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/RS63502B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">RS</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: RS20220775A</div>
                <div class="style-scope application-timeline">Filing date: 2018-04-18</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US11370801B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline" this="">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US16/605,962</div>
                <div class="style-scope application-timeline">Filing date: 2018-04-18</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP3612537B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP18718452.8A</div>
                <div class="style-scope application-timeline">Filing date: 2018-04-18</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/DK3612537T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">DK</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: DK18718452.8T</div>
                <div class="style-scope application-timeline">Filing date: 2018-04-18</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/BR112019021942A2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">BR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: BR112019021942A</div>
                <div class="style-scope application-timeline">Filing date: 2018-04-18</div>
                <div class="style-scope application-timeline">Legal status: Search and Examination</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA3059519C/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CA3059519A</div>
                <div class="style-scope application-timeline">Filing date: 2018-04-18</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/AU2018255876B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">AU</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: AU2018255876A</div>
                <div class="style-scope application-timeline">Filing date: 2018-04-18</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/MX2019012467A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">MX</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: MX2019012467A</div>
                <div class="style-scope application-timeline">Filing date: 2018-04-18</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/HRP20221063T1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">HR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: HRP20221063TT</div>
                <div class="style-scope application-timeline">Filing date: 2018-04-18</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/SI3612537T1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">SI</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: SI201830751T</div>
                <div class="style-scope application-timeline">Filing date: 2018-04-18</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/WO2018192944A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">WO</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PCT/EP2018/059846</div>
                <div class="style-scope application-timeline">Filing date: 2018-04-18</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP2020517609A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">JP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: JP2019556593A</div>
                <div class="style-scope application-timeline">Filing date: 2018-04-18</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/KR102189731B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">KR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: KR1020197031018A</div>
                <div class="style-scope application-timeline">Filing date: 2018-04-18</div>
                <div class="style-scope application-timeline">Legal status: IP Right Grant</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2019</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ZA201906675B/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">ZA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: ZA2019/06675A</div>
                <div class="style-scope application-timeline">Filing date: 2019-10-09</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/IL269945B/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">IL</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: IL269945A</div>
                <div class="style-scope application-timeline">Filing date: 2019-10-10</div>
                <div class="style-scope application-timeline">Legal status: IP Right Grant</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2021</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP7309764B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">JP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: JP2021024754A</div>
                <div class="style-scope application-timeline">Filing date: 2021-02-19</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        <template is="dom-repeat" class="style-scope application-timeline"></template>
      </div>
      <hr class="style-scope application-timeline">
      <div class="header style-scope application-timeline">Application US16/605,962 events <iron-icon id="legal" icon="icons:help-outline" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        <overlay-tooltip positioning-target="#legal" direction="right" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
          <div style="max-width: 300px;" class="style-scope application-timeline">
            A timeline of key events for this patent application, including priority claims, publications, legal status, reassignments, and litigation.<br class="style-scope application-timeline"><br class="style-scope application-timeline">
            Google has not performed a legal analysis and makes no representation as to the accuracy or completeness of the events listed.
          </div>
        
    </div>
  </overlay-tooltip>
      </div>
      <div class="event layout horizontal style-scope application-timeline"><div date="" class="external-priority style-scope application-timeline">2017-04-18</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/GB201706133D0/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Priority claimed from GBGB1706133.4A</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline"><div date="" class="external-priority style-scope application-timeline">2017-12-19</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/GB201721337D0/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Priority claimed from GBGB1721337.2A</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="filed style-scope application-timeline">2018-04-18</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_ASSIGNEE&quot;, &quot;assignee&quot;: &quot;$assignee&quot;}" class="style-scope application-timeline" data-assignee="MedImmune Ltd"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Application filed by MedImmune Ltd</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline"><div date="" class="reassignment style-scope application-timeline">2019-10-18</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_ASSIGNEE&quot;, &quot;assignee&quot;: &quot;$assignee&quot;}" class="style-scope application-timeline" data-assignee="MEDIMMUNE LIMITED"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Assigned to MEDIMMUNE LIMITED</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><iron-icon id="icon" icon="icons:help-outline" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><overlay-tooltip positioning-target="#icon" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      <div class="description-item style-scope application-timeline">ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).</div><div class="description-item style-scope application-timeline">Assignors: GREGSON, STEPHEN JOHN, HOWARD, PHILIP WILSON</div><template is="dom-repeat" class="style-scope application-timeline"></template>
    </div>
  </overlay-tooltip><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2020-04-16</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US20200115390A1/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of US20200115390A1</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="granted style-scope application-timeline">2022-06-28</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Application granted</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2022-06-28</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US11370801B2/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of US11370801B2</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" current="" critical=""><div date="" class="legal-status style-scope application-timeline">Status</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Active</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="legal-status style-scope application-timeline">2038-04-18</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Anticipated expiration</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><template is="dom-repeat" strip-whitespace="" class="style-scope application-timeline"></template>
      <template is="dom-if" class="style-scope application-timeline"></template>
    </div>
  </application-timeline>
                <hr class="style-scope patent-result">

                <dl class="links style-scope patent-result">
                  <dt class="style-scope patent-result">Info</dt>

                  
                  <dd class="style-scope patent-result"><a href="#patentCitations" class="style-scope patent-result">Patent citations (418)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#nplCitations" class="style-scope patent-result">Non-patent citations (459)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#citedBy" class="style-scope patent-result">Cited by (10)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#legalEvents" class="style-scope patent-result">Legal events</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#similarDocuments" class="style-scope patent-result">Similar documents</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#relatedApplications" class="style-scope patent-result">Priority and Related Applications</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <dt class="style-scope patent-result">External links</dt>

                  <dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&amp;Sect2=HITOFF&amp;p=1&amp;u=/netahtml/PTO/srchnum.html&amp;r=1&amp;f=G&amp;l=50&amp;d=PALL&amp;s1=11370801.PN.">USPTO</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patentcenter.uspto.gov/applications/16605962">USPTO PatentCenter</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://assignment.uspto.gov/patent/index.html#/patent/search/resultFilter?searchInput=11370801">USPTO Assignment</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=US&amp;NR=11370801B2&amp;KC=B2&amp;FT=D">Espacenet</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://globaldossier.uspto.gov/#/result/patent/US/11370801/1">Global Dossier</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patents.stackexchange.com/questions/tagged/US11370801">Discuss</a></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                </dl>
              </section>
            </div>
          </div>

          <div id="text" class="horizontal layout style-scope patent-result">
            <div class="flex flex-width style-scope patent-result" marginright="">
              <section id="description" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Description</div>
                  <div class="righthead style-scope patent-result" hidden="">translated from </div>
                </h3>
                <patent-text name="description" id="descriptionText" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><div mxw-id="PDES332309170" lang="EN" load-source="patent-office" class="description style-scope patent-text">
    
    <heading id="h-0001" class="style-scope patent-text">CROSS REFERENCE TO RELATED APPLICATIONS</heading>
    <div id="p-0003" num="0001" class="description-paragraph style-scope patent-text">This application is a national phase application under 35 U.S.C. § 371 of International Application No. PCT/EP2018/059846, filed Apr. 18, 2018, which claims the benefit of Great Britain Application No. 1721337.2, filed Dec. 19, 2017, and Great Britain Application No. 1706133.4, filed Apr. 18, 2017, each of which is herein incorporated by reference.</div>
    <heading id="h-0002" class="style-scope patent-text">INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY</heading>
    <div id="p-0004" num="0002" class="description-paragraph style-scope patent-text">Incorporated by reference in its entirety herein is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: One 47,814 Byte ASCII (Text) file named “2020-01-02_38075-251_SQL_ST25,” created on Jan. 2, 2020.</div>
    <div id="p-0005" num="0003" class="description-paragraph style-scope patent-text">The present invention relates to conjugates comprising pyrrolobenzodiazepines and related dimers (PBDs), and the precursor drug linkers used to make such conjugates.</div>
    <heading id="h-0003" class="style-scope patent-text">BACKGROUND TO THE INVENTION</heading>
    <div id="p-0006" num="0004" class="description-paragraph style-scope patent-text">Some pyrrolobenzodiazepines (PBDs) have the ability to recognise and bond to specific sequences of DNA; the preferred sequence is PuGPu. The first PBD antitumour antibiotic, anthramycin, was discovered in 1965 (Leimgruber, et al., <i class="style-scope patent-text">J. Am. Chem. Soc., </i>87, 5793-5795 (1965); Leimgruber, et al., <i class="style-scope patent-text">J. Am. Chem. Soc., </i>87, 5791-5793 (1965)). Since then, a number of naturally occurring PBDs have been reported, and over 10 synthetic routes have been developed to a variety of analogues (Thurston, et al., <i class="style-scope patent-text">Chem. Rev. </i>1994, 433-465 (1994)). Family members include abbeymycin (Hochlowski, et al., <i class="style-scope patent-text">J. Antibiotics, </i>40, 145-148 (1987)), chicamycin (Konishi, et al., <i class="style-scope patent-text">J. Antibiotics, </i>37, 200-206 (1984)), DC-81 (Japanese Patent 58-180 487; Thurston, et al., <i class="style-scope patent-text">Chem. Brit., </i>26, 767-772 (1990); Bose, et al., <i class="style-scope patent-text">Tetrahedron, </i>48, 751-758 (1992)), mazethramycin (Kuminoto, et al., <i class="style-scope patent-text">J. Antibiotics, </i>33, 665-667 (1980)), neothramycins A and B (Takeuchi, et al., <i class="style-scope patent-text">J. Antibiotics, </i>29, 93-96 (1976)), porothramycin (Tsunakawa, et al., <i class="style-scope patent-text">J. Antibiotics, </i>41, 1366-1373 (1988)), prothracarcin (Shimizu, et al, <i class="style-scope patent-text">J. Antibiotics, </i>29, 2492-2503 (1982); Langley and Thurston, <i class="style-scope patent-text">J. Org. Chem., </i>52, 91-97 (1987)), sibanomicin (DC-102)(Hara, et al., <i class="style-scope patent-text">J. Antibiotics, </i>41, 702-704 (1988); Itoh, et al., <i class="style-scope patent-text">J. Antibiotics, </i>41, 1281-1284 (1988)), sibiromycin (Leber, et al., <i class="style-scope patent-text">J. Am. Chem. Soc., </i>110, 2992-2993 (1988)) and tomamycin (Arima, et al., <i class="style-scope patent-text">J. Antibiotics, </i>25, 437-444 (1972)). PBDs are of the general structure:</div>
    <div id="p-0007" num="0005" class="description-paragraph style-scope patent-text">
      <chemistry id="CHEM-US-00002" num="00002" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/57/c3/c9/efe56900a2abb7/US11370801-20220628-C00002.png" class="style-scope patent-text"><img id="EMI-C00002" he="23.54mm" wi="31.75mm" file="US11370801-20220628-C00002.TIF" alt="Figure US11370801-20220628-C00002" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="127" height="94" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/57/c3/c9/efe56900a2abb7/US11370801-20220628-C00002.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00002" attachment-type="cdx" file="US11370801-20220628-C00002.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00002" attachment-type="mol" file="US11370801-20220628-C00002.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
    </div>
    <div id="p-0008" num="0006" class="description-paragraph style-scope patent-text">They differ in the number, type and position of substituents, in both their aromatic A rings and pyrrolo C rings, and in the degree of saturation of the C ring. In the B-ring there is either an imine (N═C), a carbinolamine (NH—CH(OH)), or a carbinolamine methyl ether (NH—CH(OMe))ram at the N10-C11 position which is the electrophilic centre responsible for alkylating DNA. All of the known natural products have an (S)-configuration at the chiral C11a position which provides them with a right-handed twist when viewed from the C ring towards the A ring. This gives them the appropriate three-dimensional shape for isohelicity with the minor groove of B-form DNA, leading to a snug fit at the binding site (Kohn, In <i class="style-scope patent-text">Antibiotics III</i>. Springer-Verlag, New York, pp. 3-11 (1975); Hurley and Needham-VanDevanter, <i class="style-scope patent-text">Acc. Chem. Res., </i>19, 230-237 (1986)). Their ability to form an adduct in the minor groove, enables them to interfere with DNA processing, hence their use as antitumour agents.</div>
    <div id="p-0009" num="0007" class="description-paragraph style-scope patent-text">It has been previously disclosed that the biological activity of this molecules can be potentiated by joining two PBD units together through their C8/C′-hydroxyl functionalities via a flexible alkylene linker (Bose, D. S., et al., <i class="style-scope patent-text">J. Am. Chem. Soc., </i>114, 4939-4941 (1992); Thurston, D. E., et al., <i class="style-scope patent-text">J. Org. Chem., </i>61, 8141-8147 (1996)). The PBD dimers are thought to form sequence-selective DNA lesions such as the palindromic 5′-Pu-GATC-Py-3′ interstrand cross-link (Smellie, M., et al., <i class="style-scope patent-text">Biochemistry, </i>42, 8232-8239 (2003); Martin, C., et al., <i class="style-scope patent-text">Biochemistry, </i>44, 4135-4147) which is thought to be mainly responsible for their biological activity.</div>
    <div id="p-0010" num="0008" class="description-paragraph style-scope patent-text">The first dimers (Bose, D. S., et al., <i class="style-scope patent-text">J. Am. Chem. Soc., </i>114, 4939-4941 (1992)) were of the general formula:</div>
    <div id="p-0011" num="0009" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00003" num="00003" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/39/e8/3e/cae786d6ea904d/US11370801-20220628-C00003.png" class="style-scope patent-text"><img id="EMI-C00003" he="20.49mm" wi="75.01mm" file="US11370801-20220628-C00003.TIF" alt="Figure US11370801-20220628-C00003" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="300" height="82" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/39/e8/3e/cae786d6ea904d/US11370801-20220628-C00003.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00003" attachment-type="cdx" file="US11370801-20220628-C00003.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00003" attachment-type="mol" file="US11370801-20220628-C00003.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
where n is from 3 to 6. The compounds where n were 3 and 5 showed promising cytoxicity in vitro. However when antitumor activity of the the n=3 compound (DSB-120) was studied (Walton, M., et al., <i class="style-scope patent-text">Cancer Chemother Pharmacol </i>(1996) 38: 431. doi:10.1007/s002800050507), this was found not to be as promising. This lack of promise was thought to be “a consequence of low tumour selectivity and drug uptake as a result of high protein binding and/or extensive drug metabolism in vivo”.
</div>
    <div id="p-0012" num="0010" class="description-paragraph style-scope patent-text">In order to improve on these compounds, compounds were investigated (Gregson, S. J., et al., Chem. Commun., 1999, 797-798. doi: 10.1039/A809791G) with the “inclusion of C2/C2′ substituents that should follow the contour of the host minor groove”. This compound SG2000 (SJG-136):</div>
    <div id="p-0013" num="0011" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00004" num="00004" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/17/b6/31/6468edbf40a546/US11370801-20220628-C00004.png" class="style-scope patent-text"><img id="EMI-C00004" he="15.75mm" wi="74.93mm" file="US11370801-20220628-C00004.TIF" alt="Figure US11370801-20220628-C00004" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="300" height="63" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/17/b6/31/6468edbf40a546/US11370801-20220628-C00004.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00004" attachment-type="cdx" file="US11370801-20220628-C00004.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00004" attachment-type="mol" file="US11370801-20220628-C00004.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
was found to have “exquisite cytotoxicity in the picomolar region . . . some 9000-fold more potent that DSB-120.”
</div>
    <div id="p-0014" num="0012" class="description-paragraph style-scope patent-text">This compound (also discussed in Gregson, S., et al., <i class="style-scope patent-text">J. Med. Chem., </i>44, 737-748 (2001); Alley, M. C., et al., <i class="style-scope patent-text">Cancer Research, </i>64, 6700-6706 (2004); and Hartley, J. A., et al., <i class="style-scope patent-text">Cancer Research, </i>64, 6693-6699 (2004)) has been involved in clinical trials as a standalone agent, for example, NCT02034227 investigating its use in treating Acute Myeloid Leukemia and Chronic Lymphocytic Leukemia (see: https://www.clinicaltrials.gov/ct2/show/NCT02034227).</div>
    <div id="p-0015" num="0013" class="description-paragraph style-scope patent-text">Dimeric PBD compounds bearing C2 aryl substituents alongside endo-unsaturation, such as SG2202 (ZC-207), are disclosed in WO 2005/085251:</div>
    <div id="p-0016" num="0014" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00005" num="00005" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/b0/aa/ee/5b1e26cb82c1b3/US11370801-20220628-C00005.png" class="style-scope patent-text"><img id="EMI-C00005" he="29.04mm" wi="145.29mm" file="US11370801-20220628-C00005.TIF" alt="Figure US11370801-20220628-C00005" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="581" height="116" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/b0/aa/ee/5b1e26cb82c1b3/US11370801-20220628-C00005.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00005" attachment-type="cdx" file="US11370801-20220628-C00005.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00005" attachment-type="mol" file="US11370801-20220628-C00005.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
and in WO2006/111759, bisulphites of such PBD compounds, for example SG2285 (ZC-423):
</div>
    <div id="p-0017" num="0015" class="description-paragraph style-scope patent-text">
      <chemistry id="CHEM-US-00006" num="00006" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e5/e8/85/ee95f4901153c5/US11370801-20220628-C00006.png" class="style-scope patent-text"><img id="EMI-C00006" he="32.17mm" wi="145.29mm" file="US11370801-20220628-C00006.TIF" alt="Figure US11370801-20220628-C00006" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="581" height="129" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e5/e8/85/ee95f4901153c5/US11370801-20220628-C00006.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00006" attachment-type="cdx" file="US11370801-20220628-C00006.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00006" attachment-type="mol" file="US11370801-20220628-C00006.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
    </div>
    <div id="p-0018" num="0016" class="description-paragraph style-scope patent-text">These compounds have been shown to be highly useful cytotoxic agents (Howard, P. W., et al., <i class="style-scope patent-text">Bioorg. Med. Chem</i>. (2009), doi: 10.1016/j.bmcl.2009.09.012).</div>
    <div id="p-0019" num="0017" class="description-paragraph style-scope patent-text">In a review of PBD containing ADCs (Mantaj, J., et al., <i class="style-scope patent-text">Angew. Chem. Int. Ed</i>. (2016), 55, 2-29; DOI: 10.1002/anie.201510610), the SAR of PBD dimers is discussed. The summary of the SAR is presented in FIG. 3-B “C2-exo and C1-C2/C2-C3 unsaturation enhances activity”. A more detailed discussion is found at section 2.4 which says:</div>
    <div id="p-0020" num="0018" class="description-paragraph style-scope patent-text">“DSB-120 has poor activity in vivo, attributed partly to its high reactivity with cellular thiol-containing molecules such as glutathione. However, introduction of C2/C2′-exo unsaturation as in SJG-136 led to an overall increase in DNA-binding affinity and cytotoxicity, and a lower reactivity toward cellular nucleophiles with more of the agent potentially reaching its target DNA.”</div>
    <div id="p-0021" num="0019" class="description-paragraph style-scope patent-text">WO 2007/085930 describes the preparation of dimer PBD compounds having linker groups for connection to a cell binding agent, such as an antibody. The linker is present in the bridge linking the monomer PBD units of the dimer.</div>
    <div id="p-0022" num="0020" class="description-paragraph style-scope patent-text">Dimer PBD compounds having linker groups for connection to a cell binding agent, such as an antibody, are described in WO 2011/130598. The linker in these compounds is attached to one of the available N10 positions, and are generally cleaved by action of an enzyme on the linker group. The dimer PBD compounds have either endo or exo unsaturation in the C-ring.</div>
    <div id="p-0023" num="0021" class="description-paragraph style-scope patent-text">WO 2014/057074 and WO 2015/052322 describes specific PBD dimer conjugates bound via the N10 position on one monomer, and all these compounds have endo unsaturation in the C-ring.</div>
    <div id="p-0024" num="0022" class="description-paragraph style-scope patent-text">WO2014/096365 discloses the compound:</div>
    <div id="p-0025" num="0023" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00007" num="00007" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/ec/f0/91/fba0fe6135c483/US11370801-20220628-C00007.png" class="style-scope patent-text"><img id="EMI-C00007" he="31.92mm" wi="157.82mm" file="US11370801-20220628-C00007.TIF" alt="Figure US11370801-20220628-C00007" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="631" height="128" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/ec/f0/91/fba0fe6135c483/US11370801-20220628-C00007.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00007" attachment-type="cdx" file="US11370801-20220628-C00007.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00007" attachment-type="mol" file="US11370801-20220628-C00007.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
where the lack of unsaturation in the C-ring is coupled with the B-ring being a dilactam and therefore not having the ability to covalently bind DNA.
</div>
    <heading id="h-0004" class="style-scope patent-text">DISCLOSURE OF THE INVENTION</heading>
    <div id="p-0026" num="0024" class="description-paragraph style-scope patent-text">The present invention provides PBD dimer drug linkers and conjugates where neither C-ring has endo- or exo-unsaturation.</div>
    <div id="p-0027" num="0025" class="description-paragraph style-scope patent-text">A first aspect of the present invention comprises a compound with the formula I:</div>
    <div id="p-0028" num="0026" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00008" num="00008" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/90/28/d8/844c2bb29b08c2/US11370801-20220628-C00008.png" class="style-scope patent-text"><img id="EMI-C00008" he="38.35mm" wi="74.85mm" file="US11370801-20220628-C00008.TIF" alt="Figure US11370801-20220628-C00008" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="299" height="153" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/90/28/d8/844c2bb29b08c2/US11370801-20220628-C00008.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00008" attachment-type="cdx" file="US11370801-20220628-C00008.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00008" attachment-type="mol" file="US11370801-20220628-C00008.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
and salts and solvates thereof, wherein:
<br class="style-scope patent-text">
R<sup class="style-scope patent-text">6 </sup>and R<sup class="style-scope patent-text">9 </sup>are independently selected from H, R, OH, OR, SH, SR, NH<sub class="style-scope patent-text">2</sub>, NHR, NRR′, nitro, Me<sub class="style-scope patent-text">3</sub>Sn and halo;
<br class="style-scope patent-text">
where R and R′ are independently selected from optionally substituted C<sub class="style-scope patent-text">1-12 </sub>alkyl, C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl and C<sub class="style-scope patent-text">5-20 </sub>aryl groups;
<br class="style-scope patent-text">
R<sup class="style-scope patent-text">7 </sup>is selected from H, R, OH, OR, SH, SR, NH<sub class="style-scope patent-text">2</sub>, NHR, NRR′, nitro, Me<sub class="style-scope patent-text">3</sub>Sn and halo;
<br class="style-scope patent-text">
R″ is a C<sub class="style-scope patent-text">3-12 </sub>alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, NR<sup class="style-scope patent-text">N2 </sup>(where R<sup class="style-scope patent-text">N2 </sup>is H or C<sub class="style-scope patent-text">1-4 </sub>alkyl), and/or aromatic rings, e.g. benzene or pyridine;
<br class="style-scope patent-text">
Y and Y′ are selected from O, S, or NH;
<br class="style-scope patent-text">
R<sup class="style-scope patent-text">6′</sup>, R<sup class="style-scope patent-text">7′</sup>, R<sup class="style-scope patent-text">9′</sup> are selected from the same groups as R<sup class="style-scope patent-text">6</sup>, R<sup class="style-scope patent-text">7 </sup>and R<sup class="style-scope patent-text">9 </sup>respectively;
<br class="style-scope patent-text">
R<sup class="style-scope patent-text">11b </sup>is selected from OH, OR<sup class="style-scope patent-text">A</sup>, where R<sup class="style-scope patent-text">A </sup>is C<sub class="style-scope patent-text">1-4 </sub>alkyl; and
<br class="style-scope patent-text">
R<sup class="style-scope patent-text">L </sup>is a linker for connection to a cell binding agent, which is selected from:
<br class="style-scope patent-text">
(iiia):
</div>
    <div id="p-0029" num="0027" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00009" num="00009" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/c9/c2/5e/85eac2d5df5462/US11370801-20220628-C00009.png" class="style-scope patent-text"><img id="EMI-C00009" he="26.84mm" wi="69.85mm" file="US11370801-20220628-C00009.TIF" alt="Figure US11370801-20220628-C00009" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="279" height="107" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/c9/c2/5e/85eac2d5df5462/US11370801-20220628-C00009.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00009" attachment-type="cdx" file="US11370801-20220628-C00009.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00009" attachment-type="mol" file="US11370801-20220628-C00009.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
wherein
<br class="style-scope patent-text">
Q is:
</div>
    <div id="p-0030" num="0028" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00010" num="00010" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/90/b2/20/97ad5894aa0441/US11370801-20220628-C00010.png" class="style-scope patent-text"><img id="EMI-C00010" he="16.51mm" wi="32.34mm" file="US11370801-20220628-C00010.TIF" alt="Figure US11370801-20220628-C00010" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="129" height="66" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/90/b2/20/97ad5894aa0441/US11370801-20220628-C00010.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00010" attachment-type="cdx" file="US11370801-20220628-C00010.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00010" attachment-type="mol" file="US11370801-20220628-C00010.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
where Q<sup class="style-scope patent-text">X </sup>is such that Q is an amino-acid residue, a dipeptide residue or a tripeptide residue;
<br class="style-scope patent-text">
X is:
</div>
    <div id="p-0031" num="0029" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00011" num="00011" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/2a/68/af/56ae764ef98695/US11370801-20220628-C00011.png" class="style-scope patent-text"><img id="EMI-C00011" he="13.89mm" wi="59.69mm" file="US11370801-20220628-C00011.TIF" alt="Figure US11370801-20220628-C00011" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="239" height="56" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/2a/68/af/56ae764ef98695/US11370801-20220628-C00011.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00011" attachment-type="cdx" file="US11370801-20220628-C00011.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00011" attachment-type="mol" file="US11370801-20220628-C00011.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
where a=0 to 5, b=0 to 16, c=0 or 1, d=0 to 5;
<br class="style-scope patent-text">
G<sup class="style-scope patent-text">L </sup>is a linker for connecting to a Ligand Unit; and
<br class="style-scope patent-text">
(iiib):
</div>
    <div id="p-0032" num="0030" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00012" num="00012" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/49/b4/b4/475e7f574089ec/US11370801-20220628-C00012.png" class="style-scope patent-text"><img id="EMI-C00012" he="19.73mm" wi="69.85mm" file="US11370801-20220628-C00012.TIF" alt="Figure US11370801-20220628-C00012" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="279" height="79" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/49/b4/b4/475e7f574089ec/US11370801-20220628-C00012.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00012" attachment-type="cdx" file="US11370801-20220628-C00012.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00012" attachment-type="mol" file="US11370801-20220628-C00012.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
where R<sup class="style-scope patent-text">L1 </sup>and R<sup class="style-scope patent-text">L2 </sup>are independently selected from H and methyl, or together with the carbon atom to which they are bound form a cyclopropylene or cyclobutylene group;
<br class="style-scope patent-text">
and e is 0 or 1;
<br class="style-scope patent-text">
either
</div> <ul class="style-scope patent-text"> <li id="ul0001-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0002-0001" num="0031" class="style-scope patent-text">(a) R<sup class="style-scope patent-text">20 </sup>is H, and R<sup class="style-scope patent-text">21 </sup>is OH or OR<sup class="style-scope patent-text">A</sup>, where R<sup class="style-scope patent-text">A </sup>is C<sub class="style-scope patent-text">1-4 </sub>alkyl; or</li> <li id="ul0002-0002" num="0032" class="style-scope patent-text">(b) R<sup class="style-scope patent-text">20 </sup>and R<sup class="style-scope patent-text">21 </sup>form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or</li> <li id="ul0002-0003" num="0033" class="style-scope patent-text">(c) R<sup class="style-scope patent-text">20 </sup>is H and R<sup class="style-scope patent-text">21 </sup>is SO<sub class="style-scope patent-text">z</sub>M, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; or</li> <li id="ul0002-0004" num="0034" class="style-scope patent-text">(d) R<sup class="style-scope patent-text">20 </sup>is H and R<sup class="style-scope patent-text">21 </sup>is H; or</li> <li id="ul0002-0005" num="0035" class="style-scope patent-text">(e) R<sup class="style-scope patent-text">21 </sup>is OH or OR<sup class="style-scope patent-text">A</sup>, where R<sup class="style-scope patent-text">A </sup>is C<sub class="style-scope patent-text">1-4 </sub>alkyl and R<sup class="style-scope patent-text">20 </sup>is selected from:
        <ul class="style-scope patent-text"> <li id="ul0003-0001" num="0036" class="style-scope patent-text">(d-i)</li> </ul>
        </li> </ul> </li> </ul>

    <div id="p-0033" num="0037" class="description-paragraph style-scope patent-text">
      <chemistry id="CHEM-US-00013" num="00013" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/54/8a/e6/4d56e71db2100a/US11370801-20220628-C00013.png" class="style-scope patent-text"><img id="EMI-C00013" he="29.29mm" wi="13.21mm" file="US11370801-20220628-C00013.TIF" alt="Figure US11370801-20220628-C00013" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="53" height="117" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/54/8a/e6/4d56e71db2100a/US11370801-20220628-C00013.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00013" attachment-type="cdx" file="US11370801-20220628-C00013.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00013" attachment-type="mol" file="US11370801-20220628-C00013.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
      </div> <ul class="style-scope patent-text">
        <li id="ul0004-0001" num="0000" class="style-scope patent-text">
          <ul class="style-scope patent-text">
            <li id="ul0005-0001" num="0000" class="style-scope patent-text">
              <ul class="style-scope patent-text">
                <li id="ul0006-0001" num="0038" class="style-scope patent-text">(d-ii)</li>
              </ul>
            </li>
          </ul>
        </li>
      </ul>
    
    <div id="p-0034" num="0039" class="description-paragraph style-scope patent-text">
      <chemistry id="CHEM-US-00014" num="00014" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/ae/76/3f/2e78b66804856f/US11370801-20220628-C00014.png" class="style-scope patent-text"><img id="EMI-C00014" he="14.39mm" wi="12.36mm" file="US11370801-20220628-C00014.TIF" alt="Figure US11370801-20220628-C00014" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="49" height="58" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/ae/76/3f/2e78b66804856f/US11370801-20220628-C00014.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00014" attachment-type="cdx" file="US11370801-20220628-C00014.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00014" attachment-type="mol" file="US11370801-20220628-C00014.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
      </div> <ul class="style-scope patent-text">
        <li id="ul0007-0001" num="0000" class="style-scope patent-text">
          <ul class="style-scope patent-text">
            <li id="ul0008-0001" num="0000" class="style-scope patent-text">
              <ul class="style-scope patent-text">
                <li id="ul0009-0001" num="0040" class="style-scope patent-text">(d-iii)</li>
              </ul>
            </li>
          </ul>
        </li>
      </ul>
    
    <div id="p-0035" num="0041" class="description-paragraph style-scope patent-text">
      <chemistry id="CHEM-US-00015" num="00015" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/c5/c3/8e/0176cd6c692132/US11370801-20220628-C00015.png" class="style-scope patent-text"><img id="EMI-C00015" he="26.59mm" wi="22.69mm" file="US11370801-20220628-C00015.TIF" alt="Figure US11370801-20220628-C00015" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="91" height="106" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/c5/c3/8e/0176cd6c692132/US11370801-20220628-C00015.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00015" attachment-type="cdx" file="US11370801-20220628-C00015.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00015" attachment-type="mol" file="US11370801-20220628-C00015.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
      </div> <ul class="style-scope patent-text">
        <li id="ul0010-0001" num="0000" class="style-scope patent-text">
          <ul class="style-scope patent-text">
            <li id="ul0011-0001" num="0000" class="style-scope patent-text">
              <ul class="style-scope patent-text">
                <li id="ul0012-0001" num="0042" class="style-scope patent-text"> where R<sup class="style-scope patent-text">Z </sup>is selected from:
            <ul class="style-scope patent-text"> <li id="ul0013-0001" num="0043" class="style-scope patent-text">(z-i)</li> </ul>
            </li>
              </ul>
            </li>
          </ul>
        </li>
      </ul>
    
    <div id="p-0036" num="0044" class="description-paragraph style-scope patent-text">
      <chemistry id="CHEM-US-00016" num="00016" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/d2/0e/d2/62b03e02018f11/US11370801-20220628-C00016.png" class="style-scope patent-text"><img id="EMI-C00016" he="26.33mm" wi="16.93mm" file="US11370801-20220628-C00016.TIF" alt="Figure US11370801-20220628-C00016" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="68" height="105" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/d2/0e/d2/62b03e02018f11/US11370801-20220628-C00016.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00016" attachment-type="cdx" file="US11370801-20220628-C00016.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00016" attachment-type="mol" file="US11370801-20220628-C00016.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
      </div> <ul class="style-scope patent-text">
        <li id="ul0014-0001" num="0000" class="style-scope patent-text">
          <ul class="style-scope patent-text">
            <li id="ul0015-0001" num="0000" class="style-scope patent-text">
              <ul class="style-scope patent-text">
                <li id="ul0016-0001" num="0000" class="style-scope patent-text">
                  <ul class="style-scope patent-text">
                    <li id="ul0017-0001" num="0045" class="style-scope patent-text">(z-ii) OC(═O)CH<sub class="style-scope patent-text">3</sub>;</li>
                    <li id="ul0017-0002" num="0046" class="style-scope patent-text">(z-iii) NO<sub class="style-scope patent-text">2</sub>;</li>
                    <li id="ul0017-0003" num="0047" class="style-scope patent-text">(z-iv) OMe;</li>
                    <li id="ul0017-0004" num="0048" class="style-scope patent-text">(z-v) glucoronide;</li>
                    <li id="ul0017-0005" num="0049" class="style-scope patent-text">(z-vi) —C(═O)—X<sub class="style-scope patent-text">1</sub>—NHC(═O)X<sub class="style-scope patent-text">2</sub>—NH—R<sup class="style-scope patent-text">ZC</sup>, where —C(═O)—X<sub class="style-scope patent-text">1</sub>—NH— and —C(═O)—X<sub class="style-scope patent-text">2</sub>—NH— represent natural amino acid residues and R<sup class="style-scope patent-text">ZC </sup>is selected from Me, OMe, OCH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">2</sub>OMe.</li>
                  </ul>
                </li>
              </ul>
            </li>
          </ul>
        </li>
      </ul>
    
    <div id="p-0037" num="0050" class="description-paragraph style-scope patent-text">Such drug linkers have been found to undergo ready conjugation to ligand units such as antibodies.</div>
    <div id="p-0038" num="0051" class="description-paragraph style-scope patent-text">A second aspect of the present invention provides Conjugates of formula II:
<br class="style-scope patent-text">
L-(D<sup class="style-scope patent-text">L</sup>)<sub class="style-scope patent-text">p</sub>  (II)
<br class="style-scope patent-text">
wherein L is a Ligand unit (i.e., a targeting agent), D<sup class="style-scope patent-text">L </sup>is a Drug Linker unit of formula I′:
</div>
    <div id="p-0039" num="0052" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00017" num="00017" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/07/ca/62/25fb86305b662f/US11370801-20220628-C00017.png" class="style-scope patent-text"><img id="EMI-C00017" he="39.37mm" wi="75.95mm" file="US11370801-20220628-C00017.TIF" alt="Figure US11370801-20220628-C00017" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="304" height="157" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/07/ca/62/25fb86305b662f/US11370801-20220628-C00017.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00017" attachment-type="cdx" file="US11370801-20220628-C00017.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00017" attachment-type="mol" file="US11370801-20220628-C00017.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
wherein R<sup class="style-scope patent-text">6</sup>, R<sup class="style-scope patent-text">7</sup>, R<sup class="style-scope patent-text">9</sup>, R<sup class="style-scope patent-text">11b</sup>, Y, R″, Y′, R<sup class="style-scope patent-text">6′</sup>, R<sup class="style-scope patent-text">7′</sup>, R<sup class="style-scope patent-text">9′</sup>, R<sup class="style-scope patent-text">20 </sup>and R<sup class="style-scope patent-text">21 </sup>are as defined in the first aspect of the invention;
<br class="style-scope patent-text">
R<sup class="style-scope patent-text">LL </sup>is a linker for connection to a cell binding agent, which is selected from:
<br class="style-scope patent-text">
(iiia):
</div>
    <div id="p-0040" num="0053" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00018" num="00018" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/ce/e0/fd/36b64054912c05/US11370801-20220628-C00018.png" class="style-scope patent-text"><img id="EMI-C00018" he="26.92mm" wi="69.93mm" file="US11370801-20220628-C00018.TIF" alt="Figure US11370801-20220628-C00018" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="108" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/ce/e0/fd/36b64054912c05/US11370801-20220628-C00018.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00018" attachment-type="cdx" file="US11370801-20220628-C00018.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00018" attachment-type="mol" file="US11370801-20220628-C00018.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
where Q and X are as defined in the first aspect and G<sup class="style-scope patent-text">LL </sup>is a linker connected to a Ligand Unit; and
<br class="style-scope patent-text">
(iiib):
</div>
    <div id="p-0041" num="0054" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00019" num="00019" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/24/bd/de/053ac6a715681b/US11370801-20220628-C00019.png" class="style-scope patent-text"><img id="EMI-C00019" he="18.20mm" wi="69.93mm" file="US11370801-20220628-C00019.TIF" alt="Figure US11370801-20220628-C00019" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="73" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/24/bd/de/053ac6a715681b/US11370801-20220628-C00019.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00019" attachment-type="cdx" file="US11370801-20220628-C00019.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00019" attachment-type="mol" file="US11370801-20220628-C00019.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
where R<sup class="style-scope patent-text">L1 </sup>and R<sup class="style-scope patent-text">L2 </sup>are as defined in the first aspect;
<br class="style-scope patent-text">
wherein p is an integer of from 1 to 20.
</div>
    <div id="p-0042" num="0055" class="description-paragraph style-scope patent-text">The Ligand unit, described more fully below, is a targeting agent that binds to a target moiety. The Ligand unit can, for example, specifically bind to a cell component (a Cell Binding Agent) or to other target molecules of interest. The Ligand unit can be, for example, a protein, polypeptide or peptide, such as an antibody, an antigen-binding fragment of an antibody, or other binding agent, such as an Fc fusion protein.</div>
    <div id="p-0043" num="0056" class="description-paragraph style-scope patent-text">These conjugates have been found to possess a high tolerability which leads to a high therapeutic index, thus making them promising candidates for clinical development.</div>
    <div id="p-0044" num="0057" class="description-paragraph style-scope patent-text">A third aspect of the present invention provides the use of a conjugate of the second aspect of the invention in the manufacture of a medicament for treating a proliferative disease. The third aspect also provides a conjugate of the second aspect of the invention for use in the treatment of a proliferative disease. The third aspect also provides a method of treating a proliferative disease comprising administering a therapeutically effective amount of a conjugate of the second aspect of the invention to a patient in need thereof.</div>
    <div id="p-0045" num="0058" class="description-paragraph style-scope patent-text">One of ordinary skill in the art is readily able to determine whether or not a candidate conjugate treats a proliferative condition for any particular cell type. For example, assays which may conveniently be used to assess the activity offered by a particular compound are described in the examples below.</div>
    <div id="p-0046" num="0059" class="description-paragraph style-scope patent-text">A fourth aspect of the present invention provides the synthesis of a conjugate of the second aspect of the invention comprising conjugating a compound (drug linker) of the first aspect of the invention with a Ligand Unit.</div>
    <heading id="h-0005" class="style-scope patent-text">Definitions</heading>
    <div id="h-0006" num="0000" class="description-paragraph style-scope patent-text">Substituents</div>
    <div id="p-0047" num="0060" class="description-paragraph style-scope patent-text">The phrase “optionally substituted” as used herein, pertains to a parent group which may be unsubstituted or which may be substituted.</div>
    <div id="p-0048" num="0061" class="description-paragraph style-scope patent-text">Unless otherwise specified, the term “substituted” as used herein, pertains to a parent group which bears one or more substituents. The term “substituent” is used herein in the conventional sense and refers to a chemical moiety which is covalently attached to, or if appropriate, fused to, a parent group. A wide variety of substituents are well known, and methods for their formation and introduction into a variety of parent groups are also well known.</div>
    <div id="p-0049" num="0062" class="description-paragraph style-scope patent-text">Examples of substituents are described in more detail below.</div>
    <div id="p-0050" num="0063" class="description-paragraph style-scope patent-text">C<sub class="style-scope patent-text">1-12 </sub>alkyl: The term “C<sub class="style-scope patent-text">1-12 </sub>alkyl” as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from a carbon atom of a hydrocarbon compound having from 1 to 12 carbon atoms, which may be aliphatic or alicyclic, and which may be saturated or unsaturated (e.g. partially unsaturated, fully unsaturated). The term “C<sub class="style-scope patent-text">1-4 </sub>alkyl” as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from a carbon atom of a hydrocarbon compound having from 1 to 4 carbon atoms, which may be aliphatic or alicyclic, and which may be saturated or unsaturated (e.g. partially unsaturated, fully unsaturated). Thus, the term “alkyl” includes the sub-classes alkenyl, alkynyl, cycloalkyl, etc., discussed below.</div>
    <div id="p-0051" num="0064" class="description-paragraph style-scope patent-text">Examples of saturated alkyl groups include, but are not limited to, methyl (C<sub class="style-scope patent-text">1</sub>), ethyl (C<sub class="style-scope patent-text">2</sub>), propyl (C<sub class="style-scope patent-text">3</sub>), butyl (C<sub class="style-scope patent-text">4</sub>), pentyl (C<sub class="style-scope patent-text">5</sub>), hexyl (C<sub class="style-scope patent-text">6</sub>) and heptyl (C<sub class="style-scope patent-text">7</sub>).</div>
    <div id="p-0052" num="0065" class="description-paragraph style-scope patent-text">Examples of saturated linear alkyl groups include, but are not limited to, methyl (C<sub class="style-scope patent-text">1</sub>), ethyl (C<sub class="style-scope patent-text">2</sub>), n-propyl (C<sub class="style-scope patent-text">3</sub>), n-butyl (C<sub class="style-scope patent-text">4</sub>), n-pentyl (amyl) (C<sub class="style-scope patent-text">5</sub>), n-hexyl (C<sub class="style-scope patent-text">6</sub>) and n-heptyl (C<sub class="style-scope patent-text">7</sub>).</div>
    <div id="p-0053" num="0066" class="description-paragraph style-scope patent-text">Examples of saturated branched alkyl groups include iso-propyl (C<sub class="style-scope patent-text">3</sub>), iso-butyl (C<sub class="style-scope patent-text">4</sub>), sec-butyl (C<sub class="style-scope patent-text">4</sub>), tert-butyl (C<sub class="style-scope patent-text">4</sub>), iso-pentyl (C<sub class="style-scope patent-text">5</sub>), and neo-pentyl (C<sub class="style-scope patent-text">5</sub>).</div>
    <div id="p-0054" num="0067" class="description-paragraph style-scope patent-text">C<sub class="style-scope patent-text">2-12 </sub>Alkenyl: The term “C<sub class="style-scope patent-text">2-12 </sub>alkenyl” as used herein, pertains to an alkyl group having one or more carbon-carbon double bonds.</div>
    <div id="p-0055" num="0068" class="description-paragraph style-scope patent-text">Examples of unsaturated alkenyl groups include, but are not limited to, ethenyl (vinyl, —CH═CH<sub class="style-scope patent-text">2</sub>), 1-propenyl (—CH═CH—CH<sub class="style-scope patent-text">3</sub>), 2-propenyl (allyl, —CH—CH═CH<sub class="style-scope patent-text">2</sub>), isopropenyl (1-methylvinyl, —C(CH<sub class="style-scope patent-text">3</sub>)═CH<sub class="style-scope patent-text">2</sub>), butenyl (C<sub class="style-scope patent-text">4</sub>), pentenyl (C<sub class="style-scope patent-text">5</sub>), and hexenyl (C<sub class="style-scope patent-text">6</sub>).</div>
    <div id="p-0056" num="0069" class="description-paragraph style-scope patent-text">C<sub class="style-scope patent-text">2-12 </sub>alkynyl: The term “C<sub class="style-scope patent-text">2-12 </sub>alkynyl” as used herein, pertains to an alkyl group having one or more carbon-carbon triple bonds.</div>
    <div id="p-0057" num="0070" class="description-paragraph style-scope patent-text">Examples of unsaturated alkynyl groups include, but are not limited to, ethynyl (—C≡CH) and 2-propynyl (propargyl, —CH<sub class="style-scope patent-text">2</sub>—C≡CH).</div>
    <div id="p-0058" num="0071" class="description-paragraph style-scope patent-text">C<sub class="style-scope patent-text">3-12 </sub>cycloalkyl: The term “C<sub class="style-scope patent-text">3-12 </sub>cycloalkyl” as used herein, pertains to an alkyl group which is also a cyclyl group; that is, a monovalent moiety obtained by removing a hydrogen atom from an alicyclic ring atom of a cyclic hydrocarbon (carbocyclic) compound, which moiety has from 3 to 7 carbon atoms, including from 3 to 7 ring atoms.</div>
    <div id="p-0059" num="0072" class="description-paragraph style-scope patent-text">Examples of cycloalkyl groups include, but are not limited to, those derived from:
</div> <ul class="style-scope patent-text"> <li id="ul0018-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0019-0001" num="0073" class="style-scope patent-text">saturated monocyclic hydrocarbon compounds:
<br class="style-scope patent-text">
cyclopropane (C<sub class="style-scope patent-text">3</sub>), cyclobutane (C<sub class="style-scope patent-text">4</sub>), cyclopentane (C<sub class="style-scope patent-text">5</sub>), cyclohexane (C<sub class="style-scope patent-text">6</sub>), cycloheptane (C<sub class="style-scope patent-text">7</sub>), methylcyclopropane (C<sub class="style-scope patent-text">4</sub>), dimethylcyclopropane (C<sub class="style-scope patent-text">5</sub>), methylcyclobutane (C<sub class="style-scope patent-text">5</sub>), dimethylcyclobutane (C<sub class="style-scope patent-text">6</sub>), methylcyclopentane (C<sub class="style-scope patent-text">6</sub>), dimethylcyclopentane (C<sub class="style-scope patent-text">7</sub>) and methylcyclohexane (C<sub class="style-scope patent-text">7</sub>);
</li> <li id="ul0019-0002" num="0074" class="style-scope patent-text">unsaturated monocyclic hydrocarbon compounds:
<br class="style-scope patent-text">
cyclopropene (C<sub class="style-scope patent-text">3</sub>), cyclobutene (C<sub class="style-scope patent-text">4</sub>), cyclopentene (C<sub class="style-scope patent-text">5</sub>), cyclohexene (C<sub class="style-scope patent-text">6</sub>), methylcyclopropene (C<sub class="style-scope patent-text">4</sub>), dimethylcyclopropene (C<sub class="style-scope patent-text">5</sub>), methylcyclobutene (C<sub class="style-scope patent-text">5</sub>), dimethylcyclobutene (C<sub class="style-scope patent-text">6</sub>), methylcyclopentene (C<sub class="style-scope patent-text">6</sub>), dimethylcyclopentene (C<sub class="style-scope patent-text">7</sub>) and methylcyclohexene (C<sub class="style-scope patent-text">7</sub>); and
</li> <li id="ul0019-0003" num="0075" class="style-scope patent-text">saturated polycyclic hydrocarbon compounds:
<br class="style-scope patent-text">
norcarane (C<sub class="style-scope patent-text">7</sub>), norpinane (C<sub class="style-scope patent-text">7</sub>), norbornane (C<sub class="style-scope patent-text">7</sub>).
</li> </ul> </li> </ul>

    <div id="p-0060" num="0076" class="description-paragraph style-scope patent-text">C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl: The term “C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl” as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from a ring atom of a heterocyclic compound, which moiety has from 3 to 20 ring atoms, of which from 1 to 10 are ring heteroatoms. Preferably, each ring has from 3 to 7 ring atoms, of which from 1 to 4 are ring heteroatoms.</div>
    <div id="p-0061" num="0077" class="description-paragraph style-scope patent-text">In this context, the prefixes (e.g. C<sub class="style-scope patent-text">3-20</sub>, C<sub class="style-scope patent-text">3-7</sub>, C<sub class="style-scope patent-text">5-6</sub>, etc.) denote the number of ring atoms, or range of number of ring atoms, whether carbon atoms or heteroatoms. For example, the term “C<sub class="style-scope patent-text">5-6</sub>heterocyclyl”, as used herein, pertains to a heterocyclyl group having 5 or 6 ring atoms.</div>
    <div id="p-0062" num="0078" class="description-paragraph style-scope patent-text">Examples of monocyclic heterocyclyl groups include, but are not limited to, those derived from:</div>
    <div id="p-0063" num="0079" class="description-paragraph style-scope patent-text">N<sub class="style-scope patent-text">1</sub>: aziridine (C<sub class="style-scope patent-text">3</sub>), azetidine (C<sub class="style-scope patent-text">4</sub>), pyrrolidine (tetrahydropyrrole) (C<sub class="style-scope patent-text">5</sub>), pyrroline (e.g., 3-pyrroline, 2,5-dihydropyrrole) (C<sub class="style-scope patent-text">5</sub>), 2H-pyrrole or 3H-pyrrole (isopyrrole, isoazole) (C<sub class="style-scope patent-text">5</sub>), piperidine (C<sub class="style-scope patent-text">6</sub>), dihydropyridine (C<sub class="style-scope patent-text">6</sub>), tetrahydropyridine (C<sub class="style-scope patent-text">6</sub>), azepine (C<sub class="style-scope patent-text">7</sub>);
<br class="style-scope patent-text">
O<sub class="style-scope patent-text">1</sub>: oxirane (C<sub class="style-scope patent-text">3</sub>), oxetane (C<sub class="style-scope patent-text">4</sub>), oxolane (tetrahydrofuran) (C<sub class="style-scope patent-text">5</sub>), oxole (dihydrofuran) (C<sub class="style-scope patent-text">5</sub>), oxane (tetrahydropyran) (C<sub class="style-scope patent-text">6</sub>), dihydropyran (C<sub class="style-scope patent-text">6</sub>), pyran (C<sub class="style-scope patent-text">6</sub>), oxepin (C<sub class="style-scope patent-text">7</sub>);
<br class="style-scope patent-text">
S<sub class="style-scope patent-text">1</sub>: thiirane (C<sub class="style-scope patent-text">3</sub>), thietane (C<sub class="style-scope patent-text">4</sub>), thiolane (tetrahydrothiophene) (C<sub class="style-scope patent-text">5</sub>), thiane (tetrahydrothiopyran) (C<sub class="style-scope patent-text">6</sub>), thiepane (C<sub class="style-scope patent-text">7</sub>);
<br class="style-scope patent-text">
O<sub class="style-scope patent-text">2</sub>: dioxolane (C<sub class="style-scope patent-text">5</sub>), dioxane (C<sub class="style-scope patent-text">6</sub>), and dioxepane (C<sub class="style-scope patent-text">7</sub>);
<br class="style-scope patent-text">
O<sub class="style-scope patent-text">3</sub>: trioxane (C<sub class="style-scope patent-text">6</sub>);
<br class="style-scope patent-text">
N<sub class="style-scope patent-text">2</sub>: imidazolidine (C<sub class="style-scope patent-text">5</sub>), pyrazolidine (diazolidine) (C<sub class="style-scope patent-text">5</sub>), imidazoline (C<sub class="style-scope patent-text">5</sub>), pyrazoline (dihydropyrazole) (C<sub class="style-scope patent-text">5</sub>), piperazine (C<sub class="style-scope patent-text">6</sub>);
<br class="style-scope patent-text">
N<sub class="style-scope patent-text">1</sub>O<sub class="style-scope patent-text">1</sub>: tetrahydrooxazole (C<sub class="style-scope patent-text">5</sub>), dihydrooxazole (C<sub class="style-scope patent-text">5</sub>), tetrahydroisoxazole (C<sub class="style-scope patent-text">5</sub>), dihydroisoxazole (C<sub class="style-scope patent-text">5</sub>), morpholine (C<sub class="style-scope patent-text">6</sub>), tetrahydrooxazine (C<sub class="style-scope patent-text">6</sub>), dihydrooxazine (C<sub class="style-scope patent-text">6</sub>), oxazine (C<sub class="style-scope patent-text">6</sub>);
<br class="style-scope patent-text">
N<sub class="style-scope patent-text">1</sub>S1: thiazoline (C<sub class="style-scope patent-text">5</sub>), thiazolidine (C<sub class="style-scope patent-text">5</sub>), thiomorpholine (C<sub class="style-scope patent-text">6</sub>);
<br class="style-scope patent-text">
N<sub class="style-scope patent-text">2</sub>O<sub class="style-scope patent-text">1</sub>: oxadiazine (C<sub class="style-scope patent-text">6</sub>);
<br class="style-scope patent-text">
O<sub class="style-scope patent-text">1</sub>S<sub class="style-scope patent-text">1</sub>: oxathiole (C<sub class="style-scope patent-text">5</sub>) and oxathiane (thioxane) (C<sub class="style-scope patent-text">6</sub>); and,
<br class="style-scope patent-text">
N<sub class="style-scope patent-text">1</sub>O<sub class="style-scope patent-text">1</sub>S<sub class="style-scope patent-text">1</sub>: oxathiazine (C<sub class="style-scope patent-text">6</sub>).
</div>
    <div id="p-0064" num="0080" class="description-paragraph style-scope patent-text">Examples of substituted monocyclic heterocyclyl groups include those derived from saccharides, in cyclic form, for example, furanoses (C<sub class="style-scope patent-text">5</sub>), such as arabinofuranose, lyxofuranose, ribofuranose, and xylofuranse, and pyranoses (C<sub class="style-scope patent-text">6</sub>), such as allopyranose, altropyranose, glucopyranose, mannopyranose, gulopyranose, idopyranose, galactopyranose, and talopyranose.</div>
    <div id="p-0065" num="0081" class="description-paragraph style-scope patent-text">C<sub class="style-scope patent-text">5-20 </sub>aryl: The term “C<sub class="style-scope patent-text">5-20 </sub>aryl”, as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from an aromatic ring atom of an aromatic compound, which moiety has from 3 to 20 ring atoms. The term “C<sub class="style-scope patent-text">5-7 </sub>aryl”, as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from an aromatic ring atom of an aromatic compound, which moiety has from 5 to 7 ring atoms and the term “C<sub class="style-scope patent-text">5-10 </sub>aryl”, as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from an aromatic ring atom of an aromatic compound, which moiety has from 5 to 10 ring atoms. Preferably, each ring has from 5 to 7 ring atoms.</div>
    <div id="p-0066" num="0082" class="description-paragraph style-scope patent-text">In this context, the prefixes (e.g. C<sub class="style-scope patent-text">3-20</sub>, C<sub class="style-scope patent-text">5-7</sub>, C<sub class="style-scope patent-text">5-6</sub>, C<sub class="style-scope patent-text">5-10</sub>, etc.) denote the number of ring atoms, or range of number of ring atoms, whether carbon atoms or heteroatoms. For example, the term “C<sub class="style-scope patent-text">5-6 </sub>aryl” as used herein, pertains to an aryl group having 5 or 6 ring atoms.</div>
    <div id="p-0067" num="0083" class="description-paragraph style-scope patent-text">The ring atoms may be all carbon atoms, as in “carboaryl groups”.</div>
    <div id="p-0068" num="0084" class="description-paragraph style-scope patent-text">Examples of carboaryl groups include, but are not limited to, those derived from benzene (i.e. phenyl) (C<sub class="style-scope patent-text">6</sub>), naphthalene (C<sub class="style-scope patent-text">10</sub>), azulene (C<sub class="style-scope patent-text">10</sub>), anthracene (C<sub class="style-scope patent-text">14</sub>), phenanthrene (C<sub class="style-scope patent-text">14</sub>), naphthacene (C<sub class="style-scope patent-text">18</sub>), and pyrene (C<sub class="style-scope patent-text">16</sub>).</div>
    <div id="p-0069" num="0085" class="description-paragraph style-scope patent-text">Examples of aryl groups which comprise fused rings, at least one of which is an aromatic ring, include, but are not limited to, groups derived from indane (e.g. 2,3-dihydro-1H-indene) (C<sub class="style-scope patent-text">5</sub>), indene (C<sub class="style-scope patent-text">5</sub>), isoindene (C<sub class="style-scope patent-text">5</sub>), tetraline (1,2,3,4-tetrahydronaphthalene (C<sub class="style-scope patent-text">10</sub>), acenaphthene (C<sub class="style-scope patent-text">12</sub>), fluorene (C<sub class="style-scope patent-text">13</sub>), phenalene (C<sub class="style-scope patent-text">13</sub>), acephenanthrene (C<sub class="style-scope patent-text">15</sub>), and aceanthrene (C<sub class="style-scope patent-text">16</sub>).</div>
    <div id="p-0070" num="0086" class="description-paragraph style-scope patent-text">Alternatively, the ring atoms may include one or more heteroatoms, as in “heteroaryl groups”. Examples of monocyclic heteroaryl groups include, but are not limited to, those derived from:</div>
    <div id="h-0007" num="0000" class="description-paragraph style-scope patent-text">N<sub class="style-scope patent-text">1</sub>: pyrrole (azole) (C<sub class="style-scope patent-text">5</sub>), pyridine (azine) (C<sub class="style-scope patent-text">6</sub>);</div>
    <div id="h-0008" num="0000" class="description-paragraph style-scope patent-text">O<sub class="style-scope patent-text">1</sub>: furan (oxole) (C<sub class="style-scope patent-text">5</sub>);</div>
    <div id="h-0009" num="0000" class="description-paragraph style-scope patent-text">S<sub class="style-scope patent-text">1</sub>: thiophene (thiole) (C<sub class="style-scope patent-text">5</sub>);</div>
    <div id="h-0010" num="0000" class="description-paragraph style-scope patent-text">N<sub class="style-scope patent-text">1</sub>O<sub class="style-scope patent-text">1</sub>: oxazole (C<sub class="style-scope patent-text">5</sub>), isoxazole (C<sub class="style-scope patent-text">5</sub>), isoxazine (C<sub class="style-scope patent-text">6</sub>);</div>
    <div id="h-0011" num="0000" class="description-paragraph style-scope patent-text">N<sub class="style-scope patent-text">2</sub>O<sub class="style-scope patent-text">1</sub>: oxadiazole (furazan) (C<sub class="style-scope patent-text">5</sub>);</div>
    <div id="h-0012" num="0000" class="description-paragraph style-scope patent-text">N<sub class="style-scope patent-text">3</sub>O<sub class="style-scope patent-text">1</sub>: oxatriazole (C<sub class="style-scope patent-text">5</sub>);</div>
    <div id="h-0013" num="0000" class="description-paragraph style-scope patent-text">N<sub class="style-scope patent-text">1</sub>S<sub class="style-scope patent-text">1</sub>: thiazole (C<sub class="style-scope patent-text">5</sub>), isothiazole (C<sub class="style-scope patent-text">5</sub>);</div>
    <div id="h-0014" num="0000" class="description-paragraph style-scope patent-text">N<sub class="style-scope patent-text">2</sub>: imidazole (1,3-diazole) (C<sub class="style-scope patent-text">5</sub>), pyrazole (1,2-diazole) (C<sub class="style-scope patent-text">5</sub>), pyridazine (1,2-diazine) (C<sub class="style-scope patent-text">6</sub>), pyrimidine (1,3-diazine) (C<sub class="style-scope patent-text">6</sub>) (e.g., cytosine, thymine, uracil), pyrazine (1,4-diazine) (C<sub class="style-scope patent-text">6</sub>);</div>
    <div id="h-0015" num="0000" class="description-paragraph style-scope patent-text">N<sub class="style-scope patent-text">3</sub>: triazole (C<sub class="style-scope patent-text">5</sub>), triazine (C<sub class="style-scope patent-text">6</sub>); and,</div>
    <div id="h-0016" num="0000" class="description-paragraph style-scope patent-text">N<sub class="style-scope patent-text">4</sub>: tetrazole (C<sub class="style-scope patent-text">5</sub>).</div>
    <div id="p-0071" num="0087" class="description-paragraph style-scope patent-text">Examples of heteroaryl which comprise fused rings, include, but are not limited to:
</div> <ul class="style-scope patent-text"> <li id="ul0020-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0021-0001" num="0088" class="style-scope patent-text">C<sub class="style-scope patent-text">9 </sub>(with 2 fused rings) derived from benzofuran (O<sub class="style-scope patent-text">1</sub>), isobenzofuran (O<sub class="style-scope patent-text">1</sub>), indole (N<sub class="style-scope patent-text">1</sub>), isoindole (N<sub class="style-scope patent-text">1</sub>), indolizine (N<sub class="style-scope patent-text">1</sub>), indoline (N<sub class="style-scope patent-text">1</sub>), isoindoline (N<sub class="style-scope patent-text">1</sub>), purine (N<sub class="style-scope patent-text">4</sub>) (e.g., adenine, guanine), benzimidazole (N<sub class="style-scope patent-text">2</sub>), indazole (N<sub class="style-scope patent-text">2</sub>), benzoxazole (N<sub class="style-scope patent-text">1</sub>O<sub class="style-scope patent-text">1</sub>), benzisoxazole (N<sub class="style-scope patent-text">1</sub>O<sub class="style-scope patent-text">1</sub>), benzodioxole (O<sub class="style-scope patent-text">2</sub>), benzofurazan (N<sub class="style-scope patent-text">2</sub>O<sub class="style-scope patent-text">1</sub>), benzotriazole (N<sub class="style-scope patent-text">3</sub>), benzothiofuran (S<sub class="style-scope patent-text">1</sub>), benzothiazole (N<sub class="style-scope patent-text">1</sub>S<sub class="style-scope patent-text">1</sub>), benzothiadiazole (N<sub class="style-scope patent-text">2</sub>S);</li> <li id="ul0021-0002" num="0089" class="style-scope patent-text">C<sub class="style-scope patent-text">10 </sub>(with 2 fused rings) derived from chromene (O<sub class="style-scope patent-text">1</sub>), isochromene (O<sub class="style-scope patent-text">1</sub>), chroman (O<sub class="style-scope patent-text">1</sub>), isochroman (O<sub class="style-scope patent-text">1</sub>), benzodioxan (O<sub class="style-scope patent-text">2</sub>), quinoline (N<sub class="style-scope patent-text">1</sub>), isoquinoline (N<sub class="style-scope patent-text">1</sub>), quinolizine (N<sub class="style-scope patent-text">1</sub>), benzoxazine (N<sub class="style-scope patent-text">1</sub>O<sub class="style-scope patent-text">1</sub>), benzodiazine (N<sub class="style-scope patent-text">2</sub>), pyridopyridine (N<sub class="style-scope patent-text">2</sub>), quinoxaline (N<sub class="style-scope patent-text">2</sub>), quinazoline (N<sub class="style-scope patent-text">2</sub>), cinnoline (N<sub class="style-scope patent-text">2</sub>), phthalazine (N<sub class="style-scope patent-text">2</sub>), naphthyridine (N<sub class="style-scope patent-text">2</sub>), pteridine (N<sub class="style-scope patent-text">4</sub>);</li> <li id="ul0021-0003" num="0090" class="style-scope patent-text">C<sub class="style-scope patent-text">11 </sub>(with 2 fused rings) derived from benzodiazepine (N<sub class="style-scope patent-text">2</sub>);</li> <li id="ul0021-0004" num="0091" class="style-scope patent-text">C<sub class="style-scope patent-text">13 </sub>(with 3 fused rings) derived from carbazole (N<sub class="style-scope patent-text">1</sub>), dibenzofuran (O<sub class="style-scope patent-text">1</sub>), dibenzothiophene (S<sub class="style-scope patent-text">1</sub>), carboline (N<sub class="style-scope patent-text">2</sub>), perimidine (N<sub class="style-scope patent-text">2</sub>), pyridoindole (N<sub class="style-scope patent-text">2</sub>); and,</li> <li id="ul0021-0005" num="0092" class="style-scope patent-text">C<sub class="style-scope patent-text">14 </sub>(with 3 fused rings) derived from acridine (N<sub class="style-scope patent-text">1</sub>), xanthene (O<sub class="style-scope patent-text">1</sub>), thioxanthene (S<sub class="style-scope patent-text">1</sub>), oxanthrene (O<sub class="style-scope patent-text">2</sub>), phenoxathiin (O<sub class="style-scope patent-text">1</sub>S<sub class="style-scope patent-text">1</sub>), phenazine (N<sub class="style-scope patent-text">2</sub>), phenoxazine (N<sub class="style-scope patent-text">1</sub>O<sub class="style-scope patent-text">1</sub>), phenothiazine (N<sub class="style-scope patent-text">1</sub>S<sub class="style-scope patent-text">1</sub>), thianthrene (S<sub class="style-scope patent-text">2</sub>), phenanthridine (N<sub class="style-scope patent-text">1</sub>), phenanthroline (N<sub class="style-scope patent-text">2</sub>), phenazine (N<sub class="style-scope patent-text">2</sub>).</li> </ul> </li> </ul>

    <div id="p-0072" num="0093" class="description-paragraph style-scope patent-text">The above groups, whether alone or part of another substituent, may themselves optionally be substituted with one or more groups selected from themselves and the additional substituents listed below.</div>
    <div id="p-0073" num="0094" class="description-paragraph style-scope patent-text">Halo: —F, —Cl, —Br, and —I.</div>
    <div id="p-0074" num="0095" class="description-paragraph style-scope patent-text">Hydroxy: —OH.</div>
    <div id="p-0075" num="0096" class="description-paragraph style-scope patent-text">Ether: —OR, wherein R is an ether substituent, for example, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group (also referred to as a C<sub class="style-scope patent-text">1-7 </sub>alkoxy group, discussed below), a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group (also referred to as a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyloxy group), or a C<sub class="style-scope patent-text">5-20 </sub>aryl group (also referred to as a C<sub class="style-scope patent-text">5-20 </sub>aryloxy group), preferably a C<sub class="style-scope patent-text">0-7</sub>alkyl group.</div>
    <div id="p-0076" num="0097" class="description-paragraph style-scope patent-text">Alkoxy: —OR, wherein R is an alkyl group, for example, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group. Examples of C<sub class="style-scope patent-text">1-7 </sub>alkoxy groups include, but are not limited to, —OMe (methoxy), —OEt (ethoxy), —O(nPr) (n-propoxy), —O(iPr) (isopropoxy), —O(nBu) (n-butoxy), —O(sBu) (sec-butoxy), —O(iBu) (isobutoxy), and —O(tBu) (tert-butoxy).</div>
    <div id="p-0077" num="0098" class="description-paragraph style-scope patent-text">Acetal: —CH(OR<sup class="style-scope patent-text">1</sup>)(OR<sup class="style-scope patent-text">2</sup>), wherein R<sup class="style-scope patent-text">1 </sup>and R<sup class="style-scope patent-text">2 </sup>are independently acetal substituents, for example, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, or, in the case of a “cyclic” acetal group, R<sup class="style-scope patent-text">1 </sup>and R<sup class="style-scope patent-text">2</sup>, taken together with the two oxygen atoms to which they are attached, and the carbon atoms to which they are attached, form a heterocyclic ring having from 4 to 8 ring atoms. Examples of acetal groups include, but are not limited to, —CH(OMe)<sub class="style-scope patent-text">2</sub>, —CH(OEt)<sub class="style-scope patent-text">2</sub>, and —CH(OMe)(OEt).</div>
    <div id="p-0078" num="0099" class="description-paragraph style-scope patent-text">Hemiacetal: —CH(OH)(OR<sup class="style-scope patent-text">1</sup>), wherein R<sup class="style-scope patent-text">1 </sup>is a hemiacetal substituent, for example, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably a C<sub class="style-scope patent-text">1-7 </sub>alkyl group.</div>
    <div id="p-0079" num="0100" class="description-paragraph style-scope patent-text">Examples of hemiacetal groups include, but are not limited to, —CH(OH)(OMe) and —CH(OH)(OEt).</div>
    <div id="p-0080" num="0101" class="description-paragraph style-scope patent-text">Ketal: —CR(OR<sup class="style-scope patent-text">1</sup>)(OR<sup class="style-scope patent-text">2</sup>), where R<sup class="style-scope patent-text">1 </sup>and R<sup class="style-scope patent-text">2 </sup>are as defined for acetals, and R is a ketal substituent other than hydrogen, for example, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably a C<sub class="style-scope patent-text">1-7 </sub>alkyl group. Examples ketal groups include, but are not limited to, —C(Me)(OMe)<sub class="style-scope patent-text">2</sub>, —C(Me)(OEt)<sub class="style-scope patent-text">2</sub>, —C(Me)(OMe)(OEt), —C(Et)(OMe)<sub class="style-scope patent-text">2</sub>, —C(Et)(OEt)<sub class="style-scope patent-text">2</sub>, and —C(Et)(OMe)(OEt).</div>
    <div id="p-0081" num="0102" class="description-paragraph style-scope patent-text">Hemiketal: —CR(OH)(OR<sup class="style-scope patent-text">1</sup>), where R<sup class="style-scope patent-text">1 </sup>is as defined for hemiacetals, and R is a hemiketal substituent other than hydrogen, for example, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably a C<sub class="style-scope patent-text">1-7 </sub>alkyl group. Examples of hemiacetal groups include, but are not limited to, —C(Me)(OH)(OMe), —C(Et)(OH)(OMe), —C(Me)(OH)(OEt), and —C(Et)(OH)(OEt).</div>
    <div id="p-0082" num="0103" class="description-paragraph style-scope patent-text">Oxo (keto, -one): ═O.</div>
    <div id="p-0083" num="0104" class="description-paragraph style-scope patent-text">Thione (thioketone): ═S.</div>
    <div id="p-0084" num="0105" class="description-paragraph style-scope patent-text">Imino (imine): ═NR, wherein R is an imino substituent, for example, hydrogen, C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably hydrogen or a C<sub class="style-scope patent-text">1-7 </sub>alkyl group. Examples of ester groups include, but are not limited to, ═NH, ═NMe, =NEt, and ═NPh.</div>
    <div id="p-0085" num="0106" class="description-paragraph style-scope patent-text">Formyl (carbaldehyde, carboxaldehyde): —C(═O)H.</div>
    <div id="p-0086" num="0107" class="description-paragraph style-scope patent-text">Acyl (keto): —C(═O)R, wherein R is an acyl substituent, for example, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group (also referred to as C<sub class="style-scope patent-text">1-7 </sub>alkylacyl or C<sub class="style-scope patent-text">1-7 </sub>alkanoyl), a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group (also referred to as C<sub class="style-scope patent-text">3-20 </sub>heterocyclylacyl), or a C<sub class="style-scope patent-text">5-20 </sub>aryl group (also referred to as C<sub class="style-scope patent-text">5-20 </sub>arylacyl), preferably a C<sub class="style-scope patent-text">1-7 </sub>alkyl group. Examples of acyl groups include, but are not limited to, —C(═O)CH<sub class="style-scope patent-text">3 </sub>(acetyl), —C(═O)CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3 </sub>(propionyl), —C(═O)C(CH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">3 </sub>(t-butyryl), and —C(═O)Ph (benzoyl, phenone).</div>
    <div id="p-0087" num="0108" class="description-paragraph style-scope patent-text">Carboxy (carboxylic acid): —C(═O)OH.</div>
    <div id="p-0088" num="0109" class="description-paragraph style-scope patent-text">Thiocarboxy (thiocarboxylic acid): —C(═S)SH.</div>
    <div id="p-0089" num="0110" class="description-paragraph style-scope patent-text">Thiolocarboxy (thiolocarboxylic acid): —C(═O)SH.</div>
    <div id="p-0090" num="0111" class="description-paragraph style-scope patent-text">Thionocarboxy (thionocarboxylic acid): —C(═S)OH.</div>
    <div id="p-0091" num="0112" class="description-paragraph style-scope patent-text">Imidic acid: —C(═NH)OH.</div>
    <div id="p-0092" num="0113" class="description-paragraph style-scope patent-text">Hydroxamic acid: —C(═NOH)OH.</div>
    <div id="p-0093" num="0114" class="description-paragraph style-scope patent-text">Ester (carboxylate, carboxylic acid ester, oxycarbonyl): —C(═O)OR, wherein R is an ester substituent, for example, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably a C<sub class="style-scope patent-text">1-7 </sub>alkyl group. Examples of ester groups include, but are not limited to, —C(═O)OCH<sub class="style-scope patent-text">3</sub>, —C(═O)OCH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>, —C(═O)OC(CH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">3</sub>, and —C(═O)OPh.</div>
    <div id="p-0094" num="0115" class="description-paragraph style-scope patent-text">Acyloxy (reverse ester): —OC(═O)R, wherein R is an acyloxy substituent, for example, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably a C<sub class="style-scope patent-text">1-7 </sub>alkyl group.</div>
    <div id="p-0095" num="0116" class="description-paragraph style-scope patent-text">Examples of acyloxy groups include, but are not limited to, —OC(═O)CH<sub class="style-scope patent-text">3 </sub>(acetoxy), —OC(═O)CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>, —OC(═O)C(CH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">3</sub>, —OC(═O)Ph, and —OC(═O)CH<sub class="style-scope patent-text">2</sub>Ph.</div>
    <div id="p-0096" num="0117" class="description-paragraph style-scope patent-text">Oxycarboyloxy: —OC(═O)OR, wherein R is an ester substituent, for example, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably a C<sub class="style-scope patent-text">1-7 </sub>alkyl group. Examples of ester groups include, but are not limited to, —OC(═O)OCH<sub class="style-scope patent-text">3</sub>, —OC(═O)OCH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>, —OC(═O)OC(CH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">3</sub>, and —OC(═O)OPh.</div>
    <div id="p-0097" num="0118" class="description-paragraph style-scope patent-text">Amino: —NR<sup class="style-scope patent-text">1</sup>R<sup class="style-scope patent-text">2</sup>, wherein R<sup class="style-scope patent-text">1 </sup>and R<sup class="style-scope patent-text">2 </sup>are independently amino substituents, for example, hydrogen, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group (also referred to as C<sub class="style-scope patent-text">1-7 </sub>alkylamino or di-C<sub class="style-scope patent-text">1-7 </sub>alkylamino), a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably H or a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, or, in the case of a “cyclic” amino group, R<sup class="style-scope patent-text">1 </sup>and R<sup class="style-scope patent-text">2</sup>, taken together with the nitrogen atom to which they are attached, form a heterocyclic ring having from 4 to 8 ring atoms. Amino groups may be primary (—NH<sub class="style-scope patent-text">2</sub>), secondary (—NHR<sup class="style-scope patent-text">1</sup>), or tertiary (—NHR<sup class="style-scope patent-text">1</sup>R<sup class="style-scope patent-text">2</sup>), and in cationic form, may be quaternary (—<sup class="style-scope patent-text">+</sup>NR<sup class="style-scope patent-text">1</sup>R<sup class="style-scope patent-text">2</sup>R<sup class="style-scope patent-text">3</sup>). Examples of amino groups include, but are not limited to, —NH<sub class="style-scope patent-text">2</sub>, —NHCH<sub class="style-scope patent-text">3</sub>, —NHC(CH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">2</sub>, —N(CH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">2</sub>, —N(CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">2</sub>, and —NHPh. Examples of cyclic amino groups include, but are not limited to, aziridino, azetidino, pyrrolidino, piperidino, piperazino, morpholino, and thiomorpholino.</div>
    <div id="p-0098" num="0119" class="description-paragraph style-scope patent-text">Amido (carbamoyl, carbamyl, aminocarbonyl, carboxamide): —C(═O)NR<sup class="style-scope patent-text">1</sup>R<sup class="style-scope patent-text">2</sup>, wherein R<sup class="style-scope patent-text">1 </sup>and R<sup class="style-scope patent-text">2 </sup>are independently amino substituents, as defined for amino groups. Examples of amido groups include, but are not limited to, —C(═O)NH<sub class="style-scope patent-text">2</sub>, —C(═O)NHCH<sub class="style-scope patent-text">3</sub>, —C(═O)N(CH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">2</sub>, —C(═O)NHCH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>, and —C(═O)N(CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">2</sub>, as well as amido groups in which R<sup class="style-scope patent-text">1 </sup>and R<sup class="style-scope patent-text">2</sup>, together with the nitrogen atom to which they are attached, form a heterocyclic structure as in, for example, piperidinocarbonyl, morpholinocarbonyl, thiomorpholinocarbonyl, and piperazinocarbonyl.</div>
    <div id="p-0099" num="0120" class="description-paragraph style-scope patent-text">Thioamido (thiocarbamyl): —C(═S)NR<sup class="style-scope patent-text">1</sup>R<sup class="style-scope patent-text">2</sup>, wherein R<sup class="style-scope patent-text">1 </sup>and R<sup class="style-scope patent-text">2 </sup>are independently amino substituents, as defined for amino groups. Examples of amido groups include, but are not limited to, —C(═S)NH<sub class="style-scope patent-text">2</sub>, —C(═S)NHCH<sub class="style-scope patent-text">3</sub>, —C(═S)N(CH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">2</sub>, and —C(═S)NHCH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>.</div>
    <div id="p-0100" num="0121" class="description-paragraph style-scope patent-text">Acylamido (acylamino): —NR<sup class="style-scope patent-text">1</sup>C(═O)R<sup class="style-scope patent-text">2</sup>, wherein R<sup class="style-scope patent-text">1 </sup>is an amide substituent, for example, hydrogen, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably hydrogen or a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, and R<sup class="style-scope patent-text">2 </sup>is an acyl substituent, for example, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably hydrogen or a C<sub class="style-scope patent-text">1-7 </sub>alkyl group.</div>
    <div id="p-0101" num="0122" class="description-paragraph style-scope patent-text">Examples of acylamide groups include, but are not limited to, —NHC(═O)CH<sub class="style-scope patent-text">3</sub>, —NHC(═O)CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>, and —NHC(═O)Ph. R<sup class="style-scope patent-text">1 </sup>and R<sup class="style-scope patent-text">2 </sup>may together form a cyclic structure, as in, for example, succinimidyl, maleimidyl, and phthalimidyl:</div>
    <div id="p-0102" num="0123" class="description-paragraph style-scope patent-text">
      <chemistry id="CHEM-US-00020" num="00020" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/01/99/23/304f623e69b343/US11370801-20220628-C00020.png" class="style-scope patent-text"><img id="EMI-C00020" he="28.70mm" wi="65.62mm" file="US11370801-20220628-C00020.TIF" alt="Figure US11370801-20220628-C00020" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="262" height="115" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/01/99/23/304f623e69b343/US11370801-20220628-C00020.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00020" attachment-type="cdx" file="US11370801-20220628-C00020.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00020" attachment-type="mol" file="US11370801-20220628-C00020.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
    </div>
    <div id="p-0103" num="0124" class="description-paragraph style-scope patent-text">Aminocarbonyloxy: —OC(═O)NR<sup class="style-scope patent-text">1</sup>R<sup class="style-scope patent-text">2</sup>, wherein R<sup class="style-scope patent-text">1 </sup>and R<sup class="style-scope patent-text">2 </sup>are independently amino substituents, as defined for amino groups. Examples of aminocarbonyloxy groups include, but are not limited to, —OC(═O)NH<sub class="style-scope patent-text">2</sub>, —OC(═O)NHMe, —OC(═O)NMe<sub class="style-scope patent-text">2</sub>, and —OC(═O)NEt<sub class="style-scope patent-text">2</sub>.</div>
    <div id="p-0104" num="0125" class="description-paragraph style-scope patent-text">Ureido: —N(R<sup class="style-scope patent-text">1</sup>)CONR<sup class="style-scope patent-text">2</sup>R<sup class="style-scope patent-text">3 </sup>wherein R<sup class="style-scope patent-text">2 </sup>and R<sup class="style-scope patent-text">3 </sup>are independently amino substituents, as defined for amino groups, and R<sup class="style-scope patent-text">1 </sup>is a ureido substituent, for example, hydrogen, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably hydrogen or a C<sub class="style-scope patent-text">1-7 </sub>alkyl group. Examples of ureido groups include, but are not limited to, —NHCONH<sub class="style-scope patent-text">2</sub>, —NHCONHMe, —NHCONHEt, —NHCONMe<sub class="style-scope patent-text">2</sub>, —NHCONEt<sub class="style-scope patent-text">2</sub>, —NMeCONH<sub class="style-scope patent-text">2</sub>, —NMeCONHMe, —NMeCONHEt, —NMeCONMe<sub class="style-scope patent-text">2</sub>, and —NMeCONEt<sub class="style-scope patent-text">2</sub>.</div>
    <div id="p-0105" num="0126" class="description-paragraph style-scope patent-text">Guanidino: —NH—C(═NH)NH<sub class="style-scope patent-text">2</sub>.</div>
    <div id="p-0106" num="0127" class="description-paragraph style-scope patent-text">Tetrazolyl: a five membered aromatic ring having four nitrogen atoms and one carbon atom,</div>
    <div id="p-0107" num="0128" class="description-paragraph style-scope patent-text">
      <chemistry id="CHEM-US-00021" num="00021" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e8/8b/66/faf6bd355be6a7/US11370801-20220628-C00021.png" class="style-scope patent-text"><img id="EMI-C00021" he="12.78mm" wi="15.41mm" file="US11370801-20220628-C00021.TIF" alt="Figure US11370801-20220628-C00021" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="62" height="51" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e8/8b/66/faf6bd355be6a7/US11370801-20220628-C00021.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00021" attachment-type="cdx" file="US11370801-20220628-C00021.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00021" attachment-type="mol" file="US11370801-20220628-C00021.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
    </div>
    <div id="p-0108" num="0129" class="description-paragraph style-scope patent-text">Imino: ═NR, wherein R is an imino substituent, for example, for example, hydrogen, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably H or a C<sub class="style-scope patent-text">1-7</sub>alkyl group. Examples of imino groups include, but are not limited to, ═NH, ═NMe, and =NEt.</div>
    <div id="p-0109" num="0130" class="description-paragraph style-scope patent-text">Amidine (amidino): —C(═NR)NR<sub class="style-scope patent-text">2</sub>, wherein each R is an amidine substituent, for example, hydrogen, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably H or a C<sub class="style-scope patent-text">1-7 </sub>alkyl group. Examples of amidine groups include, but are not limited to, —C(═NH)NH<sub class="style-scope patent-text">2</sub>, —C(═NH)NMe<sub class="style-scope patent-text">2</sub>, and —C(═NMe)NMe<sub class="style-scope patent-text">2</sub>.</div>
    <div id="p-0110" num="0131" class="description-paragraph style-scope patent-text">Nitro: —NO<sub class="style-scope patent-text">2</sub>.</div>
    <div id="p-0111" num="0132" class="description-paragraph style-scope patent-text">Nitroso: —NO.</div>
    <div id="p-0112" num="0133" class="description-paragraph style-scope patent-text">Azido: —N<sub class="style-scope patent-text">3</sub>.</div>
    <div id="p-0113" num="0134" class="description-paragraph style-scope patent-text">Cyano (nitrile, carbonitrile): —CN.</div>
    <div id="p-0114" num="0135" class="description-paragraph style-scope patent-text">Isocyano: —NC.</div>
    <div id="p-0115" num="0136" class="description-paragraph style-scope patent-text">Cyanato: —OCN.</div>
    <div id="p-0116" num="0137" class="description-paragraph style-scope patent-text">Isocyanato: —NCO.</div>
    <div id="p-0117" num="0138" class="description-paragraph style-scope patent-text">Thiocyano (thiocyanato): —SCN.</div>
    <div id="p-0118" num="0139" class="description-paragraph style-scope patent-text">Isothiocyano (isothiocyanato): —NCS.</div>
    <div id="p-0119" num="0140" class="description-paragraph style-scope patent-text">Sulfhydryl (thiol, mercapto): —SH.</div>
    <div id="p-0120" num="0141" class="description-paragraph style-scope patent-text">Thioether (sulfide): —SR, wherein R is a thioether substituent, for example, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group (also referred to as a C<sub class="style-scope patent-text">1-7</sub>alkylthio group), a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably a C<sub class="style-scope patent-text">1-7 </sub>alkyl group. Examples of C<sub class="style-scope patent-text">1-7 </sub>alkylthio groups include, but are not limited to, —SCH<sub class="style-scope patent-text">3 </sub>and —SCH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>.</div>
    <div id="p-0121" num="0142" class="description-paragraph style-scope patent-text">Disulfide: —SS—R, wherein R is a disulfide substituent, for example, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably a C<sub class="style-scope patent-text">1-7 </sub>alkyl group (also referred to herein as C<sub class="style-scope patent-text">1-7 </sub>alkyl disulfide). Examples of C<sub class="style-scope patent-text">1-7 </sub>alkyl disulfide groups include, but are not limited to, —SSCH<sub class="style-scope patent-text">3 </sub>and —SSCH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>.</div>
    <div id="p-0122" num="0143" class="description-paragraph style-scope patent-text">Sulfine (sulfinyl, sulfoxide): —S(═O)R, wherein R is a sulfine substituent, for example, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably a C<sub class="style-scope patent-text">1-7 </sub>alkyl group. Examples of sulfine groups include, but are not limited to, —S(═O)CH<sub class="style-scope patent-text">3 </sub>and —S(═O)CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>.</div>
    <div id="p-0123" num="0144" class="description-paragraph style-scope patent-text">Sulfone (sulfonyl): —S(═O)<sub class="style-scope patent-text">2</sub>R, wherein R is a sulfone substituent, for example, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, including, for example, a fluorinated or perfluorinated C<sub class="style-scope patent-text">1-7 </sub>alkyl group. Examples of sulfone groups include, but are not limited to, —S(═O)<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3 </sub>(methanesulfonyl, mesyl), —S(═O)<sub class="style-scope patent-text">2</sub>CF<sub class="style-scope patent-text">3 </sub>(triflyl), —S(═O)<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3 </sub>(esyl), —S(═O)<sub class="style-scope patent-text">2</sub>C<sub class="style-scope patent-text">4</sub>F<sub class="style-scope patent-text">9 </sub>(nonaflyl), —S(═O)<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">2</sub>CF<sub class="style-scope patent-text">3 </sub>(tresyl), —S(═O)<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">2</sub>NH<sub class="style-scope patent-text">2 </sub>(tauryl), —S(═O)<sub class="style-scope patent-text">2</sub>Ph (phenylsulfonyl, besyl), 4-methylphenylsulfonyl (tosyl), 4-chlorophenylsulfonyl (closyl), 4-bromophenylsulfonyl (brosyl), 4-nitrophenyl (nosyl), 2-naphthalenesulfonate (napsyl), and 5-dimethylamino-naphthalen-1-ylsulfonate (dansyl).</div>
    <div id="p-0124" num="0145" class="description-paragraph style-scope patent-text">Sulfinic acid (sulfino): —S(═O)OH, —SO<sub class="style-scope patent-text">2</sub>H.</div>
    <div id="p-0125" num="0146" class="description-paragraph style-scope patent-text">Sulfonic acid (sulfo): —S(═O)<sub class="style-scope patent-text">2</sub>OH, —SO<sub class="style-scope patent-text">3</sub>H.</div>
    <div id="p-0126" num="0147" class="description-paragraph style-scope patent-text">Sulfinate (sulfinic acid ester): —S(═O)OR; wherein R is a sulfinate substituent, for example, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably a C<sub class="style-scope patent-text">1-7 </sub>alkyl group. Examples of sulfinate groups include, but are not limited to, —S(═O)OCH<sub class="style-scope patent-text">3 </sub>(methoxysulfinyl; methyl sulfinate) and —S(═O)OCH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3 </sub>(ethoxysulfinyl; ethyl sulfinate).</div>
    <div id="p-0127" num="0148" class="description-paragraph style-scope patent-text">Sulfonate (sulfonic acid ester): —S(═O)<sub class="style-scope patent-text">2</sub>OR, wherein R is a sulfonate substituent, for example, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably a C<sub class="style-scope patent-text">1-7 </sub>alkyl group. Examples of sulfonate groups include, but are not limited to, —S(═O)<sub class="style-scope patent-text">2</sub>OCH<sub class="style-scope patent-text">3 </sub>(methoxysulfonyl; methyl sulfonate) and —S(═O)<sub class="style-scope patent-text">2</sub>OCH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3 </sub>(ethoxysulfonyl; ethyl sulfonate).</div>
    <div id="p-0128" num="0149" class="description-paragraph style-scope patent-text">Sulfinyloxy: —OS(═O)R, wherein R is a sulfinyloxy substituent, for example, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably a C<sub class="style-scope patent-text">1-7 </sub>alkyl group. Examples of sulfinyloxy groups include, but are not limited to, —OS(═O)CH<sub class="style-scope patent-text">3 </sub>and —OS(═O)CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>.</div>
    <div id="p-0129" num="0150" class="description-paragraph style-scope patent-text">Sulfonyloxy: —OS(═O)<sub class="style-scope patent-text">2</sub>R, wherein R is a sulfonyloxy substituent, for example, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably a C<sub class="style-scope patent-text">1-7 </sub>alkyl group. Examples of sulfonyloxy groups include, but are not limited to, —OS(═O)<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3 </sub>(mesylate) and —OS(═O)<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3 </sub>(esylate).</div>
    <div id="p-0130" num="0151" class="description-paragraph style-scope patent-text">Sulfate: —OS(═O)<sub class="style-scope patent-text">2</sub>OR; wherein R is a sulfate substituent, for example, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably a C<sub class="style-scope patent-text">1-7 </sub>alkyl group. Examples of sulfate groups include, but are not limited to, —OS(═O)<sub class="style-scope patent-text">2</sub>OCH<sub class="style-scope patent-text">3 </sub>and —SO(═O)<sub class="style-scope patent-text">2</sub>OCH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>.</div>
    <div id="p-0131" num="0152" class="description-paragraph style-scope patent-text">Sulfamyl (sulfamoyl; sulfinic acid amide; sulfinamide): —S(═O)NR<sup class="style-scope patent-text">1</sup>R<sup class="style-scope patent-text">2</sup>, wherein R<sup class="style-scope patent-text">1 </sup>and R<sup class="style-scope patent-text">2 </sup>are independently amino substituents, as defined for amino groups. Examples of sulfamyl groups include, but are not limited to, —S(═O)NH<sub class="style-scope patent-text">2</sub>, —S(═O)NH(CH<sub class="style-scope patent-text">3</sub>), —S(═O)N(CH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">2</sub>, —S(═O)NH(CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>), —S(═O)N(CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">2</sub>, and —S(═O)NHPh.</div>
    <div id="p-0132" num="0153" class="description-paragraph style-scope patent-text">Sulfonamido (sulfinamoyl; sulfonic acid amide; sulfonamide): —S(═O)<sub class="style-scope patent-text">2</sub>NR<sup class="style-scope patent-text">1</sup>R<sup class="style-scope patent-text">2</sup>, wherein R<sup class="style-scope patent-text">1 </sup>and R<sup class="style-scope patent-text">2 </sup>are independently amino substituents, as defined for amino groups. Examples of sulfonamido groups include, but are not limited to, —S(═O)<sub class="style-scope patent-text">2</sub>NH<sub class="style-scope patent-text">2</sub>, —S(═O)<sub class="style-scope patent-text">2</sub>NH(CH<sub class="style-scope patent-text">3</sub>), —S(═O)<sub class="style-scope patent-text">2</sub>N(CH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">2</sub>, —S(═O)<sub class="style-scope patent-text">2</sub>NH(CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>), —S(═O)<sub class="style-scope patent-text">2</sub>N(CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">2</sub>, and —S(═O)<sub class="style-scope patent-text">2</sub>NHPh.</div>
    <div id="p-0133" num="0154" class="description-paragraph style-scope patent-text">Sulfamino: —NR<sup class="style-scope patent-text">1</sup>S(═O)<sub class="style-scope patent-text">2</sub>OH, wherein R<sup class="style-scope patent-text">1 </sup>is an amino substituent, as defined for amino groups. Examples of sulfamino groups include, but are not limited to, —NHS(═O)<sub class="style-scope patent-text">2</sub>OH and —N(CH<sub class="style-scope patent-text">3</sub>)S(═O)<sub class="style-scope patent-text">2</sub>OH.</div>
    <div id="p-0134" num="0155" class="description-paragraph style-scope patent-text">Sulfonamino: —NR<sup class="style-scope patent-text">1</sup>S(═O)<sub class="style-scope patent-text">2</sub>R, wherein R<sup class="style-scope patent-text">1 </sup>is an amino substituent, as defined for amino groups, and R is a sulfonamino substituent, for example, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably a C<sub class="style-scope patent-text">1-7 </sub>alkyl group. Examples of sulfonamino groups include, but are not limited to, —NHS(═O)<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3 </sub>and —N(CH<sub class="style-scope patent-text">3</sub>)S(═O)<sub class="style-scope patent-text">2</sub>C<sub class="style-scope patent-text">6</sub>H<sub class="style-scope patent-text">5</sub>.</div>
    <div id="p-0135" num="0156" class="description-paragraph style-scope patent-text">Sulfinamino: —NR<sup class="style-scope patent-text">1</sup>S(═O)R, wherein R<sup class="style-scope patent-text">1 </sup>is an amino substituent, as defined for amino groups, and R is a sulfinamino substituent, for example, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably a C<sub class="style-scope patent-text">1-7 </sub>alkyl group. Examples of sulfinamino groups include, but are not limited to, —NHS(═O)CH<sub class="style-scope patent-text">3 </sub>and —N(CH<sub class="style-scope patent-text">3</sub>)S(═O)C<sub class="style-scope patent-text">6</sub>H<sub class="style-scope patent-text">5</sub>.</div>
    <div id="p-0136" num="0157" class="description-paragraph style-scope patent-text">Phosphino (phosphine): —PR<sub class="style-scope patent-text">2</sub>, wherein R is a phosphino substituent, for example, —H, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably —H, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group. Examples of phosphino groups include, but are not limited to, —PH<sub class="style-scope patent-text">2</sub>, —P(CH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">2</sub>, —P(CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">2</sub>, —P(t-Bu)<sub class="style-scope patent-text">2</sub>, and —P(Ph)<sub class="style-scope patent-text">2</sub>.</div>
    <div id="p-0137" num="0158" class="description-paragraph style-scope patent-text">Phospho: —P(═O)<sub class="style-scope patent-text">2</sub>.</div>
    <div id="p-0138" num="0159" class="description-paragraph style-scope patent-text">Phosphinyl (phosphine oxide): —P(═O)R<sub class="style-scope patent-text">2</sub>, wherein R is a phosphinyl substituent, for example, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably a C<sub class="style-scope patent-text">1-7 </sub>alkyl group or a C<sub class="style-scope patent-text">5-20 </sub>aryl group. Examples of phosphinyl groups include, but are not limited to, —P(═O)(CH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">2</sub>, —P(═O)(CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">2</sub>, —P(═O)(t-Bu)<sub class="style-scope patent-text">2</sub>, and —P(═O)(Ph)<sub class="style-scope patent-text">2</sub>.</div>
    <div id="p-0139" num="0160" class="description-paragraph style-scope patent-text">Phosphonic acid (phosphono): —P(═O)(OH)<sub class="style-scope patent-text">2</sub>.</div>
    <div id="p-0140" num="0161" class="description-paragraph style-scope patent-text">Phosphonate (phosphono ester): —P(═O)(OR)<sub class="style-scope patent-text">2</sub>, where R is a phosphonate substituent, for example, —H, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably —H, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group. Examples of phosphonate groups include, but are not limited to, —P(═O)(OCH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">2</sub>, —P(═O)(OCH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">2</sub>, —P(═O)(O-t-Bu)<sub class="style-scope patent-text">2</sub>, and —P(═O)(OPh)<sub class="style-scope patent-text">2</sub>.</div>
    <div id="p-0141" num="0162" class="description-paragraph style-scope patent-text">Phosphoric acid (phosphonooxy): —OP(═O)(OH)<sub class="style-scope patent-text">2</sub>.</div>
    <div id="p-0142" num="0163" class="description-paragraph style-scope patent-text">Phosphate (phosphonooxy ester): —OP(═O)(OR)<sub class="style-scope patent-text">2</sub>, where R is a phosphate substituent, for example, —H, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably —H, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group. Examples of phosphate groups include, but are not limited to, —OP(═O)(OCH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">2</sub>, —OP(═O)(OCH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">2</sub>, —OP(═O)(O-t-Bu)<sub class="style-scope patent-text">2</sub>, and —OP(═O)(OPh)<sub class="style-scope patent-text">2</sub>.</div>
    <div id="p-0143" num="0164" class="description-paragraph style-scope patent-text">Phosphorous acid: —OP(OH)<sub class="style-scope patent-text">2</sub>.</div>
    <div id="p-0144" num="0165" class="description-paragraph style-scope patent-text">Phosphite: —OP(OR)<sub class="style-scope patent-text">2</sub>, where R is a phosphite substituent, for example, —H, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably —H, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group. Examples of phosphite groups include, but are not limited to, —OP(OCH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">2</sub>, —OP(OCH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">2</sub>, —OP(O-t-Bu)<sub class="style-scope patent-text">2</sub>, and —OP(OPh)<sub class="style-scope patent-text">2</sub>.</div>
    <div id="p-0145" num="0166" class="description-paragraph style-scope patent-text">Phosphoramidite: —OP(OR<sup class="style-scope patent-text">1</sup>)—NR<sup class="style-scope patent-text">2</sup> <sub class="style-scope patent-text">2</sub>, where R<sup class="style-scope patent-text">1 </sup>and R<sup class="style-scope patent-text">2 </sup>are phosphoramidite substituents, for example, —H, a (optionally substituted) C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably —H, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group. Examples of phosphoramidite groups include, but are not limited to, —OP(OCH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>)—N(CH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">2</sub>, —OP(OCH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>)—N(i-Pr)<sub class="style-scope patent-text">2</sub>, and —OP(OCH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">2</sub>CN)—N(i-Pr)<sub class="style-scope patent-text">2</sub>.</div>
    <div id="p-0146" num="0167" class="description-paragraph style-scope patent-text">Phosphoramidate: —OP(═O)(OR<sup class="style-scope patent-text">1</sup>)—NR<sup class="style-scope patent-text">2</sup> <sub class="style-scope patent-text">2</sub>, where R<sup class="style-scope patent-text">1 </sup>and R<sup class="style-scope patent-text">2 </sup>are phosphoramidate substituents, for example, —H, a (optionally substituted) C<sub class="style-scope patent-text">1-7 </sub>alkyl group, a C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group, preferably —H, a C<sub class="style-scope patent-text">1-7 </sub>alkyl group, or a C<sub class="style-scope patent-text">5-20 </sub>aryl group. Examples of phosphoramidate groups include, but are not limited to, —OP(═O)(OCH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>)—N(CH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">2</sub>, —OP(═O)(OCH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>)—N(i-Pr)<sub class="style-scope patent-text">2</sub>, and —OP(═O)(OCH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">2</sub>CN)—N(i-Pr)<sub class="style-scope patent-text">2</sub>.</div>
    <div id="h-0017" num="0000" class="description-paragraph style-scope patent-text">Alkylene</div>
    <div id="p-0147" num="0168" class="description-paragraph style-scope patent-text">C<sub class="style-scope patent-text">3-12 </sub>alkylene: The term “C<sub class="style-scope patent-text">3-12 </sub>alkylene”, as used herein, pertains to a bidentate moiety obtained by removing two hydrogen atoms, either both from the same carbon atom, or one from each of two different carbon atoms, of a hydrocarbon compound having from 3 to 12 carbon atoms (unless otherwise specified), which may be aliphatic or alicyclic, and which may be saturated, partially unsaturated, or fully unsaturated. Thus, the term “alkylene” includes the sub-classes alkenylene, alkynylene, cycloalkylene, etc., discussed below.</div>
    <div id="p-0148" num="0169" class="description-paragraph style-scope patent-text">Examples of linear saturated C<sub class="style-scope patent-text">3-12 </sub>alkylene groups include, but are not limited to, —(CH<sub class="style-scope patent-text">2</sub>)<sub class="style-scope patent-text">n</sub>— where n is an integer from 3 to 12, for example, —CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">2</sub>— (propylene), —CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">2</sub>— (butylene), —CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">2</sub>— (pentylene) and —CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">2</sub>CH-<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">2</sub>— (heptylene).</div>
    <div id="p-0149" num="0170" class="description-paragraph style-scope patent-text">Examples of branched saturated C<sub class="style-scope patent-text">3-12 </sub>alkylene groups include, but are not limited to, —CH(CH<sub class="style-scope patent-text">3</sub>)CH<sub class="style-scope patent-text">2</sub>—, —CH(CH<sub class="style-scope patent-text">3</sub>)CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">2</sub>—, —CH(CH<sub class="style-scope patent-text">3</sub>)CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">2</sub>—, —CH<sub class="style-scope patent-text">2</sub>CH(CH<sub class="style-scope patent-text">3</sub>)CH<sub class="style-scope patent-text">2</sub>—, —CH<sub class="style-scope patent-text">2</sub>CH(CH<sub class="style-scope patent-text">3</sub>)CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">2</sub>—, —CH(CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>)—, —CH(CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>)CH<sub class="style-scope patent-text">2</sub>—, and —CH<sub class="style-scope patent-text">2</sub>CH(CH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">3</sub>)CH<sub class="style-scope patent-text">2</sub>—.</div>
    <div id="p-0150" num="0171" class="description-paragraph style-scope patent-text">Examples of linear partially unsaturated C<sub class="style-scope patent-text">3-12 </sub>alkylene groups (C<sub class="style-scope patent-text">3-12 </sub>alkenylene, and alkynylene groups) include, but are not limited to, —CH═CH—CH<sub class="style-scope patent-text">2</sub>—, —CH<sub class="style-scope patent-text">2</sub>—CH═CH<sub class="style-scope patent-text">2</sub>—, —CH═CH—CH<sub class="style-scope patent-text">2</sub>—CH<sub class="style-scope patent-text">2</sub>—, —CH═CH—CH<sub class="style-scope patent-text">2</sub>—CH<sub class="style-scope patent-text">2</sub>—CH<sub class="style-scope patent-text">2</sub>—, —CH═CH—CH═CH—, —CH═CH—CH═CH—CH<sub class="style-scope patent-text">2</sub>—, —CH═CH—CH═CH—CH<sub class="style-scope patent-text">2</sub>—CH<sub class="style-scope patent-text">2</sub>—, —CH═CH—CH<sub class="style-scope patent-text">2</sub>—CH═CH—, —CH═CH—CH<sub class="style-scope patent-text">2</sub>—CH<sub class="style-scope patent-text">2</sub>—CH═CH—, and —CH<sub class="style-scope patent-text">2</sub>—C≡C—CH<sub class="style-scope patent-text">2</sub>—.</div>
    <div id="p-0151" num="0172" class="description-paragraph style-scope patent-text">Examples of branched partially unsaturated C<sub class="style-scope patent-text">3-12 </sub>alkylene groups (C<sub class="style-scope patent-text">3-12 </sub>alkenylene and alkynylene groups) include, but are not limited to, —C(CH<sub class="style-scope patent-text">3</sub>)═CH—, —C(CH<sub class="style-scope patent-text">3</sub>)═CH—CH<sub class="style-scope patent-text">2</sub>—, —CH═CH—CH(CH<sub class="style-scope patent-text">3</sub>)— and —C≡C—CH(CH<sub class="style-scope patent-text">3</sub>)—.</div>
    <div id="p-0152" num="0173" class="description-paragraph style-scope patent-text">Examples of alicyclic saturated C<sub class="style-scope patent-text">3-12 </sub>alkylene groups (C<sub class="style-scope patent-text">3-12 </sub>cycloalkylenes) include, but are not limited to, cyclopentylene (e.g. cyclopent-1,3-ylene), and cyclohexylene (e.g. cyclohex-1,4-ylene).</div>
    <div id="p-0153" num="0174" class="description-paragraph style-scope patent-text">Examples of alicyclic partially unsaturated C<sub class="style-scope patent-text">3-12 </sub>alkylene groups (C<sub class="style-scope patent-text">3-12 </sub>cycloalkylenes) include, but are not limited to, cyclopentenylene (e.g. 4-cyclopenten-1,3-ylene), cyclohexenylene (e.g. 2-cyclohexen-1,4-ylene; 3-cyclohexen-1,2-ylene; 2,5-cyclohexadien-1,4-ylene).</div>
    <div id="p-0154" num="0175" class="description-paragraph style-scope patent-text">Where the C<sub class="style-scope patent-text">3-12 </sub>alkylene group is interrupted by a heteroatom, the subscript refers to the number of atoms in the chain including the heteroatoms. For example, the chain —C<sub class="style-scope patent-text">2</sub>H<sub class="style-scope patent-text">4</sub>—O—C<sub class="style-scope patent-text">2</sub>H<sub class="style-scope patent-text">4</sub>— would be a C<sub class="style-scope patent-text">5 </sub>group.</div>
    <div id="p-0155" num="0176" class="description-paragraph style-scope patent-text">Where the C<sub class="style-scope patent-text">3-12 </sub>alkylene group is interrupted by a heteroatom, the subscript refers to the number of atoms directly in the chain including the aromatic ring. For example, the chain</div>
    <div id="p-0156" num="0177" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00022" num="00022" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/de/71/dd/d3240ce26bc39c/US11370801-20220628-C00022.png" class="style-scope patent-text"><img id="EMI-C00022" he="13.72mm" wi="35.39mm" file="US11370801-20220628-C00022.TIF" alt="Figure US11370801-20220628-C00022" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="142" height="55" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/de/71/dd/d3240ce26bc39c/US11370801-20220628-C00022.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00022" attachment-type="cdx" file="US11370801-20220628-C00022.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00022" attachment-type="mol" file="US11370801-20220628-C00022.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
would be a C<sub class="style-scope patent-text">5 </sub>group.
<br class="style-scope patent-text">
Ligand Unit
</div>
    <div id="p-0157" num="0178" class="description-paragraph style-scope patent-text">The Ligand Unit may be of any kind, and include a protein, polypeptide, peptide and a non-peptidic agent that specifically binds to a target molecule. In some embodiments, the Ligand unit may be a protein, polypeptide or peptide. In some embodiments, the Ligand unit may be a cyclic polypeptide. These Ligand units can include antibodies or a fragment of an antibody that contains at least one target molecule-binding site, lymphokines, hormones, growth factors, or any other cell binding molecule or substance that can specifically bind to a target.</div>
    <div id="p-0158" num="0179" class="description-paragraph style-scope patent-text">The terms “specifically binds” and “specific binding” refer to the binding of an antibody or other protein, polypeptide or peptide to a predetermined molecule (e.g., an antigen). Typically, the antibody or other molecule binds with an affinity of at least about 1×10<sup class="style-scope patent-text">7 </sup>M<sup class="style-scope patent-text">−1</sup>, and binds to the predetermined molecule with an affinity that is at least two-fold greater than its affinity for binding to a non-specific molecule (e.g., BSA, casein) other than the predetermined molecule or a closely-related molecule.</div>
    <div id="p-0159" num="0180" class="description-paragraph style-scope patent-text">Examples of Ligand units include those agents described for use in WO 2007/085930, which is incorporated herein.</div>
    <div id="p-0160" num="0181" class="description-paragraph style-scope patent-text">In some embodiments, the Ligand unit is a Cell Binding Agent that binds to an extracellular target on a cell. Such a Cell Binding Agent can be a protein, polypeptide, peptide or a non-peptidic agent. In some embodiments, the Cell Binding Agent may be a protein, polypeptide or peptide. In some embodiments, the Cell Binding Agent may be a cyclic polypeptide. The Cell Binding Agent also may be antibody or an antigen-binding fragment of an antibody. Thus, in one embodiment, the present invention provides an antibody-drug conjugate (ADC).</div>
    <div id="h-0018" num="0000" class="description-paragraph style-scope patent-text">Cell Binding Agent</div>
    <div id="p-0161" num="0182" class="description-paragraph style-scope patent-text">A cell binding agent may be of any kind, and include peptides and non-peptides. These can include antibodies or a fragment of an antibody that contains at least one binding site, lymphokines, hormones, hormone mimetics, vitamins, growth factors, nutrient-transport molecules, or any other cell binding molecule or substance.</div>
    <div id="h-0019" num="0000" class="description-paragraph style-scope patent-text">Peptides</div>
    <div id="p-0162" num="0183" class="description-paragraph style-scope patent-text">In one embodiment, the cell binding agent is a linear or cyclic peptide comprising 4-30, preferably 6-20, contiguous amino acid residues. In this embodiment, it is preferred that one cell binding agent is linked to one monomer or dimer pyrrolobenzodiazepine compound.</div>
    <div id="p-0163" num="0184" class="description-paragraph style-scope patent-text">In one embodiment the cell binding agent comprises a peptide that binds integrin a<sub class="style-scope patent-text">v</sub>β<sub class="style-scope patent-text">6</sub>. The peptide may be selective for α<sub class="style-scope patent-text">v</sub>β<sub class="style-scope patent-text">6 </sub>over XYS.</div>
    <div id="p-0164" num="0185" class="description-paragraph style-scope patent-text">In one embodiment the cell binding agent comprises the A20FMDV-Cys polypeptide. The A20FMDV-Cys has the sequence: NAVPNLRGDLQVLAQKVARTC. Alternatively, a variant of the A20FMDV-Cys sequence may be used wherein one, two, three, four, five, six, seven, eight, nine or ten amino acid residues are substituted with another amino acid residue. Furthermore, the polypeptide may have the sequence NAVXXXXXXXXXXXXXXXRTC.</div>
    <div id="h-0020" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-0165" num="0186" class="description-paragraph style-scope patent-text">The term “antibody” herein is used in the broadest sense and specifically covers monoclonal antibodies, polyclonal antibodies, dimers, multimers, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, so long as they exhibit the desired biological activity (Miller et al (2003) <i class="style-scope patent-text">Jour. of Immunology </i>170:4854-4861). Antibodies may be murine, human, humanized, chimeric, or derived from other species. An antibody is a protein generated by the immune system that is capable of recognizing and binding to a specific antigen. (Janeway, C., Travers, P., Walport, M., Shlomchik (2001) <i class="style-scope patent-text">Immuno Biology, </i>5<i class="style-scope patent-text">th Ed</i>., Garland Publishing, New York). A target antigen generally has numerous binding sites, also called epitopes, recognized by CDRs on multiple antibodies. Each antibody that specifically binds to a different epitope has a different structure. Thus, one antigen may have more than one corresponding antibody. An antibody includes a full-length immunoglobulin molecule or an immunologically active portion of a full-length immunoglobulin molecule, i.e., a molecule that contains an antigen binding site that immunospecifically binds an antigen of a target of interest or part thereof, such targets including but not limited to, cancer cell or cells that produce autoimmune antibodies associated with an autoimmune disease. The immunoglobulin can be of any type (e.g. IgG, IgE, IgM, IgD, and IgA), class (e.g. IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule. The immunoglobulins can be derived from any species, including human, murine, or rabbit origin.</div>
    <div id="p-0166" num="0187" class="description-paragraph style-scope patent-text">“Antibody fragments” comprise a portion of a full length antibody, generally the antigen binding or variable region thereof. Examples of antibody fragments include Fab, Fab′, F(ab′)<sub class="style-scope patent-text">2</sub>, and scFv fragments; diabodies; linear antibodies; fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, CDR (complementary determining region), and epitope-binding fragments of any of the above which immunospecifically bind to cancer cell antigens, viral antigens or microbial antigens, single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.</div>
    <div id="p-0167" num="0188" class="description-paragraph style-scope patent-text">The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e. the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations which include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they may be synthesized uncontaminated by other antibodies. The modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al (1975) <i class="style-scope patent-text">Nature </i>256:495, or may be made by recombinant DNA methods (see, U.S. Pat. No. 4,816,567). The monoclonal antibodies may also be isolated from phage antibody libraries using the techniques described in Clackson et al (1991) Nature, 352:624-628; Marks et al (1991) J. Mol. Biol., 222:581-597 or from transgenic mice carrying a fully human immunoglobulin system (Lonberg (2008) Curr. Opinion 20(4):450-459).</div>
    <div id="p-0168" num="0189" class="description-paragraph style-scope patent-text">The monoclonal antibodies herein specifically include “chimeric” antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Pat. No. 4,816,567; and Morrison et al (1984) <i class="style-scope patent-text">Proc. Natl. Acad. Sci. USA, </i>81:6851-6855). Chimeric antibodies include “primatized” antibodies comprising variable domain antigen-binding sequences derived from a non-human primate (e.g. Old World Monkey or Ape) and human constant region sequences.</div>
    <div id="p-0169" num="0190" class="description-paragraph style-scope patent-text">An “intact antibody” herein is one comprising a VL and VH domains, as well as a light chain constant domain (CL) and heavy chain constant domains, CH1, CH2 and CH3. The constant domains may be native sequence constant domains (e.g. human native sequence constant domains) or amino acid sequence variant thereof. The intact antibody may have one or more “effector functions” which refer to those biological activities attributable to the Fc region (a native sequence Fc region or amino acid sequence variant Fc region) of an antibody. Examples of antibody effector functions include C1q binding; complement dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; and down regulation of cell surface receptors such as B cell receptor and BCR.</div>
    <div id="p-0170" num="0191" class="description-paragraph style-scope patent-text">Depending on the amino acid sequence of the constant domain of their heavy chains, intact antibodies can be assigned to different “classes.” There are five major classes of intact antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into “subclasses” (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA, and IgA2. The heavy-chain constant domains that correspond to the different classes of antibodies are called a, b, E, y, and p, respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known.</div>
    <div id="h-0021" num="0000" class="description-paragraph style-scope patent-text">Humanisation</div>
    <div id="p-0171" num="0192" class="description-paragraph style-scope patent-text">Techniques to reduce the in vivo immunogenicity of a non-human antibody or antibody fragment include those termed “humanisation”.</div>
    <div id="p-0172" num="0193" class="description-paragraph style-scope patent-text">A “humanized antibody” refers to a polypeptide comprising at least a portion of a modified variable region of a human antibody wherein a portion of the variable region, preferably a portion substantially less than the intact human variable domain, has been substituted by the corresponding sequence from a non-human species and wherein the modified variable region is linked to at least another part of another protein, preferably the constant region of a human antibody. The expression “humanized antibodies” includes human antibodies in which one or more complementarity determining region (“CDR”) amino acid residues and/or one or more framework region (“FW” or “FR”) amino acid residues are substituted by amino acid residues from analogous sites in rodent or other non-human antibodies. The expression “humanized antibody” also includes an immunoglobulin amino acid sequence variant or fragment thereof that comprises an FR having substantially the amino acid sequence of a human immunoglobulin and a CDR having substantially the amino acid sequence of a non-human immunoglobulin.</div>
    <div id="p-0173" num="0194" class="description-paragraph style-scope patent-text">“Humanized” forms of non-human (e.g., murine) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin. Or, looked at another way, a humanized antibody is a human antibody that also contains selected sequences from non-human (e.g. murine) antibodies in place of the human sequences. A humanized antibody can include conservative amino acid substitutions or non-natural residues from the same or different species that do not significantly alter its binding and/or biologic activity. Such antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulins.</div>
    <div id="p-0174" num="0195" class="description-paragraph style-scope patent-text">There are a range of humanisation techniques, including ‘CDR grafting’, ‘guided selection’, ‘deimmunization’, ‘resurfacing’ (also known as ‘veneering’), ‘composite antibodies’, ‘Human String Content Optimisation’ and framework shuffling.</div>
    <div id="h-0022" num="0000" class="description-paragraph style-scope patent-text">CDR Grafting</div>
    <div id="p-0175" num="0196" class="description-paragraph style-scope patent-text">In this technique, the humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementary-determining region (CDR) of the recipient antibody are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, camel, bovine, goat, or rabbit having the desired properties (in effect, the non-human CDRs are ‘grafted’ onto the human framework). In some instances, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues (this may happen when, for example, a particular FR residue has significant effect on antigen binding).</div>
    <div id="p-0176" num="0197" class="description-paragraph style-scope patent-text">Furthermore, humanized antibodies can comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are made to further refine and maximize antibody performance. Thus, in general, a humanized antibody will comprise all of at least one, and in one aspect two, variable domains, in which all or all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), or that of a human immunoglobulin.</div>
    <div id="h-0023" num="0000" class="description-paragraph style-scope patent-text">Guided Selection</div>
    <div id="p-0177" num="0198" class="description-paragraph style-scope patent-text">The method consists of combining the V<sub class="style-scope patent-text">H </sub>or V<sub class="style-scope patent-text">L </sub>domain of a given non-human antibody specific for a particular epitope with a human V<sub class="style-scope patent-text">H </sub>or V<sub class="style-scope patent-text">L </sub>library and specific human V domains are selected against the antigen of interest. This selected human VH is then combined with a VL library to generate a completely human VH×VL combination. The method is described in Nature Biotechnology (N.Y.) 12, (1994) 899-903.</div>
    <div id="h-0024" num="0000" class="description-paragraph style-scope patent-text">Composite Antibodies</div>
    <div id="p-0178" num="0199" class="description-paragraph style-scope patent-text">In this method, two or more segments of amino acid sequence from a human antibody are combined within the final antibody molecule. They are constructed by combining multiple human VH and VL sequence segments in combinations which limit or avoid human T cell epitopes in the final composite antibody V regions. Where required, T cell epitopes are limited or avoided by, exchanging V region segments contributing to or encoding a T cell epitope with alternative segments which avoid T cell epitopes. This method is described in US 2008/0206239 A1.</div>
    <div id="h-0025" num="0000" class="description-paragraph style-scope patent-text">Deimmunization</div>
    <div id="p-0179" num="0200" class="description-paragraph style-scope patent-text">This method involves the removal of human (or other second species) T-cell epitopes from the V regions of the therapeutic antibody (or other molecule). The therapeutic antibodies V-region sequence is analysed for the presence of MHC class II-binding motifs by, for example, comparison with databases of MHC-binding motifs (such as the “motifs” database hosted at www.wehi.edu.au). Alternatively, MHC class II-binding motifs may be identified using computational threading methods such as those devised by Altuvia et al. (J. Mol. Biol. 249 244-250 (1995)); in these methods, consecutive overlapping peptides from the V-region sequences are testing for their binding energies to MHC class II proteins. This data can then be combined with information on other sequence features which relate to successfully presented peptides, such as amphipathicity, Rothbard motifs, and cleavage sites for cathepsin B and other processing enzymes.</div>
    <div id="p-0180" num="0201" class="description-paragraph style-scope patent-text">Once potential second species (e.g. human) T-cell epitopes have been identified, they are eliminated by the alteration of one or more amino acids. The modified amino acids are usually within the T-cell epitope itself, but may also be adjacent to the epitope in terms of the primary or secondary structure of the protein (and therefore, may not be adjacent in the primary structure). Most typically, the alteration is by way of substitution but, in some circumstances amino acid addition or deletion will be more appropriate.</div>
    <div id="p-0181" num="0202" class="description-paragraph style-scope patent-text">All alterations can be accomplished by recombinant DNA technology, so that the final molecule may be prepared by expression from a recombinant host using well established methods such as Site Directed Mutagenesis. However, the use of protein chemistry or any other means of molecular alteration is also possible.</div>
    <div id="h-0026" num="0000" class="description-paragraph style-scope patent-text">Resurfacing</div>
    <div id="p-0182" num="0203" class="description-paragraph style-scope patent-text">This method involves:
</div> <ul class="style-scope patent-text"> <li id="ul0022-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0023-0001" num="0204" class="style-scope patent-text">(a) determining the conformational structure of the variable region of the non-human (e.g. rodent) antibody (or fragment thereof) by constructing a three-dimensional model of the non-human antibody variable region;</li> <li id="ul0023-0002" num="0205" class="style-scope patent-text">(b) generating sequence alignments using relative accessibility distributions from x-ray crystallographic structures of a sufficient number of non-human and human antibody variable region heavy and light chains to give a set of heavy and light chain framework positions wherein the alignment positions are identical in 98% of the sufficient number of non-human antibody heavy and light chains;</li> <li id="ul0023-0003" num="0206" class="style-scope patent-text">(c) defining for the non-human antibody to be humanized, a set of heavy and light chain surface exposed amino acid residues using the set of framework positions generated in step (b);</li> <li id="ul0023-0004" num="0207" class="style-scope patent-text">(d) identifying from human antibody amino acid sequences a set of heavy and light chain surface exposed amino acid residues that is most closely identical to the set of surface exposed amino acid residues defined in step (c), wherein the heavy and light chain from the human antibody are or are not naturally paired;</li> <li id="ul0023-0005" num="0208" class="style-scope patent-text">(e) substituting, in the amino acid sequence of the non-human antibody to be humanized, the set of heavy and light chain surface exposed amino acid residues defined in step (c) with the set of heavy and light chain surface exposed amino acid residues identified in step (d);</li> <li id="ul0023-0006" num="0209" class="style-scope patent-text">(f) constructing a three-dimensional model of the variable region of the non-human antibody resulting from the substituting specified in step (e);</li> <li id="ul0023-0007" num="0210" class="style-scope patent-text">(g) identifying, by comparing the three-dimensional models constructed in steps (a) and (f), any amino acid residues from the sets identified in steps (c) or (d), that are within 5 Angstroms of any atom of any residue of the complementarity determining regions of the non-human antibody to be humanized; and</li> <li id="ul0023-0008" num="0211" class="style-scope patent-text">(h) changing any residues identified in step (g) from the human to the original non-human amino acid residue to thereby define a non-human antibody humanizing set of surface exposed amino acid residues; with the proviso that step (a) need not be conducted first, but must be conducted prior to step (g).
<br class="style-scope patent-text">
Superhumanization
</li> </ul> </li> </ul>

    <div id="p-0183" num="0212" class="description-paragraph style-scope patent-text">The method compares the non-human sequence with the functional human germline gene repertoire. Those human genes encoding canonical structures identical or closely related to the non-human sequences are selected. Those selected human genes with highest homology within the CDRs are chosen as FR donors. Finally, the non-human CDRs are grafted onto these human FRs. This method is described in patent WO 2005/079479 A2.</div>
    <div id="h-0027" num="0000" class="description-paragraph style-scope patent-text">Human String Content Optimization</div>
    <div id="p-0184" num="0213" class="description-paragraph style-scope patent-text">This method compares the non-human (e.g. mouse) sequence with the repertoire of human germline genes and the differences are scored as Human String Content (HSC) that quantifies a sequence at the level of potential MHC/T-cell epitopes. The target sequence is then humanized by maximizing its HSC rather than using a global identity measure to generate multiple diverse humanized variants (described in Molecular Immunology, 44, (2007) 1986-1998).</div>
    <div id="h-0028" num="0000" class="description-paragraph style-scope patent-text">Framework Shuffling</div>
    <div id="p-0185" num="0214" class="description-paragraph style-scope patent-text">The CDRs of the non-human antibody are fused in-frame to cDNA pools encompassing all known heavy and light chain human germline gene frameworks. Humanised antibodies are then selected by e.g. panning of the phage displayed antibody library. This is described in <i class="style-scope patent-text">Methods </i>36, 43-60 (2005).</div>
    <div id="p-0186" num="0215" class="description-paragraph style-scope patent-text">Examples of cell binding agents include those agents described for use in WO 2007/085930, which is incorporated herein.</div>
    <div id="p-0187" num="0216" class="description-paragraph style-scope patent-text">Tumour-associate antigens and cognate antibodies for use in embodiments of the present invention are listed below.</div>
    <div id="h-0029" num="0000" class="description-paragraph style-scope patent-text">Tumor-Associated Antigens and Cognate Antibodies</div>
    <div id="h-0030" num="0000" class="description-paragraph style-scope patent-text">(1) BMPRIB (Bone Morphogenetic Protein Receptor-Type IB)</div>
    <div id="h-0031" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0188" num="0217" class="description-paragraph style-scope patent-text">Genbank accession no. NM_001203</div>
    <div id="p-0189" num="0218" class="description-paragraph style-scope patent-text">Genbank version no. NM_001203.2 GI: 169790809</div>
    <div id="p-0190" num="0219" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 23, 2012 02:06 PM</div>
    <div id="h-0032" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0191" num="0220" class="description-paragraph style-scope patent-text">Genbank accession no. NP_001194</div>
    <div id="p-0192" num="0221" class="description-paragraph style-scope patent-text">Genbank version no. NP_001194.1 GI: 4502431</div>
    <div id="p-0193" num="0222" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 23, 2012 02:06 PM</div>
    <div id="h-0033" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0194" num="0223" class="description-paragraph style-scope patent-text">ten Dijke, P., et al <i class="style-scope patent-text">Science </i>264 (5155): 101-104 (1994), <i class="style-scope patent-text">Oncogene </i>14 (11):1377-1382 (1997)); WO2004/063362 (Claim 2); WO2003/042661 (Claim 12); US2003/134790-A1 (Page 38-39); WO2002/102235 (Claim 13; Page 296); WO2003/055443</div>
    <div id="p-0195" num="0224" class="description-paragraph style-scope patent-text">(Page 91-92); WO2002/99122 (Example 2; Page 528-530); WO2003/029421 (Claim 6); WO2003/024392 (Claim 2; FIG. 112); WO2002/98358 (Claim 1; Page 183); WO2002/54940 (Page 100-101); WO2002/59377 (Page 349-350); WO2002/30268 (Claim 27; Page 376); WO2001/48204 (Example; FIG. 4); NP_001194 bone morphogenetic protein receptor, type IB/pid=NP_001194.1; MIM: 603248; AY065994</div>
    <div id="h-0034" num="0000" class="description-paragraph style-scope patent-text">(2) E16 (LAT1, SLC7A5)</div>
    <div id="h-0035" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0196" num="0225" class="description-paragraph style-scope patent-text">Genbank accession no. NM_003486</div>
    <div id="p-0197" num="0226" class="description-paragraph style-scope patent-text">Genbank version no. NM_003486.5 GI: 71979931</div>
    <div id="p-0198" num="0227" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 27, 2012 12:06 PM</div>
    <div id="h-0036" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0199" num="0228" class="description-paragraph style-scope patent-text">Genbank accession no. NP_003477</div>
    <div id="p-0200" num="0229" class="description-paragraph style-scope patent-text">Genbank version no. NP_003477.4 GI: 71979932</div>
    <div id="p-0201" num="0230" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 27, 2012 12:06 PM</div>
    <div id="h-0037" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0202" num="0231" class="description-paragraph style-scope patent-text"> <i class="style-scope patent-text">Biochem. Biophys. Res. Commun. </i>255 (2), 283-288 (1999), <i class="style-scope patent-text">Nature </i>395 (6699):288-291 (1998), Gaugitsch, H. W., et al (1992) <i class="style-scope patent-text">J. Biol. Chem. </i>267 (16):11267-11273); WO2004/048938 (Example 2); WO2004/032842 (Example IV); WO2003/042661 (Claim 12); WO2003/016475 (Claim 1); WO2002/78524 (Example 2); WO2002/99074 (Claim 19; Page 127-129); WO2002/86443 (Claim 27; Pages 222, 393); WO2003/003906 (Claim 10; Page 293); WO2002/64798 (Claim 33; Page 93-95); WO2000/14228 (Claim 5; Page 133-136); US2003/224454 (FIG. 3); WO2003/025138 (Claim 12; Page 150); NP_003477 solute carrier family 7 (cationic amino acid transporter, y+system), member 5/pid=NP_003477.3—<i class="style-scope patent-text">Homo sapiens</i>; MIM: 600182; NM_015923.</div>
    <div id="h-0038" num="0000" class="description-paragraph style-scope patent-text">(3) STEAP1 (Six Transmembrane Epithelial Antigen of Prostate)</div>
    <div id="h-0039" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0203" num="0232" class="description-paragraph style-scope patent-text">Genbank accession no. NM_012449</div>
    <div id="p-0204" num="0233" class="description-paragraph style-scope patent-text">Genbank version no. NM_012449.2 GI: 22027487</div>
    <div id="p-0205" num="0234" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 9, 2012 02:57 PM</div>
    <div id="h-0040" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0206" num="0235" class="description-paragraph style-scope patent-text">Genbank accession no. NP_036581</div>
    <div id="p-0207" num="0236" class="description-paragraph style-scope patent-text">Genbank version no. NP_036581.1 GI: 9558759</div>
    <div id="p-0208" num="0237" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 9, 2012 02:57 PM</div>
    <div id="h-0041" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0209" num="0238" class="description-paragraph style-scope patent-text"> <i class="style-scope patent-text">Cancer Res. </i>61 (15), 5857-5860 (2001), Hubert, R. S., et al (1999) <i class="style-scope patent-text">Proc. Natl. Acad. Sci. U.S.A. </i>96 (25):14523-14528); WO2004/065577 (Claim 6); WO2004/027049 (FIG. 1L); EP1394274 (Example 11); WO2004/016225 (Claim 2); WO2003/042661 (Claim 12); US2003/157089 (Example 5); US2003/185830 (Example 5); US2003/064397 (FIG. 2); WO2002/89747 (Example 5; Page 618-619); WO2003/022995 (Example 9; FIG. 13A, Example 53; Page 173, Example 2; FIG. 2A); six transmembrane epithelial antigen of the prostate; MIM: 604415.</div>
    <div id="h-0042" num="0000" class="description-paragraph style-scope patent-text">(4) 0772P (CA125, MUC16)</div>
    <div id="h-0043" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0210" num="0239" class="description-paragraph style-scope patent-text">Genbank accession no. AF361486</div>
    <div id="p-0211" num="0240" class="description-paragraph style-scope patent-text">Genbank version no. AF361486.3 GI: 34501466</div>
    <div id="p-0212" num="0241" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 11, 2010 07:56 AM</div>
    <div id="h-0044" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0213" num="0242" class="description-paragraph style-scope patent-text">Genbank accession no. AAK74120</div>
    <div id="p-0214" num="0243" class="description-paragraph style-scope patent-text">Genbank version no. AAK74120.3 GI: 34501467</div>
    <div id="p-0215" num="0244" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 11, 2010 07:56 AM</div>
    <div id="h-0045" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0216" num="0245" class="description-paragraph style-scope patent-text"> <i class="style-scope patent-text">J. Biol. Chem. </i>276 (29):27371-27375 (2001)); WO2004/045553 (Claim 14); WO2002/92836 (Claim 6; FIG. 12); WO2002/83866 (Claim 15; Page 116-121); US2003/124140 (Example 16); GI: 34501467;</div>
    <div id="h-0046" num="0000" class="description-paragraph style-scope patent-text">(5) MPF (MPF, MSLN, SMR, Megakaryocyte Potentiating Factor, Mesothelin)</div>
    <div id="h-0047" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0217" num="0246" class="description-paragraph style-scope patent-text">Genbank accession no. NM_005823</div>
    <div id="p-0218" num="0247" class="description-paragraph style-scope patent-text">Genbank version no. NM_005823.5 GI: 293651528</div>
    <div id="p-0219" num="0248" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 2, 2012 01:47 PM</div>
    <div id="h-0048" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0220" num="0249" class="description-paragraph style-scope patent-text">Genbank accession no. NP_005814</div>
    <div id="p-0221" num="0250" class="description-paragraph style-scope patent-text">Genbank version no. NP_005814.2 GI: 53988378</div>
    <div id="p-0222" num="0251" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 2, 2012 01:47 PM</div>
    <div id="h-0049" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0223" num="0252" class="description-paragraph style-scope patent-text">Yamaguchi, N., et al <i class="style-scope patent-text">Biol. Chem. </i>269 (2), 805-808 (1994), <i class="style-scope patent-text">Proc. Natl. Acad. Sci. U.S.A. </i>96 (20):11531-11536 (1999), <i class="style-scope patent-text">Proc. Natl. Acad. Sci. U.S.A. </i>93 (1):136-140 (1996), <i class="style-scope patent-text">J. Biol. Chem. </i>270 (37):21984-21990 (1995)); WO2003/101283 (Claim 14); (WO2002/102235 (Claim 13; Page 287-288); WO2002/101075 (Claim 4; Page 308-309); WO2002/71928 (Page 320-321); WO94/10312 (Page 52-57); IM: 601051.</div>
    <div id="h-0050" num="0000" class="description-paragraph style-scope patent-text">(6) Napi3b (NAPI-3B, NPTIIb, SLC34A2, Solute Carrier Family 34 (Sodium Phosphate), Member 2, Type II Sodium-Dependent Phosphate Transporter 3b)</div>
    <div id="h-0051" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0224" num="0253" class="description-paragraph style-scope patent-text">Genbank accession no. NM_006424</div>
    <div id="p-0225" num="0254" class="description-paragraph style-scope patent-text">Genbank version no. NM_006424.2 GI: 110611905</div>
    <div id="p-0226" num="0255" class="description-paragraph style-scope patent-text">Genbank record update date: Jul. 22, 2012 03:39 PM</div>
    <div id="h-0052" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0227" num="0256" class="description-paragraph style-scope patent-text">Genbank accession no. NP_006415</div>
    <div id="p-0228" num="0257" class="description-paragraph style-scope patent-text">Genbank version no. NP_006415.2 GI: 110611906</div>
    <div id="p-0229" num="0258" class="description-paragraph style-scope patent-text">Genbank record update date: Jul. 22, 2012 03:39 PM</div>
    <div id="h-0053" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0230" num="0259" class="description-paragraph style-scope patent-text"> <i class="style-scope patent-text">J. Biol. Chem. </i>277 (22):19665-19672 (2002), <i class="style-scope patent-text">Genomics </i>62 (2):281-284 (1999), Feild, J. A., et al (1999) <i class="style-scope patent-text">Biochem. Biophys. Res. Commun. </i>258 (3):578-582); WO2004/022778 (Claim 2); EP1394274 (Example 11); WO2002/102235 (Claim 13; Page 326); EP0875569 (Claim 1; Page 17-19); WO2001/57188 (Claim 20; Page 329); WO2004/032842 (Example IV); WO2001/75177 (Claim 24; Page 139-140); MIM: 604217.</div>
    <div id="h-0054" num="0000" class="description-paragraph style-scope patent-text">(7) Sema 5b (FLJ10372, KIAA1445, Mm.42015, SEMA5B, SEMAG, Semaphorin 5b Hlog, Sema Domain, Seven Thrombospondin Repeats (Type 1 and Type 1-Like), Transmembrane Domain™ and Short Cytoplasmic Domain, (Semaphorin) 5B)</div>
    <div id="h-0055" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0231" num="0260" class="description-paragraph style-scope patent-text">Genbank accession no. AB040878</div>
    <div id="p-0232" num="0261" class="description-paragraph style-scope patent-text">Genbank version no. AB040878.1 GI: 7959148</div>
    <div id="p-0233" num="0262" class="description-paragraph style-scope patent-text">Genbank record update date: Aug. 2, 2006 05:40 PM</div>
    <div id="h-0056" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0234" num="0263" class="description-paragraph style-scope patent-text">Genbank accession no. BAA95969</div>
    <div id="p-0235" num="0264" class="description-paragraph style-scope patent-text">Genbank version no. BAA95969.1 GI: 7959149</div>
    <div id="p-0236" num="0265" class="description-paragraph style-scope patent-text">Genbank record update date: Aug. 2, 2006 05:40 PM</div>
    <div id="h-0057" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0237" num="0266" class="description-paragraph style-scope patent-text">Nagase T., et al (2000) <i class="style-scope patent-text">DNA Res. </i>7 (2):143-150); WO2004/000997 (Claim 1); WO2003/003984 (Claim 1); WO2002/06339 (Claim 1; Page 50); WO2001/88133 (Claim 1; Page 41-43, 48-58); WO2003/054152 (Claim 20); WO2003/101400 (Claim 11); Accession: Q9P283; Genew; HGNC: 10737</div>
    <div id="h-0058" num="0000" class="description-paragraph style-scope patent-text">(8) PSCA hIg (2700050C12Rik, C530008O16Rik, RIKEN cDNA 2700050C12, RIKEN cDNA 2700050C12 gene)</div>
    <div id="h-0059" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0238" num="0267" class="description-paragraph style-scope patent-text">Genbank accession no. AY358628</div>
    <div id="p-0239" num="0268" class="description-paragraph style-scope patent-text">Genbank version no. AY358628.1 GI: 37182377</div>
    <div id="p-0240" num="0269" class="description-paragraph style-scope patent-text">Genbank record update date: Dec. 1, 2009 04:15 AM</div>
    <div id="h-0060" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0241" num="0270" class="description-paragraph style-scope patent-text">Genbank accession no. AAQ88991</div>
    <div id="p-0242" num="0271" class="description-paragraph style-scope patent-text">Genbank version no. AAQ88991.1 GI: 37182378</div>
    <div id="p-0243" num="0272" class="description-paragraph style-scope patent-text">Genbank record update date: Dec. 1, 2009 04:15 AM</div>
    <div id="h-0061" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0244" num="0273" class="description-paragraph style-scope patent-text">Ross et al (2002) <i class="style-scope patent-text">Cancer Res. </i>62:2546-2553; US2003/129192 (Claim 2); US2004/044180 (Claim 12); US2004/044179 (Claim 11); US2003/096961 (Claim 11); US2003/232056 (Example 5); WO2003/105758 16 (Claim 12); US2003/206918 (Example 5); EP1347046 (Claim 1); WO2003/025148 (Claim 20); GI: 37182378.</div>
    <div id="h-0062" num="0000" class="description-paragraph style-scope patent-text">(9) ETBR (Endothelin Type B Receptor)</div>
    <div id="h-0063" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0245" num="0274" class="description-paragraph style-scope patent-text">Genbank accession no. AY275463</div>
    <div id="p-0246" num="0275" class="description-paragraph style-scope patent-text">Genbank version no. AY275463.1 GI: 30526094</div>
    <div id="p-0247" num="0276" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 11, 2010 02:26 AM</div>
    <div id="h-0064" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0248" num="0277" class="description-paragraph style-scope patent-text">Genbank accession no. AAP32295</div>
    <div id="p-0249" num="0278" class="description-paragraph style-scope patent-text">Genbank version no. AAP32295.1 GI: 30526095</div>
    <div id="p-0250" num="0279" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 11, 2010 02:26 AM</div>
    <div id="h-0065" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0251" num="0280" class="description-paragraph style-scope patent-text">Nakamuta M., et al <i class="style-scope patent-text">Biochem. Biophys. Res. Commun. </i>177, 34-39, 1991; Ogawa Y., et al <i class="style-scope patent-text">Biochem. Biophys. Res. Commun. </i>178, 248-255, 1991; Arai H., et al <i class="style-scope patent-text">Jpn. Circ. J. </i>56, 1303-1307, 1992; Arai H., et al <i class="style-scope patent-text">J. Biol. Chem. </i>268, 3463-3470, 1993; Sakamoto A., Yanagisawa M., et al <i class="style-scope patent-text">Biochem. Biophys. Res. Commun. </i>178, 656-663, 1991; Elshourbagy N. A., et al <i class="style-scope patent-text">J. Biol. Chem. </i>268, 3873-3879, 1993; Haendler B., et al <i class="style-scope patent-text">J. Cardiovasc. Pharmacol. </i>20, s1-S4, 1992; Tsutsumi M., et al <i class="style-scope patent-text">Gene </i>228, 43-49, 1999; Strausberg R. L., et al <i class="style-scope patent-text">Proc. Natl. Acad. Sci. U.S.A. </i>99, 16899-16903, 2002; Bourgeois C., et al <i class="style-scope patent-text">J. Clin. Endocrinol. Metab. </i>82, 3116-3123, 1997; Okamoto Y., et al <i class="style-scope patent-text">Biol. Chem. </i>272, 21589-21596, 1997; Verheij J. B., et al <i class="style-scope patent-text">Am. J. Med. Genet. </i>108, 223-225, 2002; Hofstra R. M. W., et al <i class="style-scope patent-text">Eur. J. Hum. Genet. </i>5, 180-185, 1997; Puffenberger E. G., et al <i class="style-scope patent-text">Cell </i>79, 1257-1266, 1994; Attie T., et al, <i class="style-scope patent-text">Hum. Mol. Genet. </i>4, 2407-2409, 1995; Auricchio A., et al <i class="style-scope patent-text">Hum. Mol. Genet. </i>5:351-354, 1996; Amiel J., et al <i class="style-scope patent-text">Hum. Mol. Genet. </i>5, 355-357, 1996; Hofstra R. M. W., et al <i class="style-scope patent-text">Nat. Genet. </i>12, 445-447, 1996; Svensson P. J., et al <i class="style-scope patent-text">Hum. Genet. </i>103, 145-148, 1998; Fuchs S., et al <i class="style-scope patent-text">Mol. Med. </i>7, 115-124, 2001; Pingault V., et al (2002) <i class="style-scope patent-text">Hum. Genet. </i>111, 198-206; WO2004/045516 (Claim 1); WO2004/048938 (Example 2); WO2004/040000 (Claim 151); WO2003/087768 (Claim 1); WO2003/016475 (Claim 1); WO2003/016475 (Claim 1); WO2002/61087 (FIG. 1); WO2003/016494 (FIG. 6); WO2003/025138 (Claim 12; Page 144); WO2001/98351 (Claim 1;</div>
    <div id="p-0252" num="0281" class="description-paragraph style-scope patent-text">Page 124-125); EP0522868 (Claim 8; FIG. 2); WO2001/77172 (Claim 1; Page 297-299); US2003/109676; U.S. Pat. No. 6,518,404 (FIG. 3); U.S. Pat. No. 5,773,223 (Claim 1a; Col 31-34); WO2004/001004.</div>
    <div id="h-0066" num="0000" class="description-paragraph style-scope patent-text">(10) MSG783 (RNF124, Hypothetical Protein FLJ20315)</div>
    <div id="h-0067" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0253" num="0282" class="description-paragraph style-scope patent-text">Genbank accession no. NM_017763</div>
    <div id="p-0254" num="0283" class="description-paragraph style-scope patent-text">Genbank version no. NM_017763.4 GI: 167830482</div>
    <div id="p-0255" num="0284" class="description-paragraph style-scope patent-text">Genbank record update date: Jul. 22, 2012 12:34 AM</div>
    <div id="h-0068" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0256" num="0285" class="description-paragraph style-scope patent-text">Genbank accession no. NP_060233</div>
    <div id="p-0257" num="0286" class="description-paragraph style-scope patent-text">Genbank version no. NP_060233.3 GI: 56711322</div>
    <div id="p-0258" num="0287" class="description-paragraph style-scope patent-text">Genbank record update date: Jul. 22, 2012 12:34 AM</div>
    <div id="h-0069" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0259" num="0288" class="description-paragraph style-scope patent-text">WO2003/104275 (Claim 1); WO2004/046342 (Example 2); WO2003/042661 (Claim 12); WO2003/083074 (Claim 14; Page 61); WO2003/018621 (Claim 1); WO2003/024392 (Claim 2; FIG. 93); WO2001/66689 (Example 6); LocusID: 54894.</div>
    <div id="h-0070" num="0000" class="description-paragraph style-scope patent-text">(11) STEAP2 (HGNC_8639, IPCA-1, PCANAP1, STAMP1, STEAP2, STMP, Prostate Cancer Associated Gene 1, Prostate Cancer Associated Protein 1, Six Transmembrane Epithelial Antigen of Prostate 2, Six Transmembrane Prostate Protein)</div>
    <div id="h-0071" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0260" num="0289" class="description-paragraph style-scope patent-text">Genbank accession no. AF455138</div>
    <div id="p-0261" num="0290" class="description-paragraph style-scope patent-text">Genbank version no. AF455138.1 GI: 22655487</div>
    <div id="p-0262" num="0291" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 11, 2010 01:54 AM</div>
    <div id="h-0072" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0263" num="0292" class="description-paragraph style-scope patent-text">Genbank accession no. AAN04080</div>
    <div id="p-0264" num="0293" class="description-paragraph style-scope patent-text">Genbank version no. AAN04080.1 GI: 22655488</div>
    <div id="p-0265" num="0294" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 11, 2010 01:54 AM</div>
    <div id="h-0073" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0266" num="0295" class="description-paragraph style-scope patent-text">Lab. Invest. 82 (11):1573-1582 (2002)); WO2003/087306; US2003/064397 (Claim 1; FIG. 1); WO2002/72596 (Claim 13; Page 54-55); WO2001/72962 (Claim 1; FIG. 4B); WO2003/104270 (Claim 11); WO2003/104270 (Claim 16); US2004/005598 (Claim 22); WO2003/042661 (Claim 12); US2003/060612 (Claim 12; FIG. 10); WO2002/26822 (Claim 23; FIG. 2); WO2002/16429 (Claim 12; FIG. 10); GI: 22655488.</div>
    <div id="h-0074" num="0000" class="description-paragraph style-scope patent-text">(12) TrpM4 (BR22450, FLJ20041, TRPM4, TRPM4B, Transient Receptor Potential Cation Channel, Subfamily M, Member 4)</div>
    <div id="h-0075" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0267" num="0296" class="description-paragraph style-scope patent-text">Genbank accession no. NM_017636</div>
    <div id="p-0268" num="0297" class="description-paragraph style-scope patent-text">Genbank version no. NM_017636.3 GI: 304766649</div>
    <div id="p-0269" num="0298" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 29, 2012 11:27 AM</div>
    <div id="h-0076" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0270" num="0299" class="description-paragraph style-scope patent-text">Genbank accession no. NP_060106</div>
    <div id="p-0271" num="0300" class="description-paragraph style-scope patent-text">Genbank version no. NP_060106.2 GI: 21314671</div>
    <div id="p-0272" num="0301" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 29, 2012 11:27 AM</div>
    <div id="h-0077" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0273" num="0302" class="description-paragraph style-scope patent-text">Xu, X. Z., et al <i class="style-scope patent-text">Proc. Natl. Acad. Sci. U.S.A. </i>98 (19):10692-10697 (2001), <i class="style-scope patent-text">Cell </i>109 (3):397-407 (2002), <i class="style-scope patent-text">J. Biol. Chem. </i>278 (33):30813-30820 (2003)); US2003/143557 (Claim 4); WO2000/40614 (Claim 14; Page 100-103); WO2002/10382 (Claim 1; FIG. 9A); WO2003/042661 (Claim 12); WO2002/30268 (Claim 27; Page 391); US2003/219806 (Claim 4); WO2001/62794 (Claim 14; FIG. 1A-D); MIM: 606936.</div>
    <div id="h-0078" num="0000" class="description-paragraph style-scope patent-text">(13) CRIPTO (CR, CR1, CRGF, CRIPTO, TDGFI, Teratocarcinoma-Derived Growth Factor)</div>
    <div id="h-0079" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0274" num="0303" class="description-paragraph style-scope patent-text">Genbank accession no. NM_003212</div>
    <div id="p-0275" num="0304" class="description-paragraph style-scope patent-text">Genbank version no. NM_003212.3 GI: 292494881</div>
    <div id="p-0276" num="0305" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 23, 2012 02:27 PM</div>
    <div id="h-0080" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0277" num="0306" class="description-paragraph style-scope patent-text">Genbank accession no. NP_003203</div>
    <div id="p-0278" num="0307" class="description-paragraph style-scope patent-text">Genbank version no. NP_003203.1 GI: 4507425</div>
    <div id="p-0279" num="0308" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 23, 2012 02:27 PM</div>
    <div id="h-0081" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0280" num="0309" class="description-paragraph style-scope patent-text">Ciccodicola, A., et al <i class="style-scope patent-text">EMBO J. </i>8 (7):1987-1991 (1989), <i class="style-scope patent-text">Am. J. Hum. Genet. </i>49 (3):555-565 (1991)); US2003/224411 (Claim 1); WO2003/083041 (Example 1); WO2003/034984 (Claim 12); WO2002/88170 (Claim 2; Page 52-53); WO2003/024392 (Claim 2; FIG. 58); WO2002/16413 (Claim 1; Page 94-95, 105); WO2002/22808 (Claim 2; FIG. 1); U.S. Pat. No. 5,854,399 (Example 2; Col 17-18); U.S. Pat. No. 5,792,616 (FIG. 2); MIM: 187395.</div>
    <div id="h-0082" num="0000" class="description-paragraph style-scope patent-text">(14) CD21 (CR2 (Complement Receptor 2) or C3DR (C3d/Epstein Barr Virus Receptor) or Hs.73792)</div>
    <div id="h-0083" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0281" num="0310" class="description-paragraph style-scope patent-text">Genbank accession no M26004</div>
    <div id="p-0282" num="0311" class="description-paragraph style-scope patent-text">Genbank version no. M26004.1 GI: 181939</div>
    <div id="p-0283" num="0312" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 08:47 AM</div>
    <div id="h-0084" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0284" num="0313" class="description-paragraph style-scope patent-text">Genbank accession no. AAA35786</div>
    <div id="p-0285" num="0314" class="description-paragraph style-scope patent-text">Genbank version no. AAA35786.1 GI: 181940</div>
    <div id="p-0286" num="0315" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 08:47 AM</div>
    <div id="h-0085" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0287" num="0316" class="description-paragraph style-scope patent-text">Fujisaku et al (1989) <i class="style-scope patent-text">J. Biol. Chem. </i>264 (4):2118-2125); Weis J. J., et al <i class="style-scope patent-text">J. Exp. Med. </i>167, 1047-1066, 1988; Moore M., et al <i class="style-scope patent-text">Proc. Natl. Acad. Sci. U.S.A. </i>84, 9194-9198, 1987; Barel M., et al <i class="style-scope patent-text">Mol. Immunol. </i>35, 1025-1031, 1998; Weis J. J., et al <i class="style-scope patent-text">Proc. Natl. Acad. Sci. U.S.A. </i>83, 5639-5643, 1986; Sinha S. K., et al (1993) <i class="style-scope patent-text">J. Immunol. </i>150, 5311-5320; WO2004/045520 (Example 4); US2004/005538 (Example 1); WO2003/062401 (Claim 9); WO2004/045520 (Example 4); WO91/02536 (FIGS. 9.1-9.9); WO2004/020595 (Claim 1); Accession: P20023; Q13866; Q14212; EMBL; M26004; AAA35786.1.</div>
    <div id="h-0086" num="0000" class="description-paragraph style-scope patent-text">(15) CD79b (CD79B, CD793, IGb (Immunoglobulin-Associated Beta), B29)</div>
    <div id="h-0087" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0288" num="0317" class="description-paragraph style-scope patent-text">Genbank accession no NM_000626</div>
    <div id="p-0289" num="0318" class="description-paragraph style-scope patent-text">Genbank version no. NM_000626.2 GI: 90193589</div>
    <div id="p-0290" num="0319" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 26, 2012 01:53 PM</div>
    <div id="h-0088" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0291" num="0320" class="description-paragraph style-scope patent-text">Genbank accession no. NP_000617</div>
    <div id="p-0292" num="0321" class="description-paragraph style-scope patent-text">Genbank version no. NP_000617.1 GI: 11038674</div>
    <div id="p-0293" num="0322" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 26, 2012 01:53 PM</div>
    <div id="h-0089" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0294" num="0323" class="description-paragraph style-scope patent-text"> <i class="style-scope patent-text">Proc. Natl. Acad. Sci. U.S.A</i>. (2003) 100 (7):4126-4131<i class="style-scope patent-text">, Blood </i>(2002) 100 (9):3068-3076, Muller et al (1992) <i class="style-scope patent-text">Eur. J. Immunol. </i>22 (6):1621-1625); WO2004/016225 (claim 2, FIG. 140); WO2003/087768, US2004/101874 (claim 1, page 102); WO2003/062401 (claim 9); WO2002/78524 (Example 2); US2002/150573 (claim 5, page 15); U.S. Pat. No. 5,644,033; WO2003/048202 (claim 1, pages 306 and 309); WO 99/58658,</div>
    <div id="p-0295" num="0324" class="description-paragraph style-scope patent-text">U.S. Pat. No. 6,534,482 (claim 13, FIG. 17A/B); WO2000/55351 (claim 11, pages 1145-1146); MIM: 147245</div>
    <div id="h-0090" num="0000" class="description-paragraph style-scope patent-text">(16) FcRH2 (IFGP4, IRTA4, SPAP1A (SH2 Domain Containing Phosphatase Anchor Protein 1a), SPAP1B, SPAP1C)</div>
    <div id="h-0091" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0296" num="0325" class="description-paragraph style-scope patent-text">Genbank accession no NM_030764</div>
    <div id="p-0297" num="0326" class="description-paragraph style-scope patent-text">Genbank version no. NM_030764.3 GI: 227430280</div>
    <div id="p-0298" num="0327" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 30, 2012 12:30 AM</div>
    <div id="h-0092" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0299" num="0328" class="description-paragraph style-scope patent-text">Genbank accession no. NP_110391</div>
    <div id="p-0300" num="0329" class="description-paragraph style-scope patent-text">Genbank version no. NP_110391.2 GI: 19923629</div>
    <div id="p-0301" num="0330" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 30, 2012 12:30 AM</div>
    <div id="h-0093" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0302" num="0331" class="description-paragraph style-scope patent-text">AY358130); <i class="style-scope patent-text">Genome Res. </i>13 (10):2265-2270 (2003), <i class="style-scope patent-text">Immunogenetics </i>54 (2):87-95 (2002), <i class="style-scope patent-text">Blood </i>99 (8):2662-2669 (2002), <i class="style-scope patent-text">Proc. Natl. Acad. Sci. U.S.A. </i>98 (17):9772-9777 (2001), Xu, M. J., et al (2001) <i class="style-scope patent-text">Biochem. Biophys. Res. Commun. </i>280 (3):768-775; WO2004/016225 (Claim 2); WO2003/077836; WO2001/38490 (Claim 5; FIG. 18D-1-18D-2); WO2003/097803 (Claim 12); WO2003/089624 (Claim 25); MIM: 606509.</div>
    <div id="h-0094" num="0000" class="description-paragraph style-scope patent-text">(17) HER2 (ErbB2)</div>
    <div id="h-0095" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0303" num="0332" class="description-paragraph style-scope patent-text">Genbank accession no M11730</div>
    <div id="p-0304" num="0333" class="description-paragraph style-scope patent-text">Genbank version no. M11730.1 GI: 183986</div>
    <div id="p-0305" num="0334" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 08:47 AM</div>
    <div id="h-0096" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0306" num="0335" class="description-paragraph style-scope patent-text">Genbank accession no. AAA75493</div>
    <div id="p-0307" num="0336" class="description-paragraph style-scope patent-text">Genbank version no. AAA75493.1 GI: 306840</div>
    <div id="p-0308" num="0337" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 08:47 AM</div>
    <div id="h-0097" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0309" num="0338" class="description-paragraph style-scope patent-text">Coussens L., et al <i class="style-scope patent-text">Science </i>(1985) 230(4730):1132-1139); Yamamoto T., et al <i class="style-scope patent-text">Nature </i>319, 230-234, 1986; Semba K., et al <i class="style-scope patent-text">Proc. Natl. Acad. Sci. U.S.A. </i>82, 6497-6501, 1985; Swiercz J. M., et al <i class="style-scope patent-text">J. Cell Biol. </i>165, 869-880, 2004; Kuhns J. J., et al <i class="style-scope patent-text">J. Biol. Chem. </i>274, 36422-36427, 1999; Cho H.-S., et al <i class="style-scope patent-text">Nature </i>421, 756-760, 2003; Ehsani A., et al (1993) <i class="style-scope patent-text">Genomics </i>15, 426-429; WO2004/048938 (Example 2); WO2004/027049 (FIG. 11); WO2004/009622; WO2003/081210;</div>
    <div id="p-0310" num="0339" class="description-paragraph style-scope patent-text">WO2003/089904 (Claim 9); WO2003/016475 (Claim 1); US2003/118592; WO2003/008537 (Claim 1); WO2003/055439 (Claim 29; FIG. 1A-B); WO2003/025228 (Claim 37; FIG. 5C); WO2002/22636 (Example 13; Page 95-107); WO2002/12341 (Claim 68; FIG. 7); WO2002/13847 (Page 71-74); WO2002/14503 (Page 114-117); WO2001/53463 (Claim 2; Page 41-46); WO2001/41787 (Page 15); WO2000/44899 (Claim 52; FIG. 7); WO2000/20579</div>
    <div id="p-0311" num="0340" class="description-paragraph style-scope patent-text">(Claim 3; FIG. 2); U.S. Pat. No. 5,869,445 (Claim 3; Col 31-38); WO9630514 (Claim 2; Page 56-61); EP1439393 (Claim 7); WO2004/043361 (Claim 7); WO2004/022709; WO2001/00244 (Example 3; FIG. 4); Accession: P04626; EMBL; M11767; AAA35808.1. EMBL; M11761; AAA35808.1</div>
    <div id="h-0098" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-0312" num="0341" class="description-paragraph style-scope patent-text">Abbott: US20110177095
</div> <ul class="style-scope patent-text"> <li id="ul0024-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0025-0001" num="0342" class="style-scope patent-text">For example, an antibody comprising CDRs having overall at least 80% sequence identity to CDRs having amino acid sequences of SEQ ID NO:3 (CDR-H1), SEQ ID NO:4 (CDR-H2), SEQ ID NO:5 (CDR-H3), SEQ ID NO:104 and/or SEQ ID NO:6 (CDR-L1), SEQ ID NO:7 (CDR-L2), and SEQ ID NO:8 (CDR-L3), wherein the anti-HER2 antibody or anti-HER2 binding fragment has reduced immunogenicity as compared to an antibody having a VH of SEQ ID NO:1 and a VL of SEQ ID NO:2.</li> </ul> </li> </ul>

    <div id="p-0313" num="0343" class="description-paragraph style-scope patent-text">Biogen: US20100119511
</div> <ul class="style-scope patent-text"> <li id="ul0026-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0027-0001" num="0344" class="style-scope patent-text">For example, ATCC accession numbers: PTA-10355, PTA-10356, PTA-10357, PTA-10358</li> <li id="ul0027-0002" num="0345" class="style-scope patent-text">For example, a purified antibody molecule that binds to HER2 comprising a all six CDR's from an antibody selected from the group consisting of BIIB71F10 (SEQ ID NOs:11, 13), BIIB69A09 (SEQ ID NOs:15, 17); BIIB67F10 (SEQ ID NOs:19, 21); BIIB67F11 (SEQ ID NOs:23, 25), BIIB66A12 (SEQ ID NOs:27, 29), BIIB66C01 (SEQ ID NOs:31, 33), BIIB65C10 (SEQ ID NOs:35, 37), BIIB65H09 (SEQ ID NOs:39, 41) and BIIB65B03 (SEQ ID NOs:43, 45), or CDRs which are identical or which have no more than two alterations from said CDRs.</li> </ul> </li> </ul>

    <div id="p-0314" num="0346" class="description-paragraph style-scope patent-text">Herceptin (Genentech)—U.S. Pat. No. 6,054,297; ATCC accession no. CRL-10463 (Genentech)</div>
    <div id="p-0315" num="0347" class="description-paragraph style-scope patent-text">Pertuzumab (Genentech)
</div> <ul class="style-scope patent-text"> <li id="ul0028-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0029-0001" num="0348" class="style-scope patent-text">US20110117097
        <ul class="style-scope patent-text"> <li id="ul0030-0001" num="0349" class="style-scope patent-text">for example, see SEQ IDs No. 15&amp;16, SEQ IDs No. 17&amp;18, SEQ IDs No. 23&amp;24 &amp; ATCC accession numbers HB-12215, HB-12216, CRL 10463, HB-12697.</li> </ul>
        </li> <li id="ul0029-0002" num="0350" class="style-scope patent-text">US20090285837</li> <li id="ul0029-0003" num="0351" class="style-scope patent-text">US20090202546
        <ul class="style-scope patent-text"> <li id="ul0031-0001" num="0352" class="style-scope patent-text">for example, ATCC accession numbers: HB-12215, HB-12216, CRL 10463, HB-12698.</li> </ul>
        </li> <li id="ul0029-0004" num="0353" class="style-scope patent-text">US20060088523
        <ul class="style-scope patent-text"> <li id="ul0032-0001" num="0354" class="style-scope patent-text">for example, ATCC accession numbers: HB-12215, HB-12216</li> <li id="ul0032-0002" num="0355" class="style-scope patent-text">for example, an antibody comprising the variable light and variable heavy amino acid sequences in SEQ ID Nos. 3 and 4, respectively.</li> <li id="ul0032-0003" num="0356" class="style-scope patent-text">for example, an antibody comprising a light chain amino acid sequence selected from SEQ ID No. 15 and 23, and a heavy chain amino acid sequence selected from SEQ ID No. 16 and 24</li> </ul>
        </li> <li id="ul0029-0005" num="0357" class="style-scope patent-text">US20060018899
        <ul class="style-scope patent-text"> <li id="ul0033-0001" num="0358" class="style-scope patent-text">for example, ATCC accession numbers: (7C2) HB-12215, (7F3) HB-12216, (4D5) CRL-10463, (2C4) HB-12697.</li> <li id="ul0033-0002" num="0359" class="style-scope patent-text">for example, an antibody comprising the amino acid sequence in SEQ ID No. 23, or a deamidated and/or oxidized variant thereof.</li> </ul>
        </li> <li id="ul0029-0006" num="0360" class="style-scope patent-text">US2011/0159014
        <ul class="style-scope patent-text"> <li id="ul0034-0001" num="0361" class="style-scope patent-text">for example, an antibody having a light chain variable domain comprising the hypervariable regions of SEQ ID NO: 1”.</li> <li id="ul0034-0002" num="0362" class="style-scope patent-text">For example, an antibody having a heavy chain variable domain comprising the hypervariable regions of SEQ ID NO: 2.</li> </ul>
        </li> <li id="ul0029-0007" num="0363" class="style-scope patent-text">US20090187007</li> </ul> </li> </ul>

    <div id="p-0316" num="0364" class="description-paragraph style-scope patent-text">Glycotope: TrasGEX antibody http://www.glycotope.com/pipeline
</div> <ul class="style-scope patent-text"> <li id="ul0035-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0036-0001" num="0365" class="style-scope patent-text">For example, see International Joint Cancer Institute and Changhai Hospital Cancer Cent: HMTI-Fc Ab—Gao J., et al <i class="style-scope patent-text">BMB Rep. </i>2009 Oct. 31; 42(10):636-41.</li> </ul> </li> </ul>

    <div id="p-0317" num="0366" class="description-paragraph style-scope patent-text">Symphogen: US20110217305</div>
    <div id="p-0318" num="0367" class="description-paragraph style-scope patent-text">Union Stem Cell &amp; Gene Engineering, China—Liu H Q., et al <i class="style-scope patent-text">Xi Bao Yu Fen Zi Mian YiXue Za Zhi. </i>2010 May; 26(5):456-8.</div>
    <div id="h-0099" num="0000" class="description-paragraph style-scope patent-text">(18) NCA (CEACAM6)</div>
    <div id="h-0100" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0319" num="0368" class="description-paragraph style-scope patent-text">Genbank accession no M18728</div>
    <div id="p-0320" num="0369" class="description-paragraph style-scope patent-text">Genbank version no. M18728.1 GI: 189084</div>
    <div id="p-0321" num="0370" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 08:48 AM</div>
    <div id="h-0101" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0322" num="0371" class="description-paragraph style-scope patent-text">Genbank accession no. AAA59907</div>
    <div id="p-0323" num="0372" class="description-paragraph style-scope patent-text">Genbank version no. AAA59907.1 GI: 189085</div>
    <div id="p-0324" num="0373" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 08:48 AM</div>
    <div id="h-0102" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0325" num="0374" class="description-paragraph style-scope patent-text">Barnett T., et al <i class="style-scope patent-text">Genomics </i>3, 59-66, 1988; Tawaragi Y., et al <i class="style-scope patent-text">Biochem. Biophys. Res. Commun. </i>150, 89-96, 1988; Strausberg R. L., et al <i class="style-scope patent-text">Proc. Natl. Acad. Sci. U.S.A. </i>99:16899-16903, 2002; WO2004/063709; EP1439393 (Claim 7); WO2004/044178 (Example 4); WO2004/031238; WO2003/042661 (Claim 12); WO2002/78524 (Example 2); WO2002/86443 (Claim 27; Page 427); WO2002/60317 (Claim 2); Accession: P40199; Q14920; EMBL; M29541; AAA59915.1.</div>
    <div id="p-0326" num="0375" class="description-paragraph style-scope patent-text">EMBL; M18728.</div>
    <div id="h-0103" num="0000" class="description-paragraph style-scope patent-text">(19) MDP (DPEP1)</div>
    <div id="h-0104" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0327" num="0376" class="description-paragraph style-scope patent-text">Genbank accession no BC017023</div>
    <div id="p-0328" num="0377" class="description-paragraph style-scope patent-text">Genbank version no. BC017023.1 GI: 16877538</div>
    <div id="p-0329" num="0378" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 6, 2012 01:00 PM</div>
    <div id="h-0105" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0330" num="0379" class="description-paragraph style-scope patent-text">Genbank accession no. AAH17023</div>
    <div id="p-0331" num="0380" class="description-paragraph style-scope patent-text">Genbank version no. AAH17023.1 GI: 16877539</div>
    <div id="p-0332" num="0381" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 6, 2012 01:00 PM</div>
    <div id="h-0106" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0333" num="0382" class="description-paragraph style-scope patent-text"> <i class="style-scope patent-text">Proc. Natl. Acad. Sci. U.S.A. </i>99 (26):16899-16903 (2002)); WO2003/016475 (Claim 1); WO2002/64798 (Claim 33; Page 85-87); JP05003790 (FIG. 6-8); WO99/46284 (FIG. 9); MIM: 179780.</div>
    <div id="h-0107" num="0000" class="description-paragraph style-scope patent-text">(20) IL20R-Alpha (IL20Ra, ZCYTOR7)</div>
    <div id="h-0108" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0334" num="0383" class="description-paragraph style-scope patent-text">Genbank accession no AF184971</div>
    <div id="p-0335" num="0384" class="description-paragraph style-scope patent-text">Genbank version no. AF184971.1 GI: 6013324</div>
    <div id="p-0336" num="0385" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 10, 2010 10:00 PM</div>
    <div id="h-0109" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0337" num="0386" class="description-paragraph style-scope patent-text">Genbank accession no. AAF01320</div>
    <div id="p-0338" num="0387" class="description-paragraph style-scope patent-text">Genbank version no. AAF01320.1 GI: 6013325</div>
    <div id="p-0339" num="0388" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 10, 2010 10:00 PM</div>
    <div id="h-0110" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0340" num="0389" class="description-paragraph style-scope patent-text">Clark H. F., et al <i class="style-scope patent-text">Genome Res. </i>13, 2265-2270, 2003; Mungall A. J., et al <i class="style-scope patent-text">Nature </i>425, 805-811, 2003; Blumberg H., et al <i class="style-scope patent-text">Cell </i>104, 9-19, 2001; Dumoutier L., et al <i class="style-scope patent-text">J. Immunol. </i>167, 3545-3549, 2001; Parrish-Novak J., et al <i class="style-scope patent-text">J. Biol. Chem. </i>277, 47517-47523, 2002; Pletnev S., et al (2003) <i class="style-scope patent-text">Biochemistry </i>42:12617-12624; Sheikh F., et al (2004) <i class="style-scope patent-text">J. Immunol. </i>172, 2006-2010; EP1394274 (Example 11); US2004/005320 (Example 5); WO2003/029262 (Page 74-75); WO2003/002717 (Claim 2; Page 63); WO2002/22153 (Page 45-47); US2002/042366 (Page 20-21); WO2001/46261 (Page 57-59); WO2001/46232 (Page 63-65); WO98/37193 (Claim 1; Page 55-59); Accession: Q9UHF4; Q6UWA9; Q96SH8; EMBL; AF184971; AAF01320.1.</div>
    <div id="h-0111" num="0000" class="description-paragraph style-scope patent-text">(21) Brevican (BCAN, BEHAB)</div>
    <div id="h-0112" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0341" num="0390" class="description-paragraph style-scope patent-text">Genbank accession no AF229053</div>
    <div id="p-0342" num="0391" class="description-paragraph style-scope patent-text">Genbank version no. AF229053.1 GI: 10798902</div>
    <div id="p-0343" num="0392" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 11, 2010 12:58 AM</div>
    <div id="h-0113" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0344" num="0393" class="description-paragraph style-scope patent-text">Genbank accession no. AAG23135</div>
    <div id="p-0345" num="0394" class="description-paragraph style-scope patent-text">Genbank version no. AAG23135.1 GI: 10798903</div>
    <div id="p-0346" num="0395" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 11, 2010 12:58 AM</div>
    <div id="h-0114" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0347" num="0396" class="description-paragraph style-scope patent-text">Gary S. C., et al <i class="style-scope patent-text">Gene </i>256, 139-147, 2000; Clark H. F., et al <i class="style-scope patent-text">Genome Res. </i>13, 2265-2270, 2003; Strausberg R. L., et al <i class="style-scope patent-text">Proc. Natl. Acad. Sci. U.S.A. </i>99, 16899-16903, 2002; US2003/186372 (Claim 11); US2003/186373 (Claim 11); US2003/119131 (Claim 1; FIG. 52); US2003/119122 (Claim 1; FIG. 52); US2003/119126 (Claim 1); US2003/119121 (Claim 1; FIG. 52); US2003/119129 (Claim 1); US2003/119130 (Claim 1); US2003/119128 (Claim 1; FIG. 52); US2003/119125 (Claim 1); WO2003/016475 (Claim 1); WO2002/02634 (Claim 1)</div>
    <div id="h-0115" num="0000" class="description-paragraph style-scope patent-text">(22) EphB2R (DRT, ERK, Hek5, EPHT3, Tyro5)</div>
    <div id="h-0116" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0348" num="0397" class="description-paragraph style-scope patent-text">Genbank accession no NM_004442</div>
    <div id="p-0349" num="0398" class="description-paragraph style-scope patent-text">Genbank version no. NM_004442.6 GI: 111118979</div>
    <div id="p-0350" num="0399" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 8, 2012 04:43 PM</div>
    <div id="h-0117" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0351" num="0400" class="description-paragraph style-scope patent-text">Genbank accession no. NP_004433</div>
    <div id="p-0352" num="0401" class="description-paragraph style-scope patent-text">Genbank version no. NP_004433.2 GI: 21396504</div>
    <div id="p-0353" num="0402" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 8, 2012 04:43 PM</div>
    <div id="h-0118" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0354" num="0403" class="description-paragraph style-scope patent-text">Chan, J. and Watt, V. M., Oncogene 6 (6), 1057-1061 (1991) Oncogene 10 (5):897-905 (1995), Annu. Rev. Neurosci. 21:309-345 (1998), Int. Rev. Cytol. 196:177-244 (2000)); WO2003042661 (Claim 12); WO200053216 (Claim 1; Page 41); WO2004065576 (Claim 1); WO2004020583 (Claim 9); WO2003004529 (Page 128-132); WO200053216 (Claim 1; Page 42); MIM: 600997.</div>
    <div id="h-0119" num="0000" class="description-paragraph style-scope patent-text">(23) ASLG659 (B7h)</div>
    <div id="h-0120" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0355" num="0404" class="description-paragraph style-scope patent-text">Genbank accession no. AX092328</div>
    <div id="p-0356" num="0405" class="description-paragraph style-scope patent-text">Genbank version no. AX092328.1 GI: 13444478</div>
    <div id="p-0357" num="0406" class="description-paragraph style-scope patent-text">Genbank record update date: Jan. 26, 2011 07:37 AM</div>
    <div id="h-0121" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0358" num="0407" class="description-paragraph style-scope patent-text">US2004/0101899 (Claim 2); WO2003104399 (Claim 11); WO2004000221 (FIG. 3); US2003/165504 (Claim 1); US2003/124140 (Example 2); US2003/065143 (FIG. 60); WO2002/102235 (Claim 13; Page 299); US2003/091580 (Example 2); WO2002/10187 (Claim 6; FIG. 10); WO2001/94641 (Claim 12; FIG. 7b); WO2002/02624 (Claim 13; FIG. 1A-1B); US2002/034749 (Claim 54; Page 45-46); WO2002/06317 (Example 2; Page 320-321, Claim 34; Page 321-322); WO2002/71928 (Page 468-469); WO2002/02587 (Example 1; FIG. 1); WO2001/40269 (Example 3; Pages 190-192); WO2000/36107 (Example 2; Page 205-207); WO2004/053079 (Claim 12); WO2003/004989 (Claim 1); WO2002/71928 (Page 233-234, 452-453); WO 01/16318.</div>
    <div id="h-0122" num="0000" class="description-paragraph style-scope patent-text">(24) PSCA (Prostate Stem Cell Antigen Precursor)</div>
    <div id="h-0123" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0359" num="0408" class="description-paragraph style-scope patent-text">Genbank accession no AJ297436</div>
    <div id="p-0360" num="0409" class="description-paragraph style-scope patent-text">Genbank version no. AJ297436.1 GI: 9367211</div>
    <div id="p-0361" num="0410" class="description-paragraph style-scope patent-text">Genbank record update date: Feb. 1, 2011 11:25 AM</div>
    <div id="h-0124" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0362" num="0411" class="description-paragraph style-scope patent-text">Genbank accession no. CAB97347</div>
    <div id="p-0363" num="0412" class="description-paragraph style-scope patent-text">Genbank version no. CAB97347.1 GI: 9367212</div>
    <div id="p-0364" num="0413" class="description-paragraph style-scope patent-text">Genbank record update date: Feb. 1, 2011 11:25 AM</div>
    <div id="h-0125" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0365" num="0414" class="description-paragraph style-scope patent-text">Reiter R. E., et al <i class="style-scope patent-text">Proc. Natl. Acad. Sci. U.S.A. </i>95, 1735-1740, 1998; Gu Z., et al <i class="style-scope patent-text">Oncogene </i>19, 1288-1296, 2000<i class="style-scope patent-text">; Biochem. Biophys. Res. Commun</i>. (2000) 275(3):783-788; WO2004/022709; EP1394274 (Example 11); US2004/018553 (Claim 17); WO2003/008537 (Claim 1); WO2002/81646 (Claim 1; Page 164); WO2003/003906 (Claim 10; Page 288); WO2001/40309 (Example 1; FIG. 17); US2001/055751 (Example 1; FIG. 1b); WO2000/32752 (Claim 18; FIG. 1); WO98/51805 (Claim 17; Page 97); WO98/51824 (Claim 10; Page 94); WO98/40403 (Claim 2; FIG. 1B); Accession: 043653; EMBL; AF043498; AAC39607.1</div>
    <div id="h-0126" num="0000" class="description-paragraph style-scope patent-text">(25) GEDA</div>
    <div id="h-0127" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0366" num="0415" class="description-paragraph style-scope patent-text">Genbank accession no AY260763</div>
    <div id="p-0367" num="0416" class="description-paragraph style-scope patent-text">Genbank version no. AY260763.1 GI: 30102448</div>
    <div id="p-0368" num="0417" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 11, 2010 02:24 AM</div>
    <div id="h-0128" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0369" num="0418" class="description-paragraph style-scope patent-text">Genbank accession no. AAP14954</div>
    <div id="p-0370" num="0419" class="description-paragraph style-scope patent-text">Genbank version no. AAP14954.1 GI: 30102449</div>
    <div id="p-0371" num="0420" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 11, 2010 02:24 AM</div>
    <div id="h-0129" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0372" num="0421" class="description-paragraph style-scope patent-text">AP14954 lipoma HMGIC fusion-partnerlike protein/pid=AAP14954.1—<i class="style-scope patent-text">Homo sapiens </i>(human); WO2003/054152 (Claim 20); WO2003/000842 (Claim 1); WO2003/023013 (Example 3, Claim 20); US2003/194704 (Claim 45); GI: 30102449;</div>
    <div id="h-0130" num="0000" class="description-paragraph style-scope patent-text">(26) BAFF-R (B Cell-Activating Factor Receptor, BLyS Receptor 3, BR3)</div>
    <div id="h-0131" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0373" num="0422" class="description-paragraph style-scope patent-text">Genbank accession no AF116456</div>
    <div id="p-0374" num="0423" class="description-paragraph style-scope patent-text">Genbank version no. AF116456.1 GI: 4585274</div>
    <div id="p-0375" num="0424" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 10, 2010 09:44 PM</div>
    <div id="h-0132" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0376" num="0425" class="description-paragraph style-scope patent-text">Genbank accession no. AAD25356</div>
    <div id="p-0377" num="0426" class="description-paragraph style-scope patent-text">Genbank version no. AAD25356.1 GI: 4585275</div>
    <div id="p-0378" num="0427" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 10, 2010 09:44 PM</div>
    <div id="h-0133" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0379" num="0428" class="description-paragraph style-scope patent-text">BAFF receptor/pid=NP_443177.1—<i class="style-scope patent-text">Homo sapiens</i>: Thompson, J. S., et al <i class="style-scope patent-text">Science </i>293 (5537), 2108-2111 (2001); WO2004/058309; WO2004/011611; WO2003/045422 (Example; Page 32-33); WO2003/014294 (Claim 35; FIG. 6B); WO2003/035846 (Claim 70; Page 615-616); WO2002/94852 (Col 136-137); WO2002/38766 (Claim 3; Page 133); WO2002/24909 (Example 3; FIG. 3); MIM: 606269; NP_443177.1; NM_052945_1; AF132600</div>
    <div id="h-0134" num="0000" class="description-paragraph style-scope patent-text">(27) CD22 (B-Cell Receptor CD22-B Isoform, BL-CAM, Lyb-8, Lyb8, SIGLEC-2, FLJ22814)</div>
    <div id="h-0135" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0380" num="0429" class="description-paragraph style-scope patent-text">Genbank accession no AK026467</div>
    <div id="p-0381" num="0430" class="description-paragraph style-scope patent-text">Genbank version no. AK026467.1 GI: 10439337</div>
    <div id="p-0382" num="0431" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 11, 2006 11:24 PM</div>
    <div id="h-0136" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0383" num="0432" class="description-paragraph style-scope patent-text">Genbank accession no. BAB15489</div>
    <div id="p-0384" num="0433" class="description-paragraph style-scope patent-text">Genbank version no. BAB15489.1 GI: 10439338</div>
    <div id="p-0385" num="0434" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 11, 2006 11:24 PM</div>
    <div id="h-0137" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0386" num="0435" class="description-paragraph style-scope patent-text">Wilson et al (1991) <i class="style-scope patent-text">J. Exp. Med. </i>173:137-146; WO2003/072036 (Claim 1; FIG. 1); IM: 107266; NP_001762.1; NM_001771_1.</div>
    <div id="h-0138" num="0000" class="description-paragraph style-scope patent-text">(27a) Cd22 (Cd22 Molecule)</div>
    <div id="h-0139" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0387" num="0436" class="description-paragraph style-scope patent-text">Genbank accession no X52785</div>
    <div id="p-0388" num="0437" class="description-paragraph style-scope patent-text">Genbank version no. X52785.1 GI: 29778</div>
    <div id="p-0389" num="0438" class="description-paragraph style-scope patent-text">Genbank record update date: Feb. 2, 2011 10:09 AM</div>
    <div id="h-0140" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0390" num="0439" class="description-paragraph style-scope patent-text">Genbank accession no. CAA36988</div>
    <div id="p-0391" num="0440" class="description-paragraph style-scope patent-text">Genbank version no. CAA36988.1 GI: 29779</div>
    <div id="p-0392" num="0441" class="description-paragraph style-scope patent-text">Genbank record update date: Feb. 2, 2011 10:09 AM</div>
    <div id="h-0141" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0393" num="0442" class="description-paragraph style-scope patent-text">Stamenkovic I. et al., <i class="style-scope patent-text">Nature </i>345 (6270), 74-77 (1990)</div>
    <div id="h-0142" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0394" num="0443" class="description-paragraph style-scope patent-text">Official Symbol: CD22</div>
    <div id="p-0395" num="0444" class="description-paragraph style-scope patent-text">Other Aliases: SIGLEC-2, SIGLEC2</div>
    <div id="p-0396" num="0445" class="description-paragraph style-scope patent-text">Other Designations: B-cell receptor CD22; B-lymphocyte cell adhesion molecule; BL-CAM; CD22 antigen; T-cell surface antigen Leu-14; sialic acid binding Ig-like lectin 2; sialic acid-binding Ig-like lectin 2</div>
    <div id="h-0143" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-0397" num="0446" class="description-paragraph style-scope patent-text">G5/44 (Inotuzumab): DiJoseph J F., et al <i class="style-scope patent-text">Cancer Immunol Immunother. </i>2005 January; 54(1):11-24.</div>
    <div id="p-0398" num="0447" class="description-paragraph style-scope patent-text">Epratuzumab—Goldenberg D M., et al <i class="style-scope patent-text">Expert Rev Anticancer Ther. </i>6(10): 1341-53, 2006.</div>
    <div id="p-0399" num="0448" class="description-paragraph style-scope patent-text">(28) CD79a (CD79A, CD79alpha), Immunoglobulin-Associated Alpha, a B Cell-Specific Protein that Covalently Interacts with Ig Beta (CD79B) and Forms a Complex on the Surface with Ig M Molecules, Transduces a Signal Involved in B-Cell Differentiation), pI: 4.84, MW: 25028 TM: 2
<br class="style-scope patent-text">
[P] Gene Chromosome: 19q13.2).
<br class="style-scope patent-text">
Nucleotide
</div>
    <div id="p-0400" num="0449" class="description-paragraph style-scope patent-text">Genbank accession no NM_001783</div>
    <div id="p-0401" num="0450" class="description-paragraph style-scope patent-text">Genbank version no. NM_001783.3 GI: 90193587</div>
    <div id="p-0402" num="0451" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 26, 2012 01:48 PM</div>
    <div id="h-0144" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0403" num="0452" class="description-paragraph style-scope patent-text">Genbank accession no. NP_001774</div>
    <div id="p-0404" num="0453" class="description-paragraph style-scope patent-text">Genbank version no. NP_001774.1 GI: 4502685</div>
    <div id="p-0405" num="0454" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 26, 2012 01:48 PM</div>
    <div id="h-0145" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0406" num="0455" class="description-paragraph style-scope patent-text">WO2003/088808, US2003/0228319; WO2003/062401 (claim 9); US2002/150573 (claim 4, pages 13-14); WO99/58658 (claim 13, FIG. 16); WO92/07574 (FIG. 1); U.S. Pat. No. 5,644,033; Ha et al (1992) <i class="style-scope patent-text">J. Immunol. </i>148(5):1526-1531; Müller et al (1992) <i class="style-scope patent-text">Eur. J. Immunol. </i>22:1621-1625; Hashimoto et al (1994) <i class="style-scope patent-text">Immunogenetics </i>40(4):287-295; Preud'homme et al (1992) <i class="style-scope patent-text">Clin. Exp. Immunol. </i>90(1):141-146; Yu et al (1992) <i class="style-scope patent-text">J. Immunol. </i>148(2) 633-637; Sakaguchi et al (1988)</div>
    <div id="h-0146" num="0000" class="description-paragraph style-scope patent-text"> <i class="style-scope patent-text">EMBO J. </i>7(11):3457-3464</div>
    <div id="p-0407" num="0456" class="description-paragraph style-scope patent-text">(29) CXCR5 (Burkitt's Lymphoma Receptor 1, a G Protein-Coupled Receptor that is Activated by the CXCL13 Chemokine, Functions in Lymphocyte Migration and Humoral Defense, Plays a Role in HIV-2 Infection and Perhaps Development of AIDS, Lymphoma, Myeloma, and Leukemia); 372 aa, pI: 8.54 MW: 41959 TM: 7[P] Gene Chromosome: 11q23.3,
<br class="style-scope patent-text">
Nucleotide
</div>
    <div id="p-0408" num="0457" class="description-paragraph style-scope patent-text">Genbank accession no NM_001716</div>
    <div id="p-0409" num="0458" class="description-paragraph style-scope patent-text">Genbank version no. NM_001716.4 GI: 342307092</div>
    <div id="p-0410" num="0459" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 30, 2012 01:49 PM</div>
    <div id="h-0147" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0411" num="0460" class="description-paragraph style-scope patent-text">Genbank accession no. NP_001707</div>
    <div id="p-0412" num="0461" class="description-paragraph style-scope patent-text">Genbank version no. NP_001707.1 GI: 4502415</div>
    <div id="p-0413" num="0462" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 30, 2012 01:49 PM</div>
    <div id="h-0148" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0414" num="0463" class="description-paragraph style-scope patent-text">WO2004/040000; WO2004/015426; US2003/105292 (Example 2); U.S. Pat. No. 6,555,339 (Example 2); WO2002/61087 (FIG. 1); WO2001/57188 (Claim 20, page 269); WO2001/72830 (pages 12-13); WO2000/22129 (Example 1, pages 152-153, Example 2, pages 254-256); WO99/28468 (claim 1, page 38); U.S. Pat. No. 5,440,021 (Example 2, col 49-52); WO94/28931 (pages 56-58); WO92/17497 (claim 7, FIG. 5); Dobner et al (1992) <i class="style-scope patent-text">Eur. J. Immunol. </i>22:2795-2799; Barella et al (1995) <i class="style-scope patent-text">Biochem. J. </i>309:773-779</div>
    <div id="h-0149" num="0000" class="description-paragraph style-scope patent-text">(30) HLA-DOB (Beta Subunit of MHC Class II Molecule (Ia Antigen) that Binds Peptides and Presents them to CD4+T Lymphocytes); 273 aa, pI: 6.56, MW: 30820. TM: 1 [P] Gene Chromosome: 6p21.3)</div>
    <div id="h-0150" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0415" num="0464" class="description-paragraph style-scope patent-text">Genbank accession no NM_002120</div>
    <div id="p-0416" num="0465" class="description-paragraph style-scope patent-text">Genbank version no. NM_002120.3 GI: 118402587</div>
    <div id="p-0417" num="0466" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 8, 2012 04:46 PM</div>
    <div id="h-0151" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0418" num="0467" class="description-paragraph style-scope patent-text">Genbank accession no. NP_002111</div>
    <div id="p-0419" num="0468" class="description-paragraph style-scope patent-text">Genbank version no. NP_002111.1 GI: 4504403</div>
    <div id="p-0420" num="0469" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 8, 2012 04:46 PM</div>
    <div id="h-0152" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0421" num="0470" class="description-paragraph style-scope patent-text">Tonnelle et al (1985) <i class="style-scope patent-text">EMBO J. </i>4(11):2839-2847; Jonsson et al (1989) <i class="style-scope patent-text">Immunogenetics </i>29(6):411-413; Beck et al (1992) <i class="style-scope patent-text">J. Mol. Biol. </i>228:433-441; Strausberg et al (2002) <i class="style-scope patent-text">Proc. Natl. Acad. Sci USA </i>99:16899-16903; Servenius et al (1987) <i class="style-scope patent-text">J. Biol. Chem. </i>262:8759-8766; Beck et al (1996) <i class="style-scope patent-text">J. Mol. Biol. </i>255:1-13; Naruse et al (2002) <i class="style-scope patent-text">Tissue Antigens </i>59:512-519; WO99/58658 (claim 13, FIG. 15); U.S. Pat. No. 6,153,408 (Col 35-38); U.S. Pat. No. 5,976,551 (col 168-170); U.S. Pat. No. 6,011,146 (col 145-146); Kasahara et al (1989) <i class="style-scope patent-text">Immunogenetics </i>30(1):66-68; Larhammar et al (1985) <i class="style-scope patent-text">J. Biol. Chem. </i>260(26):14111-14119</div>
    <div id="p-0422" num="0471" class="description-paragraph style-scope patent-text">(31) P2X5 (Purinergic Receptor P2X Ligand-Gated Ion Channel 5, an Ion Channel Gated by Extracellular ATP, May be Involved in Synaptic Transmission and Neurogenesis, Deficiency May Contribute to the Pathophysiology of Idiopathic Detrusor Instability); 422 aa), pI: 7.63, MW: 47206 TM: 1 [P] Gene Chromosome: 17p13.3).
<br class="style-scope patent-text">
Nucleotide
</div>
    <div id="p-0423" num="0472" class="description-paragraph style-scope patent-text">Genbank accession no NM_002561</div>
    <div id="p-0424" num="0473" class="description-paragraph style-scope patent-text">Genbank version no. NM_002561.3 GI: 325197202</div>
    <div id="p-0425" num="0474" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 27, 2012 12:41 AM</div>
    <div id="h-0153" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0426" num="0475" class="description-paragraph style-scope patent-text">Genbank accession no. NP_002552</div>
    <div id="p-0427" num="0476" class="description-paragraph style-scope patent-text">Genbank version no. NP_002552.2 GI: 28416933</div>
    <div id="p-0428" num="0477" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 27, 2012 12:41 AM</div>
    <div id="h-0154" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0429" num="0478" class="description-paragraph style-scope patent-text">Le et al (1997) <i class="style-scope patent-text">FEBS Lett. </i>418(1-2):195-199; WO2004/047749; WO2003/072035 (claim 10); Touchman et al (2000) <i class="style-scope patent-text">Genome Res. </i>10:165-173; WO2002/22660 (claim 20); WO2003/093444 (claim 1); WO2003/087768 (claim 1); WO2003/029277 (page 82)</div>
    <div id="h-0155" num="0000" class="description-paragraph style-scope patent-text">(32) CD72 (B-Cell Differentiation Antigen CD72, Lyb-2); 359 aa, pI: 8.66, MW: 40225, TM: 1 [P] Gene Chromosome: 9p13.3).</div>
    <div id="h-0156" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0430" num="0479" class="description-paragraph style-scope patent-text">Genbank accession no NM_001782</div>
    <div id="p-0431" num="0480" class="description-paragraph style-scope patent-text">Genbank version no. NM_001782.2 GI: 194018444</div>
    <div id="p-0432" num="0481" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 26, 2012 01:43 PM</div>
    <div id="h-0157" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0433" num="0482" class="description-paragraph style-scope patent-text">Genbank accession no. NP_001773</div>
    <div id="p-0434" num="0483" class="description-paragraph style-scope patent-text">Genbank version no. NP_001773.1 GI: 4502683</div>
    <div id="p-0435" num="0484" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 26, 2012 01:43 PM</div>
    <div id="h-0158" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0436" num="0485" class="description-paragraph style-scope patent-text">WO2004042346 (claim 65); WO2003/026493 (pages 51-52, 57-58); WO2000/75655 (pages 105-106); Von Hoegen et al (1990) <i class="style-scope patent-text">J. Immunol. </i>144(12):4870-4877; Strausberg et al (2002) <i class="style-scope patent-text">Proc. Natl. Acad. Sci USA </i>99:16899-16903.</div>
    <div id="p-0437" num="0486" class="description-paragraph style-scope patent-text">(33) LY64 (Lymphocyte Antigen 64 (RP105), Type I Membrane Protein of the Leucine Rich Repeat (LRR) Family, Regulates B-Cell Activation and Apoptosis, Loss of Function is Associated with Increased Disease Activity in Patients with Systemic Lupus Erythematosis); 661 aa, pI: 6.20, MW: 74147 TM: 1 [P] Gene Chromosome: 5q12).
<br class="style-scope patent-text">
Nucleotide
</div>
    <div id="p-0438" num="0487" class="description-paragraph style-scope patent-text">Genbank accession no NM_005582</div>
    <div id="p-0439" num="0488" class="description-paragraph style-scope patent-text">Genbank version no. NM_005582.2 GI: 167555126</div>
    <div id="p-0440" num="0489" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 2, 2012 01:50 PM</div>
    <div id="h-0159" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0441" num="0490" class="description-paragraph style-scope patent-text">Genbank accession no. NP_005573</div>
    <div id="p-0442" num="0491" class="description-paragraph style-scope patent-text">Genbank version no. NP_005573.2 GI: 167555127</div>
    <div id="p-0443" num="0492" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 2, 2012 01:50 PM</div>
    <div id="h-0160" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0444" num="0493" class="description-paragraph style-scope patent-text">US2002/193567; WO97/07198 (claim 11, pages 39-42); Miura et al (1996) <i class="style-scope patent-text">Genomics </i>38(3):299-304; Miura et al (1998) <i class="style-scope patent-text">Blood </i>92:2815-2822; WO2003/083047; WO97/44452 (claim 8, pages 57-61); WO2000/12130 (pages 24-26).</div>
    <div id="h-0161" num="0000" class="description-paragraph style-scope patent-text">(34) FcRH1 (Fc Receptor-Like Protein 1, a Putative Receptor for the Immunoglobulin Fc Domain that Contains C2 Type Ig-Like and ITAM Domains, May have a Role in B-Lymphocyte Differentiation); 429 aa, pI: 5.28, MW: 46925 TM: 1 [P] Gene Chromosome: 1q21-1q22)</div>
    <div id="h-0162" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0445" num="0494" class="description-paragraph style-scope patent-text">Genbank accession no NM_052938</div>
    <div id="p-0446" num="0495" class="description-paragraph style-scope patent-text">Genbank version no. NM_052938.4 GI: 226958543</div>
    <div id="p-0447" num="0496" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 2, 2012 01:43 PM</div>
    <div id="h-0163" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0448" num="0497" class="description-paragraph style-scope patent-text">Genbank accession no. NP_443170</div>
    <div id="p-0449" num="0498" class="description-paragraph style-scope patent-text">Genbank version no. NP_443170.1 GI: 16418419</div>
    <div id="p-0450" num="0499" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 2, 2012 01:43 PM</div>
    <div id="h-0164" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0451" num="0500" class="description-paragraph style-scope patent-text">WO2003/077836; WO2001/38490 (claim 6, FIG. 18E-1-18-E-2); Davis et al (2001) <i class="style-scope patent-text">Proc. Natl. Acad. Sci USA </i>98(17):9772-9777; WO2003/089624 (claim 8); EP1347046 (claim 1); WO2003/089624 (claim 7).</div>
    <div id="p-0452" num="0501" class="description-paragraph style-scope patent-text">(35) IRTA2 (Immunoglobulin Superfamily Receptor Translocation Associated 2, a Putative Immunoreceptor with Possible Roles in B Cell Development and Lymphomagenesis; Deregulation of the Gene by Translocation Occurs in Some B Cell Malignancies); 977 aa, pI: 6.88, MW: 106468, TM: 1 [P] Gene Chromosome: 1q21)
<br class="style-scope patent-text">
Nucleotide
</div>
    <div id="p-0453" num="0502" class="description-paragraph style-scope patent-text">Genbank accession no AF343662</div>
    <div id="p-0454" num="0503" class="description-paragraph style-scope patent-text">Genbank version no. AF343662.1 GI: 13591709</div>
    <div id="p-0455" num="0504" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 11, 2010 01:16 AM</div>
    <div id="h-0165" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0456" num="0505" class="description-paragraph style-scope patent-text">Genbank accession no. AAK31325</div>
    <div id="p-0457" num="0506" class="description-paragraph style-scope patent-text">Genbank version no. AAK31325.1 GI: 13591710</div>
    <div id="p-0458" num="0507" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 11, 2010 01:16 AM</div>
    <div id="h-0166" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0459" num="0508" class="description-paragraph style-scope patent-text">AF343663, AF343664, AF343665, AF369794, AF397453, AK090423, AK090475, AL834187, AY358085; Mouse: AK089756, AY158090, AY506558; NP_112571.1; WO2003/024392 (claim 2, FIG. 97); Nakayama et al (2000) <i class="style-scope patent-text">Biochem. Biophys. Res. Commun. </i>277(1):124-127; WO2003/077836; WO2001/38490 (claim 3, FIG. 18B-1-18B-2).</div>
    <div id="h-0167" num="0000" class="description-paragraph style-scope patent-text">(36) TENB2 (TMEFF2, Tomoregulin, TPEF, HPPI, TR, Putative Transmembrane Proteoglycan, Related to the EGF/Heregulin Family of Growth Factors and Follistatin); 374 aa)</div>
    <div id="h-0168" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0460" num="0509" class="description-paragraph style-scope patent-text">Genbank accession no AF179274</div>
    <div id="p-0461" num="0510" class="description-paragraph style-scope patent-text">Genbank version no. AF179274.2 GI: 12280939</div>
    <div id="p-0462" num="0511" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 11, 2010 01:05 AM</div>
    <div id="h-0169" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0463" num="0512" class="description-paragraph style-scope patent-text">Genbank accession no. AAD55776</div>
    <div id="p-0464" num="0513" class="description-paragraph style-scope patent-text">Genbank version no. AAD55776.2 GI: 12280940</div>
    <div id="p-0465" num="0514" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 11, 2010 01:05 AM</div>
    <div id="h-0170" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0466" num="0515" class="description-paragraph style-scope patent-text">NCBI Accession: AAD55776, AAF91397, AAG49451, NCBI RefSeq: NP_057276; NCBI Gene: 23671; OMIM: 605734; SwissProt Q9UIK5; AY358907, CAF85723, CQ782436; WO2004/074320; JP2004113151; WO2003/042661; WO2003/009814; EP1295944 (pages 69-70); WO2002/30268 (page 329); WO2001/90304; US2004/249130; US2004/022727; WO2004/063355; US2004/197325; US2003/232350; US2004/005563; US2003/124579; Horie et al (2000) <i class="style-scope patent-text">Genomics </i>67:146-152; Uchida et al (1999) <i class="style-scope patent-text">Biochem. Biophys. Res. Commun. </i>266:593-602; Liang et al (2000) <i class="style-scope patent-text">Cancer Res. </i>60:4907-12; Glynne-Jones et al (2001) <i class="style-scope patent-text">Int J Cancer</i>. October 15; 94(2):178-84.</div>
    <div id="h-0171" num="0000" class="description-paragraph style-scope patent-text">(37) PSMA-FOLH1 (Folate Hydrolase (Prostate-Specific Membrane Antigen) 1)</div>
    <div id="h-0172" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0467" num="0516" class="description-paragraph style-scope patent-text">Genbank accession no M99487</div>
    <div id="p-0468" num="0517" class="description-paragraph style-scope patent-text">Genbank version no. M99487.1 GI: 190663</div>
    <div id="p-0469" num="0518" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 08:48 AM</div>
    <div id="h-0173" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0470" num="0519" class="description-paragraph style-scope patent-text">Genbank accession no. AAA60209</div>
    <div id="p-0471" num="0520" class="description-paragraph style-scope patent-text">Genbank version no. AAA60209.1 GI: 190664</div>
    <div id="p-0472" num="0521" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 08:48 AM</div>
    <div id="h-0174" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0473" num="0522" class="description-paragraph style-scope patent-text">Israeli R. S., et al <i class="style-scope patent-text">Cancer Res. </i>53 (2), 227-230 (1993)</div>
    <div id="h-0175" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0474" num="0523" class="description-paragraph style-scope patent-text">Official Symbol: FOLH1</div>
    <div id="p-0475" num="0524" class="description-paragraph style-scope patent-text">Other Aliases: GIG27, FGCP, FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA, mGCP</div>
    <div id="p-0476" num="0525" class="description-paragraph style-scope patent-text">Other Designations: N-acetylated alpha-linked acidic dipeptidase 1; N-acetylated-alpha-linked acidic dipeptidase I; NAALADase I; cell growth-inhibiting gene 27 protein; folylpoly-gamma-glutamate carboxypeptidase; glutamate carboxylase II; glutamate carboxypeptidase 2; glutamate carboxypeptidase II; membrane glutamate carboxypeptidase; prostate specific membrane antigen variant F; pteroylpoly-gamma-glutamate carboxypeptidase</div>
    <div id="h-0176" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-0477" num="0526" class="description-paragraph style-scope patent-text">U.S. Pat. No. 7,666,425: Antibodies produces by Hybridomas having the following ATCC references: ATCC accession No. HB-12101, ATCC accession No. HB-12109, ATCC accession No. HB-12127 and ATCC accession No. HB-12126.</div>
    <div id="p-0478" num="0527" class="description-paragraph style-scope patent-text">Proscan: a monoclonal antibody selected from the group consisting of 8H12, 3E11, 17G1, 29B4, 30C1 and 20F2 (U.S. Pat. No. 7,811,564; Moffett S., et al Hybridoma (Larchmt). 2007 December; 26(6):363-72).</div>
    <div id="p-0479" num="0528" class="description-paragraph style-scope patent-text">Cytogen: monoclonal antibodies 7E11-C5 (ATCC accession No. HB 10494) and 9H10-A4 (ATCC accession No. HB11430)—U.S. Pat. No. 5,763,202</div>
    <div id="p-0480" num="0529" class="description-paragraph style-scope patent-text">GlycoMimetics: NUH2—ATCC accession No. HB 9762 (U.S. Pat. No. 7,135,301)</div>
    <div id="p-0481" num="0530" class="description-paragraph style-scope patent-text">Human Genome Science: HPRAJ70—ATCC accession No. 97131 (U.S. Pat. No. 6,824,993); Amino acid sequence encoded by the cDNA clone (HPRAJ70) deposited as American Type Culture Collection (“ATCC”) Deposit No. 97131</div>
    <div id="p-0482" num="0531" class="description-paragraph style-scope patent-text">Medarex: Anti-PSMA antibodies that lack fucosyl residues—U.S. Pat. No. 7,875,278</div>
    <div id="p-0483" num="0532" class="description-paragraph style-scope patent-text">Mouse anti-PSMA antibodies include the 3F5.4G6, 3D7.1.1, 4E10-1.14, 3E11, 4D8, 3E6, 3C9, 2C7, 1G3, 3C4, 3C6, 4D4, 1G9, 5C8B9, 3G6, 4C8B9, and monoclonal antibodies. Hybridomas secreting 3F5.4G6, 3D7.1.1, 4E10-1.14, 3E11, 4D8, 3E6, 3C9, 2C7, 1G3, 3C4, 3C6, 4D4, 1G9, 5C8B9, 3G6 or 4C8B9 have been publicly deposited and are described in U.S. Pat. No. 6,159,508. Relevant hybridomas have been publicly deposited and are described in U.S. Pat. No. 6,107,090. Moreover, humanized anti-PSMA antibodies, including a humanized version of J591, are described in further detail in PCT Publication WO 02/098897.</div>
    <div id="p-0484" num="0533" class="description-paragraph style-scope patent-text">Other mouse anti-human PSMA antibodies have been described in the art, such as mAb 107-1A4 (Wang, S. et al. (2001) Int. J. Cancer 92:871-876) and mAb 2C9 (Kato, K. et al. (2003) Int. J. Urol. 10:439-444).</div>
    <div id="p-0485" num="0534" class="description-paragraph style-scope patent-text">Examples of human anti-PSMA monoclonal antibodies include the 4A3, 7F12, 8C12, 8A11, 16F9, 2A10, 2C6, 2F5 and 1C3 antibodies, isolated and structurally characterized as originally described in PCT Publications WO 01/09192 and WO 03/064606 and in U.S. Provisional Application Ser. No. 60/654,125, entitled “Human Monoclonal Antibodies to Prostate Specific Membrane Antigen (PSMA)”, filed on Feb. 18, 2005. The V.sub.H amino acid sequences of 4A3, 7F12, 8C12, 8A11, 16F9, 2A10, 2C6, 2F5 and 1C3 are shown in SEQ ID NOs: 1-9, respectively. The V.sub.L amino acid sequences of 4A3, 7F12, 8C12, 8A11, 16F9, 2A10, 2C6, 2F5 and 1C3 are shown in SEQ ID NOs: 10-18, respectively.</div>
    <div id="p-0486" num="0535" class="description-paragraph style-scope patent-text">Other human anti-PSMA antibodies include the antibodies disclosed in PCT Publication WO 03/034903 and US Application No. 2004/0033229.</div>
    <div id="p-0487" num="0536" class="description-paragraph style-scope patent-text">NW Biotherapeutics: A hybridoma cell line selected from the group consisting of 3F5.4G6 having ATCC accession number HB12060, 3D7-1.1. having ATCC accession number HB12309, 4E10-1.14 having ATCC accession number HB12310, 3E11 (ATCC HB12488), 4D8 (ATCC HB12487), 3E6 (ATCC HB12486), 3C9 (ATCC HB12484), 2C7 (ATCC HB12490), 1G3 (ATCC HB12489), 3C4 (ATCC HB12494), 3C6 (ATCC HB12491), 4D4 (ATCC HB12493), 1G9 (ATCC HB12495), 5C8B9 (ATCC HB12492) and 3G6 (ATCC HB12485)—see U.S. Pat. No. 6,150,508</div>
    <div id="p-0488" num="0537" class="description-paragraph style-scope patent-text">PSMA Development Company/Progenics/Cytogen—Seattle Genetics: mAb 3.9, produced by the hybridoma deposited under ATCC Accession No. PTA-3258 or mAb 10.3, produced by the hybridoma deposited under ATCC Accession No. PTA-3347—U.S. Pat. No. 7,850,971</div>
    <div id="p-0489" num="0538" class="description-paragraph style-scope patent-text">PSMA Development Company—Compositions of PSMA antibodies (US 20080286284, Table 1)
</div> <ul class="style-scope patent-text"> <li id="ul0037-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0038-0001" num="0539" class="style-scope patent-text">This application is a divisional of U.S. patent application Ser. No. 10/395,894, filed on Mar. 21, 2003 (U.S. Pat. No. 7,850,971)</li> </ul> </li> </ul>

    <div id="p-0490" num="0540" class="description-paragraph style-scope patent-text">University Hospital Freiburg, Germany—mAbs 3/A12, 3/E7, and 3/F11 (Wolf P., et al <i class="style-scope patent-text">Prostate. </i>2010 Apr. 1; 70(5):562-9).</div>
    <div id="h-0177" num="0000" class="description-paragraph style-scope patent-text">(38) SST (Somatostatin Receptor; Note that there are 5 Subtypes)</div>
    <div id="h-0178" num="0000" class="description-paragraph style-scope patent-text">(38.1) SSTR2 (Somatostatin Receptor 2)</div>
    <div id="h-0179" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0491" num="0541" class="description-paragraph style-scope patent-text">Genbank accession no NM_001050</div>
    <div id="p-0492" num="0542" class="description-paragraph style-scope patent-text">Genbank version no. NM_001050.2 GI: 44890054</div>
    <div id="p-0493" num="0543" class="description-paragraph style-scope patent-text">Genbank record update date: Aug. 19, 2012 01:37 PM</div>
    <div id="h-0180" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0494" num="0544" class="description-paragraph style-scope patent-text">Genbank accession no. NP_001041</div>
    <div id="p-0495" num="0545" class="description-paragraph style-scope patent-text">Genbank version no. NP_001041.1 GI: 4557859</div>
    <div id="p-0496" num="0546" class="description-paragraph style-scope patent-text">Genbank record update date: Aug. 19, 2012 01:37 PM</div>
    <div id="h-0181" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0497" num="0547" class="description-paragraph style-scope patent-text">Yamada Y., et al Proc. Natl. Acad. Sci. U.S.A. 89 (1), 251-255 (1992); Susini C., et al Ann Oncol. 2006 December; 17(12):1733-42</div>
    <div id="h-0182" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0498" num="0548" class="description-paragraph style-scope patent-text">Official Symbol: SSTR2</div>
    <div id="p-0499" num="0549" class="description-paragraph style-scope patent-text">Other Designations: SRIF-1; SS2R; somatostatin receptor type 2</div>
    <div id="h-0183" num="0000" class="description-paragraph style-scope patent-text">(38.2) SSTR5 (Somatostatin Receptor 5)</div>
    <div id="h-0184" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0500" num="0550" class="description-paragraph style-scope patent-text">Genbank accession no D16827</div>
    <div id="p-0501" num="0551" class="description-paragraph style-scope patent-text">Genbank version no. D16827.1 GI: 487683</div>
    <div id="p-0502" num="0552" class="description-paragraph style-scope patent-text">Genbank record update date: Aug. 1, 2006 12:45 PM</div>
    <div id="h-0185" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0503" num="0553" class="description-paragraph style-scope patent-text">Genbank accession no. BAA04107</div>
    <div id="p-0504" num="0554" class="description-paragraph style-scope patent-text">Genbank version no. BAA04107.1 GI: 487684</div>
    <div id="p-0505" num="0555" class="description-paragraph style-scope patent-text">Genbank record update date: Aug. 1, 2006 12:45 PM</div>
    <div id="h-0186" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0506" num="0556" class="description-paragraph style-scope patent-text">Yamada, Y., et al <i class="style-scope patent-text">Biochem. Biophys. Res. Commun. </i>195 (2), 844-852 (1993)</div>
    <div id="h-0187" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0507" num="0557" class="description-paragraph style-scope patent-text">Official Symbol: SSTR5</div>
    <div id="p-0508" num="0558" class="description-paragraph style-scope patent-text">Other Aliases: SS-5-R</div>
    <div id="p-0509" num="0559" class="description-paragraph style-scope patent-text">Other Designations: Somatostatin receptor subtype 5; somatostatin receptor type 5</div>
    <div id="h-0188" num="0000" class="description-paragraph style-scope patent-text">(38.3) SSTR1</div>
    <div id="h-0189" num="0000" class="description-paragraph style-scope patent-text">(38.4) SSTR3</div>
    <div id="h-0190" num="0000" class="description-paragraph style-scope patent-text">(38.5) SSTR4</div>
    <div id="h-0191" num="0000" class="description-paragraph style-scope patent-text">AvB6—Both Subunits (39+40)</div>
    <div id="h-0192" num="0000" class="description-paragraph style-scope patent-text">(39) ITGAV (Integrin, alpha V;</div>
    <div id="h-0193" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0510" num="0560" class="description-paragraph style-scope patent-text">Genbank accession no M14648 J02826 M18365</div>
    <div id="p-0511" num="0561" class="description-paragraph style-scope patent-text">Genbank version no. M14648.1 GI: 340306</div>
    <div id="p-0512" num="0562" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 08:56 AM</div>
    <div id="h-0194" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0513" num="0563" class="description-paragraph style-scope patent-text">Genbank accession no. AAA36808</div>
    <div id="p-0514" num="0564" class="description-paragraph style-scope patent-text">Genbank version no. AAA36808.1 GI: 340307</div>
    <div id="p-0515" num="0565" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 08:56 AM</div>
    <div id="h-0195" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0516" num="0566" class="description-paragraph style-scope patent-text">Suzuki S., et al <i class="style-scope patent-text">Proc. Natl. Acad. Sci. U.S.A. </i>83 (22), 8614-8618 (1986)</div>
    <div id="h-0196" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0517" num="0567" class="description-paragraph style-scope patent-text">Official Symbol: ITGAV</div>
    <div id="p-0518" num="0568" class="description-paragraph style-scope patent-text">Other Aliases: CD51, MSK8, VNRA, VTNR</div>
    <div id="p-0519" num="0569" class="description-paragraph style-scope patent-text">Other Designations: antigen identified by monoclonal antibody L230; integrin alpha-V; integrin alphaVbeta3; integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51); vitronectin receptor subunit alpha</div>
    <div id="h-0197" num="0000" class="description-paragraph style-scope patent-text">(40) ITGB6 (Integrin, Beta 6)</div>
    <div id="h-0198" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0520" num="0570" class="description-paragraph style-scope patent-text">Genbank accession no NM_000888</div>
    <div id="p-0521" num="0571" class="description-paragraph style-scope patent-text">Genbank version no. NM_000888.3 GI: 9966771</div>
    <div id="p-0522" num="0572" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 27, 2012 12:46 AM</div>
    <div id="h-0199" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0523" num="0573" class="description-paragraph style-scope patent-text">Genbank accession no. NP_000879</div>
    <div id="p-0524" num="0574" class="description-paragraph style-scope patent-text">Genbank version no. NP_000879.2 GI: 9625002</div>
    <div id="p-0525" num="0575" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 27, 2012 12:46 AM</div>
    <div id="h-0200" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0526" num="0576" class="description-paragraph style-scope patent-text">Sheppard D. J., et al <i class="style-scope patent-text">Biol. Chem. </i>265 (20), 11502-11507 (1990)</div>
    <div id="h-0201" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0527" num="0577" class="description-paragraph style-scope patent-text">Official Symbol: ITGB6</div>
    <div id="p-0528" num="0578" class="description-paragraph style-scope patent-text">Other Designations: integrin beta-6</div>
    <div id="h-0202" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-0529" num="0579" class="description-paragraph style-scope patent-text">Biogen: U.S. Pat. No. 7,943,742—Hybridoma clones 6.3G9 and 6.8G6 were deposited with the ATCC, accession numbers ATCC PTA-3649 and -3645, respectively.</div>
    <div id="p-0530" num="0580" class="description-paragraph style-scope patent-text">Biogen: U.S. Pat. No. 7,465,449—In some embodiments, the antibody comprises the same heavy and light chain polypeptide sequences as an antibody produced by hybridoma 6.1A8, 6.3G9, 6.8G6, 6.2B1, 6.2B10, 6.2A1, 6.2E5, 7.1G10, 7.7G5, or 7.1C5.</div>
    <div id="p-0531" num="0581" class="description-paragraph style-scope patent-text">Centocor (J&amp;J): U.S. Pat. Nos. 7,550,142; 7,163,681
</div> <ul class="style-scope patent-text"> <li id="ul0039-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0040-0001" num="0582" class="style-scope patent-text">For example in U.S. Pat. No. 7,550,142—an antibody having human heavy chain and human light chain variable regions comprising the amino acid sequences shown in SEQ ID NO: 7 and SEQ ID NO: 8.</li> </ul> </li> </ul>

    <div id="p-0532" num="0583" class="description-paragraph style-scope patent-text">Seattle Genetics: 15H3 (Ryan M C., et al <i class="style-scope patent-text">Cancer Res </i>Apr. 15, 2012; 72(8 Supplement): 4630)</div>
    <div id="h-0203" num="0000" class="description-paragraph style-scope patent-text">(41) CEACAM5 (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5)</div>
    <div id="h-0204" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0533" num="0584" class="description-paragraph style-scope patent-text">Genbank accession no M17303</div>
    <div id="p-0534" num="0585" class="description-paragraph style-scope patent-text">Genbank version no. M17303.1 GI: 178676</div>
    <div id="p-0535" num="0586" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 08:47 AM</div>
    <div id="h-0205" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0536" num="0587" class="description-paragraph style-scope patent-text">Genbank accession no. AAB59513</div>
    <div id="p-0537" num="0588" class="description-paragraph style-scope patent-text">Genbank version no. AAB59513.1 GI: 178677</div>
    <div id="p-0538" num="0589" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 08:47 AM</div>
    <div id="h-0206" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0539" num="0590" class="description-paragraph style-scope patent-text">Beauchemin N., et al <i class="style-scope patent-text">Mol. Cell. Biol. </i>7 (9), 3221-3230 (1987)</div>
    <div id="h-0207" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0540" num="0591" class="description-paragraph style-scope patent-text">Official Symbol: CEACAM5</div>
    <div id="p-0541" num="0592" class="description-paragraph style-scope patent-text">Other Aliases: CD66e, CEA</div>
    <div id="p-0542" num="0593" class="description-paragraph style-scope patent-text">Other Designations: meconium antigen 100</div>
    <div id="h-0208" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-0543" num="0594" class="description-paragraph style-scope patent-text">AstraZeneca-MedImmune: US 20100330103; US20080057063;
</div> <ul class="style-scope patent-text"> <li id="ul0041-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0042-0001" num="0595" class="style-scope patent-text">US20020142359
        <ul class="style-scope patent-text"> <li id="ul0043-0001" num="0596" class="style-scope patent-text">for example an antibody having complementarity determining regions (CDRs) with the following sequences: heavy chain; CDR1—DNYMH, CDR2—WIDPENGDTE YAPKFRG, CDR3—LIYAGYLAMD Y; and light chain CDR1—SASSSVTYMH, CDR2—STSNLAS, CDR3—QQRSTYPLT.</li> <li id="ul0043-0002" num="0597" class="style-scope patent-text">Hybridoma 806.077 deposited as European Collection of Cell Cultures (ECACC) deposit no. 96022936.</li> </ul>
        </li> </ul> </li> </ul>

    <div id="p-0544" num="0598" class="description-paragraph style-scope patent-text">Research Corporation Technologies, Inc.: U.S. Pat. No. 5,047,507</div>
    <div id="p-0545" num="0599" class="description-paragraph style-scope patent-text">Bayer Corporation: U.S. Pat. No. 6,013,772</div>
    <div id="p-0546" num="0600" class="description-paragraph style-scope patent-text">BioAlliance: U.S. Pat. Nos. 7,982,017; 7,674,605
</div> <ul class="style-scope patent-text"> <li id="ul0044-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0045-0001" num="0601" class="style-scope patent-text">U.S. Pat. No. 7,674,605
        <ul class="style-scope patent-text"> <li id="ul0046-0001" num="0602" class="style-scope patent-text">an antibody comprising the heavy chain variable region sequence from the amino acid sequence of SEQ ID NO: 1, and the light chain variable region sequence from the amino acid sequence of SEQ ID NO:2.</li> <li id="ul0046-0002" num="0603" class="style-scope patent-text">an antibody comprising the heavy chain variable region sequence from the amino acid sequence of SEQ ID NO:5, and the light chain variable region sequence from the amino acid sequence of SEQ ID NO:6.</li> </ul>
        </li> </ul> </li> </ul>

    <div id="p-0547" num="0604" class="description-paragraph style-scope patent-text">Celltech Therapeutics Limited: U.S. Pat. No. 5,877,293</div>
    <div id="p-0548" num="0605" class="description-paragraph style-scope patent-text">The Dow Chemical Company: U.S. Pat. Nos. 5,472,693; 6,417,337; 6,333,405
</div> <ul class="style-scope patent-text"> <li id="ul0047-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0048-0001" num="0606" class="style-scope patent-text">U.S. Pat. No. 5,472,693—for example, ATCC No. CRL-11215</li> <li id="ul0048-0002" num="0607" class="style-scope patent-text">U.S. Pat. No. 6,417,337—for example, ATCC CRL-12208</li> <li id="ul0048-0003" num="0608" class="style-scope patent-text">U.S. Pat. No. 6,333,405—for example, ATCC CRL-12208</li> </ul> </li> </ul>

    <div id="p-0549" num="0609" class="description-paragraph style-scope patent-text">Immunomedics, Inc: U.S. Pat. Nos. 7,534,431; 7,230,084; 7,300,644; 6,730,300;
</div> <ul class="style-scope patent-text"> <li id="ul0049-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0050-0001" num="0610" class="style-scope patent-text">US20110189085
        <ul class="style-scope patent-text"> <li id="ul0051-0001" num="0611" class="style-scope patent-text">an antibody having CDRs of the light chain variable region comprise: CDR1 comprises KASQDVGTSVA (SEQ ID NO: 20); CDR2 comprises WTSTRHT (SEQ ID NO: 21); and CDR3 comprises QQYSLYRS (SEQ ID NO: 22);</li> <li id="ul0051-0002" num="0612" class="style-scope patent-text">and the CDRs of the heavy chain variable region of said anti-CEA antibody comprise: CDR1 comprises TYWMS (SEQ ID NO: 23); CDR2 comprises EIHPDSSTINYAPSLKD (SEQ ID NO: 24); and CDR3 comprises LYFGFPWFAY (SEQ ID NO: 25).</li> </ul>
        </li> <li id="ul0050-0002" num="0613" class="style-scope patent-text">US20100221175; US20090092598; US20070202044; US20110064653; US20090185974; US20080069775.
<br class="style-scope patent-text">
(42) MET (Met Proto-Oncogene; Hepatocyte Growth Factor Receptor)
<br class="style-scope patent-text">
Nucleotide
</li> </ul> </li> </ul>

    <div id="p-0550" num="0614" class="description-paragraph style-scope patent-text">Genbank accession no M35073</div>
    <div id="p-0551" num="0615" class="description-paragraph style-scope patent-text">Genbank version no. M35073.1 GI: 187553</div>
    <div id="p-0552" num="0616" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 6, 2012 11:12 AM</div>
    <div id="h-0209" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0553" num="0617" class="description-paragraph style-scope patent-text">Genbank accession no. AAA59589</div>
    <div id="p-0554" num="0618" class="description-paragraph style-scope patent-text">Genbank version no. AAA59589.1 GI: 553531</div>
    <div id="p-0555" num="0619" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 6, 2012 11:12 AM</div>
    <div id="h-0210" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0556" num="0620" class="description-paragraph style-scope patent-text">Dean M., et al <i class="style-scope patent-text">Nature </i>318 (6044), 385-388 (1985)</div>
    <div id="h-0211" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0557" num="0621" class="description-paragraph style-scope patent-text">Official Symbol: MET</div>
    <div id="p-0558" num="0622" class="description-paragraph style-scope patent-text">Other Aliases: AUTS9, HGFR, RCCP2, c-Met</div>
    <div id="p-0559" num="0623" class="description-paragraph style-scope patent-text">Other Designations: HGF receptor; HGF/SF receptor; SF receptor; hepatocyte growth factor receptor; met proto-oncogene tyrosine kinase; proto-oncogene c-Met; scatter factor receptor; tyrosine-protein kinase Met</div>
    <div id="h-0212" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-0560" num="0624" class="description-paragraph style-scope patent-text">Abgenix/Pfizer: US20100040629
</div> <ul class="style-scope patent-text"> <li id="ul0052-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0053-0001" num="0625" class="style-scope patent-text">for example, the antibody produced by hybridoma 13.3.2 having American Type Culture Collection (ATCC) accession number PTA-5026; the antibody produced by hybridoma 9.1.2 having ATCC accession number PTA-5027; the antibody produced by hybridoma 8.70.2 having ATCC accession number PTA-5028; or the antibody produced by hybridoma 6.90.3 having ATCC accession number PTA-5029.</li> </ul> </li> </ul>

    <div id="p-0561" num="0626" class="description-paragraph style-scope patent-text">Amgen/Pfizer: US20050054019
</div> <ul class="style-scope patent-text"> <li id="ul0054-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0055-0001" num="0627" class="style-scope patent-text">for example, an antibody comprising a heavy chain having the amino acid sequences set forth in SEQ ID NO: 2 where X2 is glutamate and X4 is serine and a light chain having the amino acid sequence set forth in SEQ ID NO: 4 where X8 is alanine, without the signal sequences; an antibody comprising a heavy chain having the amino acid sequences set forth in SEQ ID NO: 6 and a light chain having the amino acid sequence set forth in SEQ ID NO: 8, without the signal sequences; an antibody comprising a heavy chain having the amino acid sequences set forth in SEQ ID NO: 10 and a light chain having the amino acid sequence set forth in SEQ ID NO: 12, without the signal sequences; or an antibody comprising a heavy chain having the amino acid sequences set forth in SEQ ID NO: 14 and a light chain having the amino acid sequence set forth in SEQ ID NO: 16, without the signal sequences.</li> </ul> </li> </ul>

    <div id="p-0562" num="0628" class="description-paragraph style-scope patent-text">Agouron Pharmaceuticals (Now Pfizer): US20060035907</div>
    <div id="p-0563" num="0629" class="description-paragraph style-scope patent-text">Eli Lilly: US20100129369</div>
    <div id="p-0564" num="0630" class="description-paragraph style-scope patent-text">Genentech: U.S. Pat. No. 5,686,292; US20100028337; US20100016241; US20070129301; US20070098707; US20070092520, US20060270594; US20060134104; US20060035278; US20050233960; US20050037431
</div> <ul class="style-scope patent-text"> <li id="ul0056-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0057-0001" num="0631" class="style-scope patent-text">U.S. Pat. No. 5,686,292—for example, ATCC HB-11894 and ATCC HB-11895</li> <li id="ul0057-0002" num="0632" class="style-scope patent-text">US 20100016241—for example, ATCC HB-11894 (hybridoma 1A3.3.13) or HB-11895 (hybridoma 5D5.11.6)</li> </ul> </li> </ul>

    <div id="p-0565" num="0633" class="description-paragraph style-scope patent-text">National Defense Medical Center, Taiwan: Lu R M., et al Biomaterials. 2011 April; 32(12):3265-74.</div>
    <div id="p-0566" num="0634" class="description-paragraph style-scope patent-text">Novartis: US20090175860
</div> <ul class="style-scope patent-text"> <li id="ul0058-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0059-0001" num="0635" class="style-scope patent-text">for example, an antibody comprising the sequences of CDR1, CDR2 and CDR3 of heavy chain 4687, wherein the sequences of CDR1, CDR2, and CDR3 of heavy chain 4687 are residues 26-35, 50-65, and 98-102, respectively, of SEQ ID NO: 58; and the sequences of CDR1, CDR2, and CDR3 of light chain 5097, wherein the sequences of CDR1, CDR2, and CDR3 of light chain 5097 are residues 24-39, 55-61, and 94-100 of SEQ ID NO: 37.</li> </ul> </li> </ul>

    <div id="p-0567" num="0636" class="description-paragraph style-scope patent-text">Pharmacia Corporation: US20040166544</div>
    <div id="p-0568" num="0637" class="description-paragraph style-scope patent-text">Pierre Fabre: US20110239316, US20110097262, US20100115639</div>
    <div id="p-0569" num="0638" class="description-paragraph style-scope patent-text">Sumsung: US 20110129481—for example a monoclonal antibody produced from a hybridoma cell having accession number KCLRF-BP-00219 or accession number of KCLRF-BP-00223.</div>
    <div id="p-0570" num="0639" class="description-paragraph style-scope patent-text">Samsung: US 20110104176—for example an antibody produced by a hybridoma cell having Accession Number: KCLRF-BP-00220.</div>
    <div id="p-0571" num="0640" class="description-paragraph style-scope patent-text">University of Turin Medical School: DN-30 Pacchiana G., et al <i class="style-scope patent-text">J Biol Chem. </i>2010 Nov. 12; 285(46):36149-57</div>
    <div id="p-0572" num="0641" class="description-paragraph style-scope patent-text">Van Andel Research Institute: Jiao Y., et al <i class="style-scope patent-text">Mol Biotechnol. </i>2005 September; 31(1):41-54.</div>
    <div id="h-0213" num="0000" class="description-paragraph style-scope patent-text">(43) MUCI (Mucin 1, Cell Surface Associated)</div>
    <div id="h-0214" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0573" num="0642" class="description-paragraph style-scope patent-text">Genbank accession no J05581</div>
    <div id="p-0574" num="0643" class="description-paragraph style-scope patent-text">Genbank version no. J05581.1 GI: 188869</div>
    <div id="p-0575" num="0644" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 08:48 AM</div>
    <div id="h-0215" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0576" num="0645" class="description-paragraph style-scope patent-text">Genbank accession no. AAA59876</div>
    <div id="p-0577" num="0646" class="description-paragraph style-scope patent-text">Genbank version no. AAA59876.1 GI: 188870</div>
    <div id="p-0578" num="0647" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 08:48 AM</div>
    <div id="h-0216" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0579" num="0648" class="description-paragraph style-scope patent-text">Gendler S. J., et al <i class="style-scope patent-text">J. Biol. Chem. </i>265 (25), 15286-15293 (1990)</div>
    <div id="h-0217" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0580" num="0649" class="description-paragraph style-scope patent-text">Official Symbol: MUC1</div>
    <div id="p-0581" num="0650" class="description-paragraph style-scope patent-text">Other Aliases: RP11-263K19.2, CD227, EMA, H23AG, KL-6, MAM6, MUC-1, MUC-1/SEC, MUC-1/X, MUC1/ZD, PEM, PEMT, PUM</div>
    <div id="p-0582" num="0651" class="description-paragraph style-scope patent-text">Other Designations: DF3 antigen; H23 antigen; breast carcinoma-associated antigen DF3; carcinoma-associated mucin; episialin; krebs von den Lungen-6; mucin 1, transmembrane; mucin-1; peanut-reactive urinary mucin; polymorphic epithelial mucin; tumor associated epithelial mucin; tumor-associated epithelial membrane antigen; tumor-associated mucin</div>
    <div id="h-0218" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-0583" num="0652" class="description-paragraph style-scope patent-text">AltaRex—Quest Pharma Tech: U.S. Pat. No. 6,716,966—for example an Alt-1 antibody produced by the hybridoma ATCC No PTA-975.</div>
    <div id="p-0584" num="0653" class="description-paragraph style-scope patent-text">AltaRex—Quest Pharma Tech: U.S. Pat. No. 7,147,850</div>
    <div id="p-0585" num="0654" class="description-paragraph style-scope patent-text">CRT: 5E5—Sørensen A L., et al <i class="style-scope patent-text">Glycobiology </i>vol. 16 no. 2 pp. 96-107, 2006; HMFG2—Burchell J., et al <i class="style-scope patent-text">Cancer Res., </i>47, 5476-5482 (1987); see WO2015/159076</div>
    <div id="p-0586" num="0655" class="description-paragraph style-scope patent-text">Glycotope GT-MAB: GT-MAB 2.5-GEX (Website: http://www.glycotope.com/pipeline/pankomab-gex)</div>
    <div id="p-0587" num="0656" class="description-paragraph style-scope patent-text">Immunogen: U.S. Pat. No. 7,202,346
</div> <ul class="style-scope patent-text"> <li id="ul0060-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0061-0001" num="0657" class="style-scope patent-text">for example, antibody MJ-170: hybridoma cell line MJ-170 ATCC accession no. PTA-5286Monoclonal antibody MJ-171: hybridoma cell line MJ-171 ATCC accession no. PTA-5287; monoclonal antibody MJ-172: hybridoma cell line MJ-172 ATCC accession no. PTA-5288; or monoclonal antibody MJ-173: hybridoma cell line MJ-173 ATCC accession no. PTA-5302</li> </ul> </li> </ul>

    <div id="p-0588" num="0658" class="description-paragraph style-scope patent-text">Immunomedics: U.S. Pat. No. 6,653,104</div>
    <div id="p-0589" num="0659" class="description-paragraph style-scope patent-text">Ramot Tel Aviv Uni: U.S. Pat. No. 7,897,351</div>
    <div id="p-0590" num="0660" class="description-paragraph style-scope patent-text">Regents Uni. CA: U.S. Pat. No. 7,183,388; US20040005647; US20030077676.</div>
    <div id="p-0591" num="0661" class="description-paragraph style-scope patent-text">Roche GlycArt: U.S. Pat. No. 8,021,856</div>
    <div id="p-0592" num="0662" class="description-paragraph style-scope patent-text">Russian National Cancer Research Center: Imuteran-Ivanov P K., et al <i class="style-scope patent-text">Biotechnol J. </i>2007 July; 2(7):863-70</div>
    <div id="p-0593" num="0663" class="description-paragraph style-scope patent-text">Technische Univ Braunschweig: (llB6, HT186-B7, HT186-D11, HT186-G2, HT200-3A-C1, HT220-M-D1, HT220-M-G8)—Thie H., et al <i class="style-scope patent-text">PLoS One. </i>2011 Jan. 14; 6(1):e15921</div>
    <div id="h-0219" num="0000" class="description-paragraph style-scope patent-text">(44) CA9 (Carbonic Anhydrase IX)</div>
    <div id="h-0220" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0594" num="0664" class="description-paragraph style-scope patent-text">Genbank accession no. X66839</div>
    <div id="p-0595" num="0665" class="description-paragraph style-scope patent-text">Genbank version no. X66839.1 GI: 1000701</div>
    <div id="p-0596" num="0666" class="description-paragraph style-scope patent-text">Genbank record update date: Feb. 2, 2011 10:15 AM</div>
    <div id="h-0221" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0597" num="0667" class="description-paragraph style-scope patent-text">Genbank accession no. CAA47315</div>
    <div id="p-0598" num="0668" class="description-paragraph style-scope patent-text">Genbank version no. CAA47315.1 GI: 1000702</div>
    <div id="p-0599" num="0669" class="description-paragraph style-scope patent-text">Genbank record update date: Feb. 2, 2011 10:15 AM</div>
    <div id="h-0222" num="0000" class="description-paragraph style-scope patent-text">Cross References</div>
    <div id="p-0600" num="0670" class="description-paragraph style-scope patent-text">Pastorek J., et al <i class="style-scope patent-text">Oncogene </i>9 (10), 2877-2888 (1994)</div>
    <div id="h-0223" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0601" num="0671" class="description-paragraph style-scope patent-text">Official Symbol: CA9</div>
    <div id="p-0602" num="0672" class="description-paragraph style-scope patent-text">Other Aliases: CAIX, MN</div>
    <div id="p-0603" num="0673" class="description-paragraph style-scope patent-text">Other Designations: CA-IX; P54/58N; RCC-associated antigen G250; RCC-associated protein G250; carbonate dehydratase IX; carbonic anhydrase 9; carbonic dehydratase; membrane antigen MN; pMW1; renal cell carcinoma-associated antigen G250</div>
    <div id="h-0224" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-0604" num="0674" class="description-paragraph style-scope patent-text">Abgenix/Amgen: US20040018198</div>
    <div id="p-0605" num="0675" class="description-paragraph style-scope patent-text">Affibody: Anti-CAIX Affibody molecules
</div> <ul class="style-scope patent-text"> <li id="ul0062-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0063-0001" num="0676" class="style-scope patent-text">(http://www.affibody.com/en/Product-Portfolio/Pipeline/)</li> </ul> </li> </ul>

    <div id="p-0606" num="0677" class="description-paragraph style-scope patent-text">Bayer: U.S. Pat. No. 7,462,696</div>
    <div id="p-0607" num="0678" class="description-paragraph style-scope patent-text">Bayer/Morphosys: 3ee9 mAb—Petrul H M., et al <i class="style-scope patent-text">Mol Cancer Ther. </i>2012 February; 11(2):340-9</div>
    <div id="p-0608" num="0679" class="description-paragraph style-scope patent-text">Harvard Medical School: Antibodies G10, G36, G37, G39, G45, G57, G106, G119, G6, G27, G40 and G125. Xu C., et al <i class="style-scope patent-text">PLoS One. </i>2010 Mar. 10; 5(3):e9625</div>
    <div id="p-0609" num="0680" class="description-paragraph style-scope patent-text">Institute of Virology, Slovak Academy of Sciences (Bayer)—U.S. Pat. No. 5,955,075
</div> <ul class="style-scope patent-text"> <li id="ul0064-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0065-0001" num="0681" class="style-scope patent-text">for example, M75—ATCC Accession No. HB 11128 or MN12—ATCC Accession No. HB 11647</li> </ul> </li> </ul>

    <div id="p-0610" num="0682" class="description-paragraph style-scope patent-text">Institute of Virology, Slovak Academy of Sciences: U.S. Pat. No. 7,816,493
</div> <ul class="style-scope patent-text"> <li id="ul0066-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0067-0001" num="0683" class="style-scope patent-text">for example the M75 monoclonal antibody that is secreted from the hybridoma VU-M75, which was deposited at the American Type Culture Collection under ATCC No. HB 11128; or the V/10 monoclonal antibody secreted from the hybridoma V/10-VU, which was deposited at the International Depository Authority of the Belgian Coordinated Collection of Microorganisms (BCCM) at the Laboratorium voor Moleculaire Bioloqie-Plasmidencollectie (LMBP) at the Universeit Gent in Gent, Belgium, under Accession No. LMBP 6009CB.</li> </ul> </li> </ul>

    <div id="p-0611" num="0684" class="description-paragraph style-scope patent-text">Institute of Virology, Slovak Academy of Sciences US20080177046; US20080176310; US20080176258; US20050031623</div>
    <div id="p-0612" num="0685" class="description-paragraph style-scope patent-text">Novartis: US20090252738</div>
    <div id="p-0613" num="0686" class="description-paragraph style-scope patent-text">Wilex: U.S. Pat. No. 7,691,375—for example the antibody produced by the hybridoma cell line DSM ASC 2526.</div>
    <div id="p-0614" num="0687" class="description-paragraph style-scope patent-text">Wilex: US20110123537; Rencarex: Kennett R H., et al <i class="style-scope patent-text">Curr Opin Mol Ther. </i>2003 February; 5(1):70-5</div>
    <div id="p-0615" num="0688" class="description-paragraph style-scope patent-text">Xencor: US20090162382</div>
    <div id="h-0225" num="0000" class="description-paragraph style-scope patent-text">(45) EGFRvIII (Epidermal Growth Factor Receptor (EGFR), Transcript Variant 3,</div>
    <div id="h-0226" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0616" num="0689" class="description-paragraph style-scope patent-text">Genbank accession no. NM_201283</div>
    <div id="p-0617" num="0690" class="description-paragraph style-scope patent-text">Genbank version no. NM_201283.1 GI: 41327733</div>
    <div id="p-0618" num="0691" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 30, 2012 01:47 PM</div>
    <div id="h-0227" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0619" num="0692" class="description-paragraph style-scope patent-text">Genbank accession no. NP_958440</div>
    <div id="p-0620" num="0693" class="description-paragraph style-scope patent-text">Genbank version no. NP_958440.1 GI: 41327734</div>
    <div id="p-0621" num="0694" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 30, 2012 01:47 PM</div>
    <div id="h-0228" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0622" num="0695" class="description-paragraph style-scope patent-text">Batra S K., et al <i class="style-scope patent-text">Cell Growth Differ </i>1995; 6:1251-1259.</div>
    <div id="h-0229" num="0000" class="description-paragraph style-scope patent-text">Antibodies:</div>
    <div id="p-0623" num="0696" class="description-paragraph style-scope patent-text">U.S. Pat. Nos. 7,628,986 and 7,736,644 (Amgen)
</div> <ul class="style-scope patent-text"> <li id="ul0068-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0069-0001" num="0697" class="style-scope patent-text">For example, a heavy chain variable region amino acid sequence selected from the group consisting of SEQ ID NO: 142 and variants &amp; a light chain variable region amino acid sequence selected from the group consisting of: SEQ ID NO: 144 and variants.</li> </ul> </li> </ul>

    <div id="p-0624" num="0698" class="description-paragraph style-scope patent-text">US20100111979 (Amgen)
</div> <ul class="style-scope patent-text"> <li id="ul0070-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0071-0001" num="0699" class="style-scope patent-text">For example, an antibody comprising a heavy chain amino acid sequence comprising:</li> <li id="ul0071-0002" num="0700" class="style-scope patent-text">CDR1 consisting of a sequence selected from the group consisting of the amino acid sequences for the CDR1 region of antibodies 13.1.2 (SEQ ID NO: 138), 131 (SEQ ID NO: 2), 170 (SEQ ID NO: 4), 150 (SEQ ID NO: 5), 095 (SEQ ID NO: 7), 250 (SEQ ID NO: 9), 139 (SEQ ID NO: 10), 211 (SEQ ID NO: 12), 124 (SEQ ID NO: 13), 318 (SEQ ID NO: 15), 342 (SEQ ID NO: 16), and 333 (SEQ ID NO: 17);</li> <li id="ul0071-0003" num="0701" class="style-scope patent-text">CDR2 consisting of a sequence selected from the group consisting of the amino acid sequences for the CDR2 region of antibodies 13.1.2 (SEQ ID NO: 138), 131 (SEQ ID NO: 2), 170 (SEQ ID NO: 4), 150 (SEQ ID NO: 5), 095 (SEQ ID NO: 7), 250 (SEQ ID NO: 9), 139 (SEQ ID NO: 10), 211 (SEQ ID NO: 12), 124 (SEQ ID NO: 13), 318 (SEQ ID NO: 15), 342 (SEQ ID NO: 16), and 333 (SEQ ID NO: 17); and</li> <li id="ul0071-0004" num="0702" class="style-scope patent-text">CDR3 consisting of a sequence selected from the group consisting of the amino acid sequences for the CDR3 region of antibodies 13.1.2 (SEQ ID NO: 138), 131 (SEQ ID NO: 2), 170 (SEQ ID NO: 4), 150 (SEQ ID NO: 5), 095 (SEQ ID NO: 7), 250 (SEQ ID NO: 9), 139 (SEQ ID NO: 10), 211 (SEQ ID NO: 12), 124 (SEQ ID NO: 13), 318 (SEQ ID NO: 15), 342 (SEQ ID NO: 16), and 333 (SEQ ID NO: 17).</li> </ul> </li> </ul>

    <div id="p-0625" num="0703" class="description-paragraph style-scope patent-text">US20090240038 (Amgen)
</div> <ul class="style-scope patent-text"> <li id="ul0072-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0073-0001" num="0704" class="style-scope patent-text">For example, an antibody having at least one of the heavy or light chain polypeptides comprises an amino acid sequence that is at least 90% identical to the amino acid sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 19, SEQ ID NO: 142, SEQ ID NO: 144, and any combination thereof.</li> </ul> </li> </ul>

    <div id="p-0626" num="0705" class="description-paragraph style-scope patent-text">US20090175887 (Amgen)
</div> <ul class="style-scope patent-text"> <li id="ul0074-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0075-0001" num="0706" class="style-scope patent-text">For example, an antibody having a heavy chain amino acid sequence selected from the group consisting of the heavy chain amino acid sequence of antibody 13.1.2 (SEQ ID NO: 138), 131 (SEQ ID NO: 2), 170 (SEQ ID NO: 4), 150 (SEQ ID NO: 5), 095 (SEQ ID NO: 7), 250 (SEQ ID NO: 9), 139 (SEQ ID NO: 10), 211 (SEQ ID NO: 12), 124 (SEQ ID NO: 13), 318 (SEQ ID NO: 15), 342 (SEQ ID NO: 16), and 333 (SEQ ID NO: 17).</li> </ul> </li> </ul>

    <div id="p-0627" num="0707" class="description-paragraph style-scope patent-text">US20090156790 (Amgen)
</div> <ul class="style-scope patent-text"> <li id="ul0076-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0077-0001" num="0708" class="style-scope patent-text">For example, antibody having heavy chain polypeptide and a light chain polypeptide, wherein at least one of the heavy or light chain polypeptides comprises an amino acid sequence that is at least 90% identical to the amino acid sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 19, SEQ ID NO: 142, SEQ ID NO: 144, and any combination thereof.</li> </ul> </li> </ul>

    <div id="p-0628" num="0709" class="description-paragraph style-scope patent-text">US20090155282, US20050059087 and US20050053608 (Amgen)
</div> <ul class="style-scope patent-text"> <li id="ul0078-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0079-0001" num="0710" class="style-scope patent-text">For example, an antibody heavy chain amino acid sequence selected from the group consisting of the heavy chain amino acid sequence of antibody 13.1.2 (SEQ ID NO: 138), 131 (SEQ ID NO: 2), 170 (SEQ ID NO: 4), 150 (SEQ ID NO: 5), 095 (SEQ ID NO: 7), 250 (SEQ ID NO: 9), 139 (SEQ ID NO: 10), 211 (SEQ ID NO: 12), 124 (SEQ ID NO: 13), 318 (SEQ ID NO: 15), 342 (SEQ ID NO: 16), and 333 (SEQ ID NO: 17).</li> </ul> </li> </ul>

    <div id="p-0629" num="0711" class="description-paragraph style-scope patent-text">MR1-1 (U.S. Pat. No. 7,129,332; Duke)
</div> <ul class="style-scope patent-text"> <li id="ul0080-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0081-0001" num="0712" class="style-scope patent-text">For example, a variant antibody having the sequence of SEQ ID NO. 18 with the substitutions S98P-T99Y in the CDR3 VH, and F92W in CDR3 VL.</li> </ul> </li> </ul>

    <div id="p-0630" num="0713" class="description-paragraph style-scope patent-text">L8A4, H10, Y10 (Wikstrand C J., et al <i class="style-scope patent-text">Cancer Res. </i>1995 Jul. 15; 55(14):3140-8; Duke)</div>
    <div id="p-0631" num="0714" class="description-paragraph style-scope patent-text">US20090311803 (Harvard University)
</div> <ul class="style-scope patent-text"> <li id="ul0082-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0083-0001" num="0715" class="style-scope patent-text">For example, SEQ ID NO:9 for antibody heavy chain variable region, and SEQ ID NO: 3 for light chain variable region amino acid sequences</li> </ul> </li> </ul>

    <div id="p-0632" num="0716" class="description-paragraph style-scope patent-text">US20070274991 (EMD72000, also known as matuzumab; Harvard University)
</div> <ul class="style-scope patent-text"> <li id="ul0084-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0085-0001" num="0717" class="style-scope patent-text">For example, SEQ ID NOs: 3 &amp; 9 for light chain and heavy chain respectively</li> </ul> </li> </ul>

    <div id="p-0633" num="0718" class="description-paragraph style-scope patent-text">U.S. Pat. No. 6,129,915 (Schering)
</div> <ul class="style-scope patent-text"> <li id="ul0086-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0087-0001" num="0719" class="style-scope patent-text">For example, SEQ. ID NOs: 1, 2, 3, 4, 5 and 6.</li> </ul> </li> </ul>

    <div id="p-0634" num="0720" class="description-paragraph style-scope patent-text">mAb CH12—Wang H., et al <i class="style-scope patent-text">FASEB J. </i>2012 January; 26(1):73-80 (Shanghai Cancer Institute).</div>
    <div id="p-0635" num="0721" class="description-paragraph style-scope patent-text">RAbDMvIII—Gupta P., et al <i class="style-scope patent-text">BMC Biotechnol. </i>2010 Oct. 7; 10:72 (Stanford University Medical Center).</div>
    <div id="p-0636" num="0722" class="description-paragraph style-scope patent-text">mAb Ua30—Ohman L., et al <i class="style-scope patent-text">Tumour Biol. </i>2002 March-April; 23(2):61-9 (Uppsala University).</div>
    <div id="p-0637" num="0723" class="description-paragraph style-scope patent-text">Han D G., et al <i class="style-scope patent-text">Nan Fang Yi Ke Da Xue Xue Bao. </i>2010 January; 30(1):25-9 (Xi'an Jiaotong University).</div>
    <div id="h-0230" num="0000" class="description-paragraph style-scope patent-text">(46) CD33 (CD33 Molecule)</div>
    <div id="h-0231" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0638" num="0724" class="description-paragraph style-scope patent-text">Genbank accession no. M_23197</div>
    <div id="p-0639" num="0725" class="description-paragraph style-scope patent-text">Genbank version no. NM_23197.1 GI: 180097</div>
    <div id="p-0640" num="0726" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 08:47 AM</div>
    <div id="h-0232" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0641" num="0727" class="description-paragraph style-scope patent-text">Genbank accession no. AAA51948</div>
    <div id="p-0642" num="0728" class="description-paragraph style-scope patent-text">Genbank version no. AAA51948.1 GI: 188098</div>
    <div id="p-0643" num="0729" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 08:47 AM</div>
    <div id="h-0233" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0644" num="0730" class="description-paragraph style-scope patent-text">Simmons D., et al <i class="style-scope patent-text">J. Immunol. </i>141 (8), 2797-2800 (1988)</div>
    <div id="h-0234" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0645" num="0731" class="description-paragraph style-scope patent-text">Official Symbol: CD33</div>
    <div id="p-0646" num="0732" class="description-paragraph style-scope patent-text">Other Aliases: SIGLEC-3, SIGLEC3, p67</div>
    <div id="p-0647" num="0733" class="description-paragraph style-scope patent-text">Other Designations: CD33 antigen (gp67); gp67; myeloid cell surface antigen CD33; sialic acid binding Ig-like lectin 3; sialic acid-binding Ig-like lectin</div>
    <div id="h-0235" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-0648" num="0734" class="description-paragraph style-scope patent-text">H195 (Lintuzumab)—Raza A., et al <i class="style-scope patent-text">Leuk Lymphoma. </i>2009 August; 50(8):1336-44; U.S. Pat. No. 6,759,045 (Seattle Genetics/Immunomedics)</div>
    <div id="p-0649" num="0735" class="description-paragraph style-scope patent-text">mAb OKT9: Sutherland, D. R. et al. <i class="style-scope patent-text">Proc Natl Acad Sci USA </i>78(7): 4515-4519 1981, Schneider, C., et al <i class="style-scope patent-text">J Biol Chem </i>257, 8516-8522 (1982)</div>
    <div id="p-0650" num="0736" class="description-paragraph style-scope patent-text">mAb E6: Hoogenboom, H. R., et al <i class="style-scope patent-text">J Immunol </i>144, 3211-3217 (1990)</div>
    <div id="p-0651" num="0737" class="description-paragraph style-scope patent-text">U.S. Pat. No. 6,590,088 (Human Genome Sciences)
</div> <ul class="style-scope patent-text"> <li id="ul0088-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0089-0001" num="0738" class="style-scope patent-text">For example, SEQ ID NOs: 1 and 2 and ATCC accession no. 97521</li> </ul> </li> </ul>

    <div id="p-0652" num="0739" class="description-paragraph style-scope patent-text">U.S. Pat. No. 7,557,189 (Immunogen)
</div> <ul class="style-scope patent-text"> <li id="ul0090-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0091-0001" num="0740" class="style-scope patent-text">For example, an antibody or fragment thereof comprising a heavy chain variable region which comprises three CDRs having the amino acid sequences of SEQ ID NOs:1-3 and a light chain variable region comprising three CDRs having the amino acid sequences of SEQ ID NOs:4-6.
<br class="style-scope patent-text">
(47) CD19 (CD19 Molecule)
<br class="style-scope patent-text">
Nucleotide
</li> </ul> </li> </ul>

    <div id="p-0653" num="0741" class="description-paragraph style-scope patent-text">Genbank accession no. NM_001178098</div>
    <div id="p-0654" num="0742" class="description-paragraph style-scope patent-text">Genbank version no. NM_001178098.1 GI: 296010920</div>
    <div id="p-0655" num="0743" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 10, 2012 12:43 AM</div>
    <div id="h-0236" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0656" num="0744" class="description-paragraph style-scope patent-text">Genbank accession no. NP_001171569</div>
    <div id="p-0657" num="0745" class="description-paragraph style-scope patent-text">Genbank version no. NP_001171569.1 GI: 296010921</div>
    <div id="p-0658" num="0746" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 10, 2012 12:43 AM</div>
    <div id="h-0237" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0659" num="0747" class="description-paragraph style-scope patent-text">Tedder T F., et al J. Immunol. 143 (2): 712-7 (1989)</div>
    <div id="h-0238" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0660" num="0748" class="description-paragraph style-scope patent-text">Official Symbol: CD19</div>
    <div id="p-0661" num="0749" class="description-paragraph style-scope patent-text">Other Aliases: B4, CVID3</div>
    <div id="p-0662" num="0750" class="description-paragraph style-scope patent-text">Other Designations: B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; T-cell surface antigen Leu-12; differentiation antigen CD19</div>
    <div id="h-0239" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-0663" num="0751" class="description-paragraph style-scope patent-text">Immunogen: HuB4—Al-Katib A M., et al <i class="style-scope patent-text">Clin Cancer Res. </i>2009 Jun. 15; 15(12):4038-45.</div>
    <div id="p-0664" num="0752" class="description-paragraph style-scope patent-text">4G7: Kügler M., et al <i class="style-scope patent-text">Protein Eng Des Sel. </i>2009 March; 22(3):135-47
</div> <ul class="style-scope patent-text"> <li id="ul0092-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0093-0001" num="0753" class="style-scope patent-text">For example, sequences in FIG. 3 of of Knappik, A. et al. <i class="style-scope patent-text">J Mol Biol </i>2000 February; 296(1):57-86</li> </ul> </li> </ul>

    <div id="p-0665" num="0754" class="description-paragraph style-scope patent-text">AstraZeneca/MedImmune: MEDI-551—Herbst R., et al <i class="style-scope patent-text">J Pharmacol Exp Ther. </i>2010 October; 335(1):213-22</div>
    <div id="p-0666" num="0755" class="description-paragraph style-scope patent-text">Glenmark Pharmaceuticals: GBR-401—Hou S., et al Mol Cancer Ther November 2011 (Meeting Abstract Supplement) C164</div>
    <div id="p-0667" num="0756" class="description-paragraph style-scope patent-text">U.S. Pat. No. 7,109,304 (Immunomedics)
</div> <ul class="style-scope patent-text"> <li id="ul0094-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0095-0001" num="0757" class="style-scope patent-text">For example, an antibody comprising the sequence of hA19Vk (SEQ ID NO:7) and the sequence of hA19VH (SEQ ID NO:10)</li> </ul> </li> </ul>

    <div id="p-0668" num="0758" class="description-paragraph style-scope patent-text">U.S. Pat. No. 7,902,338 (Immunomedics)
</div> <ul class="style-scope patent-text"> <li id="ul0096-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0097-0001" num="0759" class="style-scope patent-text">For example, an antibody or antigen-binding fragment thereof that comprises the light chain complementarity determining region CDR sequences CDR1 of SEQ ID NO: 16 (KASQSVDYDGDSYLN); CDR2 of SEQ ID NO: 17 (DASNLVS); and CDR3 of SEQ ID NO: 18 (QQSTEDPWT) and the heavy chain CDR sequences CDR1 of SEQ ID NO: 19 (SYWMN); CDR2 of SEQ ID NO: 20 (QIWPGDGDTNYNGKFKG) and CDR3 of SEQ ID NO: 21 (RETTTVGRYYYAMDY) and also comprises human antibody framework (FR) and constant region sequences with one or more framework region amino acid residues substituted from the corresponding framework region sequences of the parent murine antibody, and wherein said substituted FR residues comprise the substitution of serine for phenylalanine at Kabat residue 91 of the heavy chain variable region.</li> </ul> </li> </ul>

    <div id="p-0669" num="0760" class="description-paragraph style-scope patent-text">Medarex: MDX-1342—Cardarelli P M., et al <i class="style-scope patent-text">Cancer Immunol Immunother. </i>2010 February; 59(2):257-65.</div>
    <div id="p-0670" num="0761" class="description-paragraph style-scope patent-text">MorphoSys/Xencor: MOR-208/XmAb-5574—Zalevsky J., et al <i class="style-scope patent-text">Blood. </i>2009 Apr. 16; 113(16):3735-43</div>
    <div id="p-0671" num="0762" class="description-paragraph style-scope patent-text">U.S. Pat. No. 7,968,687 (Seattle Genetics)
</div> <ul class="style-scope patent-text"> <li id="ul0098-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0099-0001" num="0763" class="style-scope patent-text">An antibody or antigen-binding fragment comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:9 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 24.</li> </ul> </li> </ul>

    <div id="p-0672" num="0764" class="description-paragraph style-scope patent-text">4G7 chim—Lang P., et al Blood. 2004 May 15; 103(10):3982-5 (University of Tübingen)
</div> <ul class="style-scope patent-text"> <li id="ul0100-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0101-0001" num="0765" class="style-scope patent-text">For example, FIG. 6 and SEQ ID No: 80 of US20120082664</li> </ul> </li> </ul>

    <div id="p-0673" num="0766" class="description-paragraph style-scope patent-text">Zhejiang University School of Medicine: 2E8—Zhang J., et al <i class="style-scope patent-text">J Drug Target. </i>2010 November; 18(9):675-8</div>
    <div id="h-0240" num="0000" class="description-paragraph style-scope patent-text">(48) IL2RA (Interleukin 2 Receptor, Alpha); NCBI Reference Sequence: NM_000417.2);</div>
    <div id="h-0241" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0674" num="0767" class="description-paragraph style-scope patent-text">Genbank accession no. NM_000417</div>
    <div id="p-0675" num="0768" class="description-paragraph style-scope patent-text">Genbank version no. NM_000417.2 GI: 269973860</div>
    <div id="p-0676" num="0769" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 9, 2012 04:59 PM</div>
    <div id="h-0242" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0677" num="0770" class="description-paragraph style-scope patent-text">Genbank accession no. NP_000408</div>
    <div id="p-0678" num="0771" class="description-paragraph style-scope patent-text">Genbank version no. NP_000408.1 GI: 4557667</div>
    <div id="p-0679" num="0772" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 9, 2012 04:59 PM</div>
    <div id="h-0243" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0680" num="0773" class="description-paragraph style-scope patent-text">Kuziel W. A., et al <i class="style-scope patent-text">J. Invest. Dermatol. </i>94 (6 SUPPL), 27S-32S (1990)</div>
    <div id="h-0244" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0681" num="0774" class="description-paragraph style-scope patent-text">Official Symbol: IL2RA</div>
    <div id="p-0682" num="0775" class="description-paragraph style-scope patent-text">Other Aliases: RP11-536K7.1, CD25, IDDM10, IL2R, TCGFR</div>
    <div id="p-0683" num="0776" class="description-paragraph style-scope patent-text">Other Designations: FIL-2 receptor subunit alpha; IL-2-RA; IL-2R subunit alpha; IL2-RA; TAC antigen; interleukin-2 receptor subunit alpha; p55</div>
    <div id="h-0245" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-0684" num="0777" class="description-paragraph style-scope patent-text">U.S. Pat. No. 6,383,487 (Novartis/UCL: Baxilisimab [Simulect])</div>
    <div id="p-0685" num="0778" class="description-paragraph style-scope patent-text">U.S. Pat. No. 6,521,230 (Novartis/UCL: Baxilisimab [Simulect])
</div> <ul class="style-scope patent-text"> <li id="ul0102-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0103-0001" num="0779" class="style-scope patent-text">For example, an antibody having an antigen binding site comprises at least one domain which comprises CDR1 having the amino acid sequence in SEQ. ID. NO: 7, CDR2 having the amino acid sequence in SEQ. ID. NO: 8, and CDR3 having the amino acid sequence in SEQ. ID. NO: 9; or said CDR1, CDR2 and CDR3 taken in sequence as a whole comprise an amino acid sequence which is at least 90% identical to SEQ. ID. NOs: 7, 8 and 9 taken in sequence as a whole.</li> </ul> </li> </ul>

    <div id="p-0686" num="0780" class="description-paragraph style-scope patent-text">Daclizumab—Rech A J., et al <i class="style-scope patent-text">Ann N Y Acad Sci. </i>2009 September; 1174:99-106 (Roche)</div>
    <div id="h-0246" num="0000" class="description-paragraph style-scope patent-text">(49) AXL (AXL Receptor Tyrosine Kinase)</div>
    <div id="h-0247" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0687" num="0781" class="description-paragraph style-scope patent-text">Genbank accession no. M76125</div>
    <div id="p-0688" num="0782" class="description-paragraph style-scope patent-text">Genbank version no. M76125.1 GI: 292869</div>
    <div id="p-0689" num="0783" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 08:53 AM</div>
    <div id="h-0248" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0690" num="0784" class="description-paragraph style-scope patent-text">Genbank accession no. AAA61243</div>
    <div id="p-0691" num="0785" class="description-paragraph style-scope patent-text">Genbank version no. AAA61243.1 GI: 29870</div>
    <div id="p-0692" num="0786" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 08:53 AM</div>
    <div id="h-0249" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0693" num="0787" class="description-paragraph style-scope patent-text">O'Bryan J. P., et al <i class="style-scope patent-text">Mol. Cell. Biol. </i>11 (10), 5016-5031 (1991); Bergsagel P. L., et al <i class="style-scope patent-text">J. Immunol. </i>148 (2), 590-596 (1992)</div>
    <div id="h-0250" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0694" num="0788" class="description-paragraph style-scope patent-text">Official Symbol: AXL</div>
    <div id="p-0695" num="0789" class="description-paragraph style-scope patent-text">Other Aliases: JTK11, UFO</div>
    <div id="p-0696" num="0790" class="description-paragraph style-scope patent-text">Other Designations: AXL oncogene; AXL transforming sequence/gene; oncogene AXL; tyrosine-protein kinase receptor UFO</div>
    <div id="h-0251" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-0697" num="0791" class="description-paragraph style-scope patent-text">YW327.6S2—Ye X., et al <i class="style-scope patent-text">Oncogene. </i>2010 Sep. 23; 29(38):5254-64. (Genentech)</div>
    <div id="p-0698" num="0792" class="description-paragraph style-scope patent-text">BergenBio: BGB324 (http://www.bergenbio.com/BGB324)</div>
    <div id="h-0252" num="0000" class="description-paragraph style-scope patent-text">(50) CD30—TNFRSF8 (Tumor Necrosis Factor Receptor Superfamily, Member 8)</div>
    <div id="h-0253" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0699" num="0793" class="description-paragraph style-scope patent-text">Genbank accession no. M83554</div>
    <div id="p-0700" num="0794" class="description-paragraph style-scope patent-text">Genbank version no. M83554.1 GI: 180095</div>
    <div id="p-0701" num="0795" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 08:53 AM</div>
    <div id="h-0254" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0702" num="0796" class="description-paragraph style-scope patent-text">Genbank accession no. AAA51947</div>
    <div id="p-0703" num="0797" class="description-paragraph style-scope patent-text">Genbank version no. AAA51947.1 GI: 180096</div>
    <div id="p-0704" num="0798" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 08:53 AM</div>
    <div id="h-0255" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0705" num="0799" class="description-paragraph style-scope patent-text">Durkop H., et al <i class="style-scope patent-text">Cell </i>68 (3), 421-427 (1992)</div>
    <div id="h-0256" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0706" num="0800" class="description-paragraph style-scope patent-text">Official Symbol: TNFRSF8</div>
    <div id="p-0707" num="0801" class="description-paragraph style-scope patent-text">Other Aliases: CD30, D1S166E, Ki-1</div>
    <div id="p-0708" num="0802" class="description-paragraph style-scope patent-text">Other Designations: CD30L receptor; Ki-1 antigen; cytokine receptor CD30; lymphocyte activation antigen CD30; tumor necrosis factor receptor superfamily member 8</div>
    <div id="h-0257" num="0000" class="description-paragraph style-scope patent-text">(51) BCMA (B-cell maturation antigen)—TNFRSF17 (Tumor necrosis factor receptor superfamily, member 17)</div>
    <div id="h-0258" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0709" num="0803" class="description-paragraph style-scope patent-text">Genbank accession no. Z29574</div>
    <div id="p-0710" num="0804" class="description-paragraph style-scope patent-text">Genbank version no. Z29574.1 GI: 471244</div>
    <div id="p-0711" num="0805" class="description-paragraph style-scope patent-text">Genbank record update date: Feb. 2, 2011 10:40 AM</div>
    <div id="h-0259" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0712" num="0806" class="description-paragraph style-scope patent-text">Genbank accession no. CAA82690</div>
    <div id="p-0713" num="0807" class="description-paragraph style-scope patent-text">Genbank version no. CAA82690.1 GI: 471245</div>
    <div id="p-0714" num="0808" class="description-paragraph style-scope patent-text">Genbank record update date: Feb. 2, 2011 10:40 AM</div>
    <div id="h-0260" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0715" num="0809" class="description-paragraph style-scope patent-text">Laabi Y., et al <i class="style-scope patent-text">Nucleic Acids Res. </i>22 (7), 1147-1154 (1994)</div>
    <div id="h-0261" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0716" num="0810" class="description-paragraph style-scope patent-text">Official Symbol: TNFRSF17</div>
    <div id="p-0717" num="0811" class="description-paragraph style-scope patent-text">Other Aliases: BCM, BCMA, CD269</div>
    <div id="p-0718" num="0812" class="description-paragraph style-scope patent-text">Other Designations: B cell maturation antigen; B-cell maturation factor; B-cell maturation protein; tumor necrosis factor receptor superfamily member 17</div>
    <div id="h-0262" num="0000" class="description-paragraph style-scope patent-text">(52) CT Ags—CTA (Cancer Testis Antigens)</div>
    <div id="h-0263" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0719" num="0813" class="description-paragraph style-scope patent-text">Fratta E., et al. <i class="style-scope patent-text">Mol Oncol. </i>2011 April; 5(2):164-82; Lim S H., at al <i class="style-scope patent-text">Am J Blood Res. </i>2012; 2(1):29-35.</div>
    <div id="h-0264" num="0000" class="description-paragraph style-scope patent-text">(53) CD174 (Lewis Y)—FUT3 (fucosyltransferase 3 (Galactoside 3(4)-L-fucosyltransferase, Lewis Blood Group)</div>
    <div id="h-0265" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0720" num="0814" class="description-paragraph style-scope patent-text">Genbank accession no. NM000149</div>
    <div id="p-0721" num="0815" class="description-paragraph style-scope patent-text">Genbank version no. NM000149.3 GI: 148277008</div>
    <div id="p-0722" num="0816" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 26, 2012 04:49 PM</div>
    <div id="h-0266" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0723" num="0817" class="description-paragraph style-scope patent-text">Genbank accession no. NP_000140</div>
    <div id="p-0724" num="0818" class="description-paragraph style-scope patent-text">Genbank version no. NP_000140.1 GI: 4503809</div>
    <div id="p-0725" num="0819" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 26, 2012 04:49 PM</div>
    <div id="h-0267" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0726" num="0820" class="description-paragraph style-scope patent-text">Kukowska-Latallo, J. F., et al <i class="style-scope patent-text">Genes Dev. </i>4 (8), 1288-1303 (1990)</div>
    <div id="h-0268" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0727" num="0821" class="description-paragraph style-scope patent-text">Official Symbol: FUT3</div>
    <div id="p-0728" num="0822" class="description-paragraph style-scope patent-text">Other Aliases: CD174, FT3B, FucT-III, LE, Les</div>
    <div id="p-0729" num="0823" class="description-paragraph style-scope patent-text">Other Designations: Lewis FT; alpha-(1,3/1,4)-fucosyltransferase; blood group Lewis alpha-4-fucosyltransferase; fucosyltransferase III; galactoside 3(4)-L-fucosyltransferase</div>
    <div id="h-0269" num="0000" class="description-paragraph style-scope patent-text">(54) CLEC14A (C-Type Lectin Domain Family 14, Member a; Genbank Accession No. NM175060)</div>
    <div id="h-0270" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0730" num="0824" class="description-paragraph style-scope patent-text">Genbank accession no. NM175060</div>
    <div id="p-0731" num="0825" class="description-paragraph style-scope patent-text">Genbank version no. NM175060.2 GI: 371123930</div>
    <div id="p-0732" num="0826" class="description-paragraph style-scope patent-text">Genbank record update date: Apr. 1, 2012 03:34 PM</div>
    <div id="h-0271" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0733" num="0827" class="description-paragraph style-scope patent-text">Genbank accession no. NP_778230</div>
    <div id="p-0734" num="0828" class="description-paragraph style-scope patent-text">Genbank version no. NP_778230.1 GI: 28269707</div>
    <div id="p-0735" num="0829" class="description-paragraph style-scope patent-text">Genbank record update date: Apr. 1, 2012 03:34 PM</div>
    <div id="h-0272" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0736" num="0830" class="description-paragraph style-scope patent-text">Official Symbol: CLEC14A</div>
    <div id="p-0737" num="0831" class="description-paragraph style-scope patent-text">Other Aliases: UNQ236/PRO269, C14orf27, CEG1, EGFR-5</div>
    <div id="p-0738" num="0832" class="description-paragraph style-scope patent-text">Other Designations: C-type lectin domain family 14 member A; CIECT and EGF-like domain containing protein; epidermal growth factor receptor 5</div>
    <div id="h-0273" num="0000" class="description-paragraph style-scope patent-text">(55) GRP78—HSPA5 (Heat Shock 70 kDa Protein 5 (Glucose-Regulated Protein, 78 kDa)</div>
    <div id="h-0274" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0739" num="0833" class="description-paragraph style-scope patent-text">Genbank accession no. NM005347</div>
    <div id="p-0740" num="0834" class="description-paragraph style-scope patent-text">Genbank version no. NM005347.4 GI: 305855105</div>
    <div id="p-0741" num="0835" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 30, 2012 01:42 PM</div>
    <div id="h-0275" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0742" num="0836" class="description-paragraph style-scope patent-text">Genbank accession no. NP_005338</div>
    <div id="p-0743" num="0837" class="description-paragraph style-scope patent-text">Genbank version no. NP_005338.1 GI: 16507237</div>
    <div id="p-0744" num="0838" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 30, 2012 01:42 PM</div>
    <div id="h-0276" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0745" num="0839" class="description-paragraph style-scope patent-text">Ting J., et al <i class="style-scope patent-text">DNA </i>7 (4), 275-286 (1988)</div>
    <div id="h-0277" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0746" num="0840" class="description-paragraph style-scope patent-text">Official Symbol: HSPA5</div>
    <div id="p-0747" num="0841" class="description-paragraph style-scope patent-text">Other Aliases: BIP, GRP78, MIF2</div>
    <div id="p-0748" num="0842" class="description-paragraph style-scope patent-text">Other Designations: 78 kDa glucose-regulated protein; endoplasmic reticulum lumenal Ca(2+)-binding protein grp78; immunoglobulin heavy chain-binding protein</div>
    <div id="h-0278" num="0000" class="description-paragraph style-scope patent-text">(56) Cd70 (Cd70 Molecule) L08096</div>
    <div id="h-0279" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0749" num="0843" class="description-paragraph style-scope patent-text">Genbank accession no. L08096</div>
    <div id="p-0750" num="0844" class="description-paragraph style-scope patent-text">Genbank version no. L08096.1 GI: 307127</div>
    <div id="p-0751" num="0845" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2012 08:54 AM</div>
    <div id="h-0280" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0752" num="0846" class="description-paragraph style-scope patent-text">Genbank accession no. AAA36175</div>
    <div id="p-0753" num="0847" class="description-paragraph style-scope patent-text">Genbank version no. AAA36175.1 GI: 307128</div>
    <div id="p-0754" num="0848" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2012 08:54 AM</div>
    <div id="h-0281" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0755" num="0849" class="description-paragraph style-scope patent-text">Goodwin R. G., et al <i class="style-scope patent-text">Cell </i>73 (3), 447-456 (1993)</div>
    <div id="h-0282" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0756" num="0850" class="description-paragraph style-scope patent-text">Official Symbol: CD70</div>
    <div id="p-0757" num="0851" class="description-paragraph style-scope patent-text">Other Aliases: CD27L, CD27LG, TNFSF7</div>
    <div id="p-0758" num="0852" class="description-paragraph style-scope patent-text">Other Designations: CD27 ligand; CD27-L; CD70 antigen; Ki-24 antigen; surface antigen CD70; tumor necrosis factor (ligand) superfamily, member 7; tumor necrosis factor ligand superfamily member 7</div>
    <div id="h-0283" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-0759" num="0853" class="description-paragraph style-scope patent-text">MDX-1411 against CD70 (Medarex)</div>
    <div id="p-0760" num="0854" class="description-paragraph style-scope patent-text">h1F6 (Oflazoglu, E., et al, Clin Cancer Res. 2008 Oct. 1; 14(19):6171-80; Seattle Genetics)
</div> <ul class="style-scope patent-text"> <li id="ul0104-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0105-0001" num="0855" class="style-scope patent-text">For example, see US20060083736 SEQ ID NOs: 1, 2, 11 and 12 and FIG. 1.
<br class="style-scope patent-text">
(57) Stem Cell Specific Antigens. For Example:
</li> <li id="ul0105-0002" num="0856" class="style-scope patent-text">5T4 (see entry (63) below)</li> <li id="ul0105-0003" num="0857" class="style-scope patent-text">CD25 (see entry (48) above)</li> <li id="ul0105-0004" num="0858" class="style-scope patent-text">CD32
        <ul class="style-scope patent-text"> <li id="ul0106-0001" num="0859" class="style-scope patent-text">Polypeptide
            <ul class="style-scope patent-text"> <li id="ul0107-0001" num="0860" class="style-scope patent-text">Genbank accession no. ABK42161</li> <li id="ul0107-0002" num="0861" class="style-scope patent-text">Genbank version no. ABK42161.1 GI: 117616286</li> <li id="ul0107-0003" num="0862" class="style-scope patent-text">Genbank record update date: Jul. 25, 2007 03:00 PM</li> </ul>
            </li> </ul>
        </li> <li id="ul0105-0005" num="0863" class="style-scope patent-text">LGR5/GPR49
        <ul class="style-scope patent-text"> <li id="ul0108-0001" num="0864" class="style-scope patent-text">Nucleotide
            <ul class="style-scope patent-text"> <li id="ul0109-0001" num="0865" class="style-scope patent-text">Genbank accession no. NM_003667</li> <li id="ul0109-0002" num="0866" class="style-scope patent-text">Genbank version no. NM_003667.2 GI: 24475886</li> <li id="ul0109-0003" num="0867" class="style-scope patent-text">Genbank record update date: Jul. 22, 2012 03:38 PM</li> </ul>
            </li> <li id="ul0108-0002" num="0868" class="style-scope patent-text">Polypeptide
            <ul class="style-scope patent-text"> <li id="ul0110-0001" num="0869" class="style-scope patent-text">Genbank accession no. NP_003658</li> <li id="ul0110-0002" num="0870" class="style-scope patent-text">Genbank version no. NP_003658.1 GI: 4504379</li> <li id="ul0110-0003" num="0871" class="style-scope patent-text">Genbank record update date: Jul. 22, 2012 03:38 PM</li> </ul>
            </li> </ul>
        </li> <li id="ul0105-0006" num="0872" class="style-scope patent-text">Prominin/CD133
        <ul class="style-scope patent-text"> <li id="ul0111-0001" num="0873" class="style-scope patent-text">Nucleotide
            <ul class="style-scope patent-text"> <li id="ul0112-0001" num="0874" class="style-scope patent-text">Genbank accession no. NM_006017</li> <li id="ul0112-0002" num="0875" class="style-scope patent-text">Genbank version no. NM_006017.2 GI: 224994187</li> <li id="ul0112-0003" num="0876" class="style-scope patent-text">Genbank record update date: Sep. 30, 2012 01:47 PM</li> </ul>
            </li> <li id="ul0111-0002" num="0877" class="style-scope patent-text">Polypeptide
            <ul class="style-scope patent-text"> <li id="ul0113-0001" num="0878" class="style-scope patent-text">Genbank accession no. NP_006008</li> <li id="ul0113-0002" num="0879" class="style-scope patent-text">Genbank version no. NP_006008.1 GI: 5174387</li> <li id="ul0113-0003" num="0880" class="style-scope patent-text">Genbank record update date: Sep. 30, 2012 01:47 PM
<br class="style-scope patent-text">
(58) ASG-5
<br class="style-scope patent-text">
Cross-References
</li> </ul>
            </li> </ul>
        </li> </ul> </li> </ul>

    <div id="p-0761" num="0881" class="description-paragraph style-scope patent-text">(Smith L. M., et. al <i class="style-scope patent-text">AACR </i>2010 <i class="style-scope patent-text">Annual Meeting </i>(abstract #2590); Gudas J. M., et. al. <i class="style-scope patent-text">AACR </i>2010 <i class="style-scope patent-text">Annual Meeting </i>(abstract #4393)</div>
    <div id="h-0284" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-0762" num="0882" class="description-paragraph style-scope patent-text">Anti-AGS-5 Antibody: M6.131 (Smith, L. M., et. al <i class="style-scope patent-text">AACR </i>2010 <i class="style-scope patent-text">Annual Meeting </i>(abstract #2590)</div>
    <div id="h-0285" num="0000" class="description-paragraph style-scope patent-text">(59) ENPP3 (Ectonucleotide Pyrophosphatase/Phosphodiesterase 3)</div>
    <div id="h-0286" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0763" num="0883" class="description-paragraph style-scope patent-text">Genbank accession no. AF005632</div>
    <div id="p-0764" num="0884" class="description-paragraph style-scope patent-text">Genbank version no. AF005632.2 GI: 4432589</div>
    <div id="p-0765" num="0885" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 10, 2010 09:41 PM</div>
    <div id="h-0287" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0766" num="0886" class="description-paragraph style-scope patent-text">Genbank accession no. AAC51813</div>
    <div id="p-0767" num="0887" class="description-paragraph style-scope patent-text">Genbank version no. AAC51813.1 GI: 2465540</div>
    <div id="p-0768" num="0888" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 10, 2010 09:41 PM</div>
    <div id="h-0288" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0769" num="0889" class="description-paragraph style-scope patent-text">Jin-Hua P., et al <i class="style-scope patent-text">Genomics </i>45 (2), 412-415 (1997)</div>
    <div id="h-0289" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0770" num="0890" class="description-paragraph style-scope patent-text">Official Symbol: ENPP3</div>
    <div id="p-0771" num="0891" class="description-paragraph style-scope patent-text">Other Aliases: RP5-988G15.3, B10, CD203c, NPP3, PD-IBETA, PDNP3</div>
    <div id="p-0772" num="0892" class="description-paragraph style-scope patent-text">Other Designations: E-NPP 3; dJ1005H11.3 (phosphodiesterase 1/nucleotide pyrophosphatase 3); dJ914N13.3 (phosphodiesterase 1/nucleotide pyrophosphatase 3); ectonucleotide pyrophosphatase/phosphodiesterase family member 3; gp130RB13-6; phosphodiesterase I beta; phosphodiesterase I/nucleotide pyrophosphatase 3; phosphodiesterase-I beta</div>
    <div id="h-0290" num="0000" class="description-paragraph style-scope patent-text">(60) PRR4 (Proline Rich 4 (Lacrimal))</div>
    <div id="h-0291" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0773" num="0893" class="description-paragraph style-scope patent-text">Genbank accession no. NM_007244</div>
    <div id="p-0774" num="0894" class="description-paragraph style-scope patent-text">Genbank version no. NM_007244.2 GI: 154448885</div>
    <div id="p-0775" num="0895" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 28, 2012 12:39 PM</div>
    <div id="h-0292" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0776" num="0896" class="description-paragraph style-scope patent-text">Genbank accession no. NP_009175</div>
    <div id="p-0777" num="0897" class="description-paragraph style-scope patent-text">Genbank version no. NP_009175.2 GI: 154448886</div>
    <div id="p-0778" num="0898" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 28, 2012 12:39 PM</div>
    <div id="h-0293" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0779" num="0899" class="description-paragraph style-scope patent-text">Dickinson D. P., et al <i class="style-scope patent-text">Invest. Ophthalmol. Vis. Sci. </i>36 (10), 2020-2031 (1995)</div>
    <div id="h-0294" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0780" num="0900" class="description-paragraph style-scope patent-text">Official Symbol: PRR4</div>
    <div id="p-0781" num="0901" class="description-paragraph style-scope patent-text">Other Aliases: LPRP, PROL4</div>
    <div id="p-0782" num="0902" class="description-paragraph style-scope patent-text">Other Designations: lacrimal proline-rich protein; nasopharyngeal carcinoma-associated proline-rich protein 4; proline-rich polypeptide 4; proline-rich protein 4</div>
    <div id="h-0295" num="0000" class="description-paragraph style-scope patent-text">(61) GCC—GUCY2C (Guanylate Cyclase 2C (Heat Stable Enterotoxin Receptor)</div>
    <div id="h-0296" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0783" num="0903" class="description-paragraph style-scope patent-text">Genbank accession no. NM_004963</div>
    <div id="p-0784" num="0904" class="description-paragraph style-scope patent-text">Genbank version no. NM_004963.3 GI: 222080082</div>
    <div id="p-0785" num="0905" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 2, 2012 01:50 PM</div>
    <div id="h-0297" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0786" num="0906" class="description-paragraph style-scope patent-text">Genbank accession no. NP_004954</div>
    <div id="p-0787" num="0907" class="description-paragraph style-scope patent-text">Genbank version no. NP_004954.2 GI: 222080083</div>
    <div id="p-0788" num="0908" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 2, 2012 01:50 PM</div>
    <div id="h-0298" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0789" num="0909" class="description-paragraph style-scope patent-text">De Sauvage F. J., et al <i class="style-scope patent-text">J. Biol. Chem. </i>266 (27), 17912-17918 (1991); Singh S., et al <i class="style-scope patent-text">Biochem. Biophys. Res. Commun. </i>179 (3), 1455-1463 (1991)</div>
    <div id="h-0299" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0790" num="0910" class="description-paragraph style-scope patent-text">Official Symbol: GUCY2C</div>
    <div id="p-0791" num="0911" class="description-paragraph style-scope patent-text">Other Aliases: DIAR6, GUC2C, MUCIL, STAR</div>
    <div id="p-0792" num="0912" class="description-paragraph style-scope patent-text">Other Designations: GC-C; STA receptor; guanylyl cyclase C; hSTAR; heat-stable enterotoxin receptor; intestinal guanylate cyclase</div>
    <div id="h-0300" num="0000" class="description-paragraph style-scope patent-text">(62) Liv-1—SLC39A6 (Solute Carrier Family 39 (Zinc Transporter), Member 6)</div>
    <div id="h-0301" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0793" num="0913" class="description-paragraph style-scope patent-text">Genbank accession no. U41060</div>
    <div id="p-0794" num="0914" class="description-paragraph style-scope patent-text">Genbank version no. U41060.2 GI: 12711792</div>
    <div id="p-0795" num="0915" class="description-paragraph style-scope patent-text">Genbank record update date: Nov. 30, 2009 04:35 PM</div>
    <div id="h-0302" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0796" num="0916" class="description-paragraph style-scope patent-text">Genbank accession no. AAA96258</div>
    <div id="p-0797" num="0917" class="description-paragraph style-scope patent-text">Genbank version no. AAA96258.2 GI: 12711793</div>
    <div id="p-0798" num="0918" class="description-paragraph style-scope patent-text">Genbank record update date: Nov. 30, 2009 04:35 PM</div>
    <div id="h-0303" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0799" num="0919" class="description-paragraph style-scope patent-text">Taylor K M., et al <i class="style-scope patent-text">Biochim Biophys Acta. </i>2003 Apr. 1; 1611(1-2):16-30</div>
    <div id="h-0304" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0800" num="0920" class="description-paragraph style-scope patent-text">Official Symbol: SLC39A6</div>
    <div id="p-0801" num="0921" class="description-paragraph style-scope patent-text">Other Aliases: LIV-1</div>
    <div id="p-0802" num="0922" class="description-paragraph style-scope patent-text">Other Designations: LIV-1 protein, estrogen regulated; ZIP-6; estrogen-regulated protein LIV-1; solute carrier family 39 (metal ion transporter), member 6; solute carrier family 39 member 6; zinc transporter ZIP6; zrt- and lrt-like protein 6</div>
    <div id="h-0305" num="0000" class="description-paragraph style-scope patent-text">(63) 5T4, Trophoblast Glycoprotein, TPBG—TPBG (Trophoblast Glycoprotein)</div>
    <div id="h-0306" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0803" num="0923" class="description-paragraph style-scope patent-text">Genbank accession no. AJ012159</div>
    <div id="p-0804" num="0924" class="description-paragraph style-scope patent-text">Genbank version no. AJ012159.1 GI: 3805946</div>
    <div id="p-0805" num="0925" class="description-paragraph style-scope patent-text">Genbank record update date: Feb. 1, 2011 10:27 AM</div>
    <div id="h-0307" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0806" num="0926" class="description-paragraph style-scope patent-text">Genbank accession no. CAA09930</div>
    <div id="p-0807" num="0927" class="description-paragraph style-scope patent-text">Genbank version no. CAA09930.1 GI: 3805947</div>
    <div id="p-0808" num="0928" class="description-paragraph style-scope patent-text">Genbank record update date: Feb. 1, 2011 10:27 AM</div>
    <div id="h-0308" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0809" num="0929" class="description-paragraph style-scope patent-text">King K. W., et al <i class="style-scope patent-text">Biochim. Biophys. Acta </i>1445 (3), 257-270 (1999)</div>
    <div id="h-0309" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0810" num="0000" class="description-paragraph style-scope patent-text">
      </div> <ul class="style-scope patent-text">
        <li id="ul0114-0001" num="0000" class="style-scope patent-text">
          <ul class="style-scope patent-text">
            <li id="ul0115-0001" num="0930" class="style-scope patent-text">Official Symbol: TPBG</li>
            <li id="ul0115-0002" num="0931" class="style-scope patent-text">Other Aliases: 5T4, 5T4AG, M6P1</li>
            <li id="ul0115-0003" num="0932" class="style-scope patent-text">Other Designations: 5T4 oncofetal antigen; 5T4 oncofetal trophoblast glycoprotein; 5T4 oncotrophoblast glycoprotein</li>
            <li id="ul0115-0004" num="0933" class="style-scope patent-text">See WO2015/155345
<br class="style-scope patent-text">
(64) CD56—NCMA1 (Neural Cell Adhesion Molecule 1)
<br class="style-scope patent-text">
Nucleotide
</li>
          </ul>
        </li>
      </ul>
    
    <div id="p-0811" num="0934" class="description-paragraph style-scope patent-text">Genbank accession no. NM_000615</div>
    <div id="p-0812" num="0935" class="description-paragraph style-scope patent-text">Genbank version no. NM_000615.6 GI: 336285433</div>
    <div id="p-0813" num="0936" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 23, 2012 02:32 PM</div>
    <div id="h-0310" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0814" num="0937" class="description-paragraph style-scope patent-text">Genbank accession no. NP_000606</div>
    <div id="p-0815" num="0938" class="description-paragraph style-scope patent-text">Genbank version no. NP_000606.3 GI: 94420689</div>
    <div id="p-0816" num="0939" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 23, 2012 02:32 PM</div>
    <div id="h-0311" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0817" num="0940" class="description-paragraph style-scope patent-text">Dickson, G., et al, <i class="style-scope patent-text">Cell </i>50 (7), 1119-1130 (1987)</div>
    <div id="h-0312" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0818" num="0941" class="description-paragraph style-scope patent-text">Official Symbol: NCAM1</div>
    <div id="p-0819" num="0942" class="description-paragraph style-scope patent-text">Other Aliases: CD56, MSK39, NCAM</div>
    <div id="p-0820" num="0943" class="description-paragraph style-scope patent-text">Other Designations: antigen recognized by monoclonal antibody 5.1H11; neural cell adhesion molecule, NCAM</div>
    <div id="h-0313" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-0821" num="0944" class="description-paragraph style-scope patent-text">Immunogen: HuN901 (Smith S V., et al <i class="style-scope patent-text">Curr Opin Mol Ther. </i>2005 August; 7(4):394-401)
</div> <ul class="style-scope patent-text"> <li id="ul0116-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0117-0001" num="0945" class="style-scope patent-text">For example, see humanized from murine N901 antibody. See FIGS. 1b and 1e of Roguska, M. A., et al. Proc Natl Acad Sci USA February 1994; 91:969-973.
<br class="style-scope patent-text">
(65) CanAg (Tumor Associated Antigen CA242)
<br class="style-scope patent-text">
Cross-References
</li> </ul> </li> </ul>

    <div id="p-0822" num="0946" class="description-paragraph style-scope patent-text">Haglund C., et al <i class="style-scope patent-text">Br J Cancer </i>60:845-851, 1989; Baeckstrom D., et al <i class="style-scope patent-text">J Biol Chem </i>266:21537-21547, 1991</div>
    <div id="h-0314" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-0823" num="0947" class="description-paragraph style-scope patent-text">huC242 (Tolcher A W et al., <i class="style-scope patent-text">J Clin Oncol. </i>2003 Jan. 15; 21(2):211-22; Immunogen)
</div> <ul class="style-scope patent-text"> <li id="ul0118-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0119-0001" num="0948" class="style-scope patent-text">For example, see US20080138898A1 SEQ ID NO: 1 and 2
<br class="style-scope patent-text">
(66) FOLR1 (Folate Receptor 1)
<br class="style-scope patent-text">
Nucleotide
</li> </ul> </li> </ul>

    <div id="p-0824" num="0949" class="description-paragraph style-scope patent-text">Genbank accession no. J05013</div>
    <div id="p-0825" num="0950" class="description-paragraph style-scope patent-text">Genbank version no. J05013.1 GI: 182417</div>
    <div id="p-0826" num="0951" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 08:47 AM</div>
    <div id="h-0315" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0827" num="0952" class="description-paragraph style-scope patent-text">Genbank accession no. AAA35823</div>
    <div id="p-0828" num="0953" class="description-paragraph style-scope patent-text">Genbank version no. AAA35823.1 GI: 182418</div>
    <div id="p-0829" num="0954" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 08:47 AM</div>
    <div id="h-0316" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0830" num="0955" class="description-paragraph style-scope patent-text">Elwood P. C., et al <i class="style-scope patent-text">J. Biol. Chem. </i>264 (25), 14893-14901 (1989)</div>
    <div id="h-0317" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0831" num="0956" class="description-paragraph style-scope patent-text">Official Symbol: FOLR1</div>
    <div id="p-0832" num="0957" class="description-paragraph style-scope patent-text">Other Aliases: FBP, FOLR</div>
    <div id="p-0833" num="0958" class="description-paragraph style-scope patent-text">Other Designations: FR-alpha; KB cells FBP; adult folate-binding protein; folate binding protein; folate receptor alpha; folate receptor, adult; ovarian tumor-associated antigen MOv18</div>
    <div id="h-0318" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-0834" num="0959" class="description-paragraph style-scope patent-text">M9346A—Whiteman K R., et al <i class="style-scope patent-text">Cancer Res </i>Apr. 15, 2012; 72(8 Supplement): 4628 (Immunogen)</div>
    <div id="h-0319" num="0000" class="description-paragraph style-scope patent-text">(67) GPNMB (Glycoprotein (transmembrane) nmb)</div>
    <div id="h-0320" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0835" num="0960" class="description-paragraph style-scope patent-text">Genbank accession no. X76534</div>
    <div id="p-0836" num="0961" class="description-paragraph style-scope patent-text">Genbank version no. X76534.1 GI: 666042</div>
    <div id="p-0837" num="0962" class="description-paragraph style-scope patent-text">Genbank record update date: Feb. 2, 2011 10:10 AM</div>
    <div id="h-0321" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0838" num="0963" class="description-paragraph style-scope patent-text">Genbank accession no. CAA54044</div>
    <div id="p-0839" num="0964" class="description-paragraph style-scope patent-text">Genbank version no. CAA54044.1 GI: 666043</div>
    <div id="p-0840" num="0965" class="description-paragraph style-scope patent-text">Genbank record update date: Feb. 2, 2011 10:10 AM</div>
    <div id="h-0322" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0841" num="0966" class="description-paragraph style-scope patent-text">Weterman M. A., et al <i class="style-scope patent-text">Int. J. Cancer </i>60 (1), 73-81 (1995)</div>
    <div id="h-0323" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0842" num="0967" class="description-paragraph style-scope patent-text">Official Symbol: GPNMB</div>
    <div id="p-0843" num="0968" class="description-paragraph style-scope patent-text">Other Aliases: UNQ1725/PRO9925, HGFIN, NMB</div>
    <div id="p-0844" num="0969" class="description-paragraph style-scope patent-text">Other Designations: glycoprotein NMB; glycoprotein nmb-like protein; osteoactivin; transmembrane glycoprotein HGFIN; transmembrane glycoprotein NMB</div>
    <div id="h-0324" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-0845" num="0970" class="description-paragraph style-scope patent-text">Celldex Therapeutics: CR011 (Tse K F., et al <i class="style-scope patent-text">Clin Cancer Res. </i>2006 Feb. 15; 12(4):1373-82)
</div> <ul class="style-scope patent-text"> <li id="ul0120-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0121-0001" num="0971" class="style-scope patent-text">For example, see EP1827492B1 SEQ ID NO: 22, 24, 26, 31, 33 and 35
<br class="style-scope patent-text">
(68) TIM-1—HAVCR1 (Hepatitis a Virus Cellular Receptor 1)
<br class="style-scope patent-text">
Nucleotide
</li> </ul> </li> </ul>

    <div id="p-0846" num="0972" class="description-paragraph style-scope patent-text">Genbank accession no. AF043724</div>
    <div id="p-0847" num="0973" class="description-paragraph style-scope patent-text">Genbank version no. AF043724.1 GI: 2827453</div>
    <div id="p-0848" num="0974" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 10, 2010 06:24 PM</div>
    <div id="h-0325" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0849" num="0975" class="description-paragraph style-scope patent-text">Genbank accession no. AAC39862</div>
    <div id="p-0850" num="0976" class="description-paragraph style-scope patent-text">Genbank version no. AAC39862.1 GI: 2827454</div>
    <div id="p-0851" num="0977" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 10, 2010 06:24 PM</div>
    <div id="h-0326" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0852" num="0978" class="description-paragraph style-scope patent-text">Feigelstock D., et al <i class="style-scope patent-text">J. Virol. </i>72 (8), 6621-6628 (1998)</div>
    <div id="h-0327" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0853" num="0979" class="description-paragraph style-scope patent-text">Official Symbol: HAVCR1</div>
    <div id="p-0854" num="0980" class="description-paragraph style-scope patent-text">Other Aliases: HAVCR, HAVCR-1, KIM-1, KIM1, TIM, TIM-1, TIM1, TIMD-1, TIMD1</div>
    <div id="p-0855" num="0981" class="description-paragraph style-scope patent-text">Other Designations: T cell immunoglobin domain and mucin domain protein 1; T-cell membrane protein 1; kidney injury molecule 1</div>
    <div id="h-0328" num="0000" class="description-paragraph style-scope patent-text">(69) RG-1/Prostate Tumor Target Mindin—Mindin/RG-1</div>
    <div id="h-0329" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0856" num="0982" class="description-paragraph style-scope patent-text">Parry R., et al <i class="style-scope patent-text">Cancer Res. </i>2005 Sep. 15; 65(18):8397-405</div>
    <div id="h-0330" num="0000" class="description-paragraph style-scope patent-text">(70) B7-H4—VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1</div>
    <div id="h-0331" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0857" num="0983" class="description-paragraph style-scope patent-text">Genbank accession no. BX648021</div>
    <div id="p-0858" num="0984" class="description-paragraph style-scope patent-text">Genbank version no. BX648021.1 GI: 34367180</div>
    <div id="p-0859" num="0985" class="description-paragraph style-scope patent-text">Genbank record update date: Feb. 2, 2011 08:40 AM</div>
    <div id="h-0332" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0860" num="0986" class="description-paragraph style-scope patent-text">Sica G L., et al <i class="style-scope patent-text">Immunity. </i>2003 June; 18(6):849-61</div>
    <div id="h-0333" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0861" num="0987" class="description-paragraph style-scope patent-text">Official Symbol: VTCN1</div>
    <div id="p-0862" num="0988" class="description-paragraph style-scope patent-text">Other Aliases: RP11-229A19.4, B7-H4, B7H4, B7S1, B7X, B7h.5, PRO1291, VCTN1</div>
    <div id="p-0863" num="0989" class="description-paragraph style-scope patent-text">Other Designations: B7 family member, H4; B7 superfamily member 1; T cell costimulatory molecule B7x; T-cell costimulatory molecule B7x; V-set domain-containing T-cell activation inhibitor 1; immune costimulatory protein B7-H4</div>
    <div id="h-0334" num="0000" class="description-paragraph style-scope patent-text">(71) PTK7 (PTK7 Protein Tyrosine Kinase 7)</div>
    <div id="h-0335" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0864" num="0990" class="description-paragraph style-scope patent-text">Genbank accession no. AF447176</div>
    <div id="p-0865" num="0991" class="description-paragraph style-scope patent-text">Genbank version no. AF447176.1 GI: 17432420</div>
    <div id="p-0866" num="0992" class="description-paragraph style-scope patent-text">Genbank record update date: Nov. 28, 2008 01:51 PM</div>
    <div id="h-0336" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0867" num="0993" class="description-paragraph style-scope patent-text">Genbank accession no. AAL39062</div>
    <div id="p-0868" num="0994" class="description-paragraph style-scope patent-text">Genbank version no. AAL39062.1 GI: 17432421</div>
    <div id="p-0869" num="0995" class="description-paragraph style-scope patent-text">Genbank record update date: Nov. 28, 2008 01:51 PM</div>
    <div id="h-0337" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0870" num="0996" class="description-paragraph style-scope patent-text">Park S. K., et al <i class="style-scope patent-text">J. Biochem. </i>119 (2), 235-239 (1996)</div>
    <div id="h-0338" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0871" num="0997" class="description-paragraph style-scope patent-text">Official Symbol: PTK7</div>
    <div id="p-0872" num="0998" class="description-paragraph style-scope patent-text">Other Aliases: CCK-4, CCK4</div>
    <div id="p-0873" num="0999" class="description-paragraph style-scope patent-text">Other Designations: colon carcinoma kinase 4; inactive tyrosine-protein kinase 7; pseudo tyrosine kinase receptor 7; tyrosine-protein kinase-like 7</div>
    <div id="h-0339" num="0000" class="description-paragraph style-scope patent-text">(72) Cd37 (Cd37 Molecule)</div>
    <div id="h-0340" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0874" num="1000" class="description-paragraph style-scope patent-text">Genbank accession no. NM_001040031</div>
    <div id="p-0875" num="1001" class="description-paragraph style-scope patent-text">Genbank version no. NM_001040031.1 GI: 91807109</div>
    <div id="p-0876" num="1002" class="description-paragraph style-scope patent-text">Genbank record update date: Jul. 29, 2012 02:08 PM</div>
    <div id="h-0341" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0877" num="1003" class="description-paragraph style-scope patent-text">Genbank accession no. NP_001035120</div>
    <div id="p-0878" num="1004" class="description-paragraph style-scope patent-text">Genbank version no. NP_001035120.1 GI: 91807110</div>
    <div id="p-0879" num="1005" class="description-paragraph style-scope patent-text">Genbank record update date: Jul. 29, 2012 02:08 PM</div>
    <div id="h-0342" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0880" num="1006" class="description-paragraph style-scope patent-text">Schwartz-Albiez R., et al <i class="style-scope patent-text">J. Immunol. </i>140 (3), 905-914 (1988)</div>
    <div id="h-0343" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0881" num="1007" class="description-paragraph style-scope patent-text">Official Symbol: CD37</div>
    <div id="p-0882" num="1008" class="description-paragraph style-scope patent-text">Other Aliases: GP52-40, TSPAN26</div>
    <div id="p-0883" num="1009" class="description-paragraph style-scope patent-text">Other Designations: CD37 antigen; cell differentiation antigen 37; leukocyte antigen CD37; leukocyte surface antigen CD37; tetraspanin-26; tspan-26</div>
    <div id="h-0344" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-0884" num="1010" class="description-paragraph style-scope patent-text">Boehringer Ingelheim: mAb 37.1 (Heider K H., et al <i class="style-scope patent-text">Blood. </i>2011 Oct. 13; 118(15):4159-68)</div>
    <div id="p-0885" num="1011" class="description-paragraph style-scope patent-text">Trubion: CD37-SMIP (G28-1 scFv-lg) ((Zhao X., et al <i class="style-scope patent-text">Blood. </i>2007; 110: 2569-2577)
</div> <ul class="style-scope patent-text"> <li id="ul0122-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0123-0001" num="1012" class="style-scope patent-text">For example, see US20110171208A1 SEQ ID NO: 253</li> </ul> </li> </ul>

    <div id="p-0886" num="1013" class="description-paragraph style-scope patent-text">Immunogen: K7153A (Deckert J., et al <i class="style-scope patent-text">Cancer Res </i>Apr. 15, 2012; 72(8 Supplement): 4625)</div>
    <div id="h-0345" num="0000" class="description-paragraph style-scope patent-text">(73) CD138—SDC1 (Syndecan 1)</div>
    <div id="h-0346" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0887" num="1014" class="description-paragraph style-scope patent-text">Genbank accession no. AJ551176</div>
    <div id="p-0888" num="1015" class="description-paragraph style-scope patent-text">Genbank version no. AJ551176.1 GI: 29243141</div>
    <div id="p-0889" num="1016" class="description-paragraph style-scope patent-text">Genbank record update date: Feb. 1, 2011 12:09 PM</div>
    <div id="h-0347" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0890" num="1017" class="description-paragraph style-scope patent-text">Genbank accession no. CAD80245</div>
    <div id="p-0891" num="1018" class="description-paragraph style-scope patent-text">Genbank version no. CAD80245.1 GI: 29243142</div>
    <div id="p-0892" num="1019" class="description-paragraph style-scope patent-text">Genbank record update date: Feb. 1, 2011 12:09 PM</div>
    <div id="h-0348" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0893" num="1020" class="description-paragraph style-scope patent-text">O'Connell F P., et al <i class="style-scope patent-text">Am J Clin Pathol. </i>2004 February; 121(2):254-63</div>
    <div id="h-0349" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0894" num="1021" class="description-paragraph style-scope patent-text">Official Symbol: SDC1</div>
    <div id="p-0895" num="1022" class="description-paragraph style-scope patent-text">Other Aliases: CD138, SDC, SYND1, syndecan</div>
    <div id="p-0896" num="1023" class="description-paragraph style-scope patent-text">Other Designations: CD138 antigen; heparan sulfate proteoglycan fibroblast growth factor receptor; syndecan proteoglycan 1; syndecan-1</div>
    <div id="h-0350" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-0897" num="1024" class="description-paragraph style-scope patent-text">Biotest: chimerized MAb (nBT062)—(Jagannath S., et al Poster ASH #3060, 2010; WIPO Patent Application WO/2010/128087)
</div> <ul class="style-scope patent-text"> <li id="ul0124-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0125-0001" num="1025" class="style-scope patent-text">For example, see US20090232810 SEQ ID NO: 1 and 2</li> </ul> </li> </ul>

    <div id="p-0898" num="1026" class="description-paragraph style-scope patent-text">Immunogen: B-B4 (Tassone P., et al <i class="style-scope patent-text">Blood </i>104_3688-3696)
</div> <ul class="style-scope patent-text"> <li id="ul0126-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0127-0001" num="1027" class="style-scope patent-text">For example, see US20090175863A1 SEQ ID NO: 1 and 2
<br class="style-scope patent-text">
(74) CD74 (CD74 Molecule, Major Histocompatibility Complex, Class II Invariant Chain)
<br class="style-scope patent-text">
Nucleotide
</li> </ul> </li> </ul>

    <div id="p-0899" num="1028" class="description-paragraph style-scope patent-text">Genbank accession no. NM_004355</div>
    <div id="p-0900" num="1029" class="description-paragraph style-scope patent-text">Genbank version no. NM_004355.1 GI: 343403784</div>
    <div id="p-0901" num="1030" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 23, 2012 02:30 PM</div>
    <div id="h-0351" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0902" num="1031" class="description-paragraph style-scope patent-text">Genbank accession no. NP_004346</div>
    <div id="p-0903" num="1032" class="description-paragraph style-scope patent-text">Genbank version no. NP_004346.1 GI: 10835071</div>
    <div id="p-0904" num="1033" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 23, 2012 02:30 PM</div>
    <div id="h-0352" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0905" num="1034" class="description-paragraph style-scope patent-text">Kudo, J., et al <i class="style-scope patent-text">Nucleic Acids Res. </i>13 (24), 8827-8841 (1985)</div>
    <div id="h-0353" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0906" num="1035" class="description-paragraph style-scope patent-text">Official Symbol: CD74</div>
    <div id="p-0907" num="1036" class="description-paragraph style-scope patent-text">Other Aliases: DHLAG, HLADG, II, Ia-GAMMA</div>
    <div id="p-0908" num="1037" class="description-paragraph style-scope patent-text">Other Designations: CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated); HLA class II histocompatibility antigen gamma chain; HLA-DR antigens-associated invariant chain; HLA-DR-gamma; Ia-associated invariant chain; MHC HLA-DR gamma chain; gamma chain of class II antigens; p33</div>
    <div id="h-0354" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-0909" num="1038" class="description-paragraph style-scope patent-text">Immunomedics: hLL1 (Milatuzumab)—Berkova Z., et al <i class="style-scope patent-text">Expert Opin Investig Drugs. </i>2010 January; 19(1):141-9)
</div> <ul class="style-scope patent-text"> <li id="ul0128-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0129-0001" num="1039" class="style-scope patent-text">For example, see US20040115193 SEQ ID NOs: 19, 20, 21, 22, 23 and 24</li> </ul> </li> </ul>

    <div id="p-0910" num="1040" class="description-paragraph style-scope patent-text">Genmab: HuMax-CD74 (see website)</div>
    <div id="h-0355" num="0000" class="description-paragraph style-scope patent-text">(75) Claudins—CLs (Claudins)</div>
    <div id="h-0356" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0911" num="1041" class="description-paragraph style-scope patent-text">Offner S., et al <i class="style-scope patent-text">Cancer Immunol Immunother. </i>2005 May; 54(5):431-45, Suzuki H., et al <i class="style-scope patent-text">Ann N Y Acad Sci. </i>2012 July; 1258:65-70)</div>
    <div id="p-0912" num="1042" class="description-paragraph style-scope patent-text">In humans, 24 members of the family have been described—see literature reference.</div>
    <div id="h-0357" num="0000" class="description-paragraph style-scope patent-text">(76) EGFR (Epidermal Growth Factor Receptor)</div>
    <div id="h-0358" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0913" num="1043" class="description-paragraph style-scope patent-text">Genbank accession no. NM_005228</div>
    <div id="p-0914" num="1044" class="description-paragraph style-scope patent-text">Genbank version no. NM_005228.3 GI: 41927737</div>
    <div id="p-0915" num="1045" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 30, 2012 01:47 PM</div>
    <div id="h-0359" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0916" num="1046" class="description-paragraph style-scope patent-text">Genbank accession no. NP_005219</div>
    <div id="p-0917" num="1047" class="description-paragraph style-scope patent-text">Genbank version no. NP_005219.2 GI: 29725609</div>
    <div id="p-0918" num="1048" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 30, 2012 01:47 PM</div>
    <div id="h-0360" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0919" num="1049" class="description-paragraph style-scope patent-text">Dhomen N S., et al <i class="style-scope patent-text">Crit Rev Oncog. </i>2012; 17(1):31-50</div>
    <div id="h-0361" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0920" num="1050" class="description-paragraph style-scope patent-text">Official Symbol: EGFR</div>
    <div id="p-0921" num="1051" class="description-paragraph style-scope patent-text">Other Aliases: ERBB, ERBB1, HER1, PIG61, mENA</div>
    <div id="p-0922" num="1052" class="description-paragraph style-scope patent-text">Other Designations: avian erythroblastic leukemia viral (v-erb-b) oncogene homolog; cell growth inhibiting protein 40; cell proliferation-inducing protein 61; proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1</div>
    <div id="h-0362" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-0923" num="1053" class="description-paragraph style-scope patent-text">BMS: Cetuximab (Erbitux)—Broadbridge V T., et al <i class="style-scope patent-text">Expert Rev Anticancer Ther. </i>2012 May; 12(5):555-65.
</div> <ul class="style-scope patent-text"> <li id="ul0130-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0131-0001" num="1054" class="style-scope patent-text">For example, see U.S. Pat. No. 6,217,866—ATTC deposit No. 9764.</li> </ul> </li> </ul>

    <div id="p-0924" num="1055" class="description-paragraph style-scope patent-text">Amgen: Panitumumab (Vectibix)—Argiles G., et al <i class="style-scope patent-text">Future Oncol. </i>2012 April; 8(4):373-89
</div> <ul class="style-scope patent-text"> <li id="ul0132-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0133-0001" num="1056" class="style-scope patent-text">For example, see U.S. Pat. No. 6,235,883 SEQ ID NOs: 23-38.</li> </ul> </li> </ul>

    <div id="p-0925" num="1057" class="description-paragraph style-scope patent-text">Genmab: Zalutumumab—Rivera F., et al <i class="style-scope patent-text">Expert Opin Biol Ther. </i>2009 May; 9(5):667-74.</div>
    <div id="p-0926" num="1058" class="description-paragraph style-scope patent-text">YM Biosciences: Nimotuzumab—Ramakrishnan M S., et al MAbs. 2009 January-February; 1(1):41-8.
</div> <ul class="style-scope patent-text"> <li id="ul0134-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0135-0001" num="1059" class="style-scope patent-text">For example, see U.S. Pat. No. 5,891,996 SEQ ID NOs: 27-34.
<br class="style-scope patent-text">
(77) Her3 (ErbB3)—ERBB3 (v-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog 3 (Avian))
<br class="style-scope patent-text">
Nucleotide
</li> </ul> </li> </ul>

    <div id="p-0927" num="1060" class="description-paragraph style-scope patent-text">Genbank accession no. M34309</div>
    <div id="p-0928" num="1061" class="description-paragraph style-scope patent-text">Genbank version no. M34309.1 GI: 183990</div>
    <div id="p-0929" num="1062" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 08:47 PM</div>
    <div id="h-0363" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0930" num="1063" class="description-paragraph style-scope patent-text">Genbank accession no. AAA35979</div>
    <div id="p-0931" num="1064" class="description-paragraph style-scope patent-text">Genbank version no. AAA35979.1 GI: 306841</div>
    <div id="p-0932" num="1065" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 08:47 PM</div>
    <div id="h-0364" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0933" num="1066" class="description-paragraph style-scope patent-text">Plowman, G. D., et al., <i class="style-scope patent-text">Proc. Natl. Acad. Sci. U.S.A. </i>87 (13), 4905-4909 (1990)</div>
    <div id="h-0365" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0934" num="1067" class="description-paragraph style-scope patent-text">Official Symbol: ERBB3</div>
    <div id="p-0935" num="1068" class="description-paragraph style-scope patent-text">Other Aliases: ErbB-3, HER3, LCCS2, MDA-BF-1, c-erbB-3, c-erbB3, erbB3-S, p180-ErbB3, p45-sErbB3, p85-sErbB3</div>
    <div id="p-0936" num="1069" class="description-paragraph style-scope patent-text">Other Designations: proto-oncogene-like protein c-ErbB-3; receptor tyrosine-protein kinase erbB-3; tyrosine kinase-type cell surface receptor HER3</div>
    <div id="h-0366" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-0937" num="1070" class="description-paragraph style-scope patent-text">Merimack Pharma: MM-121 (Schoeberl B., et al Cancer Res. 2010 Mar. 15; 70(6):2485-2494)
</div> <ul class="style-scope patent-text"> <li id="ul0136-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0137-0001" num="1071" class="style-scope patent-text">For example, see US2011028129 SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7 and 8.
<br class="style-scope patent-text">
(78) RON—MST1R (Macrophage Stimulating I Receptor (c-Met-Related Tyrosine Kinase))
<br class="style-scope patent-text">
Nucleotide
</li> </ul> </li> </ul>

    <div id="p-0938" num="1072" class="description-paragraph style-scope patent-text">Genbank accession no. X70040</div>
    <div id="p-0939" num="1073" class="description-paragraph style-scope patent-text">Genbank version no. X70040.1 GI: 36109</div>
    <div id="p-0940" num="1074" class="description-paragraph style-scope patent-text">Genbank record update date: Feb. 2, 2011 10:17 PM</div>
    <div id="h-0367" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0941" num="1075" class="description-paragraph style-scope patent-text">Genbank accession no. CCA49634</div>
    <div id="p-0942" num="1076" class="description-paragraph style-scope patent-text">Genbank version no. CCA49634.1 GI: 36110</div>
    <div id="p-0943" num="1077" class="description-paragraph style-scope patent-text">Genbank record update date: Feb. 2, 2011 10:17 PM</div>
    <div id="h-0368" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0944" num="1078" class="description-paragraph style-scope patent-text">Ronsin C., et al <i class="style-scope patent-text">Oncogene </i>8 (5), 1195-1202 (1993)</div>
    <div id="h-0369" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0945" num="1079" class="description-paragraph style-scope patent-text">Official Symbol: MST1R</div>
    <div id="p-0946" num="1080" class="description-paragraph style-scope patent-text">Other Aliases: CD136, CDw136, PTK8, RON</div>
    <div id="p-0947" num="1081" class="description-paragraph style-scope patent-text">Other Designations: MSP receptor; MST1R variant RON30; MST1R variant RON62; PTK8 protein tyrosine kinase 8; RON variant E2E3; c-met-related tyrosine kinase; macrophage-stimulating protein receptor; p185-Ron; soluble RON variant 1; soluble RON variant 2; soluble RON variant 3; soluble RONvariant 4</div>
    <div id="h-0370" num="0000" class="description-paragraph style-scope patent-text">(79) EPHA2 (EPH Receptor A2)</div>
    <div id="h-0371" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0948" num="1082" class="description-paragraph style-scope patent-text">Genbank accession no. BC037166</div>
    <div id="p-0949" num="1083" class="description-paragraph style-scope patent-text">Genbank version no. BC037166.2 GI: 33879863</div>
    <div id="p-0950" num="1084" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 6, 2012 01:59 PM</div>
    <div id="h-0372" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0951" num="1085" class="description-paragraph style-scope patent-text">Genbank accession no. AAH37166</div>
    <div id="p-0952" num="1086" class="description-paragraph style-scope patent-text">Genbank version no. AAH37166.1 GI: 22713539</div>
    <div id="p-0953" num="1087" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 6, 2012 01:59 PM</div>
    <div id="h-0373" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0954" num="1088" class="description-paragraph style-scope patent-text">Strausberg R. L., et al <i class="style-scope patent-text">Proc. Natl. Acad. Sci. U.S.A. </i>99 (26), 16899-16903 (2002)</div>
    <div id="h-0374" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0955" num="1089" class="description-paragraph style-scope patent-text">Official Symbol: EPHA2</div>
    <div id="p-0956" num="1090" class="description-paragraph style-scope patent-text">Other Aliases: ARCC2, CTPA, CTPP1, ECK</div>
    <div id="p-0957" num="1091" class="description-paragraph style-scope patent-text">Other Designations: ephrin type-A receptor 2; epithelial cell receptor protein tyrosine kinase; soluble EPHA2 variant 1; tyrosine-protein kinase receptor ECK</div>
    <div id="h-0375" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-0958" num="1092" class="description-paragraph style-scope patent-text">Medimmune: 1C1 (Lee J W., et al <i class="style-scope patent-text">Clin Cancer Res. </i>2010 May 1; 16(9):2562-2570)
</div> <ul class="style-scope patent-text"> <li id="ul0138-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0139-0001" num="1093" class="style-scope patent-text">For example, see US20090304721A1 FIGS. 7 and 8.
<br class="style-scope patent-text">
(80) CD20—MS4A1 (Membrane-Spanning 4-Domains, Subfamily A, Member 1)
<br class="style-scope patent-text">
Nucleotide
</li> </ul> </li> </ul>

    <div id="p-0959" num="1094" class="description-paragraph style-scope patent-text">Genbank accession no. M27394</div>
    <div id="p-0960" num="1095" class="description-paragraph style-scope patent-text">Genbank version no. M27394.1 GI: 179307</div>
    <div id="p-0961" num="1096" class="description-paragraph style-scope patent-text">Genbank record update date: Nov. 30, 2009 11:16 AM</div>
    <div id="h-0376" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0962" num="1097" class="description-paragraph style-scope patent-text">Genbank accession no. AAA35581</div>
    <div id="p-0963" num="1098" class="description-paragraph style-scope patent-text">Genbank version no. AAA35581.1 GI: 179308</div>
    <div id="p-0964" num="1099" class="description-paragraph style-scope patent-text">Genbank record update date: Nov. 30, 2009 11:16 AM</div>
    <div id="h-0377" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0965" num="1100" class="description-paragraph style-scope patent-text">Tedder T. F., et al <i class="style-scope patent-text">Proc. Natl. Acad. Sci. U.S.A. </i>85 (1), 208-212 (1988)</div>
    <div id="h-0378" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0966" num="1101" class="description-paragraph style-scope patent-text">Official Symbol: MS4A1</div>
    <div id="p-0967" num="1102" class="description-paragraph style-scope patent-text">Other Aliases: B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7</div>
    <div id="p-0968" num="1103" class="description-paragraph style-scope patent-text">Other Designations: B-lymphocyte antigen CD20; B-lymphocyte cell-surface antigen B1; CD20 antigen; CD20 receptor; leukocyte surface antigen Leu-16</div>
    <div id="h-0379" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-0969" num="1104" class="description-paragraph style-scope patent-text">Genentech/Roche: Rituximab—Abdulla N E., et al <i class="style-scope patent-text">BioDrugs. </i>2012 Apr. 1; 26(2):71-82.
</div> <ul class="style-scope patent-text"> <li id="ul0140-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0141-0001" num="1105" class="style-scope patent-text">For example, see U.S. Pat. No. 5,736,137, ATCC deposit No. HB-69119.</li> </ul> </li> </ul>

    <div id="p-0970" num="1106" class="description-paragraph style-scope patent-text">GSK/Genmab: Ofatumumab—Nightingale G., et al Ann Pharmacother. 2011 October; 45(10):1248-55.
</div> <ul class="style-scope patent-text"> <li id="ul0142-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0143-0001" num="1107" class="style-scope patent-text">For example, see US20090169550A1 SEQ ID NOs: 2, 4 and 5.</li> </ul> </li> </ul>

    <div id="p-0971" num="1108" class="description-paragraph style-scope patent-text">Immunomedics: Veltuzumab—Goldenberg D M., et al <i class="style-scope patent-text">Leuk Lymphoma. </i>2010 May; 51(5):747-55.
</div> <ul class="style-scope patent-text"> <li id="ul0144-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0145-0001" num="1109" class="style-scope patent-text">For example, see U.S. Pat. No. 7,919,273B2 SEQ ID NOs: 1, 2, 3, 4, 5 and 6.
<br class="style-scope patent-text">
(81) Tenascin C—TNC (Tenascin C)
<br class="style-scope patent-text">
Nucleotide
</li> </ul> </li> </ul>

    <div id="p-0972" num="1110" class="description-paragraph style-scope patent-text">Genbank accession no. NM_002160</div>
    <div id="p-0973" num="1111" class="description-paragraph style-scope patent-text">Genbank version no. NM_002160.3 GI: 340745336</div>
    <div id="p-0974" num="1112" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 23, 2012 02:33 PM</div>
    <div id="h-0380" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0975" num="1113" class="description-paragraph style-scope patent-text">Genbank accession no. NP_002151</div>
    <div id="p-0976" num="1114" class="description-paragraph style-scope patent-text">Genbank version no. NP_002151.2 GI: 153946395</div>
    <div id="p-0977" num="1115" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 23, 2012 02:33 PM</div>
    <div id="h-0381" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0978" num="1116" class="description-paragraph style-scope patent-text">Nies D. E., et al <i class="style-scope patent-text">J. Biol. Chem. </i>266 (5), 2818-2823 (1991); Siri A., et al <i class="style-scope patent-text">Nucleic Acids Res. </i>19 (3), 525-531 (1991)</div>
    <div id="h-0382" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0979" num="1117" class="description-paragraph style-scope patent-text">Official Symbol: TNC</div>
    <div id="p-0980" num="1118" class="description-paragraph style-scope patent-text">Other Aliases: 150-225, GMEM, GP, HXB, JI, TN, TN-C</div>
    <div id="p-0981" num="1119" class="description-paragraph style-scope patent-text">Other Designations: GP 150-225; cytotactin; glioma-associated-extracellular matrix antigen; hexabrachion (tenascin); myotendinous antigen; neuronectin; tenascin; tenascin-C isoform 14/AD1/16</div>
    <div id="h-0383" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-0982" num="1120" class="description-paragraph style-scope patent-text">Philogen: G11 (von Lukowicz T., et al <i class="style-scope patent-text">J Nucl Med. </i>2007 April; 48(4):582-7) and F16 (Pedretti M., et al <i class="style-scope patent-text">Lung Cancer. </i>2009 April; 64(1):28-33)
</div> <ul class="style-scope patent-text"> <li id="ul0146-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0147-0001" num="1121" class="style-scope patent-text">For example, see U.S. Pat. No. 7,968,685 SEQ ID NOs: 29, 35, 45 and 47.
<br class="style-scope patent-text">
(82) FAP (Fibroblast Activation Protein, Alpha)
<br class="style-scope patent-text">
Nucleotide
</li> </ul> </li> </ul>

    <div id="p-0983" num="1122" class="description-paragraph style-scope patent-text">Genbank accession no. U09278</div>
    <div id="p-0984" num="1123" class="description-paragraph style-scope patent-text">Genbank version no. U09278.1 GI: 1888315</div>
    <div id="p-0985" num="1124" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 09:22 AM</div>
    <div id="h-0384" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0986" num="1125" class="description-paragraph style-scope patent-text">Genbank accession no. AAB49652</div>
    <div id="p-0987" num="1126" class="description-paragraph style-scope patent-text">Genbank version no. AAB49652.1 GI: 1888316</div>
    <div id="p-0988" num="1127" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 09:22 AM</div>
    <div id="h-0385" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0989" num="1128" class="description-paragraph style-scope patent-text">Scanlan, M. J., et al <i class="style-scope patent-text">Proc. Natl. Acad. Sci. U.S.A. </i>91 (12), 5657-5661 (1994)</div>
    <div id="h-0386" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-0990" num="1129" class="description-paragraph style-scope patent-text">Official Symbol: FAP</div>
    <div id="p-0991" num="1130" class="description-paragraph style-scope patent-text">Other Aliases: DPPIV, FAPA</div>
    <div id="p-0992" num="1131" class="description-paragraph style-scope patent-text">Other Designations: 170 kDa melanoma membrane-bound gelatinase; integral membrane serine protease; seprase</div>
    <div id="h-0387" num="0000" class="description-paragraph style-scope patent-text">(83) DKK-1 (Dickkopf 1 Homolog (<i class="style-scope patent-text">Xenopus laevis</i>)</div>
    <div id="h-0388" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-0993" num="1132" class="description-paragraph style-scope patent-text">Genbank accession no. NM_012242</div>
    <div id="p-0994" num="1133" class="description-paragraph style-scope patent-text">Genbank version no. NM_012242.2 GI: 61676924</div>
    <div id="p-0995" num="1134" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 30, 2012 01:48 PM</div>
    <div id="h-0389" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-0996" num="1135" class="description-paragraph style-scope patent-text">Genbank accession no. NP_036374</div>
    <div id="p-0997" num="1136" class="description-paragraph style-scope patent-text">Genbank version no. NP_036374.1 GI: 7110719</div>
    <div id="p-0998" num="1137" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 30, 2012 01:48 PM</div>
    <div id="h-0390" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-0999" num="1138" class="description-paragraph style-scope patent-text">Fedi P. et al <i class="style-scope patent-text">J. Biol. Chem. </i>274 (27), 19465-19472 (1999)</div>
    <div id="h-0391" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-1000" num="1139" class="description-paragraph style-scope patent-text">Official Symbol: DKK1</div>
    <div id="p-1001" num="1140" class="description-paragraph style-scope patent-text">Other Aliases: UNQ492/PRO1008, DKK-1, SK</div>
    <div id="p-1002" num="1141" class="description-paragraph style-scope patent-text">Other Designations: dickkopf related protein-1; dickkopf-1 like; dickkopf-like protein 1; dickkopf-related protein 1; hDkk-1</div>
    <div id="h-0392" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-1003" num="1142" class="description-paragraph style-scope patent-text">Novartis: BHQ880 (Fulciniti M., et al <i class="style-scope patent-text">Blood. </i>2009 Jul. 9; 114(2):371-379)
</div> <ul class="style-scope patent-text"> <li id="ul0148-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0149-0001" num="1143" class="style-scope patent-text">For example, see US20120052070A1 SEQ ID NOs: 100 and 108.
<br class="style-scope patent-text">
(84) CD52 (CD52 Molecule)
<br class="style-scope patent-text">
Nucleotide
</li> </ul> </li> </ul>

    <div id="p-1004" num="1144" class="description-paragraph style-scope patent-text">Genbank accession no. NM_001803</div>
    <div id="p-1005" num="1145" class="description-paragraph style-scope patent-text">Genbank version no. NM_001803.2 GI: 68342029</div>
    <div id="p-1006" num="1146" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 30, 2012 01:48 PM</div>
    <div id="h-0393" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-1007" num="1147" class="description-paragraph style-scope patent-text">Genbank accession no. NP_001794</div>
    <div id="p-1008" num="1148" class="description-paragraph style-scope patent-text">Genbank version no. NP_001794.2 GI: 68342030</div>
    <div id="p-1009" num="1149" class="description-paragraph style-scope patent-text">Genbank record update date: Sep. 30, 2012 01:48 PM</div>
    <div id="h-0394" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-1010" num="1150" class="description-paragraph style-scope patent-text">Xia M. Q., et al <i class="style-scope patent-text">Eur. J. Immunol. </i>21 (7), 1677-1684 (1991)</div>
    <div id="h-0395" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-1011" num="1151" class="description-paragraph style-scope patent-text">Official Symbol: CD52</div>
    <div id="p-1012" num="1152" class="description-paragraph style-scope patent-text">Other Aliases: CDW52</div>
    <div id="p-1013" num="1153" class="description-paragraph style-scope patent-text">Other Designations: CAMPATH-1 antigen; CD52 antigen (CAMPATH-1 antigen); CDW52 antigen (CAMPATH-1 antigen); cambridge pathology 1 antigen; epididymal secretory protein E5; he5; human epididymis-specific protein 5</div>
    <div id="h-0396" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-1014" num="1154" class="description-paragraph style-scope patent-text">Alemtuzumab (Campath)—Skoetz N., et al <i class="style-scope patent-text">Cochrane Database Syst Rev. </i>2012 Feb. 15; 2:CD008078.
</div> <ul class="style-scope patent-text"> <li id="ul0150-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0151-0001" num="1155" class="style-scope patent-text">For example, see Drugbank Acc. No. DB00087 (BIOD00109, BTD00109)
<br class="style-scope patent-text">
(85) CS1—SLAMF7 (SLAM Family Member 7)
<br class="style-scope patent-text">
Nucleotide
</li> </ul> </li> </ul>

    <div id="p-1015" num="1156" class="description-paragraph style-scope patent-text">Genbank accession no. NM_021181</div>
    <div id="p-1016" num="1157" class="description-paragraph style-scope patent-text">Genbank version no. NM_021181.3 GI: 1993571</div>
    <div id="p-1017" num="1158" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 29, 2012 11:24 AM</div>
    <div id="h-0397" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-1018" num="1159" class="description-paragraph style-scope patent-text">Genbank accession no. NP_067004</div>
    <div id="p-1019" num="1160" class="description-paragraph style-scope patent-text">Genbank version no. NP_067004.3 GI: 19923572</div>
    <div id="p-1020" num="1161" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 29, 2012 11:24 AM</div>
    <div id="h-0398" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-1021" num="1162" class="description-paragraph style-scope patent-text">Boles K. S., et al <i class="style-scope patent-text">Immunogenetics </i>52 (3-4), 302-307 (2001)</div>
    <div id="h-0399" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-1022" num="1163" class="description-paragraph style-scope patent-text">Official Symbol: SLAMF7</div>
    <div id="p-1023" num="1164" class="description-paragraph style-scope patent-text">Other Aliases: UNQ576/PRO1138, 19A, CD319, CRACC, CS1</div>
    <div id="p-1024" num="1165" class="description-paragraph style-scope patent-text">Other Designations: 19A24 protein; CD2 subset 1; CD2-like receptor activating cytotoxic cells; CD2-like receptor-activating cytotoxic cells; membrane protein FOAP-12; novel LY9 (lymphocyte antigen 9) like protein; protein 19A</div>
    <div id="h-0400" num="0000" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div id="p-1025" num="1166" class="description-paragraph style-scope patent-text">BMS: elotuzumab/HuLuc63 (Benson D M., et al <i class="style-scope patent-text">J Clin Oncol. </i>2012 Jun. 1; 30(16):2013-2015)
</div> <ul class="style-scope patent-text"> <li id="ul0152-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0153-0001" num="1167" class="style-scope patent-text">For example, see US20110206701 SEQ ID NOs: 9, 10, 11, 12, 13, 14, 15 and 16.
<br class="style-scope patent-text">
(86) Endoglin—ENG (Endoglin)
<br class="style-scope patent-text">
Nucleotide
</li> </ul> </li> </ul>

    <div id="p-1026" num="1168" class="description-paragraph style-scope patent-text">Genbank accession no. AF035753</div>
    <div id="p-1027" num="1169" class="description-paragraph style-scope patent-text">Genbank version no. AF035753.1 GI: 3452260</div>
    <div id="p-1028" num="1170" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 10, 2010 06:36 PM</div>
    <div id="h-0401" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-1029" num="1171" class="description-paragraph style-scope patent-text">Genbank accession no. AAC32802</div>
    <div id="p-1030" num="1172" class="description-paragraph style-scope patent-text">Genbank version no. AAC32802.1 GI: 3452261</div>
    <div id="p-1031" num="1173" class="description-paragraph style-scope patent-text">Genbank record update date: Mar. 10, 2010 06:36 PM</div>
    <div id="h-0402" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-1032" num="1174" class="description-paragraph style-scope patent-text">Rius C., et al <i class="style-scope patent-text">Blood </i>92 (12), 4677-4690 (1998)</div>
    <div id="p-1033" num="1175" class="description-paragraph style-scope patent-text">Official Symbol: ENG</div>
    <div id="h-0403" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-1034" num="1176" class="description-paragraph style-scope patent-text">Other Aliases: RP11-228B15.2, CD105, END, HHT1, ORW, ORW1</div>
    <div id="p-1035" num="1177" class="description-paragraph style-scope patent-text">Other Designations: CD105 antigen</div>
    <div id="h-0404" num="0000" class="description-paragraph style-scope patent-text">(87) Annexin A1—ANXA1 (Annexin A1)</div>
    <div id="h-0405" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-1036" num="1178" class="description-paragraph style-scope patent-text">Genbank accession no. X05908</div>
    <div id="p-1037" num="1179" class="description-paragraph style-scope patent-text">Genbank version no. X05908.1 GI: 34387</div>
    <div id="p-1038" num="1180" class="description-paragraph style-scope patent-text">Genbank record update date: Feb. 2, 2011 10:02 AM</div>
    <div id="h-0406" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-1039" num="1181" class="description-paragraph style-scope patent-text">Genbank accession no. CCA29338</div>
    <div id="p-1040" num="1182" class="description-paragraph style-scope patent-text">Genbank version no. CCA29338.1 GI: 34388</div>
    <div id="p-1041" num="1183" class="description-paragraph style-scope patent-text">Genbank record update date: Feb. 2, 2011 10:02 AM</div>
    <div id="h-0407" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-1042" num="1184" class="description-paragraph style-scope patent-text">Wallner B. P., et al <i class="style-scope patent-text">Nature </i>320 (6057), 77-81 (1986)</div>
    <div id="h-0408" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-1043" num="1185" class="description-paragraph style-scope patent-text">Official Symbol: ANXA1</div>
    <div id="p-1044" num="1186" class="description-paragraph style-scope patent-text">Other Aliases: RP11-71A24.1, ANX1, LPC1</div>
    <div id="p-1045" num="1187" class="description-paragraph style-scope patent-text">Other Designations: annexin I (lipocortin I); annexin-1; calpactin II; calpactin-2; chromobindin-9; lipocortin I; p35; phospholipase A2 inhibitory protein</div>
    <div id="h-0409" num="0000" class="description-paragraph style-scope patent-text">(88) V-CAM (CD106)—VCAM1 (Vascular Cell Adhesion Molecule 1)</div>
    <div id="h-0410" num="0000" class="description-paragraph style-scope patent-text">Nucleotide</div>
    <div id="p-1046" num="1188" class="description-paragraph style-scope patent-text">Genbank accession no. M60335</div>
    <div id="p-1047" num="1189" class="description-paragraph style-scope patent-text">Genbank version no. M60335.1 GI: 340193</div>
    <div id="p-1048" num="1190" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 08:56 AM</div>
    <div id="h-0411" num="0000" class="description-paragraph style-scope patent-text">Polypeptide</div>
    <div id="p-1049" num="1191" class="description-paragraph style-scope patent-text">Genbank accession no. AAA61269</div>
    <div id="p-1050" num="1192" class="description-paragraph style-scope patent-text">Genbank version no. AAA61269.1 GI: 340194</div>
    <div id="p-1051" num="1193" class="description-paragraph style-scope patent-text">Genbank record update date: Jun. 23, 2010 08:56 AM</div>
    <div id="h-0412" num="0000" class="description-paragraph style-scope patent-text">Cross-References</div>
    <div id="p-1052" num="1194" class="description-paragraph style-scope patent-text">Hession C., et al <i class="style-scope patent-text">J. Biol. Chem. </i>266 (11), 6682-6685 (1991)</div>
    <div id="h-0413" num="0000" class="description-paragraph style-scope patent-text">Other Information</div>
    <div id="p-1053" num="1195" class="description-paragraph style-scope patent-text">Official Symbol VCAM1</div>
    <div id="p-1054" num="1196" class="description-paragraph style-scope patent-text">Other Aliases: CD106, INCAM-100</div>
    <div id="p-1055" num="1197" class="description-paragraph style-scope patent-text">Other Designations: CD106 antigen; vascular cell adhesion protein 1</div>
    <div id="p-1056" num="1198" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00001" num="00001" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Antibody Sequences</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Anti-Integrin αvβ6</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">RHAB6.2</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 5)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">QVQLVQSGSELKKPGASVKISCKASGFAFTDSYMHWVRQAPGQGLEWMGWIDPENGDT</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">EYAPKFQGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCTRGTPTAVPNLRGDLQVLAQKVA</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">GPYPFDYWGQGTLVTVSS</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">RHCB6.2</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 6)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">QVQLVQSGAEVKKPGASVKVSCKASGYTFIDSYMHWVRQAPGQRLEWMGWIDPENGDT</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">EYAPKFQGRVTITTDTSASTAYMELSSLRSEDTAVYYCARGTPTAVPNLRGDLQVLAQKV</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">AGPYPFDYWGQGTLVTVSS</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">RHF</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 7)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">QVQLVQSGAEVKKPGASVKVSCKASGFNFIDSYMHWVRQAPGQRLEWMGWIDPENGD</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">TEYAPKFQGRVTFTTDTSASTAYMELSSLRSEDTAVYYCNEGTPTGPYYFDYWGQGTLV</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">TVSS</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">RHFB6</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 8)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">QVQLVQSGAEVKKPGASVKVSCKASGFNFIDSYMHWVRQAPGQRLEWMGWDPENGD</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">TEYAPKFQGRVTFTTDTSASTAYMELSSLRSEDTAVYYCNEGTPTAVPNLRGDLQVLAQK</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">VAGPYYFDYWGQGTLVTVSS</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">RHAY100bP</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 9)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">QVQLVQSGSELKKPGASVKISCKASGFAFTDSYMHWVRQAPGQGLEWMGWIDPENGDT</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">EYAPKFQGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCTRGTPTGPYPFDYWGQGTLVTV</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">SS</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">RKF</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 10)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">ENVLTQSPGTLSLSPGERATLSCSASSSVSYMHWFQQKPGQAPRLLIYSTSNLASGIPDR</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">FSGSGSGTDFTLTISRLEPEDFAVYYCQQRSSYPLTFGGGTKVEIK</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">RKFL36L50</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 11)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">ENVLTQSPGTLSLSPGERATLSCSASSSVSYMHWLQQKPGQAPRLLIYLTSNLASGIPDR</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">FSGSGSGTDFTLTISRLEPEDFAVYYCQQRSSYPLTFGGGTKVEIK</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">RKC</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 12)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">EIVLTQSPGTLSLSPGERATLSCSASSSVSYMHWFQQKPGQAPRLLIYSTSNLASGIPDRF</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">SGSGSGTDFTLTISRLEPEDFAVYYCQQRSSYPLTFGGGTKVEIK</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Anti-CD33</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">CD33 Hum195 VH</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 13)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYNMHWVRQAPGQGLEWIGYIYPYNGGT</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">GYNQKFKSKATITADESTNTAYMELSSLRSEDTAVYYCARGRPAMDYWGQGTLVTVSS</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">CD33 Hum195 VK</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 14)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">DIQMTQSPSSLSASVGDRVTITCRASESVDNYGISFMNWFQQKPGKAPKLLIYAASNQGS</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">GVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQSKEVPWTFGQGTKVEIK</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Anti-CD19</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">CD19 B4 resurfaced VH</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 15)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">QVQLVQPGAEVVKPGASVKLSCKTSGYTFTSNWMHWVKQRPGQGLEWIGEIDPSDSYT</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">NYNQNFKGKAKLTVDKSTSTAYMEVSSLRSDDTAVYYCARGSNPYYYAMDYWGQGTSV</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">TVSS</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">CD19 B4 resurfaced VK</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 16)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">EIVLTQSPAIMSASPGERVTMTCSASSGVNYMHWYQQKPGTSPRRWIYDTSKLASGVPA</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">RFSGSGSGTSYSLTISSMEPEDAATYYCHQRGSYTFGGGTKLEIK</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Anti-Her2</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Herceptin VH chain</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 1)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTR</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">YADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVT</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">VSS</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Herceptin VL chain</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 2)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPS</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">RFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Anti-CD25</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Simulect VK (also known as Basiliximab)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 17)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">QIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPA</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">RFSGSGSGTSYSLTISSMEAEDAATYYCHQRSSYTFGGGTKLEIK</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Simulect VH</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 18)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">QLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSY</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">NQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSS</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Anti-PSMA</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Deimmunised VH ‘1</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 19)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">EVQLVQSGPEVKKPGATVKISCKTSGYTFTEYTIHWVKQAPGKGLEWIGNINPNNGGTTY</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">NQKFEDKATLTVDKSTDTAYMELSSLRSEDTAVYYCAAGWNFDYWGQGTLLTVSS</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Deimmunised VK ‘1</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 20)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">DIQMTQSPSSLSTSVGDRVTLTCKASQDVGTAVDWYQQKPGPSPKLLIYWASTRHTGIPS</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">RFSGSGSGTDFTLTISSLQPEDFADYYCQQYNSYPLTFGPGTKVDIK</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Deimmunised VH1 ‘5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 21)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">EVKLVESGGGLVQPGGSMKLSCVASGFTFSNYWMNWVRQAPGKGLEWVAEIRSQSNN</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">FATHYAESVKGRVTISRDDSKSIVYLQMNNLRAEDTGVYYCTRRWNNFWGQGTTVTVSS</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Deimmunised VH2 ‘5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 22)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">EVKLVESGGGLVQPGGSLKLSCVASGFTFSNYWMNWVRQAPGKGLEWVAEIRSQSNNF</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">ATHYAESVKGRVTISRDDSKSIVYLQMNNLRAEDTAVYYCTRRWNNFWGQGTTVTVSS</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Deimmunised VH3 ‘5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 23)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">EVQLVESGGGLVQPGGSLKLSCVASGFTFSNYWMNWVRQAPGKGLEWVAEIRSQSNNF</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">ATHYAESVKGRVTISRDDSKSIVYLQMNNLRAEDTAVYYCTRRWNNFWGQGTTVTVSS</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Deimmunised VH4 ‘5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 24)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">EVQLVESGGGLVQPGGSLKLSCVASGFTFSNYWMNWVRQAPGKGLEWVAEIRSQSNNF</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">ATHYAESVKGRFTISRDDSKSIVYLQMNNLRAEDTAVYYCTRRWNNFWGQGTTVTVSS</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Deimmunised VK1 ‘5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 25)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">NIVMTQFPSSMSASVGDRVTITCKASENVGTYVSWYQQKPDQSPKMLIYGASNRFTGVP</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">DRFTGSGSATDFTLTISSLQTEDLADYYCGQSYTFPYTFGQGTKLEMK</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Deimmunised VK2 ‘5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 26)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">NIVMTQFPSSMSASVGDRVTITCKASENVGTYVSWYQQKPDQSPKMLIYGASNRFTGVP</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">DRFSGSGSGTDFTLTISSLQAEDLADYYCGQSYTFPYTFGQGTKLEIK</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Deimmunised VK3 ‘5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 27)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">NIQMTQFPSAMSASVGDRVTITCKASENVGTYVSWYQQKPDQSPKMLIYGASNRFTGVP</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">DRFSGSGSGTDFTLTISSLQAEDLADYYCGQSYTFPYTFGQGTKLEIK</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Deimmunised VK4 ‘5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 28)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">NIQMTQFPSAMSASVGDRVTITCKASENVGTYVSWYQQKPDQSPKMLIYGASNRFTGVP</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">DRFSGSGSGTDFTLTISSLQAEDEADYYCGQSYTFPYTFGQGTKLEIK</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Deimmunised VK DI ‘5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 29)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">NIVMTQFPKSMSASAGERMTLTCKASENVGTYVSWYQQKPTQSPKMLIYGASNRFTGVP</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">DRFSGSGSGTDFILTISSVQAEDLVDYYCGQSYTFPYTFGGGTKLEMK</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Deimmunised VH DI ‘5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 30)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">EVKLEESGGGLVQPGGSMKISCVASGFTFSNYWMNWVRQSPEKGLEWVAEIRSQSNNF</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">ATHYAESVKGRVIISRDDSKSSVYLQMNSLRAEDTAVYYCTRRWNNFWGQGTTVTVSS</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Humanised RHA ‘5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 31)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">EVQLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNWVRQASGKGLEWVGEIRSQSNNF</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">ATHYAESVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCTRRWNNFWGQGTTVTVSS</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Humanised RHB ‘5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 32)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">EVKLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNVVVRQASGKGLEWVAEIRSQSNNF</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">ATHYAESVKGRVIISRDDSKNTVYLQMNSLRTEDTAVYYCTRRWNNFWGQGTTVTVSS</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Humanised RHC ‘5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 33)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">EVQLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNVWRQASGKGLEVVVAEIRSQSNNF</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">ATHYAESVKGRVIISRDDSKNTVYLQMNSLRTEDTAVYYCTRRWNNFWGQGTTVTVSS</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Humanised RHD ‘5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 34)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">EVKLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNVWRQASGKGLEWVGEIRSQSNNF</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">ATHYAESVKGRVIISRDDSKNTVYLQMNSLRTEDTAVYYCTRRWNNFWGQGTTVTVSS</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Humanised RHE ‘5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 35)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">EVKLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNVWRQASGKGLEWVAEIRSQSNNF</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">ATHYAESVKGRFTISRDDSKNTVYLQMNSLRTEDTAVYYCTRRWNNFWGQGTTVTVSS</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Humanised RHF ‘5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 36)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">EVKLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNVWRQASGKGLEWVAEIRSQSNNF</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">ATHYAESVKGRVIISRDDSKNTAYLQMNSLRTEDTAVYYCTRRWNNFWGQGTTVTVSS</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Humanised RHG ‘5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 37)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">EVKLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNVWRQASGKGLEWVAEIRSQSNNF</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">ATHYAESVKGRVIISRDDSKNTAYLQMNSLRTEDTAVYYCTRRWNNFWGQGTTVTVSS</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Humanised RKA ‘5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 38)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">DIQMTQSPSSVSASVGDRVTITCKASENVGTYVSWYQQKPGTAPKLLIYGASNRFTGVPS</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">RFSGSGSATDFTLTINNLQPEDFATYYCGQSYTFPYTFGQGTKVEIK</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Humanised RKB ‘5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 39)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">DIQMTQSPSSVSASVGDRVTITCKASENVGTYVSWYQQKPGTAPKLLIYGASNRFTGVPS</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">RFSGSGSATDFTLTINNLQPEDFATYYCGQSYTFPYTFGQGTKVEIK</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Humanised RKC ‘5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 40)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">DIQMTQSPSSVSASVGDRVTITCKASENVGTYVSWYQQKPGTAPKMLIYGASNRFTGVPS</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">RFSGSGSATDFTLTINNLQPEDFATYYCGQSYTFPYTFGQGTKVEIK</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Humanised RKD ‘5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 41)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">DIQMTQSPSSVSASVGDRVTITCKASENVGTYVSWYQQKPGTAPKMLIYGASNRFTGVPS</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">RFSGSGSATDFTLTINNLQPEDFATYYCGQSYTFPYTFGQGTKVEIK</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Humanised RKE ‘5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 42)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">NIVMTQSPSSVSASVGDRVTITCKASENVGTYVSWYQQKPGTAPKLLIYGASNRFTGVPD</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">RFTGSGSATDFILTINNLQPEDFATYYCGQSYTFPYTFGQGTKVEIK</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Humanised RKF ‘5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 43)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">NIVMTQSPSSVSASVGDRVTITCKASENVGTYVSWYQQKPGTAPKMLIYGASNRFTGVPS</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">RFSGSGSATDFILTINNLQPEDFATYYCGQSYTFPYTFGQGTKVEIK</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Humanised RKG ‘5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(SEQ ID NO: 44)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">NIVMTQSPSSVSASVGDRVTITCKASENVGTYVSWYQQKPGTAPKMLIYGASNRFTGVPD</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">RFTGSGSATDFTLTINNLQPEDFATYYCGQSYTFPYTFGQGTKVEIK</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <div id="p-1057" num="1199" class="description-paragraph style-scope patent-text">The parent antibody may also be a fusion protein comprising an albumin-binding peptide (ABP) sequence (Dennis et al. (2002) “Albumin Binding As A General Strategy For Improving The Pharmacokinetics Of Proteins” <i class="style-scope patent-text">J Biol Chem. </i>277:35035-35043; WO 01/45746). Antibodies of the invention include fusion proteins with ABP sequences taught by: (i) Dennis et al (2002) <i class="style-scope patent-text">J Biol Chem. </i>277:35035-35043 at Tables III and IV, page 35038; (ii) US 2004/0001827 at [0076]; and (iii) WO 01/45746 at pages 12-13, and all of which are incorporated herein by reference.</div>
    <div id="p-1058" num="1200" class="description-paragraph style-scope patent-text">In one embodiment, the antibody has been raised to target specific the tumour related antigen α<sub class="style-scope patent-text">v</sub>β<sub class="style-scope patent-text">6</sub>.</div>
    <div id="p-1059" num="1201" class="description-paragraph style-scope patent-text">The cell binding agent may be labelled, for example to aid detection or purification of the agent either prior to incorporation as a conjugate, or as part of the conjugate. The label may be a biotin label. In another embodiment, the cell binding agent may be labelled with a radioisotope.</div>
    <div id="h-0414" num="0000" class="description-paragraph style-scope patent-text">Connection of Linker Unit to Ligand Unit</div>
    <div id="p-1060" num="1202" class="description-paragraph style-scope patent-text">The Ligand unit is connected to the Linker unit through a disulfide bond.</div>
    <div id="p-1061" num="1203" class="description-paragraph style-scope patent-text">In one embodiment, the connection between the Ligand unit and the Drug Linker is formed between a thiol group of a cysteine residue of the Ligand unit and a maleimide group of the Drug Linker unit.</div>
    <div id="p-1062" num="1204" class="description-paragraph style-scope patent-text">The cysteine residues of the Ligand unit may be available for reaction with the functional group of the Linker unit to form a connection. In other embodiments, for example where the Ligand unit is an antibody, the thiol groups of the antibody may participate in interchain disulfide bonds. These interchain bonds may be converted to free thiol groups by e.g. treatment of the antibody with DTT prior to reaction with the functional group of the Linker unit.</div>
    <div id="p-1063" num="1205" class="description-paragraph style-scope patent-text">In some embodiments, the cysteine residue is an introduced into the heavy or light chain of an antibody. Positions for cysteine insertion by substitution in antibody heavy or light chains include those described in Published U.S. Application No. 2007-0092940 and International Patent Publication WO2008070593, which are incorporated herein.</div>
    <div id="h-0415" num="0000" class="description-paragraph style-scope patent-text">Methods of Treatment</div>
    <div id="p-1064" num="1206" class="description-paragraph style-scope patent-text">The compounds of the present invention may be used in a method of therapy. Also provided is a method of treatment, comprising administering to a subject in need of treatment a therapeutically-effective amount of a conjugate of formula II. The term “therapeutically effective amount” is an amount sufficient to show benefit to a patient. Such benefit may be at least amelioration of at least one symptom. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage, is within the responsibility of general practitioners and other medical doctors.</div>
    <div id="p-1065" num="1207" class="description-paragraph style-scope patent-text">A conjugate may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated. Examples of treatments and therapies include, but are not limited to, chemotherapy (the administration of active agents, including, e.g. drugs; surgery; and radiation therapy.</div>
    <div id="p-1066" num="1208" class="description-paragraph style-scope patent-text">Pharmaceutical compositions according to the present invention, and for use in accordance with the present invention, may comprise, in addition to the active ingredient, i.e. a conjugate of formula I, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material will depend on the route of administration, which may be oral, or by injection, e.g. cutaneous, subcutaneous, or intravenous.</div>
    <div id="p-1067" num="1209" class="description-paragraph style-scope patent-text">Pharmaceutical compositions for oral administration may be in tablet, capsule, powder or liquid form. A tablet may comprise a solid carrier or an adjuvant. Liquid pharmaceutical compositions generally comprise a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included. A capsule may comprise a solid carrier such a gelatin.</div>
    <div id="p-1068" num="1210" class="description-paragraph style-scope patent-text">For intravenous, cutaneous or subcutaneous injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.</div>
    <div id="p-1069" num="1211" class="description-paragraph style-scope patent-text">The Conjugates can be used to treat proliferative disease and autoimmune disease. The term “proliferative disease” pertains to an unwanted or uncontrolled cellular proliferation of excessive or abnormal cells which is undesired, such as, neoplastic or hyperplastic growth, whether in vitro or in vivo.</div>
    <div id="p-1070" num="1212" class="description-paragraph style-scope patent-text">Examples of proliferative conditions include, but are not limited to, benign, pre-malignant, and malignant cellular proliferation, including but not limited to, neoplasms and tumours (e.g., histocytoma, glioma, astrocyoma, osteoma), cancers (e.g. lung cancer, small cell lung cancer, gastrointestinal cancer, bowel cancer, colon cancer, breast carinoma, ovarian carcinoma, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, pancreatic cancer, brain cancer, sarcoma, osteosarcoma, Kaposi's sarcoma, melanoma), leukemias, psoriasis, bone diseases, fibroproliferative disorders (e.g. of connective tissues), and atherosclerosis. Other cancers of interest include, but are not limited to, haematological; malignancies such as leukemias and lymphomas, such as non-Hodgkin lymphoma, and subtypes such as DLBCL, marginal zone, mantle zone, and follicular, Hodgkin lymphoma, AML, and other cancers of B or T cell origin.</div>
    <div id="p-1071" num="1213" class="description-paragraph style-scope patent-text">Examples of autoimmune disease include the following: rheumatoid arthritis, autoimmune demyelinative diseases (e.g., multiple sclerosis, allergic encephalomyelitis), psoriatic arthritis, endocrine ophthalmopathy, uveoretinitis, systemic lupus erythematosus, myasthenia gravis, Graves' disease, glomerulonephritis, autoimmune hepatological disorder, inflammatory bowel disease (e.g., Crohn's disease), anaphylaxis, allergic reaction, Sjögren's syndrome, type I diabetes mellitus, primary biliary cirrhosis, Wegener's granulomatosis, fibromyalgia, polymyositis, dermatomyositis, multiple endocrine failure, Schmidt's syndrome, autoimmune uveitis, Addison's disease, adrenalitis, thyroiditis, Hashimoto's thyroiditis, autoimmune thyroid disease, pernicious anemia, gastric atrophy, chronic hepatitis, lupoid hepatitis, atherosclerosis, subacute cutaneous lupus erythematosus, hypoparathyroidism, Dressler's syndrome, autoimmune thrombocytopenia, idiopathic thrombocytopenic purpura, hemolytic anemia, pemphigus vulgaris, pemphigus, dermatitis herpetiformis, alopecia arcata, pemphigoid, scleroderma, progressive systemic sclerosis, CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia), male and female autoimmune infertility, ankylosing spondolytis, ulcerative colitis, mixed connective tissue disease, polyarteritis nedosa, systemic necrotizing vasculitis, atopic dermatitis, atopic rhinitis, Goodpasture's syndrome, Chagas' disease, sarcoidosis, rheumatic fever, asthma, recurrent abortion, anti-phospholipid syndrome, farmer's lung, erythema multiforme, post cardiotomy syndrome, Cushing's syndrome, autoimmune chronic active hepatitis, bird-fancier's lung, toxic epidermal necrolysis, Alport's syndrome, alveolitis, allergic alveolitis, fibrosing alveolitis, interstitial lung disease, erythema nodosum, pyoderma gangrenosum, transfusion reaction, Takayasu's arteritis, polymyalgia rheumatica, temporal arteritis, schistosomiasis, giant cell arteritis, ascariasis, aspergillosis, Sampter's syndrome, eczema, lymphomatoid granulomatosis, Behcet's disease, Caplan's syndrome, Kawasaki's disease, dengue, encephalomyelitis, endocarditis, endomyocardial fibrosis, endophthalmitis, erythema elevatum et diutinum, psoriasis, erythroblastosis fetalis, eosinophilic faciitis, Shulman's syndrome, Felty's syndrome, filariasis, cyclitis, chronic cyclitis, heterochronic cyclitis, Fuch's cyclitis, IgA nephropathy, Henoch-Schonlein purpura, graft versus host disease, transplantation rejection, cardiomyopathy, Eaton-Lambert syndrome, relapsing polychondritis, cryoglobulinemia, Waldenstrom's macroglobulemia, Evan's syndrome, and autoimmune gonadal failure.</div>
    <div id="p-1072" num="1214" class="description-paragraph style-scope patent-text">In some embodiments, the autoimmune disease is a disorder of B lymphocytes (e.g., systemic lupus erythematosus, Goodpasture's syndrome, rheumatoid arthritis, and type I diabetes), Th1-lymphocytes (e.g., rheumatoid arthritis, multiple sclerosis, psoriasis, Sjögren's syndrome, Hashimoto's thyroiditis, Graves' disease, primary biliary cirrhosis, Wegener's granulomatosis, tuberculosis, or graft versus host disease), or Th2-lymphocytes (e.g., atopic dermatitis, systemic lupus erythematosus, atopic asthma, rhinoconjunctivitis, allergic rhinitis, Omenn's syndrome, systemic sclerosis, or chronic graft versus host disease). Generally, disorders involving dendritic cells involve disorders of Th1-lymphocytes or Th2-lymphocytes. In some embodiments, the autoimmunie disorder is a T cell-mediated immunological disorder.</div>
    <div id="p-1073" num="1215" class="description-paragraph style-scope patent-text">In some embodiments, the amount of the Conjugate administered ranges from about 0.01 to about 10 mg/kg per dose. In some embodiments, the amount of the Conjugate administered ranges from about 0.01 to about 5 mg/kg per dose. In some embodiments, the amount of the Conjugate administered ranges from about 0.05 to about 5 mg/kg per dose. In some embodiments, the amount of the Conjugate administered ranges from about 0.1 to about 5 mg/kg per dose. In some embodiments, the amount of the Conjugate administered ranges from about 0.1 to about 4 mg/kg per dose. In some embodiments, the amount of the Conjugate administered ranges from about 0.05 to about 3 mg/kg per dose. In some embodiments, the amount of the Conjugate administered ranges from about 0.1 to about 3 mg/kg per dose. In some embodiments, the amount of the Conjugate administered ranges from about 0.1 to about 2 mg/kg per dose.</div>
    <div id="h-0416" num="0000" class="description-paragraph style-scope patent-text">Drug Loading</div>
    <div id="p-1074" num="1216" class="description-paragraph style-scope patent-text">The drug loading (p) is the average number of PBD drugs per cell binding agent, e.g. antibody. Where the compounds of the invention are bound to cysteines, drug loading may range from 1 to 8 drugs (D) per cell binding agent, i.e. where 1, 2, 3, 4, 5, 6, 7, and 8 drug moieties are covalently attached to the cell binding agent. Compositions of conjugates include collections of cell binding agents, e.g. antibodies, conjugated with a range of drugs, from 1 to 8. Where the compounds of the invention are bound to lysines, drug loading may range from 1 to 80 drugs (D) per cell binding agent, although an upper limit of 40, 20, 10 or 8 may be preferred. Compositions of conjugates include collections of cell binding agents, e.g. antibodies, conjugated with a range of drugs, from 1 to 80, 1 to 40, 1 to 20, 1 to 10 or 1 to 8.</div>
    <div id="p-1075" num="1217" class="description-paragraph style-scope patent-text">The average number of drugs per antibody in preparations of ADC from conjugation reactions may be characterized by conventional means such as UV, reverse phase HPLC, HIC, mass spectroscopy, ELISA assay, and electrophoresis. The quantitative distribution of ADC in terms of p may also be determined. By ELISA, the averaged value of p in a particular preparation of ADC may be determined (Hamblett et al (2004) Clin. Cancer Res. 10:7063-7070; Sanderson et al (2005) Clin. Cancer Res. 11:843-852). However, the distribution of p (drug) values is not discernible by the antibody-antigen binding and detection limitation of ELISA. Also, ELISA assay for detection of antibody-drug conjugates does not determine where the drug moieties are attached to the antibody, such as the heavy chain or light chain fragments, or the particular amino acid residues. In some instances, separation, purification, and characterization of homogeneous ADC where p is a certain value from ADC with other drug loadings may be achieved by means such as reverse phase HPLC or electrophoresis. Such techniques are also applicable to other types of conjugates.</div>
    <div id="p-1076" num="1218" class="description-paragraph style-scope patent-text">For some antibody-drug conjugates, p may be limited by the number of attachment sites on the antibody. For example, an antibody may have only one or several cysteine thiol groups, or may have only one or several sufficiently reactive thiol groups through which a linker may be attached. Higher drug loading, e.g. p&gt;5, may cause aggregation, insolubility, toxicity, or loss of cellular permeability of certain antibody-drug conjugates.</div>
    <div id="p-1077" num="1219" class="description-paragraph style-scope patent-text">Typically, fewer than the theoretical maximum of drug moieties are conjugated to an antibody during a conjugation reaction. An antibody may contain, for example, many lysine residues that do not react with the Drug Linker. Only the most reactive lysine groups may react with an amine-reactive linker reagent. Also, only the most reactive cysteine thiol groups may react with a thiol-reactive linker reagent. Generally, antibodies do not contain many, if any, free and reactive cysteine thiol groups which may be linked to a drug moiety. Most cysteine thiol residues in the antibodies of the compounds exist as disulfide bridges and must be reduced with a reducing agent such as dithiothreitol (DTT) or TCEP, under partial or total reducing conditions. The loading (drug/antibody ratio) of an ADC may be controlled in several different manners, including: (i) limiting the molar excess of Drug Linker relative to antibody, (ii) limiting the conjugation reaction time or temperature, and (iii) partial or limiting reductive conditions for cysteine thiol modification.</div>
    <div id="p-1078" num="1220" class="description-paragraph style-scope patent-text">Certain antibodies have reducible interchain disulfides, i.e. cysteine bridges. Antibodies may be made reactive for conjugation with linker reagents by treatment with a reducing agent such as DTT (dithiothreitol). Each cysteine bridge will thus form, theoretically, two reactive thiol nucleophiles. Additional nucleophilic groups can be introduced into antibodies through the reaction of lysines with 2-iminothiolane (Traut's reagent) resulting in conversion of an amine into a thiol. Reactive thiol groups may be introduced into the antibody (or fragment thereof) by engineering one, two, three, four, or more cysteine residues (e.g., preparing mutant antibodies comprising one or more non-native cysteine amino acid residues). U.S. Pat. No. 7,521,541 teaches engineering antibodies by introduction of reactive cysteine amino acids.</div>
    <div id="p-1079" num="1221" class="description-paragraph style-scope patent-text">Cysteine amino acids may be engineered at reactive sites in an antibody and which do not form intrachain or intermolecular disulfide linkages (Junutula, et al., 2008b Nature Biotech., 26(8):925-932; Dornan et al (2009) Blood 114(13):2721-2729; U.S. Pat. Nos. 7,521,541; 7,723,485; WO2009/052249). The engineered cysteine thiols may react with linker reagents or the drug-linker reagents of the present invention which have thiol-reactive, electrophilic groups such as maleimide or alpha-halo amides to form ADC with cysteine engineered antibodies and the PBD drug moieties. The location of the drug moiety can thus be designed, controlled, and known. The drug loading can be controlled since the engineered cysteine thiol groups typically react with thiol-reactive linker reagents or drug-linker reagents in high yield. Engineering an IgG antibody to introduce a cysteine amino acid by substitution at a single site on the heavy or light chain gives two new cysteines on the symmetrical antibody. A drug loading near 2 can be achieved with near homogeneity of the conjugation product ADC.</div>
    <div id="p-1080" num="1222" class="description-paragraph style-scope patent-text">Where more than one nucleophilic or electrophilic group of the antibody reacts with a drug-linker intermediate, or linker reagent followed by drug moiety reagent, then the resulting product is a mixture of ADC compounds with a distribution of drug moieties attached to an antibody, e.g. 1, 2, 3, etc. Liquid chromatography methods such as polymeric reverse phase (PLRP) and hydrophobic interaction (HIC) may separate compounds in the mixture by drug loading value. Preparations of ADC with a single drug loading value (p) may be isolated, however, these single loading value ADCs may still be heterogeneous mixtures because the drug moieties may be attached, via the linker, at different sites on the antibody.</div>
    <div id="p-1081" num="1223" class="description-paragraph style-scope patent-text">Thus the antibody-drug conjugate compositions of the invention include mixtures of antibody-drug conjugate compounds where the antibody has one or more PBD drug moieties and where the drug moieties may be attached to the antibody at various amino acid residues.</div>
    <div id="p-1082" num="1224" class="description-paragraph style-scope patent-text">In one embodiment, the average number of dimer pyrrolobenzodiazepine groups per cell binding agent is in the range 1 to 20. In some embodiments the range is selected from 1 to 8, 2 to 8, 2 to 6, 2 to 4, and 4 to 8.</div>
    <div id="p-1083" num="1225" class="description-paragraph style-scope patent-text">In some embodiments, there is one dimer pyrrolobenzodiazepine group per cell binding agent.</div>
    <div id="h-0417" num="0000" class="description-paragraph style-scope patent-text">General Synthetic Routes</div>
    <div id="p-1084" num="1226" class="description-paragraph style-scope patent-text">The synthesis of PBD compounds is extensively discussed in the following references, which discussions are incorporated herein by reference:
</div> <ul class="style-scope patent-text"> <li id="ul0154-0001" num="1227" class="style-scope patent-text">a) WO 00/12508 (pages 14 to 30);</li> <li id="ul0154-0002" num="1228" class="style-scope patent-text">b) WO 2005/023814 (pages 3 to 10);</li> <li id="ul0154-0003" num="1229" class="style-scope patent-text">c) WO 2004/043963 (pages 28 to 29); and</li> <li id="ul0154-0004" num="1230" class="style-scope patent-text">d) WO 2005/085251 (pages 30 to 39).
<br class="style-scope patent-text">
Synthesis Route
</li> </ul>

    <div id="p-1085" num="1231" class="description-paragraph style-scope patent-text">Compounds of the present invention of formula I where R<sup class="style-scope patent-text">20 </sup>and R<sup class="style-scope patent-text">21 </sup>form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound can be synthesised from a compound of Formula II:</div>
    <div id="p-1086" num="1232" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00023" num="00023" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/b1/17/1d/b103564008d8fe/US11370801-20220628-C00023.png" class="style-scope patent-text"><img id="EMI-C00023" he="39.20mm" wi="75.95mm" file="US11370801-20220628-C00023.TIF" alt="Figure US11370801-20220628-C00023" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="304" height="157" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/b1/17/1d/b103564008d8fe/US11370801-20220628-C00023.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00023" attachment-type="cdx" file="US11370801-20220628-C00023.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00023" attachment-type="mol" file="US11370801-20220628-C00023.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
where R<sup class="style-scope patent-text">6</sup>, R<sup class="style-scope patent-text">7</sup>, R<sup class="style-scope patent-text">9</sup>, R<sup class="style-scope patent-text">6′</sup>, R<sup class="style-scope patent-text">7′</sup>, R<sup class="style-scope patent-text">9′</sup>, R<sup class="style-scope patent-text">11b</sup>, Y, Y′ and R″ are as defined for compounds of formula I, and R<sup class="style-scope patent-text">LL </sup>is a precursor of R<sup class="style-scope patent-text">L</sup>—this method is particularly applicable to compounds of formula I where R<sup class="style-scope patent-text">L </sup>is of formula IIIa. For these compounds, R<sup class="style-scope patent-text">LL </sup>will typically be a portion of R<sup class="style-scope patent-text">L</sup>, such as a group of formula IIIa′:
</div>
    <div id="p-1087" num="1233" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00024" num="00024" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/c5/28/35/d5f884a0160bb1/US11370801-20220628-C00024.png" class="style-scope patent-text"><img id="EMI-C00024" he="26.92mm" wi="69.93mm" file="US11370801-20220628-C00024.TIF" alt="Figure US11370801-20220628-C00024" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="108" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/c5/28/35/d5f884a0160bb1/US11370801-20220628-C00024.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00024" attachment-type="cdx" file="US11370801-20220628-C00024.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00024" attachment-type="mol" file="US11370801-20220628-C00024.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
In such as case, the reaction involves adding the group G<sup class="style-scope patent-text">L</sup>. The second required step is removal of the Prot<sup class="style-scope patent-text">O </sup>group.
</div>
    <div id="p-1088" num="1234" class="description-paragraph style-scope patent-text">The compounds of Formula 2 may be made by deprotecting the R<sup class="style-scope patent-text">LL </sup>group of compounds of Formula 3:</div>
    <div id="p-1089" num="1235" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00025" num="00025" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/35/35/d9/358cadaedbb276/US11370801-20220628-C00025.png" class="style-scope patent-text"><img id="EMI-C00025" he="39.20mm" wi="75.95mm" file="US11370801-20220628-C00025.TIF" alt="Figure US11370801-20220628-C00025" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="304" height="157" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/35/35/d9/358cadaedbb276/US11370801-20220628-C00025.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00025" attachment-type="cdx" file="US11370801-20220628-C00025.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00025" attachment-type="mol" file="US11370801-20220628-C00025.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
where R<sup class="style-scope patent-text">6</sup>, R<sup class="style-scope patent-text">7</sup>, R<sup class="style-scope patent-text">9</sup>, R<sup class="style-scope patent-text">6′</sup>, R<sup class="style-scope patent-text">7′</sup>, R<sup class="style-scope patent-text">9′</sup>, R<sup class="style-scope patent-text">11b</sup>, Y, Y′ and R″ are as defined for compounds of formula I, R<sup class="style-scope patent-text">LL-Prot </sup>is a protected version of R<sup class="style-scope patent-text">LL</sup>, and the Prot<sup class="style-scope patent-text">N </sup>represents a simple nitrogen protecting group (e.g. Fmoc, Boc) that is orthogonal to the R<sup class="style-scope patent-text">LL </sup>protecting group.
</div>
    <div id="p-1090" num="1236" class="description-paragraph style-scope patent-text">Compounds of formula 3 may be made by ring-closure of compounds of Formula 4:</div>
    <div id="p-1091" num="1237" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00026" num="00026" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/af/83/fd/e2d777dbe85a62/US11370801-20220628-C00026.png" class="style-scope patent-text"><img id="EMI-C00026" he="39.12mm" wi="75.78mm" file="US11370801-20220628-C00026.TIF" alt="Figure US11370801-20220628-C00026" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="156" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/af/83/fd/e2d777dbe85a62/US11370801-20220628-C00026.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00026" attachment-type="cdx" file="US11370801-20220628-C00026.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00026" attachment-type="mol" file="US11370801-20220628-C00026.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
where the ring closure is carried out by oxidation, e.g. Swern.
</div>
    <div id="p-1092" num="1238" class="description-paragraph style-scope patent-text">Compounds of formula 4 can be synthesised from compounds of formula 5:</div>
    <div id="p-1093" num="1239" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00027" num="00027" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/2b/9b/40/b7dc986db96833/US11370801-20220628-C00027.png" class="style-scope patent-text"><img id="EMI-C00027" he="30.40mm" wi="75.95mm" file="US11370801-20220628-C00027.TIF" alt="Figure US11370801-20220628-C00027" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="304" height="122" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/2b/9b/40/b7dc986db96833/US11370801-20220628-C00027.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00027" attachment-type="cdx" file="US11370801-20220628-C00027.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00027" attachment-type="mol" file="US11370801-20220628-C00027.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
by a step-wise addition of two protecting groups. This can be achieved by simple protection of the amino group which will result in the imino bond in the final compound (e.g. by Fmoc, Boc), followed by installation of a desired protecting group at the other amino group.
</div>
    <div id="p-1094" num="1240" class="description-paragraph style-scope patent-text">Compounds of formula I where R<sup class="style-scope patent-text">L </sup>is of formula IIIb, may be synthesised in a similar manner, although the complete R<sup class="style-scope patent-text">L </sup>group may be installed starting from a compound of Formula 5, rather than with the use of a protected precursor.</div>
    <div id="p-1095" num="1241" class="description-paragraph style-scope patent-text">Compounds of Formula 5 can be synthesised by known methods, such as those disclosed in WO 2011/130598.</div>
    <div id="p-1096" num="1242" class="description-paragraph style-scope patent-text">Alternatively, compounds of Formula 4 can be synthesised by a monomeric route, as shown in example 3.</div>
    <div id="p-1097" num="1243" class="description-paragraph style-scope patent-text">Compounds of the present invention of formula I where R<sup class="style-scope patent-text">20 </sup>and R<sup class="style-scope patent-text">21 </sup>do not form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound can by made by modifications to the above routes.</div>
    <div id="h-0418" num="0000" class="description-paragraph style-scope patent-text">Synthesis of Drug Conjugates</div>
    <div id="p-1098" num="1244" class="description-paragraph style-scope patent-text">Conjugates can be prepared as previously described. Antibodies can be conjugated to the Drug Linker compound as described in Doronina et al., Nature Biotechnology, 2003, 21, 778-784). Briefly, antibodies (4-5 mg/mL) in PBS containing 50 mM sodium borate at pH 7.4 are reduced with tris(carboxyethyl)phosphine hydrochloride (TCEP) at 37° C. The progress of the reaction, which reduces interchain disulfides, is monitored by reaction with 5,5′-dithiobis(2-nitrobenzoic acid) and allowed to proceed until the desired level of thiols/mAb is achieved. The reduced antibody is then cooled to 0° C. and alkylated with 1.5 equivalents of maleimide drug-linker per antibody thiol. After 1 hour, the reaction is quenched by the addition of 5 equivalents of N-acetyl cysteine. Quenched drug-linker is removed by gel filtration over a PD-10 column. The ADC is then sterile-filtered through a 0.22 μm syringe filter. Protein concentration can be determined by spectral analysis at 280 nm and 329 nm, respectively, with correction for the contribution of drug absorbance at 280 nm. Size exclusion chromatography can be used to determine the extent of antibody aggregation, and RP-HPLC can be used to determine the levels of remaining NAC-quenched drug-linker.</div>
    <div id="h-0419" num="0000" class="description-paragraph style-scope patent-text">Further Preferences</div>
    <div id="p-1099" num="1245" class="description-paragraph style-scope patent-text">The following preferences may apply to all aspects of the invention as described above, or may relate to a single aspect. The preferences may be combined together in any combination.</div>
    <div id="p-1100" num="1246" class="description-paragraph style-scope patent-text">In some embodiments, R<sup class="style-scope patent-text">6′</sup>, R<sup class="style-scope patent-text">7′</sup>, R<sup class="style-scope patent-text">9′</sup>, and Y′ are selected from the same groups as R<sup class="style-scope patent-text">6</sup>, R<sup class="style-scope patent-text">7</sup>, R<sup class="style-scope patent-text">9</sup>, and Y respectively. In some of these embodiments, R<sup class="style-scope patent-text">6′</sup>, R<sup class="style-scope patent-text">7′</sup>, R<sup class="style-scope patent-text">9′</sup>, and Y′ are the same as R<sup class="style-scope patent-text">6</sup>, R<sup class="style-scope patent-text">7</sup>, R<sup class="style-scope patent-text">9</sup>, and Y respectively.</div>
    <div id="h-0420" num="0000" class="description-paragraph style-scope patent-text">N10′-C11′</div>
    <div id="p-1101" num="1247" class="description-paragraph style-scope patent-text">In some embodiment, R<sup class="style-scope patent-text">20 </sup>is H, and R<sup class="style-scope patent-text">21 </sup>is OH, OR<sup class="style-scope patent-text">A</sup>, where R<sup class="style-scope patent-text">A </sup>is C<sub class="style-scope patent-text">1-4 </sub>alkyl. In some of these embodiments, R<sup class="style-scope patent-text">21 </sup>is OH. In others of these embodiments, R<sup class="style-scope patent-text">21 </sup>is OR<sup class="style-scope patent-text">A</sup>, where R<sup class="style-scope patent-text">A </sup>is C<sub class="style-scope patent-text">1-4 </sub>alkyl. In some of these embodiments, R<sup class="style-scope patent-text">A </sup>is methyl.</div>
    <div id="p-1102" num="1248" class="description-paragraph style-scope patent-text">In some embodiments, R<sup class="style-scope patent-text">20 </sup>and R<sup class="style-scope patent-text">21 </sup>form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound.</div>
    <div id="p-1103" num="1249" class="description-paragraph style-scope patent-text">In some embodiments, R<sup class="style-scope patent-text">20 </sup>is H and R<sup class="style-scope patent-text">21 </sup>is SO<sub class="style-scope patent-text">z</sub>M, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation. In some of these embodiments, M is a monovalent pharmaceutically acceptable cation, and may be Na<sup class="style-scope patent-text">+</sup>. Furthermore, in some embodiments z is 3.</div>
    <div id="p-1104" num="1250" class="description-paragraph style-scope patent-text">In some embodiments, R<sup class="style-scope patent-text">20 </sup>is H and R<sup class="style-scope patent-text">21 </sup>is H.</div>
    <div id="p-1105" num="1251" class="description-paragraph style-scope patent-text">In some embodiments where R<sup class="style-scope patent-text">20 </sup>is (d-iii), there may be an additional nitro group on the benzene ring, e.g. ortho to R<sup class="style-scope patent-text">Z</sup>.</div>
    <div id="p-1106" num="1252" class="description-paragraph style-scope patent-text">In some embodiments, R<sup class="style-scope patent-text">21 </sup>is OH or OR<sup class="style-scope patent-text">A</sup>, where R<sup class="style-scope patent-text">A </sup>is C<sub class="style-scope patent-text">1-4 </sub>alkyl and R<sup class="style-scope patent-text">20 </sup>is selected from:</div>
    <div id="p-1107" num="1253" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00028" num="00028" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/33/f8/e4/2176aa54510be4/US11370801-20220628-C00028.png" class="style-scope patent-text"><img id="EMI-C00028" he="243.50mm" wi="69.85mm" file="US11370801-20220628-C00028.TIF" alt="Figure US11370801-20220628-C00028" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="279" height="974" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/33/f8/e4/2176aa54510be4/US11370801-20220628-C00028.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00028" attachment-type="cdx" file="US11370801-20220628-C00028.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00028" attachment-type="mol" file="US11370801-20220628-C00028.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <chemistry id="CHEM-US-00029" num="00029" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/7a/ab/13/9bfb212a248f04/US11370801-20220628-C00029.png" class="style-scope patent-text"><img id="EMI-C00029" he="35.90mm" wi="69.85mm" file="US11370801-20220628-C00029.TIF" alt="Figure US11370801-20220628-C00029" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="279" height="144" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/7a/ab/13/9bfb212a248f04/US11370801-20220628-C00029.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00029" attachment-type="cdx" file="US11370801-20220628-C00029.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00029" attachment-type="mol" file="US11370801-20220628-C00029.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
—C(═O)—X<sub class="style-scope patent-text">1</sub>—NHC(═O)X<sub class="style-scope patent-text">2</sub>—NH— represent a dipeptide. The amino acids in the dipeptide may be any combination of natural amino acids. The dipeptide may be the site of action for cathepsin-mediated cleavage.
</div>
    <div id="p-1108" num="1254" class="description-paragraph style-scope patent-text">In one embodiment, the dipeptide, —C(═O)—X<sub class="style-scope patent-text">1</sub>—NHC(═O)X<sub class="style-scope patent-text">2</sub>—NH—, is selected from:
</div> <ul class="style-scope patent-text"> <li id="ul0155-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0156-0001" num="1255" class="style-scope patent-text">Phe-Lys-,</li> <li id="ul0156-0002" num="1256" class="style-scope patent-text">Val-Ala-,</li> <li id="ul0156-0003" num="1257" class="style-scope patent-text">Val-Lys-,</li> <li id="ul0156-0004" num="1258" class="style-scope patent-text">Ala-Lys-,</li> <li id="ul0156-0005" num="1259" class="style-scope patent-text">Val-Cit-,</li> <li id="ul0156-0006" num="1260" class="style-scope patent-text">Phe-Cit-,</li> <li id="ul0156-0007" num="1261" class="style-scope patent-text">Leu-Cit-,</li> <li id="ul0156-0008" num="1262" class="style-scope patent-text">Ile-Cit-,</li> <li id="ul0156-0009" num="1263" class="style-scope patent-text">Phe-Arg-,</li> <li id="ul0156-0010" num="1264" class="style-scope patent-text">Trp-Cit-
<br class="style-scope patent-text">
where Cit is citrulline.
</li> </ul> </li> </ul>

    <div id="p-1109" num="1265" class="description-paragraph style-scope patent-text">Preferably, the dipeptide, —C(═O)—X<sub class="style-scope patent-text">1</sub>—NHC(═O)X<sub class="style-scope patent-text">2</sub>—NH—, is selected from:
</div> <ul class="style-scope patent-text"> <li id="ul0157-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0158-0001" num="1266" class="style-scope patent-text">Phe-Lys-,</li> <li id="ul0158-0002" num="1267" class="style-scope patent-text">Val-Ala-,</li> <li id="ul0158-0003" num="1268" class="style-scope patent-text">Val-Lys-,</li> <li id="ul0158-0004" num="1269" class="style-scope patent-text">Ala-Lys-,</li> <li id="ul0158-0005" num="1270" class="style-scope patent-text">Val-Cit-.</li> </ul> </li> </ul>

    <div id="p-1110" num="1271" class="description-paragraph style-scope patent-text">Most preferably, the dipeptide, —C(═O)—X<sub class="style-scope patent-text">1</sub>—NHC(═O)X<sub class="style-scope patent-text">2</sub>—NH—, is -Phe-Lys- or -Val-Ala-.</div>
    <div id="p-1111" num="1272" class="description-paragraph style-scope patent-text">Other dipeptide combinations may be used, including those described by Dubowchik et al., <i class="style-scope patent-text">Bioconjugate Chemistry, </i>2002, 13, 855-869, which is incorporated herein by reference.</div>
    <div id="p-1112" num="1273" class="description-paragraph style-scope patent-text">In one embodiment, the amino acid side chain is derivatised, where appropriate. For example, an amino group or carboxy group of an amino acid side chain may be derivatised.</div>
    <div id="p-1113" num="1274" class="description-paragraph style-scope patent-text">In one embodiment, an amino group NH<sub class="style-scope patent-text">2 </sub>of a side chain amino acid, such as lysine, is a derivatised form selected from the group consisting of NHR and NRR′.</div>
    <div id="p-1114" num="1275" class="description-paragraph style-scope patent-text">In one embodiment, a carboxy group COOH of a side chain amino acid, such as aspartic acid, is a derivatised form selected from the group consisting of COOR, CONH<sub class="style-scope patent-text">2</sub>, CONHR and CONRR′.</div>
    <div id="p-1115" num="1276" class="description-paragraph style-scope patent-text">In one embodiment, the amino acid side chain is chemically protected, where appropriate. The side chain protecting group may be a group as discussed above. The present inventors have established that protected amino acid sequences are cleavable by enzymes. For example, it has been established that a dipeptide sequence comprising a Boc side chain-protected Lys residue is cleavable by cathepsin.</div>
    <div id="p-1116" num="1277" class="description-paragraph style-scope patent-text">Protecting groups for the side chains of amino acids are well known in the art and are described in the Novabiochem Catalog. Additional protecting group strategies are set out in Protective Groups in Organic Synthesis, Greene and Wuts.</div>
    <div id="p-1117" num="1278" class="description-paragraph style-scope patent-text">Possible side chain protecting groups are shown below for those amino acids having reactive side chain functionality:
</div> <ul class="style-scope patent-text"> <li id="ul0159-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0160-0001" num="1279" class="style-scope patent-text">Arg: Z, Mtr, Tos;</li> <li id="ul0160-0002" num="1280" class="style-scope patent-text">Asn: Trt, Xan;</li> <li id="ul0160-0003" num="1281" class="style-scope patent-text">Asp: Bzl, t-Bu;</li> <li id="ul0160-0004" num="1282" class="style-scope patent-text">Cys: Acm, Bzl, Bzl-OMe, Bzl-Me, Trt;</li> <li id="ul0160-0005" num="1283" class="style-scope patent-text">Glu: Bzl, t-Bu;</li> <li id="ul0160-0006" num="1284" class="style-scope patent-text">Gin: Trt, Xan;</li> <li id="ul0160-0007" num="1285" class="style-scope patent-text">His: Boc, Dnp, Tos, Trt;</li> <li id="ul0160-0008" num="1286" class="style-scope patent-text">Lys: Boc, Z—Cl, Fmoc, Z, Alloc;</li> <li id="ul0160-0009" num="1287" class="style-scope patent-text">Ser: Bzl, TBDMS, TBDPS;</li> <li id="ul0160-0010" num="1288" class="style-scope patent-text">Thr: Bz;</li> <li id="ul0160-0011" num="1289" class="style-scope patent-text">Trp: Boc;</li> <li id="ul0160-0012" num="1290" class="style-scope patent-text">Tyr: Bzl, Z, Z—Br.</li> </ul> </li> </ul>

    <div id="p-1118" num="1291" class="description-paragraph style-scope patent-text">In one embodiment, the side chain protection is selected to be orthogonal to a group provided as, or as part of, a capping group, where present. Thus, the removal of the side chain protecting group does not remove the capping group, or any protecting group functionality that is part of the capping group.</div>
    <div id="p-1119" num="1292" class="description-paragraph style-scope patent-text">In other embodiments of the invention, the amino acids selected are those having no reactive side chain functionality. For example, the amino acids may be selected from: Ala, Gly, lie, Leu, Met, Phe, Pro, and Val.</div>
    <div id="p-1120" num="1293" class="description-paragraph style-scope patent-text">It is particularly preferred in the present invention, that if L<sup class="style-scope patent-text">1 </sup>comprises a dipeptide, then —C(═O)—X<sub class="style-scope patent-text">1</sub>—NHC(═O)X<sub class="style-scope patent-text">2</sub>—NH— is the same dipeptide.</div>
    <div id="p-1121" num="1294" class="description-paragraph style-scope patent-text">Other preferred R<sup class="style-scope patent-text">20 </sup>groups include:</div>
    <div id="p-1122" num="1295" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00030" num="00030" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/1d/cf/ef/561b896f91eca3/US11370801-20220628-C00030.png" class="style-scope patent-text"><img id="EMI-C00030" he="97.11mm" wi="51.82mm" file="US11370801-20220628-C00030.TIF" alt="Figure US11370801-20220628-C00030" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="207" height="388" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/1d/cf/ef/561b896f91eca3/US11370801-20220628-C00030.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00030" attachment-type="cdx" file="US11370801-20220628-C00030.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00030" attachment-type="mol" file="US11370801-20220628-C00030.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
Dimer Link
</div>
    <div id="p-1123" num="1296" class="description-paragraph style-scope patent-text">In some embodiments, Y and Y′ are both O.</div>
    <div id="p-1124" num="1297" class="description-paragraph style-scope patent-text">In some embodiments, R″ is a C<sub class="style-scope patent-text">3-7 </sub>alkylene group with no substituents. In some of these embodiments, R″ is a C<sub class="style-scope patent-text">3</sub>, C<sub class="style-scope patent-text">5 </sub>or C<sub class="style-scope patent-text">7 </sub>alkylene. In particular, R″ may be a C<sub class="style-scope patent-text">3 </sub>or C<sub class="style-scope patent-text">5 </sub>alkylene.</div>
    <div id="p-1125" num="1298" class="description-paragraph style-scope patent-text">In other embodiments, R″ is a group of formula:</div>
    <div id="p-1126" num="1299" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00031" num="00031" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/a1/0c/4d/ec8f34d8daab71/US11370801-20220628-C00031.png" class="style-scope patent-text"><img id="EMI-C00031" he="13.72mm" wi="35.39mm" file="US11370801-20220628-C00031.TIF" alt="Figure US11370801-20220628-C00031" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="142" height="55" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/a1/0c/4d/ec8f34d8daab71/US11370801-20220628-C00031.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00031" attachment-type="cdx" file="US11370801-20220628-C00031.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00031" attachment-type="mol" file="US11370801-20220628-C00031.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
where r is 1 or 2.
</div>
    <div id="p-1127" num="1300" class="description-paragraph style-scope patent-text">The phenylene group may be replaced by a pyridylene group.</div>
    <div id="h-0421" num="0000" class="description-paragraph style-scope patent-text">R<sup class="style-scope patent-text">6 </sup>to R<sup class="style-scope patent-text">9 </sup> </div>
    <div id="p-1128" num="1301" class="description-paragraph style-scope patent-text">In some embodiments, R<sup class="style-scope patent-text">9 </sup>is H.</div>
    <div id="p-1129" num="1302" class="description-paragraph style-scope patent-text">In some embodiments, R<sup class="style-scope patent-text">6 </sup>is selected from H, OH, OR, SH, NH<sub class="style-scope patent-text">2</sub>, nitro and halo, and may be selected from H or halo. In some of these embodiments R<sup class="style-scope patent-text">6 </sup>is H.</div>
    <div id="p-1130" num="1303" class="description-paragraph style-scope patent-text">In some embodiments, R<sup class="style-scope patent-text">7 </sup>is selected from H, OH, OR, SH, SR, NH<sub class="style-scope patent-text">2</sub>, NHR, NRR′, and halo. In some of these embodiments R<sup class="style-scope patent-text">7 </sup>is selected from H, OH and OR, where R is selected from optionally substituted C<sub class="style-scope patent-text">1-7 </sub>alkyl, C<sub class="style-scope patent-text">3-10 </sub>heterocyclyl and C<sub class="style-scope patent-text">5-10 </sub>aryl groups. R may be more preferably a C<sub class="style-scope patent-text">1-4 </sub>alkyl group, which may or may not be substituted. A substituent of interest is a C<sub class="style-scope patent-text">5-6 </sub>aryl group (e.g. phenyl). Particularly preferred substituents at the 7-positions are OMe and OCH<sub class="style-scope patent-text">2</sub>Ph. Other substituents of particular interest are dimethylamino (i.e. —NMe<sub class="style-scope patent-text">2</sub>); —(OC<sub class="style-scope patent-text">2</sub>H<sub class="style-scope patent-text">4</sub>)<sub class="style-scope patent-text">q</sub>OMe, where q is from 0 to 2; nitrogen-containing C<sub class="style-scope patent-text">6 </sub>heterocyclyls, including morpholino, piperidinyl and N-methyl-piperazinyl.</div>
    <div id="p-1131" num="1304" class="description-paragraph style-scope patent-text">These embodiments and preferences apply to R<sup class="style-scope patent-text">9′</sup>, R<sup class="style-scope patent-text">6′</sup> and R<sup class="style-scope patent-text">7′</sup> respectively.</div>
    <div id="h-0422" num="0000" class="description-paragraph style-scope patent-text">R<sup class="style-scope patent-text">11b </sup> </div>
    <div id="p-1132" num="1305" class="description-paragraph style-scope patent-text">In some embodiments, R<sup class="style-scope patent-text">11b </sup>is OH.</div>
    <div id="p-1133" num="1306" class="description-paragraph style-scope patent-text">In some embodiments, R<sup class="style-scope patent-text">11b </sup>is OR<sup class="style-scope patent-text">A</sup>, where R<sup class="style-scope patent-text">A </sup>is C<sub class="style-scope patent-text">1-4 </sub>alkyl. In some of these embodiments, R<sup class="style-scope patent-text">A </sup>is methyl.</div>
    <div id="p-1134" num="1307" class="description-paragraph style-scope patent-text">In some embodiments of the first aspect of the present invention are of formula Ia, Ib or Ic:</div>
    <div id="p-1135" num="1308" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00032" num="00032" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/52/d7/66/73ff966b76810b/US11370801-20220628-C00032.png" class="style-scope patent-text"><img id="EMI-C00032" he="120.31mm" wi="75.95mm" file="US11370801-20220628-C00032.TIF" alt="Figure US11370801-20220628-C00032" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="304" height="481" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/52/d7/66/73ff966b76810b/US11370801-20220628-C00032.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00032" attachment-type="cdx" file="US11370801-20220628-C00032.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00032" attachment-type="mol" file="US11370801-20220628-C00032.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
where R<sup class="style-scope patent-text">1a </sup>is selected from methyl and benzyl;
<br class="style-scope patent-text">
R<sup class="style-scope patent-text">L </sup>and R<sup class="style-scope patent-text">11b </sup>are as defined above.
</div>
    <div id="p-1136" num="1309" class="description-paragraph style-scope patent-text">These embodiments and preferences also apply to the second aspect of the invention.</div>
    <div id="h-0423" num="0000" class="description-paragraph style-scope patent-text">Linker (R<sup class="style-scope patent-text">L</sup>)</div>
    <div id="p-1137" num="1310" class="description-paragraph style-scope patent-text">In some embodiments, R<sup class="style-scope patent-text">L </sup>is of formula IIIa.</div>
    <div id="p-1138" num="1311" class="description-paragraph style-scope patent-text">In some embodiments, R<sup class="style-scope patent-text">LL </sup>is of formula IIIa′.</div>
    <div id="h-0424" num="0000" class="description-paragraph style-scope patent-text">G<sup class="style-scope patent-text">L </sup> </div>
    <div id="p-1139" num="1312" class="description-paragraph style-scope patent-text">G<sup class="style-scope patent-text">L </sup>may be selected from</div>
    <div id="p-1140" num="1313" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00033" num="00033" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/8a/8e/36/ed6fca458ae120/US11370801-20220628-C00033.png" class="style-scope patent-text"><img id="EMI-C00033" he="245.70mm" wi="69.93mm" file="US11370801-20220628-C00033.TIF" alt="Figure US11370801-20220628-C00033" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="983" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/8a/8e/36/ed6fca458ae120/US11370801-20220628-C00033.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00033" attachment-type="cdx" file="US11370801-20220628-C00033.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00033" attachment-type="mol" file="US11370801-20220628-C00033.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <chemistry id="CHEM-US-00034" num="00034" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/21/7e/e3/608fbcc3b48860/US11370801-20220628-C00034.png" class="style-scope patent-text"><img id="EMI-C00034" he="98.89mm" wi="69.93mm" file="US11370801-20220628-C00034.TIF" alt="Figure US11370801-20220628-C00034" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="396" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/21/7e/e3/608fbcc3b48860/US11370801-20220628-C00034.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00034" attachment-type="cdx" file="US11370801-20220628-C00034.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00034" attachment-type="mol" file="US11370801-20220628-C00034.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
where Ar represents a C<sub class="style-scope patent-text">5-6 </sub>arylene group, e.g. phenylene.
</div>
    <div id="p-1141" num="1314" class="description-paragraph style-scope patent-text">In some embodiments, G<sup class="style-scope patent-text">L </sup>is selected from G<sup class="style-scope patent-text">L1-1 </sup>and G<sup class="style-scope patent-text">L1-2</sup>. In some of these embodiments, G<sup class="style-scope patent-text">L </sup>is G<sup class="style-scope patent-text">L1-1</sup>.</div>
    <div id="h-0425" num="0000" class="description-paragraph style-scope patent-text">G<sup class="style-scope patent-text">LL </sup> </div>
    <div id="p-1142" num="1315" class="description-paragraph style-scope patent-text">G<sup class="style-scope patent-text">LL </sup>may be selected from:</div>
    <div id="p-1143" num="1316" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00035" num="00035" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/74/cf/17/28d494f5f1b86c/US11370801-20220628-C00035.png" class="style-scope patent-text"><img id="EMI-C00035" he="245.79mm" wi="69.93mm" file="US11370801-20220628-C00035.TIF" alt="Figure US11370801-20220628-C00035" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="983" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/74/cf/17/28d494f5f1b86c/US11370801-20220628-C00035.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00035" attachment-type="cdx" file="US11370801-20220628-C00035.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00035" attachment-type="mol" file="US11370801-20220628-C00035.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <chemistry id="CHEM-US-00036" num="00036" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/6b/ce/44/62da359cdb7d41/US11370801-20220628-C00036.png" class="style-scope patent-text"><img id="EMI-C00036" he="55.88mm" wi="69.93mm" file="US11370801-20220628-C00036.TIF" alt="Figure US11370801-20220628-C00036" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="224" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/6b/ce/44/62da359cdb7d41/US11370801-20220628-C00036.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00036" attachment-type="cdx" file="US11370801-20220628-C00036.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00036" attachment-type="mol" file="US11370801-20220628-C00036.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
where Ar represents a C<sub class="style-scope patent-text">5-6 </sub>arylene group, e.g. phenylene.
</div>
    <div id="p-1144" num="1317" class="description-paragraph style-scope patent-text">In some embodiments, G<sup class="style-scope patent-text">LL </sup>is selected from G<sup class="style-scope patent-text">LL1-1 </sup>and G<sup class="style-scope patent-text">LL1-2</sup>. In some of these embodiments, G<sup class="style-scope patent-text">LL </sup>is G<sup class="style-scope patent-text">LL1-1</sup>.</div>
    <div id="h-0426" num="0000" class="description-paragraph style-scope patent-text">X</div>
    <div id="p-1145" num="1318" class="description-paragraph style-scope patent-text">X is:</div>
    <div id="p-1146" num="1319" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00037" num="00037" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/28/2d/45/e13646d30cd927/US11370801-20220628-C00037.png" class="style-scope patent-text"><img id="EMI-C00037" he="13.89mm" wi="63.16mm" file="US11370801-20220628-C00037.TIF" alt="Figure US11370801-20220628-C00037" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="253" height="56" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/28/2d/45/e13646d30cd927/US11370801-20220628-C00037.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00037" attachment-type="cdx" file="US11370801-20220628-C00037.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00037" attachment-type="mol" file="US11370801-20220628-C00037.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
where a=0 to 5, b=0 to 16, c=0 or 1, d=0 to 5.
</div>
    <div id="p-1147" num="1320" class="description-paragraph style-scope patent-text">a may be 0, 1, 2, 3, 4 or 5. In some embodiments, a is 0 to 3. In some of these embodiments, a is 0 or 1. In further embodiments, a is 0.</div>
    <div id="p-1148" num="1321" class="description-paragraph style-scope patent-text">b may be 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16. In some embodiments, b is 0 to 12. In some of these embodiments, b is 0 to 8, and may be 0, 2, 4 or 8.</div>
    <div id="p-1149" num="1322" class="description-paragraph style-scope patent-text">c may be 0 or 1.</div>
    <div id="p-1150" num="1323" class="description-paragraph style-scope patent-text">d may be 0, 1, 2, 3, 4 or 5. In some embodiments, d is 0 to 3. In some of these embodiments, d is 1 or 2. In further embodiments, d is 2.</div>
    <div id="p-1151" num="1324" class="description-paragraph style-scope patent-text">In some embodiments of X, a is 0, c is 1 and d is 2, and b may be from 0 to 8. In some of these embodiments, b is 0, 4 or 8.</div>
    <div id="h-0427" num="0000" class="description-paragraph style-scope patent-text">Q</div>
    <div id="p-1152" num="1325" class="description-paragraph style-scope patent-text">In one embodiment, Q is an amino acid residue. The amino acid may a natural amino acids or a non-natural amino acid.</div>
    <div id="p-1153" num="1326" class="description-paragraph style-scope patent-text">In one embodiment, Q is selected from: Phe, Lys, Val, Ala, Cit, Leu, lie, Arg, and Trp, where Cit is citrulline.</div>
    <div id="p-1154" num="1327" class="description-paragraph style-scope patent-text">In one embodiment, Q comprises a dipeptide residue. The amino acids in the dipeptide may be any combination of natural amino acids and non-natural amino acids. In some embodiments, the dipeptide comprises natural amino acids. Where the linker is a cathepsin labile linker, the dipeptide is the site of action for cathepsin-mediated cleavage. The dipeptide then is a recognition site for cathepsin.</div>
    <div id="p-1155" num="1328" class="description-paragraph style-scope patent-text">In one embodiment, Q is selected from:
</div> <ul class="style-scope patent-text"> <li id="ul0161-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0162-0001" num="1329" class="style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Phe-Lys-<sup class="style-scope patent-text">NH</sup>,</li> <li id="ul0162-0002" num="1330" class="style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Val-Ala-<sup class="style-scope patent-text">NH</sup>,</li> <li id="ul0162-0003" num="1331" class="style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Val-Lys-<sup class="style-scope patent-text">NH</sup>,</li> <li id="ul0162-0004" num="1332" class="style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Ala-Lys-<sup class="style-scope patent-text">NH</sup>,</li> <li id="ul0162-0005" num="1333" class="style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Val-Cit-<sup class="style-scope patent-text">NH</sup>,</li> <li id="ul0162-0006" num="1334" class="style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Phe-Cit-<sup class="style-scope patent-text">NH</sup>,</li> <li id="ul0162-0007" num="1335" class="style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Leu-Cit-<sup class="style-scope patent-text">NH</sup>,</li> <li id="ul0162-0008" num="1336" class="style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Ile-Cit-<sup class="style-scope patent-text">NH</sup>,</li> <li id="ul0162-0009" num="1337" class="style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Phe-Arg-<sup class="style-scope patent-text">NH</sup>, and</li> <li id="ul0162-0010" num="1338" class="style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Trp-Cit-<sup class="style-scope patent-text">NH</sup>;
<br class="style-scope patent-text">
where Cit is citrulline.
</li> </ul> </li> </ul>

    <div id="p-1156" num="1339" class="description-paragraph style-scope patent-text">Preferably, Q is selected from:
</div> <ul class="style-scope patent-text"> <li id="ul0163-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0164-0001" num="1340" class="style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Phe-Lys-<sup class="style-scope patent-text">NH</sup>,</li> <li id="ul0164-0002" num="1341" class="style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Val-Ala-<sup class="style-scope patent-text">NH</sup>,</li> <li id="ul0164-0003" num="1342" class="style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Val-Lys-<sup class="style-scope patent-text">NH</sup>,</li> <li id="ul0164-0004" num="1343" class="style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Ala-Lys-<sup class="style-scope patent-text">NH</sup>,</li> <li id="ul0164-0005" num="1344" class="style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Val-Cit-<sup class="style-scope patent-text">NH</sup>.</li> </ul> </li> </ul>

    <div id="p-1157" num="1345" class="description-paragraph style-scope patent-text">Most preferably, Q is selected from <sup class="style-scope patent-text">CO</sup>-Phe-Lys-<sup class="style-scope patent-text">NH</sup>, <sup class="style-scope patent-text">CO</sup>-Val-Cit-<sup class="style-scope patent-text">NH </sup>and <sup class="style-scope patent-text">CO</sup>-Val-Ala-<sup class="style-scope patent-text">NH</sup>.</div>
    <div id="p-1158" num="1346" class="description-paragraph style-scope patent-text">Other dipeptide combinations of interest include:
</div> <ul class="style-scope patent-text"> <li id="ul0165-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0166-0001" num="1347" class="style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Gly-Gly-<sup class="style-scope patent-text">NH </sup> </li> <li id="ul0166-0002" num="1348" class="style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Pro-Pro-<sup class="style-scope patent-text">NH</sup>, and</li> <li id="ul0166-0003" num="1349" class="style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Val-Glu-<sup class="style-scope patent-text">NH</sup>.</li> </ul> </li> </ul>

    <div id="p-1159" num="1350" class="description-paragraph style-scope patent-text">Other dipeptide combinations may be used, including those described by Dubowchik et al., <i class="style-scope patent-text">Bioconjugate Chemistry, </i>2002, 13, 855-869, which is incorporated herein by reference.</div>
    <div id="p-1160" num="1351" class="description-paragraph style-scope patent-text">In some embodiments, Q<sup class="style-scope patent-text">X </sup>is a tripeptide residue. The amino acids in the tripeptide may be any combination of natural amino acids and non-natural amino acids. In some embodiments, the tripeptide comprises natural amino acids. Where the linker is a cathepsin labile linker, the tripeptide is the site of action for cathepsin-mediated cleavage. The tripeptide then is a recognition site for cathepsin.</div>
    <div id="p-1161" num="1352" class="description-paragraph style-scope patent-text">In one embodiment, the amino acid side chain is chemically protected, where appropriate. The side chain protecting group may be a group as discussed below. Protected amino acid sequences are cleavable by enzymes. For example, a dipeptide sequence comprising a Boc side chain-protected Lys residue is cleavable by cathepsin.</div>
    <div id="p-1162" num="1353" class="description-paragraph style-scope patent-text">Protecting groups for the side chains of amino acids are well known in the art and are described in the Novabiochem Catalog, and as described above.</div>
    <div id="p-1163" num="1354" class="description-paragraph style-scope patent-text">In some embodiments, R<sup class="style-scope patent-text">L </sup>is of formula IIIb.</div>
    <div id="p-1164" num="1355" class="description-paragraph style-scope patent-text">In some embodiments, R<sup class="style-scope patent-text">LL </sup>is formula IIIb′.</div>
    <div id="p-1165" num="1356" class="description-paragraph style-scope patent-text">R<sup class="style-scope patent-text">L1 </sup>and R<sup class="style-scope patent-text">L2 </sup>are independently selected from H and methyl, or together with the carbon atom to which they are bound form a cyclopropylene or cyclobutylene group.</div>
    <div id="p-1166" num="1357" class="description-paragraph style-scope patent-text">In some embodiments, both R<sup class="style-scope patent-text">L1 </sup>and R<sup class="style-scope patent-text">L2 </sup>are H.</div>
    <div id="p-1167" num="1358" class="description-paragraph style-scope patent-text">In some embodiments, R<sup class="style-scope patent-text">L1 </sup>is H and R<sup class="style-scope patent-text">L2 </sup>is methyl.</div>
    <div id="p-1168" num="1359" class="description-paragraph style-scope patent-text">In some embodiments, both R<sup class="style-scope patent-text">L1 </sup>and R<sup class="style-scope patent-text">L2 </sup>are methyl.</div>
    <div id="p-1169" num="1360" class="description-paragraph style-scope patent-text">In some embodiments, R<sup class="style-scope patent-text">L1 </sup>and R<sup class="style-scope patent-text">L2 </sup>together with the carbon atom to which they are bound form a cyclopropylene group.</div>
    <div id="p-1170" num="1361" class="description-paragraph style-scope patent-text">In some embodiments, R<sup class="style-scope patent-text">L1 </sup>and R<sup class="style-scope patent-text">L2 </sup>together with the carbon atom to which they are bound form a cyclobutylene group.</div>
    <div id="p-1171" num="1362" class="description-paragraph style-scope patent-text">In the group IIIb, in some embodiments, e is 0. In other embodiments, e is 1 and the nitro group may be in any available position of the ring. In some of these embodiments, it is in the ortho position. In others of these embodiments, it is in the para position.</div>
    <div id="p-1172" num="1363" class="description-paragraph style-scope patent-text">In one particular embodiment, the first aspect of the invention comprises a compound of formula Id:</div>
    <div id="p-1173" num="1364" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00038" num="00038" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/f2/0d/f4/7ad4c3d3347fd1/US11370801-20220628-C00038.png" class="style-scope patent-text"><img id="EMI-C00038" he="45.47mm" wi="142.49mm" file="US11370801-20220628-C00038.TIF" alt="Figure US11370801-20220628-C00038" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="570" height="182" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/f2/0d/f4/7ad4c3d3347fd1/US11370801-20220628-C00038.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00038" attachment-type="cdx" file="US11370801-20220628-C00038.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00038" attachment-type="mol" file="US11370801-20220628-C00038.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
where Q is selected from:
<br class="style-scope patent-text">
(a) —CH<sub class="style-scope patent-text">2</sub>—;
<br class="style-scope patent-text">
(b) —C<sub class="style-scope patent-text">3</sub>H<sub class="style-scope patent-text">6</sub>—; and
<br class="style-scope patent-text">
(c)
</div>
    <div id="p-1174" num="1365" class="description-paragraph style-scope patent-text">
      <chemistry id="CHEM-US-00039" num="00039" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/d1/be/13/49ac4b102f9a9f/US11370801-20220628-C00039.png" class="style-scope patent-text"><img id="EMI-C00039" he="13.72mm" wi="36.41mm" file="US11370801-20220628-C00039.TIF" alt="Figure US11370801-20220628-C00039" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="146" height="55" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/d1/be/13/49ac4b102f9a9f/US11370801-20220628-C00039.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00039" attachment-type="cdx" file="US11370801-20220628-C00039.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00039" attachment-type="mol" file="US11370801-20220628-C00039.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
    </div>
    <div id="p-1175" num="1366" class="description-paragraph style-scope patent-text">In one particular embodiment, the second aspect of the invention, the Drug linker (D<sup class="style-scope patent-text">L</sup>) is of formula (Id′):</div>
    <div id="p-1176" num="1367" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00040" num="00040" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/d6/53/cf/4818c12318a80d/US11370801-20220628-C00040.png" class="style-scope patent-text"><img id="EMI-C00040" he="45.55mm" wi="147.49mm" file="US11370801-20220628-C00040.TIF" alt="Figure US11370801-20220628-C00040" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="590" height="182" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/d6/53/cf/4818c12318a80d/US11370801-20220628-C00040.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00040" attachment-type="cdx" file="US11370801-20220628-C00040.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00040" attachment-type="mol" file="US11370801-20220628-C00040.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
where Q is selected from:
<br class="style-scope patent-text">
(a) —CH<sub class="style-scope patent-text">2</sub>—;
<br class="style-scope patent-text">
(b) —C<sub class="style-scope patent-text">3</sub>H<sub class="style-scope patent-text">6</sub>—; and
<br class="style-scope patent-text">
(c)
</div>
    <div id="p-1177" num="1368" class="description-paragraph style-scope patent-text">
      <chemistry id="CHEM-US-00041" num="00041" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/35/84/f9/f08cdf7c668c8f/US11370801-20220628-C00041.png" class="style-scope patent-text"><img id="EMI-C00041" he="13.63mm" wi="36.41mm" file="US11370801-20220628-C00041.TIF" alt="Figure US11370801-20220628-C00041" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="146" height="55" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/35/84/f9/f08cdf7c668c8f/US11370801-20220628-C00041.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00041" attachment-type="cdx" file="US11370801-20220628-C00041.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00041" attachment-type="mol" file="US11370801-20220628-C00041.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
    </div>
    <div id="p-1178" num="1369" class="description-paragraph style-scope patent-text">In some embodiments of the present invention, the C11 substituent may be in the following stereochemical arrangement relative to neighbouring groups:</div>
    <div id="p-1179" num="1370" class="description-paragraph style-scope patent-text">
      <chemistry id="CHEM-US-00042" num="00042" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/f4/ed/d3/f7cc7673c4e4eb/US11370801-20220628-C00042.png" class="style-scope patent-text"><img id="EMI-C00042" he="18.03mm" wi="23.45mm" file="US11370801-20220628-C00042.TIF" alt="Figure US11370801-20220628-C00042" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="94" height="72" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/f4/ed/d3/f7cc7673c4e4eb/US11370801-20220628-C00042.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00042" attachment-type="cdx" file="US11370801-20220628-C00042.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00042" attachment-type="mol" file="US11370801-20220628-C00042.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
    </div>
    <div id="p-1180" num="1371" class="description-paragraph style-scope patent-text">In other embodiments, the C11 substituent may be in the following stereochemical arrangement relative to neighbouring groups:</div>
    <div id="p-1181" num="1372" class="description-paragraph style-scope patent-text">
      <chemistry id="CHEM-US-00043" num="00043" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/46/21/6d/f4d6a73c9559e9/US11370801-20220628-C00043.png" class="style-scope patent-text"><img id="EMI-C00043" he="18.29mm" wi="23.45mm" file="US11370801-20220628-C00043.TIF" alt="Figure US11370801-20220628-C00043" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="94" height="73" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/46/21/6d/f4d6a73c9559e9/US11370801-20220628-C00043.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00043" attachment-type="cdx" file="US11370801-20220628-C00043.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00043" attachment-type="mol" file="US11370801-20220628-C00043.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
    </div>
    
    
    <heading id="h-0428" class="style-scope patent-text">EXAMPLES</heading>
    <div id="h-0429" num="0000" class="description-paragraph style-scope patent-text">General Information</div>
    <div id="p-1182" num="1373" class="description-paragraph style-scope patent-text">Flash chromatography was performed using a Biotage Isolera 1™ using gradient elution starting from either 88% hexane/EtOAc or 99.9% DCM/MeOH until all UV active components (detection at 214 and 254 nm) eluted from the column. The gradient was manually held whenever substantial elution of UV active material was observed. Fractions were checked for purity using thin-layer chromatography (TLC) using Merck Kieselgel 60 F254 silica gel, with fluorescent indicator on aluminium plates. Visualisation of TLC was achieved with UV light or iodine vapour unless otherwise stated. Extraction and chromatography solvents were bought and used without further purification from VWR U.K. All fine chemicals were purchased from Sigma-Aldrich or TCI Europe unless otherwise stated. Pegylated reagents were obtained from Quanta biodesign US via Stratech UK.</div>
    <div id="p-1183" num="1374" class="description-paragraph style-scope patent-text"> <sup class="style-scope patent-text">1</sup>H and <sup class="style-scope patent-text">13</sup>C NMR spectra were obtained on a Bruker Avance® 400 spectrometer. Coupling constants are quoted in hertz (Hz). Chemical shifts are recorded in parts per million (ppm) downfield from tetramethylsilane. Spin multiplicities are described as s (singlet), bs (broad singlet), d (doublet), t (triplet), and m (multiplet).</div>
    <div id="p-1184" num="1375" class="description-paragraph style-scope patent-text">The analytical LC/MS conditions (for reaction monitoring and purity determination) were as follows: Positive mode electrospray mass spectrometry was performed using a Shimadzu Nexera®/Prominence® LCMS-2020. Mobile phases used were solvent A (H<sub class="style-scope patent-text">2</sub>O with 0.1% formic acid) and solvent B (CH<sub class="style-scope patent-text">3</sub>CN with 0.1% formic acid). Gradient for routine 3-minute run: Initial composition 5% B held over 25 seconds, then increased from 5% B to 100% B over a 1 minute 35 second period. The composition was held for 50 seconds at 100% B, then returned to 5% B in 5 seconds and held there for 5 seconds. The total duration of the gradient run was 3.0 minutes. Gradient for 15-minute run: Initial composition 5% B held over 1 minute, then increased from 5% B to 100% B over a 9 minute period. The composition was held for 2 minutes at 100% B, then returned to 5% B in 10 seconds and held there for 2 minutes 50 seconds. The total duration of the gradient run was 15.0 minutes. Flow rate was 0.8 mL/minute (for 3-minute run) and 0.6 mL/minute (for 15-minute run). Detection was at 254 nm. Columns: Waters Acquity UPLC® BEH Shield RP18 1.7 μm 2.1×50 mm at 50° C. fitted with Waters Acquity UPLC® BEH Shield RP18 VanGuard Pre-column, 130A, 1.7 μm, 2.1 mm×5 mm (routine 3-minute run); and ACE Excel 2 C18-AR, 2μ, 3.0×100 mm fitted with Waters Acquity UPLC® BEH Shield RP18 VanGuard Pre-column, 130A, 1.7 μm, 2.1 mm×5 mm (15-minute run).</div>
    <div id="p-1185" num="1376" class="description-paragraph style-scope patent-text">The preparative HPLC conditions were as follows: Reverse-phase ultra-fast high-performance liquid chromatography (UFLC) was carried out on a Shimazdzu Prominence® machine using a Phenomenex® Gemini NX 5μ C18 column (at 50° C.) 150×21.2 mm. Eluents used were solvent A (H<sub class="style-scope patent-text">2</sub>O with 0.1% formic acid) and solvent B (CH<sub class="style-scope patent-text">3</sub>CN with 0.1% formic acid). All UFLC experiments were performed with gradient conditions:</div>
    <div id="p-1186" num="1377" class="description-paragraph style-scope patent-text">Method A: Initial composition 13% B increased to 60% B over a 15 minute period then increased to 100% B over 2 minutes. The composition was held for 1 minute at 100% B, then returned to 13% B in 0.1 minute and held there for 1.9 minutes. The total duration of the gradient run was 20.0 minutes. Flow was 20.0 mL/minute and detection was at 254 and 280 nm.</div>
    <div id="p-1187" num="1378" class="description-paragraph style-scope patent-text">Method B: Initial composition 13% B increased to 70% B over a 17 minute period and maintained over 2 minutes, then returned to 13% B in 0.1 minute and held there for 1.9 minutes. The total duration of the gradient run was 20.0 minutes. Flow was 20.0 mL/minute and detection was at 223 nm.</div>
    <div id="p-1188" num="1379" class="description-paragraph style-scope patent-text">Method C: Initial composition 13% B increased to 75% B over a 15 minute period then increased to 100% B over 2 minutes. The composition was held for 1 minute at 100% B, then returned to 13% B in 0.1 minute and held there for 1.9 minutes. The total duration of the gradient run was 20.0 minutes. Flow rate was 20.0 mL/minute and detection was at 254 and 280 nm.</div>
    <heading id="h-0430" class="style-scope patent-text">Example 1</heading>
    <div id="p-1189" num="1380" class="description-paragraph style-scope patent-text">
      <chemistry id="CHEM-US-00044" num="00044" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/3b/64/ca/2995cf2b3649a6/US11370801-20220628-C00044.png" class="style-scope patent-text"><img id="EMI-C00044" he="187.62mm" wi="115.32mm" file="US11370801-20220628-C00044.TIF" alt="Figure US11370801-20220628-C00044" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="461" height="750" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/3b/64/ca/2995cf2b3649a6/US11370801-20220628-C00044.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00044" attachment-type="cdx" file="US11370801-20220628-C00044.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00044" attachment-type="mol" file="US11370801-20220628-C00044.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00045" num="00045" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/cf/7d/90/fcbbf6645da489/US11370801-20220628-C00045.png" class="style-scope patent-text"><img id="EMI-C00045" he="210.99mm" wi="146.30mm" file="US11370801-20220628-C00045.TIF" alt="Figure US11370801-20220628-C00045" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="585" height="844" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/cf/7d/90/fcbbf6645da489/US11370801-20220628-C00045.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00045" attachment-type="cdx" file="US11370801-20220628-C00045.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00045" attachment-type="mol" file="US11370801-20220628-C00045.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00046" num="00046" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/24/97/ed/91851cea57a018/US11370801-20220628-C00046.png" class="style-scope patent-text"><img id="EMI-C00046" he="188.38mm" wi="156.63mm" file="US11370801-20220628-C00046.TIF" alt="Figure US11370801-20220628-C00046" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="627" height="754" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/24/97/ed/91851cea57a018/US11370801-20220628-C00046.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00046" attachment-type="cdx" file="US11370801-20220628-C00046.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00046" attachment-type="mol" file="US11370801-20220628-C00046.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
    </div>
    <heading id="h-0431" class="style-scope patent-text">(a) ((Propane-1,3-diylbis(oxy))bis(5-methoxy-2-nitro-4,1-phenylene))bis(((S)-2-(hydroxymethyl)pyrrolidin-1-yl)methanone) (I2)</heading>
    <div id="p-1190" num="1381" class="description-paragraph style-scope patent-text">DMF (12 drops) was added to a stirred suspension of the bis-nitrobenzoic acid 11 (10 g, 21.5 mmol) and oxalyl chloride (5.6 mL, 8.2 g, 64.5 mmol) in anhydrous DCM (150 mL).</div>
    <div id="p-1191" num="1382" class="description-paragraph style-scope patent-text">Following initial effervescence the reaction suspension became a solution and the mixture was allowed to stir at room temperature for 16 hours. The majority of solvent was removed by evaporation in vacuo and the resulting concentrated solution was re-dissolved in a minimum amount of dry DCM and triturated with diethyl ether. The resulting yellow precipitate was collected by vacuum filtration, washed with cold diethyl ether and dried for 1 hour in a vacuum oven at 40° C. The solid acid chloride was added portion-wise to a stirred suspension of (S)-(+)-2-pyrrolidinemethanol (5.0 g, 4.9 mL, 49.5 mmol) and TEA (15.0 mL, 10.9 g, 108 mmol) in DCM (100 mL) at −40° C. (dry ice/CH<sub class="style-scope patent-text">3</sub>CN). After 1 hour stirring, the reaction was complete as judged by LC/MS with exclusively desired product at retention time 1.33 minutes, ES+ m/z 655 [M+Na]<sup class="style-scope patent-text">+</sup>, 633 [M+H]<sup class="style-scope patent-text">+</sup>. The mixture was diluted with DCM (100 mL) and washed with 1N HCl (2×50 mL), saturated NaHCO<sub class="style-scope patent-text">3 </sub>(3×40 mL), brine (50 mL), dried (MgSO<sub class="style-scope patent-text">4</sub>), filtered and the solvent evaporated in vacuo to give the pure product I2 as a yellow solid (13.6 g, 100% yield).</div>
    <heading id="h-0432" class="style-scope patent-text">(b) ((2S,2′S)-(4,4′-(propane-1,3-diylbis(oxy))bis(5-methoxy-2-nitrobenzoyl))bis(pyrrolidine-1,2-diyl))bis(methylene) diacetate (I3)</heading>
    <div id="p-1192" num="1383" class="description-paragraph style-scope patent-text">A solution of Ac<sub class="style-scope patent-text">2</sub>O (4.47 mL, 4.83 g, 47.3 mmol) in dry DCM (25 mL) was added drop-wise to a stirred solution of the bis-alcohol 12 (13.6 g, 21.5 mmol), DMAP (263 mg, 2.15 mmol) and pyridine (4.17 mL, 4.08 g, 51.6 mmol) in dry DCM (125 mL) at 0° C. (ice/acetone) under an argon atmosphere. The reaction mixture was allowed to warm-up and after 1 hour at room temperature analysis by LC/MS revealed completion of reaction and clean conversion to desired product at retention time 1.55 minutes, ES+ m/z 740 [M+Na]<sup class="style-scope patent-text">+</sup>, 717 [M+H]<sup class="style-scope patent-text">+</sup>. The mixture was diluted with DCM (20 mL) and washed with 1N HCl (2×100 mL), H<sub class="style-scope patent-text">2</sub>O (25 mL), brine (50 mL), dried (MgSO<sub class="style-scope patent-text">4</sub>), filtered and the solvent evaporated in vacuo to give the crude bis-acetate 13 as a yellow solid (14.4 g, 94% yield) which was of satisfactory purity to be carried through to the next step without further purification.</div>
    <heading id="h-0433" class="style-scope patent-text">(c) ((2S,2′S)-(4,4′-(propane-1,3-diylbis(oxy))bis(2-amino-5-methoxybenzoyl))bis(pyrrolidine-1,2-diyl))bis(methylene) diacetate (I4)</heading>
    <div id="p-1193" num="1384" class="description-paragraph style-scope patent-text">A sample of 10% Pd—C (132 mg) was treated carefully with EtOAc (10 mL) to give a slurry which was added to a solution of the nitro compound I3 (1.32 g, 1.84 mmol) in EtOAc (20 mL) and EtOH (30 mL) in a hydrogenation vessel. Using Parr® apparatus, the mixture was treated with hydrogen gas to 10 psi and shaken at room temperature then degassed in vacuo, this process was repeated a further two times. The vessel was filled with hydrogen gas to 45 psi, shaken and the pressure maintained upon consumption of hydrogen. Analysis by LC/MS showed the reaction was incomplete after 3 hours and was left shaking at 45 psi for 3 days (the weekend) after which time satisfactory conversion to product was achieved, retention time=1.32 minutes, ES+ m/z 657 [M+H]<sup class="style-scope patent-text">+</sup>. The reaction mixture was degassed in vacuo and then filtered through a Celite® pad. The filtrate was evaporated in vacuo, the resulting residue re-dissolved in DCM (30 mL), dried (MgSO<sub class="style-scope patent-text">4</sub>), filtered and the solvent evaporated in vacuo to give the crude bis-aniline I4 as a yellowish foam (1.1 g, 91% yield) which contained an 8% impurity but was carried through to the next step without further purification.</div>
    <heading id="h-0434" class="style-scope patent-text">(d) ((S)-1-(4-(3-(4-((S)-2-(acetoxymethyl)pyrrolidine-1-carbonyl)-5-((tert-butoxycarbonyl)amino)-2-methoxyphenoxy)propoxy)-2-amino-5-methoxybenzoyl)pyrrolidin-2-yl)methyl acetate (I5)</heading>
    <div id="p-1194" num="1385" class="description-paragraph style-scope patent-text">Boc<sub class="style-scope patent-text">2</sub>O (330 mg, 1.51 mmol) was added to a stirred solution of the bis-aniline 14 (1.1 g, 1.68 mmol) in dry THF (10 mL). The reaction mixture was heated and stirred at 75° C. for 16 hours. Analysis by LC/MS revealed desired mono Boc product I5 at retention time 1.58 minutes, I %=50, ES+ m/z 779 [M+Na]<sup class="style-scope patent-text">+</sup>, 757 [M+H]<sup class="style-scope patent-text">+</sup> along with unreacted starting material at retention time 1.32 minutes, I %=30, and bis-Boc material at retention time 1.81 minutes, I %=21, ES+ m/z 879 [M+Na]<sup class="style-scope patent-text">+</sup>, 857 [M+H]<sup class="style-scope patent-text">+</sup>. The reaction mixture was allowed to cool to room temperature and the THF removed by evaporation in vacuo. Purification by Isolera™ (DCM/MeOH, SNAP Ultra 50 g, 100 mL per minute) provided the mono Boc product I5 as an orange foam (519 mg, 46% yield based on Boc<sub class="style-scope patent-text">2</sub>O, eluting at 97% DCM/MeOH) unreacted bis-aniline 14 (285 mg, eluting at 95% DCM/MeOH) and bis-Boc (248 mg, eluting at 98% DCM/MeOH).</div>
    <heading id="h-0435" class="style-scope patent-text">(e) ((S)-1-(4-(3-(4-((S)-2-(acetoxymethyl)pyrrolidine-1-carbonyl)-5-((((4-((S)-2-((S)-2-(((allyloxy)carbonyl)amino)-3-methylbutanamido)propanamido)benzyl)oxy)carbonyl)amino)-2-methoxyphenoxy)propoxy)-2-((tert-butoxycarbonyl)amino)-5-methoxybenzoyl)pyrrolidin-2-yl)methyl acetate (I7)</heading>
    <div id="p-1195" num="1386" class="description-paragraph style-scope patent-text">Triphosgene (380 mg, 1.28 mmol) was added to a stirred solution of the mono Boc product I5 (2.69 g, 3.56 mmol) and TEA (1.09 mL, 791 mg, 7.83 mmol) in dry DCM (30 mL) at room temperature. After stirring for 10 minutes under argon, analysis by LC/MS revealed complete conversion to isocyanate (sampled in MeOH to give methyl carbamate, retention time 1.66 minutes, ES+ m/z 837 [M+Na]<sup class="style-scope patent-text">+</sup>, 815 [M+H]<sup class="style-scope patent-text">+</sup>). The mixture was treated with additional TEA (740 μL, 539 mg, 5.34 mmol) followed by the addition of linker 16 (1.34 g, 3.56 mmol). After 2 hours stirring under argon, LC/MS revealed satisfactory conversion to carbamate 17 (retention time 1.74 minutes, (ES+) m/z 1182 [M+Na]<sup class="style-scope patent-text">+</sup>, 1160 [M+H]<sup class="style-scope patent-text">+</sup>). The mixture was diluted with DCM (80 mL) and washed with saturated NH<sub class="style-scope patent-text">4</sub>Cl (2×30 mL), H<sub class="style-scope patent-text">2</sub>O (30 mL), brine (50 mL), dried (MgSO<sub class="style-scope patent-text">4</sub>), filtered and evaporated in vacuo to give the crude product. Purification by Isolera™ (Hexane/EtOAc, SNAP Ultra 100 g, 100 mL per minute) provided the pure carbamate 17 (eluting at 65% Hexane/EtOAc) as a yellow foam (2.95 g, 71% yield).</div>
    <heading id="h-0436" class="style-scope patent-text">(f) tert-butyl (5-(3-(5-((((4-((S)-2-((S)-2-(((allyloxy)carbonyl)amino)-3-methylbutanamido)propanamido)benzyl)oxy)carbonyl)amino)-4-((S)-2-(hydroxymethyl)pyrrolidine-1-carbonyl)-2-methoxyphenoxy)propoxy)-2-((S)-2-(hydroxymethyl)pyrrolidine-1-carbonyl)-4-methoxyphenyl)carbamate (I8)</heading>
    <div id="p-1196" num="1387" class="description-paragraph style-scope patent-text">Solid K<sub class="style-scope patent-text">2</sub>CO<sub class="style-scope patent-text">3 </sub>(1.75 g, 12.7 mmol) was added to a stirred solution of the acetate-protected compound I7 (2.93 g, 2.53 mmol) in MeOH (60 mL) and H<sub class="style-scope patent-text">2</sub>O (12 mL). After 1 hour stirring at room temperature the reaction was deemed to be complete as judged by LC/MS with desired product at retention time 1.57 minutes, ES+ m/z 1098 [M+Na]<sup class="style-scope patent-text">+</sup>, 1076 [M+H]<sup class="style-scope patent-text">+</sup>. The MeOH was removed by evaporation in vacuo and the resulting residue was partitioned between water (75 mL) and DCM (75 mL). The layers were separated and the aqueous phase was extracted with DCM (3×25 mL). The combined organic layers were washed with water (3×50 mL), brine (60 mL), dried (MgSO<sub class="style-scope patent-text">4</sub>), filtered and evaporated in vacuo to provide the crude product. Purification by Isolera™ (DCM/MeOH, SNAP Ultra 100 g, 100 mL per minute) the bis-alcohol 18 (eluting at 97% DCM/MeOH) as a white foam (2.44 g, 90% yield).</div>
    <heading id="h-0437" class="style-scope patent-text">(g) 4-((S)-2-((S)-2-(((allyloxy)carbonyl)amino)-3-methylbutanamido)propanamido)benzyl(11S,11aS)-8-(3-(((11S,11aS)-10-(tert-butoxycarbonyl)-11-hydroxy-7-methoxy-5-oxo-2,3,5,10,11,11a-hexahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl)oxy)propoxy)-11-hydroxy-7-methoxy-5-oxo-2,3,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylate (I9)</heading>
    <div id="p-1197" num="1388" class="description-paragraph style-scope patent-text">A solution of anhydrous DMSO (710 μL, 780 mg, 9.99 mmol) in dry DCM (20 mL) was added drop-wise to a stirred solution of oxalyl chloride (2.72 mL of a 2.0M solution in DCM, 5.44 mmol) in dry DCM (20 mL) at −45° C. (dry ice/CH<sub class="style-scope patent-text">3</sub>CN) under an argon atmosphere. After 15 minutes stirring at −45° C., the reaction mixture was treated drop-wise with a solution of the bis-alcohol 18 (2.44 g, 2.27 mmol) in dry DCM (30 mL). After stirring at −45° C. for a further 1 hour, the reaction mixture was treated drop-wise with a solution of TEA (3.16 mL, 2.29 g, 22.7 mmol) in dry DCM (20 mL). The reaction mixture was allowed to warm to room temperature over a period of 1.5 hours and diluted with DCM (100 mL) then washed with saturated NH<sub class="style-scope patent-text">4</sub>Cl (2×50 mL), saturated NaHCO<sub class="style-scope patent-text">3 </sub>(50 mL), water (30 mL), brine (50 mL), dried (MgSO<sub class="style-scope patent-text">4</sub>), filtered and evaporated in vacuo to give the crude product. Purification by Isolera™ (DCM/MeOH, SNAP Ultra 100 g, 100 mL per minute) gave the cyclised compound I9 (eluting at 95.7% DCM/MeOH) as a yellowish foam (1.61 g, 66% yield): LC/MS I9 at retention time 1.46 minutes, ES+ m/z 1072 [M+H]<sup class="style-scope patent-text">+</sup>, 1094 [M+Na]<sup class="style-scope patent-text">+</sup>.</div>
    <heading id="h-0438" class="style-scope patent-text">(h) 4-((S)-2-((S)-2-amino-3-methylbutanamido)propanamido)benzyl(11S,11aS)-8-(3-(((11S,11aS)-10-(tert-butoxycarbonyl)-11-hydroxy-7-methoxy-5-oxo-2,3,5,10,11,11a-hexahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl)oxy)propoxy)-11-hydroxy-7-methoxy-5-oxo-2,3,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylate (I10)</heading>
    <div id="p-1198" num="1389" class="description-paragraph style-scope patent-text">Pd(PPh<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">4 </sub>(6.47 mg, 5.6 μmol) was added to a stirred solution of pyrrolidine (29 μL, 25 mg, 0.35 mmol) and the Alloc compound I9 (300 mg, 0.28 mmol) in dry DCM (10 mL). After stirring for 4 hours under argon at room temperature, analysis by LC/MS revealed reaction completion with desired product observed at retention time 1.10 minutes, ES+, m/z 1010 [M+Na]<sup class="style-scope patent-text">+</sup>, 988 [M+H]<sup class="style-scope patent-text">+</sup>. The reaction mixture was diluted with DCM (30 mL) then washed with saturated NH<sub class="style-scope patent-text">4</sub>Cl (2×20 mL), brine (30 mL), dried (MgSO<sub class="style-scope patent-text">4</sub>), filtered and evaporated in vacuo to give the crude product. Trituration with diethyl ether followed by evaporation in vacuo gave the crude amine I10 (261 mg, 95% yield) which was carried through to the next step without further purification or analysis.</div>
    <heading id="h-0439" class="style-scope patent-text">(i) tert-butyl(11S,11aS)-8-(3-(((11S,11aS)-10-(((4-((2S,5S)-37-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5-isopropyl-2-methyl-4,7,35-trioxo-10,13,16,19,22,25,28,31-octaoxa-3,6,34-triazaheptatriacontanamido)benzyl)oxy)carbonyl)-1-hydroxy-7-methoxy-5-oxo-2,3,5,10,11,11a-hexahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl)oxy)propoxy)-11-hydroxy-7-methoxy-5-oxo-2,3,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylate (I11)</heading>
    <div id="p-1199" num="1390" class="description-paragraph style-scope patent-text">EDCl (56 mg, 0.29 mmol) was added to a stirred solution of MAL-dPEG®<sub class="style-scope patent-text">8</sub>-acid (172 mg, 0.29 mmol, Stratech Scientific Limited) and the amine I10 (261 mg, 0.26 mmol) in dry DCM (10 mL) at room temperature. The reaction mixture was stirred under an argon atmosphere for 2.5 hours at which point analysis by LC/MS showed complete conversion to desired product at retention time 1.38 minutes, ES+ m/z 1585 [M+Na]<sup class="style-scope patent-text">+</sup>, 1563 [M+H]<sup class="style-scope patent-text">+</sup>. The reaction mixture was diluted with DCM (30 mL) and washed with H<sub class="style-scope patent-text">2</sub>O (20 mL), brine (2×20 mL), dried (MgSO<sub class="style-scope patent-text">4</sub>), filtered and evaporated in vacuo to provide the crude product. Purification by Isolera™ (DCM/MeOH, SNAP Ultra 25 g, 75 mL per minute) gave the amide I11 (eluting at 91% DCM/MeOH) as a white foam (277 mg, 67% yield).</div>
    <heading id="h-0440" class="style-scope patent-text">(j) 4-((2S,5S)-37-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5-isopropyl-2-methyl-4,7,35-trioxo-10,13,16,19,22,25,28,31-octaoxa-3,6,34-triazaheptatriacontanamido)benzyl(11S,11aS)-11-hydroxy-7-methoxy-8-(3-(((S)-7-methoxy-5-oxo-2,3,5,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl)oxy)propoxy)-5-oxo-2,3,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylate (1)</heading>
    <div id="p-1200" num="1391" class="description-paragraph style-scope patent-text">A solution of 95:5 v/v TFA/H<sub class="style-scope patent-text">2</sub>O (2 mL) was added to a crude sample of the Boc-protected compound I11 (262 mg, 0.17 mmol) at 0° C. (ice/acetone). After stirring at 0° C. for 3 hours the reaction was deemed complete as judged by LC/MS, desired product peak at retention time 1.30 minutes, ES+ m/z 1445 [M+H]<sup class="style-scope patent-text">+</sup>. The reaction mixture was kept cold and added drop-wise to a chilled saturated aqueous solution of NaHCO<sub class="style-scope patent-text">3 </sub>(100 mL). The mixture was extracted with DCM (3×30 mL) and the combined organic layers washed with brine (30 mL), dried (MgSO<sub class="style-scope patent-text">4</sub>), filtered and evaporated in vacuo to provide the crude product. Purification by Isolera™ (CHCl<sub class="style-scope patent-text">3</sub>/MeOH, SNAP Ultra 25 g, 25 mL per minute) gave 1 (eluting at 89.6% CHCl<sub class="style-scope patent-text">3</sub>/MeOH) as a yellow foam (170 mg, 70% yield). Further purification by preparative HPLC (Method A) gave 1 as a light yellow foam (105 mg, 43% yield): LC/MS (15-minute run), retention time 5.25 minutes, ES+ m/z 1445 [M+H]<sup class="style-scope patent-text">+</sup>; <sup class="style-scope patent-text">1</sup>H NMR (400 MHz, d6-DMSO) δ 9.92 (s, 1H), 8.16 (d, 1H, J=6.8 Hz), 7.99 (t, 1H, J=5.7 Hz), 7.86 (d, 1H, J=8.6 Hz), 7.80 (d, 1H, J=4.5 Hz), 7.64-7.50 (m, 2H), 7.34 (s, 1H), 7.24-7.13 (m, 2H), 7.06 (s, 1H), 7.00 (s, 2H), 6.88 (s, 1H), 6.75 (s, 1H), 6.53-6.41 (m, 1H), 5.52-5.41 (m, 1H), 5.13 (d, 1H, J=12.2 Hz), 4.93-4.77 (m, 1H), 4.42-4.34 (m, 1H), 4.30-3.90 (m, 6H), 3.80-3.60 (m, 4H), 3.80 (s, 3H), 3.79 (s, 3H), 3.60 (t, 4H, J=7.3 Hz), 3.53-3.46 (m, 28H), 3.41-3.33 (m, 1H), 3.32-3.29 (m, 2H, obscured by H<sub class="style-scope patent-text">2</sub>O), 3.19-3.12 (m, 2H), 2.48-1.60, m, 15H), 1.35-1.20 (m, 3H), 0.87 (d, 3H, J=6.6 Hz), 0.83 (d, 3H, J=6.8 Hz).</div>
    <heading id="h-0441" class="style-scope patent-text">Example 2</heading>
    <div id="p-1201" num="1392" class="description-paragraph style-scope patent-text">
      <chemistry id="CHEM-US-00047" num="00047" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/2d/6e/15/abc5b47aaeb3f1/US11370801-20220628-C00047.png" class="style-scope patent-text"><img id="EMI-C00047" he="190.42mm" wi="126.07mm" file="US11370801-20220628-C00047.TIF" alt="Figure US11370801-20220628-C00047" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="504" height="762" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/2d/6e/15/abc5b47aaeb3f1/US11370801-20220628-C00047.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00047" attachment-type="cdx" file="US11370801-20220628-C00047.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00047" attachment-type="mol" file="US11370801-20220628-C00047.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00048" num="00048" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/c3/9c/72/27b9c536df313e/US11370801-20220628-C00048.png" class="style-scope patent-text"><img id="EMI-C00048" he="186.44mm" wi="149.35mm" file="US11370801-20220628-C00048.TIF" alt="Figure US11370801-20220628-C00048" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="597" height="746" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/c3/9c/72/27b9c536df313e/US11370801-20220628-C00048.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00048" attachment-type="cdx" file="US11370801-20220628-C00048.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00048" attachment-type="mol" file="US11370801-20220628-C00048.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00049" num="00049" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/1d/d0/08/c9d5716d6b2ed4/US11370801-20220628-C00049.png" class="style-scope patent-text"><img id="EMI-C00049" he="160.36mm" wi="153.75mm" file="US11370801-20220628-C00049.TIF" alt="Figure US11370801-20220628-C00049" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="615" height="641" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/1d/d0/08/c9d5716d6b2ed4/US11370801-20220628-C00049.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00049" attachment-type="cdx" file="US11370801-20220628-C00049.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00049" attachment-type="mol" file="US11370801-20220628-C00049.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
    </div>
    <heading id="h-0442" class="style-scope patent-text">(a) ((pentane-1,5-diylbis(oxy))bis(5-methoxy-2-nitro-4,1-phenylene))bis(((S)-2-(hydroxymethyl)pyrrolidin-1-yl)methanone) (I13)</heading>
    <div id="p-1202" num="1393" class="description-paragraph style-scope patent-text">DMF (5 drops) was added to a stirred suspension of the bis-nitrobenzoic acid I12 (4.05 g, 8.192 mmol, 1.0 eq.) and oxalyl chloride (12.3 mL of 2M solution, 24.57 mmol, 3.0 eq.) in anhydrous CH<sub class="style-scope patent-text">2</sub>Cl<sub class="style-scope patent-text">2 </sub>(65 mL). Following initial effervescence the reaction suspension became a solution and the mixture was allowed to stir at room temperature for 16 hours. The reaction mixture was concentrated in vacuo and the resulting solid was triturated with Et<sub class="style-scope patent-text">2</sub>O and dried in a vacuum oven at 40° C. for 3 hours. The solid acid chloride was added portion-wise to a stirred suspension of (S)-(+)-2-pyrrolidinemethanol (1.78 mL, 18.02 mmol, 2.2 eq.) and i-Pr<sub class="style-scope patent-text">2</sub>NEt (7.13 mL, 40.96 mmol, 5.0 eq.) in CH<sub class="style-scope patent-text">2</sub>Cl<sub class="style-scope patent-text">2 </sub>(65 mL) at −40° C. (dry ice/CH<sub class="style-scope patent-text">3</sub>CN). After 1 hour stirring, the reaction temperature had reached OC, and was complete as judged by LC/MS with exclusively desired product at retention time 1.44 minutes, ES+ m/z 661 [M+H]<sup class="style-scope patent-text">+</sup>, 683 [M+Na]<sup class="style-scope patent-text">+</sup>. The mixture was diluted with CH<sub class="style-scope patent-text">2</sub>Cl<sub class="style-scope patent-text">2 </sub>(100 mL) and washed consecutively with H<sub class="style-scope patent-text">2</sub>O, 1N NaOH and 1M HCl (50 mL), dried (MgSO<sub class="style-scope patent-text">4</sub>), filtered and the solvent evaporated in vacuo to give the pure product I13 as a yellow foam (4.44 g, 82% yield), which was used without further purification.</div>
    <heading id="h-0443" class="style-scope patent-text">(b) ((pentane-1,5-diylbis(oxy))bis(5-methoxy-2-nitro-4,1-phenylene))bis(((S)-2-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidin-1-yl)methanone) (I14)</heading>
    <div id="p-1203" num="1394" class="description-paragraph style-scope patent-text">Imidazole (2.74 g, 40.32 mmol, 6.0 eq.) then TBSCl (3.04 g, 20.16 mmol, 3.0 eq.) were added portion-wise to a stirred solution of bis-alcohol I13 (4.44 g, 6.720 mmol, 1.0 eq.) under an argon atmosphere. After 90 minutes, the reaction mixture was filtered and the filtrated washed with H<sub class="style-scope patent-text">2</sub>O, dried over MgSO<sub class="style-scope patent-text">4 </sub>and concentrated in vacuo. Flash column chromatography (50-80% EtOAc in hexane) afforded the product I14 as a yellow foam (4.84 g, 5.443 mmol, 81% yield). LC/MS retention time=2.18 min, ES+ m/z 889 [M+H]<sup class="style-scope patent-text">+</sup>, 911 [M+Na]<sup class="style-scope patent-text">+</sup>.</div>
    <heading id="h-0444" class="style-scope patent-text">(c) ((pentane-1,5-diylbis(oxy))bis(2-amino-5-methoxy-4,1-phenylene))bis(((S)-2-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidin-1-yl)methanone) (I15)</heading>
    <div id="p-1204" num="1395" class="description-paragraph style-scope patent-text">Zn powder was added to a stirring solution of bis-nitro compound I14 (1.32 g, 1.84 mmol) in MeOH (40 mL) at 0° C. 5% HCO<sub class="style-scope patent-text">2</sub>H in MeOH was added dropwise at 0° C. and the mixture stirred for 2 hours. The reaction mixture was diluted with EtOAc and washed with sat. NaHCO<sub class="style-scope patent-text">3 </sub>solution, the organic phase dried over MgSO<sub class="style-scope patent-text">4 </sub>and concentrated in vacuo. Flash column chromatography (0-2% MeOH in CHCl<sub class="style-scope patent-text">3</sub>) afforded the product I15 as a pale yellow foam (3.098 mmol, 3.736 mmol, 69% yield). LC/MS retention time=2.09 min, ES+ m/z 415 [M+2H]<sup class="style-scope patent-text">2+</sup>, 829 [M+H]<sup class="style-scope patent-text">+</sup>, 851 [M+Na]<sup class="style-scope patent-text">+</sup>.</div>
    <heading id="h-0445" class="style-scope patent-text">(d) tert-butyl (5-((5-(5-amino-4-((S)-2-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidine-1-carbon yl)-2-methoxyphenoxy)pentyl)oxy)-2-((S)-2-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidine-1-carbonyl)-4-methoxyphenyl)carbamate (I16)</heading>
    <div id="p-1205" num="1396" class="description-paragraph style-scope patent-text">Boc<sub class="style-scope patent-text">2</sub>O (734 mg, 3.362 mmol) was added to a stirred solution of the bis-aniline I15 (3.098 g, 3.736 mmol) in dry THF (20 mL). The reaction mixture was stirred for 16 hours and concentrated in vacuo. Flash column chromatography (30-50% EtOAc in hexane) provided the mono Boc product I16 as a yellow foam (1.474 g, 47% yield based on Boc<sub class="style-scope patent-text">2</sub>O) unreacted bis-aniline I15 (1.043 g, 30% yield) and bis-Boc (419 mg, 15% yield, LC/MS retention time=2.37 min). LC/MS retention time of 116=2.25 min, ES<sup class="style-scope patent-text">+</sup> m/z 929 [M+H]<sup class="style-scope patent-text">+</sup>, 951 [M+Na]<sup class="style-scope patent-text">+</sup>.</div>
    <heading id="h-0446" class="style-scope patent-text">(e) tert-butyl (5-((5-(5-((((4-((S)-2-((S)-2-(((allyloxy)carbonyl)amino)-3-methylbutanamido)propanamido)benzyl)oxy)carbonyl)amino)-4-((S)-2-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidine-1-carbonyl)-2-hydroxyphenoxy)pentyl)oxy)-2-((S)-2-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidine-1-carbonyl)-4-methoxyphenyl) carbamate (I17)</heading>
    <div id="p-1206" num="1397" class="description-paragraph style-scope patent-text">Triphosgene (169 mg, 0.5710 mmol, 0.36 eq.) was added to a stirred solution of the mono Boc product I16 (1.474 g, 1.586 mmol, 1.0 eq.) and Et<sub class="style-scope patent-text">3</sub>N (486 μL, 3.489 mmol, 2.2 eq.) in dry CH<sub class="style-scope patent-text">2</sub>Cl<sub class="style-scope patent-text">2 </sub>(9 mL) at −10° C. After stirring for 10 minutes under argon, analysis by LC/MS revealed complete conversion to isocyanate (sampled in MeOH to give methyl carbamate, retention time 2.30 minutes, ES+ m/z 1009 [M+Na]<sup class="style-scope patent-text">+</sup>, 987 [M+H]<sup class="style-scope patent-text">+</sup>). A solution of 16 (898 mg, 2.379 mmol, 1.5 eq.) and Et<sub class="style-scope patent-text">3</sub>N (332 μL, 2.379 mmol, 1.5 eq.) in dry CH<sub class="style-scope patent-text">2</sub>Cl<sub class="style-scope patent-text">2 </sub>(14 mL) was added. The reaction was gradually warmed to rt and stirred for 16 h. 15 minute LC/MS analysis revealed starting material had been consumed. The reaction mixture was filtered through a SiO<sub class="style-scope patent-text">2 </sub>pad (5% MeOH in CH<sub class="style-scope patent-text">2</sub>Cl<sub class="style-scope patent-text">2 </sub>elution) to remove excess 16. Flash column chromatography (20-80% EtOAc in hexane) provided I17 as a yellow foam (1.439 g, 68% yield). LC/MS retention time=2.26 min (3 minute run) and 10.43 min (15 minute run) ES<sup class="style-scope patent-text">+</sup> m/z 1355 [M+Na]<sup class="style-scope patent-text">+</sup>, 1333 [M+H]<sup class="style-scope patent-text">+</sup>. A negligible amount of urea dimer was observed (LC/MS retention time=12.11 min, ES<sup class="style-scope patent-text">+</sup> m/z 1906 [M+Na]<sup class="style-scope patent-text">+</sup>) which was removed in subsequent purification steps.</div>
    <heading id="h-0447" class="style-scope patent-text">(f) tert-butyl (5-((5-(5-((((4-((S)-2-((S)-2-(((allyloxy)carbonyl)amino)-3-methylbutanamido)propanamido)benzyl)oxy)carbonyl)amino)-2-hydroxy-4-((S)-2-(hydroxymethyl)pyrrolidine-1-carbonyl)phenoxy)pentyl)oxy)-2-((S)-2-(hydroxymethyl)pyrrolidine-1-carbonyl)-4-methoxyphenyl) carbamate (I18)</heading>
    <div id="p-1207" num="1398" class="description-paragraph style-scope patent-text">Acetic acid (124 μL, 2.160 mmol, 2.0 eq.) was added to a 1M solution of TBAF (3.2 mL, 3.200 mmol, 3.0 eq.) and subsequently added to a stirring solution of I17 in THF (67 mL) at 0° C. The reaction mixture was warmed to room temperature and stirred for 16 hours. LC/MS indicated reaction incomplete. TBAF (1.00 mL of 1M solution, 1 mmol, 1.0 eq.) was added and the reaction mixture stirred for a further 24 hours. The reaction mixture was concentrated in vacuo and purified by Isolera™ (0-5% MeOH in CH<sub class="style-scope patent-text">2</sub>Cl<sub class="style-scope patent-text">2</sub>) to afford the product I18 as a pale yellow foam (916 mg, 77% yield). LC/MS retention time=1.62 min, ES<sup class="style-scope patent-text">+</sup> m/z 1126 [M+Na]<sup class="style-scope patent-text">+</sup>, 1104 [M+H]<sup class="style-scope patent-text">+</sup>.</div>
    <heading id="h-0448" class="style-scope patent-text">(g) 4-((S)-2-((S)-2-(((allyloxy)carbonyl)amino)-3-methylbutanamido)propanamido)benzyl (11S,11aS)-8-((5-(((11S,11aS)-10-(tert-butoxycarbonyl)-11-hydroxy-7-methoxy-5-oxo-2,3,5,10,11,11a-hexahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)pentyl)oxy)-11-hydroxy-7-methoxy-5-oxo-2,3,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10(5H)-carboxylate (I19)</heading>
    <div id="p-1208" num="1399" class="description-paragraph style-scope patent-text">IBX (1.14 g, 1.825 mmol, 2.2 eq.) was added to a stirring solution of diol I18 (916 mg, 0.8296 mmol, 1.0 eq.) in DMSO. The reaction mixture was warmed to 35° C. and stirred for 60 hours. H<sub class="style-scope patent-text">2</sub>O was added and the aqueous was extracted with CHCl<sub class="style-scope patent-text">3 </sub>several times. The organic extracts were combined, washed with sat. NaHCO<sub class="style-scope patent-text">3 </sub>and dried over MgSO<sub class="style-scope patent-text">4</sub>. Purification by Isolera™ (1-8% MeOH in CH<sub class="style-scope patent-text">2</sub>Cl<sub class="style-scope patent-text">2</sub>) provided I19 as an orange foam (908 mg, 99% yield): LC/MS retention time=1.50 minutes, ES+ m/z 1122 [M+Na]<sup class="style-scope patent-text">+</sup>, 1100 [M+H]<sup class="style-scope patent-text">+</sup>.</div>
    <heading id="h-0449" class="style-scope patent-text">(h) 4-((S)-2-((S)-2-amino-3-methylbutanamido)propanamido)benzyl (11S,11aS)-8-((5-(((11S,11aS)-10-(tert-butoxycarbonyl)-11-hydroxy-7-methoxy-5-oxo-2,3,5,10,11,11a-hexahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)pentyl)oxy)-11-hydroxy-7-methoxy-5-oxo-2,3,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10(5H)-carboxylate (I20)</heading>
    <div id="p-1209" num="1400" class="description-paragraph style-scope patent-text">Pd(PPh<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">4 </sub>(15.8 mg, 13.64 μmol, 0.050 eq.) was added to a stirring solution of pyrrolidine (56 μL, 0.6818 mmol, 2.5 eq.) and I19 (300 mg, 0.2727 mmol) in CH<sub class="style-scope patent-text">2</sub>Cl<sub class="style-scope patent-text">2 </sub>(10 mL) under argon. After 30 minutes, sat. NH<sub class="style-scope patent-text">4</sub>Cl solution was added and the mixture vigorously stirred and transferred to an Isolute® Phase Separator. The collected organic phase was concentrated in vacuo to afford an orange foam I20 which was used without further purification.</div>
    <heading id="h-0450" class="style-scope patent-text">(i) tert-butyl (11S,11aS)-8-((5-(((11S,11aS)-10-(((4-((2S,5S)-37-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5-isopropyl-2-methyl-4,7,35-trioxo-10,13,16,19,22,25,28,31-octaoxa-3,6,34-triazaheptatriacontanamido)benzyl)oxy)carbonyl)-11-hydroxy-7-methoxy-5-oxo-2,3,5,10,11,11a-hexahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)pentyl)oxy)-11-hydroxy-7-methoxy-5-oxo-2,3,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10(5H)-carboxylate (I21)</heading>
    <div id="p-1210" num="1401" class="description-paragraph style-scope patent-text">EDCl.HCl (117 mg, 0.29 mmol) was added to a stirred solution of MAL-dPEG®<sub class="style-scope patent-text">8</sub>-acid (360 mg, 0.6079 mmol, Stratech Scientific Limited) and amine I20 (608 mg, 0.5526 mmol) in CH<sub class="style-scope patent-text">2</sub>Cl<sub class="style-scope patent-text">2 </sub>(15 mL) at room temperature. The reaction mixture was stirred under an argon atmosphere for 24 hours, at which point analysis by LC/MS showed complete consumption of I20. The reaction mixture was diluted with CH<sub class="style-scope patent-text">2</sub>Cl<sub class="style-scope patent-text">2 </sub>and washed successively with sat. NH<sub class="style-scope patent-text">4</sub>Cl and sat. NaHCO<sub class="style-scope patent-text">3</sub>, dried over MgSO<sub class="style-scope patent-text">4</sub>, and concentrated in vacuo to provide the crude product. Purification by Isolera™ (4-16% MeOH in CH<sub class="style-scope patent-text">2</sub>Cl<sub class="style-scope patent-text">2</sub>) gave amide I21 as a white solid (77 mg, 79% purity (UV integration @ 223 nm) 8.8% crude yield; 107 mg, 88% purity, 12% crude yield; 224 mg, 86% purity, 25% crude yield).</div>
    <heading id="h-0451" class="style-scope patent-text">(j) 4-((2S,5S)-37-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5-isopropyl-2-methyl-4,7,35-trioxo-10,13,16,19,22,25,28,31-octaoxa-3,6,34-triazaheptatriacontanamido)benzyl(11S,11aS)-11-hydroxy-7-methoxy-8-(3-(((S)-7-methoxy-5-oxo-2,3,5,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl)oxy)propoxy)-5-oxo-2,3,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylate (2)</heading>
    <div id="p-1211" num="1402" class="description-paragraph style-scope patent-text">An ice-cold solution of 95:5 v/v TFA/H<sub class="style-scope patent-text">2</sub>O (3 mL) was added to a crude sample of the Boc-protected compound I21 (107 mg, 67.51 μmol) at 0° C. (ice/brine). After stirring at 0° C. for 30 min, the reaction was deemed complete as judged by LC/MS, desired product peak at retention time 1.38 minutes, ES+ m/z 737 [M+2H]<sup class="style-scope patent-text">2+</sup>, 748 [M+H+Na]<sup class="style-scope patent-text">2</sup>+; 1472 [M+H]<sup class="style-scope patent-text">+</sup>. The reaction mixture was kept cold and added drop-wise to a chilled saturated aqueous solution of NaHCO<sub class="style-scope patent-text">3</sub>. The mixture was extracted with CH<sub class="style-scope patent-text">2</sub>Cl<sub class="style-scope patent-text">2</sub>, then 10% MeOH in CH<sub class="style-scope patent-text">2</sub>Cl<sub class="style-scope patent-text">2</sub>, the combined organic layers dried over MgSO<sub class="style-scope patent-text">4 </sub>and concentrated in vacuo to provide the crude product. This process was repeated for the other batches of 121, the crude products combined and purified by preparative HPLC (Method B) to afford 2 as a white solid after lyophilisation (126 mg, 33% yield, 96% purity by UV @ 223 nm): LC/MS (30 minute run), retention time=10.96 minutes, ES+ m/z 1472 [M+H]<sup class="style-scope patent-text">+</sup>.</div>
    <heading id="h-0452" class="style-scope patent-text">Example 3</heading>
    <div id="p-1212" num="1403" class="description-paragraph style-scope patent-text">
      <chemistry id="CHEM-US-00050" num="00050" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/74/8e/d4/6d48d0e2fb7777/US11370801-20220628-C00050.png" class="style-scope patent-text"><img id="EMI-C00050" he="214.12mm" wi="152.74mm" file="US11370801-20220628-C00050.TIF" alt="Figure US11370801-20220628-C00050" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="611" height="856" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/74/8e/d4/6d48d0e2fb7777/US11370801-20220628-C00050.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00050" attachment-type="cdx" file="US11370801-20220628-C00050.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00050" attachment-type="mol" file="US11370801-20220628-C00050.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00051" num="00051" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/ed/bd/30/8bef8f6982cc3c/US11370801-20220628-C00051.png" class="style-scope patent-text"><img id="EMI-C00051" he="226.14mm" wi="151.30mm" file="US11370801-20220628-C00051.TIF" alt="Figure US11370801-20220628-C00051" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="605" height="905" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/ed/bd/30/8bef8f6982cc3c/US11370801-20220628-C00051.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00051" attachment-type="cdx" file="US11370801-20220628-C00051.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00051" attachment-type="mol" file="US11370801-20220628-C00051.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00052" num="00052" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/6c/44/2b/f0197294bc0608/US11370801-20220628-C00052.png" class="style-scope patent-text"><img id="EMI-C00052" he="185.42mm" wi="153.08mm" file="US11370801-20220628-C00052.TIF" alt="Figure US11370801-20220628-C00052" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="612" height="742" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/6c/44/2b/f0197294bc0608/US11370801-20220628-C00052.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00052" attachment-type="cdx" file="US11370801-20220628-C00052.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00052" attachment-type="mol" file="US11370801-20220628-C00052.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00053" num="00053" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/38/a9/05/6c725b41d4a872/US11370801-20220628-C00053.png" class="style-scope patent-text"><img id="EMI-C00053" he="102.45mm" wi="154.35mm" file="US11370801-20220628-C00053.TIF" alt="Figure US11370801-20220628-C00053" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="617" height="410" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/38/a9/05/6c725b41d4a872/US11370801-20220628-C00053.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00053" attachment-type="cdx" file="US11370801-20220628-C00053.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00053" attachment-type="mol" file="US11370801-20220628-C00053.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
    </div>
    <heading id="h-0453" class="style-scope patent-text">(a) I23</heading>
    <div id="p-1213" num="1404" class="description-paragraph style-scope patent-text">This step may be carried out as in the literature (see for example WO2005085259A2; or Wells, et al., <i class="style-scope patent-text">Bioorganic </i>&amp; <i class="style-scope patent-text">Medicinal Chemistry Letters, </i>18 (2008) 2147-2151). The method involves a Parr Hydrogenation at room temperature with 10% Pd/C in EtOH. The yield is quantitative. Ethanol is removed by two evaporations (EtOAc, followed by DCM).</div>
    <heading id="h-0454" class="style-scope patent-text">(b) Tert-butyl (11S,11aS)-8-((3-(bromomethyl)benzyl)oxy)-7-methoxy-5-oxo-11-((tetrahydro-2H-pyran-2-yl)oxy)-2,3,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10(5H)-carboxylate (I25)</heading>
    <div id="p-1214" num="1405" class="description-paragraph style-scope patent-text">A mixture of phenol I23 (4 g, 8.91 mmol, 1 eq), 1,3-bis(bromomethyl)benzene I24 (9.42 g, 35.7 mmol, 4 eq), potassium carbonate (1.23 g, 8.91 mmol, 1 eq), and acetone (40 mL) were heated at 60° C. for 5 hours. After completion was observed by LC/MS, the solids were removed by filtration and the filtrate was concentrated to dryness under vacuum. The residue was purified by chromatography (Biotage Isolera, 100 g Ultra, gradient EtOAc/Hexane 30/70 up to 80/20 in 12CV). Yield 4.25 g (75%). LC/MS, 3 min method, 1.82 min (ES+) m/z (relative intensity) 631.15 ([M+H]<sup class="style-scope patent-text">+</sup>, 100), split peak: THP diastereoisomers. <sup class="style-scope patent-text">1</sup>H NMR (400 MHz, DMSO-d<sub class="style-scope patent-text">6</sub>) δ 7.67-7.27 (m, 4H), 7.20-6.57 (m, 2H), 5.72-5.57 (m, 1H), 5.24-4.84 (m, 3H), 4.72 (s, 2H), 3.91-3.73 (m, 4H), 3.61-3.33 (m, 4H), 2.20-1.75 (m, 4H), 1.74-1.57 (m, 2H), 1.55-1.01 (m, 13H).</div>
    <div id="p-1215" num="1406" class="description-paragraph style-scope patent-text">I28 is known in the literature (see WO2013053872A1, Compound 2, page 60)</div>
    <heading id="h-0455" class="style-scope patent-text">(c) (S)-(2-(hydroxymethyl)pyrrolidin-1-yl) (5-methoxy-2-nitro-4-((triisopropylsilyl)oxy)phenyl)methanone (I29)</heading>
    <div id="p-1216" num="1407" class="description-paragraph style-scope patent-text">EDCl (12.4 g, 65 mmol, 1.2 eq) was added to a solution of acid I28 (20 g, 54.1 mmol, 1 eq), and hydroxybenzotriazole hydrate (8.05 g, 59.5 mmol, 1.1 eq) in dichloromethane (200 mL) at 0° C. The cold bath was removed and the reaction was allowed to proceed for 30 mins at room temperature, at which time a solution of (S)-pyrrolidin-2-ylmethanol (5.87 mL, 59.5 mmol, 1.1 eq) and triethylamine (11.32 mL, 81.1 mmol, 1.5 eq) in dichloromethane (100 mL) was added rapidly at −10° C. under argon. The reaction mixture was allowed to stir at room temperature for 40 min to 1 h and monitored by LC/MS and TLC (EtOAc). The solids were removed by filtration over celite and the organic phase was washed with cold aqueous 0.1 M HCl until the pH was measured at 4 or 5. The organic phase was then washed with water, followed by saturated aqueous sodium bicarbonate and brine. The organic layer was dried over magnesium sulphate, filtered and excess solvent removed by rotary evaporation under reduced pressure. The residue was subjected to column flash chromatography (Isolera Biotage, 340 g Ultra; gradient 25/75 ethyl acetate/hexane to 100/0 ethyl acetate/hexane in 6 CV). Excess solvent was removed by rotary evaporation under reduced pressure afforded the pure product I29 as a pale yellow foam (15.7 g, 64%). LC/MS 1.92 min (ES+) m/z (relative intensity) 453.15 ([M+H]<sup class="style-scope patent-text">+</sup>, 30%; 328.15, 100%); <sup class="style-scope patent-text">1</sup>H NMR (400 MHz, Chloroform-d) δ 7.70 (s, 1H), 6.77 (s, 1H), 4.57-4.24 (m, 2H), 4.01-3.69 (m, 5H), 3.25-3.06 (m, 2H), 2.18 (dt, J=7.5, 5.6 Hz, 1H), 1.96-1.62 (m, 3H), 1.42-1.18 (m, 3H), 1.10 (d, J=7.4 Hz, 18H).</div>
    <heading id="h-0456" class="style-scope patent-text">(d) (S)-(2-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidin-1-yl) (5-methoxy-2-nitro-4-((triisopropylsilyl)oxy)phenyl)methanone (I30)</heading>
    <div id="p-1217" num="1408" class="description-paragraph style-scope patent-text">t-Butyldimethylsilyl chloride (10.39 g, 68.9 mmol, 2 eq) was added to a solution of alcohol I29 (15.6 g, 34.5 mmol, 1 eq), and imidazole (5.87 g, 86.2 mmol, 2.5 eq) in DCM (100 mL). The reaction mixture stirred overnight at room temperature. The reaction mixture was sequentially washed with water (300 mL), 0.5 M citric acid (200 mL), brine (100 mL), and dried (MgSO4). Filtration and removal of excess solvent furnished the crude product, which was subjected to flash column chromatography (Biotage Isolera, KP-Sil 340 g; 10/90 v/v ethyl acetate/hexane up to 30/70 v/v ethyl acetate/hexane) to isolate the silyl ether I30 as a thick yellow oil. Yield: 18.9 g, 97%. LC/MS 2.32 min (ES+) m/z (relative intensity) 567.55 ([M+H]<sup class="style-scope patent-text">+</sup>, 100%)</div>
    <heading id="h-0457" class="style-scope patent-text">(e) (S)-(2-amino-5-methoxy-4-((triisopropylsilyl)oxy)phenyl) (2-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidin-1-yl)methanone (I31)</heading>
    <div id="p-1218" num="1409" class="description-paragraph style-scope patent-text">A solution of nitro compound I30 (18.9 g, 33.3 mmol, 1 eq) in ethyl acetate (200 mL) over 10% Pd/C (10% w/w, 1.89 g) was hydrogenated under pressure (45 psi) on a Parr apparatus for 6 h. The reaction mixture was filtered through celite to remove the Pd/C, and the filter pad was rinsed with ethyl acetate. Excess solvent was removed by rotary evaporation under reduced pressure, followed by drying under high vacuum to give amine I31 as a thick oil. LC/MS, 3 min method, 2.28 min (ES+) m/z (relative intensity) 537.30 ([M+H]<sup class="style-scope patent-text">+</sup>, 100); <sup class="style-scope patent-text">1</sup>H NMR (400 MHz, Chloroform-d) δ 6.73 (s, 1H), 6.24 (s, 1H), 4.54-4.13 (m, 3H), 4.07-3.80 (m, 1H), 3.79-3.61 (m, 4H), 3.50 (dd, J=9.2, 4.2 Hz, 2H), 2.10-1.97 (m, 2H), 1.92 (dt, J=11.7, 6.2 Hz, 1H), 1.80-1.65 (m, 1H), 1.24 (ddt, J=13.7, 9.9, 6.4 Hz, 3H), 1.09 (d, J=7.3 Hz, 18H), 0.90 (s, 9H), 0.04 (d, J=2.8 Hz, 6H).</div>
    <heading id="h-0458" class="style-scope patent-text">(f) Allyl ((S)-1-(((S)-1-((4-((((2-((S)-2-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidine-1-carbonyl)-4-methoxy-5-((triisopropylsilyl)oxy)phenyl)carbamoyl)oxy)methyl)phenyl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl) carbamate (I32)</heading>
    <div id="p-1219" num="1410" class="description-paragraph style-scope patent-text">Triethylamine (10.1 mL, 72.4 mmol, 2.2 eq) was added to a stirred solution of the amine I31 (17.68 g, 32.9 mmol, 1 eq) and triphosgene (3.51 g, 11.8 mmol, 0.36 eq) in dry tetrahydrofuran (180 mL) at 5° C. (ice bath). The progress of the isocyanate reaction was monitored by periodically removing aliquots from the reaction mixture and quenching with methanol and performing LC/MS analysis. Once the isocyanate formation was complete a suspension of the alloc-Val-Ala-PABOH 16 (18.6 g, 49.4 mmol, 1.5 eq) and triethylamine (6.88 mL, 49.4 mmol, 1.5 eq) in dry tetrahydrofuran (70 mL) was rapidly added to the freshly prepared isocyanate. The reaction mixture was allowed to stir at 40° C. for 4 hours. The solids were removed by filtration. Excess solvent was removed by rotary evaporation under reduced pressure. The resulting residue was dry loaded on silica gel and subjected to manual flash column chromatography; 40/60 v/v ethyl acetate/hexane up to 70/30 v/v ethyl acetate/hexane. Pure fractions were collected and combined and excess eluent was removed by rotary evaporation under reduced pressure to give the product I32 8.17 g (26.4%). LC/MS, 3 min method, 2.29 min (ES+) m/z (relative intensity) 962.45 ([M+Na]<sup class="style-scope patent-text">+</sup>, 100; 940.40 ([M+H]<sup class="style-scope patent-text">+</sup>, 30); <sup class="style-scope patent-text">1</sup>H NMR (400 MHz, Chloroform-d) δ 8.95 (s, 1H), 8.53 (s, 1H), 7.78 (s, 1H), 7.53 (d, J=8.1 Hz, 2H), 7.32 (d, J=8.3 Hz, 2H), 6.80 (s, 1H), 6.71 (d, J=7.5 Hz, 1H), 5.89 (tt, J=10.8, 5.3 Hz, 1H), 5.44-5.15 (m, 3H), 5.10 (s, 2H), 4.66 (p, J=7.2 Hz, 1H), 4.62-4.53 (m, 2H), 4.32 (s, 1H), 4.08-3.86 (m, 2H), 3.74 (s, 4H), 3.52 (dd, J=27.4, 7.6 Hz, 2H), 2.15 (h, J=6.8 Hz, 1H), 2.09-1.85 (m, 3H), 1.71 (s, 1H), 1.46 (d, J=7.0 Hz, 3H), 1.29 (dq, J=15.0, 7.4 Hz, 3H), 1.11 (d, J=7.4 Hz, 18H), 0.95 (dd, J=14.1, 6.8 Hz, 6H), 0.89 (s, 9H), 0.02 (d, J=13.1 Hz, 6H).</div>
    <heading id="h-0459" class="style-scope patent-text">(g) Allyl ((S)-1-(((S)-1-((4-((((2-((S)-2-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidine-1-carbonyl)-5-hydroxy-4-methoxyphenyl)carbamoyl)oxy)methyl)phenyl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl) carbamate (I33)</heading>
    <div id="p-1220" num="1411" class="description-paragraph style-scope patent-text">Lithium acetate (50 mg, 0.49 mmol) was added to a solution of compound I32 (7 g, 7.44 mmol, 1 eq) in wet dimethylformamide (61.2 mL, 50:1 DMF/water). After 4 hours, the reaction was complete. Excess DMF was removed under vacuum and the residue was diluted with ethyl acetate (300 mL) and washed with 0.5M aqueous citric acid (100 mL), water (300 mL) and brine (100 mL). The organic layer was dried over magnesium sulphate filtered and excess ethyl acetate was removed by rotary evaporation under reduced pressure. The resulting residue was subjected to column flash chromatography (Biotage Isolera 100 g Ultra; gradient, 40/60 to 80/20 v/v ethyl acetate/hexane in 8 CV). Pure fractions were collected and combined and excess eluent was removed by rotary evaporation under reduced pressure to give the product I33 (5.13 g, 88%). LC/MS, 3 min method, 1.82 min (ES+) m/z (relative intensity) 784.40 ([M+H]<sup class="style-scope patent-text">+</sup>, 100). <sup class="style-scope patent-text">1</sup>H NMR (400 MHz, Chloroform-d) δ 9.06 (s, 1H), 8.62 (s, 1H), 7.78 (s, 1H), 7.45 (d, J=8.2 Hz, 2H), 7.35-7.18 (m, 2H), 6.92 (d, J=7.5 Hz, 1H), 6.80 (s, 1H), 6.50 (s, 1H), 5.89 (ddd, J=16.2, 10.7, 5.4 Hz, 1H), 5.44 (d, J=8.1 Hz, 1H), 5.37-5.15 (m, 2H), 5.14-5.01 (m, 2H), 4.67 (p, J=7.1 Hz, 1H), 4.63-4.50 (m, 2H), 4.33 (s, 1H), 4.13-3.89 (m, 2H), 3.81 (s, 3H), 3.74-3.33 (m, 3H), 2.24-1.84 (m, 4H), 1.69 (d, J=21.2 Hz, 1H), 1.43 (d, J=7.0 Hz, 3H), 1.07-0.71 (m, 15H), 0.23-−0.20 (m, 6H).</div>
    <heading id="h-0460" class="style-scope patent-text">(h) Tert-butyl (11S,11aS)-8-((3-((5-((((4-((S)-2-((S)-2-(((allyloxy)carbonyl)amino)-3-methylbutanamido)propanamido)benzyl)oxy)carbonyl)amino)-4-((S)-2-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidine-1-carbonyl)-2-methoxyphenoxy)methyl)benzyl)oxy)-7-methoxy-5-oxo-11-((tetrahydro-2H-pyran-2-yl)oxy)-2,3,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10(5H)-carboxylate (I34)</heading>
    <div id="p-1221" num="1412" class="description-paragraph style-scope patent-text">Potassium carbonate (582 mg, 4.21 mmol, 1.1 eq) was added to a solution of I25 (2.66 g, 4.21 mmol, 1.1 eq) and phenol I33 (3 g, 3.82 mmol, 1 eq) in acetone (18 mL). The reaction was stirred for 4 hours at 63° C. The solids were removed by filtration over cotton wool. Acetone was removed by rotary evaporation under reduced pressure. The resulting residue was subjected to flash column chromatography (Biotage isolera, 100 g Ultra, silica gel; gradient, 50/50 to 100/0 v/v ethyl acetate/hexane in 8 CV, elution from 83%). Pure fractions were collected and combined and excess eluent was removed by rotary evaporation under reduced pressure to give the product I34 (4.71 g, 92%). LC/MS, 3 min method, 2.08 min (ES+) m/z (relative intensity) 1335.15 ([M+H]<sup class="style-scope patent-text">+</sup>, 50). <sup class="style-scope patent-text">1</sup>H NMR (400 MHz, DMSO-d<sub class="style-scope patent-text">6</sub>) δ 9.98 (s, 1H), 9.20 (s, 1H), 8.13 (d, J=7.0 Hz, 1H), 7.68-7.50 (m, 3H), 7.50-7.37 (m, 3H), 7.32 (d, J=8.2 Hz, 2H), 7.28-7.01 (m, 2H), 6.86 (s, 2H), 5.90 (ddd, J=16.0, 10.7, 5.2 Hz, 1H), 5.64 (t, J=9.8 Hz, 1H), 5.30 (d, J=17.2 Hz, 1H), 5.23-4.84 (m, 8H), 4.57-4.36 (m, 3H), 4.11 (s, 1H), 3.95-3.59 (m, 9H), 3.56-3.34 (m, 4H), 1.94 (d, J=34.0 Hz, 10H), 1.74-1.06 (m, 21H), 1.01-0.59 (m, 15H), 0.03 (s, 6H).</div>
    <heading id="h-0461" class="style-scope patent-text">(i) Tert-butyl (11S,11aS)-8-((3-((5-((((4-((S)-2-((S)-2-(((allyloxy)carbonyl)amino)-3-methylbutanamido)propanamido)benzyl)oxy)carbonyl)amino)-4-((S)-2-(hydroxymethyl)pyrrolidine-1-carbonyl)-2-methoxyphenoxy)methyl)benzyl)oxy)-7-methoxy-5-oxo-11-((tetrahydro-2H-pyran-2-yl)oxy)-2,3,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10 (5H)-carboxylate (I35)</heading>
    <div id="p-1222" num="1413" class="description-paragraph style-scope patent-text">Tetra-n-butylammonium fluoride (1M, 6.94 mL, 6.94 mmol, 2 eq) was added to a solution of I34 (4.63 g, 3.47 mmol, 1 eq) in tetrahydrofuran (28 mL). The starting material was totally consumed after 1 h. The reaction mixture was diluted with ethyl acetate (30 mL) and washed sequentially with water and brine. The organic phase was dried over magnesium sulphate filtered and excess ethyl acetate removed by rotary evaporation under reduced pressure. The resulting residue was subjected to flash column chromatography (Biotage isolera, 50 g Ultra; gradient, 98/2 to 90/10 v/v ethyl acetate/methanol in 4 CV, elution from 10% methanol). Pure fractions were collected and combined and excess eluent was removed by rotary evaporation under reduced pressure to give the product I35 (4.23 g, quantitative). LC/MS, 3 min, 1.75 min (ES+) m/z (relative intensity) 1220.30 ([M+H]<sup class="style-scope patent-text">+</sup>, 100). <sup class="style-scope patent-text">1</sup>H NMR (400 MHz, DMSO-d<sub class="style-scope patent-text">6</sub>) δ 9.98 (s, 1H), 9.17 (s, 1H), 8.13 (d, J=7.0 Hz, 1H), 7.70-7.49 (m, 3H), 7.51-7.27 (m, 6H), 7.21 (d, J=8.8 Hz, 1H), 7.15-6.58 (m, 3H), 5.90 (dt, J=10.9, 5.5 Hz, 1H), 5.66 (d, J=9.3 Hz, 1H), 5.38-4.82 (m, 9H), 4.73 (t, J=5.8 Hz, 1H), 4.59-4.34 (m, 3H), 4.05 (dd, J=15.4, 8.3 Hz, 1H), 3.96-3.68 (m, 8H), 3.66-3.32 (m, 6H), 2.16-1.72 (m, 8H), 1.63 (d, J=9.8 Hz, 3H), 1.54-1.02 (m, 18H), 0.86 (dd, J=18.2, 6.7 Hz, 6H).</div>
    <heading id="h-0462" class="style-scope patent-text">(j) 4-((S)-2-((S)-2-(((allyloxy)carbonyl)amino)-3-methylbutanamido)propanamido)benzyl (11S,11aS)-8-((3-((((11S,11aS)-10-(tert-butoxycarbonyl)-7-methoxy-5-oxo-11-((tetrahydro-2H-pyran-2-yl)oxy)-2,3,5,10,11,11a-hexahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)methyl)benzyl)oxy)-11-hydroxy-7-methoxy-5-oxo-2,3,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10(5H)-carboxylate (I36)</heading>
    <div id="p-1223" num="1414" class="description-paragraph style-scope patent-text">Stabilised IBX 45% (2.72 g, 4.36 mmol, 1.2 eq) was added to a solution of I35 (4.44 g, 3.64 mmol, 1 eq) in DMSO (2.6 mL). The reaction mixture was allowed to stir overnight. Another 0.2 eq of IBX (450 mg, 0.73 mmol, 0.2 eq) was added and the solution allowed to stir for another 18 h until reaction completion was observed by LC/MS. The solution was precipitated in water (250 mL) and filtered. The product was dissolved in DCM and the residual white solid removed by filtration. The organic phase was washed with aqueous NaHCO<sub class="style-scope patent-text">3</sub>, water, brine, and dried over magnesium sulphate. The dichloromethane was removed by rotary evaporation under reduced pressure. The resulting residue was subjected to column flash chromatography (Biotage Isolera 100 g Ultra; gradient, 99/1 to 92/8 v/v DCM/methanol in 10 CV). Pure fractions were collected and combined and removal of excess eluent by rotary evaporation under reduced pressure afforded the product I36 (3.04 g, 69%). LC/MS, 15 min method Ace Excel 2, 7.89 and 7.97 min (THP diastereoisomers) (ES+) m/z (relative intensity) 1218.30 ([M]<sup class="style-scope patent-text">+</sup>, 100). <sup class="style-scope patent-text">1</sup>H NMR (400 MHz, DMSO-d<sub class="style-scope patent-text">6</sub>) δ 9.93 (s, 1H), 8.11 (d, J=6.9 Hz, 1H), 7.68-7.27 (m, 6H), 7.27-7.01 (m, 4H), 7.01-6.32 (m, 3H), 6.02-5.81 (m, 1H), 5.71-5.57 (m, 1H), 5.57-5.40 (m, 1H), 5.29 (d, J=17.2 Hz, 1H), 5.21-4.78 (m, 8H), 4.58-4.32 (m, 3H), 3.99-3.68 (m, 8H), 3.58-3.31 (m, 8H), 2.23-1.72 (m, 9H), 1.72-1.04 (m, 18H), 0.85 (dd, J=18.0, 6.7 Hz, 6H).</div>
    <heading id="h-0463" class="style-scope patent-text">(k) 4-((S)-2-((S)-2-amino-3-methylbutanamido)propanamido)benzyl (11S,11aS)-8-((3-((((11S,11aS)-10-(tert-butoxycarbonyl)-7-methoxy-5-oxo-11-((tetrahydro-2H-pyran-2-yl)oxy)-2,3,5,10,11,11a-hexahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)methyl)benzyl)oxy)-11-hydroxy-7-methoxy-5-oxo-2,3,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10(5H)-carboxylate (I37)</heading>
    <div id="p-1224" num="1415" class="description-paragraph style-scope patent-text">Tetrakis(triphenylphosphine)palladium(0) (11 mg, 0.01 mmol, 0.02 eq) was added to a solution of I36 (600 mg, 0.49 mmol, 1 eq) and pyrrolidine (51 μL, 0.62 mmol, 1.25 eq) in dry dichloromethane (10 mL). The reaction was flushed with argon three times and stirred 20 minutes at room temperature. Then the reaction was diluted with dichloromethane (50 mL) and washed sequentially with saturated aqueous ammonium chloride (50 mL) and brine (30 mL). The organic phase was dried over magnesium sulphate filtered and excess dichloromethane removed by rotary evaporation under reduced pressure. The resulting residue I37 was used as a crude mixture for the next reaction. LC/MS, 3 min method, 1.29 min (ES+) m/z (relative intensity) 1134.35 ([M+H]<sup class="style-scope patent-text">+</sup>, 80).</div>
    <heading id="h-0464" class="style-scope patent-text">(l) tert-butyl (11S,11aS)-8-((3-((((11S,11aS)-10-(((4-((2S,5S)-37-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5-isopropyl-2-methyl-4,7,35-trioxo-10,13,16,19,22,25,28,31-octaoxa-3,6,34-triazaheptatriacontanamido)benzyl)oxy)carbonyl)-11-hydroxy-7-methoxy-5-oxo-2,3,5,10,11,11a-hexahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)methyl)benzyl)oxy)-7-methoxy-5-oxo-11-((tetrahydro-2H-pyran-2-yl)oxy)-2,3,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10(5H)-carboxylate (I38)</heading>
    <div id="p-1225" num="1416" class="description-paragraph style-scope patent-text">1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide (94 mg, 0.79 mmol, 1 eq) was added to a solution of crude I37 (558 mg, 0.49 mmol, 1 eq) and Mal-(PEG)<sub class="style-scope patent-text">8</sub>-acid (292 mg, 0.49 mmol, 1 eq) in chloroform (12 mL). The reaction was degassed three times with Argon and stirred for 2 hours and the presence of starting material was no longer observed by LC/MS. The reaction was diluted with dichloromethane and washed sequentially with water and brine. The organic phase was dried over magnesium sulphate filtered and excess dichloromethane removed by rotary evaporation under reduced pressure. The resulting residue was subjected to flash column chromatography (Biotage Isolera 50 g Ultra; 98/2 to 90/10 v/v DCM/methanol in 10 CV). Pure fractions were collected and combined and excess eluent was removed by rotary evaporation under reduced pressure to give I38 (485 mg, 58%). LC/MS, 3 min method, 1.58 min (ES+) m/z (relative intensity) 1709.30 ([M+H]<sup class="style-scope patent-text">+</sup>, 100). <sup class="style-scope patent-text">1</sup>H NMR (400 MHz, DMSO-d<sub class="style-scope patent-text">6</sub>) δ 9.88 (s, 1H), 8.13 (d, J=7.0 Hz, 1H), 8.06-7.92 (m, 1H), 7.85 (d, J=8.6 Hz, 1H), 7.68-7.04 (m, 9H), 6.99 (s, 2H), 6.89 (d, J=15.0 Hz, 2H), 6.52 (s, 1H), 5.66 (d, J=9.4 Hz, 1H), 5.47 (d, J=8.0 Hz, 1H), 5.26-4.75 (m, 6H), 4.49-4.31 (m, 1H), 4.20 (t, J=7.6 Hz, 1H), 3.80 (d, J=11.9 Hz, 6H), 3.59 (t, J=7.2 Hz, 4H), 3.55-3.41 (m, 32H), 3.41-3.30 (m, 11H), 3.21-3.09 (m, 3H), 2.48-2.28 (m, 4H), 2.18-1.08 (m, 24H), 0.84 (dd, J=15.0, 6.7 Hz, 5H).</div>
    <heading id="h-0465" class="style-scope patent-text">(m) 4-((2S,5S)-37-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5-isopropyl-2-methyl-4,7,35-trioxo-10,13,16,19,22,25,28,31-octaoxa-3,6,34-triazaheptatriacontanamido)benzyl (11S,11aS)-11-hydroxy-7-methoxy-8-((3-((((S)-7-methoxy-5-oxo-2,3,5,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)methyl)benzyl)oxy)-5-oxo-2,3,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10(5H)-carboxylate (3)</heading>
    <div id="p-1226" num="1417" class="description-paragraph style-scope patent-text">A cold mixture of TFA/water (6 mL) was added to I38 (460 mg, 0.27 mmol, 1 eq) and the resulting solution was allowed to stir at 0° C. for 2 hours. The reaction was neutralised with saturated aqueous NaHCO<sub class="style-scope patent-text">3 </sub>(200 mL) and dichloromethane (50 mL). The DCM layer was washed sequentially with water and brine. The organic phase was dried over magnesium sulphate filtered and excess dichloromethane removed by rotary evaporation under reduced pressure. The resulting residue was subjected to flash column chromatography (Biotage Isolera 50 g Ultra; 98/2 to 88/12 v/v DCM/methanol in 10 CV). The pure fractions were collected, combined (154 mg, 38%), and further purified by reverse phase preparative HPLC (Method C) (gradient up to 75/25 acetonitrile/water, 0.02% formic) to give pure 3 (78 mg, 19%). LC/MS, 15 min method, Ace-Excel2, 6.18 min (ES+) m/z (relative intensity) 1506.70 ([M+H]<sup class="style-scope patent-text">+</sup>, 100). <sup class="style-scope patent-text">1</sup>H NMR (400 MHz, DMSO-d<sub class="style-scope patent-text">6</sub>) δ 10.07-9.79 (m, 1H), 8.14 (d, J=7.2 Hz, 1H), 7.98 (t, J=5.6 Hz, 1H), 7.85 (d, J=8.6 Hz, 1H), 7.78 (d, J=4.4 Hz, 1H), 7.67-7.30 (m, 7H), 7.28-7.05 (m, 3H), 6.99 (s, 2H), 6.98-6.85 (m, 2H), 6.58-6.47 (m, 1H), 5.59-5.34 (m, 1H), 5.32-4.77 (m, 6H), 4.48-4.30 (m, 1H), 4.28-4.08 (m, 1H), 3.88-3.75 (m, 5H), 3.75-3.55 (m, 6H), 3.55-3.42 (m, 28H), 3.42-3.32 (m, 6H), 3.14 (q, J=5.8 Hz, 2H), 2.48-2.16 (m, 6H), 2.08-1.77 (m, 6H), 1.36-1.17 (m, 4H), 0.84 (dd, J=15.4, 6.7 Hz, 6H).</div>
    <heading id="h-0466" class="style-scope patent-text">Example 4</heading>
    <div id="p-1227" num="1418" class="description-paragraph style-scope patent-text">
      <chemistry id="CHEM-US-00054" num="00054" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/b1/82/8d/038c38502f634e/US11370801-20220628-C00054.png" class="style-scope patent-text"><img id="EMI-C00054" he="187.62mm" wi="116.67mm" file="US11370801-20220628-C00054.TIF" alt="Figure US11370801-20220628-C00054" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="467" height="750" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/b1/82/8d/038c38502f634e/US11370801-20220628-C00054.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00054" attachment-type="cdx" file="US11370801-20220628-C00054.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00054" attachment-type="mol" file="US11370801-20220628-C00054.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00055" num="00055" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/c2/eb/46/e003f116ceea79/US11370801-20220628-C00055.png" class="style-scope patent-text"><img id="EMI-C00055" he="210.99mm" wi="148.17mm" file="US11370801-20220628-C00055.TIF" alt="Figure US11370801-20220628-C00055" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="593" height="844" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/c2/eb/46/e003f116ceea79/US11370801-20220628-C00055.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00055" attachment-type="cdx" file="US11370801-20220628-C00055.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00055" attachment-type="mol" file="US11370801-20220628-C00055.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00056" num="00056" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/2e/9f/56/0f1159bc2116df/US11370801-20220628-C00056.png" class="style-scope patent-text"><img id="EMI-C00056" he="118.62mm" wi="153.84mm" file="US11370801-20220628-C00056.TIF" alt="Figure US11370801-20220628-C00056" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="615" height="474" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/2e/9f/56/0f1159bc2116df/US11370801-20220628-C00056.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00056" attachment-type="cdx" file="US11370801-20220628-C00056.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00056" attachment-type="mol" file="US11370801-20220628-C00056.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
    </div>
    <heading id="h-0467" class="style-scope patent-text">(a) ((Propane-1,3-diylbis(oxy))bis(5-methoxy-2-nitro-4,1-phenylene))bis(((S)-2-(hydroxymethyl)pyrrolidin-1-yl)methanone) (I2)</heading>
    <div id="p-1228" num="1419" class="description-paragraph style-scope patent-text">DMF (12 drops) was added to a stirred suspension of 11 (10 g, 21.5 mmol) and oxalyl chloride (5.6 mL, 8.2 g, 64.5 mmol) in anhydrous DCM (150 mL). Following initial effervescence the reaction suspension became a solution and the mixture was allowed to stir at room temperature for 16 hr. Majority of solvent was removed by evaporation under reduced pressure. The resulting concentrated solution was re-dissolved in a minimum amount of dry DCM and triturated with diethyl ether. The yellow precipitate was collected by vacuum filtration, washed with cold diethyl ether and dried for 1 hr in a vacuum oven at 40° C. The acid chloride was added, in portions, to a stirred suspension of (S)-(+)-2-pyrrolidinemethanol (5.0 g, 4.9 mL, 49.5 mmol) and TEA (15.0 mL, 10.9 g, 108 mmol) in anhydrous DCM (100 mL) at −40° C. (dry ice/CH<sub class="style-scope patent-text">3</sub>CN). The resulting solution was stirred for a further 60 mins, diluted with DCM (100 mL) and washed with 1N HCl (2×50 mL), saturated NaHCO<sub class="style-scope patent-text">3 </sub>(3×40 mL), brine (50 mL), dried (MgSO<sub class="style-scope patent-text">4</sub>) and the solvent evaporated under vacuum to give the pure product I2 as a yellow solid (13.6 g, 100% yield). LC/MS (method A): retention time 1.33 mins (ES+) m/z 655 [M+Na]<sup class="style-scope patent-text">+</sup>, 633 [M+H]<sup class="style-scope patent-text">+</sup> (see appendix). <sup class="style-scope patent-text">1</sup>H NMR (400 MHz, DMSO-d<sub class="style-scope patent-text">6</sub>) δ 1.68-1.80 (m, 2H), 1.80-2.00 (m, 6H), 2.27 (d, 2H), 3.05-3.25 (m, 4H), 3.37-3.48 (m, 2H), 3.56-3.76 (m, 2H), 3.92 (s, 6H), 4.09 (dd, 2H), 4.25-4.31 (m, 4H), 4.82 (t, 2H), 7.08 (s, 2H), 7.73 (s, 2H).</div>
    <heading id="h-0468" class="style-scope patent-text">(b) ((propane-1,3-diylbis(oxy))bis(5-methoxy-2-nitro-4,1-phenylene))bis(((S)-2-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidin-1-yl)methanone) (I39)</heading>
    <div id="p-1229" num="1420" class="description-paragraph style-scope patent-text">TBS-Cl (8.12 g, 53.90 mmol) was added to a solution of 12 (15.5 g, 24.50 mmol) and imidazole (4.17 g, 61.25 mmol) in DCM (300 mL) at room temperature under nitrogen. The resulting mixture was stirred at room temperature for 12 hr. Water (200 mL) was added, the organic layer removed, and the aqueous phase extracted with DCM (2×300 mL). The combined organic phases were dried (Na<sub class="style-scope patent-text">2</sub>SO<sub class="style-scope patent-text">4</sub>) and evaporated under vacuum to afford dark residue which was purified by column chromatography (0 to 2% methanol/DCM). Pure fractions were evaporated under vacuum to afford I39 as a brown solid (17.0 g, 81% yield). LC/MS (method A): retention time 1.83 mins (ES+) m/z 861 [M+H]<sup class="style-scope patent-text">+</sup>. <sup class="style-scope patent-text">1</sup>H NMR (400 MHz, DMSO-d<sub class="style-scope patent-text">6</sub>) δ 0.09 (s, 12H), 0.91 (s, 18H), 1.70-1.81 (m, 2H), 1.87-1.99 (m, 6H), 2.22-2.30 (m, 2H), 3.10 (t, 4H), 3.40-3.51 (m, 2H), 3.59-3.67 (m, 2H), 3.88-3.95 (m, 2H), 3.91 (s, 6H), 4.28 (t, 6H), 6.96 (s, 2H), 7.72 (s, 2H).</div>
    <heading id="h-0469" class="style-scope patent-text">(c) ((propane-1,3-diylbis(oxy))bis(2-amino-5-methoxy-4, I-phenylene))bis(((S)-2-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidin-1-yl)methanone) (I40)</heading>
    <div id="p-1230" num="1421" class="description-paragraph style-scope patent-text">Zinc (25.8 g, 394.8 mmol) and saturated NH<sub class="style-scope patent-text">4</sub>Cl (150 mL) were added to a solution of I39 (17 g, 19.74 mmol) in EtOH (300 mL) at room temperature. The resulting mixture was stirred at 50° C. for 3 hr, cooled and filtered through a bed of celite which was then washed with EtOAc (300 mL) and water (300 mL). The organic layer was removed and the aqueous layer extracted with EtOAc (3×400 mL). The combined organic phases were dried (MgSO<sub class="style-scope patent-text">4</sub>) and evaporated under vacuum to afford a yellow residue which was purified by column chromatography (0 to 5% methanol/DCM). Pure fractions were evaporated to dryness to give I40 as a yellow solid (13.00 g, 82% yield). LC/MS (method A): retention time 2.30 mins (ES+) m/z 802.2 [M+H]<sup class="style-scope patent-text">+ </sup>1H NMR (400 MHz, DMSO-d<sub class="style-scope patent-text">6</sub>) δ 0.06 (s, 12H), 0.85 (s, 18H), 1.52-1.78 (m, 2H), 1.81-2.00 (m, 6H), 2.14-2.22 (m, 2H), 3.41 (d, 4H), 3.61-3.75 (m, 4H), 3.63 (s, 6H), 4.01-4.16 (m, 6H), 4.98-5.22 (m, 4H), 6.40 (s, 2H), 6.66 (s, 2H).</div>
    <heading id="h-0470" class="style-scope patent-text">(d) allyl (5-(3-(5-amino-4-((S)-2-(((t-butyldimethylsilyl)oxy)methyl)pyrrolidine-1-carbonyl)-2-methoxyphenoxy)propoxy)-2-((S)-2-(((t-butyldimethylsilyl)oxy)methyl)pyrrolidine-1-carbonyl)-4-methoxyphenyl) carbamate (I41)</heading>
    <div id="p-1231" num="1422" class="description-paragraph style-scope patent-text">Allyl chloroformate (784 μL, 0.9 g, 7.36 mmol) was added dropwise to a solution of I40 (5.9 g, 7.36 mmol) and pyridine (715 μL, 0.7 g, 8.84 mmol) in DCM (100 mL) at 00° C. The reaction mixture was warmed to room temperature and stirred for a further 2 hr. The reaction mixture was washed with 0.5M HCl (50 mL), saturated sodium hydrogen carbonate (50 mL) and brine (50 mL). The solvent was removed under reduced pressure and the resulting oil purified by column chromatography; (initial elution with 50% ethyl acetate/heptane removed the bis-alloc protected amine, this was followed by elution with ethyl acetate to remove the desired mono-alloc protected product (141). Finally, any unreacted starting material was removed with 5% methanol/DCM). Pure fractions were evaporated under reduced pressure to leave I41 as a yellow solid (3.5 g, 54% yield). LC/MS (method B): retention time 2.41 mins (ES+) m/z 886.5 [M+H]<sup class="style-scope patent-text">+</sup> </div>
    <heading id="h-0471" class="style-scope patent-text">(e) allyl (5-(3-(5-((((4-((S)-2-((S)-2-(((allyloxy)carbonyl)amino)-3-methylbutanamido)propanamido)benzyl)oxy)carbonyl)amino)-4-((S)-2-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidine-1-carbonyl)-2-methoxyphenoxy)propoxy)-2-((S)-2-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidine-1-carbonyl)-4-methoxyphenyl)carbamate (I42)</heading>
    <div id="p-1232" num="1423" class="description-paragraph style-scope patent-text">Triphosgene (0.41 g, 1.4 mmol) was added to a stirred solution of I41 (3.5 g, 3.95 mmol) in dry THF (70 mL) at room temperature under Argon. Triethylamine (1.2 mL, 0.87 g, 8.6 mmol) was added, and the resulting mixture stirred for 10 mins. Analysis by LC/MS revealed complete conversion to isocyanate (sampled in MeOH to give methyl carbamate, retention time 2.48 mins, (ES+) m/z 944.4 [M+H]<sup class="style-scope patent-text">+</sup>). A mixture of 16 (1.64 g, 4.35 mmol) and triethylamine (0.83 mL, 0.6 g, 5.9 mmol) in dry THF (30 mL) was added. The reaction mixture was stirred under argon for 2 hr at 40° C. The solvent was removed under vacuum and the residue purified by column chromatography (0.5 to 2.5% methanol/DCM) to leave I42 as a white solid (3.58 g, 70% yield). LC/MS (method B): retention time 2.45 mins, (ES+) m/z 1290.0 [M+H]<sup class="style-scope patent-text">+</sup>.</div>
    <heading id="h-0472" class="style-scope patent-text">(f) allyl (5-(3-(5-((((4-((S)-2-((S)-2-(((allyloxy)carbonyl)amino)-3-methylbutanamido)propanamido)benzyl)oxy)carbonyl)amino)-4-((S)-2-(hydroxymethyl)pyrrolidine-1-carbonyl)-2-methoxyphenoxy)propoxy)-2-((S)-2-(hydroxymethyl)pyrrolidine-1-carbonyl)-4-methoxyphenyl)carbamate (I43)</heading>
    <div id="p-1233" num="1424" class="description-paragraph style-scope patent-text">1M tetrabutylammonium fluoride (6.1 mL, 6.1 mmol) was added to a solution of I42 (3.58 g, 2.78 mmol) in THF (35 mL) at room temperature. The resulting solution was stirred for 60 mins, then evaporated to dryness under reduced pressure. The residue was purified by column chromatography (2 to 5% methanol/DCM) to leave I43 as a white foam (2.95 g, 98% yield). LC/MS (method B): retention time 1.70 mins, (ES+) m/z 1061.3 [M+H]<sup class="style-scope patent-text">+</sup> </div>
    <heading id="h-0473" class="style-scope patent-text">(g) allyl (11S,11aS)-8-(3-(((11S,11aS)-10-(((4-((S)-2-((S)-2-(((allyloxy)carbonyl)amino)-3-methylbutanamido)propanamido)benzyl)oxy)carbonyl)-11-hydroxy-7-methoxy-5-oxo-2,3,5,10,11,11a-hexahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)propoxy)-11-hydroxy-7-methoxy-5-oxo-2,3,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10(5H)-carboxylate (I44)</heading>
    <div id="p-1234" num="1425" class="description-paragraph style-scope patent-text">Stahl aerobic oxidation TEMPO solution 0.2M in MeCN (5.47 mL, 1.1 mmol) followed by tetrakisacetonitrile copper (I) triflate (0.41 g, 1.1 mmol) was added to a solution of I43 (2.9 g, 2.74 mmol) in DCM (30 mL) and acetonitrile (6 mL) and stirred at 35° C. for 36 hr under an atmosphere of air. The reaction mixture was washed with water (25 mL), dried (biotage phase separator) and evaporated to dryness under reduced pressure. The residue was purified by column chromatography (3 to 6% methanol/DCM) to leave the oxidised product I44 as a white solid (2.46 g, 85% yield). LC/MS (method B): retention time 1.60 mins, (ES+) m/z 1057.1 [M+H]<sup class="style-scope patent-text">+</sup>.</div>
    <heading id="h-0474" class="style-scope patent-text">(h) 4-((S)-2-((S)-2-amino-3-methylbutanamido)propanamido)benzyl (11S,11aS)-11-hydroxy-7-methoxy-8-(3-(((S)-7-methoxy-5-oxo-2,3,5,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)propoxy)-5-oxo-2,3,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10(5H)-carboxylate (I45)</heading>
    <div id="p-1235" num="1426" class="description-paragraph style-scope patent-text">Pd(Ph<sub class="style-scope patent-text">3</sub>P)<sub class="style-scope patent-text">4 </sub>(10 mg, 5 mol %) was added to a solution of I44 (200 mg, 0.19 mmol) and pyrrolidine (40 μL, 0.34 g, 0.48 mmol) in DCM (10 mL) at room temperature. The resulting solution was stirred for 30 mins. The reaction mixture was washed with saturated ammonium chloride (10 mL), dried (biotage phase separator) and evaporated to dryness under reduced pressure. The residue was then placed on a high vacuum line for 4 hr to remove traces of pyrrolidine. The resulting off-white solid was used in the next step without further purification (160 mg, 97% yield). LC/MS (method B): retention time 1.17 mins, (ES+) m/z 871.1 [M+H]<sup class="style-scope patent-text">+</sup>.</div>
    <heading id="h-0475" class="style-scope patent-text">(i) 4-((2S,5S)-37-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5-isopropyl-2-methyl-4,7,35-trioxo-10,13,16,19,22,25,28,31-octaoxa-3,6,34-triazaheptatriacontanamido)benzyl (11S,11aS)-11-hydroxy-7-methoxy-8-(3-(((S)-7-methoxy-5-oxo-2,3,5,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)propoxy)-5-oxo-2,3,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10(5H)-carboxylate (1)</heading>
    <div id="p-1236" num="1427" class="description-paragraph style-scope patent-text">EDCl.HCl (46 mg, 0.24 mmol) was added to a solution of I45 and Mal-PEG<sub class="style-scope patent-text">8</sub>-acid (130 mg, 0.22 mmol) in CHCl<sub class="style-scope patent-text">3 </sub>(10 mL) and stirred at room temperature for 2 hr. LC/MS shows 78% starting material present. A further 2 eq EDCl.HCl was added in portions to push the reaction to completion. The reaction mixture was washed with water (10 mL), dried (Biotage PS) and evaporated to dryness, under reduced pressure, to leave a yellow solid which was purified by prep HPLC to leave the product 1 as an off-white solid (90 mg, 34% yield). LC/MS (method B): retention time 1.47 mins, (ES+) m/z 1445.9 [M+H]<sup class="style-scope patent-text">+</sup>.</div>
    <heading id="h-0476" class="style-scope patent-text">Example 5</heading>
    <heading id="h-0477" class="style-scope patent-text">(i) 4-((29S,32S)-1-azido-29-isopropyl-32-methyl-27,30-dioxo-3,6,9,12,15,18,21,24-octaoxa-28,31-diazatritriacontan-33-amido)benzyl (11S,11aS)-11-hydroxy-7-methoxy-8-(3-(((S)-7-methoxy-5-oxo-2,3,5,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)propoxy)-5-oxo-2,3,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10(5H)-carboxylate (4)</heading>
    <div id="p-1237" num="1428" class="description-paragraph style-scope patent-text">
      <chemistry id="CHEM-US-00057" num="00057" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/49/bd/61/9b86c417908079/US11370801-20220628-C00057.png" class="style-scope patent-text"><img id="EMI-C00057" he="128.19mm" wi="153.42mm" file="US11370801-20220628-C00057.TIF" alt="Figure US11370801-20220628-C00057" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="614" height="513" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/49/bd/61/9b86c417908079/US11370801-20220628-C00057.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00057" attachment-type="cdx" file="US11370801-20220628-C00057.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00057" attachment-type="mol" file="US11370801-20220628-C00057.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
    </div>
    <div id="p-1238" num="1429" class="description-paragraph style-scope patent-text">EDCl.HCl (27 mg, 0.14 mmol) was added to a solution of I45 and Azido-PEG<sub class="style-scope patent-text">8</sub>-acid (49 mg, 0.10 mmol) in CHCl<sub class="style-scope patent-text">3 </sub>(6 mL) and stirred at room temperature for 1 hr. The solvent was evaporated under reduced pressure, to leave a yellow foam. Purification by prep HPLC gave the product 4 as an off-white solid (20 mg, 17% yield). LC/MS (method B): retention time 6.01 min, (ES+) m/z 1320 [M+H]<sup class="style-scope patent-text">+</sup>.</div>
    <heading id="h-0478" class="style-scope patent-text">(ii) (R)-2-((3-nitropyridin-2-yl)disulfaneyl)propyl (11S,11aS)-11-hydroxy-7-methoxy-8-(3-(((S)-7-methoxy-5-oxo-2,3,5,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)propoxy)-5-oxo-2,3,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10(5H)-carboxylate (5)</heading>
    <div id="p-1239" num="1430" class="description-paragraph style-scope patent-text">
      <chemistry id="CHEM-US-00058" num="00058" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/3a/b1/3a/3fea8d26a17bbf/US11370801-20220628-C00058.png" class="style-scope patent-text"><img id="EMI-C00058" he="207.09mm" wi="112.10mm" file="US11370801-20220628-C00058.TIF" alt="Figure US11370801-20220628-C00058" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="448" height="828" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/3a/b1/3a/3fea8d26a17bbf/US11370801-20220628-C00058.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00058" attachment-type="cdx" file="US11370801-20220628-C00058.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00058" attachment-type="mol" file="US11370801-20220628-C00058.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00059" num="00059" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/1c/13/5d/ac4c7cb4b85265/US11370801-20220628-C00059.png" class="style-scope patent-text"><img id="EMI-C00059" he="48.26mm" wi="87.12mm" file="US11370801-20220628-C00059.TIF" alt="Figure US11370801-20220628-C00059" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="348" height="193" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/1c/13/5d/ac4c7cb4b85265/US11370801-20220628-C00059.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00059" attachment-type="cdx" file="US11370801-20220628-C00059.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00059" attachment-type="mol" file="US11370801-20220628-C00059.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
    </div>
    <heading id="h-0479" class="style-scope patent-text">(a) tert-butyl (5-(3-(5-amino-4-((S)-2-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidine-1-carbonyl)-2-methoxyphenoxy)propoxy)-2-((S)-2-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidine-1-carbonyl)-4-methoxyphenyl)carbamate (I46)</heading>
    <div id="p-1240" num="1431" class="description-paragraph style-scope patent-text">Boc anhydride (0.5 g, 2.3 mmol, 1.0 eq) was added to a solution of I40 (1.9 g, 2.3 mmol, 1.0 eq) in THF (50 mL) and stirred at 55° C. for 5 hr. The solvent was removed by evaporation under reduced pressure and the residue purified by column chromatography (50-100% ethyl acetate/hexane) to leave the product as a yellow solid, 1.7 g (80%). LC/MS (method 1): rt 2.48 min, m/z (902.5) M+H.</div>
    <heading id="h-0480" class="style-scope patent-text">(b) tert-butyl (2-((S)-2-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidine-1-carbonyl)-5-(3-(4-((S)-2-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidine-1-carbonyl)-2-methoxy-5-((((R)-2-((3-nitropyridin-2-yl)disulfaneyl)propoxy)carbonyl)amino)phenoxy)propoxy)-4-methoxyphenyl)carbamate (I47)</heading>
    <div id="p-1241" num="1432" class="description-paragraph style-scope patent-text">Triphosgene (0.135 g, 0.455 mmol, 0.35 eq) was added to a solution of (2R)-2-[(3-nitro-2-pyridyl)disulfanyl]propan-1-ol (0.316 g, 1.28 mmol, 1.05 eq) and pyridine (111 mg, 1.4 mmol, 1.15 eq) in anhydrous dichloromethane (5 mL) and stirred at room temperature for 30 min. The resulting solution was then added to a solution of I46 (1.10 g, 1.22 mmol, 1.0 eq) and pyridine (106 mg, 1.34 mmol, 1.1 eq) in anhydrous dichloromethane (10 mL) and stirred at room temperature for 60 min. The solvent was removed by evaporation under reduced pressure and the residue purified by column chromatography (40-50% ethyl acetate/hexane) to leave the product as a yellow foam, 1.21 g (85%). LC/MS (method 1): rt 2.53 min, m/z (1174.5) M+H.</div>
    <heading id="h-0481" class="style-scope patent-text">(c) tert-butyl (2-((S)-2-(hydroxymethyl)pyrrolidine-1-carbonyl)-5-(3-(4-((S)-2-(hydroxymethyl)pyrrolidine-1-carbonyl)-2-methoxy-5-((((R)-2-((3-nitropyridin-2-yl)disulfaneyl)propoxy)carbonyl)amino)phenoxy)propoxy)-4-methoxyphenyl)carbamate (I48)</heading>
    <div id="p-1242" num="1433" class="description-paragraph style-scope patent-text">I47 (1.21 g, 1.03 mmol) was dissolved in a mixture of acetic acid (5 mL), THF (1 mL), methanol (1 mL) and water (2 mL). The resulting solution was stirred at room temperature for 90 mins then evaporated to dryness. The residue was taken up in ethyl acetate (50 mL), washed with water (50 mL), then sat NaHCO<sub class="style-scope patent-text">3 </sub>(50 mL), dried (MgSO<sub class="style-scope patent-text">4</sub>) and evaporated under reduced pressure. The residue was purified by column (4% methanol/DCM) to leave the product as a yellow solid, 0.97 g (100%). LC/MS (method 1): rt 1.87 min, m/z (946.0) M+H.</div>
    <heading id="h-0482" class="style-scope patent-text">(d) tert-butyl (11S,11aS)-11-hydroxy-8-(3-(((11S,11aS)-11-hydroxy-7-methoxy-10-(((R)-2-((3-nitropyridin-2-yl)disulfaneyl)propoxy)carbonyl)-5-oxo-2,3,5,10,11,11a-hexahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)propoxy)-7-methoxy-5-oxo-2,3,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10(5H)-carboxylate (I49)</heading>
    <div id="p-1243" num="1434" class="description-paragraph style-scope patent-text">Stahl Aerobic Oxidation TEMPO solution (2.05 mL, 0.4 mmol, 0.2 mol/L) followed by Tetrakisacetonitrile copper(I) triflate (0.15 g, 0.40 mmol) was added to a solution of 148 (0.97 g, 1.0 mmol) in DCM (20 mL, 312.0 mmol). The resulting mixture was heated at 35° C. for 15 hrs. The organic phase was washed with water (25 mL), dried (biotage) and evaporated to dryness under reduced pressure and purified by column chromatography (3-6% methanol/DCM) to leave the product as a white solid, 0.77 g (79%). LC/MS (method 1): rt 1.70 min, m/z (941.9) M+H.</div>
    <heading id="h-0483" class="style-scope patent-text">(e) (R)-2-((3-nitropyridin-2-yl)disulfaneyl)propyl (11S,11aS)-11-hydroxy-7-methoxy-8-(3-(((S)-7-methoxy-5-oxo-2,3,5,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)propoxy)-5-oxo-2,3,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10(5H)-carboxylate (5)</heading>
    <div id="p-1244" num="1435" class="description-paragraph style-scope patent-text">Trifluoroacetic acid (4.5 mL) was added to water (0.5 mL) and cooled to 0° C. This solution was then added to I49 (0.75 g, 0.80 mmol) and the resulting mixture stirred at 0° C. for 2 hrs. The solvent was removed under reduced pressure, the residue taken up in DCM (10 mL) and the reaction mixture neutralised by the addition of sat NaHCO<sub class="style-scope patent-text">3</sub>. After drying (biotage) and evaporation under reduced pressure, the residue was purified by column (4-6% methanol/DCM) to leave the product as a bright yellow solid, 0.6 g (91%). LC/MS (method 2): rt 6.04 min, m/z (824.0) M+H.</div>
    <div id="h-0484" num="0000" class="description-paragraph style-scope patent-text">Analytical LC/MS Conditions for Example 5(ii)</div>
    <div id="p-1245" num="1436" class="description-paragraph style-scope patent-text">Positive mode electrospray mass spectrometry was performed using a Waters Aquity H-class SQD2. Mobile phases used were solvent A (water with 0.1% formic acid) and solvent B (acetonitrile with 0.1% formic acid).</div>
    <div id="p-1246" num="1437" class="description-paragraph style-scope patent-text">Method 1:</div>
    <div id="p-1247" num="1438" class="description-paragraph style-scope patent-text">Gradient for routine 3-minute run: Initial composition 5% B held over 25 seconds, then increased from 5% B to 100% B over a 1 minute 35 seconds' period. The composition was held for 50 seconds at 100% B, then returned to 5% B in 5 seconds and held there for 5 seconds. The total duration of the gradient run was 3.0 minutes. Flow rate was 0.8 mL/minute. Detection was at 254 nm. Column: Waters Acquity UPLC® BEH Shield RP18 1.7 μm 2.1×50 mm at 50° C. fitted with Waters Acquity UPLC® BEH Shield RP18 VanGuard Pre-column, 130A, 1.7 μm, 2.1 mm×5 mm.</div>
    <div id="p-1248" num="1439" class="description-paragraph style-scope patent-text">Method 2:</div>
    <div id="p-1249" num="1440" class="description-paragraph style-scope patent-text">Gradient for 15-minute run: Initial composition 5% B held over 1 minute, then increased from 5% B to 100% B over a 9 minute period. The composition was held for 2 minutes at 100% B, then returned to 5% B in 10 seconds and held there for 2 minutes 50 seconds. The total duration of the gradient run was 15.0 minutes. Flow rate was 0.8 mL/minute (for 3-minute run) and 0.6 mL/minute (for 15-minute run). Detection was at 254 nm. Column: ACE Excel 2 C18-AR, 2μ, 3.0×100 mm fitted with Waters Acquity UPLC® BEH Shield RP18 VanGuard Pre-column, 130A, 1.7 μm, 2.1 mm×5 mm.</div>
    <heading id="h-0485" class="style-scope patent-text">Example 6—Conjugation</heading>
    <div id="h-0486" num="0000" class="description-paragraph style-scope patent-text">Conj-HER-1</div>
    <div id="p-1250" num="1441" class="description-paragraph style-scope patent-text">A 50 mM solution of Dithiothreitol (DTT) in phosphate-buffered saline pH 7.4 (PBS) was added (80 molar equivalent/antibody, 16 micromoles, 0.32 mL at 50 mM) to a 12 mL solution of antibody Herceptin (30 mg, 0.2 micromoles) in reduction buffer containing PBS and 1 mM ethylenediaminetetraacetic acid (EDTA) and a final antibody concentration of 2.5 mg/mL. The reduction mixture was heated at +25° C. for 4 hours (or until full reduction observed by UHPLC) in an orbital shaker with gentle (60 rpm) shaking. After cooling down to room temperature, the reduced antibody was buffer exchanged, via spin filter using 50 KDa MWCO vivaspin, into a reoxidation buffer containing PBS pH 7.4 and 1 mM EDTA to remove all the excess reducing agent. A 50 mM solution of dehydroascorbic acid (DHAA, 15 molar equivalent/antibody, 3 micromoles, 0.08 mL at 50 mM) in DMSO was added and the reoxidation mixture was allowed to react for 16 hours at room temperature with gentle (60 rpm) shaking at an antibody concentration of 1.5 mg/mL (or until full reoxidation of the cysteine thiols to reform the inter-chain cysteine disulfides is observed by UHPLC). The reoxidation mixture was centrifuged for 3 min at 4000 rpm and then sterile-filtered using 0.22 μm membrane filter. Compound 1 was added as a DMSO solution (10 molar equivalent/antibody, 1.0 micromoles, in 1.5 mL DMSO) to 13.5 mL of this reoxidised antibody solution (15 mg, 0.1 micromoles) for a 10% (v/v) final DMSO concentration. The solution was shaken for 3 hours at +25° C. and then the conjugation was quenched with N-acetyl cysteine (15 micromoles, 0.150 mL at 100 mM).</div>
    <div id="p-1251" num="1442" class="description-paragraph style-scope patent-text">Excess free drug was removed via spin filter using 50 kDa MWCO vivaspin into buffer containing PBS pH 7.4. Extent of free drug removal was monitored by UHPLC-RP using neat conjugate. After complete removal of free drug, the ADC was filtered using 0.22 μm, Mustang filter under sterile atmosphere and then stored at +4° C.</div>
    <div id="p-1252" num="1443" class="description-paragraph style-scope patent-text">UHPLC analysis on a Shimadzu Prominence system using a Phenomenex Aeris 3.6u XB-C18 150×2.1 mm column eluting with a gradient of water and acetonitrile on a reduced sample of Conj-HER-1 at 214 nm and 330 nm (Compound 1 specific) shows a mixture of light and heavy chains attached to several molecules of Compound 1, consistent with a drug-per-antibody ratio (DAR) of 1.74 molecules of Compound 1 per antibody.</div>
    <div id="p-1253" num="1444" class="description-paragraph style-scope patent-text">UHPLC analysis on a Shimadzu Prominence system using a Tosoh Bioscience TSKgel SuperSW mAb HTP 4 μm 4.6×150 mm column (with a 4 μm 3.0×20 mm guard column) eluting with 0.3 mL/minute sterile-filtered SEC buffer containing 200 mM potassium phosphate pH 6.95, 250 mM potassium chloride and 10% isopropanol (v/v) on a sample of Conj-HER-1 at 280 nm shows a monomer purity of greater than 99%. UHPLC SEC analysis gives a concentration of final ADC at 1.39 mg/mL in 7.8 mL, obtained mass of ADC is 10.8 mg (72% yield).</div>
    <div id="h-0487" num="0000" class="description-paragraph style-scope patent-text">Conj-HER-2</div>
    <div id="p-1254" num="1445" class="description-paragraph style-scope patent-text">A 50 mM solution of Dithiothreitol (DTT) in phosphate-buffered saline pH 7.4 (PBS) was added (80 molar equivalent/antibody, 55.5 micromoles, 1.11 mL at 50 mM) to a 11.8 mL solution of antibody Herceptin (104 mg, 0.69 micromoles) in reduction buffer containing PBS and 1 mM ethylenediaminetetraacetic acid (EDTA) and a final antibody concentration of 4.0 mg/mL. The reduction mixture was heated at +25° C. for 3.5 hours (or until full reduction observed by UHPLC) in an orbital shaker with gentle (60 rpm) shaking. After cooling down to room temperature, the reduced antibody was buffer exchanged, via spin filter using 50 KDa MWCO vivaspin, into a reoxidation buffer containing PBS pH 7.4 and 1 mM EDTA to remove all the excess reducing agent. A 50 mM solution of dehydroascorbic acid (DHAA, 20 molar equivalent/antibody, 12.4 micromoles, 0.25 mL at 50 mM) in DMSO was added and the reoxidation mixture was allowed to react for 16 hours at room temperature with gentle (60 rpm) shaking at an antibody concentration of 2.4 mg/mL (or until full reoxidation of the cysteine thiols to reform the inter-chain cysteine disulfides is observed by UHPLC). The reoxidation mixture was centrifuged for 3 min at 4000 rpm and then sterile-filtered using 0.22 μm membrane filter. Compound 2 was added as a DMSO solution (10 molar equivalent/antibody, 1.03 micromoles, in 1.40 mL DMSO) to 14 mL of this reoxidised antibody solution (15.5 mg, 0.103 micromoles) for a 10% (v/v) final DMSO concentration. The solution was shaken for 1.5 hours at +25° C. and then the conjugation was quenched with N-acetyl cysteine (5.15 micromoles, 0.051 mL at 100 mM).</div>
    <div id="p-1255" num="1446" class="description-paragraph style-scope patent-text">Excess free drug was removed via Tangential Flow Filtration unit (TFF) using mPES, MidiKros® 30 kDa fiber filter with 115 cm<sup class="style-scope patent-text">2 </sup>surface area, into buffer containing PBS pH 7.4. Extent of free drug removal was monitored by UHPLC-RP using neat conjugate. After complete removal of free drug, ADC was filtered using 0.22 μm, Mustang filter under sterile atmosphere and then stored at +4° C.</div>
    <div id="p-1256" num="1447" class="description-paragraph style-scope patent-text">UHPLC analysis on a Shimadzu Prominence system using a Phenomenex Aeris 3.6u XB-C18 150×2.1 mm column eluting with a gradient of water and acetonitrile on a reduced sample of Conj-HER-2 at 214 nm and 330 nm (Compound 2 specific) shows a mixture of light and heavy chains attached to several molecules of Compound 2, consistent with a drug-per-antibody ratio (DAR) of 1.85 molecules of Compound 2 per antibody.</div>
    <div id="p-1257" num="1448" class="description-paragraph style-scope patent-text">UHPLC analysis on a Shimadzu Prominence system using a Tosoh Bioscience TSKgel SuperSW mAb HTP 4 μm 4.6×150 mm column (with a 4 μm 3.0×20 mm guard column) eluting with 0.3 mL/minute sterile-filtered SEC buffer containing 200 mM potassium phosphate pH 6.95, 250 mM potassium chloride and 10% isopropanol (v/v) on a sample of Conj-HER-2 at 280 nm shows a monomer purity of greater than 98%. UHPLC SEC analysis gives a concentration of final ADC at 0.88 mg/mL in 8.5 mL, obtained mass of ADC is 7.5 mg (48% yield).</div>
    <div id="h-0488" num="0000" class="description-paragraph style-scope patent-text">Conj-HER-3</div>
    <div id="p-1258" num="1449" class="description-paragraph style-scope patent-text">A 50 mM solution of tris(2-carboxyethyl)phosphine (TCEP) in phosphate-buffered saline pH 7.4 (PBS) was added (40 molar equivalent/antibody, 40 micromoles, 0.08 mL at 50 mM) to a 1.39 mL solution of antibody Herceptin (15 mg, 0.1 micromoles) in reduction buffer containing PBS and 1 mM ethylenediaminetetraacetic acid (EDTA) and a final antibody concentration of 4.0 mg/mL. The reduction mixture was heated at +37° C. for 2 hours (or until full reduction observed by UHPLC) in an orbital shaker with gentle (60 rpm) shaking. After cooling down to room temperature, the reduced antibody was buffer exchanged, via Dialysis using 50 KDa MWCO cassette, into a reoxidation buffer containing PBS pH 7.4 and 1 mM EDTA to remove all the excess reducing agent for 16 hours at RT. A 50 mM solution of dehydroascorbic acid (DHAA, 25 molar equivalent/antibody, 2.5 micromoles, 0.04 mL at 50 mM) in DMSO was added and the reoxidation mixture was allowed to react for 2 hours at room temperature with gentle (60 rpm) shaking at an antibody concentration of ˜1.5 mg/mL. Due to incomplete oxidation another 0.04 mL of 50 mM DHAA added and further shaken at room temperature for 2 h. After that full reoxidation of the cysteine thiols to reform the inter-chain cysteine disulfides is observed by UHPLC. The reoxidation mixture was centrifuged for 3 min at 4000 rpm and then sterile-filtered using 0.22 μm membrane filter. Compound 3 was added as a DMSO solution (10 molar equivalent/antibody, 0.8 micromoles, in 1.1 mL DMSO) to 11 mL of this reoxidised antibody solution (12 mg, 0.08 micromoles) for a 10% (v/v) final DMSO concentration. The solution was shaken for 1 hours at +25° C. and then the conjugation was quenched with N-acetyl cysteine (3.2 micromoles, 0.032 mL at 100 mM).</div>
    <div id="p-1259" num="1450" class="description-paragraph style-scope patent-text">Excess free drug was removed via spin filter using 50 kDa MWCO vivaspin into buffer containing PBS pH 7.4. Extent of free drug removal was monitored by UHPLC-RP using neat conjugate. After complete removal of free drug, ADC was filtered using 0.22 μm, Mustang filter under sterile atmosphere and then stored at +4° C.</div>
    <div id="p-1260" num="1451" class="description-paragraph style-scope patent-text">UHPLC analysis on a Shimadzu Prominence system using a Phenomenex Aeris 3.6u XB-C18 150×2.1 mm column eluting with a gradient of water and acetonitrile on a reduced sample of Conj-HER-3 at 214 nm and 330 nm (Compound 3 specific) shows a mixture of light and heavy chains attached to several molecules of Compound 3, consistent with a drug-per-antibody ratio (DAR) of 1.78 molecules of Compound 3 per antibody.</div>
    <div id="p-1261" num="1452" class="description-paragraph style-scope patent-text">UHPLC analysis on a Shimadzu Prominence system using a Tosoh Bioscience TSKgel SuperSW mAb HTP 4 μm 4.6×150 mm column (with a 4 μm 3.0×20 mm guard column) eluting with 0.3 mL/minute sterile-filtered SEC buffer containing 200 mM potassium phosphate pH 6.95, 250 mM potassium chloride and 10% isopropanol (v/v) on a sample of Conj-HER-3 at 280 nm shows a monomer purity of greater than 94%. UHPLC SEC analysis gives a concentration of final ADC at 1.14 mg/mL in 8.2 mL, obtained mass of ADC is 9.3 mg (62% yield).</div>
    <div id="h-0489" num="0000" class="description-paragraph style-scope patent-text">Conj-R347-1</div>
    <div id="p-1262" num="1453" class="description-paragraph style-scope patent-text">A 50 mM solution of Dithiothreitol (DTT) in phosphate-buffered saline pH 7.4 (PBS) was added (80 molar equivalent/antibody, 697 micromoles, 13.87 mL at 50 mM) to a 44.36 mL solution of antibody R<sup class="style-scope patent-text">347 </sup>(1300 mg, 8.67 micromoles) in reduction buffer containing PBS and 1 mM ethylenediaminetetraacetic acid (EDTA) and a final antibody concentration of 5.0 mg/mL. The reduction mixture was heated at +25° C. for 3.5 hours (or until full reduction observed by UHPLC) in an orbital shaker with gentle (60 rpm) shaking. After cooling down to room temperature, the reduced antibody was buffer exchanged, via Tangential Flow Filtration unit (TFF) using mPES, MidiKros® 30 kDa fiber filter with 235 cm<sup class="style-scope patent-text">2 </sup>surface area, into a reoxidation buffer containing PBS pH 7.4 and 1 mM EDTA to remove all the excess reducing agent. The reduced antibody was centrifuged for 3 min at 4000 rpm and then filtered using 0.22 μm membrane filter. A 50 mM solution of dehydroascorbic acid (DHAA, 15 molar equivalent/antibody, 130 micromoles, 2.6 mL at 50 mM) in DMSO was added and the reoxidation mixture was allowed to react for 16 hours at room temperature with gentle (60 rpm) shaking at an antibody concentration of 5.0 mg/mL (or until full reoxidation of the cysteine thiols to reform the inter-chain cysteine disulfides is observed by UHPLC). The reoxidation mixture was centrifuged for 3 min at 4000 rpm and then sterile-filtered using 0.22 μm membrane filter. Compound 1 was added as a DMSO solution (10 molar equivalent/antibody, 86.7 micromoles, in 23.4 mL DMSO) to 330 mL of this reoxidised antibody solution (1300 mg, 8.67 micromoles) for a 10% (v/v) final DMSO concentration. The solution was shaken for 3 hours at +25° C. and then the conjugation was quenched with N-acetyl cysteine (433 micromoles, 4.33 mL at 100 mM).</div>
    <div id="p-1263" num="1454" class="description-paragraph style-scope patent-text">Excess free drug was removed via Tangential Flow Filtration unit (TFF) using mPES, MidiKros® 30 kDa fiber filter with 235 cm<sup class="style-scope patent-text">2 </sup>surface area, into buffer containing PBS pH 7.4. Extent of free drug removal was monitored by UHPLC-RP using neat conjugate. After complete removal of free drug, ADC was formulated onto 25 mM Histidine, 200 mM Sucrose, pH 6.0. ADC was filtered using 0.22 μm, Mustang filter under sterile atmosphere and then stored at −78° C.</div>
    <div id="p-1264" num="1455" class="description-paragraph style-scope patent-text">UHPLC analysis on a Shimadzu Prominence system using a Phenomenex Aeris 3.6u XB-C18 150×2.1 mm column eluting with a gradient of water and acetonitrile on a reduced sample of Conj-R347-1 at 214 nm and 330 nm (Compound 1 specific) shows a mixture of light and heavy chains attached to several molecules of Compound 1, consistent with a drug-per-antibody ratio (DAR) of 1.82 molecules of Compound 1 per antibody.</div>
    <div id="p-1265" num="1456" class="description-paragraph style-scope patent-text">UHPLC analysis on a Shimadzu Prominence system using a Tosoh Bioscience TSKgel SuperSW mAb HTP 4 μm 4.6×150 mm column (with a 4 μm 3.0×20 mm guard column) eluting with 0.3 mL/minute sterile-filtered SEC buffer containing 200 mM potassium phosphate pH 6.95, 250 mM potassium chloride and 10% isopropanol (v/v) on a sample of ADC at 280 nm shows a monomer purity of greater than 99%. UHPLC SEC analysis gives a concentration of final Conj-R347-1 at 10.11 mg/mL in 113 mL, obtained mass of ADC is 1141 mg (88% yield).</div>
    <div id="h-0490" num="0000" class="description-paragraph style-scope patent-text">Conj-R347-2</div>
    <div id="p-1266" num="1457" class="description-paragraph style-scope patent-text">A 50 mM solution of Dithiothreitol (DTT) in phosphate-buffered saline pH 7.4 (PBS) was added (80 molar equivalent/antibody, 213 micromoles, 4.3 mL at 50 mM) to a 13.7 mL solution of antibody R347 (400 mg, 2.67 micromoles) in reduction buffer containing PBS and 1 mM ethylenediaminetetraacetic acid (EDTA) and a final antibody concentration of 5.0 mg/mL. The reduction mixture was heated at +25° C. for 3.5 hours (or until full reduction observed by UHPLC) in an orbital shaker with gentle (60 rpm) shaking. After cooling down to room temperature, the reduced antibody was buffer exchanged, via Tangential Flow Filtration unit (TFF) using mPES, MidiKros® 30 kDa fiber filter with 115 cm<sup class="style-scope patent-text">2 </sup>surface area, into a reoxidation buffer containing PBS pH 7.4 and 1 mM EDTA to remove all the excess reducing agent. The reduced antibody was centrifuged for 3 min at 4000 rpm and then filtered using 0.22 μm membrane filter. A 50 mM solution of dehydroascorbic acid (DHAA, 15 molar equivalent/antibody, 40 micromoles, 0.8 mL at 50 mM) in DMSO was added and the reoxidation mixture was allowed to react for 16 hours at room temperature with gentle (60 rpm) shaking at an antibody concentration of 3.0 mg/mL (or until full reoxidation of the cysteine thiols to reform the inter-chain cysteine disulfides is observed by UHPLC). The reoxidation mixture was centrifuged for 3 min at 4000 rpm and then sterile-filtered using 0.22 μm membrane filter. Compound 2 was added as a DMSO solution (10 molar equivalent/antibody, 26.7 micromoles, in 15.5 mL DMSO) to 330 mL of this reoxidised antibody solution (400 mg, 2.67 micromoles) for a 10% (v/v) final DMSO concentration. The solution was shaken for 1.5 hours at +25° C. and then the conjugation was quenched with N-acetyl cysteine (125 micromoles, 1.25 mL at 100 mM).</div>
    <div id="p-1267" num="1458" class="description-paragraph style-scope patent-text">Excess free drug was removed via Tangential Flow Filtration unit (TFF) using mPES, MidiKros® 30 kDa fiber filter with 115 cm<sup class="style-scope patent-text">2 </sup>surface area, into buffer containing PBS pH 7.4. Extent of free drug removal was monitored by UHPLC-RP using neat conjugate. After complete removal of free drug, ADC was formulated onto 25 mM Histidine, 200 mM Sucrose, pH 6.0. ADC was filtered using 0.22 μm, Mustang filter under sterile atmosphere and then stored at −78° C.</div>
    <div id="p-1268" num="1459" class="description-paragraph style-scope patent-text">UHPLC analysis on a Shimadzu Prominence system using a Phenomenex Aeris 3.6u XB-C18 150×2.1 mm column eluting with a gradient of water and acetonitrile on a reduced sample of Conj-R347-2 at 214 nm and 330 nm (Compound 2 specific) shows a mixture of light and heavy chains attached to several molecules of Compound 2, consistent with a drug-per-antibody ratio (DAR) of 1.8 molecules of Compound 2 per antibody.</div>
    <div id="p-1269" num="1460" class="description-paragraph style-scope patent-text">UHPLC analysis on a Shimadzu Prominence system using a Tosoh Bioscience TSKgel SuperSW mAb HTP 4 μm 4.6×150 mm column (with a 4 μm 3.0×20 mm guard column) eluting with 0.3 mL/minute sterile-filtered SEC buffer containing 200 mM potassium phosphate pH 6.95, 250 mM potassium chloride and 10% isopropanol (v/v) on a sample of Conj-R347-2 at 280 nm shows a monomer purity of greater than 99%. UHPLC SEC analysis gives a concentration of final ADC at 3.06 mg/mL in 93 mL, obtained mass of ADC is 284 mg (71% yield).</div>
    <div id="h-0491" num="0000" class="description-paragraph style-scope patent-text">Conj-R347-3</div>
    <div id="p-1270" num="1461" class="description-paragraph style-scope patent-text">A 50 mM solution of Dithiothreitol (DTT) in phosphate-buffered saline pH 7.4 (PBS) was added (80 molar equivalent/antibody, 240 micromoles, 4.8 mL at 50 mM) to a 15.36 mL solution of antibody R347 (450 mg, 3.0 micromoles) in reduction buffer containing PBS and 1 mM ethylenediaminetetraacetic acid (EDTA) and a final antibody concentration of 5.0 mg/mL. The reduction mixture was heated at +25° C. for 3.5 hours (or until full reduction observed by UHPLC) in an orbital shaker with gentle (60 rpm) shaking. After cooling down to room temperature, the reduced antibody was buffer exchanged, via Tangential Flow Filtration unit (TFF) using mPES, MidiKros® 30 kDa fiber filter with 235 cm<sup class="style-scope patent-text">2 </sup>surface area, into a reoxidation buffer containing PBS pH 7.4 and 1 mM EDTA to remove all the excess reducing agent. The reduced antibody was centrifuged for 3 min at 4000 rpm and then filtered using 0.22 μm membrane filter. A 50 mM solution of dehydroascorbic acid (DHAA, 15 molar equivalent/antibody, 45 micromoles, 0.9 mL at 50 mM) in DMSO was added and the reoxidation mixture was allowed to react for 16 hours at room temperature with gentle (60 rpm) shaking at an antibody concentration of 3.5 mg/mL (or until full reoxidation of the cysteine thiols to reform the inter-chain cysteine disulfides is observed by UHPLC). The reoxidation mixture was centrifuged for 3 min at 4000 rpm and then sterile-filtered using 0.22 μm membrane filter. Compound 3 was added as a DMSO solution (10 molar equivalent/antibody, 30.0 micromoles, in 13.0 mL DMSO) to 330 mL of this reoxidised antibody solution (450 mg, 3.0 micromoles) for a 10% (v/v) final DMSO concentration. The solution was shaken for 3 hours at +25° C. and then the conjugation was quenched with N-acetyl cysteine (150 micromoles, 1.5 mL at 100 mM).</div>
    <div id="p-1271" num="1462" class="description-paragraph style-scope patent-text">Excess free drug was removed via Tangential Flow Filtration unit (TFF) using mPES, MidiKros® 30 kDa fiber filter with 235 cm<sup class="style-scope patent-text">2 </sup>surface area, into buffer containing PBS pH 7.4. Extent of free drug removal was monitored by UHPLC-RP using neat conjugate. After complete removal of free drug, ADC was formulated onto 25 mM Histidine, 200 mM Sucrose, pH 6.0. ADC was filtered using 0.22 μm, Mustang filter under sterile atmosphere and then stored at −78° C.</div>
    <div id="p-1272" num="1463" class="description-paragraph style-scope patent-text">UHPLC analysis on a Shimadzu Prominence system using a Phenomenex Aeris 3.6u XB-C18 150×2.1 mm column eluting with a gradient of water and acetonitrile on a reduced sample of Conjugate at 214 nm and 330 nm (Compound 3 specific) shows a mixture of light and heavy chains attached to several molecules of Compound 3, consistent with a drug-per-antibody ratio (DAR) of 1.82 molecules of Compound 3 per antibody.</div>
    <div id="p-1273" num="1464" class="description-paragraph style-scope patent-text">UHPLC analysis on a Shimadzu Prominence system using a Tosoh Bioscience TSKgel SuperSW mAb HTP 4 μm 4.6×150 mm column (with a 4 μm 3.0×20 mm guard column) eluting with 0.3 mL/minute sterile-filtered SEC buffer containing 200 mM potassium phosphate pH 6.95, 250 mM potassium chloride and 10% isopropanol (v/v) on a sample of Conj-R347-3 at 280 nm shows a monomer purity of greater than 99%. UHPLC SEC analysis gives a concentration of final ADC at 2.35 mg/mL in 174 mL, obtained mass of Conj-R347-3 is 409 mg (91% yield).</div>
    <div id="h-0492" num="0000" class="description-paragraph style-scope patent-text">Conj-HLL2-1</div>
    <div id="p-1274" num="1465" class="description-paragraph style-scope patent-text">A 50 mM solution of Dithiothreitol (DTT) in phosphate-buffered saline pH 7.4 (PBS) was added (80 molar equivalent/antibody, 53.3 micromoles, 1.07 mL at 50 mM) to a 11.8 mL solution of antibody HLL2 (100 mg, 0.6 micromoles) in reduction buffer containing PBS and 1 mM ethylenediaminetetraacetic acid (EDTA) and a final antibody concentration of 5.0 mg/mL. The reduction mixture was heated at +25° C. for 3.5 hours (or until full reduction observed by UHPLC) in an orbital shaker with gentle (60 rpm) shaking. After cooling down to room temperature, the reduced antibody was buffer exchanged, via spin filter using 50 KDa MWCO vivaspin, into a reoxidation buffer containing PBS pH 7.4 and 1 mM EDTA to remove all the excess reducing agent. A 50 mM solution of dehydroascorbic acid (DHAA, 15 molar equivalent/antibody, 9 micromoles, 0.18 mL at 50 mM) in DMSO was added and the reoxidation mixture was allowed to react for 16 hours at room temperature with gentle (60 rpm) shaking at an antibody concentration of 3.0 mg/mL (or until full reoxidation of the cysteine thiols to reform the inter-chain cysteine disulfides is observed by UHPLC). The reoxidation mixture was centrifuged for 3 min at 4000 rpm and then sterile-filtered using 0.22 μm membrane filter. Compound 1 was added as a DMSO solution (10 molar equivalent/antibody, 1.2 micromoles, in 0.58 mL DMSO) to 7 mL of this reoxidised antibody solution (18 mg, 0.12 micromoles) for a 10% (v/v) final DMSO concentration. The solution was shaken for 3 hours at +25° C. and then the conjugation was quenched with N-acetyl cysteine (6 micromoles, 0.06 mL at 100 mM).</div>
    <div id="p-1275" num="1466" class="description-paragraph style-scope patent-text">Excess free drug was removed via spin filter using 50 kDa MWCO vivaspin into buffer containing PBS pH 7.4. Extent of free drug removal was monitored by UHPLC-RP using neat conjugate. After complete removal of free drug, ADC was filtered using 0.22 μm, Mustang filter under sterile atmosphere and then stored at +4° C.</div>
    <div id="p-1276" num="1467" class="description-paragraph style-scope patent-text">UHPLC analysis on a Shimadzu Prominence system using a Phenomenex Aeris 3.6u XB-C18 150×2.1 mm column eluting with a gradient of water and acetonitrile on a reduced sample of Conj-HLL2-1 at 214 nm and 330 nm (Compound 1 specific) shows a mixture of light and heavy chains attached to several molecules of Compound 1, consistent with a drug-per-antibody ratio (DAR) of 1.74 molecules of Compound 1 per antibody.</div>
    <div id="p-1277" num="1468" class="description-paragraph style-scope patent-text">UHPLC analysis on a Shimadzu Prominence system using a Tosoh Bioscience TSKgel SuperSW mAb HTP 4 μm 4.6×150 mm column (with a 4 μm 3.0×20 mm guard column) eluting with 0.3 mL/minute sterile-filtered SEC buffer containing 200 mM potassium phosphate pH 6.95, 250 mM potassium chloride and 10% isopropanol (v/v) on a sample of Conj-HLL2-1 at 280 nm shows a monomer purity of greater than 98%. UHPLC SEC analysis gives a concentration of final ADC at 1.6 mg/mL in 7.5 mL, obtained mass of ADC is 12 mg (67% yield).</div>
    <div id="h-0493" num="0000" class="description-paragraph style-scope patent-text">Conj-HLL2-2</div>
    <div id="p-1278" num="1469" class="description-paragraph style-scope patent-text">A 50 mM solution of Dithiothreitol (DTT) in phosphate-buffered saline pH 7.4 (PBS) was added (80 molar equivalent/antibody, 53.3 micromoles, 1.07 mL at 50 mM) to a 11.8 mL solution of antibody HLL2 (100 mg, 0.6 micromoles) in reduction buffer containing PBS and 1 mM ethylenediaminetetraacetic acid (EDTA) and a final antibody concentration of 5.0 mg/mL. The reduction mixture was heated at +25° C. for 3.5 hours (or until full reduction observed by UHPLC) in an orbital shaker with gentle (60 rpm) shaking. After cooling down to room temperature, the reduced antibody was buffer exchanged, via spin filter using 50 KDa MWCO vivaspin, into a reoxidation buffer containing PBS pH 7.4 and 1 mM EDTA to remove all the excess reducing agent. A 50 mM solution of dehydroascorbic acid (DHAA, 15 molar equivalent/antibody, 9 micromoles, 0.18 mL at 50 mM) in DMSO was added and the reoxidation mixture was allowed to react for 16 hours at room temperature with gentle (60 rpm) shaking at an antibody concentration of 3.0 mg/mL (or until full reoxidation of the cysteine thiols to reform the inter-chain cysteine disulfides is observed by UHPLC). The reoxidation mixture was centrifuged for 3 min at 4000 rpm and then sterile-filtered using 0.22 μm membrane filter. Compound 2 was added as a DMSO solution (10 molar equivalent/antibody, 1.2 micromoles, in 0.58 mL DMSO) to 7 mL of this reoxidised antibody solution (18 mg, 0.12 micromoles) for a 10% (v/v) final DMSO concentration. The solution was shaken for 3 hours at +25° C. and then the conjugation was quenched with N-acetyl cysteine (6 micromoles, 0.06 mL at 100 mM).</div>
    <div id="p-1279" num="1470" class="description-paragraph style-scope patent-text">Excess free drug was removed via spin filter using 50 kDa MWCO vivaspin into buffer containing PBS pH 7.4. Extent of free drug removal was monitored by UHPLC-RP using neat conjugate. After complete removal of free drug, ADC was filtered using 0.22 μm, Mustang filter under sterile atmosphere and then stored at +4° C.</div>
    <div id="p-1280" num="1471" class="description-paragraph style-scope patent-text">UHPLC analysis on a Shimadzu Prominence system using a Phenomenex Aeris 3.6u XB-C18 150×2.1 mm column eluting with a gradient of water and acetonitrile on a reduced sample of Conjugate at 214 nm and 330 nm (Compound 2 specific) shows a mixture of light and heavy chains attached to several molecules of Compound 2, consistent with a drug-per-antibody ratio (DAR) of 1.78 molecules of Compound 2 per antibody.</div>
    <div id="p-1281" num="1472" class="description-paragraph style-scope patent-text">UHPLC analysis on a Shimadzu Prominence system using a Tosoh Bioscience TSKgel SuperSW mAb HTP 4 μm 4.6×150 mm column (with a 4 μm 3.0×20 mm guard column) eluting with 0.3 mL/minute sterile-filtered SEC buffer containing 200 mM potassium phosphate pH 6.95, 250 mM potassium chloride and 10% isopropanol (v/v) on a sample of Conj-HLL2-2 at 280 nm shows a monomer purity of greater than 98%. UHPLC SEC analysis gives a concentration of final ADC at 1.56 mg/mL in 8.0 mL, obtained mass of Conj-HLL2-2 is 12.5 mg (69% yield).</div>
    <div id="h-0494" num="0000" class="description-paragraph style-scope patent-text">Conj-HLL2-3</div>
    <div id="p-1282" num="1473" class="description-paragraph style-scope patent-text">A 50 mM solution of Dithiothreitol (DTT) in phosphate-buffered saline pH 7.4 (PBS) was added (80 molar equivalent/antibody, 53.3 micromoles, 1.07 mL at 50 mM) to a 11.8 mL solution of antibody HLL2 (100 mg, 0.6 micromoles) in reduction buffer containing PBS and 1 mM ethylenediaminetetraacetic acid (EDTA) and a final antibody concentration of 5.0 mg/mL. The reduction mixture was heated at +25° C. for 3.5 hours (or until full reduction observed by UHPLC) in an orbital shaker with gentle (60 rpm) shaking. After cooling down to room temperature, the reduced antibody was buffer exchanged, via spin filter using 50 KDa MWCO vivaspin, into a reoxidation buffer containing PBS pH 7.4 and 1 mM EDTA to remove all the excess reducing agent. A 50 mM solution of dehydroascorbic acid (DHAA, 15 molar equivalent/antibody, 9 micromoles, 0.18 mL at 50 mM) in DMSO was added and the reoxidation mixture was allowed to react for 16 hours at room temperature with gentle (60 rpm) shaking at an antibody concentration of 3.0 mg/mL (or until full reoxidation of the cysteine thiols to reform the inter-chain cysteine disulfides is observed by UHPLC). The reoxidation mixture was centrifuged for 3 min at 4000 rpm and then sterile-filtered using 0.22 μm membrane filter. Compound 3 was added as a DMSO solution (10 molar equivalent/antibody, 1.2 micromoles, in 0.58 mL DMSO) to 7 mL of this reoxidised antibody solution (18 mg, 0.12 micromoles) for a 10% (v/v) final DMSO concentration. The solution was shaken for 3 hours at +25° C. and then the conjugation was quenched with N-acetyl cysteine (6 micromoles, 0.06 mL at 100 mM).</div>
    <div id="p-1283" num="1474" class="description-paragraph style-scope patent-text">Excess free drug was removed via spin filter using 50 kDa MWCO vivaspin into buffer containing PBS pH 7.4. Extent of free drug removal was monitored by UHPLC-RP using neat conjugate. After complete removal of free drug, ADC was filtered using 0.22 μm, Mustang filter under sterile atmosphere and then stored at +4° C.</div>
    <div id="p-1284" num="1475" class="description-paragraph style-scope patent-text">UHPLC analysis on a Shimadzu Prominence system using a Phenomenex Aeris 3.6u XB-C18 150×2.1 mm column eluting with a gradient of water and acetonitrile on a reduced sample of Conjugate at 214 nm and 330 nm (Compound 3 specific) shows a mixture of light and heavy chains attached to several molecules of Compound 3, consistent with a drug-per-antibody ratio (DAR) of 1.79 molecules of Compound 3 per antibody.</div>
    <div id="p-1285" num="1476" class="description-paragraph style-scope patent-text">UHPLC analysis on a Shimadzu Prominence system using a Tosoh Bioscience TSKgel SuperSW mAb HTP 4 μm 4.6×150 mm column (with a 4 μm 3.0×20 mm guard column) eluting with 0.3 mL/minute sterile-filtered SEC buffer containing 200 mM potassium phosphate pH 6.95, 250 mM potassium chloride and 10% isopropanol (v/v) on a sample of Conj-HLL2-3 at 280 nm shows a monomer purity of greater than 98%. UHPLC SEC analysis gives a concentration of final ADC at 1.73 mg/mL in 8.2 mL, obtained mass of Conj-HLL2-3 is 14.2 mg (79% yield).</div>
    <div id="h-0495" num="0000" class="description-paragraph style-scope patent-text">Conj-CD79b-1</div>
    <div id="p-1286" num="1477" class="description-paragraph style-scope patent-text">A 50 mM solution of Dithiothreitol (DTT) in phosphate-buffered saline pH 7.4 (PBS) was added (80 molar equivalent/antibody, 53.6 micromoles, 1.07 mL at 50 mM) to a 13.9 mL solution of antibody CD79b (100 mg, 0.67 micromoles) in reduction buffer containing PBS and 1 mM ethylenediaminetetraacetic acid (EDTA) and a final antibody concentration of 4.0 mg/mL. The reduction mixture was heated at +25° C. for 4 hours (or until full reduction observed by UHPLC) in an orbital shaker with gentle (60 rpm) shaking. After cooling down to room temperature, the reduced antibody was buffer exchanged, via spin filter using 50 KDa MWCO vivaspin, into a reoxidation buffer containing PBS pH 7.4 and 1 mM EDTA to remove all the excess reducing agent. A 50 mM solution of dehydroascorbic acid (DHAA, 15 molar equivalent/antibody, 9 micromoles, 0.18 mL at 50 mM) in DMSO was added and the reoxidation mixture was allowed to react for 16 hours at room temperature with gentle (60 rpm) shaking at an antibody concentration of 2.0 mg/mL (or until full reoxidation of the cysteine thiols to reform the inter-chain cysteine disulfides is observed by UHPLC). The reoxidation mixture was centrifuged for 3 min at 4000 rpm and then sterile-filtered using 0.22 μm membrane filter. Compound 1 was added as a DMSO solution (10 molar equivalent/antibody, 1.2 micromoles, in 1.0 mL DMSO) to 9.0 mL of this reoxidised antibody solution (18 mg, 0.12 micromoles) for a 10% (v/v) final DMSO concentration. The solution was shaken for 2 hours at +25° C. and then the conjugation was quenched with N-acetyl cysteine (4.8 micromoles, 0.048 mL at 100 mM).</div>
    <div id="p-1287" num="1478" class="description-paragraph style-scope patent-text">Excess free drug was removed via spin filter using 50 kDa MWCO vivaspin into buffer containing PBS pH 7.4. Extent of free drug removal was monitored by UHPLC-RP using neat conjugate. After complete removal of free drug, ADC was filtered using 0.22 μm, Mustang filter under sterile atmosphere and then stored at +4° C.</div>
    <div id="p-1288" num="1479" class="description-paragraph style-scope patent-text">UHPLC analysis on a Shimadzu Prominence system using a Phenomenex Aeris 3.6u XB-C18 150×2.1 mm column eluting with a gradient of water and acetonitrile on a reduced sample of Conjugate at 214 nm and 330 nm (Compound 1 specific) shows a mixture of light and heavy chains attached to several molecules of Compound 1, consistent with a drug-per-antibody ratio (DAR) of 1.90 molecules of Compound 1 per antibody.</div>
    <div id="p-1289" num="1480" class="description-paragraph style-scope patent-text">UHPLC analysis on a Shimadzu Prominence system using a Tosoh Bioscience TSKgel SuperSW mAb HTP 4 μm 4.6×150 mm column (with a 4 μm 3.0×20 mm guard column) eluting with 0.3 mL/minute sterile-filtered SEC buffer containing 200 mM potassium phosphate pH 6.95, 250 mM potassium chloride and 10% isopropanol (v/v) on a sample of Conj-CD79b-1 at 280 nm shows a monomer purity of greater than 98%. UHPLC SEC analysis gives a concentration of final ADC at 2.00 mg/mL in 7.85 mL, obtained mass of Conj-CD79b-1 is 15.7 mg (79% yield).</div>
    <div id="h-0496" num="0000" class="description-paragraph style-scope patent-text">Conj-CD79b-2</div>
    <div id="p-1290" num="1481" class="description-paragraph style-scope patent-text">A 50 mM solution of Dithiothreitol (DTT) in phosphate-buffered saline pH 7.4 (PBS) was added (80 molar equivalent/antibody, 53.6 micromoles, 1.07 mL at 50 mM) to a 13.9 mL solution of antibody CD79b (100 mg, 0.67 micromoles) in reduction buffer containing PBS and 1 mM ethylenediaminetetraacetic acid (EDTA) and a final antibody concentration of 4.0 mg/mL. The reduction mixture was heated at +25° C. for 4 hours (or until full reduction observed by UHPLC) in an orbital shaker with gentle (60 rpm) shaking. After cooling down to room temperature, the reduced antibody was buffer exchanged, via spin filter using 50 KDa MWCO vivaspin, into a reoxidation buffer containing PBS pH 7.4 and 1 mM EDTA to remove all the excess reducing agent. A 50 mM solution of dehydroascorbic acid (DHAA, 15 molar equivalent/antibody, 9 micromoles, 0.18 mL at 50 mM) in DMSO was added and the reoxidation mixture was allowed to react for 16 hours at room temperature with gentle (60 rpm) shaking at an antibody concentration of 2.0 mg/mL (or until full reoxidation of the cysteine thiols to reform the inter-chain cysteine disulfides is observed by UHPLC). The reoxidation mixture was centrifuged for 3 min at 4000 rpm and then sterile-filtered using 0.22 μm membrane filter. Compound 2 was added as a DMSO solution (10 molar equivalent/antibody, 1.2 micromoles, in 1.0 mL DMSO) to 9.0 mL of this reoxidised antibody solution (18 mg, 0.12 micromoles) for a 10% (v/v) final DMSO concentration. The solution was shaken for 2 hours at +25° C. and then the conjugation was quenched with N-acetyl cysteine (4.8 micromoles, 0.048 mL at 100 mM).</div>
    <div id="p-1291" num="1482" class="description-paragraph style-scope patent-text">Excess free drug was removed via spin filter using 50 kDa MWCO vivaspin into buffer containing PBS pH 7.4. Extent of free drug removal was monitored by UHPLC-RP using neat conjugate. After complete removal of free drug, ADC was filtered using 0.22 μm, Mustang filter under sterile atmosphere and then stored at +4° C.</div>
    <div id="p-1292" num="1483" class="description-paragraph style-scope patent-text">UHPLC analysis on a Shimadzu Prominence system using a Phenomenex Aeris 3.6u XB-C18 150×2.1 mm column eluting with a gradient of water and acetonitrile on a reduced sample of Conjugate at 214 nm and 330 nm (Compound 2 specific) shows a mixture of light and heavy chains attached to several molecules of Compound 2, consistent with a drug-per-antibody ratio (DAR) of 1.87 molecules of Compound 2 per antibody. UHPLC analysis on a Shimadzu Prominence system using a Tosoh Bioscience TSKgel SuperSW mAb HTP 4 μm 4.6×150 mm column (with a 4 μm 3.0×20 mm guard column) eluting with 0.3 mL/minute sterile-filtered SEC buffer containing 200 mM potassium phosphate pH 6.95, 250 mM potassium chloride and 10% isopropanol (v/v) on a sample of Conj-CD79b-2 at 280 nm shows a monomer purity of greater than 98%. UHPLC SEC analysis gives a concentration of final ADC at 2.25 mg/mL in 5.9 mL, obtained mass of Conj-CD79b-2 is 13.3 mg (66% yield).</div>
    <div id="h-0497" num="0000" class="description-paragraph style-scope patent-text">Conj-1C1-1</div>
    <div id="p-1293" num="1484" class="description-paragraph style-scope patent-text">A 50 mM solution of Dithiothreitol (DTT) in phosphate-buffered saline pH 7.4 (PBS) was added (80 molar equivalent/antibody, 75 micromoles, 1.5 mL at 50 mM) to a 26.4 mL solution of antibody 1C1 (140 mg, 0.93 micromoles) in reduction buffer containing PBS and 1 mM ethylenediaminetetraacetic acid (EDTA) and a final antibody concentration of 5.0 mg/mL. The reduction mixture was heated at +25° C. for 3.5 hours (or until full reduction observed by UHPLC) in an orbital shaker with gentle (60 rpm) shaking. After cooling down to room temperature, the reduced antibody was buffer exchanged, via spin filter using 50 KDa MWCO vivaspin, into a reoxidation buffer containing PBS pH 7.4 and 1 mM EDTA to remove all the excess reducing agent. A 50 mM solution of dehydroascorbic acid (DHAA, 15 molar equivalent/antibody, 14 micromoles, 0.28 mL at 50 mM) in DMSO was added and the reoxidation mixture was allowed to react for 16 hours at room temperature with gentle (60 rpm) shaking at an antibody concentration of 3.0 mg/mL (or until full reoxidation of the cysteine thiols to reform the inter-chain cysteine disulfides is observed by UHPLC). The reoxidation mixture was centrifuged for 3 min at 4000 rpm and then sterile-filtered using 0.22 μm membrane filter. Compound 1 was added as a DMSO solution (10 molar equivalent/antibody, 1.3 micromoles, in 0.6 mL DMSO) to 6 mL of this reoxidised antibody solution (20 mg, 0.133 micromoles) for a 10% (v/v) final DMSO concentration. The solution was shaken for 4 hours at +25° C. and then the conjugation was quenched with N-acetyl cysteine (6.65 micromoles, 0.067 mL at 100 mM).</div>
    <div id="p-1294" num="1485" class="description-paragraph style-scope patent-text">Excess free drug was removed via spin filter using 50 kDa MWCO vivaspin into buffer containing PBS pH 7.4. Extent of free drug removal was monitored by UHPLC-RP using neat conjugate. After complete removal of free drug, buffer exchanged onto 25 mM Histidine, 200 mM Sucrose, pH 6.0. ADC was filtered using 0.22 μm, Mustang filter under sterile atmosphere and then stored at −78° C.</div>
    <div id="p-1295" num="1486" class="description-paragraph style-scope patent-text">UHPLC analysis on a Shimadzu Prominence system using a Phenomenex Aeris 3.6u XB-C18 150×2.1 mm column eluting with a gradient of water and acetonitrile on a reduced sample of Conjugate at 214 nm and 330 nm (Compound 1 specific) shows a mixture of light and heavy chains attached to several molecules of Compound 1, consistent with a drug-per-antibody ratio (DAR) of 1.86 molecules of Compound 1 per antibody.</div>
    <div id="p-1296" num="1487" class="description-paragraph style-scope patent-text">UHPLC analysis on a Shimadzu Prominence system using a Tosoh Bioscience TSKgel SuperSW mAb HTP 4 μm 4.6×150 mm column (with a 4 μm 3.0×20 mm guard column) eluting with 0.3 mL/minute sterile-filtered SEC buffer containing 200 mM potassium phosphate pH 6.95, 250 mM potassium chloride and 10% isopropanol (v/v) on a sample of ADC at 280 nm shows a monomer purity of greater than 98%. UHPLC SEC analysis gives a concentration of final ADC at 1.49 mg/mL in 8.0 mL, obtained mass of ADC is 11.9 mg (60% yield).</div>
    <div id="h-0498" num="0000" class="description-paragraph style-scope patent-text">Conj-HER-1++ (High DAR)</div>
    <div id="p-1297" num="1488" class="description-paragraph style-scope patent-text">A 50 mM solution of Dithiothreitol (DTT) in phosphate-buffered saline pH 7.4 (PBS) was added (100 molar equivalent/antibody, 6.7 micromoles, 0.13 mL at 50 mM) to a 5 mL solution of antibody (10 mg, 67 nanomoles) in reduction buffer containing PBS and 1 mM ethylenediaminetetraacetic acid (EDTA) and a final antibody concentration of 2.0 mg/mL. The resultant mixture was incubated at +25° C. for overnight (or until full reduction observed by UHPLC) in an orbital shaker with gentle (60 rpm) shaking. After cooling down to room temperature, the reduced antibody was buffer exchanged, via spin filter using 50 KDa MWCO vivaspin, into conjugation buffer containing PBS pH 7.4 and 1 mM EDTA to remove all the excess reducing agent. Compound 1 was added as a DMSO solution (20 molar equivalent/antibody, 1.34 micromoles, in 0.4 mL DMSO) to 4.0 mL of this reduced antibody solution (10 mg, 67 nanomoles) for a 10% (v/v) final DMSO concentration. The solution was shaken for 1 hour at +25° C. and then conjugation was quenched with excess N-acetyl cysteine (6.7 micromoles, 67 μL at 100 mM).</div>
    <div id="p-1298" num="1489" class="description-paragraph style-scope patent-text">Resultant ADC was purified via preparative size exclusion column (GE Sephadex 26/60) fitted to an AKTA Start instrument using PBS, pH 7.4 buffer. Fractions were collected and analysed for the monomeric content using Shimadzu Prominence system using a Tosoh Bioscience TSKgel SuperSW mAb HTP 4 μm 4.6×150 mm column (with a 4 μm 3.0×20 mm guard column) eluting with 0.3 mL/minute sterile-filtered SEC buffer containing 200 mM potassium phosphate pH 6.95, 250 mM potassium chloride and 10% isopropanol (v/v) at 280 nm. Fractions with monomer content &gt;92% were pooled and then concentrated using 50 kDa MWCO vivaspin into buffer containing PBS pH 7.4. Extent of free drug removal was monitored by UHPLC-RP using neat conjugate and after complete removal of free drug, ADC was filtered using 0.22 μm, Mustang filter under sterile atmosphere and then stored at +4° C.</div>
    <div id="p-1299" num="1490" class="description-paragraph style-scope patent-text">UHPLC analysis on a Shimadzu Prominence system using a Phenomenex Aeris 3.6u XB-C18 150×2.1 mm column eluting with a gradient of water and acetonitrile on a reduced sample of Conjugate at 214 nm and 330 nm (Compound 1 specific) shows a mixture of light and heavy chains attached to several molecules of Compound 1, consistent with a drug-per-antibody ratio (DAR) of 7.41 molecules of Compound 1 per antibody.</div>
    <div id="p-1300" num="1491" class="description-paragraph style-scope patent-text">UHPLC analysis on a Shimadzu Prominence system using a Tosoh Bioscience TSKgel SuperSW mAb HTP 4 μm 4.6×150 mm column (with a 4 μm 3.0×20 mm guard column) eluting with 0.3 mL/minute sterile-filtered SEC buffer containing 200 mM potassium phosphate pH 6.95, 250 mM potassium chloride and 10% isopropanol (v/v) on a sample of ADC at 280 nm shows a monomer purity of 95%. UHPLC SEC analysis gives a concentration of final ADC at 1.44 mg/mL in 4.5 mL, obtained mass of ADC is 6.5 mg (65% yield).</div>
    <div id="h-0499" num="0000" class="description-paragraph style-scope patent-text">Conj-HER-1+ (Medium DAR)</div>
    <div id="p-1301" num="1492" class="description-paragraph style-scope patent-text">A 10 mM solution of tris(2-carboxyethyl)phosphine (TCEP) in phosphate-buffered saline pH 7.4 (PBS) was added (2 molar equivalent/antibody, 0.134 micromoles, 13.3 μL at 10 mM) to a 4 mL solution of antibody (10 mg, 67 nanomoles) in reduction buffer containing PBS and 1 mM ethylenediaminetetraacetic acid (EDTA) and a final antibody concentration of 2.5 mg/mL. The reduction mixture was heated at +37° C. for 2 hours in an orbital shaker with gentle (60 rpm) shaking. Compound 1 was added as a DMSO solution (15 molar equivalent/antibody, 1.0 micromoles, 0.1 mL of 10 mM in 0.3 mL DMSO) and the resultant mixture was shaken for 1.5 hours at +25° C. and then the conjugation was quenched with N-acetyl cysteine (5 micromoles, 50 μL at 100 mM).</div>
    <div id="p-1302" num="1493" class="description-paragraph style-scope patent-text">Excess free drug was removed via spin filter using 50 kDa MWCO vivaspin into buffer containing PBS pH 7.4. Extent of free drug removal was monitored by UHPLC-RP using neat conjugate. After complete removal of free drug, ADC was filtered using 0.22 μm, Mustang filter under sterile atmosphere and then stored at +4° C.</div>
    <div id="p-1303" num="1494" class="description-paragraph style-scope patent-text">UHPLC analysis on a Shimadzu Prominence system using a Phenomenex Aeris 3.6u XB-C18 150×2.1 mm column eluting with a gradient of water and acetonitrile on a reduced sample of Conjugate at 214 nm and 330 nm (Compound 1 specific) shows a mixture of light and heavy chains attached to several molecules of Compound 1, consistent with a drug-per-antibody ratio (DAR) of 4.2 molecules of Compound 1 per antibody.</div>
    <div id="p-1304" num="1495" class="description-paragraph style-scope patent-text">UHPLC analysis on a Shimadzu Prominence system using a Tosoh Bioscience TSKgel SuperSW mAb HTP 4 μm 4.6×150 mm column (with a 4 μm 3.0×20 mm guard column) eluting with 0.3 mL/minute sterile-filtered SEC buffer containing 200 mM potassium phosphate pH 6.95, 250 mM potassium chloride and 10% isopropanol (v/v) on a sample of ADC at 280 nm shows a monomer purity of greater than 99%. UHPLC SEC analysis gives a concentration of final ADC at 2.05 mg/mL in 3.6 mL, obtained mass of ADC is 7.36 mg (74% yield).</div>
    <heading id="h-0500" class="style-scope patent-text">Example 7—In Vitro Testing</heading>
    <div id="h-0501" num="0000" class="description-paragraph style-scope patent-text">MTS Cytotoxicity Method</div>
    <div id="p-1305" num="1496" class="description-paragraph style-scope patent-text">The concentration and viability of cells from a sub-confluent (80-90% confluency) T75 flask are measured by trypan blue staining, and counted using the LUNA-II™ Automated Cell Counter. Cells were diluted to 2×10<sup class="style-scope patent-text">5</sup>/ml, dispensed (50 μl per well) into 96-well flat-bottom plates.</div>
    <div id="p-1306" num="1497" class="description-paragraph style-scope patent-text">A stock solution (1 ml) of the antibody drug conjugate (ADC) to be tested (20 μg/ml) was made by dilution of filter-sterilised ADC into cell culture medium. A set of 8×10-fold dilutions of stock ADC were made in a 24-well plate by serial transfer of 100 μl into 900 μl of cell culture medium. ADC dilution was dispensed (50 μl per well) into 4 replicate wells of the 96-well plate, containing 50 μl cell suspension seeded the previously. Control wells received 50 μl cell culture medium. The 96-well plate containing cells and ADCs was incubated at 37° C. in a CO<sub class="style-scope patent-text">2</sub>-gassed incubator for the exposure time.</div>
    <div id="p-1307" num="1498" class="description-paragraph style-scope patent-text">At the end of the incubation period, cell viability was measured by MTS assay. MTS (Promega) was dispensed (20 μl per well) into each well and incubated for 4 hours at 37° C. in the CO<sub class="style-scope patent-text">2</sub>-gassed incubator. Well absorbance was measured at 490 nm. Percentage cell survival was calculated from the mean absorbance in the 4 ADC-treated wells compared to the mean absorbance in the 4 control untreated wells (100%). IC<sub class="style-scope patent-text">50 </sub>was determined from the dose-response data using GraphPad Prism using the non-linear curve fit algorithm: sigmoidal dose-response curve with variable slope.</div>
    <div id="p-1308" num="1499" class="description-paragraph style-scope patent-text">ADC incubation times were 4 days with SK-BR-3, MDA-MB-468, WSU-DLCL2, and SU-DHL-4, 5 days for Granta-519, 6 days for BJAB and 7 days for NCI-N87. MDA-MB-468, NCI-N87, WSU-DLCL2 and SU-DHL-4 were cultured in RPMI 1640 with Glutamax+10% (v/v) HyClone™ Fetal Bovine Serum, Granta-519 in DMEM+Glutamax with 10% (v/v) HyClone™ Fetal Bovine Serum, SK-BR-3 in McCoys 5A with 10% (v/v) HyClone™ Fetal Bovine Serum and BJAB in RPMI 1640+Glutamax with 20% (v/v) HyClone™ Fetal Bovine Serum.</div>
    <div id="h-0502" num="0000" class="description-paragraph style-scope patent-text">CellTiter-Glo Cytotoxicity Method</div>
    <div id="p-1309" num="1500" class="description-paragraph style-scope patent-text">The concentration and viability of cells from a sub-confluent (80-90% confluency) T75 flask are measured by trypan blue staining, and counted using the LUNA-II™ Automated Cell Counter. Cells were diluted and plated at 1500 cells per well (50 μl suspension per well) into white 96-well flat-bottom plates.</div>
    <div id="p-1310" num="1501" class="description-paragraph style-scope patent-text">A stock solution (1 ml) of antibody drug conjugate (ADC) to be tested (20 μg per ml) was made by dilution of filter-sterilised ADC into cell culture medium. A set of 8×10-fold dilutions of stock ADC were made in a 24-well plate by serial transfer of 100 μl into 900 μl of cell culture medium. ADC dilution was dispensed (50 μl per well) into 4 replicate wells of the 96-well plate, containing 50 μl cell suspension seeded the previously. Control wells received 50 μl cell culture medium. The 96-well plate containing cells and ADCs was incubated at 37° C. in a CO<sub class="style-scope patent-text">2</sub>-gassed incubator for the exposure time.</div>
    <div id="p-1311" num="1502" class="description-paragraph style-scope patent-text">At the end of the incubation period, cell viability was measured by CellTiter-Glo assay. CellTiter-Glo (Promega) was dispensed at 100 μl per well and shaken for 2 min before 10 min stabilisation at room temperature. Luminescence of each well was read. Percentage cell survival was calculated from the mean absorbance in the 4 ADC-treated wells compared to the mean absorbance in the 4 control untreated wells (100%). IC<sub class="style-scope patent-text">50 </sub>was determined from the dose-response data using GraphPad Prism using the non-linear curve fit algorithm: sigmoidal dose-response curve with variable slope.</div>
    <div id="p-1312" num="1503" class="description-paragraph style-scope patent-text">ADC incubation time for PC-3 is 6 days. PC-3 were cultured in RPMI 1640 with Glutamax+10% (v/v) HyClone™ Fetal Bovine Serum.</div>
    <div id="h-0503" num="0000" class="description-paragraph style-scope patent-text">Results</div>
    <div id="p-1313" num="1504" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00002" num="00002" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="5"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">GRANTA-</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">EC<sub class="style-scope patent-text">50 </sub>(μg/mL)</td>
                <td class="description-td style-scope patent-text">SU-DHL-4</td>
                <td class="description-td style-scope patent-text">519</td>
                <td class="description-td style-scope patent-text">BJAB</td>
                <td class="description-td style-scope patent-text">WSU-DLCL2</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="5"> </td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Conj-CD79b-1</td>
                <td class="description-td style-scope patent-text">1.216</td>
                <td class="description-td style-scope patent-text">49.69</td>
                <td class="description-td style-scope patent-text">0.2211</td>
                <td class="description-td style-scope patent-text">&gt;100</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Conj-CD79b-2</td>
                <td class="description-td style-scope patent-text">0.4781</td>
                <td class="description-td style-scope patent-text">0.1124</td>
                <td class="description-td style-scope patent-text">0.005712</td>
                <td class="description-td style-scope patent-text">0.7559</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Conj-R347-2</td>
                <td class="description-td style-scope patent-text">&gt;10</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <div id="p-1314" num="1505" class="description-paragraph style-scope patent-text">The cell lines SU-DHL-4, GRANTA519, BJAB and WSU-DL-CL2 all express CD79b.</div>
    <div id="p-1315" num="1506" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00003" num="00003" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="5"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">EC<sub class="style-scope patent-text">50 </sub>(μg/mL)</td>
                <td class="description-td style-scope patent-text">SK-BR-3</td>
                <td class="description-td style-scope patent-text">NCI-N87</td>
                <td class="description-td style-scope patent-text">MDA-MB-468</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="5"> </td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Conj-Her-1</td>
                <td class="description-td style-scope patent-text">0.06953</td>
                <td class="description-td style-scope patent-text">0.9677</td>
                <td class="description-td style-scope patent-text">3.492</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Conj-Her-3</td>
                <td class="description-td style-scope patent-text">0.0175</td>
                <td class="description-td style-scope patent-text">0.02502</td>
                <td class="description-td style-scope patent-text">2.322</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Conj-Her-2</td>
                <td class="description-td style-scope patent-text">0.07427</td>
                <td class="description-td style-scope patent-text">0.08078</td>
                <td class="description-td style-scope patent-text">0.9533</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Conj-HER-1++</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">0.1108</td>
                <td class="description-td style-scope patent-text">12.18</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Conj-HER-1+</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">0.3226</td>
                <td class="description-td style-scope patent-text">&gt;10</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <div id="p-1316" num="1507" class="description-paragraph style-scope patent-text">The cell lines SK-BR-3 and NCI-N87 express Her2. The cell line MDA-MB-468 does not express HER2.</div>
    <div id="p-1317" num="1508" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00004" num="00004" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">EC<sub class="style-scope patent-text">50 </sub>(μg/mL)</td>
                <td class="description-td style-scope patent-text">PC-3</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Conj-1C1-1</td>
                <td class="description-td style-scope patent-text">0.5408</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Conj-R347-1</td>
                <td class="description-td style-scope patent-text">&gt;100</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <heading id="h-0504" class="style-scope patent-text">Example 8—In Vivo Assays</heading>
    <div id="h-0505" num="0000" class="description-paragraph style-scope patent-text">(i) Daudi</div>
    <div id="p-1318" num="1509" class="description-paragraph style-scope patent-text">Conjugates tested: Conj-HLL2-1; Conj-HLL2-2; Conj-HLL2-3</div>
    <div id="p-1319" num="1510" class="description-paragraph style-scope patent-text">Female CB.17 SCID mice, aged ten weeks, were injected with 0.1 ml of 1×10<sup class="style-scope patent-text">7 </sup>Daudi cells subcutaneously in the right flank. When tumours reached an average size of 100-150 mm<sup class="style-scope patent-text">3</sup>, treatment began. Mice were weighed twice a week. Tumour size was measured twice a week. Animals were monitored individually. The endpoint of the experiment was a tumour volume of 1500 mm<sup class="style-scope patent-text">3 </sup>or 60 days, whichever came first.</div>
    <div id="p-1320" num="1511" class="description-paragraph style-scope patent-text">Groups of 10 xenografted mice were injected i.v. with 0.2 ml per 20 g of body weight of antibody drug conjugate (ADC) in phosphate buffered saline (vehicle) or with 0.2 ml per 20 g of body weight of vehicle alone.</div>
    <div id="p-1321" num="1512" class="description-paragraph style-scope patent-text">The concentration of ADC was adjusted to give the following doses:</div>
    <div id="p-1322" num="1513" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00005" num="00005" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Conjuagte</td>
                <td class="description-td style-scope patent-text">Doses (mg ADC/kg body eight)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Conj-HLL2-1</td>
                <td class="description-td style-scope patent-text">0.6 or 1.8</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Conj-HLL2-2</td>
                <td class="description-td style-scope patent-text">0.3 or 1</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Conj-HLL2-3</td>
                <td class="description-td style-scope patent-text">0.1 or 0.3</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <div id="p-1323" num="1514" class="description-paragraph style-scope patent-text">All regimens were acceptably tolerated with little body weight loss.</div>
    <div id="p-1324" num="1515" class="description-paragraph style-scope patent-text">Conj-HLL2-1:</div>
    <div id="p-1325" num="1516" class="description-paragraph style-scope patent-text">The median time to end point (TTE) for vehicle-treated controls was 27.8 days, establishing a maximum possible tumour growth delay (TGD) of 32.2 days (116%) for the 60-day study. One non-treatment related death was recorded on day 28, and this animal was excluded from the analysis.</div>
    <div id="p-1326" num="1517" class="description-paragraph style-scope patent-text">The 0.6 mg/kg regimen resulted in a TGD of 48.1 days (73%), which was statistically significant from controls (p&lt;0.001). Furthermore, this regimen had five of nine 59-regression responses consisting of two partial and three complete regressions. Six animals attained the 1500 mm3 endpoint, leaving 3 survivors after 60 days. The three survivors had a mean tumour volume of 221 mm<sup class="style-scope patent-text">3</sup>. There was one non-treatment related death and this animal was excluded from the analysis.</div>
    <div id="p-1327" num="1518" class="description-paragraph style-scope patent-text">The 1.8 mg/kg regimen resulted in the maximum possible, significant TGD (vs controls, p&lt;0.001), had eight of ten 60-day survivors and produced a survival benefit that was statistically significantly different from vehicle-treated controls (p&lt;0.001). Eight animals showed complete regression responses. Five of these animals were tumour free after 60 days.</div>
    <div id="p-1328" num="1519" class="description-paragraph style-scope patent-text">Both treatment regimens produced statistically significant survival benefits compared to control (p&lt;0.001 for both 0.6 and 1.8 mg/ml).</div>
    <div id="p-1329" num="1520" class="description-paragraph style-scope patent-text">Conj-HLL2-2:</div>
    <div id="p-1330" num="1521" class="description-paragraph style-scope patent-text">The median time to end point (TTE) for vehicle-treated controls was 27.8 days, establishing a maximum possible tumour growth delay (TGD) of 32.2 days (116%) for the 60-day study.</div>
    <div id="p-1331" num="1522" class="description-paragraph style-scope patent-text">The 0.3 and 1 mg/kg regimens both resulted in maximum achievable TGDs (32.2 days, 116%). Both of these results were statistically significant from controls (p&lt;0.001 for each regimen).</div>
    <div id="p-1332" num="1523" class="description-paragraph style-scope patent-text">Eighty percent of 0.3 mg/kg treated animals evinced regression responses consisting of two partial responses and six complete responses, four of which remained tumour free at the study end. Four 0.3 mg/kg treated animals reached the tumour volume endpoint leaving six study survivors tumour free at the end of the study.</div>
    <div id="p-1333" num="1524" class="description-paragraph style-scope patent-text">One hundred percent of 1 mg/kg treated animals showed regression responses and all animals were tumour free on day 60.</div>
    <div id="p-1334" num="1525" class="description-paragraph style-scope patent-text">Both treatment regimens resulted in significant overall survival differences versus controls (controls versus either 0.3 or 1 mg/kg, p&lt;0.0001).</div>
    <div id="p-1335" num="1526" class="description-paragraph style-scope patent-text">Conj-HLL2-3:</div>
    <div id="p-1336" num="1527" class="description-paragraph style-scope patent-text">The median time to end point (TTE) for vehicle-treated controls was 27.8 days, establishing a maximum possible tumour growth delay (TGD) of 32.2 days (116%) for the 60-day study.</div>
    <div id="p-1337" num="1528" class="description-paragraph style-scope patent-text">The 0.1 and 0.3 mg/kg regimens resulted in TGDs of 12.9 days (46%) and 24.6 days (88%). Both of these results were statistically significant from controls (p&lt;0.001 for each regimen).</div>
    <div id="p-1338" num="1529" class="description-paragraph style-scope patent-text">Thirty percent regression responses were observed in animals treated with the 0.1 mg/ml regimen with three partial responses. All the animals in this group reached the tumour volume endpoint by day 60.</div>
    <div id="p-1339" num="1530" class="description-paragraph style-scope patent-text">Seventy percent of 0.3 mg/kg treated animals evinced regression responses consisting of three partial responses and four complete responses, one of which remained tumour free at the study end. Four 0.3 mg/kg treated animals reached the tumour volume endpoint leaving six study survivors tumour free at the end of the study. Seven animals in this group reached the tumour volume endpoint leaving three 60 day survivors with an MTV of 750 mm<sup class="style-scope patent-text">3 </sup>at study end.</div>
    <div id="p-1340" num="1531" class="description-paragraph style-scope patent-text">Both treatment regimens resulted in significant overall survival differences versus controls (controls versus either 0.1 or 0.13 mg/kg, p&lt;0.0001).</div>
    <div id="h-0506" num="0000" class="description-paragraph style-scope patent-text">(ii) JIMT-1</div>
    <div id="p-1341" num="1532" class="description-paragraph style-scope patent-text">Conjugate tested: Conj-Her-3</div>
    <div id="p-1342" num="1533" class="description-paragraph style-scope patent-text">Female CB.17 SCID mice, aged 10 weeks, were injected with 0.1 ml of 1×10<sup class="style-scope patent-text">7 </sup>JIMT-1 cells in 50% Matrigel subcutaneously in the right flank. When tumours reached an average size of 100-150 mm<sup class="style-scope patent-text">3</sup>, treatment began. Mice were weighed twice a week. Tumour size was measured twice a week. Animals were monitored individually. The endpoint of the experiment was a tumour volume of 1000 mm<sup class="style-scope patent-text">3 </sup>or 59 days, whichever came first.</div>
    <div id="p-1343" num="1534" class="description-paragraph style-scope patent-text">Groups of 10 xenografted mice were injected i.v. with 0.2 ml per 20 g of body weight of antibody drug conjugate (ADC) in phosphate buffered saline (vehicle) or with 0.2 ml per 20 g of body weight of vehicle alone. The concentration of ADC was adjusted to give 1 or 3 mg ADC/kg body weight in a single dose.</div>
    <div id="p-1344" num="1535" class="description-paragraph style-scope patent-text">All regimens were acceptably tolerated with little body weight loss. The median time to end point (TTE) for vehicle-treated controls was 48.4 days, establishing a maximum possible tumour growth delay (TGD) of 10.6 days (22%) for the 59-day study.</div>
    <div id="p-1345" num="1536" class="description-paragraph style-scope patent-text">A dose dependent effect was observed where in animals that received the 1 mg/kg dose the median tumour volume remained static until day 34, then progressed thereafter, while for animals treated with 3 mg/kg there was a small reduction in tumour size to an MTV of 81 mm<sup class="style-scope patent-text">3</sup>. Both dosing regimens resulted in a maximal TGD of 10.6 days (22%) versus the control group (p&lt;0.001 for both treated groups).</div>
    <div id="p-1346" num="1537" class="description-paragraph style-scope patent-text">The 1 mg/kg regimen resulted in nine study survivors with an MTV of 650 mm<sup class="style-scope patent-text">3 </sup>and no objective regression responses.</div>
    <div id="p-1347" num="1538" class="description-paragraph style-scope patent-text">The 3 mg/kg regimen resulted in nine study survivors with 20% objective regression responses consisting of two partial responses. The MTV of the study survivors was 108 mm<sup class="style-scope patent-text">3</sup>. The treatment regimens were not significantly different from each other (p&gt;0.05).</div>
    <div id="p-1348" num="1539" class="description-paragraph style-scope patent-text">Both treatment regimens resulted in significant overall survival differences versus controls (controls versus either 1 or 3 mg/kg, p&lt;0.0001).</div>
    <div id="h-0507" num="0000" class="description-paragraph style-scope patent-text">(iii) NCI-N87</div>
    <div id="p-1349" num="1540" class="description-paragraph style-scope patent-text">Conjugate tested: Conj-Her-3</div>
    <div id="p-1350" num="1541" class="description-paragraph style-scope patent-text">Female CB.17 SCID mice, aged ten weeks, were injected with 0.1 ml of 1×10<sup class="style-scope patent-text">7 </sup>NCI-N87 cells in 50% Matrigel subcutaneously in the right flank. When tumours reached an average size of 100-150 mm<sup class="style-scope patent-text">3</sup>, treatment began. Mice were weighed twice a week. Tumour size was measured twice a week. Animals were monitored individually. The endpoint of the experiment was a tumour volume of 800 mm<sup class="style-scope patent-text">3 </sup>or 81 days, whichever came first.</div>
    <div id="p-1351" num="1542" class="description-paragraph style-scope patent-text">Groups of 10 xenografted mice were injected i.v. with 0.2 ml per 20 g of body weight of antibody drug conjugate (ADC) in phosphate buffered saline (vehicle) or with 0.2 ml per 20 g of body weight of vehicle alone. The concentration of ADC was adjusted to give 0.3 or 1 mg ADC/kg body weight in a single dose.</div>
    <div id="p-1352" num="1543" class="description-paragraph style-scope patent-text">All regimens were acceptably tolerated with little body weight loss. Six of ten control tumours reached the 800 mm<sup class="style-scope patent-text">3</sup>, with time to endpoints (TTE) ranging 36.8 to 81.0 days. The median time to end point (TTE) for vehicle-treated controls was 77 days, establishing a maximum possible tumour growth delay (TGD) of 4 days (5%) for the 81-day study. Four control animals survived with a median tumour volume (MTV) of 696 mm<sup class="style-scope patent-text">3</sup>.</div>
    <div id="p-1353" num="1544" class="description-paragraph style-scope patent-text">The 0.3 and 1 mg/kg regimens resulted in TGDs of 0.5 (1%) and 4.0 days (5%) respectively. Both of these results were not statistically significant from controls, not each other (p&gt;0.05). There were no objective regressions recorded in either group. Five 0.3 mg/kg and seven 1 mg/kg treated animals survived with MTVs of 550 mm<sup class="style-scope patent-text">3 </sup>in both groups.</div>
    <div id="p-1354" num="1545" class="description-paragraph style-scope patent-text">Neither treatment regimen resulted in statistically significant survival benefits compared to control (p&gt;0.05 for both treatment groups), and there was no significant difference between the treatment groups (p&gt;0.05).</div>
    <div id="h-0508" num="0000" class="description-paragraph style-scope patent-text">(iv) NCI-N87</div>
    <div id="p-1355" num="1546" class="description-paragraph style-scope patent-text">Conjugates tested: Conj-Her-1, Conj-Her-3</div>
    <div id="p-1356" num="1547" class="description-paragraph style-scope patent-text">Female CB.17 SCID mice, aged eight weeks, were injected with 0.1 ml of 1×10<sup class="style-scope patent-text">7 </sup>NCI-N87 in 50% Matrigel cells subcutaneously in the right flank. When tumours reached an average size of 100-150 mm<sup class="style-scope patent-text">3</sup>, treatment began. Mice were weighed twice a week. Tumour size was measured twice a week. Animals were monitored individually. The endpoint of the experiment was a tumour volume of 800 mm<sup class="style-scope patent-text">3 </sup>or 78 days, whichever came first.</div>
    <div id="p-1357" num="1548" class="description-paragraph style-scope patent-text">Groups of 10 xenografted mice were injected i.v. with 0.2 ml per 20 g of body weight of antibody drug conjugate (ADC) in phosphate buffered saline (vehicle) or with 0.2 ml per 20 g of body weight of vehicle alone.</div>
    <div id="p-1358" num="1549" class="description-paragraph style-scope patent-text">The concentration of ADC was adjusted to give the following doses:</div>
    <div id="p-1359" num="1550" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00006" num="00006" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Conjugate</td>
                <td class="description-td style-scope patent-text">Doses (mg ADC/kg body eight)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Conj-Her-1</td>
                <td class="description-td style-scope patent-text">1, 3, or 6</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Conj-Her-3</td>
                <td class="description-td style-scope patent-text">0.3, 1 and 3</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <div id="p-1360" num="1551" class="description-paragraph style-scope patent-text">All regimens were acceptably tolerated with little body weight loss.</div>
    <div id="p-1361" num="1552" class="description-paragraph style-scope patent-text">Conj-Her-1:</div>
    <div id="p-1362" num="1553" class="description-paragraph style-scope patent-text">The median time to end point (TTE) for vehicle-treated controls was 42 days, establishing a maximum possible tumour growth delay (TGD) of 36 days (86%) for the 60-day study.</div>
    <div id="p-1363" num="1554" class="description-paragraph style-scope patent-text">The 0.6 and 1 mg/kg regimens resulted in TGDs of 9.9 (24%) and 11.6 days (28%) respectively. Neither of these results were statistically significant from controls (p&gt;0.05). All animals in both groups attained the 800 mm<sup class="style-scope patent-text">3 </sup>endpoint.</div>
    <div id="p-1364" num="1555" class="description-paragraph style-scope patent-text">The 6 mg/kg regimen resulted in the maximum possible, significant TGD (vs controls, p&lt;0.001), had eight of ten 60-day survivors and produced a survival benefit that was statistically significantly different from vehicle-treated controls (p&lt;0.0001). One animal reached the 800 mm<sup class="style-scope patent-text">3 </sup>endpoint at day 78, leaving nine survivors with mean tumour volumes of 550 mm<sup class="style-scope patent-text">3</sup>.</div>
    <div id="p-1365" num="1556" class="description-paragraph style-scope patent-text">There were no observable regression responses with 1, 3, or 6 mg/kg regimens.</div>
    <div id="p-1366" num="1557" class="description-paragraph style-scope patent-text">Conj-Her-3:</div>
    <div id="p-1367" num="1558" class="description-paragraph style-scope patent-text">The median time to end point (TTE) for vehicle-treated controls was 42.0 days, establishing a maximum possible tumour growth delay (TGD) of 36.0 days (86%) for the 78-day study.</div>
    <div id="p-1368" num="1559" class="description-paragraph style-scope patent-text">The TGDs for 0.3, 1 and 3 mg/kg were 15.1 (36%), 30.6 (73%) and 36.0 (86%) days respectively. There were significant differences for 1 and 3 mg/kg versus controls (p&lt;0.001 for both treatment groups, but not 0.3 mg/kg (p&gt;0.05). No regression responses were observed in animals treated with 0.3 and 1 mg/kg ADC. Ninety percent regression responses were observed in 3 mg/kg treated animals. This consisted of eight partial responses and one complete response, which remained tumour free at study end. All animals treated with 0.3 mg/kg reached the 800 mm<sup class="style-scope patent-text">3 </sup>endpoint. Five 1 mg/kg treated animals attained endpoint leaving five 78 day survivors. These had an MTV of 486 mm<sup class="style-scope patent-text">3</sup>. All ten 3 mg/kg treated animals survived the study with an MTV of 63 mm<sup class="style-scope patent-text">3</sup>.</div>
    <div id="p-1369" num="1560" class="description-paragraph style-scope patent-text">The 1 and 3 mg/kg regimens resulted in significant survival differences versus controls (p&lt;0.001 for both treatment groups). The 0.3 mg/kg treatment group was not statistically significant from control (p&gt;0.05). Both 1 and 3 mg/kg treatment were significantly different from the 0.3 mg/kg group (p&lt;0.001 and p&lt;0.0001 respectively).</div>
    <div id="h-0509" num="0000" class="description-paragraph style-scope patent-text">(v) NCI-N87</div>
    <div id="p-1370" num="1561" class="description-paragraph style-scope patent-text">Conjugate tested: Conj-Her-2</div>
    <div id="p-1371" num="1562" class="description-paragraph style-scope patent-text">Female CB.17 SCID mice, aged eight weeks, were injected with 0.1 ml of 1×10<sup class="style-scope patent-text">7 </sup>NCI-N87 cells in 50% Matrigel subcutaneously in the right flank. When tumours reached an average size of 100-150 mm<sup class="style-scope patent-text">3</sup>, treatment began. Mice were weighed twice a week. Tumour size was measured twice a week. Animals were monitored individually. The endpoint of the experiment was a tumour volume of 800 mm<sup class="style-scope patent-text">3 </sup>or 79 days, whichever came first.</div>
    <div id="p-1372" num="1563" class="description-paragraph style-scope patent-text">Groups of 10 xenografted mice were injected i.v. with 0.2 ml per 20 g of body weight of antibody drug conjugate (ADC) in phosphate buffered saline (vehicle) or with 0.2 ml per 20 g of body weight of vehicle alone. The concentration of ADC was adjusted to give 1 or 2 mg ADC/kg body weight in a single dose.</div>
    <div id="p-1373" num="1564" class="description-paragraph style-scope patent-text">All regimens were acceptably tolerated with little body weight loss. The median time to end point (TTE) for vehicle-treated controls was 49.6 days, establishing a maximum possible tumour growth delay (TGD) of 29.4 days (59%) for the 79-day study.</div>
    <div id="p-1374" num="1565" class="description-paragraph style-scope patent-text">The 1 and 2 mg/kg regimens resulted in TGDs of 7.6 (15%) and 23.6 days (48%) respectively. Both of these results were statistically significant from controls (p&lt;0.05 and p&lt;0.001 respectively).</div>
    <div id="p-1375" num="1566" class="description-paragraph style-scope patent-text">Eight animals treated with the 1 mg/kg regimen attained the 800 mm<sup class="style-scope patent-text">3 </sup>endpoint leaving two 79-day survivors with an MTV of 694 mm<sup class="style-scope patent-text">3</sup>. Seven animals in the 2 mg/ml treated group reached the tumour volume endpoint by day 79 leaving three end of study survivors with an MTV of 600 mm<sup class="style-scope patent-text">3</sup>.</div>
    <div id="p-1376" num="1567" class="description-paragraph style-scope patent-text">Both treatment regimens resulted in significant overall survival differences versus controls (controls versus 1 mg/kg, p&lt;0.05; controls versus 2 mg/kg, p&lt;0.001).</div>
    <div id="p-1377" num="1568" class="description-paragraph style-scope patent-text">Regression responses were not recorded with either regimen.</div>
    <div id="h-0510" num="0000" class="description-paragraph style-scope patent-text">(vi) NCI-N87</div>
    <div id="p-1378" num="1569" class="description-paragraph style-scope patent-text">Conjugates tested: Conj-Her-1, Conj-Her-1++</div>
    <div id="p-1379" num="1570" class="description-paragraph style-scope patent-text">Female CB.17 SCID mice, aged eight weeks, were injected with 0.1 ml of 1×10<sup class="style-scope patent-text">7 </sup>NCI-N87 in 50% Matrigel cells subcutaneously in the right flank. When tumours reached an average size of 100-150 mm<sup class="style-scope patent-text">3</sup>, treatment began. Mice were weighed twice a week. Tumour size was measured twice a week. Animals were monitored individually. The endpoint of the experiment was a tumour volume of 800 mm<sup class="style-scope patent-text">3 </sup>or 81 days, whichever came first.</div>
    <div id="p-1380" num="1571" class="description-paragraph style-scope patent-text">Groups of 10 xenografted mice were injected i.v. with 0.2 ml per 20 g of body weight of antibody drug conjugate (ADC) in phosphate buffered saline (vehicle) or with 0.2 ml per 20 g of body weight of vehicle alone.</div>
    <div id="p-1381" num="1572" class="description-paragraph style-scope patent-text">The concentration of ADC was adjusted to give the following doses:</div>
    <div id="p-1382" num="1573" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00007" num="00007" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Conjugate</td>
                <td class="description-td style-scope patent-text">Doses (mg ADC/kg body weight)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Conj-Her-1</td>
                <td class="description-td style-scope patent-text">6, 18, 6 (qwk × 3), 8 (qwk × 3)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Conj-Her-1++</td>
                <td class="description-td style-scope patent-text">6</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <div id="p-1383" num="1574" class="description-paragraph style-scope patent-text">All regimens were acceptably tolerated with little body weight loss.</div>
    <div id="p-1384" num="1575" class="description-paragraph style-scope patent-text">The median time to end point (TTE) for vehicle-treated controls was 40.2 days, establishing a maximum possible tumour growth delay (TGD) of 40 days (86%) for the 80-day study.</div>
    <div id="p-1385" num="1576" class="description-paragraph style-scope patent-text">Conj-Her-1:</div>
    <div id="p-1386" num="1577" class="description-paragraph style-scope patent-text">The 6 and 18 mg/kg single-dose regimens resulted in the maximum possible tumor growth delays. In the 6 mg/kg single-dose regimen the mean tumour volume for 5 mice was 600 mm<sup class="style-scope patent-text">3</sup>, with no observable regression responses. In the 18 mg/kg single-dose regimen there were ten survivors with a mean tumour volume of 36 mm<sup class="style-scope patent-text">3</sup>. There were 4 partial regressions and 6 complete regressions.</div>
    <div id="p-1387" num="1578" class="description-paragraph style-scope patent-text">The 6 and 8 mg/kg three weekly dose regimens also resulted in the in the maximum possible tumor growth delays. In the 6 mg/kg three weekly dose regimen the mean tumour volume for 9 mice at the end of the study was 245 mm<sup class="style-scope patent-text">3</sup>, with two partial regressions. In the 8 mg/kg three weekly dose regimen there were ten survivors with a mean tumour volume of 92 mm<sup class="style-scope patent-text">3</sup>. There were 7 partial regressions, 3 complete regressions and 2 tumour free survivors.</div>
    <div id="p-1388" num="1579" class="description-paragraph style-scope patent-text">Conj-Her-1++:</div>
    <div id="p-1389" num="1580" class="description-paragraph style-scope patent-text">The 6 mg/kg single-dose regimen resulted in the maximum possible tumor growth delays. There were ten survivors with a mean tumour volume of 161 mm<sup class="style-scope patent-text">3</sup>. There were 5 partial regressions, 5 complete regressions and 2 tumour free survivors.</div>
    <div id="h-0511" num="0000" class="description-paragraph style-scope patent-text">(vii) NCI-N87</div>
    <div id="p-1390" num="1581" class="description-paragraph style-scope patent-text">Conjugates tested: Conj-Her-1, Conj-Her1+, Conj-Her-1++</div>
    <div id="p-1391" num="1582" class="description-paragraph style-scope patent-text">Female CB.17 SCID mice, aged eight weeks, were injected with 0.1 ml of 1×10<sup class="style-scope patent-text">7 </sup>NCI-N87 in 50% Matrigel cells subcutaneously in the right flank. When tumours reached an average size of 100-150 mm<sup class="style-scope patent-text">3</sup>, treatment began. Mice were weighed twice a week. Tumour size was measured twice a week. Animals were monitored individually. The endpoint of the experiment was a tumour volume of 800 mm<sup class="style-scope patent-text">3 </sup>or 83 days, whichever came first.</div>
    <div id="p-1392" num="1583" class="description-paragraph style-scope patent-text">Groups of 10 xenografted mice were injected i.v. with 0.2 ml per 20 g of body weight of antibody drug conjugate (ADC) in phosphate buffered saline (vehicle) or with 0.2 ml per 20 g of body weight of vehicle alone.</div>
    <div id="p-1393" num="1584" class="description-paragraph style-scope patent-text">The concentration of ADC was adjusted to give the following doses:</div>
    <div id="p-1394" num="1585" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00008" num="00008" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Conjugate</td>
                <td class="description-td style-scope patent-text">Doses (mg ADC/kg body weight)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Conj-Her-1</td>
                <td class="description-td style-scope patent-text"> 6, 18</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Conj-Her-1+</td>
                <td class="description-td style-scope patent-text">3, 6</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Conj-Her-1++</td>
                <td class="description-td style-scope patent-text">1.5, 3  </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <div id="p-1395" num="1586" class="description-paragraph style-scope patent-text">All regimens were acceptably tolerated with little body weight loss.</div>
    <div id="p-1396" num="1587" class="description-paragraph style-scope patent-text">The median time to end point (TTE) for vehicle-treated controls was 36.8 days, establishing a maximum possible tumour growth delay (TGD) of 46.2 days (126%) for the 80-day study.</div>
    <div id="p-1397" num="1588" class="description-paragraph style-scope patent-text">Conj-Her-1:</div>
    <div id="p-1398" num="1589" class="description-paragraph style-scope patent-text">The 6 and 18 mg/kg regimens resulted in tumor growth delays of 45.9 days (125%) and 46.2 days (126%). In the 6 mg/kg regimen the mean tumour volume for 4 mice was 564 mm<sup class="style-scope patent-text">3</sup>, with no observable regression responses. In the 18 mg/kg regimen there were nine survivors with a mean tumour volume of 108 mm<sup class="style-scope patent-text">3</sup>. There were 9 partial regressions and 1 complete regressions.</div>
    <div id="p-1399" num="1590" class="description-paragraph style-scope patent-text">Conj-Her-1++:</div>
    <div id="p-1400" num="1591" class="description-paragraph style-scope patent-text">The 1.5 and 3 mg/kg regimen resulted in tumor growth delays of 45.9 days (125%) and 46.2 days (126%). In the 1.5 mg/kg regimen there were two survivors with a mean tumour volume of 634 mm<sup class="style-scope patent-text">3</sup>. In the 3 mg/kg regimen there were ten survivors with a mean tumour volume of 451 mm<sup class="style-scope patent-text">3</sup>.</div>
    <div id="p-1401" num="1592" class="description-paragraph style-scope patent-text">Conj-Her-1+:</div>
    <div id="p-1402" num="1593" class="description-paragraph style-scope patent-text">The 3 and 6 mg/kg regimens resulted in maximum tumor growth delays of 46.2 days (126%). In the 3 mg/kg regimen there were seven survivors with a mean tumour volume of 600 mm<sup class="style-scope patent-text">3</sup>. In the 6 mg/kg regimen there were ten survivors with a mean tumour volume of 256 mm<sup class="style-scope patent-text">3</sup>. There were two partial regressions.</div>
    <div id="h-0512" num="0000" class="description-paragraph style-scope patent-text">(viii) JIMT1</div>
    <div id="p-1403" num="1594" class="description-paragraph style-scope patent-text">Conjugates tested: Conj-Her-1, Conj-Her-1++</div>
    <div id="p-1404" num="1595" class="description-paragraph style-scope patent-text">Female CB.17 SCID mice, aged eight weeks, were injected with 0.1 ml of 1×10<sup class="style-scope patent-text">7 </sup>JIMT1 in 50% Matrigel cells subcutaneously in the right flank. When tumours reached an average size of 100-150 mm<sup class="style-scope patent-text">3</sup>, treatment began. Mice were weighed twice a week. Tumour size was measured twice a week. Animals were monitored individually. The endpoint of the experiment was a tumour volume of 1000 mm<sup class="style-scope patent-text">3 </sup>or 60 days, whichever came first.</div>
    <div id="p-1405" num="1596" class="description-paragraph style-scope patent-text">Groups of 10 xenografted mice were injected i.v. with 0.2 ml per 20 g of body weight of antibody drug conjugate (ADC) in phosphate buffered saline (vehicle) or with 0.2 ml per 20 g of body weight of vehicle alone.</div>
    <div id="p-1406" num="1597" class="description-paragraph style-scope patent-text">The concentration of ADC was adjusted to give the following doses:</div>
    <div id="p-1407" num="1598" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00009" num="00009" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Conjugate</td>
                <td class="description-td style-scope patent-text">Doses (mg ADC/kg body weight)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Conj-Her-1</td>
                <td class="description-td style-scope patent-text">18, 24</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Conj-Her-1++</td>
                <td class="description-td style-scope patent-text">4, 6, 8</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <div id="p-1408" num="1599" class="description-paragraph style-scope patent-text">All regimens were acceptably tolerated with little body weight loss.</div>
    <div id="p-1409" num="1600" class="description-paragraph style-scope patent-text">The median time to end point (TTE) for vehicle-treated controls was 37.5 days, establishing a maximum possible tumour growth delay (TGD) of 22.5 days (60%) for the 60-day study.</div>
    <div id="p-1410" num="1601" class="description-paragraph style-scope patent-text">Conj-Her-1:</div>
    <div id="p-1411" num="1602" class="description-paragraph style-scope patent-text">The 18 and 24 mg/kg regimens resulted in tumor growth delays of 5.3 days (14%) and 3.2 days (9%). In the 18 mg/kg regimen all animals reached the 1000 mm<sup class="style-scope patent-text">3 </sup>endpoint. In the 24 mg/kg regimen there was a single survivor with a tumour volume of 968 mm<sup class="style-scope patent-text">3</sup>. Both regimens resulted in a significant overall survival difference versus controls (P&lt;0.01).</div>
    <div id="p-1412" num="1603" class="description-paragraph style-scope patent-text">Conj-Her-1++:</div>
    <div id="p-1413" num="1604" class="description-paragraph style-scope patent-text">The 4, 6 and 8 mg/kg regimen resulted in tumor growth delays of 4.4 days (12%). 6.9 days (18%) and 17.7 days (47%). In the 4 mg/kg regimen all animals reached the 1000 mm<sup class="style-scope patent-text">3 </sup>endpoint. In the 6 mg/kg regimen there was a single survivor with a tumour volume of 650 mm<sup class="style-scope patent-text">3</sup>. In the 8 mg/kg regimen there was a single survivor with a tumour volume of 847 mm<sup class="style-scope patent-text">3</sup>. All regimens resulted in a significant overall survival difference versus controls (P&lt;0.01).</div>
    <heading id="h-0513" class="style-scope patent-text">Example 9—Toxicology Assay</heading>
    <div id="p-1414" num="1605" class="description-paragraph style-scope patent-text">A single dose nonGLP toxicity study was used to determine the maximum tolerated dose (MTD) and safety profile of the ADCs tested, which were: Conj-R347-1; Conj-R347-2; Conj-R347-3.</div>
    <div id="p-1415" num="1606" class="description-paragraph style-scope patent-text">Male Sprague Dawley rats (Envigo, Inc) were dosed once by slow bolus intravenous injection via the tail vein with ADC. The vehicle for dilution used was 25 mM Histidine-HCl, 7% sucrose, 0.02% Polysorbate 80, pH 6.0. Parameters evaluated during the study included mortality, physical examinations, cageside observations, body weights, body weight changes, clinical pathology (clinical chemistry, hematology, and coagulation), and gross pathology findings. All animals were terminated on Study Day (SD) 29.</div>
    <div id="h-0514" num="0000" class="description-paragraph style-scope patent-text">Conj-R347-1</div>
    <div id="p-1416" num="1607" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00010" num="00010" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Group</td>
                <td class="description-td style-scope patent-text">Dose (mg/kg)</td>
                <td class="description-td style-scope patent-text">N</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">2</td>
                <td class="description-td style-scope patent-text">5</td>
                <td class="description-td style-scope patent-text">5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">4</td>
                <td class="description-td style-scope patent-text">7</td>
                <td class="description-td style-scope patent-text">5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">6</td>
                <td class="description-td style-scope patent-text">10</td>
                <td class="description-td style-scope patent-text">5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">8</td>
                <td class="description-td style-scope patent-text">16</td>
                <td class="description-td style-scope patent-text">5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">10</td>
                <td class="description-td style-scope patent-text">20</td>
                <td class="description-td style-scope patent-text">5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">12</td>
                <td class="description-td style-scope patent-text">25</td>
                <td class="description-td style-scope patent-text">5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <div id="p-1417" num="1608" class="description-paragraph style-scope patent-text">Tolerability was determined based on toxicity end points, including mild decreases in hematological parameters, microscopic evaluations and bone marrow suppression. Based on microscopic changes in animals receiving the highest dose, the maximum tolerated dose (MTD) in the rat after a single dose was determined to be 25 mg/kg.</div>
    <div id="h-0515" num="0000" class="description-paragraph style-scope patent-text">Conj-R347-2</div>
    <div id="p-1418" num="1609" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00011" num="00011" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Group</td>
                <td class="description-td style-scope patent-text">Dose(mg/kg)</td>
                <td class="description-td style-scope patent-text">N</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">2</td>
                <td class="description-td style-scope patent-text">2</td>
                <td class="description-td style-scope patent-text">5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">3</td>
                <td class="description-td style-scope patent-text">5</td>
                <td class="description-td style-scope patent-text">5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">4</td>
                <td class="description-td style-scope patent-text">8</td>
                <td class="description-td style-scope patent-text">5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <div id="p-1419" num="1610" class="description-paragraph style-scope patent-text">Tolerability was determined based on toxicity end points. The ADC was tolerated up to 8 mg/kg in the rat after a single dose. Findings included dose dependent body weight decrease and bone marrow suppression.</div>
    <div id="h-0516" num="0000" class="description-paragraph style-scope patent-text">Conj-R347-3</div>
    <div id="p-1420" num="1611" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00012" num="00012" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Group</td>
                <td class="description-td style-scope patent-text">Dose (mg/kg)</td>
                <td class="description-td style-scope patent-text">N</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">5</td>
                <td class="description-td style-scope patent-text">1</td>
                <td class="description-td style-scope patent-text">5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">9</td>
                <td class="description-td style-scope patent-text">2.5</td>
                <td class="description-td style-scope patent-text">5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">11</td>
                <td class="description-td style-scope patent-text">4</td>
                <td class="description-td style-scope patent-text">5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <div id="p-1421" num="1612" class="description-paragraph style-scope patent-text">Tolerability was determined based on toxicity end points. The ADC was tolerated up to 4 mg/kg in the rat after a single dose. Findings included dose-dependent body weight loss and bone marrow suppression.</div>
    <div id="h-0517" num="0000" class="description-paragraph style-scope patent-text">Therapeutic Index</div>
    <div id="p-1422" num="1613" class="description-paragraph style-scope patent-text">The therapeutic index of each ADC/drug linker was calculated using the following equation:
<br class="style-scope patent-text">
<i class="style-scope patent-text">TI</i>=MTD in rat (mg/kg)/MED in mouse efficacy model (mg/kg)
</div>
    <div id="p-1423" num="1614" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00013" num="00013" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="5"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">NCI-N87</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Drug Linker</td>
                <td class="description-td style-scope patent-text">MTD (mg/kg)</td>
                <td class="description-td style-scope patent-text">MED (mg/kg)</td>
                <td class="description-td style-scope patent-text">TI</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="5"> </td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">1</td>
                <td class="description-td style-scope patent-text">25</td>
                <td class="description-td style-scope patent-text">6</td>
                <td class="description-td style-scope patent-text">4.2</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">2</td>
                <td class="description-td style-scope patent-text">8</td>
                <td class="description-td style-scope patent-text">2</td>
                <td class="description-td style-scope patent-text">4</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">3</td>
                <td class="description-td style-scope patent-text">4</td>
                <td class="description-td style-scope patent-text">1</td>
                <td class="description-td style-scope patent-text">4</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    
  </div>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
            <div class="flex flex-width style-scope patent-result">
              <section id="claims" class="style-scope patent-result">
                <h3 class="style-scope patent-result">
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Claims <span class="style-scope patent-result">(23)</span></div>
                    <div class="collapse style-scope patent-result">
                      Hide Dependent <iron-icon style="height: 15px; width: 15px;" icon="expand-less" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 8l-6 6 1.41 1.41L12 10.83l4.59 4.58L18 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </div>
                  </div>
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result"></div>
                    <div class="righthead style-scope patent-result" hidden="">translated from </div>
                  </div>
                </h3>
                <patent-text name="claims" enable-text-selection="" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><div mxw-id="PCLM327756270" lang="EN" load-source="patent-office" class="claims style-scope patent-text">
    <claim-statement class="style-scope patent-text">The invention claimed is:</claim-statement>
    <div class="claim style-scope patent-text"> <div id="CLM-00001" num="00001" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">1. A compound of formula I:</div>
      <div class="claim-text style-scope patent-text">
        <chemistry id="CHEM-US-00060" num="00060" class="style-scope patent-text">
          <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/1a/0d/1c/8a5796d94dc4dd/US11370801-20220628-C00060.png" class="style-scope patent-text"><img id="EMI-C00060" he="38.35mm" wi="74.85mm" file="US11370801-20220628-C00060.TIF" alt="Figure US11370801-20220628-C00060" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="299" height="153" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/1a/0d/1c/8a5796d94dc4dd/US11370801-20220628-C00060.png"></a></div>
          <attachments class="style-scope patent-text">
            <attachment idref="CHEM-US-00060" attachment-type="cdx" file="US11370801-20220628-C00060.CDX" class="style-scope patent-text"> </attachment>
            <attachment idref="CHEM-US-00060" attachment-type="mol" file="US11370801-20220628-C00060.MOL" class="style-scope patent-text"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text style-scope patent-text">R<sup class="style-scope patent-text">6 </sup>and R<sup class="style-scope patent-text">9 </sup>are independently selected from H, R, OH, OR, SH, SR, NH<sub class="style-scope patent-text">2</sub>, NHR, NRR′, nitro, Me<sub class="style-scope patent-text">3</sub>Sn and halo;</div>
        <div class="claim-text style-scope patent-text">where R and R′ are independently selected from optionally substituted C<sub class="style-scope patent-text">1-12 </sub>alkyl, C<sub class="style-scope patent-text">3-20 </sub>heterocyclyl and C<sub class="style-scope patent-text">5-20 </sub>aryl groups;</div>
        <div class="claim-text style-scope patent-text">R<sup class="style-scope patent-text">7 </sup>is selected from H, R, OH, OR, SH, SR, NH<sub class="style-scope patent-text">2</sub>, NHR, NRR′, nitro, Me<sub class="style-scope patent-text">3</sub>Sn and halo;</div>
        <div class="claim-text style-scope patent-text">R″ is a C<sub class="style-scope patent-text">3-12 </sub>alkylene group, which chain may be interrupted by one or more heteroatoms selected from O, S, NR<sup class="style-scope patent-text">N2 </sup>(where R<sup class="style-scope patent-text">N2 </sup>is H or C<sub class="style-scope patent-text">1-4 </sub>alkyl), and/or aromatic rings selected from benzene or pyridine;</div>
        <div class="claim-text style-scope patent-text">Y and Y′ are selected from O, S, or NH;</div>
        <div class="claim-text style-scope patent-text">R<sup class="style-scope patent-text">6′</sup>, R<sup class="style-scope patent-text">7′</sup>, R<sup class="style-scope patent-text">9′</sup> are selected from the same groups as R<sup class="style-scope patent-text">6</sup>, R<sup class="style-scope patent-text">7 </sup>and R<sup class="style-scope patent-text">9 </sup>respectively;</div>
        <div class="claim-text style-scope patent-text">R<sup class="style-scope patent-text">11b </sup>is selected from OH, OR<sup class="style-scope patent-text">A</sup>, where R<sup class="style-scope patent-text">A </sup>is C<sub class="style-scope patent-text">1-4 </sub>alkyl; and</div>
        <div class="claim-text style-scope patent-text">R<sup class="style-scope patent-text">L </sup>is a linker for connection to a cell binding agent, which has the formula IIIa:</div>
      </div>
      <div class="claim-text style-scope patent-text">
        <chemistry id="CHEM-US-00061" num="00061" class="style-scope patent-text">
          <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/27/ea/0b/9f22a170dc75ea/US11370801-20220628-C00061.png" class="style-scope patent-text"><img id="EMI-C00061" he="26.84mm" wi="69.93mm" file="US11370801-20220628-C00061.TIF" alt="Figure US11370801-20220628-C00061" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="107" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/27/ea/0b/9f22a170dc75ea/US11370801-20220628-C00061.png"></a></div>
          <attachments class="style-scope patent-text">
            <attachment idref="CHEM-US-00061" attachment-type="cdx" file="US11370801-20220628-C00061.CDX" class="style-scope patent-text"> </attachment>
            <attachment idref="CHEM-US-00061" attachment-type="mol" file="US11370801-20220628-C00061.MOL" class="style-scope patent-text"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text style-scope patent-text">wherein</div>
        <div class="claim-text style-scope patent-text">Q is:</div>
      </div>
      <div class="claim-text style-scope patent-text">
        <chemistry id="CHEM-US-00062" num="00062" class="style-scope patent-text">
          <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/b3/c9/10/7f4b0ad54adaf4/US11370801-20220628-C00062.png" class="style-scope patent-text"><img id="EMI-C00062" he="14.99mm" wi="31.33mm" file="US11370801-20220628-C00062.TIF" alt="Figure US11370801-20220628-C00062" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="125" height="60" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/b3/c9/10/7f4b0ad54adaf4/US11370801-20220628-C00062.png"></a></div>
          <attachments class="style-scope patent-text">
            <attachment idref="CHEM-US-00062" attachment-type="cdx" file="US11370801-20220628-C00062.CDX" class="style-scope patent-text"> </attachment>
            <attachment idref="CHEM-US-00062" attachment-type="mol" file="US11370801-20220628-C00062.MOL" class="style-scope patent-text"> </attachment>
          </attachments>
        </chemistry>
      </div>
      <div class="claim-text style-scope patent-text">where Q<sup class="style-scope patent-text">X </sup>is such that Q is an amino-acid residue, a dipeptide residue or a tripeptide residue;
<div class="claim-text style-scope patent-text">X is:</div>
</div>
      <div class="claim-text style-scope patent-text">
        <chemistry id="CHEM-US-00063" num="00063" class="style-scope patent-text">
          <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/17/c7/c0/1cac464d40e703/US11370801-20220628-C00063.png" class="style-scope patent-text"><img id="EMI-C00063" he="13.89mm" wi="64.43mm" file="US11370801-20220628-C00063.TIF" alt="Figure US11370801-20220628-C00063" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="258" height="56" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/17/c7/c0/1cac464d40e703/US11370801-20220628-C00063.png"></a></div>
          <attachments class="style-scope patent-text">
            <attachment idref="CHEM-US-00063" attachment-type="cdx" file="US11370801-20220628-C00063.CDX" class="style-scope patent-text"> </attachment>
            <attachment idref="CHEM-US-00063" attachment-type="mol" file="US11370801-20220628-C00063.MOL" class="style-scope patent-text"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text style-scope patent-text">where a=0 to 5, b=0 to 16, c=0 or 1, d=0 to 5;</div>
        <div class="claim-text style-scope patent-text">G<sup class="style-scope patent-text">L </sup>is a linker for connecting to a Ligand Unit; and</div>
        <div class="claim-text style-scope patent-text">either
<div class="claim-text style-scope patent-text">(a) R<sup class="style-scope patent-text">20 </sup>is H, and R<sup class="style-scope patent-text">21 </sup>is OH or OR<sup class="style-scope patent-text">A</sup>, where R<sup class="style-scope patent-text">A </sup>is C<sub class="style-scope patent-text">1-4 </sub>alkyl; or</div>
<div class="claim-text style-scope patent-text">(b) R<sup class="style-scope patent-text">20 </sup>and R<sup class="style-scope patent-text">21 </sup>form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or</div>
<div class="claim-text style-scope patent-text">(c) R<sup class="style-scope patent-text">20 </sup>is H and R<sup class="style-scope patent-text">21 </sup>is SO<sub class="style-scope patent-text">z</sub>M, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; or</div>
<div class="claim-text style-scope patent-text">(d) R<sup class="style-scope patent-text">20 </sup>is H and R<sup class="style-scope patent-text">21 </sup>is H; or</div>
<div class="claim-text style-scope patent-text">(e) R<sup class="style-scope patent-text">21 </sup>is OH or OR<sup class="style-scope patent-text">A</sup>, where R<sup class="style-scope patent-text">A </sup>is C<sub class="style-scope patent-text">1-4 </sub>alkyl and R<sup class="style-scope patent-text">20 </sup>is selected from:
<div class="claim-text style-scope patent-text">(d-i)</div>
</div>
</div>
      </div>
      <div class="claim-text style-scope patent-text">
        <chemistry id="CHEM-US-00064" num="00064" class="style-scope patent-text">
          <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/ab/72/a6/cfac2bcbbd3e7a/US11370801-20220628-C00064.png" class="style-scope patent-text"><img id="EMI-C00064" he="29.38mm" wi="13.12mm" file="US11370801-20220628-C00064.TIF" alt="Figure US11370801-20220628-C00064" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="52" height="118" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/ab/72/a6/cfac2bcbbd3e7a/US11370801-20220628-C00064.png"></a></div>
          <attachments class="style-scope patent-text">
            <attachment idref="CHEM-US-00064" attachment-type="cdx" file="US11370801-20220628-C00064.CDX" class="style-scope patent-text"> </attachment>
            <attachment idref="CHEM-US-00064" attachment-type="mol" file="US11370801-20220628-C00064.MOL" class="style-scope patent-text"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text style-scope patent-text">
          <div class="claim-text style-scope patent-text">
            <div class="claim-text style-scope patent-text">(d-ii)</div>
          </div>
        </div>
      </div>
      <div class="claim-text style-scope patent-text">
        <chemistry id="CHEM-US-00065" num="00065" class="style-scope patent-text">
          <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/2c/70/37/419c5d5871f06d/US11370801-20220628-C00065.png" class="style-scope patent-text"><img id="EMI-C00065" he="14.39mm" wi="12.36mm" file="US11370801-20220628-C00065.TIF" alt="Figure US11370801-20220628-C00065" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="49" height="58" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/2c/70/37/419c5d5871f06d/US11370801-20220628-C00065.png"></a></div>
          <attachments class="style-scope patent-text">
            <attachment idref="CHEM-US-00065" attachment-type="cdx" file="US11370801-20220628-C00065.CDX" class="style-scope patent-text"> </attachment>
            <attachment idref="CHEM-US-00065" attachment-type="mol" file="US11370801-20220628-C00065.MOL" class="style-scope patent-text"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text style-scope patent-text">
          <div class="claim-text style-scope patent-text">
            <div class="claim-text style-scope patent-text">(d-iii)</div>
          </div>
        </div>
      </div>
      <div class="claim-text style-scope patent-text">
        <chemistry id="CHEM-US-00066" num="00066" class="style-scope patent-text">
          <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/ba/a2/80/094cd50d74b33d/US11370801-20220628-C00066.png" class="style-scope patent-text"><img id="EMI-C00066" he="27.01mm" wi="23.11mm" file="US11370801-20220628-C00066.TIF" alt="Figure US11370801-20220628-C00066" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="92" height="108" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/ba/a2/80/094cd50d74b33d/US11370801-20220628-C00066.png"></a></div>
          <attachments class="style-scope patent-text">
            <attachment idref="CHEM-US-00066" attachment-type="cdx" file="US11370801-20220628-C00066.CDX" class="style-scope patent-text"> </attachment>
            <attachment idref="CHEM-US-00066" attachment-type="mol" file="US11370801-20220628-C00066.MOL" class="style-scope patent-text"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text style-scope patent-text">
          <div class="claim-text style-scope patent-text">
            <div class="claim-text style-scope patent-text"> where R<sup class="style-scope patent-text">Z </sup>is selected from:
<div class="claim-text style-scope patent-text">(z-i)</div>
</div>
          </div>
        </div>
      </div>
      <div class="claim-text style-scope patent-text">
        <chemistry id="CHEM-US-00067" num="00067" class="style-scope patent-text">
          <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/50/2f/8d/5e58a47392f6dc/US11370801-20220628-C00067.png" class="style-scope patent-text"><img id="EMI-C00067" he="26.33mm" wi="16.93mm" file="US11370801-20220628-C00067.TIF" alt="Figure US11370801-20220628-C00067" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="68" height="105" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/50/2f/8d/5e58a47392f6dc/US11370801-20220628-C00067.png"></a></div>
          <attachments class="style-scope patent-text">
            <attachment idref="CHEM-US-00067" attachment-type="cdx" file="US11370801-20220628-C00067.CDX" class="style-scope patent-text"> </attachment>
            <attachment idref="CHEM-US-00067" attachment-type="mol" file="US11370801-20220628-C00067.MOL" class="style-scope patent-text"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text style-scope patent-text">
          <div class="claim-text style-scope patent-text">
            <div class="claim-text style-scope patent-text">
              <div class="claim-text style-scope patent-text">(z-ii) OC(═O)CH<sub class="style-scope patent-text">3</sub>;</div>
              <div class="claim-text style-scope patent-text">(z-iii) NO<sub class="style-scope patent-text">2</sub>;</div>
              <div class="claim-text style-scope patent-text">(z-iv) OMe; and</div>
              <div class="claim-text style-scope patent-text">(z-v) —C(═)—X<sub class="style-scope patent-text">1</sub>—NHC(═O)X<sub class="style-scope patent-text">2</sub>—NH—R<sup class="style-scope patent-text">ZC</sup>, where —C(═O)—X<sub class="style-scope patent-text">1</sub>—NH— and —C(═O)—X<sub class="style-scope patent-text">2</sub>—NH— represent natural amino acid residues and R<sup class="style-scope patent-text">ZC </sup>is selected from Me, OMe, OCH<sub class="style-scope patent-text">2</sub>CH<sub class="style-scope patent-text">2</sub>OMe.</div>
            </div>
          </div>
        </div>
      </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00002" num="00002" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">2. The compound according to <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein both and Y′ are O and R″ is:
<div class="claim-text style-scope patent-text">(a) C<sub class="style-scope patent-text">3-7 </sub>alkylene; or</div>
<div class="claim-text style-scope patent-text">(b) a group of formula:</div>
</div>
      <div class="claim-text style-scope patent-text">
        <chemistry id="CHEM-US-00068" num="00068" class="style-scope patent-text">
          <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/97/12/52/61adbee9d1d336/US11370801-20220628-C00068.png" class="style-scope patent-text"><img id="EMI-C00068" he="13.63mm" wi="35.39mm" file="US11370801-20220628-C00068.TIF" alt="Figure US11370801-20220628-C00068" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="142" height="55" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/97/12/52/61adbee9d1d336/US11370801-20220628-C00068.png"></a></div>
          <attachments class="style-scope patent-text">
            <attachment idref="CHEM-US-00068" attachment-type="cdx" file="US11370801-20220628-C00068.CDX" class="style-scope patent-text"> </attachment>
            <attachment idref="CHEM-US-00068" attachment-type="mol" file="US11370801-20220628-C00068.MOL" class="style-scope patent-text"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text style-scope patent-text">where r is 1 or 2.</div>
      </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00003" num="00003" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">3. The compound according to <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein R<sup class="style-scope patent-text">9 </sup>is H and R<sup class="style-scope patent-text">6 </sup>is H.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00004" num="00004" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">4. The compound according to <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein R<sup class="style-scope patent-text">7 </sup>is a C<sub class="style-scope patent-text">1-4 </sub>alkyloxy group.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00005" num="00005" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">5. The compound according to <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein RU is the same group as R<sup class="style-scope patent-text">6</sup>, R<sup class="style-scope patent-text">7′</sup> is the same group as R<sup class="style-scope patent-text">7</sup>, R<sup class="style-scope patent-text">9′</sup> is the same group as R<sup class="style-scope patent-text">9 </sup>and Y′ is the same group as Y.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00006" num="00006" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">6. The compound according to <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein R<sup class="style-scope patent-text">20 </sup>and R<sup class="style-scope patent-text">21 </sup>form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00007" num="00007" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">7. The compound according to <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, which is of formula Ia, Ib or Ic:</div>
      <div class="claim-text style-scope patent-text">
        <chemistry id="CHEM-US-00069" num="00069" class="style-scope patent-text">
          <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/3e/7e/16/7c3440d186ef28/US11370801-20220628-C00069.png" class="style-scope patent-text"><img id="EMI-C00069" he="121.24mm" wi="75.95mm" file="US11370801-20220628-C00069.TIF" alt="Figure US11370801-20220628-C00069" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="304" height="485" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/3e/7e/16/7c3440d186ef28/US11370801-20220628-C00069.png"></a></div>
          <attachments class="style-scope patent-text">
            <attachment idref="CHEM-US-00069" attachment-type="cdx" file="US11370801-20220628-C00069.CDX" class="style-scope patent-text"> </attachment>
            <attachment idref="CHEM-US-00069" attachment-type="mol" file="US11370801-20220628-C00069.MOL" class="style-scope patent-text"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text style-scope patent-text">where R<sup class="style-scope patent-text">1a </sup>is selected from methyl and benzyl;</div>
        <div class="claim-text style-scope patent-text">R<sup class="style-scope patent-text">L </sup>and R<sup class="style-scope patent-text">11b </sup>are as defined in <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>.</div>
      </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00008" num="00008" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">8. The compound according to <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein R<sup class="style-scope patent-text">11b </sup>is OH.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00009" num="00009" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">9. The compound according to <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein Q is a dipeptide residue selected from:
<div class="claim-text style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Phe-Lys-<sup class="style-scope patent-text">NH</sup>,</div>
<div class="claim-text style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Val-Ala-<sup class="style-scope patent-text">NH</sup>,</div>
<div class="claim-text style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Val-Lys-<sup class="style-scope patent-text">NH</sup>,</div>
<div class="claim-text style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Ala-Lys-<sup class="style-scope patent-text">NH</sup>,</div>
<div class="claim-text style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Val-Cit-<sup class="style-scope patent-text">NH</sup>,</div>
<div class="claim-text style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Phe-Cit-<sup class="style-scope patent-text">NH</sup>,</div>
<div class="claim-text style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Leu-Cit-<sup class="style-scope patent-text">NH</sup>,</div>
<div class="claim-text style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Ile-Cit-<sup class="style-scope patent-text">NH</sup>,</div>
<div class="claim-text style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Phe-Arg-<sup class="style-scope patent-text">NH</sup>, and</div>
<div class="claim-text style-scope patent-text"> <sup class="style-scope patent-text">CO</sup>-Trp-Cit-<sup class="style-scope patent-text">NH</sup>.</div>
</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00010" num="00010" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">10. The compound according to <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein a is 0.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00011" num="00011" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">11. The compound according to <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein b is 0 to 8.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00012" num="00012" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">12. The compound according to <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein d is 2.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00013" num="00013" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">13. The compound according to <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein G<sup class="style-scope patent-text">L </sup>is selected from:</div>
      <div class="claim-text style-scope patent-text">
        <chemistry id="CHEM-US-00070" num="00070" class="style-scope patent-text">
          <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/b0/b8/4c/624bf1dfced32b/US11370801-20220628-C00070.png" class="style-scope patent-text"><img id="EMI-C00070" he="109.64mm" wi="69.85mm" file="US11370801-20220628-C00070.TIF" alt="Figure US11370801-20220628-C00070" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="279" height="439" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/b0/b8/4c/624bf1dfced32b/US11370801-20220628-C00070.png"></a></div>
          <attachments class="style-scope patent-text">
            <attachment idref="CHEM-US-00070" attachment-type="cdx" file="US11370801-20220628-C00070.CDX" class="style-scope patent-text"> </attachment>
            <attachment idref="CHEM-US-00070" attachment-type="mol" file="US11370801-20220628-C00070.MOL" class="style-scope patent-text"> </attachment>
          </attachments>
        </chemistry>
        <chemistry id="CHEM-US-00071" num="00071" class="style-scope patent-text">
          <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/01/f2/a1/9a2c00fa8f528b/US11370801-20220628-C00071.png" class="style-scope patent-text"><img id="EMI-C00071" he="213.95mm" wi="69.85mm" file="US11370801-20220628-C00071.TIF" alt="Figure US11370801-20220628-C00071" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="279" height="856" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/01/f2/a1/9a2c00fa8f528b/US11370801-20220628-C00071.png"></a></div>
          <attachments class="style-scope patent-text">
            <attachment idref="CHEM-US-00071" attachment-type="cdx" file="US11370801-20220628-C00071.CDX" class="style-scope patent-text"> </attachment>
            <attachment idref="CHEM-US-00071" attachment-type="mol" file="US11370801-20220628-C00071.MOL" class="style-scope patent-text"> </attachment>
          </attachments>
        </chemistry>
        <chemistry id="CHEM-US-00072" num="00072" class="style-scope patent-text">
          <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/2c/c1/17/a828d51faeafb7/US11370801-20220628-C00072.png" class="style-scope patent-text"><img id="EMI-C00072" he="38.27mm" wi="69.85mm" file="US11370801-20220628-C00072.TIF" alt="Figure US11370801-20220628-C00072" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="279" height="153" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/2c/c1/17/a828d51faeafb7/US11370801-20220628-C00072.png"></a></div>
          <attachments class="style-scope patent-text">
            <attachment idref="CHEM-US-00072" attachment-type="cdx" file="US11370801-20220628-C00072.CDX" class="style-scope patent-text"> </attachment>
            <attachment idref="CHEM-US-00072" attachment-type="mol" file="US11370801-20220628-C00072.MOL" class="style-scope patent-text"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text style-scope patent-text">where Ar represents a C<sub class="style-scope patent-text">5-6 </sub>arylene group, and Hal represents I, Br or Cl.</div>
      </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00014" num="00014" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">14. The compound according to <claim-ref idref="CLM-00013" class="style-scope patent-text">claim 13</claim-ref>, wherein G<sup class="style-scope patent-text">L </sup>is G<sup class="style-scope patent-text">L1-1</sup>.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00015" num="00015" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">15. The compound according to <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein the compound is of formula Id:</div>
      <div class="claim-text style-scope patent-text">
        <chemistry id="CHEM-US-00073" num="00073" class="style-scope patent-text">
          <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/3a/4e/46/1a359dcc8af80f/US11370801-20220628-C00073.png" class="style-scope patent-text"><img id="EMI-C00073" he="48.68mm" wi="142.49mm" file="US11370801-20220628-C00073.TIF" alt="Figure US11370801-20220628-C00073" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="570" height="195" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/3a/4e/46/1a359dcc8af80f/US11370801-20220628-C00073.png"></a></div>
          <attachments class="style-scope patent-text">
            <attachment idref="CHEM-US-00073" attachment-type="cdx" file="US11370801-20220628-C00073.CDX" class="style-scope patent-text"> </attachment>
            <attachment idref="CHEM-US-00073" attachment-type="mol" file="US11370801-20220628-C00073.MOL" class="style-scope patent-text"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text style-scope patent-text">where Q′ is selected from:</div>
        <div class="claim-text style-scope patent-text">(a) —CH<sub class="style-scope patent-text">2</sub>—;</div>
        <div class="claim-text style-scope patent-text">(b) —C<sub class="style-scope patent-text">3</sub>H<sub class="style-scope patent-text">6</sub>—; and</div>
        <div class="claim-text style-scope patent-text">(c)</div>
      </div>
      <div class="claim-text style-scope patent-text">
        <chemistry id="CHEM-US-00074" num="00074" class="style-scope patent-text">
          <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/60/a6/19/85aabb8905a205/US11370801-20220628-C00074.png" class="style-scope patent-text"><img id="EMI-C00074" he="14.31mm" wi="36.32mm" file="US11370801-20220628-C00074.TIF" alt="Figure US11370801-20220628-C00074" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="145" height="57" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/60/a6/19/85aabb8905a205/US11370801-20220628-C00074.png"></a></div>
          <attachments class="style-scope patent-text">
            <attachment idref="CHEM-US-00074" attachment-type="cdx" file="US11370801-20220628-C00074.CDX" class="style-scope patent-text"> </attachment>
            <attachment idref="CHEM-US-00074" attachment-type="mol" file="US11370801-20220628-C00074.MOL" class="style-scope patent-text"> </attachment>
          </attachments>
        </chemistry>
      </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00016" num="00016" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">16. A conjugate of formula II:
<div class="claim-text style-scope patent-text"> <br class="style-scope patent-text">L-(D<sup class="style-scope patent-text">L</sup>)<sub class="style-scope patent-text">p</sub>  (II)
</div>
<div class="claim-text style-scope patent-text">wherein L is a Ligand unit, D<sup class="style-scope patent-text">L </sup>is a Drug Linker unit of formula I′:</div>
</div>
      <div class="claim-text style-scope patent-text">
        <chemistry id="CHEM-US-00075" num="00075" class="style-scope patent-text">
          <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/ff/82/62/6892e9c959ab1d/US11370801-20220628-C00075.png" class="style-scope patent-text"><img id="EMI-C00075" he="39.37mm" wi="75.95mm" file="US11370801-20220628-C00075.TIF" alt="Figure US11370801-20220628-C00075" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="304" height="157" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/ff/82/62/6892e9c959ab1d/US11370801-20220628-C00075.png"></a></div>
          <attachments class="style-scope patent-text">
            <attachment idref="CHEM-US-00075" attachment-type="cdx" file="US11370801-20220628-C00075.CDX" class="style-scope patent-text"> </attachment>
            <attachment idref="CHEM-US-00075" attachment-type="mol" file="US11370801-20220628-C00075.MOL" class="style-scope patent-text"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text style-scope patent-text">wherein R<sup class="style-scope patent-text">6</sup>, R<sup class="style-scope patent-text">7</sup>, R<sup class="style-scope patent-text">9</sup>, R<sup class="style-scope patent-text">11b</sup>, Y, R″, Y′, R<sup class="style-scope patent-text">6′</sup>, R<sup class="style-scope patent-text">7</sup>, R<sup class="style-scope patent-text">9′</sup>, R<sup class="style-scope patent-text">20 </sup>and R<sup class="style-scope patent-text">21</sup>, are as defined in <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>;</div>
        <div class="claim-text style-scope patent-text">R<sup class="style-scope patent-text">LL </sup>is a linker for connection to the ligand unit, which has the formula IIIa′:</div>
      </div>
      <div class="claim-text style-scope patent-text">
        <chemistry id="CHEM-US-00076" num="00076" class="style-scope patent-text">
          <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/d9/57/b4/83cf4782745b7d/US11370801-20220628-C00076.png" class="style-scope patent-text"><img id="EMI-C00076" he="27.01mm" wi="69.85mm" file="US11370801-20220628-C00076.TIF" alt="Figure US11370801-20220628-C00076" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="279" height="108" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/d9/57/b4/83cf4782745b7d/US11370801-20220628-C00076.png"></a></div>
          <attachments class="style-scope patent-text">
            <attachment idref="CHEM-US-00076" attachment-type="cdx" file="US11370801-20220628-C00076.CDX" class="style-scope patent-text"> </attachment>
            <attachment idref="CHEM-US-00076" attachment-type="mol" file="US11370801-20220628-C00076.MOL" class="style-scope patent-text"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text style-scope patent-text">where Q and X are as defined in <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref> and G<sup class="style-scope patent-text">LL </sup>is a linker connected to a Ligand Unit;</div>
        <div class="claim-text style-scope patent-text">and</div>
        <div class="claim-text style-scope patent-text">wherein p is an integer of from 1 to 20.</div>
      </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00017" num="00017" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">17. The conjugate according to <claim-ref idref="CLM-00016" class="style-scope patent-text">claim 16</claim-ref>, wherein is selected from:</div>
      <div class="claim-text style-scope patent-text">
        <chemistry id="CHEM-US-00077" num="00077" class="style-scope patent-text">
          <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/92/22/6f/c74763fc1ecffa/US11370801-20220628-C00077.png" class="style-scope patent-text"><img id="EMI-C00077" he="135.30mm" wi="69.85mm" file="US11370801-20220628-C00077.TIF" alt="Figure US11370801-20220628-C00077" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="279" height="541" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/92/22/6f/c74763fc1ecffa/US11370801-20220628-C00077.png"></a></div>
          <attachments class="style-scope patent-text">
            <attachment idref="CHEM-US-00077" attachment-type="cdx" file="US11370801-20220628-C00077.CDX" class="style-scope patent-text"> </attachment>
            <attachment idref="CHEM-US-00077" attachment-type="mol" file="US11370801-20220628-C00077.MOL" class="style-scope patent-text"> </attachment>
          </attachments>
        </chemistry>
        <chemistry id="CHEM-US-00078" num="00078" class="style-scope patent-text">
          <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/cb/19/57/eff5dc22f31113/US11370801-20220628-C00078.png" class="style-scope patent-text"><img id="EMI-C00078" he="99.31mm" wi="69.85mm" file="US11370801-20220628-C00078.TIF" alt="Figure US11370801-20220628-C00078" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="279" height="397" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/cb/19/57/eff5dc22f31113/US11370801-20220628-C00078.png"></a></div>
          <attachments class="style-scope patent-text">
            <attachment idref="CHEM-US-00078" attachment-type="cdx" file="US11370801-20220628-C00078.CDX" class="style-scope patent-text"> </attachment>
            <attachment idref="CHEM-US-00078" attachment-type="mol" file="US11370801-20220628-C00078.MOL" class="style-scope patent-text"> </attachment>
          </attachments>
        </chemistry>
        <chemistry id="CHEM-US-00079" num="00079" class="style-scope patent-text">
          <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/bb/c3/bb/8168505f91c95b/US11370801-20220628-C00079.png" class="style-scope patent-text"><img id="EMI-C00079" he="84.58mm" wi="69.85mm" file="US11370801-20220628-C00079.TIF" alt="Figure US11370801-20220628-C00079" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="279" height="338" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/bb/c3/bb/8168505f91c95b/US11370801-20220628-C00079.png"></a></div>
          <attachments class="style-scope patent-text">
            <attachment idref="CHEM-US-00079" attachment-type="cdx" file="US11370801-20220628-C00079.CDX" class="style-scope patent-text"> </attachment>
            <attachment idref="CHEM-US-00079" attachment-type="mol" file="US11370801-20220628-C00079.MOL" class="style-scope patent-text"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text style-scope patent-text">where Ar represents a C<sub class="style-scope patent-text">5-6 </sub>arylene group.</div>
      </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00018" num="00018" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">18. The conjugate according to <claim-ref idref="CLM-00017" class="style-scope patent-text">claim 17</claim-ref>, wherein G<sup class="style-scope patent-text">LL </sup>is G<sup class="style-scope patent-text">LL1-1</sup>.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00019" num="00019" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">19. The conjugate according to <claim-ref idref="CLM-00016" class="style-scope patent-text">claim 16</claim-ref>, wherein D<sup class="style-scope patent-text">L </sup>is of formula (Id′):</div>
      <div class="claim-text style-scope patent-text">
        <chemistry id="CHEM-US-00080" num="00080" class="style-scope patent-text">
          <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/64/b4/f2/337745e3855f8d/US11370801-20220628-C00080.png" class="style-scope patent-text"><img id="EMI-C00080" he="48.77mm" wi="148.00mm" file="US11370801-20220628-C00080.TIF" alt="Figure US11370801-20220628-C00080" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="592" height="195" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/64/b4/f2/337745e3855f8d/US11370801-20220628-C00080.png"></a></div>
          <attachments class="style-scope patent-text">
            <attachment idref="CHEM-US-00080" attachment-type="cdx" file="US11370801-20220628-C00080.CDX" class="style-scope patent-text"> </attachment>
            <attachment idref="CHEM-US-00080" attachment-type="mol" file="US11370801-20220628-C00080.MOL" class="style-scope patent-text"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text style-scope patent-text">where Q′ is selected from:</div>
        <div class="claim-text style-scope patent-text">(a) —CH<sub class="style-scope patent-text">2</sub>—;</div>
        <div class="claim-text style-scope patent-text">(b) —C<sub class="style-scope patent-text">3</sub>H<sub class="style-scope patent-text">6</sub>—; and</div>
        <div class="claim-text style-scope patent-text">(c)</div>
      </div>
      <div class="claim-text style-scope patent-text">
        <chemistry id="CHEM-US-00081" num="00081" class="style-scope patent-text">
          <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/61/93/01/da32de687a8026/US11370801-20220628-C00081.png" class="style-scope patent-text"><img id="EMI-C00081" he="14.31mm" wi="36.32mm" file="US11370801-20220628-C00081.TIF" alt="Figure US11370801-20220628-C00081" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="145" height="57" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/61/93/01/da32de687a8026/US11370801-20220628-C00081.png"></a></div>
          <attachments class="style-scope patent-text">
            <attachment idref="CHEM-US-00081" attachment-type="cdx" file="US11370801-20220628-C00081.CDX" class="style-scope patent-text"> </attachment>
            <attachment idref="CHEM-US-00081" attachment-type="mol" file="US11370801-20220628-C00081.MOL" class="style-scope patent-text"> </attachment>
          </attachments>
        </chemistry>
      </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00020" num="00020" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">20. The conjugate according to <claim-ref idref="CLM-00016" class="style-scope patent-text">claim 16</claim-ref>, wherein the Ligand Unit is an antibody or an active fragment thereof which binds to one or more tumor-associated antigens or cell-surface receptors selected from:
<div class="claim-text style-scope patent-text">(1) BMPR1B;</div>
<div class="claim-text style-scope patent-text">(2) E16;</div>
<div class="claim-text style-scope patent-text">(3) STEAP1;</div>
<div class="claim-text style-scope patent-text">(4) 0772P;</div>
<div class="claim-text style-scope patent-text">(5) MPF;</div>
<div class="claim-text style-scope patent-text">(6) Napi3b;</div>
<div class="claim-text style-scope patent-text">(7) Sema 5b;</div>
<div class="claim-text style-scope patent-text">(8) PSCA hlg;</div>
<div class="claim-text style-scope patent-text">(9) ETBR;</div>
<div class="claim-text style-scope patent-text">(10) MSG783;</div>
<div class="claim-text style-scope patent-text">(11) STEAP2;</div>
<div class="claim-text style-scope patent-text">(12) TrpM4;</div>
<div class="claim-text style-scope patent-text">(13) CRIPTO;</div>
<div class="claim-text style-scope patent-text">(14) CD21;</div>
<div class="claim-text style-scope patent-text">(15) CD79b;</div>
<div class="claim-text style-scope patent-text">(16) FcRH2;</div>
<div class="claim-text style-scope patent-text">(17) HER2;</div>
<div class="claim-text style-scope patent-text">(18) NCA;</div>
<div class="claim-text style-scope patent-text">(19) MDP;</div>
<div class="claim-text style-scope patent-text">(20) IL20R-alpha;</div>
<div class="claim-text style-scope patent-text">(21) Brevican;</div>
<div class="claim-text style-scope patent-text">(22) EphB2R;</div>
<div class="claim-text style-scope patent-text">(23) ASLG659;</div>
<div class="claim-text style-scope patent-text">(24) PSCA;</div>
<div class="claim-text style-scope patent-text">(25) GEDA;</div>
<div class="claim-text style-scope patent-text">(26) BAFF-R;</div>
<div class="claim-text style-scope patent-text">(27) CD22;</div>
<div class="claim-text style-scope patent-text">(28) CD79a;</div>
<div class="claim-text style-scope patent-text">(29) CXCR5;</div>
<div class="claim-text style-scope patent-text">(30) HLA-DOB;</div>
<div class="claim-text style-scope patent-text">(31) P2X5;</div>
<div class="claim-text style-scope patent-text">(32) CD72;</div>
<div class="claim-text style-scope patent-text">(33) LY64;</div>
<div class="claim-text style-scope patent-text">(34) FcRH1;</div>
<div class="claim-text style-scope patent-text">(35) IRTA2;</div>
<div class="claim-text style-scope patent-text">(36) TENB2;</div>
<div class="claim-text style-scope patent-text">(37) PSMA—FOLH1;</div>
<div class="claim-text style-scope patent-text">(38) SST;</div>
<div class="claim-text style-scope patent-text">(38.1) SSTR2;</div>
<div class="claim-text style-scope patent-text">(38.2) SSTR5;</div>
<div class="claim-text style-scope patent-text">(38.3) SSTR1;</div>
<div class="claim-text style-scope patent-text">(38.4) SSTR3;</div>
<div class="claim-text style-scope patent-text">(38.5) SSTR4;</div>
<div class="claim-text style-scope patent-text">(39) ITGAV;</div>
<div class="claim-text style-scope patent-text">(40) ITGB6;</div>
<div class="claim-text style-scope patent-text">(41) CEACAM5;</div>
<div class="claim-text style-scope patent-text">(42) MET;</div>
<div class="claim-text style-scope patent-text">(43) MUC1;</div>
<div class="claim-text style-scope patent-text">(44) CA9;</div>
<div class="claim-text style-scope patent-text">(45) EGFRvIII;</div>
<div class="claim-text style-scope patent-text">(46) CD33;</div>
<div class="claim-text style-scope patent-text">(47) CD19;</div>
<div class="claim-text style-scope patent-text">(48) IL2RA;</div>
<div class="claim-text style-scope patent-text">(49) AXL;</div>
<div class="claim-text style-scope patent-text">(50) CD30—TNFRS8;</div>
<div class="claim-text style-scope patent-text">(51) BCMA—TNFRSF17;</div>
<div class="claim-text style-scope patent-text">(52) CT Ags—CTA;</div>
<div class="claim-text style-scope patent-text">(53) CD174 (Lewis Y)—FUT3;</div>
<div class="claim-text style-scope patent-text">(54) CLEC14A;</div>
<div class="claim-text style-scope patent-text">(55) GRP78—HSPA5;</div>
<div class="claim-text style-scope patent-text">(56) CD70;</div>
<div class="claim-text style-scope patent-text">(57) Stem Cell specific antigens;</div>
<div class="claim-text style-scope patent-text">(58) ASG-5;</div>
<div class="claim-text style-scope patent-text">(59) ENPP3;</div>
<div class="claim-text style-scope patent-text">(60) PRR4;</div>
<div class="claim-text style-scope patent-text">(61) GCC—GUCY2C;</div>
<div class="claim-text style-scope patent-text">(62) Liv-1—SLC39A6;</div>
<div class="claim-text style-scope patent-text">(63) 5T4;</div>
<div class="claim-text style-scope patent-text">(64) CD56—NCMA1;</div>
<div class="claim-text style-scope patent-text">(65) CanAg;</div>
<div class="claim-text style-scope patent-text">(66) FOLR1;</div>
<div class="claim-text style-scope patent-text">(67) GPNMB;</div>
<div class="claim-text style-scope patent-text">(68) TIM-1—HAVCR1;</div>
<div class="claim-text style-scope patent-text">(69) RG-1/Prostate tumor target Mindin—Mindin/RG-1;</div>
<div class="claim-text style-scope patent-text">(70) B7-H4—VTCN1;</div>
<div class="claim-text style-scope patent-text">(71) PTK7;</div>
<div class="claim-text style-scope patent-text">(72) CD37;</div>
<div class="claim-text style-scope patent-text">(73) CD138—SDC1;</div>
<div class="claim-text style-scope patent-text">(74) CD74;</div>
<div class="claim-text style-scope patent-text">(75) Claudins—CLs;</div>
<div class="claim-text style-scope patent-text">(76) EGFR;</div>
<div class="claim-text style-scope patent-text">(77) Her3;</div>
<div class="claim-text style-scope patent-text">(78) RON—MST1R;</div>
<div class="claim-text style-scope patent-text">(79) EPHA2;</div>
<div class="claim-text style-scope patent-text">(80) CD20—MS4A1;</div>
<div class="claim-text style-scope patent-text">(81) Tenascin C—TNC;</div>
<div class="claim-text style-scope patent-text">(82) FAP;</div>
<div class="claim-text style-scope patent-text">(83) DKK-1;</div>
<div class="claim-text style-scope patent-text">(84) CD52;</div>
<div class="claim-text style-scope patent-text">(85) CS1-SLAMF7;</div>
<div class="claim-text style-scope patent-text">(86) Endoglin—ENG;</div>
<div class="claim-text style-scope patent-text">(87) Annexin A1—ANXA1; and</div>
<div class="claim-text style-scope patent-text">(88) V-CAM (CD106)—VCAM1.</div>
</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00021" num="00021" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">21. The conjugate according to <claim-ref idref="CLM-00016" class="style-scope patent-text">claim 16</claim-ref> wherein p is an integer from 1 to 8.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00022" num="00022" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">22. A pharmaceutical composition comprising the conjugate of <claim-ref idref="CLM-00016" class="style-scope patent-text">claim 16</claim-ref>, and a pharmaceutically acceptable diluent, carrier or excipient.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00023" num="00023" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">23. A method of treating a mammal having ovarian cancer, comprising administering to the mammal an effective amount of a conjugate according to <claim-ref idref="CLM-00016" class="style-scope patent-text">claim 16</claim-ref>.</div>
    </div>
  </div> </div>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
          </div>

          <div class="footer style-scope patent-result">

            
            <h3 id="patentCitations" class="scroll-target style-scope patent-result">
              Patent Citations (418)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US3361742A/en"><a id="link" href="#" class="style-scope state-modifier">US3361742A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1964-12-07</span>
                    <span class="td style-scope patent-result">1968-01-02</span>
                    <span class="td style-scope patent-result">Hoffmann La Roche</span>
                    <span class="td style-scope patent-result">5-oxo-1h-pyrrolo-[2, 1-c][1, 4]-benzodiazepin-2-crylamides 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US3523941A/en"><a id="link" href="#" class="style-scope state-modifier">US3523941A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1967-03-06</span>
                    <span class="td style-scope patent-result">1970-08-11</span>
                    <span class="td style-scope patent-result">Hoffmann La Roche</span>
                    <span class="td style-scope patent-result">Benzodiazepine compounds and process for their preparation 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US3524849A/en"><a id="link" href="#" class="style-scope state-modifier">US3524849A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1967-10-27</span>
                    <span class="td style-scope patent-result">1970-08-18</span>
                    <span class="td style-scope patent-result">Hoffmann La Roche</span>
                    <span class="td style-scope patent-result">Process for the preparation of pyrrolo-benzodiazepine acrylamides and intermediates useful therein 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/FR2027356A1/en"><a id="link" href="#" class="style-scope state-modifier">FR2027356A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1968-12-30</span>
                    <span class="td style-scope patent-result">1970-09-25</span>
                    <span class="td style-scope patent-result">Fujisawa Pharmaceutical Co</span>
                    <span class="td style-scope patent-result">Benzodiazepinone antibiotics 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB1299198A/en"><a id="link" href="#" class="style-scope state-modifier">GB1299198A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1968-12-30</span>
                    <span class="td style-scope patent-result">1972-12-06</span>
                    <span class="td style-scope patent-result">Fujisawa Pharmaceutical Co</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepinone derivatives 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US3794644A/en"><a id="link" href="#" class="style-scope state-modifier">US3794644A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1969-06-26</span>
                    <span class="td style-scope patent-result">1974-02-26</span>
                    <span class="td style-scope patent-result">Fujisawa Pharmaceutical Co</span>
                    <span class="td style-scope patent-result">Pyrrolo-benzodiazepinone compounds 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4185016A/en"><a id="link" href="#" class="style-scope state-modifier">US4185016A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1977-12-27</span>
                    <span class="td style-scope patent-result">1980-01-22</span>
                    <span class="td style-scope patent-result">The Green Cross Corporation</span>
                    <span class="td style-scope patent-result">Pyrrolo benzodiazepine compounds 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB2053894A/en"><a id="link" href="#" class="style-scope state-modifier">GB2053894A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1979-07-17</span>
                    <span class="td style-scope patent-result">1981-02-11</span>
                    <span class="td style-scope patent-result">Green Cross Corp</span>
                    <span class="td style-scope patent-result">Benzodiazepines processes for producing them and compositions containing them 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JPS57131791A/en"><a id="link" href="#" class="style-scope state-modifier">JPS57131791A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1980-12-31</span>
                    <span class="td style-scope patent-result">1982-08-14</span>
                    <span class="td style-scope patent-result">Fujisawa Pharmaceut Co Ltd</span>
                    <span class="td style-scope patent-result">Benzodiazepine derivative and its preparation 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4353827A/en"><a id="link" href="#" class="style-scope state-modifier">US4353827A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1981-02-27</span>
                    <span class="td style-scope patent-result">1982-10-12</span>
                    <span class="td style-scope patent-result">Hoffmann-La Roche Inc.</span>
                    <span class="td style-scope patent-result">Diazepine derivatives 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4382032A/en"><a id="link" href="#" class="style-scope state-modifier">US4382032A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1981-02-27</span>
                    <span class="td style-scope patent-result">1983-05-03</span>
                    <span class="td style-scope patent-result">Hoffmann-La Roche Inc.</span>
                    <span class="td style-scope patent-result">Diazepine derivatives 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4386028A/en"><a id="link" href="#" class="style-scope state-modifier">US4386028A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1981-02-27</span>
                    <span class="td style-scope patent-result">1983-05-31</span>
                    <span class="td style-scope patent-result">Hoffmann-La Roche Inc.</span>
                    <span class="td style-scope patent-result">Imidazo[1,5a][1,4]benzodiazepines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JPS58180487A/en"><a id="link" href="#" class="style-scope state-modifier">JPS58180487A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1982-04-16</span>
                    <span class="td style-scope patent-result">1983-10-21</span>
                    <span class="td style-scope patent-result">Kyowa Hakko Kogyo Co Ltd</span>
                    <span class="td style-scope patent-result">Antibiotic dc-81 and its preparation 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4427587A/en"><a id="link" href="#" class="style-scope state-modifier">US4427587A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1982-11-10</span>
                    <span class="td style-scope patent-result">1984-01-24</span>
                    <span class="td style-scope patent-result">Bristol-Myers Company</span>
                    <span class="td style-scope patent-result">Total synthesis of antitumor antibiotics BBM-2040A and BBM-2040B 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4427588A/en"><a id="link" href="#" class="style-scope state-modifier">US4427588A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1982-11-08</span>
                    <span class="td style-scope patent-result">1984-01-24</span>
                    <span class="td style-scope patent-result">Bristol-Myers Company</span>
                    <span class="td style-scope patent-result">Process for conversion of oxotomaymycin to tomaymycin 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/FR2586683A1/en"><a id="link" href="#" class="style-scope state-modifier">FR2586683A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1985-08-29</span>
                    <span class="td style-scope patent-result">1987-03-06</span>
                    <span class="td style-scope patent-result">Centre Nat Rech Scient</span>
                    <span class="td style-scope patent-result">New neothramycin derivatives, process for their preparation and their application as medicaments 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4701325A/en"><a id="link" href="#" class="style-scope state-modifier">US4701325A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1983-02-17</span>
                    <span class="td style-scope patent-result">1987-10-20</span>
                    <span class="td style-scope patent-result">The Green Cross Corporation</span>
                    <span class="td style-scope patent-result">Injectable aqueous solution containing hydrogensulfite and/or sulfite and anticancerous benzodiazepine compound 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4816567A/en"><a id="link" href="#" class="style-scope state-modifier">US4816567A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1983-04-08</span>
                    <span class="td style-scope patent-result">1989-03-28</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Recombinant immunoglobin preparations 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4923984A/en"><a id="link" href="#" class="style-scope state-modifier">US4923984A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1988-08-05</span>
                    <span class="td style-scope patent-result">1990-05-08</span>
                    <span class="td style-scope patent-result">Shionogi &amp; Co., Ltd.</span>
                    <span class="td style-scope patent-result">Pyrrolo(1,4)benzodiazepine derivatives 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1991002536A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1991002536A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1989-08-23</span>
                    <span class="td style-scope patent-result">1991-03-07</span>
                    <span class="td style-scope patent-result">Scripps Clinic And Research Foundation</span>
                    <span class="td style-scope patent-result">Compositions and methods for detection and treatment of epstein-barr virus infection and immune disorders 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1992007574A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1992007574A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1990-10-25</span>
                    <span class="td style-scope patent-result">1992-05-14</span>
                    <span class="td style-scope patent-result">Tanox Biosystems, Inc.</span>
                    <span class="td style-scope patent-result">Glycoproteins associated with membrane-bound immunoglobulins as antibody targets on b cells 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1992017497A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1992017497A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1991-03-29</span>
                    <span class="td style-scope patent-result">1992-10-15</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Human pf4a receptors and their use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1992019620A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1992019620A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1991-05-07</span>
                    <span class="td style-scope patent-result">1992-11-12</span>
                    <span class="td style-scope patent-result">Centre National De La Recherche Scientifique (Cnrs)</span>
                    <span class="td style-scope patent-result">Novel derivatives of pyrrolo [1, 4]-benzodiazepines, method of preparation and medicaments containing them 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP0522868A1/en"><a id="link" href="#" class="style-scope state-modifier">EP0522868A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1991-07-12</span>
                    <span class="td style-scope patent-result">1993-01-13</span>
                    <span class="td style-scope patent-result">SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI &amp;amp; CO. LTD.</span>
                    <span class="td style-scope patent-result">A human endothelin receptor 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JPH053790A/en"><a id="link" href="#" class="style-scope state-modifier">JPH053790A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1990-04-19</span>
                    <span class="td style-scope patent-result">1993-01-14</span>
                    <span class="td style-scope patent-result">Fujisawa Pharmaceut Co Ltd</span>
                    <span class="td style-scope patent-result">Dehydropeptidase-i 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1993018045A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1993018045A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-03-09</span>
                    <span class="td style-scope patent-result">1993-09-16</span>
                    <span class="td style-scope patent-result">Cancer Research Campaign Technology Limited</span>
                    <span class="td style-scope patent-result">Anti-cancer pyrrolobenzodiazepine derivatives 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1994010312A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1994010312A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-10-23</span>
                    <span class="td style-scope patent-result">1994-05-11</span>
                    <span class="td style-scope patent-result">Chugai Seiyaku Kabushiki Kaisha</span>
                    <span class="td style-scope patent-result">Gene coding for megakaryocyte potentiator 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5362852A/en"><a id="link" href="#" class="style-scope state-modifier">US5362852A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1991-09-27</span>
                    <span class="td style-scope patent-result">1994-11-08</span>
                    <span class="td style-scope patent-result">Pfizer Inc.</span>
                    <span class="td style-scope patent-result">Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1994028931A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1994028931A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1993-06-11</span>
                    <span class="td style-scope patent-result">1994-12-22</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Methods for treating inflammatory disorders 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1995004718A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1995004718A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1993-08-04</span>
                    <span class="td style-scope patent-result">1995-02-16</span>
                    <span class="td style-scope patent-result">Zeneca Limited</span>
                    <span class="td style-scope patent-result">4-methyleneproline derivatives as fungicides 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5418241A/en"><a id="link" href="#" class="style-scope state-modifier">US5418241A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-09-28</span>
                    <span class="td style-scope patent-result">1995-05-23</span>
                    <span class="td style-scope patent-result">Synthelabo</span>
                    <span class="td style-scope patent-result">Piperidine derivatives, their preparation and their application in therapeutics 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5440021A/en"><a id="link" href="#" class="style-scope state-modifier">US5440021A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1991-03-29</span>
                    <span class="td style-scope patent-result">1995-08-08</span>
                    <span class="td style-scope patent-result">Chuntharapai; Anan</span>
                    <span class="td style-scope patent-result">Antibodies to human IL-8 type B receptor 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5561119A/en"><a id="link" href="#" class="style-scope state-modifier">US5561119A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1991-04-30</span>
                    <span class="td style-scope patent-result">1996-10-01</span>
                    <span class="td style-scope patent-result">Laboratoires Hoechst</span>
                    <span class="td style-scope patent-result">Glycosylated prodrugs, their method of preparation and their uses 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1996030514A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1996030514A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1995-03-31</span>
                    <span class="td style-scope patent-result">1996-10-03</span>
                    <span class="td style-scope patent-result">University Of Washington</span>
                    <span class="td style-scope patent-result">Intracellular domain of the her-2/neu protein for prevention or treatment of malignancies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5583024A/en"><a id="link" href="#" class="style-scope state-modifier">US5583024A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1985-12-02</span>
                    <span class="td style-scope patent-result">1996-12-10</span>
                    <span class="td style-scope patent-result">The Regents Of The University Of California</span>
                    <span class="td style-scope patent-result">Recombinant expression of Coleoptera luciferase 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1997007198A2/en"><a id="link" href="#" class="style-scope state-modifier">WO1997007198A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1995-08-11</span>
                    <span class="td style-scope patent-result">1997-02-27</span>
                    <span class="td style-scope patent-result">Genetics Institute, Inc.</span>
                    <span class="td style-scope patent-result">Dna sequences and secreted proteins encoded thereby 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5621002A/en"><a id="link" href="#" class="style-scope state-modifier">US5621002A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1993-09-09</span>
                    <span class="td style-scope patent-result">1997-04-15</span>
                    <span class="td style-scope patent-result">Behringwerke Aktiengesellschaft</span>
                    <span class="td style-scope patent-result">Prodrugs for enzyme mediated activation 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5644033A/en"><a id="link" href="#" class="style-scope state-modifier">US5644033A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-12-22</span>
                    <span class="td style-scope patent-result">1997-07-01</span>
                    <span class="td style-scope patent-result">Health Research, Inc.</span>
                    <span class="td style-scope patent-result">Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1997044452A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1997044452A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-05-17</span>
                    <span class="td style-scope patent-result">1997-11-27</span>
                    <span class="td style-scope patent-result">Schering Corporation</span>
                    <span class="td style-scope patent-result">Human b-cell antigens, related reagents 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5700670A/en"><a id="link" href="#" class="style-scope state-modifier">US5700670A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1995-04-13</span>
                    <span class="td style-scope patent-result">1997-12-23</span>
                    <span class="td style-scope patent-result">Mitsubishi Chemical Corporation</span>
                    <span class="td style-scope patent-result">Method for producing optically active ester of γ-substituted-β-hydroxybutyric acid 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1998013059A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1998013059A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-09-27</span>
                    <span class="td style-scope patent-result">1998-04-02</span>
                    <span class="td style-scope patent-result">Bristol-Myers Squibb Company</span>
                    <span class="td style-scope patent-result">Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5773223A/en"><a id="link" href="#" class="style-scope state-modifier">US5773223A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1993-09-02</span>
                    <span class="td style-scope patent-result">1998-06-30</span>
                    <span class="td style-scope patent-result">Chiron Corporation</span>
                    <span class="td style-scope patent-result">Endothelin B1, (ETB1) receptor polypeptide and its encoding nucleic acid methods, and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5792616A/en"><a id="link" href="#" class="style-scope state-modifier">US5792616A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1990-05-29</span>
                    <span class="td style-scope patent-result">1998-08-11</span>
                    <span class="td style-scope patent-result">The United States Of America</span>
                    <span class="td style-scope patent-result">Antibodies to human cripto protein 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1998037193A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1998037193A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-02-20</span>
                    <span class="td style-scope patent-result">1998-08-27</span>
                    <span class="td style-scope patent-result">Zymogenetics, Inc.</span>
                    <span class="td style-scope patent-result">Zcytor7 cytokine receptor 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1998040403A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1998040403A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-03-10</span>
                    <span class="td style-scope patent-result">1998-09-17</span>
                    <span class="td style-scope patent-result">The Regents Of The University Of California</span>
                    <span class="td style-scope patent-result">Psca: prostate stem cell antigen 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP0875569A1/en"><a id="link" href="#" class="style-scope state-modifier">EP0875569A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-04-28</span>
                    <span class="td style-scope patent-result">1998-11-04</span>
                    <span class="td style-scope patent-result">Smithkline Beecham Corporation</span>
                    <span class="td style-scope patent-result">A human sodium dependent phosphate transporter (IPT-1) 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1998051805A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1998051805A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-05-15</span>
                    <span class="td style-scope patent-result">1998-11-19</span>
                    <span class="td style-scope patent-result">Abbott Laboratories</span>
                    <span class="td style-scope patent-result">Reagents and methods useful for detecting diseases of the prostate 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1998051824A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1998051824A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-05-15</span>
                    <span class="td style-scope patent-result">1998-11-19</span>
                    <span class="td style-scope patent-result">Abbott Laboratories</span>
                    <span class="td style-scope patent-result">Reagents and methods useful for detecting disease of the urinary tract 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5854399A/en"><a id="link" href="#" class="style-scope state-modifier">US5854399A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1991-08-23</span>
                    <span class="td style-scope patent-result">1998-12-29</span>
                    <span class="td style-scope patent-result">The United States Of America As Represented By The Department Of Health And Human Services</span>
                    <span class="td style-scope patent-result">Antibodies specific for human cripto-related polypeptide CR-3 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5869445A/en"><a id="link" href="#" class="style-scope state-modifier">US5869445A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1993-03-17</span>
                    <span class="td style-scope patent-result">1999-02-09</span>
                    <span class="td style-scope patent-result">University Of Washington</span>
                    <span class="td style-scope patent-result">Methods for eliciting or enhancing reactivity to HER-2/neu protein 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1999028468A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1999028468A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-12-02</span>
                    <span class="td style-scope patent-result">1999-06-10</span>
                    <span class="td style-scope patent-result">The Regents Of The University Of California</span>
                    <span class="td style-scope patent-result">Modulating b lymphocyte chemokine/receptor interactions 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1999046284A2/en"><a id="link" href="#" class="style-scope state-modifier">WO1999046284A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-03-13</span>
                    <span class="td style-scope patent-result">1999-09-16</span>
                    <span class="td style-scope patent-result">The Burnham Institute</span>
                    <span class="td style-scope patent-result">Molecules that home to various selected organs or tissues 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5976551A/en"><a id="link" href="#" class="style-scope state-modifier">US5976551A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1991-11-15</span>
                    <span class="td style-scope patent-result">1999-11-02</span>
                    <span class="td style-scope patent-result">Institut Pasteur And Institut Nationale De La Sante Et De La Recherche Medicale</span>
                    <span class="td style-scope patent-result">Altered major histocompatibility complex (MHC) determinant and method of using the determinant 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1999058658A2/en"><a id="link" href="#" class="style-scope state-modifier">WO1999058658A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-05-13</span>
                    <span class="td style-scope patent-result">1999-11-18</span>
                    <span class="td style-scope patent-result">Epimmune, Inc.</span>
                    <span class="td style-scope patent-result">Expression vectors for stimulating an immune response and methods of using the same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2000003291A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2000003291A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-07-08</span>
                    <span class="td style-scope patent-result">2000-01-20</span>
                    <span class="td style-scope patent-result">E Ink Corporation</span>
                    <span class="td style-scope patent-result">Methods for achieving improved color in microencapsulated electrophoretic devices 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2000012509A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2000012509A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-08-27</span>
                    <span class="td style-scope patent-result">2000-03-09</span>
                    <span class="td style-scope patent-result">Spirogen Limited</span>
                    <span class="td style-scope patent-result">Collections of compounds 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2000012506A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2000012506A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-08-27</span>
                    <span class="td style-scope patent-result">2000-03-09</span>
                    <span class="td style-scope patent-result">Spirogen Limited</span>
                    <span class="td style-scope patent-result">Collections of compounds 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2000012508A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2000012508A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-08-27</span>
                    <span class="td style-scope patent-result">2000-03-09</span>
                    <span class="td style-scope patent-result">Spirogen Limited</span>
                    <span class="td style-scope patent-result">Pyrrolbenzodiazepines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2000012130A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2000012130A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-08-27</span>
                    <span class="td style-scope patent-result">2000-03-09</span>
                    <span class="td style-scope patent-result">Smithkline Beecham Corporation</span>
                    <span class="td style-scope patent-result">Rp105 agonists and antagonists 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2000012507A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2000012507A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-08-27</span>
                    <span class="td style-scope patent-result">2000-03-09</span>
                    <span class="td style-scope patent-result">Spirogen Limited</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2000014228A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2000014228A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-09-03</span>
                    <span class="td style-scope patent-result">2000-03-16</span>
                    <span class="td style-scope patent-result">Japan Science And Technology Corporation</span>
                    <span class="td style-scope patent-result">Neutral amino acid transporter and gene thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2000020579A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2000020579A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-10-02</span>
                    <span class="td style-scope patent-result">2000-04-13</span>
                    <span class="td style-scope patent-result">Mcmaster University</span>
                    <span class="td style-scope patent-result">Spliced form of erbb-2/neu oncogene 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2000022129A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2000022129A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-10-13</span>
                    <span class="td style-scope patent-result">2000-04-20</span>
                    <span class="td style-scope patent-result">Arena Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Non-endogenous, constitutively activated human g protein-coupled receptors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2000032752A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2000032752A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-12-02</span>
                    <span class="td style-scope patent-result">2000-06-08</span>
                    <span class="td style-scope patent-result">The Regents Of The University Of California</span>
                    <span class="td style-scope patent-result">Psca: prostate stem cell antigen and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2000036107A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2000036107A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-12-17</span>
                    <span class="td style-scope patent-result">2000-06-22</span>
                    <span class="td style-scope patent-result">Corixa Corporation</span>
                    <span class="td style-scope patent-result">Compositions and methods for therapy and diagnosis of ovarian cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2000040614A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2000040614A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-12-30</span>
                    <span class="td style-scope patent-result">2000-07-13</span>
                    <span class="td style-scope patent-result">Beth Israel Deaconess Medical Center, Inc.</span>
                    <span class="td style-scope patent-result">Characterization of the soc/crac calcium channel protein family 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2000044899A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2000044899A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-01-29</span>
                    <span class="td style-scope patent-result">2000-08-03</span>
                    <span class="td style-scope patent-result">Corixa Corporation</span>
                    <span class="td style-scope patent-result">Her-2/neu fusion proteins 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2000053216A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2000053216A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-03-05</span>
                    <span class="td style-scope patent-result">2000-09-14</span>
                    <span class="td style-scope patent-result">Smithkline Beecham Biologicals S.A.</span>
                    <span class="td style-scope patent-result">Use of casb616 polypeptides and polynucleotides for cancer treatment 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2000055351A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2000055351A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-03-12</span>
                    <span class="td style-scope patent-result">2000-09-21</span>
                    <span class="td style-scope patent-result">Human Genome Sciences, Inc.</span>
                    <span class="td style-scope patent-result">Human colon cancer associated gene sequences and polypeptides 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6153408A/en"><a id="link" href="#" class="style-scope state-modifier">US6153408A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1991-11-15</span>
                    <span class="td style-scope patent-result">2000-11-28</span>
                    <span class="td style-scope patent-result">Institut Pasteur And Institut National De La Sante Et De La Recherche Medicale</span>
                    <span class="td style-scope patent-result">Altered major histocompatibility complex (MHC) determinant and methods of using the determinant 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2000075655A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2000075655A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-06-03</span>
                    <span class="td style-scope patent-result">2000-12-14</span>
                    <span class="td style-scope patent-result">Takeda Chemical Industries, Ltd.</span>
                    <span class="td style-scope patent-result">Screening method with the use of cd100 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001000244A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2001000244A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-06-25</span>
                    <span class="td style-scope patent-result">2001-01-04</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001016318A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2001016318A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-09-01</span>
                    <span class="td style-scope patent-result">2001-03-08</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Secreted and transmembrane polypeptides and nucleic acids encoding the same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001016104A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2001016104A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-08-27</span>
                    <span class="td style-scope patent-result">2001-03-08</span>
                    <span class="td style-scope patent-result">Spirogen Limited</span>
                    <span class="td style-scope patent-result">Cyclopropylindole derivatives 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6214345B1/en"><a id="link" href="#" class="style-scope state-modifier">US6214345B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1993-05-14</span>
                    <span class="td style-scope patent-result">2001-04-10</span>
                    <span class="td style-scope patent-result">Bristol-Myers Squibb Co.</span>
                    <span class="td style-scope patent-result">Lysosomal enzyme-cleavable antitumor drug conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6218519B1/en"><a id="link" href="#" class="style-scope state-modifier">US6218519B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-04-12</span>
                    <span class="td style-scope patent-result">2001-04-17</span>
                    <span class="td style-scope patent-result">Pro-Neuron, Inc.</span>
                    <span class="td style-scope patent-result">Compounds and methods for the selective treatment of cancer and bacterial infections 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001038490A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2001038490A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-11-29</span>
                    <span class="td style-scope patent-result">2001-05-31</span>
                    <span class="td style-scope patent-result">The Trustees Of Columbia University In The City Of New York</span>
                    <span class="td style-scope patent-result">ISOLATION OF FIVE NOVEL GENES CODING FOR NEW Fc RECEPTORS-TYPE MELANOMA INVOLVED IN THE PATHOGENESIS OF LYMPHOMA/MELANOMA 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001040309A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2001040309A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-10-29</span>
                    <span class="td style-scope patent-result">2001-06-07</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Anti-prostate stem cell antigen (psca) antibody compositions and methods of use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001040269A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2001040269A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-11-30</span>
                    <span class="td style-scope patent-result">2001-06-07</span>
                    <span class="td style-scope patent-result">Corixa Corporation</span>
                    <span class="td style-scope patent-result">Compositions and methods for therapy and diagnosis of breast cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001041787A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2001041787A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-12-10</span>
                    <span class="td style-scope patent-result">2001-06-14</span>
                    <span class="td style-scope patent-result">Epimmune Inc.</span>
                    <span class="td style-scope patent-result">INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001045746A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2001045746A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-12-24</span>
                    <span class="td style-scope patent-result">2001-06-28</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Methods and compositions for prolonging elimination half-times of bioactive compounds 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001046261A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2001046261A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-12-23</span>
                    <span class="td style-scope patent-result">2001-06-28</span>
                    <span class="td style-scope patent-result">Zymogenetics, Inc.</span>
                    <span class="td style-scope patent-result">Method for treating inflammation 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001046232A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2001046232A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-12-23</span>
                    <span class="td style-scope patent-result">2001-06-28</span>
                    <span class="td style-scope patent-result">Zymogenetics, Inc.</span>
                    <span class="td style-scope patent-result">Soluble interleukin-20 receptor 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001048204A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2001048204A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-12-23</span>
                    <span class="td style-scope patent-result">2001-07-05</span>
                    <span class="td style-scope patent-result">Agresearch Limited</span>
                    <span class="td style-scope patent-result">Mutated bmp1b receptor as regulator of ovulation rate 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001053463A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2001053463A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-01-21</span>
                    <span class="td style-scope patent-result">2001-07-26</span>
                    <span class="td style-scope patent-result">Corixa Corporation</span>
                    <span class="td style-scope patent-result">COMPOUNDS AND METHODS FOR PREVENTION AND TREATMENT OF HER-2/neu ASSOCIATED MALIGNANCIES 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6268488B1/en"><a id="link" href="#" class="style-scope state-modifier">US6268488B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-05-25</span>
                    <span class="td style-scope patent-result">2001-07-31</span>
                    <span class="td style-scope patent-result">Barbas, Iii Carlos F.</span>
                    <span class="td style-scope patent-result">Prodrug activation using catalytic antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001057188A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2001057188A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-02-03</span>
                    <span class="td style-scope patent-result">2001-08-09</span>
                    <span class="td style-scope patent-result">Hyseq, Inc.</span>
                    <span class="td style-scope patent-result">Novel nucleic acids and polypeptides 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001062794A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2001062794A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-02-22</span>
                    <span class="td style-scope patent-result">2001-08-30</span>
                    <span class="td style-scope patent-result">Millennium Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">18607, a human calcium channel 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001066689A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2001066689A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-03-07</span>
                    <span class="td style-scope patent-result">2001-09-13</span>
                    <span class="td style-scope patent-result">Hyseq, Inc.</span>
                    <span class="td style-scope patent-result">Novel nucleic acids and polypeptides 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001072962A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2001072962A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-03-24</span>
                    <span class="td style-scope patent-result">2001-10-04</span>
                    <span class="td style-scope patent-result">Fahri Saatcioglu</span>
                    <span class="td style-scope patent-result">Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001072830A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2001072830A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-03-31</span>
                    <span class="td style-scope patent-result">2001-10-04</span>
                    <span class="td style-scope patent-result">Ipf Pharmaceuticals Gmbh</span>
                    <span class="td style-scope patent-result">Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001075177A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2001075177A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-04-03</span>
                    <span class="td style-scope patent-result">2001-10-11</span>
                    <span class="td style-scope patent-result">The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services</span>
                    <span class="td style-scope patent-result">Tumor markers in ovarian cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001077172A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2001077172A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-04-07</span>
                    <span class="td style-scope patent-result">2001-10-18</span>
                    <span class="td style-scope patent-result">Arena Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Non-endogenous, constitutively activated known g protein-coupled receptors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001088133A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2001088133A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-05-18</span>
                    <span class="td style-scope patent-result">2001-11-22</span>
                    <span class="td style-scope patent-result">Lexicon Genetics Incorporated</span>
                    <span class="td style-scope patent-result">Human semaphorin homologs and polynucleotides encoding the same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001090304A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2001090304A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-05-19</span>
                    <span class="td style-scope patent-result">2001-11-29</span>
                    <span class="td style-scope patent-result">Human Genome Sciences, Inc.</span>
                    <span class="td style-scope patent-result">Nucleic acids, proteins, and antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001094641A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2001094641A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-06-09</span>
                    <span class="td style-scope patent-result">2001-12-13</span>
                    <span class="td style-scope patent-result">Idec Pharmaceuticals Corporation</span>
                    <span class="td style-scope patent-result">Gene targets and ligands that bind thereto for treatment and diagnosis of ovarian carcinomas 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20010055751A1/en"><a id="link" href="#" class="style-scope state-modifier">US20010055751A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-03-10</span>
                    <span class="td style-scope patent-result">2001-12-27</span>
                    <span class="td style-scope patent-result">Reiter Robert E</span>
                    <span class="td style-scope patent-result">PSCA: Prostate stem cell antigen and uses thereof 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001098351A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2001098351A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-06-16</span>
                    <span class="td style-scope patent-result">2001-12-27</span>
                    <span class="td style-scope patent-result">Incyte Genomics, Inc.</span>
                    <span class="td style-scope patent-result">G-protein coupled receptors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002002587A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2002002587A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-06-30</span>
                    <span class="td style-scope patent-result">2002-01-10</span>
                    <span class="td style-scope patent-result">Human Genome Sciences, Inc.</span>
                    <span class="td style-scope patent-result">B7-like polynucleotides, polypeptides, and antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002002624A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002002624A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-06-30</span>
                    <span class="td style-scope patent-result">2002-01-10</span>
                    <span class="td style-scope patent-result">Amgen, Inc.</span>
                    <span class="td style-scope patent-result">B7-like molecules and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002002634A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002002634A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-06-30</span>
                    <span class="td style-scope patent-result">2002-01-10</span>
                    <span class="td style-scope patent-result">Incyte Genomics, Inc.</span>
                    <span class="td style-scope patent-result">Human extracellular matrix and cell adhesion polypeptides 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002006317A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002006317A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-07-17</span>
                    <span class="td style-scope patent-result">2002-01-24</span>
                    <span class="td style-scope patent-result">Corixa Corporation</span>
                    <span class="td style-scope patent-result">Compositions and methods for the therapy and diagnosis of ovarian cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002006339A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002006339A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-07-03</span>
                    <span class="td style-scope patent-result">2002-01-24</span>
                    <span class="td style-scope patent-result">Curagen Corporation</span>
                    <span class="td style-scope patent-result">Proteins and nucleic acids encoding same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002010382A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002010382A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-07-28</span>
                    <span class="td style-scope patent-result">2002-02-07</span>
                    <span class="td style-scope patent-result">Ulrich Wissenbach</span>
                    <span class="td style-scope patent-result">Trp8, trp9 and trp10, markers for cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002010187A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2002010187A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-07-27</span>
                    <span class="td style-scope patent-result">2002-02-07</span>
                    <span class="td style-scope patent-result">Mayo Foundation For Medical Education And Research</span>
                    <span class="td style-scope patent-result">B7-h3 and b7-h4, novel immunoregulatory molecules 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002012341A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002012341A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-08-03</span>
                    <span class="td style-scope patent-result">2002-02-14</span>
                    <span class="td style-scope patent-result">Corixa Corporation</span>
                    <span class="td style-scope patent-result">Her-2/neu fusion proteins 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002013847A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002013847A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-08-14</span>
                    <span class="td style-scope patent-result">2002-02-21</span>
                    <span class="td style-scope patent-result">Corixa Corporation</span>
                    <span class="td style-scope patent-result">Methods for diagnosis and therapy of hematological and virus-associated malignancies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002014503A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002014503A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-08-14</span>
                    <span class="td style-scope patent-result">2002-02-21</span>
                    <span class="td style-scope patent-result">Corixa Corporation</span>
                    <span class="td style-scope patent-result">Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002016413A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002016413A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-08-24</span>
                    <span class="td style-scope patent-result">2002-02-28</span>
                    <span class="td style-scope patent-result">Glaxosmithkline Biologicals S.A.</span>
                    <span class="td style-scope patent-result">Cripto tumour polypeptide 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002016429A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002016429A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-08-24</span>
                    <span class="td style-scope patent-result">2002-02-28</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Compositions and methods for the diagnosis and treatment of tumor 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20020034749A1/en"><a id="link" href="#" class="style-scope state-modifier">US20020034749A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-11-18</span>
                    <span class="td style-scope patent-result">2002-03-21</span>
                    <span class="td style-scope patent-result">Billing-Medel Patricia A.</span>
                    <span class="td style-scope patent-result">Reagents and methods useful for detecting diseases of the breast 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002022660A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002022660A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-09-11</span>
                    <span class="td style-scope patent-result">2002-03-21</span>
                    <span class="td style-scope patent-result">Hyseq, Inc.</span>
                    <span class="td style-scope patent-result">Novel nucleic acids and polypeptides 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002022808A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002022808A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-09-18</span>
                    <span class="td style-scope patent-result">2002-03-21</span>
                    <span class="td style-scope patent-result">Biogen, Inc.</span>
                    <span class="td style-scope patent-result">Cripto mutant and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002022153A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002022153A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-09-15</span>
                    <span class="td style-scope patent-result">2002-03-21</span>
                    <span class="td style-scope patent-result">Zymogenetics, Inc.</span>
                    <span class="td style-scope patent-result">Use of a polypeptide comprising the extracellular domains of il-20rb for the treatment of inflammation 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002022636A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2002022636A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-09-15</span>
                    <span class="td style-scope patent-result">2002-03-21</span>
                    <span class="td style-scope patent-result">Isis Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Antisense modulation of her-2 expression 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6362331B1/en"><a id="link" href="#" class="style-scope state-modifier">US6362331B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-03-30</span>
                    <span class="td style-scope patent-result">2002-03-26</span>
                    <span class="td style-scope patent-result">Council Of Scientific And Industrial Research</span>
                    <span class="td style-scope patent-result">Process for the preparation of antitumor agents 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002024909A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002024909A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-09-18</span>
                    <span class="td style-scope patent-result">2002-03-28</span>
                    <span class="td style-scope patent-result">Biogen, Inc.</span>
                    <span class="td style-scope patent-result">Receptor nucleic acids and polypeptides 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20020042366A1/en"><a id="link" href="#" class="style-scope state-modifier">US20020042366A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-12-23</span>
                    <span class="td style-scope patent-result">2002-04-11</span>
                    <span class="td style-scope patent-result">Penny Thompson</span>
                    <span class="td style-scope patent-result">Method for treating inflammation 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002030268A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002030268A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-10-13</span>
                    <span class="td style-scope patent-result">2002-04-18</span>
                    <span class="td style-scope patent-result">Eos Biotechnology, Inc.</span>
                    <span class="td style-scope patent-result">Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002038766A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002038766A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-11-07</span>
                    <span class="td style-scope patent-result">2002-05-16</span>
                    <span class="td style-scope patent-result">Zymogenetics, Inc.</span>
                    <span class="td style-scope patent-result">Human tumor necrosis factor receptor 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002054940A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002054940A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-01-12</span>
                    <span class="td style-scope patent-result">2002-07-18</span>
                    <span class="td style-scope patent-result">University Of Medicine &amp; Dentistry Of New Jersey</span>
                    <span class="td style-scope patent-result">Bone morphogenetic protein-2 in the treatment and diagnosis of cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002059377A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002059377A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-01-24</span>
                    <span class="td style-scope patent-result">2002-08-01</span>
                    <span class="td style-scope patent-result">Protein Design Labs</span>
                    <span class="td style-scope patent-result">Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002061087A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002061087A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-12-19</span>
                    <span class="td style-scope patent-result">2002-08-08</span>
                    <span class="td style-scope patent-result">Lifespan Biosciences, Inc.</span>
                    <span class="td style-scope patent-result">Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002060317A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002060317A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-01-30</span>
                    <span class="td style-scope patent-result">2002-08-08</span>
                    <span class="td style-scope patent-result">Corixa Corporation</span>
                    <span class="td style-scope patent-result">Compositions and methods for the therapy and diagnosis of pancreatic cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002064798A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2002064798A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-02-12</span>
                    <span class="td style-scope patent-result">2002-08-22</span>
                    <span class="td style-scope patent-result">Bionomics Limited</span>
                    <span class="td style-scope patent-result">Dna sequences differentially expressed in tumour cell lines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002071928A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002071928A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-03-14</span>
                    <span class="td style-scope patent-result">2002-09-19</span>
                    <span class="td style-scope patent-result">Millennium Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002072596A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2002072596A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-03-09</span>
                    <span class="td style-scope patent-result">2002-09-19</span>
                    <span class="td style-scope patent-result">Incyte Genomics, Inc.</span>
                    <span class="td style-scope patent-result">Steap-related protein 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002078524A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002078524A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-03-28</span>
                    <span class="td style-scope patent-result">2002-10-10</span>
                    <span class="td style-scope patent-result">Zycos Inc.</span>
                    <span class="td style-scope patent-result">Translational profiling 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20020150573A1/en"><a id="link" href="#" class="style-scope state-modifier">US20020150573A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-11-10</span>
                    <span class="td style-scope patent-result">2002-10-17</span>
                    <span class="td style-scope patent-result">The Rockefeller University</span>
                    <span class="td style-scope patent-result">Anti-Igalpha-Igbeta antibody for lymphoma therapy 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002081646A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002081646A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-04-06</span>
                    <span class="td style-scope patent-result">2002-10-17</span>
                    <span class="td style-scope patent-result">Mannkind Corporation</span>
                    <span class="td style-scope patent-result">Epitope sequences 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002083866A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002083866A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-04-17</span>
                    <span class="td style-scope patent-result">2002-10-24</span>
                    <span class="td style-scope patent-result">The Board Of Trustees Of The University Of Arkansas</span>
                    <span class="td style-scope patent-result">Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002086443A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002086443A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-04-18</span>
                    <span class="td style-scope patent-result">2002-10-31</span>
                    <span class="td style-scope patent-result">Protein Design Labs, Inc</span>
                    <span class="td style-scope patent-result">Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002088172A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002088172A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-04-30</span>
                    <span class="td style-scope patent-result">2002-11-07</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">Pentapeptide compounds and uses related thereto 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002088170A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002088170A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-04-26</span>
                    <span class="td style-scope patent-result">2002-11-07</span>
                    <span class="td style-scope patent-result">Biogen, Inc.</span>
                    <span class="td style-scope patent-result">Cripto blocking antibodies and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002089747A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002089747A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-05-09</span>
                    <span class="td style-scope patent-result">2002-11-14</span>
                    <span class="td style-scope patent-result">Corixa Corporation</span>
                    <span class="td style-scope patent-result">Compositions and methods for the therapy and diagnosis of prostate cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002092836A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002092836A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-05-11</span>
                    <span class="td style-scope patent-result">2002-11-21</span>
                    <span class="td style-scope patent-result">Sloan-Kettering Institute For Cancer Research</span>
                    <span class="td style-scope patent-result">Nucleic acid sequence encoding ovarian antigen, ca125, and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002094852A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002094852A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-05-24</span>
                    <span class="td style-scope patent-result">2002-11-28</span>
                    <span class="td style-scope patent-result">Zymogenetics, Inc.</span>
                    <span class="td style-scope patent-result">Taci-immunoglobulin fusion proteins 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002099122A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2002099122A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-06-05</span>
                    <span class="td style-scope patent-result">2002-12-12</span>
                    <span class="td style-scope patent-result">Exelixis, Inc.</span>
                    <span class="td style-scope patent-result">Modifiers of the p53 pathway and methods of use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002098358A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002098358A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-06-04</span>
                    <span class="td style-scope patent-result">2002-12-12</span>
                    <span class="td style-scope patent-result">Eos Biotechnology, Inc.</span>
                    <span class="td style-scope patent-result">Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002099074A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002099074A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-06-05</span>
                    <span class="td style-scope patent-result">2002-12-12</span>
                    <span class="td style-scope patent-result">Exelixis, Inc.</span>
                    <span class="td style-scope patent-result">Slc7s as modifiers of the p53 pathway and methods of use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20020193567A1/en"><a id="link" href="#" class="style-scope state-modifier">US20020193567A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1995-08-11</span>
                    <span class="td style-scope patent-result">2002-12-19</span>
                    <span class="td style-scope patent-result">Genetics Institute, Inc.</span>
                    <span class="td style-scope patent-result">Secreted proteins and polynucleotides encoding them 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002101075A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002101075A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-06-13</span>
                    <span class="td style-scope patent-result">2002-12-19</span>
                    <span class="td style-scope patent-result">Millennium Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002102235A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002102235A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-06-18</span>
                    <span class="td style-scope patent-result">2002-12-27</span>
                    <span class="td style-scope patent-result">Eos Biotechnology Inc.</span>
                    <span class="td style-scope patent-result">Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003000842A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003000842A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-06-04</span>
                    <span class="td style-scope patent-result">2003-01-03</span>
                    <span class="td style-scope patent-result">Curagen Corporation</span>
                    <span class="td style-scope patent-result">Novel proteins and nucleic acids encoding same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003002717A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003002717A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-06-28</span>
                    <span class="td style-scope patent-result">2003-01-09</span>
                    <span class="td style-scope patent-result">Schering Corporation</span>
                    <span class="td style-scope patent-result">Biological activity of ak155 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003003906A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003003906A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-07-03</span>
                    <span class="td style-scope patent-result">2003-01-16</span>
                    <span class="td style-scope patent-result">Eos Biotechnology, Inc.</span>
                    <span class="td style-scope patent-result">Diagnostic and screening methods for bladder cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003004529A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003004529A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-07-02</span>
                    <span class="td style-scope patent-result">2003-01-16</span>
                    <span class="td style-scope patent-result">Licentia Ltd.</span>
                    <span class="td style-scope patent-result">Ephrin-tie receptor materials and methods 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003004989A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003004989A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-06-21</span>
                    <span class="td style-scope patent-result">2003-01-16</span>
                    <span class="td style-scope patent-result">Millennium Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003003984A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003003984A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-07-05</span>
                    <span class="td style-scope patent-result">2003-01-16</span>
                    <span class="td style-scope patent-result">Curagen Corporation</span>
                    <span class="td style-scope patent-result">Novel proteins and nucleic acids encoding same 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003009814A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003009814A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-07-25</span>
                    <span class="td style-scope patent-result">2003-02-06</span>
                    <span class="td style-scope patent-result">Millennium Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6518404B1/en"><a id="link" href="#" class="style-scope state-modifier">US6518404B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1994-10-17</span>
                    <span class="td style-scope patent-result">2003-02-11</span>
                    <span class="td style-scope patent-result">Human Genome Sciences, Inc.</span>
                    <span class="td style-scope patent-result">Human endothelin-bombesin receptor antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003014294A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003014294A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-08-03</span>
                    <span class="td style-scope patent-result">2003-02-20</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Tacis and br3 polypeptides and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003016475A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003016475A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-08-14</span>
                    <span class="td style-scope patent-result">2003-02-27</span>
                    <span class="td style-scope patent-result">The General Hospital Corporation</span>
                    <span class="td style-scope patent-result">Nucleic acid and amino acid sequences involved in pain 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003016494A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003016494A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-08-16</span>
                    <span class="td style-scope patent-result">2003-02-27</span>
                    <span class="td style-scope patent-result">Vitivity, Inc.</span>
                    <span class="td style-scope patent-result">Diagnosis and treatment of vascular disease 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003018621A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003018621A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-08-23</span>
                    <span class="td style-scope patent-result">2003-03-06</span>
                    <span class="td style-scope patent-result">Oxford Biomedica (Uk) Limited</span>
                    <span class="td style-scope patent-result">Genes 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003023013A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003023013A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-09-13</span>
                    <span class="td style-scope patent-result">2003-03-20</span>
                    <span class="td style-scope patent-result">Nuvelo, Inc.</span>
                    <span class="td style-scope patent-result">Novel nucleic acids and polypeptides 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003022995A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003022995A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-09-06</span>
                    <span class="td style-scope patent-result">2003-03-20</span>
                    <span class="td style-scope patent-result">Agensys, Inc.</span>
                    <span class="td style-scope patent-result">Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP1295944A2/en"><a id="link" href="#" class="style-scope state-modifier">EP1295944A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-03-19</span>
                    <span class="td style-scope patent-result">2003-03-26</span>
                    <span class="td style-scope patent-result">Otsuka Pharmaceutical Co., Ltd.</span>
                    <span class="td style-scope patent-result">GDP dissociation stimulating protein, brain-specific nucleosome assembly protein, skeletal muscle specific ubiquitin-conjugating enzyme, cell proliferation protein, phosphatidylinositolkinase, nel related proteins 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003025148A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003025148A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-09-19</span>
                    <span class="td style-scope patent-result">2003-03-27</span>
                    <span class="td style-scope patent-result">Nuvelo, Inc.</span>
                    <span class="td style-scope patent-result">Novel nucleic acids and polypeptides 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003024392A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003024392A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-09-18</span>
                    <span class="td style-scope patent-result">2003-03-27</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Compositions and methods for the diagnosis and treatment of tumor 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003025138A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003025138A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-09-17</span>
                    <span class="td style-scope patent-result">2003-03-27</span>
                    <span class="td style-scope patent-result">Protein Design Labs, Inc.</span>
                    <span class="td style-scope patent-result">Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003025228A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2003025228A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-09-18</span>
                    <span class="td style-scope patent-result">2003-03-27</span>
                    <span class="td style-scope patent-result">Proteologics, Inc.</span>
                    <span class="td style-scope patent-result">Methods and compositions for treating hcap associated diseases 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030060612A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030060612A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-10-28</span>
                    <span class="td style-scope patent-result">2003-03-27</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Compositions and methods for the diagnosis and treatment of tumor 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003026577A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003026577A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-09-24</span>
                    <span class="td style-scope patent-result">2003-04-03</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">P-amidobenzylethers in drug delivery agents 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030062401A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030062401A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-06-29</span>
                    <span class="td style-scope patent-result">2003-04-03</span>
                    <span class="td style-scope patent-result">Hasz Wayne Charles</span>
                    <span class="td style-scope patent-result">Method of providing wear-resistant coatings, and related articles 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030064397A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030064397A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-05-22</span>
                    <span class="td style-scope patent-result">2003-04-03</span>
                    <span class="td style-scope patent-result">Incyte Genomics, Inc.</span>
                    <span class="td style-scope patent-result">Transmembrane protein differentially expressed in prostate and lung tumors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030065143A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030065143A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-12-30</span>
                    <span class="td style-scope patent-result">2003-04-03</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Secreted and transmembrane polypeptides and nucleic acids encoding the same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003026493A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003026493A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-09-28</span>
                    <span class="td style-scope patent-result">2003-04-03</span>
                    <span class="td style-scope patent-result">Bing Yang</span>
                    <span class="td style-scope patent-result">Diagnosis and treatment of diseases caused by mutations in cd72 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003029421A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003029421A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-10-03</span>
                    <span class="td style-scope patent-result">2003-04-10</span>
                    <span class="td style-scope patent-result">Origene Technologies, Inc.</span>
                    <span class="td style-scope patent-result">Regulated breast cancer genes 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003029277A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003029277A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-10-03</span>
                    <span class="td style-scope patent-result">2003-04-10</span>
                    <span class="td style-scope patent-result">Rigel Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Modulators of lymphocyte activation and migration 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003029262A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003029262A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-08-29</span>
                    <span class="td style-scope patent-result">2003-04-10</span>
                    <span class="td style-scope patent-result">Vanderbilt University</span>
                    <span class="td style-scope patent-result">The human mob-5 (il-24) receptors and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003034984A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003034984A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-10-19</span>
                    <span class="td style-scope patent-result">2003-05-01</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003035846A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003035846A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-10-24</span>
                    <span class="td style-scope patent-result">2003-05-01</span>
                    <span class="td style-scope patent-result">National Jewish Medical And Research Center</span>
                    <span class="td style-scope patent-result">Structure of tall-1 and its cognate receptor 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030091580A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030091580A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-06-18</span>
                    <span class="td style-scope patent-result">2003-05-15</span>
                    <span class="td style-scope patent-result">Mitcham Jennifer L.</span>
                    <span class="td style-scope patent-result">Compositions and methods for the therapy and diagnosis of ovarian cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003042661A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003042661A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-11-13</span>
                    <span class="td style-scope patent-result">2003-05-22</span>
                    <span class="td style-scope patent-result">Protein Design Labs, Inc.</span>
                    <span class="td style-scope patent-result">Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030096961A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030096961A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-06-01</span>
                    <span class="td style-scope patent-result">2003-05-22</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Secreted and transmembrane polypeptides and nucleic acids encoding the same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030096743A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030096743A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-09-24</span>
                    <span class="td style-scope patent-result">2003-05-22</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">p-Amidobenzylethers in drug delivery agents 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003043583A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003043583A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-11-20</span>
                    <span class="td style-scope patent-result">2003-05-30</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">Treatment of immunological disorders using anti-cd30 antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003045422A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2003045422A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-11-29</span>
                    <span class="td style-scope patent-result">2003-06-05</span>
                    <span class="td style-scope patent-result">Genset S.A.</span>
                    <span class="td style-scope patent-result">Agonists and antagonists of prolixin for the treatment of metabolic disorders 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003048202A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003048202A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-12-03</span>
                    <span class="td style-scope patent-result">2003-06-12</span>
                    <span class="td style-scope patent-result">Asahi Kasei Pharma Corporation</span>
                    <span class="td style-scope patent-result">Nf-kappab activating genes 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030119125A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030119125A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-01-16</span>
                    <span class="td style-scope patent-result">2003-06-26</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Secreted and transmembrane polypeptides and nucleic acids encoding the same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030119121A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030119121A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-09-15</span>
                    <span class="td style-scope patent-result">2003-06-26</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Secreted and transmembrane polypeptides and nucleic acids encoding the same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030119126A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030119126A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-01-16</span>
                    <span class="td style-scope patent-result">2003-06-26</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Secreted and transmembrane polypeptides and nucleic acids encoding the same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030118592A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030118592A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-01-17</span>
                    <span class="td style-scope patent-result">2003-06-26</span>
                    <span class="td style-scope patent-result">Genecraft, Inc.</span>
                    <span class="td style-scope patent-result">Binding domain-immunoglobulin fusion proteins 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030119122A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030119122A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-05-11</span>
                    <span class="td style-scope patent-result">2003-06-26</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Secreted and transmembrane polypeptides and nucleic acids encoding the same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030119128A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030119128A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-07-20</span>
                    <span class="td style-scope patent-result">2003-06-26</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Secreted and transmembrane polypeptides and nucleic acids encoding the same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030119129A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030119129A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-08-10</span>
                    <span class="td style-scope patent-result">2003-06-26</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Secreted and transmembrane polypeptides and nucleic acids encoding the same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030119130A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030119130A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-08-17</span>
                    <span class="td style-scope patent-result">2003-06-26</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Secreted and transmembrane polypeptides and nucleic acids encoding the same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030119131A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030119131A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-01-20</span>
                    <span class="td style-scope patent-result">2003-06-26</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Secreted and transmembrane polypeptides and nucleic acids encoding the same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030124579A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030124579A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-09-05</span>
                    <span class="td style-scope patent-result">2003-07-03</span>
                    <span class="td style-scope patent-result">Eos Biotechnology, Inc.</span>
                    <span class="td style-scope patent-result">Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003054152A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003054152A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-12-10</span>
                    <span class="td style-scope patent-result">2003-07-03</span>
                    <span class="td style-scope patent-result">Nuvelo, Inc.</span>
                    <span class="td style-scope patent-result">Novel nucleic acids and polypeptides 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030124140A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030124140A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-12-17</span>
                    <span class="td style-scope patent-result">2003-07-03</span>
                    <span class="td style-scope patent-result">Corixa Corporation</span>
                    <span class="td style-scope patent-result">Compositions and methods for the therapy and diagnosis of ovarian cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003055439A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003055439A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-07-18</span>
                    <span class="td style-scope patent-result">2003-07-10</span>
                    <span class="td style-scope patent-result">The Regents Of The University Of California</span>
                    <span class="td style-scope patent-result">Her2/neu target antigen and use of same to stimulate an immune response 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003055443A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003055443A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-10-31</span>
                    <span class="td style-scope patent-result">2003-07-10</span>
                    <span class="td style-scope patent-result">Alcon, Inc.</span>
                    <span class="td style-scope patent-result">Bone morphogenic proteins (bmp), bmp receptors and bmp binding proteins and their use in the diagnosis and treatment of glaucoma 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030129192A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030129192A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-09-10</span>
                    <span class="td style-scope patent-result">2003-07-10</span>
                    <span class="td style-scope patent-result">Corixa Corporation</span>
                    <span class="td style-scope patent-result">Compositions and methods for the therapy and diagnosis of ovarian cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030134790A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030134790A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-01-11</span>
                    <span class="td style-scope patent-result">2003-07-17</span>
                    <span class="td style-scope patent-result">University Of Medicine And Dentistry Of New Jersey</span>
                    <span class="td style-scope patent-result">Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003060612A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2003060612A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-01-16</span>
                    <span class="td style-scope patent-result">2003-07-24</span>
                    <span class="td style-scope patent-result">Japan Science And Technology Agency</span>
                    <span class="td style-scope patent-result">Moving image holography reproducing device and color moving image holography reproducing device 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030143557A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030143557A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-01-25</span>
                    <span class="td style-scope patent-result">2003-07-31</span>
                    <span class="td style-scope patent-result">Reinhold Penner</span>
                    <span class="td style-scope patent-result">Methods of screening for TRPM4b modulators 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003062401A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003062401A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-01-22</span>
                    <span class="td style-scope patent-result">2003-07-31</span>
                    <span class="td style-scope patent-result">Corixa Corporation</span>
                    <span class="td style-scope patent-result">Compositions and methods for the detection, diagnosis and therapy of hematological malignancies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6602677B1/en"><a id="link" href="#" class="style-scope state-modifier">US6602677B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-09-19</span>
                    <span class="td style-scope patent-result">2003-08-05</span>
                    <span class="td style-scope patent-result">Promega Corporation</span>
                    <span class="td style-scope patent-result">Thermostable luciferases and methods of production 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030157089A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030157089A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-02-25</span>
                    <span class="td style-scope patent-result">2003-08-21</span>
                    <span class="td style-scope patent-result">Corixa Corporation</span>
                    <span class="td style-scope patent-result">Compositions and methods for the therapy and diagnosis of prostate cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003072035A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003072035A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-02-22</span>
                    <span class="td style-scope patent-result">2003-09-04</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Compositions and methods for the treatment of immune related diseases 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030165504A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030165504A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-09-24</span>
                    <span class="td style-scope patent-result">2003-09-04</span>
                    <span class="td style-scope patent-result">Retter Marc W.</span>
                    <span class="td style-scope patent-result">Compositions and methods for the therapy and diagnosis of ovarian cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003072036A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003072036A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-02-21</span>
                    <span class="td style-scope patent-result">2003-09-04</span>
                    <span class="td style-scope patent-result">Duke University</span>
                    <span class="td style-scope patent-result">Treatment methods using anti-cd22 antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030175775A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030175775A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-01-07</span>
                    <span class="td style-scope patent-result">2003-09-18</span>
                    <span class="td style-scope patent-result">Lepoul Emmanuel</span>
                    <span class="td style-scope patent-result">Ligand for G-protein coupled receptor GPR43 and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP1347046A1/en"><a id="link" href="#" class="style-scope state-modifier">EP1347046A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-03-22</span>
                    <span class="td style-scope patent-result">2003-09-24</span>
                    <span class="td style-scope patent-result">Research Association for Biotechnology</span>
                    <span class="td style-scope patent-result">Full-length cDNA sequences 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003077836A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003077836A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-11-06</span>
                    <span class="td style-scope patent-result">2003-09-25</span>
                    <span class="td style-scope patent-result">Corixa Corporation</span>
                    <span class="td style-scope patent-result">Compositions and methods for the detection, diagnosis and therapy of hematological malignancies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030186372A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030186372A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-02-11</span>
                    <span class="td style-scope patent-result">2003-10-02</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Secreted and transmembrane polypeptides and nucleic acids encoding the same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003081210A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003081210A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-03-21</span>
                    <span class="td style-scope patent-result">2003-10-02</span>
                    <span class="td style-scope patent-result">Sunesis Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Identification of kinase inhibitors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030185830A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030185830A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-02-25</span>
                    <span class="td style-scope patent-result">2003-10-02</span>
                    <span class="td style-scope patent-result">Corixa Corporation</span>
                    <span class="td style-scope patent-result">Compositions and methods for the therapy and diagnosis of prostate cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003083041A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003083041A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-03-22</span>
                    <span class="td style-scope patent-result">2003-10-09</span>
                    <span class="td style-scope patent-result">Biogen, Inc.</span>
                    <span class="td style-scope patent-result">Cripto-specific antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003083047A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003083047A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-03-01</span>
                    <span class="td style-scope patent-result">2003-10-09</span>
                    <span class="td style-scope patent-result">Exelixis, Inc.</span>
                    <span class="td style-scope patent-result">MP53s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003083074A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003083074A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-03-28</span>
                    <span class="td style-scope patent-result">2003-10-09</span>
                    <span class="td style-scope patent-result">Idec Pharmaceuticals Corporation</span>
                    <span class="td style-scope patent-result">Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030194704A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030194704A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-04-03</span>
                    <span class="td style-scope patent-result">2003-10-16</span>
                    <span class="td style-scope patent-result">Penn Sharron Gaynor</span>
                    <span class="td style-scope patent-result">Human genome-derived single exon nucleic acid probes useful for gene expression analysis two 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003087768A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003087768A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-04-12</span>
                    <span class="td style-scope patent-result">2003-10-23</span>
                    <span class="td style-scope patent-result">Mitokor</span>
                    <span class="td style-scope patent-result">Targets for therapeutic intervention identified in the mitochondrial proteome 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003087306A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003087306A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-04-05</span>
                    <span class="td style-scope patent-result">2003-10-23</span>
                    <span class="td style-scope patent-result">Agensys, Inc.</span>
                    <span class="td style-scope patent-result">Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003088808A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003088808A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-04-16</span>
                    <span class="td style-scope patent-result">2003-10-30</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Compositions and methods for the diagnosis and treatment of tumor 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003089624A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003089624A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-03-25</span>
                    <span class="td style-scope patent-result">2003-10-30</span>
                    <span class="td style-scope patent-result">Uab Research Foundation</span>
                    <span class="td style-scope patent-result">Fc receptor homolog, reagents, and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003089904A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003089904A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-04-17</span>
                    <span class="td style-scope patent-result">2003-10-30</span>
                    <span class="td style-scope patent-result">Baylor College Of Medicine</span>
                    <span class="td style-scope patent-result">Aib1 as a prognostic marker and predictor of resistance to encocrine therapy 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030206918A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030206918A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-09-10</span>
                    <span class="td style-scope patent-result">2003-11-06</span>
                    <span class="td style-scope patent-result">Corixa Corporation</span>
                    <span class="td style-scope patent-result">Compositions and methods for the therapy and diagnosis of ovarian cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003093444A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003093444A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-05-03</span>
                    <span class="td style-scope patent-result">2003-11-13</span>
                    <span class="td style-scope patent-result">Incyte Corporation</span>
                    <span class="td style-scope patent-result">Transporters and ion channels 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003097803A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003097803A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-05-15</span>
                    <span class="td style-scope patent-result">2003-11-27</span>
                    <span class="td style-scope patent-result">Avalon Pharmaceuticals</span>
                    <span class="td style-scope patent-result">Cancer-linked gene as target for chemotherapy 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030219806A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030219806A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-02-22</span>
                    <span class="td style-scope patent-result">2003-11-27</span>
                    <span class="td style-scope patent-result">Millennium Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030224411A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030224411A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-03-13</span>
                    <span class="td style-scope patent-result">2003-12-04</span>
                    <span class="td style-scope patent-result">Stanton Lawrence W.</span>
                    <span class="td style-scope patent-result">Genes that are up- or down-regulated during differentiation of human embryonic stem cells 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030224454A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030224454A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-05-30</span>
                    <span class="td style-scope patent-result">2003-12-04</span>
                    <span class="td style-scope patent-result">Ryseck Rolf Peter</span>
                    <span class="td style-scope patent-result">Human solute carrier family 7, member 11 (hSLC7A11) 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6660856B2/en"><a id="link" href="#" class="style-scope state-modifier">US6660856B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-03-08</span>
                    <span class="td style-scope patent-result">2003-12-09</span>
                    <span class="td style-scope patent-result">Kaohsiung Medical University</span>
                    <span class="td style-scope patent-result">Synthesis of pyrrolo[2,1-c][1,4]benzodiazepine analogues 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6660742B2/en"><a id="link" href="#" class="style-scope state-modifier">US6660742B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-09-19</span>
                    <span class="td style-scope patent-result">2003-12-09</span>
                    <span class="td style-scope patent-result">Taiho Pharmaceutical Co. Ltd.</span>
                    <span class="td style-scope patent-result">Compositions and methods of the use thereof achiral analogues of CC-1065 and the duocarmycins 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003101283A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003101283A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-06-04</span>
                    <span class="td style-scope patent-result">2003-12-11</span>
                    <span class="td style-scope patent-result">Incyte Corporation</span>
                    <span class="td style-scope patent-result">Diagnostics markers for lung cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003101400A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003101400A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-06-04</span>
                    <span class="td style-scope patent-result">2003-12-11</span>
                    <span class="td style-scope patent-result">Avalon Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Cancer-linked gene as target for chemotherapy 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003104270A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003104270A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-06-06</span>
                    <span class="td style-scope patent-result">2003-12-18</span>
                    <span class="td style-scope patent-result">Ingenium Pharmaceuticals Ag</span>
                    <span class="td style-scope patent-result">Dudulin 2 genes, expression products, non-human animal model: uses in human hematological disease 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030232350A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030232350A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-11-13</span>
                    <span class="td style-scope patent-result">2003-12-18</span>
                    <span class="td style-scope patent-result">Eos Biotechnology, Inc.</span>
                    <span class="td style-scope patent-result">Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003104275A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003104275A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-06-06</span>
                    <span class="td style-scope patent-result">2003-12-18</span>
                    <span class="td style-scope patent-result">Oncotherapy Science, Inc.</span>
                    <span class="td style-scope patent-result">Genes and polypeptides relating to human colon cancers 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003104399A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003104399A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-06-07</span>
                    <span class="td style-scope patent-result">2003-12-18</span>
                    <span class="td style-scope patent-result">Avalon Pharmaceuticals, Inc</span>
                    <span class="td style-scope patent-result">Cancer-linked gene as target for chemotherapy 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030232056A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030232056A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-09-10</span>
                    <span class="td style-scope patent-result">2003-12-18</span>
                    <span class="td style-scope patent-result">Corixa Corporation</span>
                    <span class="td style-scope patent-result">Compositions and methods for the therapy and diagnosis of ovarian cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003105758A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003105758A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-06-12</span>
                    <span class="td style-scope patent-result">2003-12-24</span>
                    <span class="td style-scope patent-result">Avalon Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Cancer-linked gene as target for chemotherapy 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004000997A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004000997A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-03-19</span>
                    <span class="td style-scope patent-result">2003-12-31</span>
                    <span class="td style-scope patent-result">Curagen Corporation</span>
                    <span class="td style-scope patent-result">Therapeutic polypeptides, nucleic acids encoding same, and methods of use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004000221A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004000221A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-06-20</span>
                    <span class="td style-scope patent-result">2003-12-31</span>
                    <span class="td style-scope patent-result">The Regents Of The University Of California</span>
                    <span class="td style-scope patent-result">Compositions and methods for modulating lymphocyte activity 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004001004A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004001004A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-06-21</span>
                    <span class="td style-scope patent-result">2003-12-31</span>
                    <span class="td style-scope patent-result">Johns Hopkins University School Of Medicine</span>
                    <span class="td style-scope patent-result">Membrane associated tumor endothelium markers 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20040001827A1/en"><a id="link" href="#" class="style-scope state-modifier">US20040001827A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-06-28</span>
                    <span class="td style-scope patent-result">2004-01-01</span>
                    <span class="td style-scope patent-result">Dennis Mark S.</span>
                    <span class="td style-scope patent-result">Serum albumin binding peptides for tumor targeting 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20040005538A1/en"><a id="link" href="#" class="style-scope state-modifier">US20040005538A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-04-11</span>
                    <span class="td style-scope patent-result">2004-01-08</span>
                    <span class="td style-scope patent-result">Xiaojiang Chen</span>
                    <span class="td style-scope patent-result">Three-dimensional structure of complement receptor type 2 and uses thereof 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20040005563A1/en"><a id="link" href="#" class="style-scope state-modifier">US20040005563A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-06-18</span>
                    <span class="td style-scope patent-result">2004-01-08</span>
                    <span class="td style-scope patent-result">Eos Biotechnology, Inc.</span>
                    <span class="td style-scope patent-result">Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004005598A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2004005598A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-07-03</span>
                    <span class="td style-scope patent-result">2004-01-15</span>
                    <span class="td style-scope patent-result">Saurer Gmbh &amp; Co. Kg</span>
                    <span class="td style-scope patent-result">Drafting assembly for spinning machines comprising a compacting device 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004009622A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004009622A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-07-19</span>
                    <span class="td style-scope patent-result">2004-01-29</span>
                    <span class="td style-scope patent-result">Cellzome Ag</span>
                    <span class="td style-scope patent-result">Protein complexes of cellular networks underlying the development of cancer and other diseases 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20040018194A1/en"><a id="link" href="#" class="style-scope state-modifier">US20040018194A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-11-28</span>
                    <span class="td style-scope patent-result">2004-01-29</span>
                    <span class="td style-scope patent-result">Francisco Joseph A.</span>
                    <span class="td style-scope patent-result">Recombinant anti-CD30 antibodies and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004011611A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004011611A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-07-25</span>
                    <span class="td style-scope patent-result">2004-02-05</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Taci antibodies and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20040022727A1/en"><a id="link" href="#" class="style-scope state-modifier">US20040022727A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-06-18</span>
                    <span class="td style-scope patent-result">2004-02-05</span>
                    <span class="td style-scope patent-result">Martin Stanton</span>
                    <span class="td style-scope patent-result">Aptamer-toxin molecules and methods for using same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004015426A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2004015426A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-08-06</span>
                    <span class="td style-scope patent-result">2004-02-19</span>
                    <span class="td style-scope patent-result">Bayer Healthcare Ag</span>
                    <span class="td style-scope patent-result">Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 5(cxcr5) 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004016225A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004016225A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-08-19</span>
                    <span class="td style-scope patent-result">2004-02-26</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Compositions and methods for the diagnosis and treatment of tumor 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP1394274A2/en"><a id="link" href="#" class="style-scope state-modifier">EP1394274A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-08-06</span>
                    <span class="td style-scope patent-result">2004-03-03</span>
                    <span class="td style-scope patent-result">Genox Research, Inc.</span>
                    <span class="td style-scope patent-result">Methods of testing for bronchial asthma or chronic obstructive pulmonary disease 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20040044179A1/en"><a id="link" href="#" class="style-scope state-modifier">US20040044179A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-07-25</span>
                    <span class="td style-scope patent-result">2004-03-04</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Secreted and transmembrane polypeptides and nucleic acids encoding the same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004020595A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004020595A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-08-29</span>
                    <span class="td style-scope patent-result">2004-03-11</span>
                    <span class="td style-scope patent-result">Five Prime Therapeutics, Inc.</span>
                    <span class="td style-scope patent-result">Novel human polypeptides encoded by polynucleotides 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004020583A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004020583A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-08-27</span>
                    <span class="td style-scope patent-result">2004-03-11</span>
                    <span class="td style-scope patent-result">Bristol-Myers Squibb Company</span>
                    <span class="td style-scope patent-result">Polynucleotide predictor set for identifying protein tyrosine kinase modulators 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20040052793A1/en"><a id="link" href="#" class="style-scope state-modifier">US20040052793A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-02-22</span>
                    <span class="td style-scope patent-result">2004-03-18</span>
                    <span class="td style-scope patent-result">Carter Paul J.</span>
                    <span class="td style-scope patent-result">Caspase activivated prodrugs therapy 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004022778A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2004022778A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-09-05</span>
                    <span class="td style-scope patent-result">2004-03-18</span>
                    <span class="td style-scope patent-result">Garvan Institute Of Medical Research</span>
                    <span class="td style-scope patent-result">Methods of diagnosis and prognosis of ovarian cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004022709A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004022709A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-09-06</span>
                    <span class="td style-scope patent-result">2004-03-18</span>
                    <span class="td style-scope patent-result">Mannkind Corporation</span>
                    <span class="td style-scope patent-result">Epitope sequences 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004027049A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004027049A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-09-20</span>
                    <span class="td style-scope patent-result">2004-04-01</span>
                    <span class="td style-scope patent-result">Astral, Inc.</span>
                    <span class="td style-scope patent-result">Methods and compositions to generate and control the effector profile of t cells by simultaneous loading and activation of selected subsets of antigen presenting cells 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2004113151A/en"><a id="link" href="#" class="style-scope state-modifier">JP2004113151A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-09-27</span>
                    <span class="td style-scope patent-result">2004-04-15</span>
                    <span class="td style-scope patent-result">Sankyo Co Ltd</span>
                    <span class="td style-scope patent-result">Oncogene and its application 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004031238A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004031238A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-10-03</span>
                    <span class="td style-scope patent-result">2004-04-15</span>
                    <span class="td style-scope patent-result">Mcgill Univeristy</span>
                    <span class="td style-scope patent-result">Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004032842A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004032842A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-10-04</span>
                    <span class="td style-scope patent-result">2004-04-22</span>
                    <span class="td style-scope patent-result">Van Andel Research Institute</span>
                    <span class="td style-scope patent-result">Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004032828A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004032828A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-07-31</span>
                    <span class="td style-scope patent-result">2004-04-22</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004040000A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004040000A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-09-09</span>
                    <span class="td style-scope patent-result">2004-05-13</span>
                    <span class="td style-scope patent-result">Nura, Inc</span>
                    <span class="td style-scope patent-result">G protein coupled receptors and uses thereof 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004042346A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004042346A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-04-24</span>
                    <span class="td style-scope patent-result">2004-05-21</span>
                    <span class="td style-scope patent-result">Expression Diagnostics, Inc.</span>
                    <span class="td style-scope patent-result">Methods and compositions for diagnosing and monitoring transplant rejection 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004044178A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004044178A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-11-13</span>
                    <span class="td style-scope patent-result">2004-05-27</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Methods and compositions for diagnosing dysplasia 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004043963A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2004043963A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-11-14</span>
                    <span class="td style-scope patent-result">2004-05-27</span>
                    <span class="td style-scope patent-result">Spirogen Limited</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004043361A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004043361A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-11-08</span>
                    <span class="td style-scope patent-result">2004-05-27</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Compositions and methods for the treatment of natural killer cell related diseases 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004045553A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004045553A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-11-15</span>
                    <span class="td style-scope patent-result">2004-06-03</span>
                    <span class="td style-scope patent-result">The Board Of Trustees Of The University Of Arkansas</span>
                    <span class="td style-scope patent-result">Ca125 gene and its use for diagnostic and therapeutic interventions 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004046342A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004046342A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-11-20</span>
                    <span class="td style-scope patent-result">2004-06-03</span>
                    <span class="td style-scope patent-result">Biogen Idec Inc.</span>
                    <span class="td style-scope patent-result">Novel gene targets and ligands that bind thereto for treatment and diagnosis of carcinomas 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004045520A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004045520A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-11-15</span>
                    <span class="td style-scope patent-result">2004-06-03</span>
                    <span class="td style-scope patent-result">Musc Foundation For Research Development</span>
                    <span class="td style-scope patent-result">Complement receptor 2 targeted complement modulators 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004045516A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004045516A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-11-15</span>
                    <span class="td style-scope patent-result">2004-06-03</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Compositions and methods for the diagnosis and treatment of tumor 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004047749A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004047749A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-11-21</span>
                    <span class="td style-scope patent-result">2004-06-10</span>
                    <span class="td style-scope patent-result">University Of Utah Research Foundation</span>
                    <span class="td style-scope patent-result">Purinergic modulation of smell 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004048938A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004048938A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-11-26</span>
                    <span class="td style-scope patent-result">2004-06-10</span>
                    <span class="td style-scope patent-result">Protein Design Labs, Inc.</span>
                    <span class="td style-scope patent-result">Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004053079A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004053079A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-12-06</span>
                    <span class="td style-scope patent-result">2004-06-24</span>
                    <span class="td style-scope patent-result">Diadexus, Inc.</span>
                    <span class="td style-scope patent-result">Compositions, splice variants and methods relating to ovarian specific genes and proteins 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20040121940A1/en"><a id="link" href="#" class="style-scope state-modifier">US20040121940A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-03-23</span>
                    <span class="td style-scope patent-result">2004-06-24</span>
                    <span class="td style-scope patent-result">De Groot Franciscus Marinus Hendrikus</span>
                    <span class="td style-scope patent-result">Elongated and multiple spacers in activatible produgs 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6759509B1/en"><a id="link" href="#" class="style-scope state-modifier">US6759509B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-11-05</span>
                    <span class="td style-scope patent-result">2004-07-06</span>
                    <span class="td style-scope patent-result">Bristol-Myers Squibb Company</span>
                    <span class="td style-scope patent-result">Branched peptide linkers 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004058309A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2004058309A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-12-23</span>
                    <span class="td style-scope patent-result">2004-07-15</span>
                    <span class="td style-scope patent-result">Human Genome Sciences, Inc.</span>
                    <span class="td style-scope patent-result">Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20040138269A1/en"><a id="link" href="#" class="style-scope state-modifier">US20040138269A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-10-11</span>
                    <span class="td style-scope patent-result">2004-07-15</span>
                    <span class="td style-scope patent-result">Sugen, Inc.</span>
                    <span class="td style-scope patent-result">Substituted pyrroles as kinase inhibitors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP1439393A2/en"><a id="link" href="#" class="style-scope state-modifier">EP1439393A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-12-13</span>
                    <span class="td style-scope patent-result">2004-07-21</span>
                    <span class="td style-scope patent-result">Bayer Healthcare LLC</span>
                    <span class="td style-scope patent-result">Detection methods using TIMP 1 for colon cancer diagnosis 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004063362A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004063362A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-01-10</span>
                    <span class="td style-scope patent-result">2004-07-29</span>
                    <span class="td style-scope patent-result">Cyclacel Limited</span>
                    <span class="td style-scope patent-result">Cell cycle progression proteins 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004063355A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004063355A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-01-10</span>
                    <span class="td style-scope patent-result">2004-07-29</span>
                    <span class="td style-scope patent-result">Protein Design Labs, Inc.</span>
                    <span class="td style-scope patent-result">Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004063709A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004063709A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-01-08</span>
                    <span class="td style-scope patent-result">2004-07-29</span>
                    <span class="td style-scope patent-result">Bristol-Myers Squibb Company</span>
                    <span class="td style-scope patent-result">Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004065576A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004065576A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-01-15</span>
                    <span class="td style-scope patent-result">2004-08-05</span>
                    <span class="td style-scope patent-result">Millennium Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Methods and compositions for the treatment of urological disorder using differential expressed polypeptides 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004065577A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004065577A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-01-14</span>
                    <span class="td style-scope patent-result">2004-08-05</span>
                    <span class="td style-scope patent-result">Bristol-Myers Squibb Company</span>
                    <span class="td style-scope patent-result">Polynucleotides and polypeptides associated with the nf-kb pathway 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004074320A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004074320A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-02-14</span>
                    <span class="td style-scope patent-result">2004-09-02</span>
                    <span class="td style-scope patent-result">Sagres Discovery, Inc.</span>
                    <span class="td style-scope patent-result">Therapeutic targets in cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20040197325A1/en"><a id="link" href="#" class="style-scope state-modifier">US20040197325A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-12-20</span>
                    <span class="td style-scope patent-result">2004-10-07</span>
                    <span class="td style-scope patent-result">Debbie Law</span>
                    <span class="td style-scope patent-result">Antibodies against GPR64 and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20040249130A1/en"><a id="link" href="#" class="style-scope state-modifier">US20040249130A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-06-18</span>
                    <span class="td style-scope patent-result">2004-12-09</span>
                    <span class="td style-scope patent-result">Martin Stanton</span>
                    <span class="td style-scope patent-result">Aptamer-toxin molecules and methods for using same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6835807B1/en"><a id="link" href="#" class="style-scope state-modifier">US6835807B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-05-22</span>
                    <span class="td style-scope patent-result">2004-12-28</span>
                    <span class="td style-scope patent-result">Daiichi Pharmaceuticals Co., Ltd.</span>
                    <span class="td style-scope patent-result">Drug complex and drug delivery system 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2005023814A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2005023814A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-09-11</span>
                    <span class="td style-scope patent-result">2005-03-17</span>
                    <span class="td style-scope patent-result">Spirogen Limited</span>
                    <span class="td style-scope patent-result">Synthesis of protected pyrrolobenzodiazepines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6884799B2/en"><a id="link" href="#" class="style-scope state-modifier">US6884799B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-03-31</span>
                    <span class="td style-scope patent-result">2005-04-26</span>
                    <span class="td style-scope patent-result">Council Of Scientific And Industrial Research</span>
                    <span class="td style-scope patent-result">Non-cross-linking pyrrolo[2,1-c][1,4]benzodiazepines and process thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2005040170A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2005040170A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-10-22</span>
                    <span class="td style-scope patent-result">2005-05-06</span>
                    <span class="td style-scope patent-result">Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2005042535A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2005042535A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-10-22</span>
                    <span class="td style-scope patent-result">2005-05-12</span>
                    <span class="td style-scope patent-result">Spirogen Limited</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2005079479A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2005079479A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-02-17</span>
                    <span class="td style-scope patent-result">2005-09-01</span>
                    <span class="td style-scope patent-result">Absalus, Inc.</span>
                    <span class="td style-scope patent-result">Super-humanized antibodies against respiratory syncytial virus 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2005082023A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2005082023A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-02-23</span>
                    <span class="td style-scope patent-result">2005-09-09</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Heterocyclic self-immolative linkers and conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2005085250A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2005085250A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-03-01</span>
                    <span class="td style-scope patent-result">2005-09-15</span>
                    <span class="td style-scope patent-result">Spirogen Limited</span>
                    <span class="td style-scope patent-result">C8, c8' linked 5-oxo-1,2,3,11a-tetrahydro-5h-pyrrolo[2,1-c][1,4]benzodiazepine dimers with 1h-pyrrole-dicarboxylic acid amide linkers and oligomeric analogs therof as well as related compounds for the treatment of proliferative diseases 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2005085177A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2005085177A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-03-01</span>
                    <span class="td style-scope patent-result">2005-09-15</span>
                    <span class="td style-scope patent-result">Spirogen Limited</span>
                    <span class="td style-scope patent-result">Biaryl amino acids and their use in dna binding oligomers 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2005085260A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2005085260A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-03-09</span>
                    <span class="td style-scope patent-result">2005-09-15</span>
                    <span class="td style-scope patent-result">Spirogen Limited</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2005085259A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2005085259A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-03-01</span>
                    <span class="td style-scope patent-result">2005-09-15</span>
                    <span class="td style-scope patent-result">Spirogen Limited</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2005085251A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2005085251A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-03-01</span>
                    <span class="td style-scope patent-result">2005-09-15</span>
                    <span class="td style-scope patent-result">Spirogen Limited</span>
                    <span class="td style-scope patent-result">11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2005105113A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2005105113A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-04-27</span>
                    <span class="td style-scope patent-result">2005-11-10</span>
                    <span class="td style-scope patent-result">Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) [S.A.S.]</span>
                    <span class="td style-scope patent-result">Therapeutic compositions containing at least one pyrrolobenzodiazepine derivative and fludarabine 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2005110423A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2005110423A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-05-13</span>
                    <span class="td style-scope patent-result">2005-11-24</span>
                    <span class="td style-scope patent-result">Spirogen Limited</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine therapeutic agents useful in the treatment of leukaemias 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20050271615A1/en"><a id="link" href="#" class="style-scope state-modifier">US20050271615A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-08-30</span>
                    <span class="td style-scope patent-result">2005-12-08</span>
                    <span class="td style-scope patent-result">Doron Shabat</span>
                    <span class="td style-scope patent-result">Self-immolative dendrimers releasing many active moieties upon a single activating event 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20060116422A1/en"><a id="link" href="#" class="style-scope state-modifier">US20060116422A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-11-14</span>
                    <span class="td style-scope patent-result">2006-06-01</span>
                    <span class="td style-scope patent-result">De Groot Franciscus Marinus H</span>
                    <span class="td style-scope patent-result">Prodrugs built as multiple self-elimination-release spacers 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2006065533A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2006065533A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-11-29</span>
                    <span class="td style-scope patent-result">2006-06-22</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">Engineered antibodies and immunoconjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2006111759A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2006111759A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-04-21</span>
                    <span class="td style-scope patent-result">2006-10-26</span>
                    <span class="td style-scope patent-result">Spirogen Limited</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2007039752A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2007039752A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-10-05</span>
                    <span class="td style-scope patent-result">2007-04-12</span>
                    <span class="td style-scope patent-result">Spirogen Limited</span>
                    <span class="td style-scope patent-result">Alkyl 4- [4- (5-oxo-2, 3, 5, 11a-tetrahyd0-5h-pyrr0l0 [2, 1-c] [1, 4] benzodiazepine-8-yloxy) -butyrylamino]-1h-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2007044515A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2007044515A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-10-07</span>
                    <span class="td style-scope patent-result">2007-04-19</span>
                    <span class="td style-scope patent-result">Exelixis, Inc.</span>
                    <span class="td style-scope patent-result">Azetidines as mek inhibitors for the treatment of proliferative diseases 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20070154906A1/en"><a id="link" href="#" class="style-scope state-modifier">US20070154906A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-10-05</span>
                    <span class="td style-scope patent-result">2007-07-05</span>
                    <span class="td style-scope patent-result">Spirogen Ltd.</span>
                    <span class="td style-scope patent-result">Methods to identify therapeutic candidates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP1813614A1/en"><a id="link" href="#" class="style-scope state-modifier">EP1813614A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-01-25</span>
                    <span class="td style-scope patent-result">2007-08-01</span>
                    <span class="td style-scope patent-result">Sanofi-Aventis</span>
                    <span class="td style-scope patent-result">Cytotoxic agents comprising new tomaymycin derivatives 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20070185336A1/en"><a id="link" href="#" class="style-scope state-modifier">US20070185336A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-03-03</span>
                    <span class="td style-scope patent-result">2007-08-09</span>
                    <span class="td style-scope patent-result">Degussa Ag</span>
                    <span class="td style-scope patent-result">Process for preparing n-protected 4-ketoproline derivatives 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2008010101A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2008010101A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-07-18</span>
                    <span class="td style-scope patent-result">2008-01-24</span>
                    <span class="td style-scope patent-result">Sanofi-Aventis</span>
                    <span class="td style-scope patent-result">Antagonist antibody against epha2 for the treatment of cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2008022152A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2008022152A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-08-14</span>
                    <span class="td style-scope patent-result">2008-02-21</span>
                    <span class="td style-scope patent-result">Xencor, Inc.</span>
                    <span class="td style-scope patent-result">Optimized antibodies that target cd19 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2008047242A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2008047242A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-10-19</span>
                    <span class="td style-scope patent-result">2008-04-24</span>
                    <span class="td style-scope patent-result">Sanofi-Aventis</span>
                    <span class="td style-scope patent-result">Novel anti-cd38 antibodies for the treatment of cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20080092940A1/en"><a id="link" href="#" class="style-scope state-modifier">US20080092940A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-12-24</span>
                    <span class="td style-scope patent-result">2008-04-24</span>
                    <span class="td style-scope patent-result">Showa Denko K.K.</span>
                    <span class="td style-scope patent-result">Production Method of Thermoelectric Semiconductor Alloy, Thermoelectric Conversion Module and Thermoelectric Power Generating Device 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN101171257A/en"><a id="link" href="#" class="style-scope state-modifier">CN101171257A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-04-21</span>
                    <span class="td style-scope patent-result">2008-04-30</span>
                    <span class="td style-scope patent-result">斯皮罗根有限公司</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines compound 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2008050140A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2008050140A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-10-27</span>
                    <span class="td style-scope patent-result">2008-05-02</span>
                    <span class="td style-scope patent-result">Spirogen Limited</span>
                    <span class="td style-scope patent-result">Compounds for treatment of parasitic infection 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20080112961A1/en"><a id="link" href="#" class="style-scope state-modifier">US20080112961A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-10-09</span>
                    <span class="td style-scope patent-result">2008-05-15</span>
                    <span class="td style-scope patent-result">Macrogenics, Inc.</span>
                    <span class="td style-scope patent-result">Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2008070593A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2008070593A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-12-01</span>
                    <span class="td style-scope patent-result">2008-06-12</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">Variant target binding agents and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20080206239A1/en"><a id="link" href="#" class="style-scope state-modifier">US20080206239A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-02-03</span>
                    <span class="td style-scope patent-result">2008-08-28</span>
                    <span class="td style-scope patent-result">Antitope Limited</span>
                    <span class="td style-scope patent-result">Human Antibodies And Proteins 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20080213289A1/en"><a id="link" href="#" class="style-scope state-modifier">US20080213289A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-07-31</span>
                    <span class="td style-scope patent-result">2008-09-04</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">Recombinant anti-cd30 antibodies and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2019104A1/en"><a id="link" href="#" class="style-scope state-modifier">EP2019104A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-07-19</span>
                    <span class="td style-scope patent-result">2009-01-28</span>
                    <span class="td style-scope patent-result">Sanofi-Aventis</span>
                    <span class="td style-scope patent-result">Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2009016647A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2009016647A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-08-01</span>
                    <span class="td style-scope patent-result">2009-02-05</span>
                    <span class="td style-scope patent-result">Council Of Scientific &amp; Industrial Research</span>
                    <span class="td style-scope patent-result">Pyrrolo [2,1-c][1, 4] benzodiazepine-glycoside prodrugs useful as a selective anti tumor agent 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7498298B2/en"><a id="link" href="#" class="style-scope state-modifier">US7498298B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-11-06</span>
                    <span class="td style-scope patent-result">2009-03-03</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">Monomethylvaline compounds capable of conjugation to ligands 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7521541B2/en"><a id="link" href="#" class="style-scope state-modifier">US7521541B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-09-23</span>
                    <span class="td style-scope patent-result">2009-04-21</span>
                    <span class="td style-scope patent-result">Genetech Inc.</span>
                    <span class="td style-scope patent-result">Cysteine engineered antibodies and conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2009052249A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2009052249A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-10-19</span>
                    <span class="td style-scope patent-result">2009-04-23</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2009060215A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2009060215A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-11-09</span>
                    <span class="td style-scope patent-result">2009-05-14</span>
                    <span class="td style-scope patent-result">Spirogen Limited</span>
                    <span class="td style-scope patent-result">Polyamides 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2009060208A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2009060208A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-11-09</span>
                    <span class="td style-scope patent-result">2009-05-14</span>
                    <span class="td style-scope patent-result">Spirogen Limited</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20090148942A1/en"><a id="link" href="#" class="style-scope state-modifier">US20090148942A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-04-19</span>
                    <span class="td style-scope patent-result">2009-06-11</span>
                    <span class="td style-scope patent-result">Mcdonagh Charlotte</span>
                    <span class="td style-scope patent-result">Humanized anti-cd70 binding agents and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2009117531A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2009117531A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-03-18</span>
                    <span class="td style-scope patent-result">2009-09-24</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">Auristatin drug linker conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20090274713A1/en"><a id="link" href="#" class="style-scope state-modifier">US20090274713A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-04-30</span>
                    <span class="td style-scope patent-result">2009-11-05</span>
                    <span class="td style-scope patent-result">Immunogen Inc.</span>
                    <span class="td style-scope patent-result">Cross-linkers and their uses 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2010010347A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2010010347A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-07-22</span>
                    <span class="td style-scope patent-result">2010-01-28</span>
                    <span class="td style-scope patent-result">Spirogen Limited</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20100028346A1/en"><a id="link" href="#" class="style-scope state-modifier">US20100028346A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-06-16</span>
                    <span class="td style-scope patent-result">2010-02-04</span>
                    <span class="td style-scope patent-result">Immunogen Inc.</span>
                    <span class="td style-scope patent-result">Novel synergistic effects 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2010043880A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2010043880A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-10-17</span>
                    <span class="td style-scope patent-result">2010-04-22</span>
                    <span class="td style-scope patent-result">Spirogen Limited</span>
                    <span class="td style-scope patent-result">Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2010043877A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2010043877A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-10-17</span>
                    <span class="td style-scope patent-result">2010-04-22</span>
                    <span class="td style-scope patent-result">Spirogen Limited</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7723485B2/en"><a id="link" href="#" class="style-scope state-modifier">US7723485B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-05-08</span>
                    <span class="td style-scope patent-result">2010-05-25</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2010091150A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2010091150A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-02-05</span>
                    <span class="td style-scope patent-result">2010-08-12</span>
                    <span class="td style-scope patent-result">Immunogen, Inc.</span>
                    <span class="td style-scope patent-result">Novel benzodiazepine derivatives 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2010095031A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2010095031A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-02-23</span>
                    <span class="td style-scope patent-result">2010-08-26</span>
                    <span class="td style-scope patent-result">Glenmark Pharmaceuticals S.A.</span>
                    <span class="td style-scope patent-result">Humanized antibodies that bind to cd19 and their uses 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20110039969A1/en"><a id="link" href="#" class="style-scope state-modifier">US20110039969A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-05-11</span>
                    <span class="td style-scope patent-result">2011-02-17</span>
                    <span class="td style-scope patent-result">The General Hospital Corporation</span>
                    <span class="td style-scope patent-result">Methods for making oxidation resistant polymeric material 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2011023883A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2011023883A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-08-25</span>
                    <span class="td style-scope patent-result">2011-03-03</span>
                    <span class="td style-scope patent-result">Sanofi-Aventis</span>
                    <span class="td style-scope patent-result">Conjugates of pyrrolo[1,4]benzodiazepine dimers as anticancer agents 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2298817A1/en"><a id="link" href="#" class="style-scope state-modifier">EP2298817A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-12-03</span>
                    <span class="td style-scope patent-result">2011-03-23</span>
                    <span class="td style-scope patent-result">Alexion Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Hybrid antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20110070227A1/en"><a id="link" href="#" class="style-scope state-modifier">US20110070227A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-09-18</span>
                    <span class="td style-scope patent-result">2011-03-24</span>
                    <span class="td style-scope patent-result">Anna-Marie Novotney-Barry</span>
                    <span class="td style-scope patent-result">Treatment of Autoimmune and Inflammatory Diseases 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2011038159A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2011038159A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-09-24</span>
                    <span class="td style-scope patent-result">2011-03-31</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">Dr5 ligand drug conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20110091372A1/en"><a id="link" href="#" class="style-scope state-modifier">US20110091372A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-09-01</span>
                    <span class="td style-scope patent-result">2011-04-21</span>
                    <span class="td style-scope patent-result">Abbott Laboratories</span>
                    <span class="td style-scope patent-result">Dual Variable Domain Immunoglobulins and Uses Thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20110195021A1/en"><a id="link" href="#" class="style-scope state-modifier">US20110195021A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-02-10</span>
                    <span class="td style-scope patent-result">2011-08-11</span>
                    <span class="td style-scope patent-result">Immunogen Inc.</span>
                    <span class="td style-scope patent-result">Cd20 antibodies and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20110195022A1/en"><a id="link" href="#" class="style-scope state-modifier">US20110195022A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-02-10</span>
                    <span class="td style-scope patent-result">2011-08-11</span>
                    <span class="td style-scope patent-result">Immunogen Inc.</span>
                    <span class="td style-scope patent-result">Cd20 antibodies and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2011100227A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2011100227A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-02-09</span>
                    <span class="td style-scope patent-result">2011-08-18</span>
                    <span class="td style-scope patent-result">Bristol-Myers Squibb Company</span>
                    <span class="td style-scope patent-result">Benzylpyrrolidinone derivatives as modulators of chemokine receptor activity 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2011130598A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2011130598A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-04-15</span>
                    <span class="td style-scope patent-result">2011-10-20</span>
                    <span class="td style-scope patent-result">Spirogen Limited</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines and conjugates thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2011130613A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2011130613A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-04-15</span>
                    <span class="td style-scope patent-result">2011-10-20</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">Targeted pyrrolobenzodiazapine conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2011128650A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2011128650A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-04-15</span>
                    <span class="td style-scope patent-result">2011-10-20</span>
                    <span class="td style-scope patent-result">Spirogen Limited</span>
                    <span class="td style-scope patent-result">Intermediates useful for the synthesis of pyrrolobenzodiazepines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2011130616A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2011130616A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-04-15</span>
                    <span class="td style-scope patent-result">2011-10-20</span>
                    <span class="td style-scope patent-result">Spirogen Limited</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines used to treat proliferative diseases 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2011130615A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2011130615A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-04-15</span>
                    <span class="td style-scope patent-result">2011-10-20</span>
                    <span class="td style-scope patent-result">Dr. Reddy's Laboratories Ltd.</span>
                    <span class="td style-scope patent-result">Preparation of lacosamide 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2011133039A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2011133039A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-04-21</span>
                    <span class="td style-scope patent-result">2011-10-27</span>
                    <span class="td style-scope patent-result">Syntarga B.V.</span>
                    <span class="td style-scope patent-result">Novel conjugates of cc-1065 analogs and bifunctional linkers 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2012014147A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2012014147A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-07-26</span>
                    <span class="td style-scope patent-result">2012-02-02</span>
                    <span class="td style-scope patent-result">Sanofi</span>
                    <span class="td style-scope patent-result">Anticancer derivatives, preparation thereof and therapeutic use thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2012064733A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2012064733A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-11-09</span>
                    <span class="td style-scope patent-result">2012-05-18</span>
                    <span class="td style-scope patent-result">Medimmune, Llc</span>
                    <span class="td style-scope patent-result">Antibody scaffold for homogenous conjugation 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2012112687A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2012112687A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-02-15</span>
                    <span class="td style-scope patent-result">2012-08-23</span>
                    <span class="td style-scope patent-result">Immunogen, Inc.</span>
                    <span class="td style-scope patent-result">Methods of preparation of conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20120233172A1/en"><a id="link" href="#" class="style-scope state-modifier">US20120233172A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-03-07</span>
                    <span class="td style-scope patent-result">2012-09-13</span>
                    <span class="td style-scope patent-result">Aptare, Inc.</span>
                    <span class="td style-scope patent-result">System to catalog and search point-in-time instances of a file system 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8321774B2/en"><a id="link" href="#" class="style-scope state-modifier">US8321774B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-04-09</span>
                    <span class="td style-scope patent-result">2012-11-27</span>
                    <span class="td style-scope patent-result">Siemens Aktiengesellschaft</span>
                    <span class="td style-scope patent-result">Method for fail-safe transmission, safety switching device and control unit 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2013041606A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2013041606A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-09-20</span>
                    <span class="td style-scope patent-result">2013-03-28</span>
                    <span class="td style-scope patent-result">Spirogen Sàrl</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2013053873A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2013053873A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-10-14</span>
                    <span class="td style-scope patent-result">2013-04-18</span>
                    <span class="td style-scope patent-result">Spirogen Sàrl</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2013055987A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2013055987A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-10-14</span>
                    <span class="td style-scope patent-result">2013-04-18</span>
                    <span class="td style-scope patent-result">Spirogen Sàrl</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines and conjugates thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2013055990A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2013055990A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-10-14</span>
                    <span class="td style-scope patent-result">2013-04-18</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines and targeted conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2013053871A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2013053871A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-10-14</span>
                    <span class="td style-scope patent-result">2013-04-18</span>
                    <span class="td style-scope patent-result">Spirogen Sàrl</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2013055993A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2013055993A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-10-14</span>
                    <span class="td style-scope patent-result">2013-04-18</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines and targeted conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2013053872A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2013053872A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-10-14</span>
                    <span class="td style-scope patent-result">2013-04-18</span>
                    <span class="td style-scope patent-result">Spirogen Sàrl</span>
                    <span class="td style-scope patent-result">Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20130244171A1/en"><a id="link" href="#" class="style-scope state-modifier">US20130244171A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-03-19</span>
                    <span class="td style-scope patent-result">2013-09-19</span>
                    <span class="td style-scope patent-result">Fuji Xerox Co., Ltd.</span>
                    <span class="td style-scope patent-result">Polyester resin for toner, electrostatic charge image developing toner, electrostatic charge image developer, toner cartridge, process cartridge, image forming apparatus, and image forming method 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2013164593A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2013164593A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-04-30</span>
                    <span class="td style-scope patent-result">2013-11-07</span>
                    <span class="td style-scope patent-result">Spirogen Sàrl</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2013164592A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2013164592A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-04-30</span>
                    <span class="td style-scope patent-result">2013-11-07</span>
                    <span class="td style-scope patent-result">Ucl Business Plc</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2013165940A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2013165940A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-05-01</span>
                    <span class="td style-scope patent-result">2013-11-07</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Anti-pmel17 antibodies and immunoconjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20130304357A1/en"><a id="link" href="#" class="style-scope state-modifier">US20130304357A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-05-14</span>
                    <span class="td style-scope patent-result">2013-11-14</span>
                    <span class="td style-scope patent-result">Southwest Research Institute</span>
                    <span class="td style-scope patent-result">Diesel Engine Operation for Fast Transient Response and Low Emissions 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2013177481A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2013177481A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-05-25</span>
                    <span class="td style-scope patent-result">2013-11-28</span>
                    <span class="td style-scope patent-result">Immunogen, Inc.</span>
                    <span class="td style-scope patent-result">Benzodiazepines and conjugates thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP5382792B2/en"><a id="link" href="#" class="style-scope state-modifier">JP5382792B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-08-14</span>
                    <span class="td style-scope patent-result">2014-01-08</span>
                    <span class="td style-scope patent-result">独立行政法人理化学研究所</span>
                    <span class="td style-scope patent-result">
  Method for simultaneously measuring primary and secondary photosensitivity anisotropy in optical second-order nonlinear thin film, apparatus for executing the method, and program for causing computer to execute the method
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014011518A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2014011518A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-07-09</span>
                    <span class="td style-scope patent-result">2014-01-16</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Immunoconjugates comprising anti-cd22 antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014011519A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2014011519A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-07-09</span>
                    <span class="td style-scope patent-result">2014-01-16</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Immunoconjugates comprising anti-cd79b antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014022679A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2014022679A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-08-02</span>
                    <span class="td style-scope patent-result">2014-02-06</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Anti-etbr antibodies and immunoconjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014031566A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2014031566A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-08-22</span>
                    <span class="td style-scope patent-result">2014-02-27</span>
                    <span class="td style-scope patent-result">Immunogen, Inc.</span>
                    <span class="td style-scope patent-result">Cytotoxic benzodiazepine derivatives 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014057117A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2014057117A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-10-12</span>
                    <span class="td style-scope patent-result">2014-04-17</span>
                    <span class="td style-scope patent-result">Adc Therapeutics Sàrl</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine-antibody conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014057074A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2014057074A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-10-12</span>
                    <span class="td style-scope patent-result">2014-04-17</span>
                    <span class="td style-scope patent-result">Spirogen Sàrl</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines and conjugates thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014057120A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2014057120A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-10-12</span>
                    <span class="td style-scope patent-result">2014-04-17</span>
                    <span class="td style-scope patent-result">Adc Therapeutics Sàrl</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine-antibody conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014057113A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2014057113A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-10-12</span>
                    <span class="td style-scope patent-result">2014-04-17</span>
                    <span class="td style-scope patent-result">Adc Therapeutics Sarl</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine - anti-psma antibody conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014057072A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2014057072A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-10-12</span>
                    <span class="td style-scope patent-result">2014-04-17</span>
                    <span class="td style-scope patent-result">Spirogen Sàrl</span>
                    <span class="td style-scope patent-result">Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014057119A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2014057119A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-10-12</span>
                    <span class="td style-scope patent-result">2014-04-17</span>
                    <span class="td style-scope patent-result">Adc Therapeutics Sàrl</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine-antibody conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014057122A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2014057122A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-10-12</span>
                    <span class="td style-scope patent-result">2014-04-17</span>
                    <span class="td style-scope patent-result">Adc Therapeutics Sàrl</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine-anti-cd22 antibody conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014057115A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2014057115A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-10-12</span>
                    <span class="td style-scope patent-result">2014-04-17</span>
                    <span class="td style-scope patent-result">Adc Therapeutics Sàrl</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine-anti-her2 antibody conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014057118A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2014057118A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-10-12</span>
                    <span class="td style-scope patent-result">2014-04-17</span>
                    <span class="td style-scope patent-result">Adc Therapeutics Sarl</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine-anti-cd22 antibody conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014057114A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2014057114A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-10-12</span>
                    <span class="td style-scope patent-result">2014-04-17</span>
                    <span class="td style-scope patent-result">Adc Therapeutics Sàrl</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine-anti-psma antibody conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014057073A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2014057073A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-10-12</span>
                    <span class="td style-scope patent-result">2014-04-17</span>
                    <span class="td style-scope patent-result">Spirogen Sàrl</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines and conjugates thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014080251A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2014080251A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-11-24</span>
                    <span class="td style-scope patent-result">2014-05-30</span>
                    <span class="td style-scope patent-result">Hangzhou Dac Biotech Co., Ltd.</span>
                    <span class="td style-scope patent-result">Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014096365A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2014096365A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-12-21</span>
                    <span class="td style-scope patent-result">2014-06-26</span>
                    <span class="td style-scope patent-result">Spirogen Sàrl</span>
                    <span class="td style-scope patent-result">Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014096368A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2014096368A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-12-21</span>
                    <span class="td style-scope patent-result">2014-06-26</span>
                    <span class="td style-scope patent-result">Spirogen Sàrl</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines and conjugates thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014130879A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2014130879A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-02-22</span>
                    <span class="td style-scope patent-result">2014-08-28</span>
                    <span class="td style-scope patent-result">Stem Centrx, Inc.</span>
                    <span class="td style-scope patent-result">Novel antibody conjugates and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014140174A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2014140174A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-03-13</span>
                    <span class="td style-scope patent-result">2014-09-18</span>
                    <span class="td style-scope patent-result">Spirogen Sàrl</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines and conjugates thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014140862A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2014140862A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-03-13</span>
                    <span class="td style-scope patent-result">2014-09-18</span>
                    <span class="td style-scope patent-result">Spirogen Sarl</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines and conjugates thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014159981A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2014159981A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-03-13</span>
                    <span class="td style-scope patent-result">2014-10-02</span>
                    <span class="td style-scope patent-result">Spirogen Sarl</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines and conjugates thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014174111A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2014174111A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-04-26</span>
                    <span class="td style-scope patent-result">2014-10-30</span>
                    <span class="td style-scope patent-result">Pierre Fabre Medicament</span>
                    <span class="td style-scope patent-result">Axl antibody-drug conjugate and its use for the treatment of cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2015031693A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2015031693A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-08-28</span>
                    <span class="td style-scope patent-result">2015-03-05</span>
                    <span class="td style-scope patent-result">Stem Centrx, Inc.</span>
                    <span class="td style-scope patent-result">Engineered anti-dll3 conjugates and methods of use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2015052533A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2015052533A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-10-11</span>
                    <span class="td style-scope patent-result">2015-04-16</span>
                    <span class="td style-scope patent-result">Spirogen Sàrl</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine-antibody conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2015052532A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2015052532A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-10-11</span>
                    <span class="td style-scope patent-result">2015-04-16</span>
                    <span class="td style-scope patent-result">Spirogen Sàrl</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine-antibody conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2015052534A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2015052534A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-10-11</span>
                    <span class="td style-scope patent-result">2015-04-16</span>
                    <span class="td style-scope patent-result">Spirogen Sàrl</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine-antibody conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2015052334A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2015052334A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-10-11</span>
                    <span class="td style-scope patent-result">2015-04-16</span>
                    <span class="td style-scope patent-result">Maersk Olie Og Gas A/S</span>
                    <span class="td style-scope patent-result">Seismic data processing method and apparatus 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2015052322A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2015052322A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-10-11</span>
                    <span class="td style-scope patent-result">2015-04-16</span>
                    <span class="td style-scope patent-result">Spirogen Sàrl</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines and conjugates thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2015052333A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2015052333A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-10-10</span>
                    <span class="td style-scope patent-result">2015-04-16</span>
                    <span class="td style-scope patent-result">Wwinn B.V.</span>
                    <span class="td style-scope patent-result">Module, system and method for detecting acoustical failure of a loudspeaker 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2015052332A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2015052332A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-10-11</span>
                    <span class="td style-scope patent-result">2015-04-16</span>
                    <span class="td style-scope patent-result">Continental Automotive Gmbh</span>
                    <span class="td style-scope patent-result">Injection valve and method for the operation of an injection valve 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2015052321A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2015052321A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-10-11</span>
                    <span class="td style-scope patent-result">2015-04-16</span>
                    <span class="td style-scope patent-result">Spirogen Sàrl</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines and conjugates thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2015052535A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2015052535A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-10-11</span>
                    <span class="td style-scope patent-result">2015-04-16</span>
                    <span class="td style-scope patent-result">Spirogen Sàrl</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine-antibody conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2015052335A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2015052335A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-10-11</span>
                    <span class="td style-scope patent-result">2015-04-16</span>
                    <span class="td style-scope patent-result">Cellectis</span>
                    <span class="td style-scope patent-result">Methods and kits for detecting nucleic acid sequences of interest using dna-binding protein domain 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2015095124A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2015095124A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-12-16</span>
                    <span class="td style-scope patent-result">2015-06-25</span>
                    <span class="td style-scope patent-result">Genentech Inc.</span>
                    <span class="td style-scope patent-result">Peptidomimetic compounds and antibody-drug conjugates thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2015112822A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2015112822A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-01-24</span>
                    <span class="td style-scope patent-result">2015-07-30</span>
                    <span class="td style-scope patent-result">Kolltan Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Antibody-drug conjugates targeting kit receptor and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2015159076A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2015159076A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-04-15</span>
                    <span class="td style-scope patent-result">2015-10-22</span>
                    <span class="td style-scope patent-result">Cancer Research Technology Limited</span>
                    <span class="td style-scope patent-result">Humanized anti-tn-muc1 antibodies and their conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20160074527A1/en"><a id="link" href="#" class="style-scope state-modifier">US20160074527A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-09-17</span>
                    <span class="td style-scope patent-result">2016-03-17</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines and antibody disulfide conjugates thereof 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20160075787A1/en"><a id="link" href="#" class="style-scope state-modifier">US20160075787A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-09-12</span>
                    <span class="td style-scope patent-result">2016-03-17</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Anti-cll-1 antibodies and immunoconjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2016037644A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2016037644A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-09-10</span>
                    <span class="td style-scope patent-result">2016-03-17</span>
                    <span class="td style-scope patent-result">Medimmune Limited</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines and conjugates thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2016053107A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2016053107A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-10-03</span>
                    <span class="td style-scope patent-result">2016-04-07</span>
                    <span class="td style-scope patent-result">Synaffix B.V.</span>
                    <span class="td style-scope patent-result">Sulfamide linker, conjugates thereof, and methods of preparation 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2016166299A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2016166299A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-04-15</span>
                    <span class="td style-scope patent-result">2016-10-20</span>
                    <span class="td style-scope patent-result">Van Berkel Patricius Hendrikus Cornelis</span>
                    <span class="td style-scope patent-result">Site-specific antibody-drug conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2016166305A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2016166305A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-04-15</span>
                    <span class="td style-scope patent-result">2016-10-20</span>
                    <span class="td style-scope patent-result">Cancer Research Technology Limited</span>
                    <span class="td style-scope patent-result">Site-specific antibody-drug conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2016166307A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2016166307A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-04-15</span>
                    <span class="td style-scope patent-result">2016-10-20</span>
                    <span class="td style-scope patent-result">Van Berkel Patricius Hendrikus Cornelis</span>
                    <span class="td style-scope patent-result">Site-specific antibody-drug conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2016166302A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2016166302A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-04-15</span>
                    <span class="td style-scope patent-result">2016-10-20</span>
                    <span class="td style-scope patent-result">Van Berkel Patricius Hendrikus Cornelis</span>
                    <span class="td style-scope patent-result">Humanized anti-axl antibodies and their conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2016166298A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2016166298A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-04-15</span>
                    <span class="td style-scope patent-result">2016-10-20</span>
                    <span class="td style-scope patent-result">Van Berkel Patricius Hendrikus Cornelis</span>
                    <span class="td style-scope patent-result">Site-specific antibody-drug conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2016166297A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2016166297A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-04-15</span>
                    <span class="td style-scope patent-result">2016-10-20</span>
                    <span class="td style-scope patent-result">Van Berkel Patricius Hendrikus Cornelis</span>
                    <span class="td style-scope patent-result">Site-specific antibody-drug conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20170239365A1/en"><a id="link" href="#" class="style-scope state-modifier">US20170239365A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-09-12</span>
                    <span class="td style-scope patent-result">2017-08-24</span>
                    <span class="td style-scope patent-result">Medimmune Limited</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines and conjugates thereof 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2018069490A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2018069490A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-10-14</span>
                    <span class="td style-scope patent-result">2018-04-19</span>
                    <span class="td style-scope patent-result">Medimmune Limited</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine conjugates 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  <template is="dom-repeat" class="style-scope patent-result"></template>

                </div>
              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner, † Cited by third party</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="nplCitations" class="scroll-target style-scope patent-result">
              Non-Patent Citations (459)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Adair et al., "Antibody-drug conjugates—a perfect synergy," Exp. Opin. Biol. Ther. (2012), pp. 1-16.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Adams et al., "Molecular modelling of a sequence-specific DNA-binding agent based on the pyrrolo[2,1-c][1,4]benzodiazepines," Pharm. Pharmacol. Commun. (1999) 5:555-560.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Aird et al., "ABCB1 genetic polymorphism influences the pharmacology of the new pyrrolobenzodiazepine derivative SJG-136," Pharmacogenomics Journal (2008) 8(4):289-296.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Alley et al., "SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross- linking agent with potent and broad spectrum antitumor activity. Part 2: Efficacy evaluations," Cancer Res. (2004) 64:6700-6706.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Alley, M.C., "Efficacy evaluations of SJG-136 (NSC 694501), a novel pyrrolobenzodiazepine dimer with broad spectrum antitumor activity," Proceedings of the American Association for Cancer Research Annual Meeting (Mar. 2002) 43:63.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Alley, S. C., "Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates" Bioconjugate Chem 2008, 19, 759-765.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Althius, T. H. and Hess, H. J., "Synthesis and Identification of the Major Metabolites of Prazosin Formed in Dog and Rat," J. Medicinal Chem. (1977) 20(1):146-148.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Altuvia et al., "Ranking potential binding peptides to MHC molecules by a computational threading approach." J. Mol. Biol., 249, 244-250 (1995).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Amiel J., et al., "Heterozygous endothelin receptor B {EDNRB) mutations in isolated Hirschsprung disease," Hum. Mol. Genet. 5, 355-357, 1996.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Amir et al., "Self-lmmolative Dendrimers," (2003) Angew. Chem. Int. Ed. 42:4494-4499.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Amsberry, et al., "The Lactonization of 2'-Hydroxyhydrocinnamic Acid Amides: A Potential Prodrug for Amines," (1990) J. Org. Chem. 55:5867-5877.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Antonow, D. et al., "Structure-activity relationships of monomeric C2-aryl pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumor agents."J Med Chem. Apr. 8, 2010;53(7):2927-41.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Antonow, D. et al., "Synthesis of DNA-lnteractive Pyrrolo [2,1-c][1,4] benzodiazepines (PBDs)" Chemical Reviews, 2011, 111(4):2815-2864.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Antonow, D. et al.,"Parallel synthesis of a novel C2-aryl pyrrolo[2,1-c][1,4]benzodiazepine (PBD) library," J. Comb. Chem. (2007) 9:437-445.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Arai H., et al., "Molecular cloning of human endothelin receptors and their expressiOn in vascular endothelial cells and smooth muscle cells," Jpn. Circ. J. 56, 1303-1307, 1992.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Arai H., et al., "The Human Endotbelin-B Receptor Gene. Structural Organization and Chromosomal Assignment," J. Biol. Chem. 268, 3463-3470, 1993.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Arima et al., "Studies on Tomaymycin, a New Antibiotic. I. Isolation and Properties of Tomaymycin," J. Antibiotics (1972) 25:437-444.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Arnould, S., "Impact on the cell cycle and involvement of ATM, ATR, chk1 and chk2 kinases in the cytotoxicity of SJG-136, a new pyrrolobenzodiazepine dimer," Proceedings of the American Association for Cancer Research Annual Meeting (Mar. 2004) 45:1298, Abstract No. 5618.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Arnould, S., "Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling," Mol. Canc. Therap. 5(6):1602-1609 (2006).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Attoe T., et al., "Mutation of the endothelin-receptor B gene in Waardenburg-Hirschsprung disease," Hum. Mol. Genet. 4, 2407-2409, 1995.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Auricchio A., et al., "Endothelin-B receptor mutations in patients with isolated Hirschsprung disease from a non-inbred population," Hum. Mol. Genet. 5:351-354, 1996.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Axup et al., "Synthesis of site-specific antibody-drug conjugates using unnatural amino acids." Proc Natl Acad Sci U S A. Oct. 2, 2012; 109(40):16101-6.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Bahrenberg et al., "Reduced Expression of PSCA, a Member of the LY-6 Family of Cell Surface Antigens, in Bladder, Esophagus, and Stomach Tumors," Biochem. Biophys. Res. Commun. (2000) 275(3):783-788.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Banker, G.S. et al., "Modern Pharmaceutics", Third edition, Marcel Dekker, New York (1996) 451 and 596.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Barel M., et al., "Evidence for a new transcript of the Epstein-Barr virus/C3d receptor (CR2, CD21) which is due to alternative exon usage," Mol. Immunol. 35, 1025-1031, 1998.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Barella et al., "Sequence variation of a novel heptahelical leucocyte receptor through alternative transcript formation," (1995) Biochem. J. 309:773-779.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Barnett T., et al., "Carcinoembryonic Antigen Family: Characterization of cDNAs Coding for NCA and CEA and Suggestion of Nonrandom Sequence Variation in Their Conserved Loop-Domains," Genomics 3, 59-66, 1988.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Batisse, et al., "A new delivery system for Auristatin in STxB-drug conjugate therapy." European J. Medicinal Chemistry, 2015, 95: 483-491.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Beck et al., "DNA Sequence Analysis of 66 kb of the Human MHC Class II Region Encoding a Cluster of Genes for Antigen Processing," (1992) J. Mol. Biol. 228:433-441.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Beck et al., "Evolutionary Dynamics of Non-coding Sequences Within the Class II Region of the Human MHC," (1996) J. Mol. Biol. 25 255:1-13.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Berge et al., "Pharmaceutical Salts," J. Pharm. Sci. (1977) 66:1-19.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Berry, J. M. et al., "Solid-phase synthesis of DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepines," Tetrahedron Letters (2000) 41:6171-6174.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Berry, J.M. et al., "Synthesis and biological evaluation of an N10-Psec substituted pyrrolo[2,1-c][1,4]benzodiazepine prodrug," Bioorg. Med. Chem. Lett. (2002) 12:1413-1416.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Bien &amp; Balcerska, "Serum Soluble Interleukin 2 receptor in human cancer of adults and children: a review," Biomarkers, 2008, 13(1): 1-26.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Blanc et al., "SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies," Clin Cancer Res., 2011, 17(20):6448-58.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Blumberg H., et al., "Interleukin 20: Discovery, Receptor Identification, and Role in Epidermal Function," Cell 104, 9-19, 2001.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Bose et al., "New Approaches to Pyrrolo[2,1-c][1,4]benzodiazepines: Synthesis, DNA-binding and cytotoxicity of DC-81," Tetrahedron, 48, 751-758 (1992).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Bose, D.S. et al., "Effect of linker length on DNA-binding affinity, cross-linking efficiency and cytotoxicity of C8 linked pyrrolobenzodiazepine dimers," J. Chem. Soc. Chem. Commun. (1992) 20:1518-1520.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Bose, D.S. et al., "Rational Design of a Highly Efficient Irreversible DNA Interstrand Cross-Linking Agent Based on the Pyrrolobenzodiazepine Ring System," J. Am. Chem. Soc., 114, 4939-4941 (1992).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Bourgeois C., et al., "Endothelin-1 and ETA Receptor Expression in Vascular Smooth Muscle Cells from Human Placenta: A New ETA Receptor Messenger Ribonucleic Acid Is Generated by Alternative Splicing of Exon 3," J. Clin. Endocrinol. Metab. 82, 3116-3123, 1997.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Brand et al., Prospect for anti-HER2 receptor therapy in breast cancer. Anticancer Res. Jan.-Feb. 2006;26(1B):463-70.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Brinster et al., "Introits increase transcriptional efficiency in transgenic mice," (1988) Proc. Natl. Acad. Sci. USA 85:836-840.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Buchman et al., "Comparison of Intron-Dependent and Intron-Independent Gene Expression," (1988) Mol. Cell. Biol. 8:4395-4405.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Buhrow, S.A., "LC-MS/MS assay and dog pharmacokinetics of the dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501)," J. Chromat. B: Anal. Tech. Biomed. Life Sci. (2006) 840(1):56-62.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Burke, P.J. et al., "Anti-CD70 antibody-drug conjugates containing pyrrolobenzodiazepine dimers demonstrate robust antitumor activity," AACR National Meeting, Apr. 2012, Chicago, Illinois, Abstract No. 4631.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Burke, P.J. et al., "Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system," Bioorg. Med. Chem. Lett., Apr. 2009, 19(10):2650-2653.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Calcutt, M.W., "Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study," J. Mass Spectrom. (2008) 43(1):42-52.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Cancer, 2012, http://wiki.answers.eom/Q/How-many-different-types of cancer are there.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Cancer2, 2012, http://en.wikipedia.org/wiki/Management of cancer.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Carl et al., "A Novel Connector Linkage Applicable in Prodrug Design," (1981) J. Med. Chem. 24:479-480.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Carlsson et al., "Protein Thiolation and Reversible Protein-Protein Conjugation," (1978) Biochem. J. 173:723-737.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Carter, P., "Potent antibody therapeutics by design," (2006) Nature Reviews Immunology 6:343-357.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Casset et al., "A peptide mimetic of an anti-CD4 monoclonal antibody by rational design." Biochem Biophys Res Commun. Jul. 18, 2003; 307(1):198-205.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      CellTiter-Glo Luminescent Cell Viability Assay, Promega Corp. Technical Bulletin TB288, dated Jan. 13, 2012 (14 pages).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Chakravarty et al., "Plasmin-Activated Prodrugs for Cancer Chemotherapy. 2. Synthesis and Biological Activity of Peptidyl Derivatives of Doxorubicin," (1983) J. Med. Chem. 26:638-644.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Chan, J. and Watt, V.M., "eek and erk, new members of the eph subclass of receptor protein-tyrosine kinases," Oncogene 6 (6), 1057-1061 (1991).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Chang et al., "Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers," Proc. Natl. Acad. Sci. U.S.A. 93 (1):136-140 (1996).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Chen, Z. et al., "A novel approach to the synthesis of cytotoxic C2-C3 unsaturated pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) with conjugated acrylyl C2-substituents," Biorg. Med. Chem. Lett. (2004) 14:1547-1549.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Cheung, A., "Direct liquid chromatography determination of the reactive imine SJG-136 (NSC 694501)," J. Chromat. B: Anal. Techn. Biomed. Life Sci. (2005) 822(1-2):10-20.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Child et al., "Translational Control by an Upstream Open Reading Frame in the HER-2/neu Transcript," (1999) J. Bioi. Chern. 274: 24335-24341.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Cho et al., "Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab," Nature 421, 756-760, 2003.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Ciccodicola, A, et al., "Molecular characterization of a gene of the ‘EGF family’ expressed in undifferentiated human NTERA2 teratocarcinoma cells," EMBO J. 8 (7):1987-1991 (1989).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Cipolla, L., "Pyrrolo[2,1-c][1,4]benzodiazepine as a scaffold for the design and synthesis of anti-tumour drugs," Anti-Cancer Agents in Medicinal Chemistry (Jan. 2009) 9(1):1-31.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Clackson et al., "Making antibody fragments using phage display libraries," (1991) Nature, 352:624-628.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Clark H.F., et al., "The Secreted Protein Discovery Initiative (SPDI) , a Large-Scale Effort to Identify Novel Human Secreted and Transmembrane Proteins: A Bioinformatics Assessment," Genome Res. 13, 2265-2270, 2003.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Clingen, P.H., "The role of nucleotide excision repair and homologous recomination in the sensitivity of mammalian cells to the minor groove crosslinking pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136 (NSC694501)," Proceedings of the American Association for Cancer Research Annual Meeting (Jul. 2003) 44:524.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Clingen, P.H., "the XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136," Nucl. Acids Res. (2005) 33(10):3283-3291.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Clinical Trial, "Translational research: 4 ways to fix the clinical trial." 2011, http://www.nature.com/news/2011/110928/full/477526a.html.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Collins, "Generation and initial analysis of more than 15,000 full-length human and mouse eDNA sequences," Proc. Natl. Acad. Sci. U.S.A. 99 (26):16899-16903 (2002).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Cooper, N. et al., "Synthesis of novel PBDs as anti-tumour agents," Chem. Commun. (2002) 16:1764-1765.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Cooper, N., "Design, Synthesis and Evaluation of Novel C2-Aryl Pyrrolobenzodiazepines as Potential Anticancer Agents," Thesis submitted to School of Pharmacy, University of London, Dated Oct. 5, 2006.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Corey et al., "LuCap35: a new model of prostate cancer progression to androgen independence." The Prostate 2003;55:239-46.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Courtney, S. M. et al., "A new convenient procedure for the synthesis of pyrrolo[2,1-c][1,4]benzodiazepines", Tetrahedron Letters, vol. 34, No. 33, 5327-28 (1993).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Coussens L., et al., "Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location With neu Oncogene," Science (1985) 230(4730):1132-1139.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Cragg et al., "The alternative transcript of CD79b is overexpressed in B-CLL and inhibits signaling for apoptosis," Blood (2002) 100 (9):3068-3076.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Cree et al., "Methotrexate chemosensitivity by ATP luminescence in human leukemia cell lines and in breast cancer primary cultures: comparison of the TCA-100 assay with a clonogenic assay," (1995) AntiCancer Drugs 6:398-404.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Crouch et al., "The use- of ATP bioluminescence as a measure of cell proliferation and cytotoxicity," (1993) J. Immunol. Meth. 160:81-88.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Dall'acqua, W. F. et al., "Antibody humanization by framework shuffling" Methods, 36, 43-60 (2005).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Dattolo, G. et al., "Polycondensed nitrogen heterocycles. IX. 5,6-dihydro-7H-pyrrolo[1,2-d][1,4]benzodiazepin-6-one," J. Heterocyclic. Chem. (1980) 17:701-703.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Davis et al., "Identification of a family of Fe receptor homo logs with preferential B cell expression," (2001) Proc. Natl. Acad. Sci. USA 98(17):9772-9777.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      De Groot et al., "Cascade-Release Dendrimers" Liberate All End Groups upon a Single Triggering Event in the Dendritic Core, (2003) Angew. Chern. Int. Ed. 42:4490-4494.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      De Groot et al., "Elongated Multiple Electronic Cascade and Cyclization Spacer Systems in Activatible Anticancer Prodrug for Enhanced Drug Release," (2001) J. Org. Chern. 66:8815-8830.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      De Pascalis et al., "Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody." J Immunol. Sep. 15, 2002;169(6):3076-84.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Dennis et al., (2002) "Albumin Binding As A General Strategy For Improving The Pharmacokinetics Of Proteins" J Biol Chem. 277:35035-35043.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Dobner et al., "Differentiation-specific expression of a novel G protein-coupled receptor from Burkitt's lymphoma," (1992) Eur. J. Immunol. 22:2795-2799.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Dong, Q. et al., "Reductive cleavage of TROC groups under neutral conditions with cadmium-lead couple," Tetrahedron Lett. (1995) 36(32):5681-5682.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Dono et al., "Isolation and Characterization of the CRI PTO Autosomal Gene and Its X-linked Related Sequence," Am. J. Hum. Genet. 49:555-565, 1991.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Dornan et al., "Therapeutic potential of an anti -CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma," (2009) Blood 114(13):2721-2729.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Doronina et al., "Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity," (2006) Bioconj. Chem. 17:114-124.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Doronina, S.O. et al., "Development of potent monoclonal antibody auristatin conjugates for cancer therapy," Nature Biotech. (2003) 21:778-784.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Dorwald, F.Z., Side Reactions in Organic Synthesis: a Guide to Successful Synthesis Design, Weinheim: Wiley-VCH Verlag GmbH &amp; Co., KGaA (2005) Preface.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Doyle, M., "Response of staphylococcus aureus to subinhibitory concentrations of a sequence-selective, DNA minor groove cross-linking pyrrolobenzodiazepine dimer," J. Antimicrob. Chemo., Aug. 2009, 64(5):949-959.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Dubowchik et al., "Cathepsin B-Labile Dipeptide Linkers for Lysosomal Release of Doxorubicin from Internalizing Immunoconjugates: Model Studies of Enzymatic Drug Release and Antigen-Specific In Vitro Anticancer Activity," Bioconjugate Chem. (2002) 13, 855-869.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Dubowchik et al., "Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin." Bioorg Med Chem Lett. Dec. 1, 1998; 8(23):3341-6.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Dubowchik et al., "Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin." Bioorganic &amp; Medicinal Chemistry Letters, 8:3347-3352, (1998).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Dubowchik et al., "Monomethoxytrityl (MMT) as a Versatile Amino Protecting Group for Complex Prodrugs of Anticancer Compounds Sensitive to Strong Acids, Bases and Nucleophiles," (1997) Tetrahedron Letters. 38:5257-5260.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Duke, P., et al., "Characterization of Type I Receptors for Transforming Growth Factor-beta and Activin," Science 264 (5155):101-104 (1994).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Dumoutier L., et al., "Cutting Edge: STAT Activation By IL-19, IL-20 and mda-7 Through IL-20 Receptor Complexes of Two Types," J. Immunol. 167, 3545-3549, 2001.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Dupont, C. et al., "Synthesis of rhazinilam analogue acting as an inhibitor of tubulin assembly," Tetrahedron Lett. (2000) 41:5853-5856.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Ehsani A., et al., "Characterization of a New Allele of the Human ERBB2 Gene by Allele-Specific Competition Hybridization," (1993) Genomics 15, 426-429.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Eliel et al., Stereochemistry of Organic Compounds, John Wiley &amp; Sons, Inc., New York (1994).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Elshourbagy N.A., et al., "Molecular Characterization and Regulation of the Human Endothelin Receptors," J. Biol. Chem. 268, 3873-3879, 1993.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Erickson et al., "Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing," (2006) Cancer Res. 66(8): 4426-4433.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Farmer, J.D. et al., "DNA binding properties of a new class of linked anthramycin analogs,", Chemical Abstracts, Abstract No. 239940r, vol. 114, No. 25, 25 899-903 (1991).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Farmer, J.D. et al., "Synthesis and DNA crosslinking ability of a dimeric anthramycin analog," Tetrahedron Letters (1988) 29(40):5105-5108, Abstract only.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Fey, T. et al., "Silica-supported TEMPO catalyst: synthesis and application in the anelli oxidation of alcohols," J. Org. Chem. (2001) 66:8154-8159.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Field, J.A., et al., "Cloning and Functional Characterization of a Sodium-Dependent Phosphate Transporter Expressed in Human Lung and Small Intestine," (1999) Biochem. Biophys. Res. Commun. 258 (3):578-582.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Fields, G. and Noble, R. (1990) "Solid phase peptide synthesis utilizing 9-fluoroenylmethoxycarbonyl amino acids", Int. J. Peptide Protein Res. 35:161-214.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Firsching, A. et al., "Antiproliferative and angiostatic activity of suramin analogues," Cancer Res. (1995) 55:4957-4961.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Flanagan et al., "The ephrins and Eph receptors in neural development," Annu. Rev. Neurosci. 21:309-345 (1998).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Flygare, "Antibody-drug conjugates for the treatment of cancer," Chern. Biol. &amp; Drug Design (2013) 81(1):113-121.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Flynn et al., "Pre-Clinical Activity of Adct-301, a Novel Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies," https://www.researchgate.net/publication/275520174.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Foloppe, M.P. et al., "DNA-binding properties of pyrrolo[2,1-c][1,4]benzodiazephine N10-C11 amidines," Eur. J. Med. Chem., 31, 407-410 (1996).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Fox et al., "cDNA cloning and tissue distribution of five human EPH-like receptor protein-tyrosine kinases," Oncogene 10 (5):897-905 (1995).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Fuchs S., et al., "Functional Characterization of Three Mutations of the Endothelin B Receptor Gene in Patients With Hirschsprung's Disease: Evidence for Selective Loss of Gi Coupling," Mol. Med. 7, 115-124, 2001.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Fujisaku et al., "Genomic Organization and Polymorphisms of the Human C3d/Epstein-Barr Virus Receptor," (1989) J. Biol. Chem. 264 (4):2118-2125.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Fujisawa Pharmaceutical Co. Ltd., "Benzodiazepine derivatives," SciFinder Scholar, 2-3 (2002).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Fujisawa Pharmaceutical Co., Ltd., Abstract No. 139983k, "Benzodiazepine derivatives", Chemical Abstracts, vol. 99, No. 17, 603 (1983).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Fujisawa Pharmaceutical Co., Ltd., Abstract No. 72145x, "Benzodiazepine derivatives", Chemical Abstracts, vol. 98, No. 9, 638 (1983).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Fukuyama, T. et al., "Total Synthesis of (+)-Porothramycin B," Tetrahedron Letters, vol. 34, 16, 2577-2580 (1993).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Gallmeier, E., "Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options," Gastroenterology (2006) 130(7):2145-2154.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Gary S.C., et al., "cDNA cloning chromosomal localization, and expression analysis of human BEHAB/brevican, a brain specific proteoglycan regulated during cortical development and in glioma," Gene 256, 139-147, 2000.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Gaugitsch, H.W., et al., "A novel transiently expressed, integral membrane protein linked to cell activation. Molecular cloning via the rapid degradation signal AUUUA.," (1992) J. Biol. Chem. 267 (16):11267-11273.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Gavezzotti, A., "Are crystal structures predictable?" Acc. Chem. Res. (1994) 27:309-314.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Geiser et al. "Automation of solid-phase peptide synthesis" in Macromolecular Sequencing and Synthesis, Alan R. Liss, Inc., 1988, pp. 199-218.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. 11038674 (2013).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. 20 NM_006424 (2013).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. AB040878 (2001).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. AF116456 (1999).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. AF179274 (2001).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. AF229053 (2000).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. AF343662 (2001).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. AF343663 (2001).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. AF343664 (2001).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. AF343665 (2001).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. AF361486 (2003).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. AF369794 (2001).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. AF397453 (2001).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. AF455138 (2003).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. AJ297436 (2008).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. AK026467 (2006).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. AK089756 (2010).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. AK090423 (2006).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. AK090475 (2006).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. AL834187 (2008).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. AX092328 (2001).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. AY158090 (2003).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. AY260763 (2003).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. AY275463 (2003).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. AY358085 (2003).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. AY358628 (2003).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. AY358907 (2003).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. AY506558 (2004).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. BC017023 (2006).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. CAA76847.1 (2001).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. CAF85723 (2004).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. CQ782436 (2004).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. M11730 (1995).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. M18728 (1995).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. M26004 (1993).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. NM_000626 (2013).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. NM_001178098.1 (2012).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. NM_001203 (2013).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. NM_003212 (2013).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. NM_003486 (2013).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. NM_004442 (2013).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. NM_005823 (2013).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. NM_012449 (2013).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. NM_017636 (2013).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. NM_030764 (2013).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. NP 002111.1 (2013).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. NP_001171569.1 (1992).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. NP_001194 (2013).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. NP_001707.1 (2013).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. NP_001773.1 (2013).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. NP_001774.10 (2013).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. NP_002552.2 (2013).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. NP_003203 (2013).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. NP_005573.1 (2007).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Genbank accession No. NP_112571.1 (2007).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Geoghegan &amp; Stroh, "Site-Directed Conjugation of Nonpeptide Groups to Peptides and Proteins via Periodate Oxidation of a 2-Amino Alcohol. Application to Modification at N-Terminal Serine," (1992) Bioconjugate Chem. 3:138-146.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Getz et al., "A Comparison between the Sulfhydryl Reductants Tris(2-carboxyethyl)phosphine and Dithiothreitol for Use in Protein Biochemistry," (1999) Anal. Biochem. vol. 273:73-80.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Glynne-Jones et al., "TENB2, a proteogl yean identified in prostate cancer that is associated with disease progression and androgen independence," (2001) Int J Cancer. Oct. 15; 94(2): 178-184.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Gordon et al., "Somatic hypermutation of the B cell receptor genes B29 (Igβ, CD79b) and mb1 (Igα, CD79a)," PNAS, Apr. 11, 2003, vol. 100, No. 7, 4126-4131.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Greene, T.W et al., Protective Groups in Organic Synthesis, John Wiley &amp; Sons (1999) 3rd Edition, 23-200.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Greene, T.W et al., Protective Groups in Organic Synthesis, John Wiley &amp; Sons (1999) 3rd Edition, 503-549.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Greene, T.W et al., Protective Groups in Organic Synthesis, John Wiley &amp; Sons (1999) 3rd Edition, 633-647.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Greene, T.W. and Wuts, P.G.M., Protective Groups in Organic Synthesis, John Wiley &amp; Sons, 2nd ed., Ch 7, 315-345 (1991).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Gregson, S. et al., "Synthesis of a novel C2/C2'-exo unsaturated pyrrolobenzodiazepine cross-linking agent with remarkable DNA binding affinity and cytotoxicity," Chemical Communications, 797-798 (1999).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Gregson, S.J. et al., "Design, Synthesis and Evaluation of a Novel Pyrrolobenzodiazepine DNA-lnteractive Agent with Highly Efficient Cross-Linking Ability and Potent Cytotoxicity", J. Med. Chem., 44: 737-748 (2001).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Gregson, S.J. et al., "Effect of C2/C3-endo unsaturation on the cytotoxicity and DNA-binding reactivity of pyrrolo-[2,1-c][1,4]-benzodiazepines," Bioorg. Med. Chem. Lett. (2000) 10(16):1849-1851.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Gregson, S.J. et al., "Effect of C2-exo Unsaturation on the Cytotoxicity and DNA-Binding Reactivity of Pyrrolo[2,1-c]1,4]benzodiazepines", Bioorganic &amp; Medicinal Chemistry Letters, 10: 1845-1847 (2000).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Gregson, S.J. et al., "Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8'ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers," J. Med. Chem. (2004) 1161-1174.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Gregson, S.J. et al., "Synthesis of the first example of a C2-C3/C2'-C3'-endo unsaturated pyrrolo[2,1-c][1,4]benzodiazepine dimer," Biorg. Med. Chem. Lett. (2001) 11:2859-2862.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Gregson, S.J. et al., "Synthesis of the first examples of A-C8/C-C2 amide-linked pyrrolo[2,1-c][1,4]benzodiazepine dimers," Biorg. Med. Chem. Lett. (2003) 13:2277-2280.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Gu Z., et al., "Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer," Oncogene 19, 1288-1296, 2000.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Guichard, S.M., "Influence of P-glycoprotein expression on in vitro cytotoxicity and in vivo antitumour activity of the novel pyrrolobenzodiazepine dimer SJG-136," Eur. J. Cancer (2005) 41(12):1811-1818.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Guiotto, A. et al., "Synthesis of novel C7-aryl substituted pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) via Pro- N10-troc protection and Suzuki coupling," Bioorganic &amp; Medicinal Chemistry Letters, 8, No. 21, 3017-3018 (1998).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Guselnikov et al., "A family of highly diverse human and mouse genes structurally links leukocyte FcR, gp42 and PECAM-1," Immunogenetics 54 (2):87-95 (2002).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Ha et al., "molecular cloning and expression pattern of a human gene homologous to the murine mb-1 gene," (1992) J. Immunol. 148(5):1526-1531.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Hadjivassileva, T., "Antibacterial activity of pyrrolobenzodiazepine dimers, a novel group of DNA-binding compounds," Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy (Oct.-Nov. 2004) 44:202.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Hadjivassileva, T., "Interactions of pyrrolobenzodiazepine dimers and duplex DNA from methicillin-resistant staphylococcus aureus," Int. J. Antimicrob. Agents (2007) 29(6):672-678.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Hadjivassileva, T., "Pyrrolobenzodiazepine dimers: novel sequence-selective, DNA-interactive, cross-linking agents with activity against Gram-positive bacteria," J. Antimicrob. Chemo. (2005) 56(3):513-518.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Haendler B., et al., "Molecular Cloning of Human Endothelin (ET) Receptors ETA and Etb," J. Cardiovasc. Pharmacal. 20, s1-S4, 1992.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Haisma et al., "Comparison of two antracycline-based prodrugs for activation by a monoclonal antibody-β-glucuronidase conjugate in the specific treatment of cancer." Cell biophysics, Humana Press Inc. 1994, 24/25: 185-192.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Hamaguchi, A., "DNA cross-linking and in vivo antitumour activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057 (DRG-16)," EJC Supplements (Nov. 2006) 4(12):96.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Hamann P. "Monoclonal antibody-drug conjugates," (2005) Expert Opin. Ther. Patents 15(9):1087-1103.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Hamblett et al., "Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate," (2004) Clin. Cancer Res. 10:7063-7070.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Handbook of Food Additives, 2nd Ed. (eds. M. Ash and I. Ash), Synapse Information Resources, Inc., Endicott, New York, USA (2001).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Handbook of Pharmaceutical Excipients, 2nd edition, 1994, Edited by Ainley Wade and Paul J. Weller.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Hara et al., "DC 102, a new glycosidic pyrrolo(1,4)benzodiazepine antibiotic produced by streptomyces sp.", J. Antibiotics, 41, 702-704 (1988).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Hartley J A: "The development of pyrrolobenzodiazepines as antitumour agents", Expert Opinion on Investigational Drugs, Ashley Publications Ltd., vol. 28, No. 6, Jan. 1, 2011, pp. 733-744.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Hartley, J.A. et al., "Abstract 2856: pyrrolobenzodiazepine (PBD) dimers—potent next generation warheads in antibody drug conjugates (ADCs) targeted at both solid and haematological tumors," Cancer Res. (2013) 78(8)Supp 1:2856.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Hartley, J.A. et al., "SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity," Cancer Res., Sep. 2010, 70(17):6849-6858.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Hartley, J.A. et al., "SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 1: Cellular pharmacology, in vitro and initial in vivo antitumor activity," Cancer Res. (2004) 64:6693-6699.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Hartley, J.A., "In vitro antitumor activity and in vivo DNA interstrand crosslinking by the novel pyrrolobenzodiazepine dimer SJG-136 (NSC 694501)," Proceedings of the American Association for Cancer Research Annual Meeting (Mar. 2002) 43:489.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Hartley, J.A., "SJG-136 (NSC-D694501)—a novel DNA sequence specific minor groove crosslinking agent with significant antitumor activity," Proceedings of the American Association for Cancer Research Annual Meeting (Mar. 2000) 41:425.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Hashimoto et al., "Chromosomal localization, genomic structure, and allelic polymorphism of the human CD79a (lg-alpha/mb-1) gene," (1994) Immunogenetics 40(4 ):287-295.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Hay et al., "A 2-nitroimidazole carbamate prodrug of 5-amin0-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-1,2-dihydr0-3h-benz[e]indole (amino-seco-cbi-tmi) for use with adept and gdept," (1999) Bioorg. Med. Chem. Lett. 9:2237-2242.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Herdwijn et al., "Synthesis of trans(+ )6-phenoxyacetamido-1-methylene-3,3-dicarboxymethyl-1-carbapenam," Canadian Journal of Chemistry. 1982, 60, 2903-2907.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Hermanson, G.T., "Heterobifunctional Cross-linkers," (1996) Bioconjugate Techniques; Academic Press: New York, p. 228-286.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Hochhauser, D., "Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors," Clin. Cancer Res., Mar. 2009, 15(6):2140-2147.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Hochlowski, J. et al., "Abbeymycin, a new anthramycin-type antibiotic produced by a streptomycete," J. Antibiotics, 40, 145-148 (1987).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Hofstra R.M.W., et al., "A homozygous mUtation in the endothelin-3 gene associated with a combined Waardenburg type 2 and Hirschsprung phenotype (Shah-Waardenburg syndrome)" Nat. Genet. 12, 445-447, 1996.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Hofstra R.M.W., et al., "Mutations in Hirschsprung Disease: When Does a Mutation Contribute to the Phenotype," Eur. J. Hum. Genet. 5, 180-185, 1997.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Horie et al., "Identification and Characterization of TMEFF2, a Novel Surviv Factor for Hippocampal and Mesencephalic Neurons," (2000) Genomics 67: 146-152.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Howard, P.W et al., "Design, synthesis and biological evaluation of ZC-423, a novel C2-aryl substituted pyrrolobenzodiazepine (PBD) dimer," Clinical Cancer Research (2005) 11(23):9015S-9016S (A205).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Howard, P.W. et al., "Synthesis of a novel C2/C2'-aryl-substituted pyrrolo[2,1-c][1,4]benzodiazepine dimer prodrug with improved water solubility and reduced DNA reaction rate," Bioorg. Med. Chem., Sep. 2009, In Press, 4 pages now: Sep. 2009, 19:6463-6466.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Howard, P.W. et al., "The design, synthesis and biological evaluation of a set of C2-aryl substituted pyrrolo[2,1-c][1,4]benzodiazepine dimers," EJC Supplements (2006) 4(12):95—Poster Abstract 301.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Howard, P.W., "Design, synthesis and biological evaluation of novel C2-aryl-substituted pyrrolo[2,1-c][1,4]benzodiazepine monomers," Proceedings of the American Association for Cancer Research Annual Meeting (Apr. 2006) 47:132.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Hubert, R.S., et al., "STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors," (1999) Proc. Natl. Acad. Sci. U.S.A. 96 (25):14523-14528.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Hurley, L. and Needham-Vandevanter, D., "Covalent Binding of Antitumor Antibiotics in the Minor Groove of DNA. Mechanism of Action of CC-1065 and the yrrolo(1,4)benzodiazepines," Acc. Chem. Res., 19, 230-237 (1986).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Ide et al., "Cloning of human bone morphogenetic protein type IB receptor (BMPRIB) and its expression in prostate cancer in comparison with other BMPRs," Oncogene (1997) 14, 1377-1382.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Iida, H. et al. "Design and synthesis of pyrrolo[2,1-c][1,4]benzodiazepine (PBD)-polyaminoalkyl conjugates by the use of SNA4 reaction 2-nitro-5-fluorobenzoate precursor as key reaction," Heterocycles (2004) 62:693-711.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      International Search Report and Written Opinion for Application No. PCT/EP2012/070233 dated Jan. 28, 2013 (8 pages).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      International Search Report and Written Opinion for Application No. PCT/EP2013/071346 dated Feb. 5, 2014 (11 pages).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      International Search Report and Written Opinion for Application No. PCT/EP2013/071352 dated Feb. 5, 2014 (14 pages).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      International Search Report and Written Opinion for Application No. PCT/EP2014/054958 dated Jul. 2, 2014 (13 pages).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      International Search Report and Written Opinion for Application No. PCT/EP2018/053162 dated Apr. 24, 2018 (9 pages).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      International Search Report and Written Opinion for Application No. PCT/GB2015/052629 dated Nov. 2, 2015 (12 pages).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      International Search Report and Written Opinion for Application No. PCT/US2011/032664 dated Aug. 19, 2011 (13 pages).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      International Search Report and Written Opinion for Application No. PCT/US2011/032668 dated May 26, 2011 (12 pages).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      International Search Report and Written Opinion for Application No. PCT/US2015/050634 dated Jan. 29, 2016 (14 pages).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Itoh et al., "Sibanomicin, a new pyrrolo(1,4)benzodiazepine antitumor antibiotic produced by a micromonospora sp." J. Antibiotics, 41, 1281-1284 (1988).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Janjigian, Y.Y., "A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors," Cancer Chemotherapy and Pharmacology, Aug. 2009, 65(5):833-838.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Jeffrey et al., "A Potent Anti-CD70 Antibody-Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology." Bioconj. Chem. 2013, 24, 1256-1263.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Jeffrey et al., "Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates." Bioconjugate Chemistry, 5, 2006, 17, 831-840. (Abstract).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Jeffrey, S.C. et al., "Development of Pyrrolobenzodiazepine-Based Antibody-Drug Conjugates for Cancer," AACR Annual Meeting 2013, Abstract No. 4321.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Jeffrey, S.C., "Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates," J. Med. Chem. (2005) 48(5):1344-1358.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Jespers, L. S., "Guiding the Selection of Human Antibodies from Phage Display Repertoires to a Single Epitope of an Antigen" Nature Biotech., 12, 899-903 (1994).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Jia, L., "Interspecies differences in pharmacokinetics and time-dissociated toxicokinetics of SJG-136," Proceedings of the American Association for Cancer Research Annual Meeting (Mar. 2004) 45:487.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Jia, L., "Use of the comet assay as a surrogate biomarker for the in vivo measurement of DNA damage to lymphocytes," Proceedings of the American Association for Cancer Research Annual Meeting (Mar. 2004) 45:452-453.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Johnson &amp; Goldin, "The clinical impact of screening and other experimental tumor studies." Cancer Treat Rev. Mar. 1975; 2(1):1-31.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Jones et al., "Releasable Luciferin—Transporter Conjugates: Tools for the Real-Time Analysis of Cellular Uptake and Release," J. Am. Chem. Soc., 2006, 128, 6526-6527.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Jonsson et al., "Human class II DNA and DOB genes display low sequence variability," (1989) Immunogenetics 29(6):411-413.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Jordan, V.C., "Tamoxifen: a most unlikely pioneering medicine," Nature Reviews: Drug Discovery (2003) 2:205-213.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Junutula et al., "Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs," (2008) Jour of Immun. Methods 332:41-52.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Junutula, et al., "Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index," 2008b Nature Biotech., 26(8):925-932, 2008.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Kamal et a., "Pyrrolo[2,1-c][1,4]benzodiazepine-β-glucuronide prodrugs with a potential for selective therapy of solid tumors by PMT and ADEPT strategies" Bioorganic &amp; Medicinal Chemistry Letters 2008, 18:3769-3773.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Kamal et al., "Synthesis and DNA-binding affinity of A-C8/C-C2 alkoxyamido-linked pyrrolo[2,1-c][1,4]benzodiazepine dimers" Biorg. Med. Chem. Lett. (2003) 13(22): 3955-3958.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Kamal, A. et al., "Design, synthesis and evaluation of new noncross-linking pyrrolobenzodiazepine dimers with efficient DNA binding ability and potent antitumor activity," J. Med. Chem. (2002) 45:4679-4688.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Kamal, A., "Development of pyrrolo[2,1-c][1,4]benzodiazepine beta-galactoside prodrugs for selective therapy of cancer by ADEPT and PMT," Chemmedchem (2008) 3:794-802.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Kamal, A., "Remarkable DNA binding affinity and potential anticancer activity of pyrrolo[2,1- c][1,4]benzodiazepine-naphthalamide conjugates linked through piperazine side-armed alkane spacers," Bioorg. Med. Chem. (2008) 16(15):7218-7224.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Kamal, A., "Remarkable enhancement in the DNA-binding ability of C2-fluoro substituted pyrrolo[2,1- c][1,4]benzodiazepines and their anticancer potential," Bioorg. Med. Chem., Jan. 2009, 17(4):1557-1572.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Kamal, A., "Synthesis of fluorinated analogues of SJG-136 and their DNA-binding potential," Bioorg. Med. Chem. Lett (2004) 14(22):5699-5702.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Kamal, A., et al., "An Efficient Synthesis of Pyrrolo[2,1-c][1,4] Benzodiazepine Antibiotics via Reductive Cyclization," Bioorg. Med. Chem. Ltrs, 7, No. 14, 1825-1828 (1997).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Kamal, A., et al., "Synthesis of Pyrrolo [2,1-c][1,4]-Benzodiazepene Antibiotics: Oxidation of Cyclic Secondary Amine with TPAP", Tetrahedron, v. 53, No. 9, 3223-3230 (1997).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Kamal, et al., "Synthesis of pyrrolo[2,1-c][1,4]benzodiazepines via reductive cyclization of w-azido carbonyl compounds by TMSI: an efficient preparation of antibiotic DC-81 and its dimers," Biorg. Med. Chem. Lett. (2000) 10:2311-2313.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Kaneko, T. et al., "Bicyclic and tricyclic analogues of anthramycin," J. Med. Chem. (1985) 28:388-392.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Kang, G.-D et al., "Synthesis of a novel C2-aryl substituted 1,2-unsaturated pyrrolobenzodiazepine," Chern. Commun. (2003) 1680-1689.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Kasahara et al., "Nucleotide sequence of a chimpanzee DOB eDNA clone," (1989) Immunogenetics 30(1):66-68.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      King et al., "Facile synthesis of maleimide bifunctional Jinkers," (2002) Tetrahedron Letters 43:1987-1990.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Kingsbury et al., "A Novel Peptide Delivery System Involving Peptidase Activated Prodrugs as Antimicrobial Agents. Synthesis and Biological Activity of Peptidyl Derivatives of 5 Fluorouracil," (1984) J. Med. Chem. 27:1447-1451.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Kohler et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," (1975) Nature 256:495-497.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Kohn, K., "Anthramycin," Antibiotics III, Springer-Verlag, NY, 3-11 (1975).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Kojima et al., "Molecular Cloning and Expression of Megakaryocyte Potentiating Factor eDNA," The Journal of Biological Chemistry, vol. 270, No. 37, Issue of Sep. 15, pp. 21984-21990, 1995.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Konishi, M. et al., "Chicamycin, a new antitumor antibiotic II. Structure determination of chicamycins A and B," J. Antibiotics, 37, 200-206 (1984).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Kovtun et al., "Antibody-Drug Conjugates Designed to Eradicate Tumors with Homogeneous and Heterogeneous Expression of the Target Antigen," (2006) Cancer Res. 66(6):3214-3121.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Kreitman et al., "Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients with Hematologic Malignancies," J. Clin. Oncol., 2000, 18:1622-1636.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Kuhns J.J., et al., "Poor Binding of a HER-2/neu Epitope (GP2) to HLA-A2.1 Is due to a Lack of Interactions with the Center of the Peptide," J. Biol. Chem. 274, 36422-36427, 1999.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Kunimoto et al., "Mazethramycin, a new member of anthramycin group antibiotics," J. Antibiotics, 33, 665-667 (1980).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Kurebayashi et al., "Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6," (1999) Brit. Jour. Cancer 79(5-6):707-717.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Lambert, "Drug-conjugated monoclonal antibodies for the treatment of cancer," (2005) Current Opin. In Pharmacal. 5:543-549.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Langley, D.R. and Thurston, D.E., "A versatile and efficient synthesis of carbinolamine-containing pyrrolo[1,4]benzodiazepines via the cyclization of N-92-aminobenzoyl)pyrrolidine-2-carboxaldehyde diethyl thioacetals: total synthesis of prothracarcin," J. Org. Chem., 52, 91-97 (1987).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Langlois, N. et al., "Synthesis and cytotoxicity on sensitive and doxorubicin-resistant cell lines of new pyrrolo[2,1-c][1,4]benzodiazepines related to anthramycin," J. Med. Chem. (2001) 44:3754-3757.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Larhammar et al., "Sequence of Gene and eDNA Encoding Murine Major Histocompatibility Complex Class II Gene AP2*," (1985) J. Biol. Chem. 260(26):14111-14119.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Launay et al., "TRPM4 Is a Ca2+ -Activated Nonselective Cation Channel Mediating Cell Membrane Depolarization," Cell 109 (3):397-407 (2002).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Law et al., "Lymphocyte Activation Antigen CD70 Expressed by Renal Cell Carcinoma Is a Potential Therapeutic Target for Anti-CD70 Antibody-Drug Conjugates," (2006) Cancer Res. 66(4):2328-2337.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Lazar et al., "A molecular immunology approach to antibody humanization and functional optimization" Molecular Immunology, 2007, 44(8), 1986-1998.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Le et al., "Primary structure and expression of a naturally truncated human P2X ATP receptor subunit from brain and immune system," (1997) FEBS Lett. 418(1-2):195-199.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Leabman; et al., "Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys." MAbs. Nov.-Dec. 2013; 5(6):896-903.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Leber, J.D. et al., "A revised structure for sibiromycin," J. Am. Chem. Soc., 110, 2992-2993 (1988).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Leimgruber, W. et al., "Isolation and characterization of anthramycin, a new antitumor antibiotic," J. Am. Chem. Soc., 87, 5791-5793 (1965).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Leimgruber, W. et al., "The structure of anthramycin," J. Am. Chem. Soc., 87, 5793-5795 (1965).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Leimgruber, W. et al., "Total synthesis of anthramycin," J. Am. Chem. Soc., 90, 5641-5643 (1968).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Leonard et al., "Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma," J. Clin. Oncology (2003) 21(16):3051-3059.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Leonard et al., "Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies," Oncogene (2007) 26:3704-3713.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Leung et al., "Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2," Mol. Immunol. (1995) 32(17-18):1413-1427.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Levenson et al., "MCF-7: The First Hormone-responsive Breast Cancer Cell Line," (1997) Cancer Res. 57(15):3071-3078.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Lewis Phillips et al., "Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate," Cancer Res, 2008, 68: (22).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Liang et al., "The Gene for a Novel Transmembrane Protein Containing Epidermal Growth Factor and Follistatin Domains Is Frequently Hypermethylated in Human Tumor Cells," (2000) Cancer Res. 60:4907-4912.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Linden et al., "Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab," J. Clin. Cancer Res. (2005) 11:5215-5222.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Lonberg, "Fully Human antibodies from transgenic mouse and phage display platforms" Curr. Opinion, 20(4), 450-459 (2008).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Lown et al., "Molecular Mechanism of Binding of Pyrrolo(1,4)benzodiazepine antitumour agents to deoxyribonucleic acid—anthramycin and tomaymycin," Biochem. Pharmacol. (1979), 28 (13), 2017-2026.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Manfre et al., "Syntheses of Proline Analogues as Potential Mechanism-Based Inhibitors of Proline Dehydrogenase: 4-Methylene-L-, (E)- and (Z)-4 (Fluoromethylene)-L-, cis- and trans-5-Ethynyl-(±)-, and cis- and trans -5-Vinyl-L-proline," J. Org. Chem. 1992, 57, 2060-2065.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Marin, D., "Voltammetric studies of the interaction of pyrrolo[2,1-c][1,4]benzodiazepine (PBD) monomers and dimers with DNA," J. Electroanal. Chem. (2006) 593(1-2):241-246.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Marks et al., "By-passing Immunization, Human Antibodies from V-gene Libraries Displayed on Phage," (1991) J. Mol. Biol., 222:581-597.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Martin, C. et al., "Sequence-selective interaction of the minor-groove interstrand cross-linking agent SJG-136 with naked and cellular DNA: footprinting and enzyme inhibition studies," Biochem. (2005) 44(11):4135-4147.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Mastroberardino et al., "Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family," Nature 395 (6699):288-291 (1998).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Matsumoto, K. et al., "Synthesis of polyaminoalkyl substituted conjugates of pyrrolo[2,1-c][1,4]benzodiazepine (PBD)-polyaminoalkyl involving SNA4 reaction of 2-nitro-5-fluorobenzoate precursors," Heterocycles (2000) 52(3):1015-1020.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      McDonagh, "Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment," (2006) Protein Eng. Design &amp; Sel. 19(7): 299-307.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Mendoza et al., "Inhibition of Ligand-mediated HER2 Activation in Androgen-independent Prostate Cancer," (2002) Cancer Res. 62:5485-5488.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Miller et al., "Design, Construction, and In Vitro Analyses of Multivalent Antibodies," (2003) Jour, of Immunology 170:4854-4861.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Miller et al., "IRTAs: a new family of immunoglobulinlike receptors differentially expressed in B cells," Blood 99 (8):2662-2669 (2002).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Miura et al., "Molecular cloning of a human RP105 homologue and chromosomal localization of the mouse and human RP105 genes (Ly64 and LY64)." Genomics. Dec. 15, 1996; 38(3):299-304.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Miura et al., "RPIOS Is Associated With MD-1 and Transmits an Activation Signal in Human B Cells," (1998) Blood 92:2815-2822.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Moore M., et al., "Molecular cloning of the eDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes," Proc. Natl. Acad. Sci. U.S.A. 84, 9194-9198, 1987.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Mori, M. et al., "Total syntheses of prothracarcin and tomaymycin by use of palladium catalyzed carbonylation," Tetrahedron (1986) 42(14):3793-3806.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Morrison et al., "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains," (1984) Proc. Natl. Acad. Sci. USA, 81:6851-6855.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Mountzouris, J.A. et al., "Comparison of a DSB-120 DNA interstrand cross-linked adduct with the corresponding bis-Tomamycin adduct," J. Med. Chem. (1994) 37:3132-3140.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Muller et al., "Cloning and sequencing of the eDNA encoding the human homologue of the murine immunoglobulin-associated protein B29," (1992) Eur. J. Immunol. 22 (6): 1621-1625.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Mungall A.J., et al., "The DNA sequence and analysis of human chromosome 6," Nature 425, 805-811, 2003.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Nadler et al., "B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes," Journal of Immunology, 1983, 131(1):244-250.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Nagasaka, T. and Koseki, Y, "Stereoselective Synthesis of Tilivalline," Journal of Organic Chemistry, vol. 63, No. 20, 6797-6801 (1998).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Nagasaka, T. et al., "Stereoselective Synthesis of Tilivalline," Tetrahedron Letters, 30:14, 1871-1872(1989).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Nagase T., et al., "Prediction of the Coding Sequences of Unidentified Human Genes. XVII. The Complete Sequences of 100 New eDNA Clones from Brain Which Code for Large Proteins in vitro," (2000) DNA Res. 7 (2):143-150.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Nakamuta M., et al., "Cloning and sequence analysis of a cDNA encoding human non—selective type of endothelin receptor," Biochem. Biophys. Res. Commun. 177, 34-39, 1991.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Nakayama et al., "Altered Gene Expression upon BCR Cross-Linking in Burkitt's Lymphoma B Cell Line," (2000) Biochem. Biophys. Res. Commun. 277(1):124-127.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Narayanaswamy, M., "A novel HPLC/MS assay to measure DNA interstrand cross-linking efficacy in oligonucleotides of varying sequence," EJC Supplements (Nov. 2006) 4(12):92-93.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Narayanaswamy, M., "An assay combinding high-performance liquid chromatography and mass spectrometry to measure DNA interstrand cross-linking efficiency in oligonucleotides of varying sequences," Anal. Biochem. (2008) 374(1):173-181.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Narayanaswamy, M., "Use of HPLC-MS to characterize novel mono and intrastrand cross-linked DNA adducts formed by the sequence-selective DNA-interactive agent SJG-136," Proceedings of the American Association for Cancer Research Annual Meeting (Apr. 2007) 48:760-761.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Narukawa, Y., "General and efficient synthesis of 2-alkylcarbapenems synthesis of dethia carba analogs of clinically useful carbapenems via palladium-catalyzed cross-coupling reaction," Tetrahedron (1997) 53:539-556.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Naruse et al., "The HLA-DOB gene displays limited polymorphism with only one amino acid substitution," (2002) Tissue Antigens 59:512-519.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Neuberger and Williams, "The intron requirement for immunoglobulin gene expression is dependent upon the promoter," (1988) Nucleic Acids Res. 16:6713-6724.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Nicolaou et al., "Calicheamicin θ: A Rationally Designed Molecule with Extremely Potent and Selective DNA Cleaving Properties and Apoptosis Inducing Activity," Angew Chem. Intl. Ed. Engl. (1994) 33:183-186.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Nilius et al., "Voltage Dependence of the Ca2+ -activated Cation Channel TRPM4," The Journal of Biological Chemistry, vol. 278, No. 33, Issue of Aug. 15, p. 30813-30820, 2003.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Ogawa Y., et al., "Molecular Cloning of a Non-Isopeptide-Selective Human Endothelin Receptor," Biochem. Biophys. Res. Commun. 178, 248-255, 1991.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Okamoto Y., et al. "Palmitoylation of Human Endothelin B," Biol. Chem. 272, 21589-21596, 1997.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      O'Neil, Chemical Abstract No. 171573p, "The synthesis of Functionalized Pyrrolo-[2,1-c][1,4]-Benzodiazepines", Chemical Abstracts, vol. 126, No. 13, 618 (1997).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      O'Neil, I.A. et al., "DPPE: A Convenient Replacement for Triphenylphosphine in the Staudinger and Mitsunobu Reactions", Tetrahedron Letters, vol. 39, No. 42, 7787-7790 (1998).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      O'Neil, I.A., et al., "The Synthesis of Functionalized Pyrrolo-[2,1-c][1,4]-Benzodiazepines," Synlett, 75-78 (1997).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Parrish-Novak J., et al., "Interleukins 19, 20, and 24 Signal through Two Distinct Receptor Complexes," J. Biol. Chem. 277, 47517-47523, 2002.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Paul, Fundamental Immunology, 3rd Edition, pp. 292-295, 1993.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Payne, G. "Progress in immunoconjugate cancer therapeutics," (2003) Cancer Cell 3:207-212.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      PCT/US2012/059864 International Search Report and Written Opinion dated Dec. 21, 2012 (7 pages).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Pepper, C., "Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells," Br. J. Cancer (2007) 97(2):253-259.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Pepper, C.J. et al., "The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53- independent mechanism of cell kill," Cancer Res. (2004) 64:6750-6755.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Phillips et al., "Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate," (2008) Cancer Res. 68(22):9280-9290.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Pingault V., et al., "SOX10 mutations in chronic intestinal pseudo-obstruction suggest a complex physiopathological mechanism," (2002) Hum. Genet. 111, 198-206.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Pletnev S., et al., "Characterization of the Recombinant Extracellular Domains of Human Interleukin-20 Receptors and Their Complexe with Interleukin-19 and Interleukin-20," (2003) Biochemistry 42:12617-12624.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Porkaa et al., "Cloning and Characterization of a Novel Six-Transmembrane Protein STEAP2, Expressed in Normal and Malignant Prostate," Lab. Invest. 82 (11):1573-1582 (2002).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Prasad et al., "Human LAT1, a Subunit of System L Amino Acid Transporter: Molecular Cloning and Transport Function," Biochem. Biophys. Res. Commun. 255 (2), 283-288 (1999).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Preud'homme et al., "Structure and expression of the mb-1 transcript in human lymphoid cells," (1992) Clin. Exp. Immunol. 90(1):141-146.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Puffenberger E.G., et al., "A Missense Mutation of the Endothelin-B Receptor Gene in Multigenic Hirschsprung's Disease," Cell 79, 1257-1266, 1994.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Purser, et al., "Fluorine in Medicinal Chemistry." Chem. Soc. Rev., 2008, 37, 320-330.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Puzanov, I., "Phase I and pharmacokinetic trial of SJG-136 administered on a daily x5 schedule," EJC Supplements (Nov. 2006) 4(12):93.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Quintas-Cardama, A., "Sequencing of subcloned PCR products facilitates earlier detetction of BCR-ABL1 and other mutants compared to direct sequencing of the ABL1 kinase domain," Leukemia (2008) 22(4):877-878.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Rahman et al. "Antistaphylococcal activity of DNA-interactive pyrrolobenzodiazepine (PBD) dimers and PBD-biaryl conjugates." J Antimicrob Chemother. Jul. 2012; 67(7):1683-96.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Rahman, K.M., "Effect of microwave irradiation on covalent ligand-DNA interactions," Chem. Commun. (Cambridge, UK), Apr. 2009, 20:2875-2877.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Rahman, K.M., "Rules of DNA adduct formation for pyrrolobenzodiazepine (PBD) dimers," Proceedings of the American Association for Cancer Research Annual Meeting (Apr. 2010) 51:851.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Rahman, K.M., "The pyrrolobenzodiazepine dimer SJG-136 forms sequencedependent intrastrand DNA cross- lins and monoalkylated adducts in addition to interstrand cross-links," J. Am. Chem. Soc., Sep. 2009, 131(38):13756-13766.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Rao et al., "Influence of diet on mammary cancer in transgenic mice bearing an oncogene expressed in mammary tissue," (1997) Breast Cancer Res. and Treatment 45:149-158.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Reid, J.M., "LC-MS/MS assay and rat pharmacokinetics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136," Proceedings of the American Association for Cancer Research Annual Meeting (Mar. 2004) 45:1248.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Reiter R.E., et al., "Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer," Proc. Natl. Acad. Sci. U.S.A. 95, 1735-1740, 1998.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Remmers et al., "Conformations of complexes between pyrrolo[1,4]benzodiazepines and DNA segments," J Med Chem. Dec. 1986;29(12):2492-2503.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Rich, I.N., "Validation and development of a predictive paradigm for hemotoxicology using a multifunctional bioluminescence colony-forming proliferation assay," Toxicological Sci. (2005) 87(2):427-441.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Rodrigues et al., "Synthesis and beta-lactamase-mediated activation of a cephalosporin-taxol prodrug," (1995) Chemistry Biology 2:223-227.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Roguska et al., "A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing," Protein Eng, 1996, 9(10):895-904.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Roguska et al., "Humanization of murine monoclonal antibodies through variable domain resurfacing," PNAS, 1994, 91(3):969-973.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Ross et al., "Prostate Stem Cell Antigen as Therapy Target: Tissue Expression and in Vivo Efficacy of an Immunoconjugate," (2002) Cancer Res. 62:2546-2553.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Rudikoff et al., Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A. Mar. 1982; 79(6):1979-83.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Sagnou, M.J. et al., "Design and Synthesis of Novel Pyrrolobenzodiazepine (PDB) Prodrugs for ADEPT and GDEPT," Bioorganic &amp; Medicinal Chemistry Letters, 10, 2083-2086 (2000).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Sakaguchi et al., "8 lymphocyte lineage-restricted expression of mb-1, a gene with CD3-like structural properties," (1988) EMBO J. 7(11):3457-3464.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Sakamoto A, Yanagisawa M., et al., "Cloning and Functional Expression of Human cDNA For the ETB Endothelin Receptor," Biochem. Biophys. Res. Commun. 178, 656-663, 1991.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Sanderson et al., "In vivo Drug-Linker Stability of an Anti-CD30 Dipeptide-Linked Auristatin Immunoconjugate," (2005) Clin. Cancer Res. 11:843-852.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Scholler et al., "Soluble member(s) of the mesothelin/ megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma," Proc. Natl. Acad. Sci. USA vol. 96, p. 11531-11536, Sep. 1999.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      SCHRODER and Lubke, The Peptides, vol. 1. pp. 76-136 (1965) Academic Press.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Schweikart, K., "In vitro myelosuppression of SJG-136, a pyrrolobenzodiazepine dimer: comparison to bizelesin," Proceedings of the American Association for Cancer Research Annual Meeting (Mar. 2004) 45:486.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Segawa et al., "Growth-related Renal Type II Na/Pi Cotransporter," The Journal of Biological Chemistry, vol. 277. No. 22, Issue of May 31, p. 19665-19672, 2002.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Semba K., et al., "A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1 /epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma," 15 Proc. Natl. Acad. Sci. U.S.A 82, 6497-6501, 1985.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Servenius et al., "Class II Genes of the Human Major Histocompatibility Complex, The DOBeta Gene is a Divergent Member of the Class II P Gene Family," (1987) J. Biol. Chem. 262:8759-8766.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Shamis et al., "Bioactivation of Self-lmmolative Dendritic Prodrugs by Catalytic Antibody 38C2," (2004) J . Am. Chem. Soc. 126:1726-1731.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Sharkey et al., "Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies," Mol. Cancer Ther. (2012) 11(1):224-234.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Sheikh F., et al., "Cutting Edge: IL-26 Signals through a Novel Receptor Complex Composed of IL-20 Receptor 1 and IL-10 Receptor 21," (2004) J.Immunol, 172, 2006-2010.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Shen et al., "Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates," (2012) Nature Biotech., 30(2):184-191.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Shimizu, K et al., "Prothracarcin, a Novel Antitumor Antibiotic," J. Antibiotics, 35, 972-978 (1982).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Sinha S.K., et al., "Characterization of the EBV /C3d Receptor on the Human Jurkat T Cell Line: Evidence for a Novel Transcript," (1993) J. Immunol. 150, 5311-5320.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Smellie, M. et al., "Cellular pharmacology of novel C8-linked anthramycin-based sequence-selective DNA minor groove cross-linking agents," Br. J. Cancer (1994) 70:48-53.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Smellie, M. et al., "Sequence selective recognition of duplex DNA through covalent interstrand cross-linking," Biochem. (2003) 42:8232-8239.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Smith, P. K et al., "Measurement of protein using bicinchoninic acid." Anal Biochem. Oct. 1985; 150(1):76-85.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Souillac, P. et al., "Characterization of delivery systems, differential scanning calorimetry," Encyclopedia of Controlled Drug Delivery (1999) 212-227 (pp. 217-218).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Storm et al., "Effect of Small Changes in Orientation on Reaction Rate," (1972) J. Amer. Chem. Soc. 94:5815-5825.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Strausberg et al., "Generation and initial analysis of more than 15,000 full-length human and mouse eDNA sequences," (2002) Proc. Natl. Acad. Sci USA 99:16899-16903.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Suggitt, M., "The hollow fibre model—facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare," Int. J. Oncol. (2006) 29(6):1493-1499.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Suggs, J.W. et al., "Synthesis and structure of anthramycin analogs via hydride reduction of dilactams," Tetrahedron Letters, 26, No. 40, 4871-4874 (1985).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Sun et al., "Enabling ScFvs as Multi-Drug Carriers: A Dendritic Approach," (2003) Bioorganic &amp; Medicinal Chemistry 11:1761-1768.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Sun et al., "Syntheses of Dendritic Linkers Containing Chlorambucil Residues for the Preparation of Antibody- Multidrug Immunoconjugates," (2002) Bioorganic &amp; Medicinal Chemistry Letters 12:2213-2215.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Sutherland, M.S.K. et al., "SGN-CD33A: a novel CD33-directed antibody-drug conjugate, utilizing pyrrolobenzodiazepine dimers, demonstrates preclinical anti-tumor activity against multi-drug resistant human AML," American Society of Hematology (Dec. 8-12, 2012) Atlanta, Georgia, Abstract No. 3589.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Svensson P.J., et al., "Phenotypic variation in a family with mutations in two Hirschsprung-related genes (RET and endothelin receptor B)," Hum. Genet. 103, 145-148, 1998.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Swiercz J.M., et al., "Plexin-81 /RhoGEF-mediated Rho A activation involves the receptor tyrosine kinase ErbB-2," J. Cell Biol. 165, 869-880, 2004.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Syrigos and Epenetos, "Antibody Directed Enzyme Prodrug Therapy (ADEPT): A Review of the Experimental and Clinical Considerations," (1999) Anticancer Research 19:605-614.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Takeuchi, T et al., "Neothramycins A and B, New Antitumor Antibiotics," J. Antibiotics, 29, 93-96 (1976).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Talpur et al., "CD25 Expression is Correlated with Histological Grade and Response to Denileukin Diftitox in Cutaneous T-Cell Lymphoma," J. Investigative Dermatology, 2006, 126: 575-583.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Tawaragi Y., et al., "Primary Structure of Nonspecific Crossreacting Antigen (NCA), a Member of Carcinoembryonic Antigen (CEA) Gene Family, Deduced From cDNA Sequence," Biochem. Biophys. Res. Commun. 150, 89-96, 1988.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Tercel, M. et al., "Unsymmetrical DNA cross-linking agents: combination of the CBI and PBD pharmacophores," J. Med. Chem. (2003) 46:2132-2151.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Thompson J.S., et al., "BAFF-R, a Newly Identified TNF Receptor That Specifically Interacts with BAFF," Science 293 (5537), 2108-2111 (2001).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Thurston, D. E., "Advances in the study of Pyrrolo[2,1-c][1,4] benzodiazepine (PBD) Antitumour Antibiotics", Molecular Aspects of Anticancer Drug-DNA Interaction, Neidle, S. and Waring, M.J., Eds.; Macmillan Press Ltd, 1:54-88 (1993).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Thurston, D.E. and Bose, D.S., "Synthesis of DNA-lnteractive Pyrrolo[2,1-c][1,4]benzodiazepines," Chem. Rev., 94:433-465 (1994).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Thurston, D.E. and Thompson, A.S., "The molecular recognition of DNA," Chem. Brit., 26, 767-772 (1990).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Thurston, D.E. et al., "Effect of A-ring modifications on the DNA-binding behavior and cytotoxicity of pyrrolo[2,1-c][1,4]benzodiazepines", Journal of Medicinal Chemistry, 42:1951-1964 (1999).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Thurston, D.E. et al., "Synthesis of a novel GC-specific covalent-binding DNA affinity-cleavage agent based on pyrrolobenzodiazepines (PBDs)," Chemical Communications, 563-565 (1996).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Thurston, D.E. et al., "Synthesis of Sequence-selective C8-linked Pyrrolo [2,1-c][1,4] Benzodiazepine DNA Interstrand Cross-linking Agent," J. Org. Chem., 61:8141-8147 (1996).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Thurston, D.E., "Nucleic acid targeting: therapeutic strategies for the 21st century," Brit. J. Cancer (1999) 80(1):65-85.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Tiberghien, A.C. et al., "Application of the stille coupling reaction to the synthesis of C2-substituted endo-exo unsaturated pyrrolo[2,1-c][1,4]benzodiazepines (PBDs)," Biorg. Med. Chem. Lett. (2004) 14:5041-5044.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Tiberghien, A.C., "Application of the stille coupling reaction to the synthesis of C2-substituted endo-exo unsaturated pyrrolo[2,1-c][1,4]benzodiazepines (PBDs)," Bioorg. Med. Chem. Lett. (2008) 18(6):2073-2077.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Toki et al., "Protease-Mediated Fragmentation of p-Amidobenzyl Ethers: A New Strategy for the Activation of Anticancer Prodrugs," (2002) J. Org. Chem. 67:1866-1872.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Tonnelle et al., "DO Beta a new chain gene in HLA-D with a distinct regulation of expression," (1985) EMBO J. 4(11):2839-2847.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Touchman et al., "The Genomic Region Encompassing the Nephropathic Cystinosis Gene (CTNS): Complete Sequencing of a 200-kb Segment and Discovery of a Novel Gene within the Common Cystinosis-Causing Deletion," (2000) Genome Res. 10:165-173.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Tozuka et al., "Studies on tomaymycin. II. Total synthesis of the antitumor antibiotics, E-and Z-tomaymycins," J. Antibiotics (Tokyo) (1983) 36:276-282.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Trail et al., "Monoclonal antibody drug immunoconjugates for targeted treatment of cancer," (2003) Cancer Immunol. Immunother. 52:328-337.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Tsunakawa, M. et al., "Porothramycin, a new antibiotic of the anthramycin group: Production, isolation, structure and biological activity," J. Antibiotics, 41:1366-1373 (1988).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Tsutsumi M., et al., "Novel endothelin B receptor transcripts with the potential of generating a new receptor," Gene 228, 43-49, 1999.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Uchida et al., "A Novel Epidermal Growth Factor-like Molecule Containing Two Follistatin Modules Stimulates Tyrosine Phosphorylation of erbB-4 in MKN28 Gastric Cancer Cells," (1999) Biochem. Biophys. Res. Commun. 266:593-602.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Umezawa, H. et al., "Mazethramycins," SciFinder Scholar, 2-3 (2002).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Umezawa, H. et al., Chemical Abstract No. 4427a, "Mazethramycins" Chemical Abstracts, vol. 90, No. 1, 428 (1979).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Van Geel et al., "Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates," (2015) Bioconjugate Chem. 26: 2233-2242.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Verheij J.B., et al., "ABCD Syndrome Is Caused by a Homozygous Mutation in the EDNRB Gene," Am. J. Med. 15 Genet. 108, 223-225, 2002.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Vippagunta, S.R. et al., "Crystalline solids," Adv. Drug Delivery Rev. (2001) 48:3-26.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Von Hoegen et al., "Identifigation of a human protein homologous to the mouse Lyb-2 B cell differentiation antigen and sequence of the corresponding cDNA," (1990) J. Immunol. 144(12):4870-4877.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Wang, J.H., "Determination of antitumor agent AJG-136 in human serum by HPLC with tandem mass spectrometric detection (HPLC-MS/MS)," Abstracts of Papers American Chemical Society (Mar. 13, 2005) 229(1):U119.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Webster et al., "Mammary tumorigenesis and metastasis in transgenic mice," (1994) Semin. Cancer Biol. 5:69-76.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Weidner-Wells, M.A. et al., "Photochemical approach to the synthesis of the pyrrolo[1,4]benzodiazepine antibiotics," J. Org. Chem. (1989) 54:5746-5758.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Weis J.J., et al., "Identification of a partial eDNA clone for the C3d/Epstein-Barr virus receptor of human B lymphocytes: Homology with the receptor for fragments C3b and C4b of the third and fourth components of complement," Proc. Natl. Acad. Sci. U.S.A. 83, 5639-5643, 1986.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Weis J.J., et al., "Structure of the human b lymphocyte receptor for c3d and the epstein-barr virus and relatedness to other members of the family of C3/C4 binding proteins," J. Exp. Med. 167, 1047-1066, 1988.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Wells, G. et al., "Design, synthesis and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugates," J. Med. Chem. (2006) 49:5442-5461.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Wilkinson "Eph Receptors and Ephrins: Regulators of Guidance and Assembly," Int. Rev. Cytol. 196:177-244 (2000).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Wilkinson, G.P., "Pharmacokinetics and intracellular pharmacological characteristics of the novel pyrrolobenzodiazepine (PBD) dimer SJG-136," Proceedings of the American Association for Cancer Research Annual Meeting (Jul. 2003) 44:320.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Wilkinson, G.P., "Pharmacokinetics, metabolism and glutathione reactivity of SJG-136," Br. J. Cancer (2003) 88(Supp. 1):S29.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Wilkinson, G.P., "Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent," Investigational New Drugs (2004) 22(3):231-240.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Wilson et al., "eDNA Cloning of the B Cell Membrane Protein CD22: A Mediator of B-B Cell Interactions," (1991) J. Exp. Med. 173:137-146.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Wilson, S.C et al., "Design and Synthesis of a Novel Epoxide-Containing Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) via a New Cyclization Procedure," Tetrahedron Letters, 36, No. 35, 6333-6336 (1995).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Wilson, S.C. et al., "Design, Synthesis, and Evaluation of a Novel Sequence-Selective Epoxide-Containing DNA Cross-Linking Agent Based on the Pyrrolo[2,1-c][1,4]benzodiazepine System", J. Med. Chem. 42: 4028-4041 (1999).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Wolff, M.E., Burger's Medicinal Chemistry, 4th Edition, Part 1, Wiley: New York (1979) 336-337.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Wolff, M.E., Burger's Medicinal Chemistry, 5th Edition, Part I, John Wiley &amp; Sons (1995) 975-977.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Workman, P. et al., "United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition)," Br. J. Cancer (1998) 77(1):1-10.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Wu et al., "Arming antibodies: prospects and challenges for immunoconjugates," (2005) Nature Biotech. 23(9):1137-1145.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Xie et al., "In vivo behaviour of antibody- drug conjugates for the targeted treatment of cancer," (2006) Expert. Opin Biol. Ther. 6(3):281-291.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Xie, G. et al., "Bisindolylmaleimides linked to DNA minor groove binding lexitropsins: synthesis, inhibitory activity against topoisomerasel, and biological evaluation," J. Med. Chem. (1996) 39:1049-1055.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Xu et al., "Molecular Cloning, Functional Characterization, Tissue Distribution, and Chromosomal Localization of a Human, Small Intestinal Sodium-Phosphate (Na + -Pi) Transporter (SLC34A2)," Genomics 62 (2):281-284 (1999).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Xu, M.J., et al., "Molecular Cloning and Characterization of SPAP1, an Inhibitory Receptor," (2001) Biochem. Biophys. Res. Commun. 280 (3):768-775.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Xu, X.Z., et al., "Regulation of melastatin, a TRP-related protein, through interaction with a cytoplasmic isoform," Proc. Natl. Acad. Sci. U.S.A. 98 (19):10692-10697 (2001).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Yamaguchi, N., et al., "A Novel Cytokine Exhibiting Megakaryocyte Potentiating Activity From a Human Pancreatic Tumor Cell Line HPC-Y5," Biol. Chem. 269 (2), 805-808 (1994).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Yamamoto T., et al., "Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor," Nature 319, 230-234, 1986.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Yang et al., "Murine Six-Transmembrane Epithelial Antigen of the Prostate, Prostate Stem Cell Antigen, and Prostate-specific Membrane Antigen: Prostate-specific Cell-Surface Antigens Highly Expressed in Prostate Cancer of Transgenic Adenocarcinoma Mouse Prostate Mice," Cancer Research, 61, 5857-5860. Aug. 1, 2001.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Yin &amp; Lloyd, "Molecular Cloning of the CA125 Ovarian Cancer Antigen," J. Biol. Chem. 276 (29):27371-27375 (2001).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Younes et al., "Phase 1 multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma," J Clin Oncol., 2012, 30(22):2776-82.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Yu et al., "Human mb-1 gene: complete edna sequence and its expression in b cells bearing membrane Ig of various isotypes," (1992) J. Immunol. 148(2) 633-637.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Zammarchi et al., "Pre-Clinical Development of Adct-4O2, a Novel Pyrrolobenzodiazepine (PBD)—Based Antibody Drug Conjugate (ADC) Targeting CD19-Expressing B-Cell Malignancies," Blood, 2015, 126:1564, Abstract.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Zhao et al., "Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors," (2016) Clin. Cancer Drugs 3: 76-86.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner, † Cited by third party</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="citedBy" class="scroll-target style-scope patent-result">
              Cited By (10)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20230106885A1/en"><a id="link" href="#" class="style-scope state-modifier">US20230106885A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-06-14</span>
                    <span class="td style-scope patent-result">2023-04-06</span>
                    <span class="td style-scope patent-result">Adc Therapeutics Sa</span>
                    <span class="td style-scope patent-result">Dosage regime 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20220096641A1/en"><a id="link" href="#" class="style-scope state-modifier">US20220096641A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-01-03</span>
                    <span class="td style-scope patent-result">2022-03-31</span>
                    <span class="td style-scope patent-result">Legochem Biosciences, Inc.</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine dimer compound with improved safety and use thereof 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/BR112021018260A2/en"><a id="link" href="#" class="style-scope state-modifier">BR112021018260A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-03-15</span>
                    <span class="td style-scope patent-result">2021-11-23</span>
                    <span class="td style-scope patent-result">Medimmune Ltd</span>
                    <span class="td style-scope patent-result">
  Azetidobenzodiazepine dimers and conjugates comprising the same for use in the treatment of cancer
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP4013494A1/en"><a id="link" href="#" class="style-scope state-modifier">EP4013494A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-08-12</span>
                    <span class="td style-scope patent-result">2022-06-22</span>
                    <span class="td style-scope patent-result">Regeneron Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Macrophage stimulating 1 receptor (mst1r) variants and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2021080608A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2021080608A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-10-25</span>
                    <span class="td style-scope patent-result">2021-04-29</span>
                    <span class="td style-scope patent-result">Medimmune, Llc</span>
                    <span class="td style-scope patent-result">Branched moiety for use in conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/MX2023002850A/en"><a id="link" href="#" class="style-scope state-modifier">MX2023002850A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-09-10</span>
                    <span class="td style-scope patent-result">2023-07-07</span>
                    <span class="td style-scope patent-result">Precirix N V</span>
                    <span class="td style-scope patent-result">Antibody fragment against fap. 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB202015226D0/en"><a id="link" href="#" class="style-scope state-modifier">GB202015226D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-09-25</span>
                    <span class="td style-scope patent-result">2020-11-11</span>
                    <span class="td style-scope patent-result">Adc Therapeutics S A</span>
                    <span class="td style-scope patent-result">Pyrrol obenzodiazepine-antibody conugates and uses thereof 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2023005463A/en"><a id="link" href="#" class="style-scope state-modifier">JP2023005463A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-06-29</span>
                    <span class="td style-scope patent-result">2023-01-18</span>
                    <span class="td style-scope patent-result">株式会社フジミインコーポレーテッド</span>
                    <span class="td style-scope patent-result">Surface-modified colloidal silica and polishing composition comprising the same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2023203135A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2023203135A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-04-22</span>
                    <span class="td style-scope patent-result">2023-10-26</span>
                    <span class="td style-scope patent-result">Precirix N.V.</span>
                    <span class="td style-scope patent-result">Improved radiolabelled antibody 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2023213801A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2023213801A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-05-02</span>
                    <span class="td style-scope patent-result">2023-11-09</span>
                    <span class="td style-scope patent-result">Precirix N.V.</span>
                    <span class="td style-scope patent-result">Pre-targeting 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>

              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner, † Cited by third party, ‡ Family to family citation</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="similarDocuments" class="scroll-target style-scope patent-result">
              Similar Documents
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication</span>
                    <span class="th style-scope patent-result">Publication Date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10799595B2/en"><a id="link" href="#" class="style-scope state-modifier">US10799595B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-10-13</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US11370801B2/en"><a id="link" href="#" class="style-scope state-modifier">US11370801B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-06-28</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9567340B2/en"><a id="link" href="#" class="style-scope state-modifier">US9567340B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-02-14</span>
                    <span class="td style-scope patent-result">Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20230143309A1/en"><a id="link" href="#" class="style-scope state-modifier">US20230143309A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2023-05-11</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine antibody conjugates 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10695439B2/en"><a id="link" href="#" class="style-scope state-modifier">US10695439B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-06-30</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10392393B2/en"><a id="link" href="#" class="style-scope state-modifier">US10392393B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-08-27</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EA038267B1/en"><a id="link" href="#" class="style-scope state-modifier">EA038267B1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-08-02</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine conjugates 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="relatedApplications" class="scroll-target style-scope patent-result">Priority And Related Applications</h3>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="appsClaimingPriority" class="scroll-target style-scope patent-result">
              Applications Claiming Priority (7)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        GB1706133.4<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2017-04-18</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201706133D0/en"><a id="link" href="#" class="style-scope state-modifier">GBGB1706133.4A</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2017-04-18</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine conjugates 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        GB1706133<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2017-04-18</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201721337D0/en"><a id="link" href="#" class="style-scope state-modifier">GBGB1721337.2A</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2017-12-19</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine conjugates 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        GB1721337.2<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2017-12-19</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        GB1721337<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2017-12-19</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2018192944A1/en"><a id="link" href="#" class="style-scope state-modifier">PCT/EP2018/059846</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2018-04-18</span>
                    <span class="td style-scope patent-result">Pyrrolobenzodiazepine conjugates 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="legalEvents" class="scroll-target style-scope patent-result">
              Legal Events
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Date</span>
                    <span class="th style-scope patent-result">Code</span>
                    <span class="th style-scope patent-result">Title</span>
                    <span class="th style-scope patent-result">Description</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2019-10-17</span>
                    <span class="td nowrap style-scope patent-result">FEPP</span>
                    <span class="td nowrap style-scope patent-result">Fee payment procedure</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2019-10-18</span>
                    <span class="td nowrap style-scope patent-result">AS</span>
                    <span class="td nowrap style-scope patent-result">Assignment</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Owner name</strong>: MEDIMMUNE LIMITED, UNITED KINGDOM</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HOWARD, PHILIP WILSON;GREGSON, STEPHEN JOHN;REEL/FRAME:050762/0621</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Effective date</strong>: 20180525</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2020-09-03</span>
                    <span class="td nowrap style-scope patent-result">STPP</span>
                    <span class="td nowrap style-scope patent-result">Information on status: patent application and granting procedure in general</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: NON FINAL ACTION MAILED</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2021-01-22</span>
                    <span class="td nowrap style-scope patent-result">STPP</span>
                    <span class="td nowrap style-scope patent-result">Information on status: patent application and granting procedure in general</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: FINAL REJECTION MAILED</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2021-04-28</span>
                    <span class="td nowrap style-scope patent-result">STPP</span>
                    <span class="td nowrap style-scope patent-result">Information on status: patent application and granting procedure in general</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: DOCKETED NEW CASE - READY FOR EXAMINATION</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2021-06-09</span>
                    <span class="td nowrap style-scope patent-result">STPP</span>
                    <span class="td nowrap style-scope patent-result">Information on status: patent application and granting procedure in general</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: NON FINAL ACTION MAILED</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2021-09-13</span>
                    <span class="td nowrap style-scope patent-result">STPP</span>
                    <span class="td nowrap style-scope patent-result">Information on status: patent application and granting procedure in general</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2021-09-17</span>
                    <span class="td nowrap style-scope patent-result">STPP</span>
                    <span class="td nowrap style-scope patent-result">Information on status: patent application and granting procedure in general</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: NON FINAL ACTION MAILED</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2021-12-31</span>
                    <span class="td nowrap style-scope patent-result">STPP</span>
                    <span class="td nowrap style-scope patent-result">Information on status: patent application and granting procedure in general</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2022-02-18</span>
                    <span class="td nowrap style-scope patent-result">STPP</span>
                    <span class="td nowrap style-scope patent-result">Information on status: patent application and granting procedure in general</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2022-05-20</span>
                    <span class="td nowrap style-scope patent-result">STPP</span>
                    <span class="td nowrap style-scope patent-result">Information on status: patent application and granting procedure in general</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2022-05-23</span>
                    <span class="td nowrap style-scope patent-result">STPP</span>
                    <span class="td nowrap style-scope patent-result">Information on status: patent application and granting procedure in general</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2022-06-08</span>
                    <span class="td nowrap style-scope patent-result">STCF</span>
                    <span class="td nowrap style-scope patent-result">Information on status: patent grant</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: PATENTED CASE</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
              <h3 id="concepts" class="scroll-target layout horizontal style-scope patent-result">
                <div class="flex style-scope patent-result">Concepts</div>
                <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
              </h3>
              <div class="layout horizontal style-scope patent-result">
                <div class="flex style-scope patent-result">
                  <span id="conceptsWarning" class="righthead tooltip-hint style-scope patent-result">machine-extracted</span>
                  <overlay-tooltip positioning-target="#conceptsWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The concepts are extracted by a computer and may be incomplete or incorrect.
    </div>
  </overlay-tooltip>
                </div>
                <span class="headerButton style-scope patent-result"><a href="#" target="_blank" style="display: inline-block;" class="style-scope patent-result"><iron-icon icon="icons:file-download" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M19 9h-4V3H9v6H5l7 7 7-7zM5 18v2h14v-2H5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download</a></span>
                <span class="style-scope patent-result">
                  <dropdown-menu multi="true" label="Filter table" show-label="true" change-action="RESULT_CONCEPT_MENU" class="style-scope patent-result">
    
    <span class="label style-scope dropdown-menu">
      <span class="style-scope dropdown-menu">Filter table</span>
      <span id="selected" class="style-scope dropdown-menu" hidden="">
        <span style="margin: 0 4px 0 2px" class="style-scope dropdown-menu">·</span>
        <span class="style-scope dropdown-menu"></span>
      </span>
      <iron-icon icon="icons:arrow-drop-down" class="style-scope dropdown-menu x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 10l5 5 5-5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><iron-icon icon="icons:arrow-drop-up" class="style-scope dropdown-menu x-scope iron-icon-0" hidden=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
    </span>
    <iron-dropdown allow-outside-scroll="" horizontal-align="left" vertical-align="top" class="style-scope dropdown-menu" aria-disabled="false" aria-hidden="true" style="outline: none; display: none;">
    

    <div id="contentWrapper" class="style-scope iron-dropdown">
      <div class="dropdown-content style-scope dropdown-menu" slot="dropdown-content" id="menu" multi="">
        <div class="style-scope dropdown-menu">
          
            <div class="item style-scope dropdown-menu">Chemical compound</div>
          <template is="dom-repeat" class="style-scope dropdown-menu"></template>
        </div>
      </div>
    </div>
  </iron-dropdown>
  </dropdown-menu>
                </span>
              </div>
              <div class="responsive-table style-scope patent-result">
                <div class="table style-scope patent-result">
                  <div class="thead style-scope patent-result">
                    <div class="tr style-scope patent-result">
                      <span class="th style-scope patent-result">Name</span>
                      <span class="th style-scope patent-result">Image</span>
                      <span class="th style-scope patent-result">Sections</span>
                      <span class="th style-scope patent-result">Count</span>
                      <span class="th style-scope patent-result">Query match</span>
                    </div>
                  </div>
                  <div class="tbody style-scope patent-result">
                    <template is="dom-repeat" initial-count="25" class="style-scope patent-result"></template>
                    
                      <div class$="tr layout horizontal conceptDomain" class="style-scope patent-result">
                        <a href="#" class="td flex style-scope patent-result">
                          Show all concepts from the description section
                        </a>
                      </div>
                    <template is="dom-if" class="style-scope patent-result"></template>
                  </div>
                </div>
              </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <div id="notices" class="vertical layout center style-scope patent-result">
              
                <span class="style-scope patent-result">Data provided by IFI CLAIMS Patent Services</span>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
          </div>
          <div class="bottombar style-scope patent-result">
            <bottom-bar class="style-scope patent-result"><template is="dom-if" class="style-scope bottom-bar"></template>
</bottom-bar>
          </div>
        </div>
      </div>
      <template is="dom-if" class="style-scope patent-result"></template>
    </div>
  </patent-result>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
  </result-container>
        </div>
      </div>
    
        </div>
      </div>
      <search-footer class="style-scope search-ui">
    
    

    <div id="footer" class="vertical layout center style-scope search-footer">
        <span class="links style-scope search-footer">
          <overlay-tooltip positioning-target="#footerAbout" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Learn more about data coverage, search syntax and other features.
    </div>
  </overlay-tooltip>
          <a id="footerAbout" data-proto="ABOUT" href="https://support.google.com/faqs/answer/6390996" target="_blank" class="style-scope search-footer">About</a>
          <overlay-tooltip positioning-target="#footerFeedback" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Send feedback about technical issues or feature requests for Google Patents.
    </div>
  </overlay-tooltip>
          <a id="footerFeedback" data-proto="SEND_FEEDBACK" href="#" onclick="sendFeedback();" class="style-scope search-footer">Send Feedback</a>
          <a data-proto="PUBLIC_DATASETS" href="https://console.cloud.google.com/marketplace/product/google_patents_public_datasets/google-patents-public-data" target="_blank" class="style-scope search-footer">Public Datasets</a>
          <a data-proto="TERMS" href="https://www.google.com/policies/terms/" target="_blank" class="style-scope search-footer">Terms</a>
          <a data-proto="PRIVACY_POLICY" href="https://www.google.com/privacy/privacy-policy.html" target="blank" class="style-scope search-footer">Privacy Policy</a>
          <a data-proto="SEARCH_HELP" href="https://support.google.com/websearch/" target="_blank" class="style-scope search-footer">Help</a>
        </span>
    </div>
  </search-footer>
    </div>

  </search-ui>
  </search-result>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <paper-toast id="toast" duration="3000" class="style-scope search-app x-scope paper-toast-0" aria-hidden="true" style="outline: none; display: none;">
    

    <span id="label" class="style-scope paper-toast"></span>
    
      <div id="noticeContent" class="style-scope search-app"></div>
    
  </paper-toast>
  </search-app>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  

<iframe id="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.206199259" name="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.206199259" style="width: 1px; height: 1px; position: absolute; top: -100px; display: none;" src="https://scone-pa.clients6.google.com/static/proxy.html?usegapi=1&amp;jsh=m%3B%2F_%2Fscs%2Fabc-static%2F_%2Fjs%2Fk%3Dgapi.lb.en.IKZeRvoAYNY.O%2Fam%3DAAAQ%2Fd%3D1%2Frs%3DAHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw%2Fm%3D__features__#parent=https%3A%2F%2Fpatents.google.com&amp;rpctoken=411984307" tabindex="-1" aria-hidden="true"></iframe><iron-a11y-announcer>
    
    <div class="style-scope iron-a11y-announcer" aria-live="polite"></div>
  </iron-a11y-announcer></body></html>